{"PMC7267806": [["FOR RELATED ARTICLE, SEE PAGE 1497Nearly 20 years have passed since the advent of low tidal volume ventilation,1 yet the mortality for patients with ARDS remains high.", [["ARDS", "DISEASE", 149, 153], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["low tidal volume ventilation", "TREATMENT", 82, 110], ["ARDS", "PROBLEM", 149, 153], ["tidal volume", "OBSERVATION", 86, 98], ["ARDS", "OBSERVATION", 149, 153]]], ["Revisiting the treatment modalities used to manage this syndrome has become increasingly important in light of the COVID-19 pandemic.", [["the treatment modalities", "TREATMENT", 11, 35], ["this syndrome", "PROBLEM", 51, 64], ["the COVID", "TEST", 111, 120], ["pandemic", "PROBLEM", 124, 132]]], ["Although ventilator management comprises a large component of ARDS care, adjunctive, nonventilator therapies also make up an important part of a clinician\u2019s toolkit.", [["ARDS", "DISEASE", 62, 66], ["ventilator management", "TREATMENT", 9, 30], ["ARDS care", "TREATMENT", 62, 71], ["nonventilator therapies", "TREATMENT", 85, 108], ["large", "OBSERVATION_MODIFIER", 43, 48], ["component", "OBSERVATION_MODIFIER", 49, 58], ["ARDS", "OBSERVATION", 62, 66]]], ["Over the years, a number of studies on adjunctive therapies for ARDS2 have been conducted, but their implementation and impact as a whole on patient outcomes are unclear.", [["ARDS2", "SIMPLE_CHEMICAL", 64, 69], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["adjunctive therapies", "TREATMENT", 39, 59], ["ARDS2", "TREATMENT", 64, 69]]], ["In this issue of CHEST, Duggal et al2 set out to address an important issue: the use of adjunctive therapies in patients with moderate to severe ARDS, a timely subject in the setting of COVID-19.", [["ARDS", "DISEASE", 145, 149], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["Duggal et al2", "TREATMENT", 24, 37], ["adjunctive therapies", "TREATMENT", 88, 108], ["moderate to severe ARDS", "PROBLEM", 126, 149], ["COVID", "TEST", 186, 191], ["CHEST", "ANATOMY", 17, 22], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["ARDS", "OBSERVATION", 145, 149]]], ["Their objectives were to evaluate the frequency and patterns of use of adjunctive therapies in this patient population, as well as to understand the factors associated with the use of these therapies.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["adjunctive therapies", "TREATMENT", 71, 91], ["these therapies", "TREATMENT", 184, 199]]], ["Although the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG-SAFE) previously assessed the frequency of adjunctive therapy use all patients with ARDS,3 a closer look at patients with a Pao2/Fio2 ratio <150 is needed, as it is primarily this subset of patients in whom adjunctive therapies are recommended.", [["ARDS", "DISEASE", 197, 201], ["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 221, 229], ["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 303, 311], ["Observational Study", "TEST", 19, 38], ["Severe Acute Respiratory Failure", "PROBLEM", 74, 106], ["adjunctive therapy", "TREATMENT", 156, 174], ["ARDS", "PROBLEM", 197, 201], ["a Pao2/Fio2 ratio", "TEST", 235, 252], ["adjunctive therapies", "TREATMENT", 320, 340], ["Large", "OBSERVATION_MODIFIER", 13, 18], ["Severe", "OBSERVATION_MODIFIER", 74, 80], ["Acute", "OBSERVATION_MODIFIER", 81, 86], ["Respiratory Failure", "OBSERVATION", 87, 106], ["LUNG", "ANATOMY", 108, 112]]], ["In this cohort assembled in 2014, a small proportion of patients with moderate to severe ARDS (29%) received early adjunctive therapy; the most frequently used modality was neuromuscular blockade (22%).", [["neuromuscular", "ANATOMY", 173, 186], ["ARDS", "DISEASE", 89, 93], ["neuromuscular blockade", "DISEASE", 173, 195], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["moderate to severe ARDS", "PROBLEM", 70, 93], ["early adjunctive therapy", "TREATMENT", 109, 133], ["neuromuscular blockade", "TREATMENT", 173, 195], ["small", "OBSERVATION_MODIFIER", 36, 41], ["moderate", "OBSERVATION_MODIFIER", 70, 78], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["ARDS", "OBSERVATION", 89, 93]]], ["Prone positioning, the adjunctive therapy that has most clearly been shown to have a survival benefit in ARDS,4 was only used in 11% of patients.", [["ARDS", "DISEASE", 105, 109], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["Prone positioning", "TREATMENT", 0, 17], ["the adjunctive therapy", "TREATMENT", 19, 41], ["ARDS", "PROBLEM", 105, 109], ["ARDS", "OBSERVATION", 105, 109]]]], "PMC7508062": [["Financial support and sponsorshipNil.Conflicts of interestThere are no conflicts of interest.", [["Financial support", "TREATMENT", 0, 17], ["sponsorshipNil", "TREATMENT", 22, 36], ["no", "UNCERTAINTY", 68, 70], ["conflicts", "OBSERVATION", 71, 80]]]], "PMC7152299": [], "PMC7258809": [["\u2018One Stop Clinic\u2019 ::: Service Re-configurationThe Accident and Emergency department (AED) had become overwhelmed by patients with COVID-19 and non-COVID-19 respiratory illness.", [["respiratory illness", "DISEASE", 156, 175], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["COVID", "TEST", 130, 135], ["non-COVID", "TEST", 143, 152], ["respiratory illness", "PROBLEM", 156, 175], ["respiratory illness", "OBSERVATION", 156, 175]]], ["The \u2018One Stop Clinic\u2019 model of care allows Consultant led decisions on all hand injuries, a definitive management plan and a package of care to ensure minimal face to face follow-ups.", [["hand", "ANATOMY", 75, 79], ["injuries", "DISEASE", 80, 88], ["hand", "ORGANISM_SUBDIVISION", 75, 79], ["all hand injuries", "PROBLEM", 71, 88], ["a definitive management", "TREATMENT", 90, 113], ["a package of care", "TREATMENT", 123, 140]]], ["Patients are reassured about self-management guidance and given options for remote consultations appointments for future advice.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Signposting vital information in virtual hand exercise and education app (e.g. Chelsea and Westminster hand therapy app) to patients enhances treatment compliance, patient confidence and satisfaction.6 Remote hand therapy ensures patient active participation and compliance.Mini \u2018C\u2019 arm image intensifier application ::: Clinical management strategiesThe availability Mini \u2018C\u2019 arm in the \u2018One Stop Clinic\u2019 allowed us to under-take manipulations of hand and wrist fractures, check reduction and application of plaster splints.", [["hand", "ANATOMY", 41, 45], ["hand", "ANATOMY", 209, 213], ["hand", "ANATOMY", 448, 452], ["wrist", "ANATOMY", 457, 462], ["fractures", "DISEASE", 463, 472], ["hand", "ORGANISM_SUBDIVISION", 41, 45], ["patients", "ORGANISM", 124, 132], ["patient", "ORGANISM", 164, 171], ["patient", "ORGANISM", 230, 237], ["hand", "ORGANISM_SUBDIVISION", 448, 452], ["wrist", "ORGANISM_SUBDIVISION", 457, 462], ["patients", "SPECIES", 124, 132], ["patient", "SPECIES", 164, 171], ["patient", "SPECIES", 230, 237], ["Westminster hand therapy", "TREATMENT", 91, 115], ["Remote hand therapy", "TREATMENT", 202, 221], ["Clinical management strategies", "TREATMENT", 321, 351], ["hand and wrist fractures", "PROBLEM", 448, 472], ["check reduction", "TREATMENT", 474, 489], ["application of plaster splints", "TREATMENT", 494, 524], ["arm", "ANATOMY", 283, 286], ["arm", "ANATOMY", 377, 380], ["hand", "ANATOMY", 448, 452], ["wrist", "ANATOMY", 457, 462], ["fractures", "OBSERVATION", 463, 472], ["plaster splints", "OBSERVATION", 509, 524]]], ["This avoided the need for a formal radiograph, saved time and prevented one more episode of transfer of patient thus supporting the infection control guidelines by minimising points of contact.", [["infection", "DISEASE", 132, 141], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["a formal radiograph", "TEST", 26, 45], ["the infection control guidelines", "TREATMENT", 128, 160], ["infection", "OBSERVATION", 132, 141]]], ["Orthopaedic doctors and staff undertook accelerated training to facilitate this process of independent practice with appropriate radiation dose monitor badge use.8,9", [["accelerated training", "TREATMENT", 40, 60], ["appropriate radiation dose", "TREATMENT", 117, 143]]]], "923790fd2479fb7f8888db709fc87e2445b0d209": [["Accidental Introduction of Viruses into Companion Animals by Commercial VaccinesNevertheless, we can be confident that all future viruses will arise from those now existent: they will be mutants, recombinants, and reassortments [1] .Accidental Introduction of Viruses into Companion Animals by Commercial VaccinesVaccination of dogs and cats has been regarded as one of the major success stories in veterinary medicine.", [["dogs", "ORGANISM", 328, 332], ["cats", "ORGANISM", 337, 341], ["dogs", "SPECIES", 328, 332], ["cats", "SPECIES", 337, 341], ["Viruses", "TREATMENT", 27, 34], ["all future viruses", "PROBLEM", 119, 137], ["Viruses", "TREATMENT", 260, 267], ["Viruses", "OBSERVATION", 260, 267]]], ["Originally, the use of vaccines was to provide a barrier to infectious agents, such as rabies, that were known to be transmitted between dogs and human beings [2] .", [["rabies", "DISEASE", 87, 93], ["rabies", "ORGANISM", 87, 93], ["dogs", "ORGANISM", 137, 141], ["human", "ORGANISM", 146, 151], ["dogs", "SPECIES", 137, 141], ["human", "SPECIES", 146, 151], ["rabies", "SPECIES", 87, 93], ["human", "SPECIES", 146, 151], ["vaccines", "TREATMENT", 23, 31], ["a barrier to infectious agents", "TREATMENT", 47, 77]]], ["As public health concerns were addressed, the use of vaccines to control infectious diseases that cause high morbidity or high morality were then included in vaccination programs [3] [4] [5] [6] .", [["infectious diseases", "DISEASE", 73, 92], ["[3] [4] [5", "SIMPLE_CHEMICAL", 179, 189], ["vaccines", "TREATMENT", 53, 61], ["infectious diseases", "PROBLEM", 73, 92], ["high morbidity", "PROBLEM", 104, 118], ["high morality", "PROBLEM", 122, 135]]], ["Vaccination has been proved to be the most efficient and cost-effective method of controlling the major infectious diseases in domestic animals [7, 8] .", [["infectious diseases", "DISEASE", 104, 123], ["Vaccination", "TREATMENT", 0, 11], ["the major infectious diseases", "PROBLEM", 94, 123], ["major", "OBSERVATION_MODIFIER", 98, 103], ["infectious", "OBSERVATION", 104, 114]]], ["Although we do not normally consider vaccination as way for an animal to become infected with a microorganism, it was originally intended for this purposea planned infection with a known infectious dose of nonlethal consequences.", [["infection", "DISEASE", 164, 173], ["vaccination", "TREATMENT", 37, 48], ["a microorganism", "PROBLEM", 94, 109], ["this purposea planned infection", "PROBLEM", 142, 173], ["nonlethal consequences", "PROBLEM", 206, 228], ["infected", "OBSERVATION", 80, 88], ["infectious", "OBSERVATION_MODIFIER", 187, 197]]], ["Later, vaccines with attenuated (modified) microorganisms that induced a sustained protective immune response with minimal side effects were used [7] [8] [9] [10] .Accidental Introduction of Viruses into Companion Animals by Commercial VaccinesThe key objective of this article is the recognition of the fact that the use of vaccines is not without risks and what clinicians can do to assist in the recognition and reporting of such adverse events.", [["[7] [8] [9] [10]", "SIMPLE_CHEMICAL", 146, 162], ["vaccines", "TREATMENT", 7, 15], ["attenuated (modified) microorganisms", "PROBLEM", 21, 57], ["a sustained protective immune response", "PROBLEM", 71, 109], ["minimal side effects", "PROBLEM", 115, 135], ["Viruses", "TREATMENT", 191, 198], ["Commercial Vaccines", "TREATMENT", 225, 244], ["vaccines", "TREATMENT", 325, 333], ["such adverse events", "PROBLEM", 428, 447], ["Viruses", "OBSERVATION", 191, 198]]], ["The main focus is on contamination of vaccines, the types of contaminants, and the effects on vaccinated animals.PRINCIPLES AND TYPES OF VACCINATIONThere are three types of vaccine strategies used in veterinary medicine [11] .", [["contamination of vaccines", "TREATMENT", 21, 46], ["vaccinated animals", "TREATMENT", 94, 112], ["VACCINATIONThere", "TREATMENT", 137, 153], ["vaccine strategies", "TREATMENT", 173, 191], ["main", "OBSERVATION_MODIFIER", 4, 8], ["focus", "OBSERVATION_MODIFIER", 9, 14], ["contaminants", "OBSERVATION", 61, 73]]], ["These include (1) routine vaccination of susceptible animals to maintain ''herd immunity'' against endemic or established infections in an area; (2) strategic vaccination that uses emergency vaccination, ring vaccination, and barrier vaccination; and (3) suppressive or dampening-down vaccination.", [["infections", "DISEASE", 122, 132], ["herd", "ORGANISM_SUBDIVISION", 75, 79], ["routine vaccination of susceptible animals", "TREATMENT", 18, 60], ["''herd immunity", "TREATMENT", 73, 88], ["endemic", "PROBLEM", 99, 106], ["established infections", "PROBLEM", 110, 132], ["strategic vaccination", "TREATMENT", 149, 170], ["emergency vaccination", "TREATMENT", 181, 202], ["ring vaccination", "TREATMENT", 204, 220], ["barrier vaccination", "TREATMENT", 226, 245], ["dampening-down vaccination", "TREATMENT", 270, 296], ["infections", "OBSERVATION", 122, 132]]], ["The primary type of vaccination used in companion animals is routine vaccination, because disease prevention in an individual animal is the objective.", [["vaccination", "TREATMENT", 20, 31], ["routine vaccination", "TREATMENT", 61, 80], ["disease prevention", "TREATMENT", 90, 108]]], ["Forms of strategic vaccination are used in areas that are trying to control infectious diseases in populations, such as in kennels or catteries, however [8] .", [["infectious diseases", "DISEASE", 76, 95], ["strategic vaccination", "TREATMENT", 9, 30], ["infectious diseases in populations", "PROBLEM", 76, 110]]], ["A further division in vaccines has been the labeling of vaccines based on their clinical importance [4, 7] .", [["A further division in vaccines", "TREATMENT", 0, 30], ["the labeling of vaccines", "TREATMENT", 40, 64]]], ["Essential, or core, vaccines are those vaccines that are recommended to be administered routinely to dogs and cats to protect them against endemic diseases that have high morbidity or mortality rates.", [["dogs", "ORGANISM", 101, 105], ["cats", "ORGANISM", 110, 114], ["dogs", "SPECIES", 101, 105], ["cats", "SPECIES", 110, 114], ["vaccines", "TREATMENT", 20, 28], ["those vaccines", "TREATMENT", 33, 47], ["endemic diseases", "PROBLEM", 139, 155], ["high morbidity", "PROBLEM", 166, 180], ["mortality rates", "PROBLEM", 184, 199]]], ["Optional, or noncore, vaccines are those vaccines that are not recommended to be used routinely because the disease risk is considered to be lower.", [["vaccines", "TREATMENT", 22, 30], ["those vaccines", "TREATMENT", 35, 49], ["the disease risk", "PROBLEM", 104, 120], ["disease", "OBSERVATION", 108, 115]]], ["It should be emphasized that noncore does not mean nonessential, however, because certain animal populations are at high risk for disease, such as canine coronavirus (CCV) in breeding kennels [12] , and canine leptospirosis in outdoor hunting dogs [4] .PRINCIPLES AND TYPES OF VACCINATIONVaccines are differentiated into two categories based on whether the immunogen is live or inactivated (killed) [7] .", [["canine coronavirus", "DISEASE", 147, 165], ["canine leptospirosis", "DISEASE", 203, 223], ["canine coronavirus", "ORGANISM", 147, 165], ["canine", "ORGANISM", 203, 209], ["canine coronavirus", "SPECIES", 147, 165], ["canine", "SPECIES", 203, 209], ["dogs", "SPECIES", 243, 247], ["canine coronavirus", "SPECIES", 147, 165], ["CCV", "SPECIES", 167, 170], ["canine", "SPECIES", 203, 209], ["disease", "PROBLEM", 130, 137], ["canine coronavirus", "PROBLEM", 147, 165], ["VACCINATIONVaccines", "TREATMENT", 277, 296], ["the immunogen", "TREATMENT", 353, 366]]], ["Live vaccines have usually been attenuated by some process to render them avirulent when introduced into an immunocompetent animal.", [["Live vaccines", "TREATMENT", 0, 13]]], ["The process can include passage of the virus in cell cultures, temperature selection of mutants, and recombinant technology using vectors [4, 7] .", [["cell cultures", "ANATOMY", 48, 61], ["cell cultures", "CELL", 48, 61], ["the virus", "PROBLEM", 35, 44], ["cell cultures", "TEST", 48, 61]]], ["Killed vaccines have been inactivated by physical or chemical methods that destroy the infectivity but retain the immunogenicity necessary to induce a protective immune response.", [["Killed vaccines", "TREATMENT", 0, 15], ["the infectivity", "PROBLEM", 83, 98]]], ["The advantages and disadvantages of live and inactivated vaccines are listed in Table 1 .VACCINE REGULATIONExtensive quality control measures have been established over the years to ensure that the vaccines used in human beings and animals are pure, safe, and efficacious [13] [14] [15] [16] [17] .", [["human", "ORGANISM", 215, 220], ["[13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 272, 296], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["live and inactivated vaccines", "TREATMENT", 36, 65], ["VACCINE REGULATIONExtensive quality control measures", "TREATMENT", 89, 141], ["the vaccines", "TREATMENT", 194, 206]]], ["Standards for animal vaccines are well outlined, and quality control is highly regulated by the US Department of Agriculture (USDA)-Animal and Plant Health Inspection Service (APHIS) [16] .", [["animal vaccines", "TREATMENT", 14, 29]]], ["Despite this scrutiny, there have been occurrences in which adventitious microorganisms, primarily viruses, have been known to enter vaccine production and become part of the vaccine on release (Fig. 1 ).", [["adventitious microorganisms", "PROBLEM", 60, 87], ["primarily viruses", "PROBLEM", 89, 106], ["adventitious", "OBSERVATION_MODIFIER", 60, 72], ["microorganisms", "OBSERVATION", 73, 87], ["viruses", "OBSERVATION", 99, 106]]], ["The ways in which viruses enter into the vaccine production cycle have been reviewed extensively [7, [18] [19] [20] [21] [22] [23] .", [["[18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 101, 130]]], ["They include (1) contamination of the original viral seed stock used to prepare the vaccine, (2) contamination of the cell cultures used in production to amplify the known virus in the vaccine pool, and (3) contamination of the reagents used to propagate the cells being used to amplify the known virus for vaccine production.", [["cell cultures", "ANATOMY", 118, 131], ["cells", "ANATOMY", 259, 264], ["cell cultures", "CELL", 118, 131], ["cells", "CELL", 259, 264], ["cell cultures", "CELL_LINE", 118, 131], ["the original viral seed stock", "TREATMENT", 34, 63], ["the vaccine", "TREATMENT", 80, 91], ["the cell cultures", "TEST", 114, 131], ["the known virus", "PROBLEM", 162, 177], ["the reagents", "TREATMENT", 224, 236], ["the cells", "TREATMENT", 255, 264], ["the known virus", "PROBLEM", 287, 302], ["vaccine production", "TREATMENT", 307, 325]]], ["These are important points to consider and are discussed in further detail.VACCINE REGULATIONContamination of the original viral seed stock would be when a known virus is being selected for eventual use in a vaccine.", [["VACCINE REGULATIONContamination", "TREATMENT", 75, 106], ["the original viral seed stock", "TREATMENT", 110, 139], ["a known virus", "PROBLEM", 154, 167], ["a vaccine", "TREATMENT", 206, 215], ["viral seed stock", "OBSERVATION", 123, 139]]], ["An example would be using an isolate of feline calicivirus that was derived from a cat with severe clinical symptoms.", [["feline calicivirus", "DISEASE", 40, 58], ["feline calicivirus", "ORGANISM", 40, 58], ["cat", "ORGANISM", 83, 86], ["feline calicivirus", "SPECIES", 40, 58], ["cat", "SPECIES", 83, 86], ["feline calicivirus", "SPECIES", 40, 58], ["feline calicivirus", "PROBLEM", 40, 58], ["severe clinical symptoms", "PROBLEM", 92, 116]]], ["In the process of isolation, a passenger virus, such as feline panleukopenia, would also be isolated but not detected because of low virus titer or absence of cytopathologic findings.", [["feline panleukopenia", "DISEASE", 56, 76], ["feline", "ORGANISM", 56, 62], ["feline", "SPECIES", 56, 62], ["feline panleukopenia", "SPECIES", 56, 76], ["isolation", "TREATMENT", 18, 27], ["a passenger virus", "PROBLEM", 29, 46], ["feline panleukopenia", "PROBLEM", 56, 76], ["low virus titer", "PROBLEM", 129, 144], ["cytopathologic findings", "PROBLEM", 159, 182], ["isolation", "OBSERVATION", 18, 27]]], ["Usually, the virus being selected would be taken through steps to exclude passenger viruses by plaque purification or limited dilution steps.", [["plaque", "ANATOMY", 95, 101], ["the virus", "PROBLEM", 9, 18], ["passenger viruses", "PROBLEM", 74, 91], ["plaque purification", "TREATMENT", 95, 114]]], ["Regulations required for vaccine production mandate seed stock purity, and vaccines must pass rigorous USDA standards referred to a 9 Code of Federal Regulations (9CFR) [16, 17, 23, 24] .VACCINE REGULATIONExamples of the latter two sources of contamination are more common and have been the most documented [21, 22, 24] .", [["vaccine production", "TREATMENT", 25, 43], ["vaccines", "TREATMENT", 75, 83], ["VACCINE", "TREATMENT", 187, 194], ["contamination", "PROBLEM", 243, 256], ["contamination", "OBSERVATION", 243, 256]]], ["Contamination of cell cultures directly by latent noncytopathogenic viruses or indirectly by reagents used to propagate the cells in the laboratory involves several viruses ( Table 2 ).", [["cell cultures", "ANATOMY", 17, 30], ["cells", "ANATOMY", 124, 129], ["cell cultures", "CELL", 17, 30], ["cells", "CELL", 124, 129], ["cell cultures", "CELL_LINE", 17, 30], ["cell cultures", "TEST", 17, 30], ["latent noncytopathogenic viruses", "PROBLEM", 43, 75], ["cell cultures", "OBSERVATION", 17, 30], ["latent", "OBSERVATION_MODIFIER", 43, 49], ["noncytopathogenic viruses", "OBSERVATION", 50, 75]]], ["Most common have been bovine viral diarrhea virus (BVDV), bovine and porcine parvoviruses, and bovine herpesvirus (BHV) type 4 [21, 24] .", [["bovine viral diarrhea virus (BVDV), bovine and porcine parvoviruses", "DISEASE", 22, 89], ["bovine herpesvirus (BHV) type", "DISEASE", 95, 124], ["bovine viral diarrhea virus", "ORGANISM", 22, 49], ["BVDV", "ORGANISM", 51, 55], ["bovine", "ORGANISM", 58, 64], ["porcine parvoviruses", "ORGANISM", 69, 89], ["bovine herpesvirus (BHV) type 4", "ORGANISM", 95, 126], ["bovine", "SPECIES", 22, 28], ["viral diarrhea virus", "SPECIES", 29, 49], ["BVDV", "SPECIES", 51, 55], ["bovine", "SPECIES", 58, 64], ["porcine", "SPECIES", 69, 76], ["bovine", "SPECIES", 95, 101], ["bovine viral diarrhea virus", "SPECIES", 22, 49], ["BVDV", "SPECIES", 51, 55], ["bovine", "SPECIES", 58, 64], ["porcine parvoviruses", "SPECIES", 69, 89], ["bovine herpesvirus", "SPECIES", 95, 113], ["BHV", "SPECIES", 115, 118], ["bovine viral diarrhea virus", "PROBLEM", 22, 49], ["BVDV", "PROBLEM", 51, 55], ["bovine and porcine parvoviruses", "TREATMENT", 58, 89], ["bovine herpesvirus", "PROBLEM", 95, 113], ["bovine", "OBSERVATION_MODIFIER", 22, 28], ["viral diarrhea virus", "OBSERVATION", 29, 49], ["porcine parvoviruses", "OBSERVATION", 69, 89], ["bovine herpesvirus", "OBSERVATION", 95, 113]]], ["These viruses are frequently present in fetal bovine serum, calf serum, bovine serum derivatives, and trypsin [21] .", [["fetal bovine serum", "ANATOMY", 40, 58], ["calf serum", "ANATOMY", 60, 70], ["serum", "ANATOMY", 79, 84], ["fetal", "ORGANISM_SUBSTANCE", 40, 45], ["bovine", "ORGANISM", 46, 52], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["calf serum", "ORGANISM_SUBSTANCE", 60, 70], ["bovine", "ORGANISM", 72, 78], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["trypsin", "GENE_OR_GENE_PRODUCT", 102, 109], ["trypsin", "PROTEIN", 102, 109], ["bovine", "SPECIES", 46, 52], ["calf", "SPECIES", 60, 64], ["bovine", "SPECIES", 72, 78], ["bovine", "SPECIES", 46, 52], ["These viruses", "PROBLEM", 0, 13], ["fetal bovine serum", "TEST", 40, 58], ["calf serum", "TEST", 60, 70], ["bovine serum derivatives", "TEST", 72, 96], ["trypsin", "TEST", 102, 109], ["viruses", "OBSERVATION", 6, 13], ["calf", "ANATOMY", 60, 64]]], ["Although these viruses may have contaminated early serials of companion animal vaccines, there were no apparent serious clinical effects documented, because these viruses did not replicate in dogs or cats or, if replication did occur, there were no symptoms noted at safety testing.", [["dogs", "ORGANISM", 192, 196], ["cats", "ORGANISM", 200, 204], ["dogs", "SPECIES", 192, 196], ["cats", "SPECIES", 200, 204], ["these viruses", "PROBLEM", 9, 22], ["animal vaccines", "TREATMENT", 72, 87], ["these viruses", "PROBLEM", 157, 170], ["symptoms", "PROBLEM", 249, 257], ["safety testing", "TEST", 267, 281], ["viruses", "OBSERVATION", 15, 22], ["no apparent", "UNCERTAINTY", 100, 111]]], ["An exception to this may have been the association of BHV-4 with urinary tract disease in cats [25, 26] .NOVEL CONTAMINATE WITH SERIOUS CONSEQUENCESIn 1992, a veterinarian noticed that pregnant dogs were aborting and, in some cases, the dam died as well.", [["urinary tract", "ANATOMY", 65, 78], ["urinary tract disease", "DISEASE", 65, 86], ["BHV-4", "ORGANISM", 54, 59], ["urinary tract", "ORGANISM_SUBDIVISION", 65, 78], ["cats", "ORGANISM", 90, 94], ["dogs", "ORGANISM", 194, 198], ["cats", "SPECIES", 90, 94], ["dogs", "SPECIES", 194, 198], ["BHV", "TEST", 54, 57], ["urinary tract disease in cats", "PROBLEM", 65, 94], ["urinary tract", "ANATOMY", 65, 78]]], ["A common feature was a history of vaccination 3 to 4 weeks before whelping with a modified-live virus (MLV) multicomponent vaccine [27] .", [["MLV", "ORGANISM", 103, 106], ["MLV", "SPECIES", 103, 106], ["vaccination", "TREATMENT", 34, 45], ["a modified-live virus (MLV) multicomponent vaccine", "TREATMENT", 80, 130]]], ["Initially, it was speculated that there was a component of the vaccine, such as canine parvovirus (CPV) type 2 or canine distemper virus (CDV), that was not properly attenuated and that because of the immune-compromised state of the dam, the virus was causing disease.", [["canine parvovirus", "DISEASE", 80, 97], ["canine parvovirus (CPV) type 2", "ORGANISM", 80, 110], ["canine distemper virus", "ORGANISM", 114, 136], ["CDV", "ORGANISM", 138, 141], ["dam", "ORGANISM_SUBDIVISION", 233, 236], ["canine parvovirus", "SPECIES", 80, 97], ["canine distemper virus", "SPECIES", 114, 136], ["canine parvovirus", "SPECIES", 80, 97], ["CPV", "SPECIES", 99, 102], ["canine distemper virus", "SPECIES", 114, 136], ["CDV", "SPECIES", 138, 141], ["the vaccine", "TREATMENT", 59, 70], ["canine parvovirus (CPV) type 2", "PROBLEM", 80, 110], ["canine distemper virus", "PROBLEM", 114, 136], ["the virus", "PROBLEM", 238, 247], ["disease", "PROBLEM", 260, 267], ["distemper virus", "OBSERVATION", 121, 136]]], ["Efforts to isolate CPV-2 and CDV were negative.", [["CPV-2", "ORGANISM", 19, 24], ["CDV", "ORGANISM", 29, 32], ["CPV-2", "SPECIES", 19, 24], ["CDV", "SPECIES", 29, 32], ["isolate CPV", "TEST", 11, 22], ["CDV", "TEST", 29, 32], ["negative", "OBSERVATION", 38, 46]]], ["A virus with properties of an orbivirus was isolated in cell culture from tissue homogenates derived from the diseased pups and dams, however [27, 28] .", [["orbivirus", "ANATOMY", 30, 39], ["cell culture", "ANATOMY", 56, 68], ["tissue homogenates", "ANATOMY", 74, 92], ["pups", "ANATOMY", 119, 123], ["orbivirus", "CANCER", 30, 39], ["cell culture", "CELL", 56, 68], ["tissue homogenates", "TISSUE", 74, 92], ["pups", "ORGANISM_SUBDIVISION", 119, 123], ["A virus", "PROBLEM", 0, 7], ["an orbivirus", "PROBLEM", 27, 39], ["cell culture", "TEST", 56, 68], ["tissue homogenates", "TEST", 74, 92], ["virus", "OBSERVATION", 2, 7], ["cell culture", "OBSERVATION", 56, 68], ["diseased", "OBSERVATION_MODIFIER", 110, 118], ["pups", "OBSERVATION_MODIFIER", 119, 123]]], ["The virus was eventually identified as bluetongue virus (BTV) type 11, a domestic strain of the virus common in the United States [28] .", [["bluetongue virus (BTV) type", "DISEASE", 39, 66], ["bluetongue virus (BTV) type 11", "ORGANISM", 39, 69], ["bluetongue virus", "SPECIES", 39, 55], ["bluetongue virus", "SPECIES", 39, 55], ["BTV", "SPECIES", 57, 60], ["The virus", "PROBLEM", 0, 9], ["bluetongue virus", "PROBLEM", 39, 55], ["virus", "OBSERVATION", 4, 9]]], ["The veterinary biologic manufacturer and the National Veterinary Services Laboratory (NVSL) in Ames, Iowa were informed of the isolation of a potential viral contaminate.", [["a potential viral contaminate", "PROBLEM", 140, 169], ["viral contaminate", "OBSERVATION", 152, 169]]], ["In subsequent testing by the NVSL, seed stock virus and repository samples were also found to be contaminated with BTV-11 [29] .", [["samples", "ANATOMY", 67, 74], ["BTV-11", "SPECIES", 115, 121], ["subsequent testing", "TEST", 3, 21], ["the NVSL", "TEST", 25, 33], ["seed stock virus", "PROBLEM", 35, 51], ["repository samples", "TEST", 56, 74], ["BTV", "TEST", 115, 118], ["stock virus", "OBSERVATION", 40, 51]]], ["The manufacturer voluntarily recalled all vials of the vaccine with serial numbers the same as those associated with the cases.", [["the vaccine", "TREATMENT", 51, 62], ["serial numbers", "TEST", 68, 82]]], ["BTV had not previously been associated with disease in dogs but has been well documented as a pathogen of small and large ruminants [30] .", [["BTV", "ORGANISM", 0, 3], ["dogs", "ORGANISM", 55, 59], ["dogs", "SPECIES", 55, 59], ["BTV", "SPECIES", 0, 3], ["BTV", "PROBLEM", 0, 3], ["disease in dogs", "PROBLEM", 44, 59], ["a pathogen of small and large ruminants", "PROBLEM", 92, 131], ["not previously been associated with", "UNCERTAINTY", 8, 43], ["disease", "OBSERVATION", 44, 51], ["small", "OBSERVATION_MODIFIER", 106, 111], ["large", "OBSERVATION_MODIFIER", 116, 121], ["ruminants", "OBSERVATION_MODIFIER", 122, 131]]], ["The virus is now known to be present in serum products derived from these ruminants, such as fetal bovine serum.", [["serum", "ANATOMY", 40, 45], ["fetal bovine serum", "ANATOMY", 93, 111], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["bovine", "ORGANISM", 99, 105], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["serum products", "PROTEIN", 40, 54], ["bovine", "SPECIES", 99, 105], ["bovine", "SPECIES", 99, 105], ["The virus", "PROBLEM", 0, 9], ["serum products", "TREATMENT", 40, 54], ["fetal bovine serum", "TEST", 93, 111], ["virus", "OBSERVATION", 4, 9]]], ["Subsequent studies have demonstrated that canine cells are capable of being infected with various serotypes of BTV, including BTV-11, without the cell cultures showing any cytopathologic change [31] .", [["cells", "ANATOMY", 49, 54], ["cell cultures", "ANATOMY", 146, 159], ["canine cells", "CELL", 42, 54], ["BTV", "ORGANISM", 111, 114], ["BTV-11", "ORGANISM", 126, 132], ["cell cultures", "CELL", 146, 159], ["canine cells", "CELL_TYPE", 42, 54], ["canine", "SPECIES", 42, 48], ["canine", "SPECIES", 42, 48], ["BTV", "SPECIES", 111, 114], ["BTV-11", "SPECIES", 126, 132], ["Subsequent studies", "TEST", 0, 18], ["canine cells", "PROBLEM", 42, 54], ["BTV", "PROBLEM", 111, 114], ["BTV", "TEST", 126, 129], ["the cell cultures", "TEST", 142, 159], ["any cytopathologic change", "PROBLEM", 168, 193], ["canine cells", "OBSERVATION", 42, 54]]], ["The aforementioned reports emphasized the importance of adding BTV detection methods to cells and virus seed stocks being used to produce companion animal vaccines.ROLE OF VACCINES IN EMERGING VIRUSESThis is a controversial topic and has been debated in the literature over the past several decades [1, [32] [33] [34] [35] [36] .", [["cells", "ANATOMY", 88, 93], ["BTV", "ORGANISM", 63, 66], ["cells", "CELL", 88, 93], ["[32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 303, 327], ["BTV", "SPECIES", 63, 66], ["BTV detection methods", "TREATMENT", 63, 84], ["virus seed stocks", "TREATMENT", 98, 115], ["animal vaccines", "TREATMENT", 148, 163]]], ["There are several ways in which the vaccines may contribute to the emergence or re-emergence of viruses in the population.", [["the vaccines", "TREATMENT", 32, 44], ["viruses", "PROBLEM", 96, 103]]], ["The first is by contaminated vaccines that are used routinely in a large percentage of the animal population.", [["contaminated vaccines", "TREATMENT", 16, 37], ["large", "OBSERVATION_MODIFIER", 67, 72], ["percentage", "OBSERVATION_MODIFIER", 73, 83]]], ["Vaccines that harbor adventitious agents for one species may be pathogenic for another species.", [["Vaccines", "TREATMENT", 0, 8], ["harbor adventitious agents", "TREATMENT", 14, 40], ["one species", "PROBLEM", 45, 56], ["another species", "PROBLEM", 79, 94]]], ["Not only may the contaminated vaccine be pathogenic in the vaccinated animal, but it may be spread to other susceptible animals horizontally with the use of aerosols, feces, or saliva, for example (Fig. 2) .", [["feces", "ANATOMY", 167, 172], ["feces", "ORGANISM_SUBDIVISION", 167, 172], ["saliva", "ORGANISM_SUBSTANCE", 177, 183], ["the contaminated vaccine", "TREATMENT", 13, 37], ["pathogenic", "PROBLEM", 41, 51], ["aerosols", "TREATMENT", 157, 165]]], ["Documentation of this form of cause and effect with a vaccine and emerging disease would need a thorough case history and laboratory data.", [["a vaccine", "TREATMENT", 52, 61], ["emerging disease", "PROBLEM", 66, 82], ["laboratory data", "TEST", 122, 137]]], ["The second way in which vaccines may contribute to the emergence of new viruses is by immune selection of escape mutants (Fig. 3) [35, 36] .", [["vaccines", "TREATMENT", 24, 32], ["new viruses", "PROBLEM", 68, 79], ["escape mutants", "PROBLEM", 106, 120], ["new", "OBSERVATION_MODIFIER", 68, 71], ["viruses", "OBSERVATION", 72, 79]]], ["Viruses are continually undergoing natural selection because they are obligate intracellular pathogens [37, 38] .", [["intracellular", "ANATOMY", 79, 92], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 92], ["Viruses", "PROBLEM", 0, 7], ["natural selection", "TREATMENT", 35, 52], ["obligate intracellular pathogens", "PROBLEM", 70, 102]]], ["The immune response is evolving with the emergence of new viruses [39, 40] .", [["new viruses", "PROBLEM", 54, 65], ["immune response", "OBSERVATION", 4, 19], ["new", "OBSERVATION_MODIFIER", 54, 57], ["viruses", "OBSERVATION", 58, 65]]], ["In some cases, it has been speculated that the use of vaccines causes an enhanced immune selection of viruses that evade the immune response, resulting in sustained infection in the population and disease in a certain percentage of the animals [35, 36] .", [["infection", "DISEASE", 165, 174], ["vaccines", "TREATMENT", 54, 62], ["an enhanced immune selection of viruses", "PROBLEM", 70, 109], ["sustained infection in the population", "PROBLEM", 155, 192], ["disease", "PROBLEM", 197, 204], ["sustained", "OBSERVATION_MODIFIER", 155, 164], ["infection", "OBSERVATION", 165, 174]]], ["The immune response is a genetically adaptable system to microbial infections [39] .", [["infections", "DISEASE", 67, 77], ["microbial infections", "PROBLEM", 57, 77]]], ["The appearance of new viral infections is most likely manifested first in immunocompromised animals, such as pregnant animals, neonates, and animals that are genetically immune deficient [41] .ENHANCED VIGILANCE: ROLE OF THE CLINICIANThe emergence or re-emergence of a novel virus occurs in a clinical setting in which (1) resembling a virus that the animal should have been protected against by the vaccine, (2) a virus occurs in immunocompromised animals, or (3) a virus is rapidly introduced into a totally immunologically native population of dogs or cats [42] .", [["viral infections", "DISEASE", 22, 38], ["neonates", "ORGANISM", 127, 135], ["dogs", "ORGANISM", 547, 551], ["cats", "ORGANISM", 555, 559], ["dogs", "SPECIES", 547, 551], ["cats", "SPECIES", 555, 559], ["new viral infections", "PROBLEM", 18, 38], ["immunocompromised animals", "PROBLEM", 74, 99], ["pregnant animals", "PROBLEM", 109, 125], ["neonates", "PROBLEM", 127, 135], ["a novel virus", "PROBLEM", 267, 280], ["a virus", "PROBLEM", 334, 341], ["a virus", "PROBLEM", 413, 420], ["immunocompromised animals", "PROBLEM", 431, 456], ["a virus", "PROBLEM", 465, 472], ["new", "OBSERVATION_MODIFIER", 18, 21], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["infections", "OBSERVATION", 28, 38], ["most likely", "UNCERTAINTY", 42, 53], ["immunocompromised", "OBSERVATION", 74, 91]]], ["The diseased animal should be quarantined, and a full diagnostic workup would proceed through a list of differentials [3, [42] [43] [44] .", [["[42] [43", "SIMPLE_CHEMICAL", 122, 130], ["a full diagnostic workup", "TEST", 47, 71], ["diseased", "OBSERVATION", 4, 12]]], ["This allows biologic manufacturers and the USDA to conduct postlicensure surveillance and to monitor the safety and efficiency of vaccines [9, 13, 16] .ENHANCED VIGILANCE: LABORATORY LEVELTesting for emerging or re-emerging viruses requires a familiarity with the common infectious agents affecting a particular species and maintaining an open mind for unusual observations, such as occurred in the BTV case mentioned previously [27] .", [["postlicensure surveillance", "TEST", 59, 85], ["vaccines", "TREATMENT", 130, 138], ["re-emerging viruses", "PROBLEM", 212, 231], ["a particular species", "PROBLEM", 299, 319]]], ["The testing for novel viruses would have to be conducted on least at two levels.", [["The testing", "TEST", 0, 11], ["novel viruses", "PROBLEM", 16, 29]]], ["This would include testing that is done on biologics to ensure their purity before inoculation into animals [20, 24] and testing that would be done at the diagnostic laboratory on diseased animals [33, [46] [47] [48] [49] .", [["testing", "TEST", 19, 26], ["biologics", "TREATMENT", 43, 52], ["testing", "TEST", 121, 128]]], ["Virus-specific detection may involve (1) viral culture in susceptible noncontaminated cell lines, (2) viral antigen detection using immunofluorescence reagents, (3) viral antigen detection using ELISA; or (4) viral nucleic acid detection using polymerase chain reaction (PCR) [19, 22, 50, 51] .DANGER OF CONTAMINATED VACCINESThe danger of a contaminated vaccine may include an immediate effect, such as the clinical effects that were reported after use of the multicomponent canine MLV that was contaminated with BTV [28] .", [["cell lines", "ANATOMY", 86, 96], ["nucleic acid", "CHEMICAL", 215, 227], ["Virus", "ORGANISM", 0, 5], ["noncontaminated cell lines", "CELL", 70, 96], ["canine", "ORGANISM", 475, 481], ["MLV", "ORGANISM", 482, 485], ["susceptible noncontaminated cell lines", "CELL_LINE", 58, 96], ["viral antigen", "PROTEIN", 102, 115], ["viral antigen", "PROTEIN", 165, 178], ["canine", "SPECIES", 475, 481], ["canine", "SPECIES", 475, 481], ["BTV", "SPECIES", 513, 516], ["Virus", "PROBLEM", 0, 5], ["specific detection", "TEST", 6, 24], ["viral culture", "TEST", 41, 54], ["susceptible noncontaminated cell lines", "PROBLEM", 58, 96], ["viral antigen detection", "TEST", 102, 125], ["immunofluorescence reagents", "TEST", 132, 159], ["viral antigen detection", "TEST", 165, 188], ["ELISA", "TEST", 195, 200], ["viral nucleic acid detection", "TEST", 209, 237], ["polymerase chain reaction", "PROBLEM", 244, 269], ["PCR", "TEST", 271, 274], ["a contaminated vaccine", "TREATMENT", 339, 361], ["the multicomponent canine MLV", "TREATMENT", 456, 485], ["cell lines", "OBSERVATION", 86, 96]]], ["The disease symptoms were confined to the inoculated dogs, and there was no evidence that further spread occurred to other potentially susceptible dogs in the vicinity.", [["dogs", "ORGANISM", 53, 57], ["dogs", "ORGANISM", 147, 151], ["dogs", "SPECIES", 53, 57], ["dogs", "SPECIES", 147, 151], ["The disease symptoms", "PROBLEM", 0, 20], ["further spread", "PROBLEM", 90, 104], ["disease", "OBSERVATION", 4, 11], ["no evidence", "UNCERTAINTY", 73, 84]]], ["In this regard, the scenario would seem similar to the spread of some viruses to a dead-end or accidental host.", [["viruses", "OBSERVATION", 70, 77]]], ["This has been well documented for insect-borne viruses, such as West Nile virus, in isolated canine cases [48] .", [["insect-borne viruses", "DISEASE", 34, 54], ["insect-borne viruses", "ORGANISM", 34, 54], ["West Nile virus", "ORGANISM", 64, 79], ["canine", "ORGANISM", 93, 99], ["West Nile virus", "SPECIES", 64, 79], ["canine", "SPECIES", 93, 99], ["West Nile virus", "SPECIES", 64, 79], ["canine", "SPECIES", 93, 99], ["insect-borne viruses", "PROBLEM", 34, 54]]], ["The long-term effects of a contaminated vaccine would be more difficult to document, and would require the availability of diagnostic assays specific for the adventitious virus.", [["adventitious virus", "ORGANISM", 158, 176], ["a contaminated vaccine", "TREATMENT", 25, 47], ["diagnostic assays", "TEST", 123, 140], ["the adventitious virus", "PROBLEM", 154, 176], ["long-term", "OBSERVATION_MODIFIER", 4, 13], ["adventitious virus", "OBSERVATION", 158, 176]]], ["Because there is a certain degree of natural cross-species infection (''spill over'') that occurs in the companion animal population, determining the origin of such an infection would require that the referring veterinarian work closely with the veterinary diagnostic laboratory with case history and sample submission (antemortem and postmortem) [42, 52, 53] .", [["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 168, 177], ["natural cross-species infection", "PROBLEM", 37, 68], ["an infection", "PROBLEM", 165, 177], ["sample submission", "TEST", 301, 318], ["certain degree", "OBSERVATION_MODIFIER", 19, 33], ["species", "OBSERVATION_MODIFIER", 51, 58], ["infection", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 168, 177]]], ["Once a virus were to spill over to another species, such as a cat to dog with feline calicivirus [46, 54, 55] , the long-term danger is that the virus would establish the dog as a host, with subsequent virus replication, disease, and further shedding to susceptible dogs.", [["feline calicivirus", "DISEASE", 78, 96], ["cat", "ORGANISM", 62, 65], ["dog", "ORGANISM", 69, 72], ["feline calicivirus", "ORGANISM", 78, 96], ["dog", "ORGANISM", 171, 174], ["dogs", "ORGANISM", 266, 270], ["cat", "SPECIES", 62, 65], ["dog", "SPECIES", 69, 72], ["feline calicivirus", "SPECIES", 78, 96], ["dog", "SPECIES", 171, 174], ["dogs", "SPECIES", 266, 270], ["feline calicivirus", "SPECIES", 78, 96], ["dog", "SPECIES", 171, 174], ["a virus", "PROBLEM", 5, 12], ["feline calicivirus", "PROBLEM", 78, 96], ["the virus", "PROBLEM", 141, 150], ["subsequent virus replication", "TREATMENT", 191, 219], ["disease", "PROBLEM", 221, 228]]], ["This is postulated to have happened when feline panleukopenia virus crossed species in the late 1970s, resulting in CPV-2 [1, 5] .", [["feline panleukopenia virus", "ORGANISM", 41, 67], ["feline panleukopenia virus", "SPECIES", 41, 67], ["CPV", "SPECIES", 116, 119], ["feline panleukopenia virus crossed species", "PROBLEM", 41, 83], ["CPV", "TEST", 116, 119]]], ["This virus continues to circulate in the canine population, continues to have minor antigenic drifts (CPV-2a/CPV-2b/CPV-2c) [56] , and has acquired a dual host range between dogs and cats [33, 57] .SUMMARYThe use of biologics in veterinary medicine has been of tremendous value in safeguarding our animal populations from debilitating and oftentimes fatal disease.", [["canine", "ORGANISM", 41, 47], ["CPV-2a", "ORGANISM", 102, 108], ["CPV-2b", "ORGANISM", 109, 115], ["CPV-2c", "ORGANISM", 116, 122], ["dogs", "ORGANISM", 174, 178], ["cats", "ORGANISM", 183, 187], ["canine", "SPECIES", 41, 47], ["dogs", "SPECIES", 174, 178], ["cats", "SPECIES", 183, 187], ["canine", "SPECIES", 41, 47], ["CPV-2a/CPV-2b/CPV-2c", "SPECIES", 102, 122], ["This virus", "PROBLEM", 0, 10], ["minor antigenic drifts", "PROBLEM", 78, 100], ["CPV", "TEST", 102, 105], ["CPV", "TEST", 109, 112], ["biologics in veterinary medicine", "TREATMENT", 216, 248], ["tremendous value", "PROBLEM", 261, 277], ["debilitating and oftentimes fatal disease", "PROBLEM", 322, 363], ["minor", "OBSERVATION_MODIFIER", 78, 83], ["antigenic drifts", "OBSERVATION", 84, 100], ["tremendous", "OBSERVATION_MODIFIER", 261, 271], ["debilitating", "OBSERVATION_MODIFIER", 322, 334]]], ["In parallel to the use of these biologics, there has been the continued evolution of new standards to maintain safety of the vaccines.", [["these biologics", "TREATMENT", 26, 41], ["new standards", "TREATMENT", 85, 98], ["the vaccines", "TREATMENT", 121, 133]]], ["This article reviewed the principles of vaccination and the extensive quality control efforts that are incorporated into preparing the vaccines.", [["vaccination", "TREATMENT", 40, 51], ["the vaccines", "TREATMENT", 131, 143]]], ["Examples of adverse events that have occurred in the past and how enhanced vigilance at the level of the veterinarian and the veterinary diagnostic laboratory help to curtail these events were discussed.", [["adverse events", "PROBLEM", 12, 26]]], ["Emphasis on understanding the ecology of viral infections in dogs and cats was introduced, together with the concepts of the potential role of vaccines in interspecies spread of viruses.", [["viral infections", "DISEASE", 41, 57], ["dogs", "ORGANISM", 61, 65], ["cats", "ORGANISM", 70, 74], ["dogs", "SPECIES", 61, 65], ["cats", "SPECIES", 70, 74], ["viral infections in dogs", "PROBLEM", 41, 65], ["vaccines", "TREATMENT", 143, 151], ["viruses", "PROBLEM", 178, 185], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infections", "OBSERVATION", 47, 57], ["viruses", "OBSERVATION", 178, 185]]]], "5f139e7f8d32031001059ea4a8fce4881a1f725b": [["Disclosures: FGPW reports serving as a site principal investigator for a multicenter trial supported by Medtronic and receiving compensation from Medtronic for participating on an advisory board.", [["a multicenter trial", "TREATMENT", 71, 90], ["Medtronic", "TREATMENT", 146, 155]]], ["HAD reports a financial relation with Silk Road Medical.", [["HAD", "DISEASE", 0, 3]]], ["MWS reports receiving consulting fees from Medtronic Inc. EM reports receiving consulting fees from Abiomed, Medtronic, Boston Scientific.", [["MWS", "DISEASE", 0, 3]]], ["He has an equity interest in Abiomed.", [["equity", "OBSERVATION_MODIFIER", 10, 16], ["interest", "OBSERVATION", 17, 25]]], ["He reports being the national PI for the Precision GRX study by Corindus and is a site PI for a multicenter trials supported by CSI Inc. and Abbot Vascular Inc. AEB served as site principal investigator for multi-center trials sponsored by Abbott, AstraZeneca, Sanofi-Aventis, CSL-Behring, for which her institution received compensation and received an honorarium from ClearView Healthcare Partners, LLC.", [["the Precision GRX study", "TEST", 37, 60], ["a multicenter trials", "TREATMENT", 94, 114], ["Vascular", "ANATOMY", 147, 155], ["LLC", "ANATOMY", 401, 404]]], ["AEB acknowldges support from an American Heart Association Mentored and Clinical Population Research Award 17MCPRP33630098 and National Institutes of Health, NHLBI grant 1K23HL146982-01A1.", [["1K23HL146982-01A1", "CHEMICAL", 170, 187], ["Heart", "ANATOMY", 41, 46]]], ["The remaining authors have nothing to disclose. it has spread widely, with specific implications of the disease on practice in the catheterization laboratory.", [["the disease", "PROBLEM", 100, 111], ["spread", "OBSERVATION_MODIFIER", 55, 61], ["widely", "OBSERVATION_MODIFIER", 62, 68], ["disease", "OBSERVATION", 104, 111]]], ["These implications include how we might modify practice for standard cardiac patients, those who are suspected COVID-19 patients, and those patients with COVID-19 who have either unrelated cardiac conditions or cardiac manifestations of the disease.", [["cardiac", "ANATOMY", 69, 76], ["cardiac", "ANATOMY", 189, 196], ["cardiac", "ANATOMY", 211, 218], ["cardiac conditions", "DISEASE", 189, 207], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 140, 148], ["cardiac", "ORGAN", 211, 218], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 140, 148], ["unrelated cardiac conditions", "PROBLEM", 179, 207], ["cardiac manifestations of the disease", "PROBLEM", 211, 248], ["cardiac", "ANATOMY", 189, 196], ["conditions", "OBSERVATION", 197, 207], ["cardiac", "ANATOMY", 211, 218], ["disease", "OBSERVATION", 241, 248]]], ["The purpose of this joint statement from the ACC Interventional Council and SCAI is to discuss issues facing catheterization laboratory personnel during this time.", [["joint", "ANATOMY", 20, 25]]]], "5498dece524f13b34ef8c5422dbed6166dcaed34": [["The human problem behind telehealth during and beyond COVID-19Cancer survivors exit hospital doors grappling with a 'new normal'.", [["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9]]], ["Yet curiously, prior to this pandemic telehealth (videoconferencing) was used only minimally by the health system.The human problem behind telehealth during and beyond COVID-19In Australia, the COVID-19 pandemic triggered swift changes to hospital services.The human problem behind telehealth during and beyond COVID-19Telehealth rapidly became routine for outpatient appointments to minimise hospital traffic.The human problem behind telehealth during and beyond COVID-19We can report that in our clinical experiences at a metropolitan, hospital-based adolescent and young adult (AYA) service, this led to 100% of our AYA patients accessing outpatient clinical psychology services remotely, of which 75% occurred using online videoconferencing (an increase of 63% from the level of videoconferencing-based telehealth use prior to .", [["AYA", "DISEASE", 619, 622], ["human", "ORGANISM", 118, 123], ["human", "ORGANISM", 261, 266], ["human", "ORGANISM", 414, 419], ["patients", "ORGANISM", 623, 631], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 414, 419], ["patients", "SPECIES", 623, 631], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 414, 419], ["COVID", "TEST", 168, 173], ["the COVID", "TEST", 190, 199], ["hospital services", "TREATMENT", 239, 256]]], ["The clinical work remained the same; AYAs' presenting issues remained unchanged.", [["unchanged", "OBSERVATION_MODIFIER", 70, 79]]], ["But the mode of service delivery was rapidly re-designed (see Table 1 ).The human problem behind telehealth during and beyond COVID-19[ TABLE 1] What enabled this necessary practice change?", [["COVID-19", "CHEMICAL", 126, 134], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["COVID", "TEST", 126, 131]]], ["(Table 2 ) Certainly, the prior existence of a versatile, secure online platform, with an interface easy to navigate using a smartphone, tablet or computer.", [["a smartphone", "TREATMENT", 123, 135]]], ["Existing protocols for undertaking telehealth and billing processes were also available.", [["Existing protocols", "TREATMENT", 0, 18], ["undertaking telehealth", "TREATMENT", 23, 45]]], ["However, although telehealth was already at our fingertips, it took COVID-19The human problem behind telehealth during and beyond COVID-19for it to become a business-as-usual option.", [["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85]]], ["So, what can we learn by reflecting on the barriers to its use prior to March 2020?The human problem behind telehealth during and beyond COVID-19This article is protected by copyright.", [["human", "ORGANISM", 87, 92], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92]]], ["All rights reserved.The human problem behind telehealth during and beyond COVID-19The human problem behind telehealth during and beyond COVID-19The human problem behind telehealth during and beyond COVID-19The relative lack of telehealth uptake pre-COVID-19 appears to be a problem of implementation.", [["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 86, 91], ["human", "ORGANISM", 148, 153], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 148, 153], ["COVID", "TEST", 74, 79], ["COVID", "TEST", 136, 141], ["COVID", "TEST", 198, 203], ["telehealth uptake pre-COVID", "TEST", 227, 254]]], ["These are usability concerns: is the technology able to do what it promises, and will I as a user, be able to navigate it?The human problem behind telehealth during and beyond COVID-19Challenges in this area, of course, remain; in some countries technological disruptions are more likely to be the rule than the exception when delivering online interventions.", [["human", "ORGANISM", 126, 131], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["COVID", "TEST", 176, 181], ["online interventions", "TREATMENT", 338, 358], ["more likely", "UNCERTAINTY", 276, 287]]], ["1, 2 However, just as beeping medical devices can be ignored during consultations in an oncology ward, the technical glitches can be ignored during telehealth-delivered clinical interventions.", [["medical devices", "TREATMENT", 30, 45], ["clinical interventions", "TREATMENT", 169, 191]]], ["1 Rather, health-professionals' anxiety about these glitches -how to resolve them, or how competent they might appear in their management -may be the more intransigent barrier.", [["anxiety", "DISEASE", 32, 39], ["anxiety", "PROBLEM", 32, 39]]], ["3 In our combined clinical and research experience, a second set of ill-defined reservations poses a greater barrier to telehealth.", [["greater", "OBSERVATION_MODIFIER", 101, 108]]], ["These concerns speak to the technology's capacity to translate and transmit human-ness: the notion that telehealth may be unable to facilitate the human-to-human connection required, or that something of the therapeutic interaction's essence may be lost in the process.", [["human", "ORGANISM", 76, 81], ["human", "ORGANISM", 147, 152], ["human", "ORGANISM", 156, 161], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 147, 152]]], ["[2] [3] [4] The development of good rapport and an effective working relationship with a distressed adolescent can be challenging at the best of times.", [["good", "OBSERVATION_MODIFIER", 31, 35], ["rapport", "OBSERVATION", 36, 43]]], ["Within paediatric/AYA oncology therefore, it is likely that concerns around how the interaction will be felt and experienced -and how each party may be perceived -are doubly challenging.The human problem behind telehealth during and beyond COVID-19This article is protected by copyright.", [["human", "ORGANISM", 190, 195], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195]]], ["All rights reserved.The human problem behind telehealth during and beyond COVID-19We argue there is a wealth of evidence to counteract these fears.", [["human", "ORGANISM", 24, 29], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29]]], ["5 Between us, we have used telehealth to undertake thorough psychological assessments, and deliver individual therapy to highly distressed cancer patients as well as therapeutic groups to young cancer survivors with vastly different prognoses.", [["cancer", "ANATOMY", 139, 145], ["cancer", "ANATOMY", 194, 200], ["cancer", "DISEASE", 139, 145], ["cancer", "DISEASE", 194, 200], ["cancer", "CANCER", 139, 145], ["patients", "ORGANISM", 146, 154], ["cancer", "CANCER", 194, 200], ["patients", "SPECIES", 146, 154], ["thorough psychological assessments", "TEST", 51, 85], ["individual therapy", "TREATMENT", 99, 117], ["highly distressed cancer", "PROBLEM", 121, 145], ["cancer", "OBSERVATION", 194, 200]]], ["Across the virtual divide AYAs have disclosed highly sensitive information (e.g., about a peer with cancer recently dying); 1, 6, 7 and palliative care consultations with families whose child was actively dying of cancer have occured.", [["cancer", "ANATOMY", 100, 106], ["cancer", "ANATOMY", 214, 220], ["cancer", "DISEASE", 100, 106], ["cancer", "DISEASE", 214, 220], ["AYAs", "CANCER", 26, 30], ["cancer", "CANCER", 100, 106], ["child", "ORGANISM", 186, 191], ["cancer", "CANCER", 214, 220], ["cancer", "PROBLEM", 214, 220], ["cancer", "OBSERVATION", 214, 220]]], ["However, to build on telehealth's potential beyond COVID-19, rigorous research will be needed to capture and evaluate these critical user experience and relational components beyond satisfaction studies.The human problem behind telehealth during and beyond COVID-19Our recent experiences throughout COVID-19 continue to highlight while telehealth can reduce some interpersonal cues (without a full-body view, we may miss noticing a patient is swinging their leg in agitation) -different information can instead become available (an adolescent's reaction as their parent knocks on their bedroom door can be instructive).The human problem behind telehealth during and beyond COVID-19Moreover, an entirely new intimacy emerges when connecting with an individual using their smartphone whilst lying on their bed.", [["leg", "ANATOMY", 458, 461], ["agitation", "DISEASE", 465, 474], ["human", "ORGANISM", 207, 212], ["body", "ORGANISM_SUBDIVISION", 398, 402], ["patient", "ORGANISM", 432, 439], ["leg", "ORGANISM_SUBDIVISION", 458, 461], ["human", "ORGANISM", 623, 628], ["human", "SPECIES", 207, 212], ["patient", "SPECIES", 432, 439], ["human", "SPECIES", 623, 628], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 623, 628], ["COVID", "TEST", 51, 56], ["satisfaction studies", "TEST", 182, 202], ["COVID", "TEST", 257, 262], ["COVID", "TEST", 299, 304], ["agitation", "PROBLEM", 465, 474]]], ["In this case, their face can fill the entire screen, magnifying every micro-emotion that flashes across their face.", [["the entire screen", "TEST", 34, 51], ["flashes across their face", "PROBLEM", 89, 114]]], ["Therapeutically, how often would we otherwise spend so much of a session closely observing the changing emotional engagement on a patient's face when they are in their own bedroom?", [["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137]]], ["Such experiences counteract the criticism that human connection is not possible.The human problem behind telehealth during and beyond COVID-19Ultimately, comparing face-to-face with telehealth-delivered psychosocial services is an apples-and-oranges scenario; each modality shines and falters in unique ways; in a post-COVID-19 world, a pragmatic, complementary combination of the two will be beneficial.The human problem behind telehealth during and beyond COVID-19But patient-centred care does mean we need to pay attention to patients' and families' whole worlds when we engage with them.", [["human", "ORGANISM", 47, 52], ["human", "ORGANISM", 84, 89], ["human", "ORGANISM", 408, 413], ["patient", "ORGANISM", 470, 477], ["patients", "ORGANISM", 529, 537], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 408, 413], ["patient", "SPECIES", 470, 477], ["patients", "SPECIES", 529, 537], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 408, 413], ["COVID", "TEST", 134, 139], ["COVID", "TEST", 458, 463], ["not possible", "UNCERTAINTY", 67, 79]]], ["Face-to-face sessions may feel more satisfying to the health-professional, but is it patient-centred if we are asking the young person to first drive (or be driven) two hours to reach us, and then pay parking costs for the visit?The human problem behind telehealth during and beyond COVID-19Also worth considering, is that some individuals who have never previously accessed services might be more inclined to do so using telehealth.", [["patient", "ORGANISM", 85, 92], ["human", "ORGANISM", 233, 238], ["patient", "SPECIES", 85, 92], ["person", "SPECIES", 128, 134], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 233, 238]]], ["Though this contention has not been well studied, this may be especially the case for AYAs, who may be particularly susceptible to the stigma associated with mental health help-seeking, and who are also vulnerable to practical issues that can hamper their capacity to attend face-to-face therapy (e.g., lack of independent transport if they do not have their driver's license).", [["face therapy", "TREATMENT", 283, 295]]], ["7, 9 Telehealth may lessen logistical barriers, and enable the comforts of the individual's home environment to dilute the anxiety or stigma associated with consulting a psychologist.", [["anxiety", "DISEASE", 123, 130], ["the anxiety", "PROBLEM", 119, 130], ["stigma", "PROBLEM", 134, 140]]], ["2, 7 This may be especially true for palliative care, a profession that continues to be hampered by stigma and taboos around its intent and core business.The human problem behind telehealth during and beyond COVID-19So, as health-professionals across the globe grapple with integrating telehealth into their patient care, we are hopeful it will live up to the hype.", [["human", "ORGANISM", 158, 163], ["patient", "ORGANISM", 308, 315], ["human", "SPECIES", 158, 163], ["patient", "SPECIES", 308, 315], ["human", "SPECIES", 158, 163], ["palliative care", "TREATMENT", 37, 52], ["globe", "ANATOMY", 255, 260]]], ["Much as exposure therapy can reduce an individual's fear of heights, we anticipate the exposure health-professionals and patients alike have experienced during this pandemic will engender a sense of competence and confidence with telehealth.", [["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["exposure therapy", "TREATMENT", 8, 24]]], ["All rights reserved.The human problem behind telehealth during and beyond COVID-19True telehealth integration requires flexibly accounting for the human factors that play into its use.", [["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 147, 152], ["human factors", "PROTEIN", 147, 160], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 147, 152], ["the human factors", "PROBLEM", 143, 160]]], ["Beyond COVID-19, when our choices between face-to-face or telehealth expand once again, the opportunity to offer true patient-centeredness in service delivery should prevail.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["COVID", "TEST", 7, 12], ["delivery", "TREATMENT", 150, 158]]], ["Amidst this pandemic, we can report that telehealth has not been ideal for some of our patients, when home and family situation may be the very crux of their problems; where achieving privacy and a sense of security during a therapeutic session may not be possible from within the four thin walls of their bedroom (Table 1) .", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["By understanding what limited telehealth's use prior to COVID-19, we can pave the way for its routine integration into the future -whatever our new physically-distanced world looks like.The human problem behind telehealth during and beyond COVID-19This article is protected by copyright.", [["human", "ORGANISM", 190, 195], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195]]], ["Telehealth-delivered outpatient clinical psychology practice with adolescent and young adults during the first three months' of the COVID-19 crisis in Australia (late March-June 2020; N=8 oncology outpatients) SexFemale (n=6, 75%); Male (n=2, 25%) Age 15-17 year old (n=3, 37%); 18-21 year old (n=1, 13%); 22-25 year old (n=4, 50%) Location from the hospital* Within 60 minutes' drive (n=2, 25%); 1-3 hours' drive (n=5, 63%); >3 hours' drive (n=1, 12%)Cancer statusActive treatment (n=2, 25%); Within 12 months post-treatment (n=2, 25%); 12-24 months post-treatment (n=3, 38%); >24 months post-treatment (n=1, 12%) Therapy focus Adjustment, re-integration and/or engagement with activities, education, work (n=6, 75%); Depression, low mood, low self-esteem (n=5, 63%); Social anxiety, social concerns, isolation, and peer-group reintegration (n=4, 50%); Family relationships, managing family conflict (n=4, 50%); Anxiety and fear of cancer recurrence (n=4, 50%); Grief, identity narrative, and post-treatment processing (n=3, 37%)Uptake during COVID-19Online videoconferencing (n=6, 75%); Telephone only (n=2, 25%) New clinical psychology client?Uptake during COVID-19New client (n=3, 67%); Pre-existing client (n=5; 63%)Telehealth user prior to COVID-19?No telehealth-delivered psychological therapy prior to COVID-19 (n=5, 63%) Telehealth-delivered psychological therapy experienced prior to COVID-19 (n=3, 37%) Example feedback regarding telehealth experiences^ \"I thought they worked well in practice the face-to-face interaction felt less rambling and distant than a phone call.", [["Cancer", "ANATOMY", 452, 458], ["cancer", "ANATOMY", 933, 939], ["Cancer", "DISEASE", 452, 458], ["Depression", "DISEASE", 719, 729], ["low mood", "DISEASE", 731, 739], ["low self-esteem", "DISEASE", 741, 756], ["anxiety", "DISEASE", 776, 783], ["family conflict", "DISEASE", 885, 900], ["Anxiety", "DISEASE", 913, 920], ["cancer", "DISEASE", 933, 939], ["cancer", "CANCER", 933, 939], ["Cancer statusActive treatment", "TREATMENT", 452, 481], ["Therapy", "TREATMENT", 615, 622], ["re-integration", "TREATMENT", 641, 655], ["Depression", "PROBLEM", 719, 729], ["low mood", "PROBLEM", 731, 739], ["Social anxiety", "PROBLEM", 769, 783], ["peer-group reintegration", "TREATMENT", 817, 841], ["Anxiety", "PROBLEM", 913, 920], ["cancer recurrence", "PROBLEM", 933, 950], ["COVID", "TEST", 1044, 1049], ["Uptake", "TEST", 1146, 1152], ["COVID", "TEST", 1160, 1165], ["COVID", "TEST", 1246, 1251], ["psychological therapy", "TREATMENT", 1279, 1300], ["COVID", "TEST", 1310, 1315], ["psychological therapy", "TREATMENT", 1351, 1372], ["COVID", "TEST", 1394, 1399], ["cancer", "OBSERVATION", 933, 939]]], ["Being in person face-to-face is more beneficial.", [["person", "SPECIES", 9, 15]]], ["But it was adaptable for that time and I knew that we would eventually be able to have sessions faceto-face.", [["face", "ANATOMY", 103, 107]]], ["I also like it because some days with treatment you may be feeling a little 'off' and unwell and being able to have the calls from home and in comfort is aThis article is protected by copyright.", [["treatment", "TREATMENT", 38, 47]]], ["(Female, 25 years) *Location during the period where telehealth-delivered clinical psychology support was provided, as some AYAs would normally live in rural locations but re-located to a metropolitan area close to the hospital for the active treatment period. ^Feedback included with permission.", [["the active treatment period", "TREATMENT", 232, 259]]], ["All rights reserved. -Have connection instructions you can email or text to patients in advance, including technology needed, and where would be an appropriate setting to connect from -Consider a 'test' session -Ensure you have their telephone number so you can 'walk them through' the process of connecting the first time if needed Relational processes Consent processes -Patients benefited from discussions about the process of telehealth, and hearing about experiences with other patients using it.\"I like being able to do the appointments online as not living in [CITY] it is easy to connect and get the support needed.", [["patients", "ORGANISM", 76, 84], ["Patients", "ORGANISM", 373, 381], ["patients", "ORGANISM", 483, 491], ["patients", "SPECIES", 76, 84], ["Patients", "SPECIES", 373, 381], ["patients", "SPECIES", 483, 491], ["a 'test' session", "TREATMENT", 194, 210]]], ["I also like it because some days with treatment you may be feeling a little 'off' and unwell and being able to have the calls from home and in comfort is a-Consider institutional and country-specific consent processes regarding telehealth -Clarify for patients the security of the platform, and whether you will be recording -Discuss in advance what you will do in the case of technical difficulties -Ensure you have contact details (e.g., phone) in case of disconnection/technical difficulties Ongoing evaluation of telehealth model -AYA patients' preferences for/comfort with telehealth was variable.", [["patients", "ORGANISM", 252, 260], ["patients", "ORGANISM", 539, 547], ["patients", "SPECIES", 252, 260], ["patients", "SPECIES", 539, 547], ["treatment", "TREATMENT", 38, 47], ["disconnection/technical difficulties", "PROBLEM", 458, 494], ["Ongoing evaluation", "TEST", 495, 513]]], ["Some patients preferred a simple telephone connection to videoconferencing. -Patients' engagement with telehealth was strengthened by continually reviewing how they were finding the modality, and openly addressing when their situations meant that telehealth was no longer feasible (eg, due to lack of privacy at home) -Do not assume that particular patient groups will feel the same way about using telehealth.\"I like being able to do the appointments online as not living in [CITY] it is easy to connect and get the support needed.", [["patients", "ORGANISM", 5, 13], ["Patients", "ORGANISM", 77, 85], ["patient", "ORGANISM", 349, 356], ["patients", "SPECIES", 5, 13], ["Patients", "SPECIES", 77, 85], ["patient", "SPECIES", 349, 356]]], ["I also like it because some days with treatment you may be feeling a little 'off' and unwell and being able to have the calls from home and in comfort is aPatients' feelings about telehealth will likely also change over time. -Acknowledge the limitations-and benefits-of communicating using telehealth upfront -Make time to explicitly 'check in' with patients at each session about how they are finding the telehealth model.", [["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359], ["treatment", "TREATMENT", 38, 47], ["telehealth upfront", "TREATMENT", 291, 309]]], ["This could include asking about perceived advantages/disadvantages, what the patient-therapist pair are learning through the process (and/or about each other), and whether they would prefer to revert to face-to-face (if possible) or telephone-only connection.Risk managementRegular screening, action plan should safety risks arise -As in face-to-face practice, patient presentation was part of risk screening as necessary. -Safety discussed with new patients upfront, also ensuring we had their home contact details in case concerns arose.Risk management-Telehealth is appropriate to use with patient groups with a range of vulnerabilities, provided adequate risk screening is put in place prior to the first session, and at each online session -Important to ensure contact details are available for the patient's home/next-of-kin, and/or a trusted health professional (eg, general practitioner) should acute mental health risks arise.Therapeutic strategiesExplicitly naming/exploring their setting -Patients engaged with describing their current setting such as where they were, what room (and what they normally do in that room, eg., an 'art -Consider explicitly using the new online connection as a point of discussion and connection with patients/families, and an opening to learn about where each is situated, both in terms of This article is protected by copyright.", [["patient", "ORGANISM", 77, 84], ["patient", "ORGANISM", 361, 368], ["patients", "ORGANISM", 450, 458], ["patient", "ORGANISM", 593, 600], ["patient", "ORGANISM", 804, 811], ["Patients", "ORGANISM", 1000, 1008], ["patients", "ORGANISM", 1242, 1250], ["patient", "SPECIES", 77, 84], ["patient", "SPECIES", 361, 368], ["patients", "SPECIES", 450, 458], ["patient", "SPECIES", 593, 600], ["patient", "SPECIES", 804, 811], ["Patients", "SPECIES", 1000, 1008], ["patients", "SPECIES", 1242, 1250], ["perceived advantages/disadvantages", "TREATMENT", 32, 66], ["Risk management", "TREATMENT", 259, 274], ["risk screening", "TEST", 394, 408], ["Therapeutic strategies", "TREATMENT", 935, 957]]], ["All rights reserved.The human problem behind telehealth during and beyond COVID-19Factor Experiences Recommendations room'), who else was home.", [["human", "ORGANISM", 24, 29], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29]]], ["This was especially helpful as rapport-building for new patients. their geography, their family/home situation, and in terms of what they have experienced in their day/week so far.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Flexible use of online tools -Collaborative exercises during sessions (e.g., case formulation development, brainstorming new concepts), were undertaken using the 'share screen' function to create a virtual notepad -Ensure familiarity with the online tool prior to use with patient so that you are ready to capitalise on all its features, to enable collaborative activities. -Ensure computer desktop is presentable and ready for screen sharing prior to session.", [["patient", "ORGANISM", 273, 280], ["patient", "SPECIES", 273, 280], ["online tools", "TEST", 16, 28]]]], "93a7d7fa0ec9d06a5ee75469e57fc000272b9259": [["IntroductionUne d\u00e9tresse respiratoire aigu\u00eb s\u00e9v\u00e8re (severe acute respiratory syndrome, SARS) a \u00e9t\u00e9 r\u00e9cemment rapport\u00e9e, identifiant ainsi une maladie infectieuse respiratoire nouvelle.", [["acute respiratory syndrome", "DISEASE", 59, 85], ["SARS", "DISEASE", 87, 91], ["severe acute respiratory syndrome", "PROBLEM", 52, 85], ["SARS", "PROBLEM", 87, 91], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["respiratory syndrome", "OBSERVATION", 65, 85]]], ["Il y eut 22 d\u00e9c\u00e8s sur ce chiffre, ce qui est inf\u00e9rieur \u00e0 3 %, mais cela permit aux autorit\u00e9s de prendre des mesures pour \u00e9viter la propagation trop rapide de la maladie.", [["ce qui est inf\u00e9rieur", "TEST", 34, 54]]], ["Le virus \u00e9tait identifi\u00e9, la polymerase chain reaction (PCR) permettait de le trouver et donc de faire un diagnostic de certitude.IntroductionCes deux articles ont permis la bonne connaissance de la maladie.", [["Le virus \u00e9tait", "PROBLEM", 0, 14], ["la polymerase chain reaction", "PROBLEM", 26, 54], ["PCR", "TEST", 56, 59], ["virus", "OBSERVATION", 3, 8]]], ["La propagation s'effectue par les gouttelettes de Pfl\u00fcgger, \u00e9mises en parlant ou toussant, ou par les f\u00e8ces, o\u00f9 des virus sont tr\u00e8s habituellement identifi\u00e9s.\u00c9tude cliniqueAu pr\u00e9alable, il faut remarquer que le terme de pneumopathie atypique d\u00e9signait, il n'y a pas si longtemps, les pneumopathies virales en g\u00e9n\u00e9ral que l'on diff\u00e9renciait ainsi des pneumopathies bact\u00e9riennes.", [["La propagation", "TEST", 0, 14], ["a pas si longtemps", "PROBLEM", 260, 278], ["les pneumopathies virales", "PROBLEM", 280, 305]]], ["La symptomatologie et la radiologie en \u00e9taient diff\u00e9rentes.", [["La symptomatologie", "PROBLEM", 0, 18]]], ["L'\u00e9chec des antibiotiques les r\u00e9unissait.\u00c9tude cliniqueIci, ce terme a \u00e9t\u00e9 utilis\u00e9 pour des pneumopathies virales, qui avaient 20 % de formes graves et entre 2 et 5 % de formes mortelles.\u00c9tude cliniqueLes formes habituelles se r\u00e9v\u00e8lent par :\u00c9tude clinique\u2022 de la fi\u00e8vre ;\u00c9tude clinique\u2022 une toux g\u00e9n\u00e9ralement s\u00e8che ;\u00c9tude clinique\u2022 des myalgies ;\u00c9tude clinique\u2022 une dyspn\u00e9e.", [["pneumopathies virales", "DISEASE", 92, 113], ["a \u00e9t\u00e9 utilis\u00e9 pour des pneumopathies virales", "TREATMENT", 69, 113], ["qui avaient", "TREATMENT", 115, 126]]], ["Ce sont l\u00e0 les sympt\u00f4mes observ\u00e9s dans plus de la moiti\u00e9 des cas.\u00c9tude cliniqueRadiologiquement, les images sont tr\u00e8s diverses :\u00c9tude clinique\u2022 localis\u00e9es ou diffuses ;\u00c9tude clinique\u2022 uni-ou souvent bilat\u00e9rales : au maximum, dans les formes graves, elles atteignent les deux poumons ; \u2022 \u00e0 limites floues et ne respectant aucune structure anatomique ; \u2022 tr\u00e8s h\u00e9t\u00e9rog\u00e8nes, \u00e9chappant \u00e0 toute syst\u00e9matisation.", [["Ce", "TEST", 0, 2], ["les images", "TEST", 97, 107], ["graves", "PROBLEM", 241, 247]]], ["D'une mani\u00e8re g\u00e9n\u00e9rale, on est frapp\u00e9 par la discr\u00e9tion des signes physiques, qui s'oppose \u00e0 l'\u00e9tendue des signes radiologiques.BiologieLes signes les plus fr\u00e9quents sont :Biologie\u2022 une \u00e9l\u00e9vation de la lacticod\u00e9shydrog\u00e9nase ;Biologie\u2022 une hypocalc\u00e9mie ;Biologie\u2022 une lymphop\u00e9nie.TraitementIl comprend la ribavirine, antiviral d'autant plus efficace qu'il est administr\u00e9 plus t\u00f4t.", [["TraitementIl", "TREATMENT", 279, 291], ["la ribavirine", "TREATMENT", 301, 314], ["antiviral d'autant", "TREATMENT", 316, 334], ["efficace qu", "TREATMENT", 340, 351]]], ["Le plus souvent une corticoth\u00e9rapie y est associ\u00e9e, sans que son efficacit\u00e9 soit certaine.TraitementAinsi sur les 144 cas de Toronto, 29 ont eu des formes graves et qui ont n\u00e9cessit\u00e9 la r\u00e9animation.", [["ont eu des", "TREATMENT", 137, 147]]], ["C'est parmi ceux qui ont eu besoin de ventilation m\u00e9canique, qu'il y a eu huit morts, soit 6,5 %, chiffre le plus \u00e9lev\u00e9 de toutes les s\u00e9ries.TraitementL'autre facteur de risque certain est le diab\u00e8te, et bien s\u00fbr les \u00e2ges extr\u00eames de la vie.TraitementD\u00e8s l'arriv\u00e9e des patients \u00e0 l'h\u00f4pital, le virus doit \u00eatre recherch\u00e9.", [["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 269, 277], ["le virus", "ANATOMY", 291, 299]]], ["Directement dans les produits d'expectoration, ou surtout par la PCR qui est tr\u00e8s utile et donne des r\u00e9sultats pr\u00e9coces \u00e0 la diff\u00e9rence des m\u00e9thodes s\u00e9rologiques conventionnelles.", [["ou surtout par la PCR", "TEST", 47, 68]]], ["Il n'y a pas de risque de d\u00e9c\u00e8s pour les patients trait\u00e9s t\u00f4t.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["Les d\u00e9c\u00e8s se voient dans les formes tardivement trait\u00e9es, ou chez les immunod\u00e9prim\u00e9s et les \u00e2ges extr\u00eames de la vie.TraitementLes recommandations sur la mani\u00e8re d'arriver au diagnostic et au traitement des SARS \u00e0 coronavirus 4 insistent sur le fait qu'au d\u00e9but surtout, ces malades paraissaient bien porteurs d'une pneumopathie virale, et que la n\u00e9gativit\u00e9 des recherches pour les virus grippaux, les virus syncytiaux et les rhinovirus conduisait \u00e0 rechercher et \u00e0 traiter le coronavirus.TraitementPour arriver au diagnostic, ils insistent sur le contage r\u00e9cent, moins de 10 j, qui leur para\u00eet essentiel (Figs.", [["SARS \u00e0 coronavirus", "DISEASE", 206, 224], ["\u00e0 traiter le coronavirus", "SPECIES", 463, 487], ["et au traitement des", "TREATMENT", 185, 205], ["coronavirus", "PROBLEM", 213, 224], ["pneumopathie", "TEST", 315, 327], ["virale", "TEST", 328, 334], ["et que la n\u00e9gativit\u00e9 des", "TREATMENT", 336, 360], ["pour les virus grippaux", "TEST", 372, 395], ["les virus syncytiaux", "PROBLEM", 397, 417], ["et les rhinovirus conduisait", "PROBLEM", 418, 446], ["et \u00e0 traiter le coronavirus", "PROBLEM", 460, 487], ["coronavirus", "OBSERVATION", 476, 487]]], ["1, 2) .TraitementUne liste des sympt\u00f4mes rencontr\u00e9s a pu \u00eatre \u00e9tablie \u00e0 propos des cas publi\u00e9s (Tableaux 1 et 2).TraitementAu total le diagnostic repose sur trois \u00e9l\u00e9ments :Traitement\u2022 le contage en milieu professionnel ou dans le milieu familial : d'o\u00f9 la n\u00e9cessit\u00e9 d'une enqu\u00eate sur l'entourage ; \u2022 le diagnostic de pneumopathie virale, qui est souvent fait, mais pour penser au coronavirus, la n\u00e9gativit\u00e9 des recherches portant sur les autres virus habituels, la notion de contage suffit souvent pour instituer le traitement pr\u00e9cocement ; \u2022 la recherche du virus dans les pr\u00e9l\u00e8vements nasopharyng\u00e9s, la s\u00e9rologie virale et surtout par la PCR qui identifieront le virus.", [["s\u00e9rologie virale et surtout par la PCR qui identifieront le virus", "SPECIES", 606, 671], ["a pu \u00eatre \u00e9tablie", "TREATMENT", 52, 69], ["propos des cas publi\u00e9s", "TREATMENT", 72, 94], ["Traitement\u2022 le contage en milieu professionnel", "TREATMENT", 173, 219], ["mais pour penser au coronavirus", "TREATMENT", 361, 392], ["la n\u00e9gativit\u00e9 des", "TREATMENT", 394, 411], ["le traitement pr\u00e9cocement", "TREATMENT", 514, 539], ["la recherche du virus dans les pr\u00e9l\u00e8vements", "TEST", 544, 587], ["nasopharyng\u00e9s", "TEST", 588, 601], ["la s\u00e9rologie", "TEST", 603, 615], ["et surtout par la PCR", "TEST", 623, 644], ["le virus", "PROBLEM", 663, 671], ["virus", "OBSERVATION", 666, 671]]], ["Il faut remarquer dans ce groupe de coronavirus, les groupes 229 E et OC 43, qui sont responsables du \u00abcommon cold \u00bb anglais, autrement dit, le rhume.", [["OC", "CHEMICAL", 70, 72], ["le", "ANATOMY", 141, 143]]], ["Celui-ci n'entra\u00eene que rarement, chez les enfants du 1 er \u00e2ge, les vieillards ou les immunod\u00e9prim\u00e9s, de v\u00e9ritables pneumopathies.", [["chez les", "TEST", 34, 42], ["de v\u00e9ritables pneumopathies", "PROBLEM", 102, 129]]], ["Il peut en revanche \u00eatre neuropathog\u00e8ne et il a \u00e9t\u00e9 retrouv\u00e9 dans les cerveaux de sujets souffrant de scl\u00e9rose en plaques.", [["Il peut en revanche", "TREATMENT", 0, 19], ["plaques", "OBSERVATION", 114, 121]]], ["L'identification du virus est r\u00e9cente et encore plus r\u00e9cemment se posait le probl\u00e8me de son r\u00f4le exclusif dans ce syndrome : en effet, nombre de viroses respiratoires peuvent donner des syndromes de d\u00e9tresse respiratoire aigu\u00eb chez les adultes sains.", [["du virus", "TREATMENT", 17, 25], ["des syndromes", "PROBLEM", 182, 195]]], ["5, 6, 7 Ils soulignent qu'un certain nombre des patients ont eu une pneumopathie bact\u00e9rienne associ\u00e9e.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["Les l\u00e9sions anatomiques, surtout bronchiques : desquamation de l'\u00e9pith\u00e9lium ciliaire, pertes des cils, m\u00e9tapla-sies squameuses, n'ont rien de sp\u00e9cifique.", [["Les l\u00e9sions anatomiques", "PROBLEM", 0, 23], ["desquamation", "PROBLEM", 47, 59], ["ciliaire", "TREATMENT", 76, 84], ["pertes des cils", "TREATMENT", 86, 101], ["m\u00e9tapla", "TREATMENT", 103, 110]]], ["Certes, le microscope \u00e9lectronique identifie le virus dans le cytoplasme des \u00e9pith\u00e9liums ciliaires.", [["Certes", "TEST", 0, 6], ["le microscope \u00e9lectronique", "TEST", 8, 34], ["le", "ANATOMY", 8, 10]]], ["La rate \u00e0 l'autopsie montre une atrophie de la pulpe blanche.", [["La rate", "TEST", 0, 7]]], ["N\u00e9anmoins, il est admis que la pr\u00e9sence du coronavirus est suffisante.", [["du coronavirus", "OBSERVATION", 40, 54]]], ["Les analyses s\u00e9quentielles l'ont trouv\u00e9 dans l'aspiration bronchique, les biopsies de la muqueuse nasale, mais \u00e9galement parfois dans les excr\u00e9ments, sans que cela prouve forc\u00e9ment que ce soit l\u00e0 une voie de contamination.TraitementL'identification du virus \u00e0 partir des la muqueuse nasale, montre bien qu'il s'agit d'un coronavirus (identifi\u00e9 par 60 % de s\u00e9quences nucl\u00e9otidiques environ).", [["Les analyses", "TEST", 0, 12], ["nt", "PROBLEM", 30, 32], ["les biopsies", "TEST", 70, 82], ["du virus", "TREATMENT", 249, 257], ["coronavirus", "PROBLEM", 321, 332], ["du virus", "OBSERVATION", 249, 257]]], ["Le virus identifi\u00e9 par PCR montre une s\u00e9quence de 300 nucl\u00e9otides de longueur.TraitementSon identification a \u00e9t\u00e9 faite au sein du groupe des coronavirus.", [["Le virus", "ORGANISM", 0, 8], ["\u00e9t\u00e9 faite au sein du groupe des coronavirus", "SPECIES", 109, 152], ["Le virus", "PROBLEM", 0, 8], ["virus", "OBSERVATION", 3, 8]]], ["Ce groupe poss\u00e8de un certain nombre de maladies humaines ou animales, de la plus b\u00e9nigne (simple rhume) \u00e0 la plus grave (processus enc\u00e9phalique).", [["Ce", "CHEMICAL", 0, 2], ["grave (processus enc\u00e9phalique", "TREATMENT", 114, 143], ["processus", "OBSERVATION", 121, 130]]], ["1 Sa connaissance a permis une prophylaxie efficace :Traitement\u2022 isolement des malades ; \u2022 traitement le plus pr\u00e9coce possible ;Traitement\u2022 isolement des personnes suspectes d'avoir \u00e9t\u00e9 contamin\u00e9es : les traiter au moindre doute, m\u00eame sans preuves virologiques et malgr\u00e9 la toxicit\u00e9 de la ribavirine.", [["ribavirine", "CHEMICAL", 289, 299], ["a permis une prophylaxie efficace", "TREATMENT", 18, 51], ["Traitement\u2022 isolement des malades", "TREATMENT", 53, 86]]]], "PMC7124665": [], "a617d4d8bab5428b0dc55a161056cb99ad10fafc": [["1Institute for Biophysical Dynamics, Department of Chemistry, University of Chicago, Chicago, IL 60637; 2 Department of Chemistry, Georgia State University, Atlanta, GA 30302; 3 National Magnetic Resonance Facility at Madison, Madison, WI 53706 Total chemical synthesis was used to prepare a series of unique analogues of the HIV-1 protease (HIV-1 PR), where we systematically substituted the residues Gly51, Gly51' at the tips of the mobile 'flaps' (residues 37-61 in each domain of the protein homodimer) with L-Ala, D-Ala in both symmetric and asymmetric fashion.", [["L-Ala", "CHEMICAL", 512, 517], ["D-Ala", "CHEMICAL", 519, 524], ["Gly51", "CHEMICAL", 402, 407], ["Gly", "CHEMICAL", 409, 412], ["L-Ala", "CHEMICAL", 512, 517], ["D-Ala", "CHEMICAL", 519, 524], ["HIV-1", "ORGANISM", 326, 331], ["HIV-1 PR", "ORGANISM", 342, 350], ["Gly51", "GENE_OR_GENE_PRODUCT", 402, 407], ["Gly51", "AMINO_ACID", 409, 414], ["L-Ala", "SIMPLE_CHEMICAL", 512, 517], ["D-Ala", "SIMPLE_CHEMICAL", 519, 524], ["HIV-1 protease", "PROTEIN", 326, 340], ["PR", "PROTEIN", 348, 350], ["residues 37-61", "PROTEIN", 451, 465], ["protein homodimer", "PROTEIN", 488, 505], ["HIV-1", "SPECIES", 326, 331], ["HIV-1", "SPECIES", 326, 331], ["HIV-1", "SPECIES", 342, 347], ["Total chemical synthesis", "TREATMENT", 245, 269], ["unique analogues", "TREATMENT", 302, 318], ["the HIV", "TEST", 322, 329], ["HIV", "TEST", 342, 345], ["the mobile 'flaps", "TREATMENT", 431, 448], ["residues", "TEST", 451, 459], ["the protein homodimer", "TEST", 484, 505], ["tips", "OBSERVATION_MODIFIER", 423, 427], ["Ala", "ANATOMY", 514, 517], ["Ala", "ANATOMY_MODIFIER", 521, 524], ["both", "ANATOMY_MODIFIER", 528, 532], ["symmetric", "ANATOMY_MODIFIER", 533, 542], ["asymmetric", "OBSERVATION_MODIFIER", 547, 557]]], ["Such substitutions, although in regions distant from the catalytic aspartates, led in most cases to very substantial reductions of catalytic activity.", [["aspartates", "CHEMICAL", 67, 77], ["catalytic aspartates", "PROTEIN", 57, 77], ["Such substitutions", "PROBLEM", 0, 18], ["catalytic activity", "OBSERVATION", 131, 149]]], ["In contrast to this, a chemically synthesized 203 amino acid residue 'covalent dimer' protein with L-Ala51 in one flap and D-Ala51' in the other flap has native-like enzyme activity.", [["amino acid", "CHEMICAL", 50, 60], ["amino acid", "CHEMICAL", 50, 60], ["L-Ala51", "CHEMICAL", 99, 106], ["amino acid", "AMINO_ACID", 50, 60], ["L-Ala51", "GENE_OR_GENE_PRODUCT", 99, 106], ["D-Ala51", "SIMPLE_CHEMICAL", 123, 130], ["covalent dimer' protein", "PROTEIN", 70, 93], ["L", "PROTEIN", 99, 100], ["Ala51", "PROTEIN", 101, 106], ["enzyme", "PROTEIN", 166, 172], ["a chemically synthesized 203 amino acid residue", "TREATMENT", 21, 68], ["L-Ala51 in one flap", "TREATMENT", 99, 118], ["D-Ala51'", "TREATMENT", 123, 131], ["the other flap", "TREATMENT", 135, 149], ["one flap", "ANATOMY", 110, 118], ["flap", "ANATOMY", 145, 149], ["native", "OBSERVATION", 154, 160], ["enzyme activity", "OBSERVATION", 166, 181]]], ["To gain insight into the molecular details of such phenomena, we have applied a variety of biophysical methods including NMR and pulse-EPR spectroscopies, as well as X-ray crystallography and appropriate enzymatic assays.", [["such phenomena", "PROBLEM", 46, 60], ["biophysical methods", "TREATMENT", 91, 110], ["NMR", "TEST", 121, 124], ["pulse-EPR spectroscopies", "TREATMENT", 129, 153], ["X-ray crystallography", "TEST", 166, 187], ["appropriate enzymatic assays", "TEST", 192, 220]]], ["Both, NMR relaxation experiments with 15N-spin labeled proteins and pulse-EPR measurements of nitroxide-labeled analogues have revealed that [L-Ala51,51'] HIV-1 PR has nearly wild-type flap mobility on sub-ns time scale, whereas [D-Ala51,51'] HIV-1 PR has much more rigid flaps both on sub-ns and s-ms time scale.", [["nitroxide", "CHEMICAL", 94, 103], ["nitroxide", "CHEMICAL", 94, 103], ["Ala", "CHEMICAL", 144, 147], ["[D-Ala51,51']", "CHEMICAL", 229, 242], ["15N", "SIMPLE_CHEMICAL", 38, 41], ["nitroxide", "SIMPLE_CHEMICAL", 94, 103], ["flap", "TISSUE", 185, 189], ["HIV-1", "ORGANISM", 243, 248], ["PR", "ORGANISM", 249, 251], ["PR", "PROTEIN", 161, 163], ["PR", "PROTEIN", 249, 251], ["HIV-1", "SPECIES", 243, 248], ["HIV-1", "SPECIES", 243, 248], ["NMR relaxation experiments", "TEST", 6, 32], ["pulse", "TEST", 68, 73], ["nitroxide", "TREATMENT", 94, 103], ["L-Ala", "TEST", 142, 147], ["HIV", "TEST", 155, 158], ["type flap mobility", "PROBLEM", 180, 198], ["HIV", "PROBLEM", 243, 246], ["much more rigid flaps", "PROBLEM", 256, 277], ["sub-ns", "TREATMENT", 286, 292], ["rigid", "OBSERVATION_MODIFIER", 266, 271], ["flaps", "OBSERVATION", 272, 277]]], ["Molecular dynamics simulations further demonstrated that the asymmetric combination of D-Ala/L-Ala flaps, but not the symmetric D/D or L/L, uniquely stabilizes the conformational state of catalytic residues Asp25 and Asp25' with the nucleophilic water molecule being prearranged for catalysis.", [["D-Ala", "CHEMICAL", 87, 92], ["L-Ala", "CHEMICAL", 93, 98], ["D-Ala", "CHEMICAL", 87, 92], ["L-Ala", "CHEMICAL", 93, 98], ["Asp25", "CHEMICAL", 207, 212], ["Asp25", "CHEMICAL", 217, 222], ["D-Ala", "SIMPLE_CHEMICAL", 87, 92], ["L-Ala flaps", "SIMPLE_CHEMICAL", 93, 104], ["D/D", "SIMPLE_CHEMICAL", 128, 131], ["Asp25", "AMINO_ACID", 207, 212], ["Asp25", "AMINO_ACID", 217, 222], ["symmetric D/D or L/L", "PROTEIN", 118, 138], ["catalytic residues", "PROTEIN", 188, 206], ["Molecular dynamics simulations", "TEST", 0, 30], ["D-Ala/L-Ala flaps", "TREATMENT", 87, 104], ["the symmetric D/D or L/L", "PROBLEM", 114, 138], ["catalytic residues Asp25", "PROBLEM", 188, 212], ["Asp25'", "TREATMENT", 217, 223], ["the nucleophilic water molecule", "TREATMENT", 229, 260], ["catalysis", "PROBLEM", 283, 292], ["asymmetric", "OBSERVATION_MODIFIER", 61, 71], ["Ala flaps", "ANATOMY", 95, 104]]], ["The results obtained also confirm that the viral HIV-1 protease and the cell-encoded monomeric aspartic proteases share the same intrinsically asymmetric chemical mechanism.P 003 DESIGN AND CHARACTERIZATION OF A PH SENSI-TIVE HOMO-DIMERIC ANTI-PARALLEL COILED COILR.", [["cell", "ANATOMY", 72, 76], ["HIV-1", "ORGANISM", 49, 54], ["cell", "CELL", 72, 76], ["viral HIV-1 protease", "PROTEIN", 43, 63], ["cell-encoded monomeric aspartic proteases", "PROTEIN", 72, 113], ["PARALLEL COILED COILR", "DNA", 244, 265], ["HIV-1", "SPECIES", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["the viral HIV", "TEST", 39, 52], ["the cell", "TEST", 68, 76], ["monomeric aspartic proteases", "TEST", 85, 113], ["A PH SENSI", "TEST", 210, 220], ["DIMERIC ANTI-PARALLEL COILED COILR", "TREATMENT", 231, 265], ["asymmetric", "OBSERVATION_MODIFIER", 143, 153], ["chemical mechanism", "OBSERVATION", 154, 172]]], ["Nagarkar and J. Schneider Department of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716 A homodimeric anti-parallel coiled coil that folds under acidic conditions has been designed.", [["homodimeric anti-parallel coiled coil", "PROTEIN", 111, 148], ["A homodimeric anti-parallel coiled coil", "TREATMENT", 109, 148], ["coil", "OBSERVATION", 144, 148], ["acidic conditions", "OBSERVATION", 166, 183]]], ["Structure-based design was used starting from the anti-parallel coiled coil BCR 30-65 from the Bcr-Abl oncoprotein.", [["BCR", "GENE_OR_GENE_PRODUCT", 76, 79], ["Bcr-Abl", "GENE_OR_GENE_PRODUCT", 95, 102], ["anti-parallel coiled coil BCR 30-65", "PROTEIN", 50, 85], ["Bcr-Abl oncoprotein", "PROTEIN", 95, 114], ["the anti-parallel coiled coil BCR", "TREATMENT", 46, 79], ["the Bcr", "TEST", 91, 98], ["Abl oncoprotein", "OBSERVATION", 99, 114]]], ["This coiled coil contains a naturally occurring glutamic acid (Glu52) in its hydrophobic core.", [["glutamic acid", "CHEMICAL", 48, 61], ["Glu52", "CHEMICAL", 63, 68], ["glutamic acid", "CHEMICAL", 48, 61], ["Glu52", "CHEMICAL", 63, 68], ["glutamic acid", "SIMPLE_CHEMICAL", 48, 61], ["Glu52", "SIMPLE_CHEMICAL", 63, 68], ["This coiled coil", "TREATMENT", 0, 16], ["a naturally occurring glutamic acid (Glu52) in its hydrophobic core", "PROBLEM", 26, 93], ["coil", "OBSERVATION", 12, 16], ["naturally", "OBSERVATION_MODIFIER", 28, 37], ["glutamic acid", "OBSERVATION", 48, 61], ["hydrophobic", "OBSERVATION_MODIFIER", 77, 88]]], ["By modulating the protonation state of Glu52 we could potentially regulate coiled coil formation based on electrostatic destabilization of the hydrophobic core by a buried charge.", [["Glu52", "CHEMICAL", 39, 44], ["Glu52", "CHEMICAL", 39, 44], ["Glu52", "SIMPLE_CHEMICAL", 39, 44], ["Glu52", "PROTEIN", 39, 44], ["coiled coil formation", "TREATMENT", 75, 96], ["a buried charge", "TREATMENT", 163, 178], ["protonation state", "OBSERVATION", 18, 35], ["coiled coil", "OBSERVATION", 75, 86]]], ["However, denaturation of this peptide revealed no significant changes in its thermal stability over a wide pH range.", [["this peptide", "TEST", 25, 37], ["significant changes in its thermal stability", "PROBLEM", 50, 94], ["no", "UNCERTAINTY", 47, 49], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["changes", "OBSERVATION", 62, 69], ["thermal", "OBSERVATION_MODIFIER", 77, 84], ["stability", "OBSERVATION_MODIFIER", 85, 94]]], ["This pH-independent behavior was purported to arise from a stabilizing salt bride between Arg55 and Glu52 that compensated for buried negative charge centered at Glu52.", [["Glu52", "CHEMICAL", 100, 105], ["Glu52", "CHEMICAL", 162, 167], ["Arg55", "CHEMICAL", 90, 95], ["Glu52", "CHEMICAL", 100, 105], ["Glu52", "CHEMICAL", 162, 167], ["Arg55", "SIMPLE_CHEMICAL", 90, 95], ["Glu52", "SIMPLE_CHEMICAL", 100, 105], ["Glu52", "SIMPLE_CHEMICAL", 162, 167], ["Arg55", "PROTEIN", 90, 95], ["Glu52", "PROTEIN", 100, 105], ["Glu52", "PROTEIN", 162, 167], ["This pH", "TEST", 0, 7], ["a stabilizing salt bride", "PROBLEM", 57, 81], ["buried negative charge", "PROBLEM", 127, 149]]], ["To induce pH responsive behavior, firstly, an Arg55Ala mutation to unmask the effect of Glu52 and second, Ile42 in the 'a-d' layer of Glu52 was mutated to Glu, to magnify the charge repulsions inhibiting coiled coil formation.", [["Glu52", "CHEMICAL", 88, 93], ["Ile42", "CHEMICAL", 106, 111], ["Glu52", "CHEMICAL", 134, 139], ["Glu", "CHEMICAL", 155, 158], ["Glu52", "CHEMICAL", 88, 93], ["Ile42", "CHEMICAL", 106, 111], ["Glu52", "CHEMICAL", 134, 139], ["Glu", "CHEMICAL", 155, 158], ["Arg55Ala", "GENE_OR_GENE_PRODUCT", 46, 54], ["Glu52", "GENE_OR_GENE_PRODUCT", 88, 93], ["Ile42", "GENE_OR_GENE_PRODUCT", 106, 111], ["Glu52", "GENE_OR_GENE_PRODUCT", 134, 139], ["Glu", "AMINO_ACID", 155, 158], ["Glu52", "PROTEIN", 88, 93], ["Glu52", "PROTEIN", 134, 139], ["pH responsive behavior", "PROBLEM", 10, 32], ["an Arg55Ala mutation", "PROBLEM", 43, 63], ["Glu52", "TEST", 88, 93], ["the charge repulsions", "TREATMENT", 171, 192], ["coiled coil formation", "TREATMENT", 204, 225], ["pH responsive", "OBSERVATION_MODIFIER", 10, 23], ["coil formation", "OBSERVATION", 211, 225]]], ["Detailed thermodynamics, AUC and orientation analyses showed that while deleting the Arg55/Glu 52 salt bridge does not significantly compromise its thermal stability, the ability of the protein to adopt an anti-parallel coiled coil is lost; a mixture of anti-parallel and parallel coiled coils is realized.", [["Glu", "CHEMICAL", 91, 94], ["Arg55", "CHEMICAL", 85, 90], ["Glu", "CHEMICAL", 91, 94], ["Arg55", "GENE_OR_GENE_PRODUCT", 85, 90], ["Glu", "AMINO_ACID", 91, 94], ["anti-parallel coiled coil", "PROTEIN", 206, 231], ["Detailed thermodynamics", "TEST", 0, 23], ["AUC and orientation analyses", "TEST", 25, 53], ["the Arg55/Glu 52 salt bridge", "TREATMENT", 81, 109], ["an anti-parallel coiled coil", "TREATMENT", 203, 231], ["a mixture of anti-parallel and parallel coiled coils", "TREATMENT", 241, 293], ["thermal", "OBSERVATION_MODIFIER", 148, 155], ["stability", "OBSERVATION_MODIFIER", 156, 165], ["coiled", "OBSERVATION_MODIFIER", 281, 287], ["coils", "OBSERVATION", 288, 293]]], ["However, Ile42Glu adopts an antiparallel homodimeric coiled coil in a pH-dependant manner with only a marginal decrease in thermal stability.P 004 SPECTROSCOPIC ANALYSIS OF A b-HAIRPIN-FORMING MINIPROTEINM.P.D. Hatfield, R.F. Murphy, S. Lovas Department of Biomedical Sciences, Creighton University, Omaha, NE Electronic and vibrational circular dichroism are often used to determine the secondary structure of proteins, because each secondary structure has a unique spectrum.", [["Ile42Glu", "CHEMICAL", 9, 17], ["Ile", "CHEMICAL", 9, 12], ["Ile42Glu", "SIMPLE_CHEMICAL", 9, 17], ["Ile42Glu", "PROTEIN", 9, 17], ["antiparallel homodimeric coiled coil", "PROTEIN", 28, 64], ["an antiparallel homodimeric coiled coil", "TREATMENT", 25, 64], ["a marginal decrease in thermal stability", "PROBLEM", 100, 140], ["vibrational circular dichroism", "TREATMENT", 325, 355], ["the secondary structure of proteins", "PROBLEM", 384, 419], ["coiled coil", "OBSERVATION", 53, 64], ["pH-dependant", "OBSERVATION_MODIFIER", 70, 82], ["marginal", "OBSERVATION_MODIFIER", 102, 110], ["decrease", "OBSERVATION_MODIFIER", 111, 119], ["thermal", "OBSERVATION_MODIFIER", 123, 130], ["stability", "OBSERVATION_MODIFIER", 131, 140]]], ["In order to determine these spectral features, polypeptides that are known to adopt the desired conformation along their entire length are studied ideally.", [["polypeptides", "PROBLEM", 47, 59]]], ["Little is known about the vibrational circular dichroism spectroscopic features of -hairpins.", [["the vibrational circular dichroism spectroscopic features", "PROBLEM", 22, 79], ["hairpins", "PROBLEM", 84, 92]]], ["In this study, we used a decapeptide, YYDPETGTWY (CLN025), which forms a stable -hairpin that is stabilized by intramolecular weakly polar interactions and hydrogen bonds.", [["YYDPETGTWY", "CHEMICAL", 38, 48], ["CLN025", "CHEMICAL", 50, 56], ["hydrogen", "CHEMICAL", 156, 164], ["YYDPETGTWY", "SIMPLE_CHEMICAL", 38, 48], ["CLN025", "SIMPLE_CHEMICAL", 50, 56], ["this study", "TEST", 3, 13], ["a decapeptide, YYDPETGTWY (CLN025", "TREATMENT", 23, 56], ["stable", "OBSERVATION_MODIFIER", 73, 79], ["hydrogen bonds", "OBSERVATION", 156, 170]]], ["CLN025 was synthesized by microwave-assisted solid phase peptide synthesis with N-a-Fmoc protected amino acids.", [["CLN025", "CHEMICAL", 0, 6], ["N-a-Fmoc", "CHEMICAL", 80, 88], ["amino acids", "CHEMICAL", 99, 110], ["CLN025", "CHEMICAL", 0, 6], ["N-a-Fmoc protected amino acids", "CHEMICAL", 80, 110], ["CLN025", "SIMPLE_CHEMICAL", 0, 6], ["N-a-Fmoc protected amino acids", "SIMPLE_CHEMICAL", 80, 110], ["microwave-assisted solid phase peptide synthesis", "TREATMENT", 26, 74], ["a-Fmoc protected amino acids", "TREATMENT", 82, 110]]], ["During purification on C 18 reversed phase HPLC columns it was found that CLN025 adopts two or more conformations, which was shown, so far, only for much larger polypeptides.", [["CLN025", "CHEMICAL", 74, 80], ["CLN025", "CHEMICAL", 74, 80], ["CLN025", "SIMPLE_CHEMICAL", 74, 80], ["C 18", "PROTEIN", 23, 27], ["C 18 reversed phase HPLC columns", "TREATMENT", 23, 55]]], ["The structure of CLN025 in aqueous and organic solvents was examined using electronic and vibrational circular dichroism spectroscopy.", [["CLN025", "CHEMICAL", 17, 23], ["CLN025", "CHEMICAL", 17, 23], ["CLN025", "SIMPLE_CHEMICAL", 17, 23], ["aqueous", "SIMPLE_CHEMICAL", 27, 34], ["organic solvents", "TREATMENT", 39, 55], ["electronic and vibrational circular dichroism spectroscopy", "TEST", 75, 133]]], ["The presence of -hairpin was confirmed by ECD and a unique VCD signal was observed.", [["-hairpin", "PROTEIN", 16, 24], ["ECD", "TEST", 42, 45], ["a unique VCD signal", "TEST", 50, 69]]], ["Molecular Dynamics simulations were used to correlate conformational features with CD spectra for CLN025 in the same aqueous and organic solvents.P 004 SPECTROSCOPIC ANALYSIS OF A b-HAIRPIN-FORMING MINIPROTEINThis work was supported by the NIH-INBRE grant P20 RR016469 and the Carpenter Endowed Chair in Biochemistry, Creighton University.P 005 NATURE OF AMIDE CARBONYL-CARBONYL INTERACTIONS IN PROTEINSA.", [["CLN025", "CHEMICAL", 98, 104], ["CLN025", "CHEMICAL", 98, 104], ["CLN025", "SIMPLE_CHEMICAL", 98, 104], ["aqueous", "SIMPLE_CHEMICAL", 117, 124], ["Molecular Dynamics simulations", "TEST", 0, 30], ["CD spectra", "TEST", 83, 93], ["CLN025", "TREATMENT", 98, 104], ["organic solvents", "TREATMENT", 129, 145], ["organic solvents", "OBSERVATION", 129, 145]]], ["In many protein secondary structures, an intimate interaction exists between adjacent carbonyl groups of the mainchain amide bonds.", [["carbonyl", "CHEMICAL", 86, 94], ["carbonyl", "CHEMICAL", 86, 94], ["mainchain amide", "CHEMICAL", 109, 124], ["carbonyl", "SIMPLE_CHEMICAL", 86, 94], ["mainchain amide bonds", "SIMPLE_CHEMICAL", 109, 130], ["secondary structures", "OBSERVATION", 16, 36], ["carbonyl groups", "OBSERVATION", 86, 101], ["amide bonds", "OBSERVATION", 119, 130]]], ["As this short contact contributes to the energetics of protein conformational stability as well as protein-ligand interactions, understanding its nature is crucial.", [["protein-ligand interactions", "TREATMENT", 99, 126]]], ["The intimacy of the carbonyl groups could arise from a charge-charge or dipole-dipole interaction, or n?* electronic delocalization.", [["carbonyl", "CHEMICAL", 20, 28], ["carbonyl", "CHEMICAL", 20, 28], ["carbonyl", "SIMPLE_CHEMICAL", 20, 28], ["the carbonyl groups", "TREATMENT", 16, 35]]], ["This last putative origin, which is reminiscent of the B\u00fcrgi-Dunitz trajectory, involves delocalization of the lone pairs (n) of the oxygen (Oi-1) of a peptide bond over the antibonding orbital (p electronic delocalization.", [["oxygen", "CHEMICAL", 133, 139], ["oxygen", "CHEMICAL", 133, 139], ["oxygen", "SIMPLE_CHEMICAL", 133, 139], ["the B\u00fcrgi-Dunitz trajectory", "TREATMENT", 51, 78], ["the oxygen (Oi-", "TREATMENT", 129, 144], ["a peptide bond over the antibonding orbital (p electronic delocalization", "TREATMENT", 150, 222], ["origin", "ANATOMY_MODIFIER", 19, 25], ["antibonding", "OBSERVATION", 174, 185], ["orbital", "ANATOMY", 186, 193]]], ["Additionally, computational analysis on an Ac-Ala4-NHMe peptidic model system suggests widespread n?* electronic delocalization in the allowed regions of the Ramachandran plot.", [["Ac-Ala4-NHMe", "CHEMICAL", 43, 55], ["Ac-Ala4", "SIMPLE_CHEMICAL", 43, 50], ["computational analysis", "TEST", 14, 36], ["an Ac", "TEST", 40, 45], ["electronic delocalization", "PROBLEM", 102, 127], ["widespread", "OBSERVATION_MODIFIER", 87, 97], ["electronic delocalization", "OBSERVATION", 102, 127]]], ["These finding have implications for organic, biological, and medicinal chemistry.", [["medicinal chemistry", "TEST", 61, 80]]], ["Critical analysis of high-resolution crystallographic structures indicated that protein helices populate a single smoothly peaked distribution, rather than the weighted bimodal distribution expected from mixed populations of -helices and 3 10 -helices.", [["protein helices", "PROTEIN", 80, 95], ["-helices and 3 10 -helices", "PROTEIN", 225, 251], ["Critical analysis", "TEST", 0, 17], ["protein helices populate a single smoothly peaked distribution", "PROBLEM", 80, 142], ["high", "OBSERVATION_MODIFIER", 21, 25], ["protein helices", "OBSERVATION", 80, 95], ["single", "OBSERVATION_MODIFIER", 107, 113], ["smoothly", "OBSERVATION_MODIFIER", 114, 122], ["peaked", "OBSERVATION_MODIFIER", 123, 129], ["distribution", "OBSERVATION_MODIFIER", 130, 142], ["mixed", "OBSERVATION_MODIFIER", 204, 209], ["populations", "OBSERVATION_MODIFIER", 210, 221]]], ["The helical population was centered at (f = \u00c062, y = \u00c043), a coordinate intermediate between the classical parameters for the ideal -helix or 3 10 -helix.", [["ideal -helix or 3 10 -helix", "PROTEIN", 126, 153]]], ["Further, the Protein Data-Bank (PDB) was shown to manifest a clear bias towards supposedly ideal helices at nominal resolutions greater than 2\u00c5 , where structure models are insufficiently constrained by experimental electron density.P 005 NATURE OF AMIDE CARBONYL-CARBONYL INTERACTIONS IN PROTEINSA new model for helices in proteins that accounts for the contributions of shared (bifurcated) hydrogen bonds evolved from a straightforward interpretation of high-resolution crystallographic data and physicochemical constraints.", [["hydrogen", "CHEMICAL", 392, 400], ["electron", "SIMPLE_CHEMICAL", 216, 224], ["Protein Data", "PROTEIN", 13, 25], ["the Protein Data", "TEST", 9, 25], ["a clear bias", "PROBLEM", 59, 71], ["PROTEINSA new model for helices in proteins", "TREATMENT", 289, 332], ["shared (bifurcated) hydrogen bonds", "PROBLEM", 372, 406], ["physicochemical constraints", "PROBLEM", 498, 525], ["electron density", "OBSERVATION", 216, 232]]], ["This new molten helical model unifies experimental observations with the concept of the protein helix as a stable secondary structure that samples conformational space from a single smooth potential well located between the classical -helical and 3 10 -helical coordinates on the energy surface.", [["surface", "CELLULAR_COMPONENT", 287, 294], ["protein helix", "PROTEIN", 88, 101], ["classical -helical and 3 10 -helical coordinates", "PROTEIN", 224, 272], ["the protein helix", "PROBLEM", 84, 101], ["a stable secondary structure that samples conformational space", "PROBLEM", 105, 167], ["stable", "OBSERVATION_MODIFIER", 107, 113]]], ["Together, these observations regarding helical models suggest simple improvements in backbone hydrogen-bond potentials, molecular mechanics force-field parameters (particularly for electrostatics), scoring functions for protein folding, and helical peptidomimetic design.", [["hydrogen", "CHEMICAL", 94, 102], ["backbone hydrogen-bond potentials", "TEST", 85, 118], ["protein folding", "PROBLEM", 220, 235], ["helical peptidomimetic design", "TREATMENT", 241, 270], ["simple", "OBSERVATION_MODIFIER", 62, 68], ["improvements", "OBSERVATION", 69, 81], ["backbone hydrogen", "OBSERVATION", 85, 102]]], ["The bias of an abundance of -helical structures seen in low-resolution (>2.0) crystal structure in the PDB severely compromised this structural database and is hypothesized to arise form the use of monopole electrostatics in modeling programs.", [["monopole electrostatics in modeling programs", "TREATMENT", 198, 242], ["abundance", "OBSERVATION_MODIFIER", 15, 24], ["low-resolution", "OBSERVATION_MODIFIER", 56, 70], ["PDB", "ANATOMY", 103, 106]]], ["A detailed statistical analysis of the impact of crystallographic resolution on protein secondary structures was suggested as well as a thorough comparison of the impact of quantum mechanics approximations and force-field methodology on the potential surfaces of bifurcated hydrogen bonds.", [["hydrogen", "CHEMICAL", 274, 282], ["bifurcated hydrogen bonds", "SIMPLE_CHEMICAL", 263, 288], ["A detailed statistical analysis", "TEST", 0, 31], ["quantum mechanics approximations", "TREATMENT", 173, 205], ["bifurcated hydrogen bonds", "TREATMENT", 263, 288], ["bifurcated", "OBSERVATION_MODIFIER", 263, 273], ["hydrogen bonds", "OBSERVATION", 274, 288]]], ["We anticipate, based on our recent analyses of helical hydrogen bonding in high-resolution crystal structures of proteins in the PDB, that a detailed re-interpretation of all secondary structures in lower-resolution (nominal resolution >2.0) structural models of proteins may be necessary.B. Kier and N. AndersenUniversity of Washington Beta-hairpin peptides have become popular model systems of beta sheet structure in proteins, but their reliance on high propensity reversing turns limits their usefulness in modeling the behavior of natural beta sheets with flexible loops or large contact order between strands.", [["hydrogen", "CHEMICAL", 55, 63], ["helical hydrogen bonding", "PROBLEM", 47, 71], ["structural models of proteins", "PROBLEM", 242, 271], ["Washington Beta-hairpin peptides", "TREATMENT", 326, 358], ["flexible loops", "PROBLEM", 561, 575], ["PDB", "ANATOMY", 129, 132], ["lower", "OBSERVATION_MODIFIER", 199, 204], ["flexible loops", "OBSERVATION", 561, 575], ["large", "OBSERVATION_MODIFIER", 579, 584]]], ["Herein we report a class of homodimeric turnless beta sheets linked by a central cystine residue.", [["cystine", "CHEMICAL", 81, 88], ["cystine", "CHEMICAL", 81, 88], ["cystine", "SIMPLE_CHEMICAL", 81, 88], ["homodimeric turnless beta sheets", "PROTEIN", 28, 60], ["a central cystine residue", "PROBLEM", 71, 96], ["central cystine residue", "OBSERVATION", 73, 96]]], ["These constructs range from 6 to 13 residues per strand, adopt well-defined beta-sheet structures, and contain no unnatural amino acids.", [["amino acids", "CHEMICAL", 124, 135], ["amino acids", "CHEMICAL", 124, 135], ["amino acids", "AMINO_ACID", 124, 135], ["beta", "PROTEIN", 76, 80], ["unnatural amino acids", "TREATMENT", 114, 135], ["amino acids", "OBSERVATION", 124, 135]]], ["Though some betasheet structure was observed for a number of diverse homodimeric sequences, the most stable of these (Tm > 70 C) employed a specific beta capping motif.", [["homodimeric sequences", "PROTEIN", 69, 90], ["beta capping motif", "PROTEIN", 149, 167], ["some betasheet structure", "PROBLEM", 7, 31], ["diverse homodimeric sequences", "TEST", 61, 90], ["a specific beta capping motif", "TREATMENT", 138, 167], ["stable", "OBSERVATION_MODIFIER", 101, 107]]], ["This motif takes the form (Pr/Ac-W_WTG) and caps both ends of the beta sheet.", [["beta", "GENE_OR_GENE_PRODUCT", 66, 70], ["Pr", "DNA", 27, 29], ["Ac", "DNA", 30, 32], ["W_WTG", "DNA", 33, 38], ["beta sheet", "DNA", 66, 76], ["Pr/Ac-W_WTG)", "TREATMENT", 27, 39]]], ["These constructs should provide useful minimized systems for studying beta sheet structure, and serve to illustrate both the potency of the beta capping motif and the context-dependent superfluity of nucleating backbone turn sequences.B. Kier and N. AndersenP 008 CRITICAL ASSESSMENT OF MINI-PROTEIN STABILITY USING MOLECULAR SIMULATIONS, CIRCULAR DICHROISM, CALORIMETRY AND NMR J. Feng, G. Marshall Washington University in St. Louis Designing mini-proteins with enhanced stability is a challenging problem.", [["St. Louis", "ORGANISM", 425, 434], ["beta capping motif", "PROTEIN", 140, 158], ["nucleating backbone turn sequences", "PROTEIN", 200, 234], ["studying beta sheet structure", "TEST", 61, 90], ["the beta capping motif", "TREATMENT", 136, 158], ["nucleating backbone turn sequences", "TREATMENT", 200, 234], ["a challenging problem", "PROBLEM", 486, 507], ["stability", "OBSERVATION", 473, 482]]], ["The thermal stability of a 28-residue synthetic mini-protein, FSD-1, and chimeric analogs were analyzed by using molecular simulations, circular dichroism, differential scanning calorimetry and NMR.", [["FSD-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["FSD", "TEST", 62, 65], ["chimeric analogs", "TREATMENT", 73, 89], ["circular dichroism", "TEST", 136, 154], ["differential scanning calorimetry", "TEST", 156, 189], ["NMR", "TEST", 194, 197], ["thermal", "OBSERVATION_MODIFIER", 4, 11], ["stability", "OBSERVATION_MODIFIER", 12, 21]]], ["Experimental melting curves were determined by using both CD and DSC.", [["Experimental melting curves", "PROBLEM", 0, 27]]], ["Melting curves were also calculated from an explicit solvent replicaexchange molecular dynamics simulation.", [["Melting curves", "TEST", 0, 14]]], ["Simulation results showed that FSD-1 exhibited only weak cooperativity between its alpha helix and beta hairpin.", [["FSD-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["alpha helix", "GENE_OR_GENE_PRODUCT", 83, 94], ["beta hairpin", "GENE_OR_GENE_PRODUCT", 99, 111], ["alpha helix", "PROTEIN", 83, 94], ["beta hairpin", "PROTEIN", 99, 111], ["Simulation results", "TEST", 0, 18], ["FSD", "TEST", 31, 34], ["weak cooperativity", "PROBLEM", 52, 70], ["its alpha helix", "TREATMENT", 79, 94], ["beta hairpin", "TREATMENT", 99, 111], ["weak", "OBSERVATION_MODIFIER", 52, 56], ["cooperativity", "OBSERVATION", 57, 70], ["beta hairpin", "OBSERVATION", 99, 111]]], ["The beta hairpin was relatively unstable but its formation was necessary for the formation of a hydrophobic core and folding.", [["beta hairpin", "GENE_OR_GENE_PRODUCT", 4, 16], ["beta hairpin", "DNA", 4, 16], ["The beta hairpin", "TREATMENT", 0, 16], ["a hydrophobic core and folding", "PROBLEM", 94, 124], ["beta hairpin", "OBSERVATION", 4, 16], ["unstable", "OBSERVATION_MODIFIER", 32, 40], ["hydrophobic core", "OBSERVATION_MODIFIER", 96, 112]]], ["The experimental melting curves resembled that of a slowly unfolding helix instead of a two-state folder.", [["The experimental melting curves", "TEST", 0, 31], ["a slowly unfolding helix", "PROBLEM", 50, 74]]], ["The weak stability of FSD-1 was further supported by NMR measurements at 78C.", [["FSD-1", "GENE_OR_GENE_PRODUCT", 22, 27], ["FSD", "TEST", 22, 25], ["NMR measurements", "TEST", 53, 69], ["weak", "OBSERVATION_MODIFIER", 4, 8], ["stability", "OBSERVATION_MODIFIER", 9, 18]]], ["We have shown that polypeptides can be rapidly immobilized on glass substrates by means of thiol catalyzed native chemical ligation (NCL) [Biopolymers/PeptideScience 90, 415; 2008] .", [["thiol", "CHEMICAL", 91, 96], ["thiol", "CHEMICAL", 91, 96], ["thiol", "SIMPLE_CHEMICAL", 91, 96], ["polypeptides", "TREATMENT", 19, 31], ["glass substrates", "TREATMENT", 62, 78], ["thiol catalyzed native chemical ligation", "TREATMENT", 91, 131], ["Biopolymers/PeptideScience", "TREATMENT", 139, 165]]], ["The aim of the present contribution is to build long molecules on glass surfaces for biosensors.B. Kier and N. Andersen-Amino-!-carboxy PEG-amino acids of 10 kDa (PEG = polyethylene glycol) were to be attached on glass surfaces and extended to 20 kDa oligomers.", [["PEG-amino acids", "CHEMICAL", 136, 151], ["PEG = polyethylene glycol", "CHEMICAL", 163, 188], ["Amino-!-carboxy PEG-amino acids", "CHEMICAL", 120, 151], ["PEG", "CHEMICAL", 163, 166], ["polyethylene glycol", "CHEMICAL", 169, 188], ["Andersen-Amino-!-carboxy PEG-amino acids", "SIMPLE_CHEMICAL", 111, 151], ["PEG = polyethylene glycol", "SIMPLE_CHEMICAL", 163, 188], ["Amino-!-carboxy PEG-amino acids", "TREATMENT", 120, 151], ["kDa (PEG = polyethylene glycol)", "TREATMENT", 158, 189]]], ["For this purpose, a first Boc-Cys(Boc)-PEG-thioester was synthesized and coupled to Cys modified glass surfaces by NCL.", [["Boc-Cys", "CHEMICAL", 26, 33], ["Boc)-PEG-thioester", "CHEMICAL", 34, 52], ["Boc-Cys", "CHEMICAL", 26, 33], ["Boc", "CHEMICAL", 34, 37], ["PEG", "CHEMICAL", 39, 42], ["thioester", "CHEMICAL", 43, 52], ["Cys", "CHEMICAL", 84, 87], ["Boc-Cys", "SIMPLE_CHEMICAL", 26, 33], ["Boc)-PEG-thioester", "SIMPLE_CHEMICAL", 34, 52], ["a first Boc-Cys(Boc)", "TREATMENT", 18, 38], ["PEG", "TREATMENT", 39, 42], ["thioester", "TREATMENT", 43, 52], ["Cys modified glass surfaces", "TREATMENT", 84, 111]]], ["A second PEG unit was then attached by the same procedure after dilute aqueous HCl deprotection of the Boc protection of the first Cys-PEG unit.", [["PEG", "CHEMICAL", 9, 12], ["HCl", "CHEMICAL", 79, 82], ["Boc", "CHEMICAL", 103, 106], ["Cys-PEG", "CHEMICAL", 131, 138], ["PEG", "CHEMICAL", 9, 12], ["HCl", "CHEMICAL", 79, 82], ["Boc", "CHEMICAL", 103, 106], ["Cys-PEG", "CHEMICAL", 131, 138], ["HCl", "SIMPLE_CHEMICAL", 79, 82], ["Boc", "SIMPLE_CHEMICAL", 103, 106], ["A second PEG unit", "TREATMENT", 0, 17], ["the same procedure", "TREATMENT", 39, 57], ["dilute aqueous HCl deprotection", "TREATMENT", 64, 95], ["the Boc protection", "TREATMENT", 99, 117], ["the first Cys-PEG unit", "TREATMENT", 121, 143], ["PEG", "OBSERVATION", 9, 12]]], ["In order to measure the length of the attached constructions, the surfaces were probed by atomic force microscopy (AFM).", [["atomic force microscopy", "TEST", 90, 113]]], ["For this purpose an -biotinyl PEG (10kDa)-!-thioester was prepared and coupled, either instead of the first PEG or as the second PEG, thus giving opportunity of molecular recognition.", [["-biotinyl PEG", "CHEMICAL", 20, 33], ["10kDa", "CHEMICAL", 35, 40], ["PEG", "CHEMICAL", 108, 111], ["PEG", "CHEMICAL", 129, 132], ["-biotinyl PEG", "CHEMICAL", 20, 33], ["thioester", "CHEMICAL", 44, 53], ["PEG", "CHEMICAL", 108, 111], ["PEG", "CHEMICAL", 129, 132], ["-biotinyl PEG", "SIMPLE_CHEMICAL", 20, 33], ["10kDa)-!-thioester", "SIMPLE_CHEMICAL", 35, 53], ["PEG", "SIMPLE_CHEMICAL", 108, 111], ["PEG", "SIMPLE_CHEMICAL", 129, 132], ["an -biotinyl PEG (10kDa)", "TREATMENT", 17, 41], ["the first PEG", "TREATMENT", 98, 111], ["the second PEG", "TREATMENT", 118, 132]]], ["In conjunction with this, AFM cantilevers were coated with biotinyl BSA and then with streptavidin.", [["biotinyl", "CHEMICAL", 59, 67], ["biotinyl", "CHEMICAL", 59, 67], ["biotinyl BSA", "SIMPLE_CHEMICAL", 59, 71], ["streptavidin", "GENE_OR_GENE_PRODUCT", 86, 98], ["this, AFM cantilevers", "TREATMENT", 20, 41], ["biotinyl BSA", "TREATMENT", 59, 71], ["streptavidin", "TREATMENT", 86, 98]]], ["The AFM was configured in force-scope mode and the biotinyl-PEG surface was probed.", [["biotinyl-PEG", "CHEMICAL", 51, 63], ["biotinyl", "CHEMICAL", 51, 59], ["PEG", "CHEMICAL", 60, 63], ["biotinyl-PEG surface", "SIMPLE_CHEMICAL", 51, 71], ["The AFM", "TEST", 0, 7], ["scope mode", "TREATMENT", 32, 42], ["the biotinyl-PEG surface", "TREATMENT", 47, 71]]], ["PEG length was measured by pulling perpendicularly and the pulling force was recorded.", [["PEG", "CHEMICAL", 0, 3], ["PEG", "CHEMICAL", 0, 3], ["PEG", "SIMPLE_CHEMICAL", 0, 3], ["PEG length", "TREATMENT", 0, 10], ["the pulling force", "TREATMENT", 55, 72], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Lengths at rupture point were close to the theoretical PEG length and with a rupture force similar to the avidinbiotin bond, confirming correct tether immobilization, length and functionality.B. Kier and N. Andersennolamine phospholipids whereas negatively-charged phospholipids did not affect membrane binding extension.", [["membrane", "ANATOMY", 294, 302], ["rupture", "DISEASE", 77, 84], ["PEG", "CHEMICAL", 55, 58], ["avidinbiotin", "CHEMICAL", 106, 118], ["avidinbiotin", "SIMPLE_CHEMICAL", 106, 118], ["N. Andersennolamine phospholipids", "SIMPLE_CHEMICAL", 204, 237], ["negatively-charged phospholipids", "SIMPLE_CHEMICAL", 246, 278], ["membrane", "CELLULAR_COMPONENT", 294, 302], ["Lengths at rupture point", "PROBLEM", 0, 24], ["the theoretical PEG length", "TREATMENT", 39, 65], ["a rupture force", "PROBLEM", 75, 90], ["Andersennolamine phospholipids", "TREATMENT", 207, 237], ["membrane binding extension", "PROBLEM", 294, 320], ["rupture", "OBSERVATION", 11, 18], ["PEG length", "OBSERVATION", 55, 65], ["rupture", "OBSERVATION", 77, 84], ["tether immobilization", "OBSERVATION", 144, 165]]], ["The presence of cholesterol to modulate membrane fluidity did not alter membrane preference.", [["membrane", "ANATOMY", 40, 48], ["membrane", "ANATOMY", 72, 80], ["cholesterol", "CHEMICAL", 16, 27], ["cholesterol", "CHEMICAL", 16, 27], ["cholesterol", "SIMPLE_CHEMICAL", 16, 27], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["cholesterol to modulate membrane fluidity", "PROBLEM", 16, 57], ["cholesterol", "OBSERVATION", 16, 27], ["modulate membrane fluidity", "OBSERVATION", 31, 57]]], ["These results clearly show that cyclotides do not prefer more rigid domains in the membrane, such as raft domains, and that the peptide-membrane binding is mainly governed by hydrophobic rather than electrostatic interactions.", [["membrane", "ANATOMY", 83, 91], ["raft", "ANATOMY", 101, 105], ["membrane", "ANATOMY", 136, 144], ["cyclotides", "CHEMICAL", 32, 42], ["cyclotides", "SIMPLE_CHEMICAL", 32, 42], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["raft", "CELLULAR_COMPONENT", 101, 105], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["raft domains", "PROTEIN", 101, 113], ["cyclotides", "TREATMENT", 32, 42], ["rigid domains in the membrane", "PROBLEM", 62, 91], ["the peptide-membrane binding", "PROBLEM", 124, 152], ["membrane", "ANATOMY_MODIFIER", 83, 91]]], ["Cyclotides belonging to the bracelet family are able to disintegrate the membrane bilayers, whereas M\u00f6bius peptides appear to form pores without membrane destruction.", [["membrane bilayers", "ANATOMY", 73, 90], ["pores", "ANATOMY", 131, 136], ["membrane", "ANATOMY", 145, 153], ["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "SIMPLE_CHEMICAL", 0, 10], ["membrane bilayers", "CELLULAR_COMPONENT", 73, 90], ["M\u00f6bius peptides", "GENE_OR_GENE_PRODUCT", 100, 115], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["bracelet family", "PROTEIN", 28, 43], ["Cyclotides", "TREATMENT", 0, 10], ["M\u00f6bius peptides", "PROBLEM", 100, 115], ["membrane destruction", "PROBLEM", 145, 165], ["destruction", "OBSERVATION", 154, 165]]], ["Overall, we have shown that even with similar membrane selectivity, different cyclotides have different effects on membrane stability, which explains the diversity of this family and also their diverse activities.", [["membrane", "ANATOMY", 46, 54], ["membrane", "ANATOMY", 115, 123], ["cyclotides", "CHEMICAL", 78, 88], ["cyclotides", "CHEMICAL", 78, 88], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["cyclotides", "SIMPLE_CHEMICAL", 78, 88], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["different cyclotides", "PROBLEM", 68, 88], ["membrane stability", "OBSERVATION_MODIFIER", 115, 133]]], ["Alzheimer's disease (AD) pathology is characterized by two distinct lesions: neurofibrillary tangles comprised of hyperphosphorylated microtubule associated tau protein, and neuritic plaque comprised principally of the amyloid -peptide (A).", [["lesions", "ANATOMY", 68, 75], ["microtubule", "ANATOMY", 134, 145], ["neuritic plaque", "ANATOMY", 174, 189], ["Alzheimer's disease", "DISEASE", 0, 19], ["AD", "DISEASE", 21, 23], ["neuritic plaque", "DISEASE", 174, 189], ["lesions", "CANCER", 68, 75], ["hyperphosphorylated microtubule associated tau protein", "GENE_OR_GENE_PRODUCT", 114, 168], ["neuritic plaque", "PATHOLOGICAL_FORMATION", 174, 189], ["amyloid -peptide", "SIMPLE_CHEMICAL", 219, 235], ["hyperphosphorylated microtubule associated tau protein", "PROTEIN", 114, 168], ["Alzheimer's disease (AD) pathology", "PROBLEM", 0, 34], ["two distinct lesions", "PROBLEM", 55, 75], ["neurofibrillary tangles", "PROBLEM", 77, 100], ["hyperphosphorylated microtubule associated tau protein", "PROBLEM", 114, 168], ["neuritic plaque", "PROBLEM", 174, 189], ["distinct", "OBSERVATION_MODIFIER", 59, 67], ["lesions", "OBSERVATION", 68, 75], ["neurofibrillary tangles", "OBSERVATION", 77, 100], ["hyperphosphorylated microtubule associated tau protein", "OBSERVATION", 114, 168], ["neuritic", "OBSERVATION_MODIFIER", 174, 182], ["plaque", "OBSERVATION", 183, 189], ["amyloid", "OBSERVATION", 219, 226]]], ["Plaque formation is thought to be key in the development of AD and much effort has been spent in the study of A aggregation and attempts to remove or prevent formation of A plaque.", [["Plaque", "ANATOMY", 0, 6], ["A plaque", "ANATOMY", 171, 179], ["Plaque", "DISEASE", 0, 6], ["AD", "DISEASE", 60, 62], ["Plaque", "PATHOLOGICAL_FORMATION", 0, 6], ["A plaque", "CANCER", 171, 179], ["Plaque formation", "PROBLEM", 0, 16], ["AD", "PROBLEM", 60, 62], ["the study", "TEST", 97, 106], ["A aggregation", "TREATMENT", 110, 123], ["A plaque", "PROBLEM", 171, 179], ["thought to be", "UNCERTAINTY", 20, 33], ["plaque", "OBSERVATION", 173, 179]]], ["The physiological role of A is much less well understood.", [["A", "GENE_OR_GENE_PRODUCT", 26, 27]]], ["We have recently shown that A binds specific G-rich DNA sequences and suggested a possible role for A as a transcription factor (Society for Neuroscience meeting, 2008).", [["A", "GENE_OR_GENE_PRODUCT", 28, 29], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["A", "GENE_OR_GENE_PRODUCT", 100, 101], ["G-rich DNA sequences", "DNA", 45, 65], ["transcription factor", "PROTEIN", 107, 127], ["A binds specific G-rich DNA sequences", "PROBLEM", 28, 65]]], ["To better understand the physiological role of A, we studied the uptake of fluorescine-conjugated A by cultured neuron-like PC12 cells under oxidative stress.", [["neuron-like PC12 cells", "ANATOMY", 112, 134], ["fluorescine", "CHEMICAL", 75, 86], ["fluorescine", "CHEMICAL", 75, 86], ["fluorescine-conjugated A", "SIMPLE_CHEMICAL", 75, 99], ["neuron-like PC12 cells", "CELL", 112, 134], ["cultured neuron-like PC12 cells", "CELL_LINE", 103, 134], ["fluorescine", "TREATMENT", 75, 86]]], ["In response to oxidative stress, A was localized to the nuclei of a portion of viable cells and nearly all dead cells, while very little nuclear localization was observed in unstressed cells.", [["nuclei", "ANATOMY", 56, 62], ["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 112, 117], ["nuclear", "ANATOMY", 137, 144], ["cells", "ANATOMY", 185, 190], ["A", "GENE_OR_GENE_PRODUCT", 33, 34], ["nuclei", "CELLULAR_COMPONENT", 56, 62], ["cells", "CELL", 86, 91], ["cells", "CELL", 112, 117], ["nuclear", "CELLULAR_COMPONENT", 137, 144], ["cells", "CELL", 185, 190], ["viable cells", "CELL_TYPE", 79, 91], ["dead cells", "CELL_TYPE", 107, 117], ["unstressed cells", "CELL_TYPE", 174, 190], ["oxidative stress", "PROBLEM", 15, 31], ["viable cells", "PROBLEM", 79, 91], ["nearly all dead cells", "PROBLEM", 96, 117], ["unstressed cells", "PROBLEM", 174, 190], ["oxidative stress", "OBSERVATION", 15, 31], ["viable cells", "OBSERVATION", 79, 91], ["dead cells", "OBSERVATION", 107, 117], ["unstressed cells", "OBSERVATION", 174, 190]]], ["This pattern of nuclear labeling is suggests a role for A in the oxidative death cascade, which is an important player in AD.", [["nuclear", "ANATOMY", 16, 23], ["death", "DISEASE", 75, 80], ["AD", "DISEASE", 122, 124], ["nuclear", "CELLULAR_COMPONENT", 16, 23], ["A", "GENE_OR_GENE_PRODUCT", 56, 57], ["A in the oxidative death cascade", "PROBLEM", 56, 88], ["nuclear labeling", "OBSERVATION", 16, 32]]], ["These results provide clues to the physiological role of A and the A-mediated toxicity seen in AD.", [["toxicity", "DISEASE", 78, 86], ["AD", "DISEASE", 95, 97], ["A", "GENE_OR_GENE_PRODUCT", 57, 58], ["the A-mediated toxicity", "PROBLEM", 63, 86]]], ["Figure 1 ) are nucleoside analogues with a conformational restriction.", [["nucleoside", "CHEMICAL", 15, 25], ["nucleoside", "CHEMICAL", 15, 25], ["nucleoside analogues", "SIMPLE_CHEMICAL", 15, 35], ["nucleoside analogues", "TREATMENT", 15, 35], ["a conformational restriction", "TREATMENT", 41, 69]]], ["In both modified nucleosides, the orientation of the C(5')-OH group around the C(4')-C(5') bond is different to that found in unmodified DNA.", [["nucleosides", "CHEMICAL", 17, 28], ["C(5')-OH", "CHEMICAL", 53, 61], ["nucleosides", "CHEMICAL", 17, 28], ["C(5')-OH", "CHEMICAL", 53, 61], ["C(4')-C(5')", "CHEMICAL", 79, 90], ["C(5')-OH", "SIMPLE_CHEMICAL", 53, 61], ["C(4')-C(5') bond", "SIMPLE_CHEMICAL", 79, 95], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["modified nucleosides", "OBSERVATION", 8, 28], ["unmodified DNA", "OBSERVATION", 126, 140]]], ["3 Tc-DNA exhibits a high RNA affinity over Watson-Crick base pairing4 and has shown promising properties as antisense oligonucleotides.", [["DNA", "CELLULAR_COMPONENT", 5, 8], ["Tc-DNA", "DNA", 2, 8], ["a high RNA affinity", "PROBLEM", 18, 37], ["antisense oligonucleotides", "TREATMENT", 108, 134]]], ["5 The anionic nature of the backbone of an oligonucleotide represents a major challenge for its cellular uptake.", [["cellular", "ANATOMY", 96, 104], ["cellular", "CELL", 96, 104], ["anionic nature", "OBSERVATION_MODIFIER", 6, 20], ["backbone", "ANATOMY_MODIFIER", 28, 36], ["oligonucleotide", "OBSERVATION", 43, 58], ["cellular uptake", "OBSERVATION", 96, 111]]], ["We reasoned that the introduction of a lipophilic substituent on modified nucleosides could improve the cellular uptake of a modified oligonucleotide.", [["cellular", "ANATOMY", 104, 112], ["nucleosides", "CHEMICAL", 74, 85], ["nucleosides", "CHEMICAL", 74, 85], ["cellular", "CELL", 104, 112], ["a lipophilic substituent", "TREATMENT", 37, 61], ["modified nucleosides", "TREATMENT", 65, 85], ["a modified oligonucleotide", "TREATMENT", 123, 149], ["cellular uptake", "OBSERVATION", 104, 119]]], ["In addition, the modification of the bicyclic core of bc-nucleoside could induce a correction of the misaligned torsion angle , resulting in a higher RNA affinity.B. Kier and N. AndersenA new thymidine bicyclo-nucleoside, bc ox -T, carrying a benzyl substituent was synthesized, using a -face selective nucleosidation.", [["bc-nucleoside", "CHEMICAL", 54, 67], ["AndersenA", "CHEMICAL", 178, 187], ["thymidine bicyclo-nucleoside", "CHEMICAL", 192, 220], ["bc ox -T", "CHEMICAL", 222, 230], ["benzyl", "CHEMICAL", 243, 249], ["bc-nucleoside", "CHEMICAL", 54, 67], ["thymidine bicyclo-nucleoside", "CHEMICAL", 192, 220], ["bc ox -T", "CHEMICAL", 222, 230], ["benzyl", "CHEMICAL", 243, 249], ["bc-nucleoside", "SIMPLE_CHEMICAL", 54, 67], ["thymidine bicyclo-nucleoside", "SIMPLE_CHEMICAL", 192, 220], ["bc ox -T", "SIMPLE_CHEMICAL", 222, 230], ["benzyl substituent", "SIMPLE_CHEMICAL", 243, 261], ["the bicyclic core of bc-nucleoside", "TREATMENT", 33, 67], ["the misaligned torsion angle", "PROBLEM", 97, 125], ["a higher RNA affinity", "PROBLEM", 141, 162], ["new thymidine bicyclo", "TREATMENT", 188, 209], ["nucleoside", "TREATMENT", 210, 220], ["bc ox", "TEST", 222, 227], ["a benzyl substituent", "TREATMENT", 241, 261], ["a -face selective nucleosidation", "TREATMENT", 285, 317], ["misaligned torsion", "OBSERVATION", 101, 119], ["RNA affinity", "OBSERVATION", 150, 162]]], ["Its structure was determined by x-ray crystallography.", [["x-ray crystallography", "TEST", 32, 53]]], ["The modified nucleoside was incorporated into oligonucleotide by solid phase synthesis using phosphoramidite chemistry.", [["nucleoside", "CHEMICAL", 13, 23], ["phosphoramidite", "CHEMICAL", 93, 108], ["nucleoside", "CHEMICAL", 13, 23], ["phosphoramidite", "CHEMICAL", 93, 108], ["nucleoside", "SIMPLE_CHEMICAL", 13, 23], ["The modified nucleoside", "TREATMENT", 0, 23], ["phosphoramidite chemistry", "TREATMENT", 93, 118]]], ["The stability of DNA duplexes and DNA-RNA hybrid duplexes containing modified nucleotides was determined by UVmelting experiment, and the shape of the duplexes were analyzed by CDspectroscopy.", [["nucleotides", "CHEMICAL", 78, 89], ["DNA", "CELLULAR_COMPONENT", 17, 20], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["DNA duplexes", "DNA", 17, 29], ["DNA duplexes", "PROBLEM", 17, 29], ["DNA", "PROBLEM", 34, 37], ["RNA hybrid duplexes", "TREATMENT", 38, 57], ["modified nucleotides", "TREATMENT", 69, 89], ["the duplexes", "TREATMENT", 147, 159], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["DNA duplexes", "OBSERVATION", 17, 29], ["hybrid duplexes", "OBSERVATION", 42, 57], ["shape", "OBSERVATION_MODIFIER", 138, 143]]], ["The base pairing selectivity of modified oligonucleotides was determined by measuring the stability of DNA duplexes containing a mismatched base opposite to the modified nucleotide.", [["nucleotide", "CHEMICAL", 170, 180], ["nucleotide", "CHEMICAL", 170, 180], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["modified oligonucleotides", "TREATMENT", 32, 57], ["DNA duplexes", "PROBLEM", 103, 115], ["base", "ANATOMY_MODIFIER", 4, 8], ["selectivity", "OBSERVATION_MODIFIER", 17, 28], ["modified oligonucleotides", "OBSERVATION", 32, 57], ["stability", "OBSERVATION_MODIFIER", 90, 99], ["DNA duplexes", "OBSERVATION", 103, 115], ["mismatched", "OBSERVATION_MODIFIER", 129, 139], ["base", "OBSERVATION_MODIFIER", 140, 144], ["opposite", "OBSERVATION_MODIFIER", 145, 153]]], ["Finally, fluorescein-labeled oligonucleotides were transfected into HeLa cell, and the cells were analyzed under fluorescence microscopy.", [["HeLa cell", "ANATOMY", 68, 77], ["cells", "ANATOMY", 87, 92], ["fluorescein", "CHEMICAL", 9, 20], ["fluorescein", "CHEMICAL", 9, 20], ["fluorescein", "SIMPLE_CHEMICAL", 9, 20], ["HeLa cell", "CELL", 68, 77], ["cells", "CELL", 87, 92], ["HeLa cell", "CELL_LINE", 68, 77], ["fluorescein-labeled oligonucleotides", "TREATMENT", 9, 45], ["fluorescence microscopy", "TEST", 113, 136], ["HeLa cell", "OBSERVATION", 68, 77]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["Chim.", [["Chim", "TEST", 0, 4]]], ["Steffens R., Leumann C., Helv.", [["Leumann", "ANATOMY", 13, 20]]], ["Chim.", [["Chim", "TEST", 0, 4]]], ["Pallan P., Ittig D., Heroux A., Wawrzak Z., Leumann C., Egli M., Chem.", [["Leumann", "ANATOMY", 44, 51]]], ["Steffens R., Leumann C., J. Amer.", [["Leumann", "ANATOMY", 13, 20]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["Ittig D., Renneberg D., Schumperli D., Leumann C., Nucleic Acids Res., 2004 , 32, 346.", [["Leumann", "ANATOMY", 39, 46]]], ["Luisier S., Leumann C., ChemBioChem., 2008 , 9, 2244 A computational approach using virtual screening combined with consensus scoring revealed drug-like compounds that inhibit the function of the PhoP response regulator by disrupting formation to its active dimer state.", [["PhoP", "GENE_OR_GENE_PRODUCT", 196, 200], ["PhoP response regulator", "PROTEIN", 196, 219], ["virtual screening", "TEST", 84, 101], ["consensus scoring", "TEST", 116, 133], ["drug-like compounds", "PROBLEM", 143, 162]]], ["PhoP, the regulatory receiver of the PhoQ/PhoP two-component signal transduction system, senses and responds to extracellular Mg2\u00fe levels by controlling the transcription level of key virulence genes in Salmonella typhimurium, as well as a number of other pathogenic species including Yersinia pestis, the causative pathogen for plague.", [["extracellular", "ANATOMY", 112, 125], ["Mg2", "CHEMICAL", 126, 129], ["Yersinia pestis", "DISEASE", 285, 300], ["plague", "DISEASE", 329, 335], ["PhoP", "GENE_OR_GENE_PRODUCT", 0, 4], ["PhoQ", "GENE_OR_GENE_PRODUCT", 37, 41], ["PhoP", "GENE_OR_GENE_PRODUCT", 42, 46], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["Mg2", "GENE_OR_GENE_PRODUCT", 126, 129], ["Salmonella typhimurium", "ORGANISM", 203, 225], ["Yersinia pestis", "ORGANISM", 285, 300], ["PhoP", "PROTEIN", 0, 4], ["PhoQ", "PROTEIN", 37, 41], ["PhoP", "PROTEIN", 42, 46], ["Mg2", "PROTEIN", 126, 129], ["virulence genes", "DNA", 184, 199], ["Salmonella typhimurium", "SPECIES", 203, 225], ["Yersinia pestis", "SPECIES", 285, 300], ["Salmonella typhimurium", "SPECIES", 203, 225], ["Yersinia pestis", "SPECIES", 285, 300], ["the PhoQ/PhoP", "TREATMENT", 33, 46], ["extracellular Mg2\u00fe levels", "TEST", 112, 137], ["Salmonella typhimurium", "PROBLEM", 203, 225], ["other pathogenic species", "PROBLEM", 250, 274], ["Yersinia pestis", "PROBLEM", 285, 300], ["the causative pathogen", "PROBLEM", 302, 324], ["plague", "PROBLEM", 329, 335], ["virulence genes", "OBSERVATION", 184, 199], ["Salmonella typhimurium", "OBSERVATION", 203, 225], ["pathogenic species", "OBSERVATION", 256, 274], ["Yersinia pestis", "OBSERVATION", 285, 300]]], ["The inactive monomeric state of PhoP is activated via phosphorylation by PhoQ, the sensor histidine kinase, at low extracellular Mg2\u00fe levels.", [["extracellular", "ANATOMY", 115, 128], ["histidine", "CHEMICAL", 90, 99], ["Mg2\u00fe", "CHEMICAL", 129, 133], ["PhoP", "GENE_OR_GENE_PRODUCT", 32, 36], ["PhoQ", "GENE_OR_GENE_PRODUCT", 73, 77], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 128], ["inactive monomeric state", "PROTEIN", 4, 28], ["PhoP", "PROTEIN", 32, 36], ["PhoQ", "PROTEIN", 73, 77], ["sensor histidine kinase", "PROTEIN", 83, 106], ["Mg2", "PROTEIN", 129, 132], ["the sensor histidine kinase", "TEST", 79, 106], ["inactive", "OBSERVATION_MODIFIER", 4, 12]]], ["Phosphorylation leads to formation of its active dimer state, that bind to its DNA promoter.", [["DNA", "CELLULAR_COMPONENT", 79, 82], ["dimer state", "PROTEIN", 49, 60], ["DNA promoter", "DNA", 79, 91], ["Phosphorylation", "TREATMENT", 0, 15], ["active dimer", "OBSERVATION", 42, 54]]], ["Compounds that bind to the surface of the dimerization interface can disrupt its DNA-binding ability, and most importantly, interfere with its function as a transcription factor regulating virulence.", [["surface", "ANATOMY", 27, 34], ["surface", "CELLULAR_COMPONENT", 27, 34], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["transcription factor", "PROTEIN", 157, 177]]], ["Experimental methods including electrophoretic mobility-shift assays and gel filtration chromatography were used to test the predictability of the computational approach and confirmed the mechanism of action for the predicted inhibitors.", [["Experimental methods", "TREATMENT", 0, 20], ["electrophoretic mobility", "TEST", 31, 55], ["shift assays", "TEST", 56, 68], ["gel filtration chromatography", "TEST", 73, 102], ["the predicted inhibitors", "TREATMENT", 212, 236]]], ["This study serves as a proof-of-principle for targeting the dimerization interface of a response regulator to inhibit its function and modulate gene regulation of the expression of virulence.", [["This study", "TEST", 0, 10], ["virulence", "PROBLEM", 181, 190]]], ["With the increasing resistance of pathogenic bacteria to current antibiotics, the success of this strategy suggests targeting two-component signal transduction systems as a promising approach for development of novel antibiotics.", [["pathogenic bacteria", "PROBLEM", 34, 53], ["current antibiotics", "TREATMENT", 57, 76], ["this strategy", "TREATMENT", 93, 106], ["novel antibiotics", "TREATMENT", 211, 228], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["resistance", "OBSERVATION_MODIFIER", 20, 30], ["pathogenic bacteria", "OBSERVATION", 34, 53]]], ["The cyclic lipodepsipeptides are a diverse class of natural products with significant pharmacotherapeutic potential.", [["cyclic lipodepsipeptides", "CHEMICAL", 4, 28], ["cyclic lipodepsipeptides", "SIMPLE_CHEMICAL", 4, 28], ["The cyclic lipodepsipeptides", "TREATMENT", 0, 28], ["cyclic lipodepsipeptides", "OBSERVATION", 4, 28], ["diverse", "OBSERVATION_MODIFIER", 35, 42], ["natural products", "OBSERVATION", 52, 68], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["pharmacotherapeutic", "OBSERVATION_MODIFIER", 86, 105], ["potential", "OBSERVATION_MODIFIER", 106, 115]]], ["Daptomycin is a semi-synthetic 13-membered cyclic lipodepsipeptide, with a decadepsipeptide core ring.", [["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "CHEMICAL", 0, 10], ["cyclic lipodepsipeptide", "CHEMICAL", 43, 66], ["decadepsipeptide", "CHEMICAL", 75, 91], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["13-membered cyclic lipodepsipeptide", "SIMPLE_CHEMICAL", 31, 66], ["decadepsipeptide core ring", "PROTEIN", 75, 101], ["Daptomycin", "TREATMENT", 0, 10], ["cyclic lipodepsipeptide", "TREATMENT", 43, 66], ["a decadepsipeptide core ring", "TREATMENT", 73, 101]]], ["It is produced from the fermentation products of Streptomyces roseosporus.", [["Streptomyces roseosporus", "ORGANISM", 49, 73], ["Streptomyces roseosporus", "SPECIES", 49, 73], ["Streptomyces roseosporus", "SPECIES", 49, 73], ["the fermentation products", "TREATMENT", 20, 45], ["Streptomyces roseosporus", "TREATMENT", 49, 73]]], ["Daptomycin is an effective bactericidal agent against multi-drug resistant Grampositive bacteria such as MRSA.", [["Daptomycin", "CHEMICAL", 0, 10], ["MRSA", "DISEASE", 105, 109], ["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["MRSA", "SPECIES", 105, 109], ["MRSA", "SPECIES", 105, 109], ["Daptomycin", "TREATMENT", 0, 10], ["an effective bactericidal agent", "TREATMENT", 14, 45], ["multi-drug resistant Grampositive bacteria", "PROBLEM", 54, 96], ["MRSA", "PROBLEM", 105, 109], ["MRSA", "OBSERVATION", 105, 109]]], ["Successful solid-phase synthesis of various cyclic lipodepsipeptide daptomycin analogues was achieved using glutamic acid in place of (2S,3R)-methylglutamic acid at position 12 in the cyclic core structure.", [["daptomycin", "CHEMICAL", 68, 78], ["glutamic acid", "CHEMICAL", 108, 121], ["(2S,3R)-methylglutamic acid", "CHEMICAL", 134, 161], ["daptomycin", "CHEMICAL", 68, 78], ["glutamic acid", "CHEMICAL", 108, 121], ["(2S,3R)-methylglutamic acid", "CHEMICAL", 134, 161], ["cyclic lipodepsipeptide daptomycin analogues", "SIMPLE_CHEMICAL", 44, 88], ["glutamic acid", "SIMPLE_CHEMICAL", 108, 121], ["(2S,3R)-methylglutamic acid", "SIMPLE_CHEMICAL", 134, 161], ["Successful solid-phase synthesis", "TREATMENT", 0, 32], ["various cyclic lipodepsipeptide daptomycin analogues", "TREATMENT", 36, 88], ["glutamic acid", "TEST", 108, 121], ["methylglutamic acid at position", "TREATMENT", 142, 173]]], ["The C-terminal kynurenine residue, utilised for depsipeptide bond formation, was substituted with tryptophan, valine or isoleucine.", [["kynurenine", "CHEMICAL", 15, 25], ["depsipeptide", "CHEMICAL", 48, 60], ["tryptophan", "CHEMICAL", 98, 108], ["valine", "CHEMICAL", 110, 116], ["isoleucine", "CHEMICAL", 120, 130], ["kynurenine", "CHEMICAL", 15, 25], ["depsipeptide", "CHEMICAL", 48, 60], ["tryptophan", "CHEMICAL", 98, 108], ["valine", "CHEMICAL", 110, 116], ["isoleucine", "CHEMICAL", 120, 130], ["C-terminal kynurenine", "SIMPLE_CHEMICAL", 4, 25], ["depsipeptide bond", "SIMPLE_CHEMICAL", 48, 65], ["tryptophan", "SIMPLE_CHEMICAL", 98, 108], ["valine", "AMINO_ACID", 110, 116], ["isoleucine", "AMINO_ACID", 120, 130], ["The C-terminal kynurenine residue", "PROBLEM", 0, 33], ["depsipeptide bond formation", "TREATMENT", 48, 75], ["tryptophan", "TREATMENT", 98, 108], ["valine", "TREATMENT", 110, 116], ["isoleucine", "TREATMENT", 120, 130], ["kynurenine residue", "OBSERVATION", 15, 33]]], ["Macrolactamisation took place on the solid-phase between the Glu12 -carboxyl and the Trp/Val/Ile -amino group.", [["Macrolactamisation", "CHEMICAL", 0, 18], ["Glu12 -carboxyl", "CHEMICAL", 61, 76], ["Trp", "CHEMICAL", 85, 88], ["Val/Ile -amino", "CHEMICAL", 89, 103], ["Glu12", "CHEMICAL", 61, 66], ["carboxyl", "CHEMICAL", 68, 76], ["Trp", "CHEMICAL", 85, 88], ["Val", "CHEMICAL", 89, 92], ["Ile", "CHEMICAL", 93, 96], ["Glu12 -carboxyl", "SIMPLE_CHEMICAL", 61, 76], ["Trp", "AMINO_ACID", 85, 88], ["Val/Ile -amino", "SIMPLE_CHEMICAL", 89, 103], ["Trp/Val/Ile -amino group", "PROTEIN", 85, 109], ["Macrolactamisation", "TEST", 0, 18], ["carboxyl", "TREATMENT", 68, 76], ["the Trp/Val/Ile -amino group", "TREATMENT", 81, 109]]], ["Synthesis of the protected (2S,3R)-methylglutamic acid for buildingblock was also accomplished via enzymatic resolution of racemic Naacetyl -methylaspartic acid -methyl ester.", [["2S,3R)-methylglutamic acid", "CHEMICAL", 28, 54], ["Naacetyl -methylaspartic acid -methyl ester", "CHEMICAL", 131, 174], ["(2S,3R)-methylglutamic acid", "CHEMICAL", 27, 54], ["Naacetyl -methylaspartic acid -methyl ester", "CHEMICAL", 131, 174], ["(2S,3R)-methylglutamic acid", "SIMPLE_CHEMICAL", 27, 54], ["buildingblock", "SIMPLE_CHEMICAL", 59, 72], ["Naacetyl -methylaspartic acid -methyl ester", "SIMPLE_CHEMICAL", 131, 174], ["methylglutamic acid", "TREATMENT", 35, 54], ["buildingblock", "TREATMENT", 59, 72], ["racemic Naacetyl", "TREATMENT", 123, 139], ["methylaspartic acid -methyl ester", "TREATMENT", 141, 174]]], ["Through the successful synthesis of the daptomycin analogues and the non-proteineogenic amino acid MeGlu, we demonstrate the feasibility of the total SPPS of daptomycin.", [["daptomycin", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 88, 98], ["SPPS", "CHEMICAL", 150, 154], ["daptomycin", "CHEMICAL", 158, 168], ["daptomycin", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 88, 98], ["daptomycin", "CHEMICAL", 158, 168], ["daptomycin analogues", "SIMPLE_CHEMICAL", 40, 60], ["amino acid", "AMINO_ACID", 88, 98], ["MeGlu", "SIMPLE_CHEMICAL", 99, 104], ["daptomycin", "SIMPLE_CHEMICAL", 158, 168], ["the daptomycin analogues", "TREATMENT", 36, 60], ["the non-proteineogenic amino acid MeGlu", "TREATMENT", 65, 104], ["daptomycin", "TREATMENT", 158, 168]]], ["Due to the growing increase in antibiotic resistance, antimicrobial peptides (AMPs) have become important candidates as potential therapeutic agents.", [["antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 54, 76], ["antibiotic resistance", "TREATMENT", 31, 52], ["antimicrobial peptides (AMPs", "TREATMENT", 54, 82], ["therapeutic agents", "TREATMENT", 130, 148], ["growing", "OBSERVATION_MODIFIER", 11, 18], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["antibiotic resistance", "OBSERVATION", 31, 52]]], ["They have two unique features: 1) a net positive charge of \u00fe2 or greater, owing to an excess of basic amino acids (Lys, Arg) over acidic amino acids (Asp, Glu); 2) an amphipathic nature, with a nonpolar face and a polar face.", [["amino acids", "CHEMICAL", 102, 113], ["Lys, Arg", "CHEMICAL", 115, 123], ["amino acids", "CHEMICAL", 137, 148], ["Asp, Glu", "CHEMICAL", 150, 158], ["amino acids", "CHEMICAL", 102, 113], ["Lys", "CHEMICAL", 115, 118], ["Arg", "CHEMICAL", 120, 123], ["amino acids", "CHEMICAL", 137, 148], ["Asp", "CHEMICAL", 150, 153], ["Glu", "CHEMICAL", 155, 158], ["amino acids", "AMINO_ACID", 102, 113], ["Lys", "AMINO_ACID", 115, 118], ["Arg", "AMINO_ACID", 120, 123], ["acidic", "AMINO_ACID", 130, 136], ["amino acids", "AMINO_ACID", 137, 148], ["Asp", "AMINO_ACID", 150, 153], ["Glu", "AMINO_ACID", 155, 158], ["a net positive charge of \u00fe2", "PROBLEM", 34, 61], ["basic amino acids", "TEST", 96, 113], ["Lys", "TEST", 115, 118], ["acidic amino acids", "TEST", 130, 148], ["Asp", "TEST", 150, 153], ["Glu", "TEST", 155, 158], ["nonpolar", "ANATOMY_MODIFIER", 194, 202], ["polar", "ANATOMY_MODIFIER", 214, 219]]], ["Their main target is the cell membrane of microorganisms.", [["cell membrane", "ANATOMY", 25, 38], ["cell membrane", "CELLULAR_COMPONENT", 25, 38], ["main", "OBSERVATION_MODIFIER", 6, 10], ["target", "OBSERVATION_MODIFIER", 11, 17], ["cell membrane", "OBSERVATION", 25, 38], ["microorganisms", "OBSERVATION", 42, 56]]], ["Our lead compound, a 26-residue peptide, V13K, showed that a single valine to lysine substitution (compared to its parent peptide) in the center of the non-polar face dramatically reduced toxicity and increased the therapeutic index.", [["valine", "CHEMICAL", 68, 74], ["lysine", "CHEMICAL", 78, 84], ["toxicity", "DISEASE", 188, 196], ["valine", "CHEMICAL", 68, 74], ["lysine", "CHEMICAL", 78, 84], ["V13K", "SIMPLE_CHEMICAL", 41, 45], ["valine", "AMINO_ACID", 68, 74], ["lysine", "AMINO_ACID", 78, 84], ["a 26-residue peptide", "TEST", 19, 39], ["a single valine to lysine substitution", "TREATMENT", 59, 97], ["reduced toxicity", "PROBLEM", 180, 196], ["lysine substitution", "OBSERVATION", 78, 97], ["non-polar face", "ANATOMY", 152, 166], ["dramatically", "OBSERVATION_MODIFIER", 167, 179], ["reduced", "OBSERVATION_MODIFIER", 180, 187], ["toxicity", "OBSERVATION", 188, 196], ["increased", "OBSERVATION_MODIFIER", 201, 210], ["therapeutic index", "OBSERVATION", 215, 232]]], ["We then systematically substituted positively charged residues on the polar face to give a net positive charge from \u00fe5 to \u00fe11 as well as changing the relative location of these charged residues while maintaining the identical non-polar face for all analogs.", [["a net positive charge", "TREATMENT", 89, 110], ["these charged residues", "PROBLEM", 171, 193], ["charged residues", "OBSERVATION", 177, 193], ["non-polar", "ANATOMY_MODIFIER", 226, 235]]], ["We evaluated these peptide analogs for their antimicrobial activity against six clinical strains of Pseudomonas aeruginosa and their hemolytic activity to human red blood cells.", [["red blood cells", "ANATOMY", 161, 176], ["hemolytic", "DISEASE", 133, 142], ["Pseudomonas aeruginosa", "ORGANISM", 100, 122], ["human", "ORGANISM", 155, 160], ["red blood cells", "CELL", 161, 176], ["human red blood cells", "CELL_TYPE", 155, 176], ["Pseudomonas aeruginosa", "SPECIES", 100, 122], ["human", "SPECIES", 155, 160], ["Pseudomonas aeruginosa", "SPECIES", 100, 122], ["human", "SPECIES", 155, 160], ["these peptide analogs", "TREATMENT", 13, 34], ["their antimicrobial activity", "TREATMENT", 39, 67], ["Pseudomonas aeruginosa", "PROBLEM", 100, 122], ["red blood cells", "TEST", 161, 176]]], ["Increasing net positive charge and varying the location of these charged residues had a dramatic effect on antimicrobial activity and the resulting therapeutic index.FIGURE 1Structure and atom numbering of bc-, tc-, and bc OXnucleosides.", [["bc-, tc-, and bc OXnucleosides", "CHEMICAL", 206, 236], ["bc-", "SIMPLE_CHEMICAL", 206, 209], ["tc-", "SIMPLE_CHEMICAL", 211, 214], ["bc OXnucleosides", "SIMPLE_CHEMICAL", 220, 236], ["Increasing net positive charge", "PROBLEM", 0, 30], ["these charged residues", "PROBLEM", 59, 81], ["antimicrobial activity", "TREATMENT", 107, 129], ["bc-", "TEST", 206, 209], ["tc-", "TEST", 211, 214], ["bc OXnucleosides", "PROBLEM", 220, 236], ["net", "OBSERVATION_MODIFIER", 11, 14], ["positive charge", "OBSERVATION", 15, 30], ["charged residues", "OBSERVATION", 65, 81], ["dramatic", "OBSERVATION_MODIFIER", 88, 96], ["antimicrobial activity", "OBSERVATION_MODIFIER", 107, 129], ["therapeutic index", "OBSERVATION", 148, 165]]], ["In the last two decades the incidence of human fungal infections has increased, mainly in immunocompromised patients and additionally many microorganisms have shown resistance to common antibiotics.", [["fungal infections", "DISEASE", 47, 64], ["human", "ORGANISM", 41, 46], ["patients", "ORGANISM", 108, 116], ["human", "SPECIES", 41, 46], ["patients", "SPECIES", 108, 116], ["human", "SPECIES", 41, 46], ["human fungal infections", "PROBLEM", 41, 64], ["many microorganisms", "PROBLEM", 134, 153], ["common antibiotics", "TREATMENT", 179, 197], ["human", "OBSERVATION_MODIFIER", 41, 46], ["fungal", "OBSERVATION_MODIFIER", 47, 53], ["infections", "OBSERVATION", 54, 64], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["immunocompromised", "OBSERVATION_MODIFIER", 90, 107]]], ["Therefore alternative antimicrobial agents have to be found.", [["alternative antimicrobial agents", "TREATMENT", 10, 42]]], ["Natural antimicrobial peptides are optimal candidates because they fight against resistant microorganisms and they have a broad-spectrum activity.", [["Natural antimicrobial peptides", "TREATMENT", 0, 30], ["resistant microorganisms", "PROBLEM", 81, 105]]], ["Recently we have reported that -MSH, an endogenous linear peptide, and particularly the C-terminal tripeptide Lys-Pro-Val have a potent antimicrobial activity against two representative pathogens:FIGURE 1Staphylococcus aureus and C. albicans.", [["Pro-Val", "CHEMICAL", 114, 121], ["C", "CHEMICAL", 88, 89], ["Lys-Pro-Val", "CHEMICAL", 110, 121], ["-MSH", "GENE_OR_GENE_PRODUCT", 31, 35], ["Lys-Pro-Val", "SIMPLE_CHEMICAL", 110, 121], ["FIGURE 1Staphylococcus aureus", "ORGANISM", 196, 225], ["C. albicans", "ORGANISM", 230, 241], ["1Staphylococcus aureus", "SPECIES", 203, 225], ["C. albicans", "SPECIES", 230, 241], ["FIGURE 1Staphylococcus aureus", "SPECIES", 196, 225], ["C. albicans", "SPECIES", 230, 241], ["MSH", "PROBLEM", 32, 35], ["an endogenous linear peptide", "PROBLEM", 37, 65], ["a potent antimicrobial activity", "TREATMENT", 127, 158], ["FIGURE 1Staphylococcus aureus", "PROBLEM", 196, 225], ["C. albicans", "PROBLEM", 230, 241], ["aureus", "OBSERVATION", 219, 225]]], ["Indeed the candidacidal effect of -MSH is linked to the increase of intracellular cAMP in the C.albicans and it has been possible to hypothesize an interaction of peptide with a yeast isoform of melanocortin receptor.FIGURE 1Previous studies allowed to obtain [(D)Nal-7, Phe-12]-a -MSH(6-13), originated from changes into the sequence of -MSH(6-13).", [["intracellular", "ANATOMY", 68, 81], ["MSH", "CHEMICAL", 35, 38], ["cAMP", "CHEMICAL", 82, 86], ["C.albicans", "CHEMICAL", 94, 104], ["cAMP", "CHEMICAL", 82, 86], ["[(D)Nal-7, Phe-12]-a -MSH", "CHEMICAL", 260, 285], ["MSH", "GENE_OR_GENE_PRODUCT", 35, 38], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 81], ["cAMP", "SIMPLE_CHEMICAL", 82, 86], ["melanocortin receptor", "GENE_OR_GENE_PRODUCT", 195, 216], ["[(D)Nal-7, Phe-12]-a -MSH", "SIMPLE_CHEMICAL", 260, 285], ["6-13)", "SIMPLE_CHEMICAL", 286, 291], ["melanocortin receptor", "PROTEIN", 195, 216], ["yeast", "SPECIES", 178, 183], ["yeast", "SPECIES", 178, 183], ["MSH", "PROBLEM", 35, 38], ["intracellular cAMP in the C.albicans", "PROBLEM", 68, 104], ["an interaction of peptide", "PROBLEM", 145, 170], ["melanocortin receptor", "TREATMENT", 195, 216], ["Nal", "TEST", 264, 267], ["candidacidal effect", "OBSERVATION", 11, 30], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["intracellular cAMP", "OBSERVATION", 68, 86]]], ["This -MSH analog showed the most potent candidacidal activity and it became our lead compound.", [["MSH", "GENE_OR_GENE_PRODUCT", 6, 9], ["This -MSH analog", "TEST", 0, 16], ["most potent", "OBSERVATION_MODIFIER", 28, 39], ["candidacidal activity", "OBSERVATION", 40, 61]]], ["T o improve antifungal activity the residue of glycine of lead compound was replaced with natural and unnatural amino acids and new potent antifungal compounds were identified.P 022 DESIGN AND SYNTHESIS OF ANTIMICROBIAL PEPTIDES.", [["glycine", "CHEMICAL", 47, 54], ["amino acids", "CHEMICAL", 112, 123], ["glycine", "CHEMICAL", 47, 54], ["amino acids", "CHEMICAL", 112, 123], ["glycine", "AMINO_ACID", 47, 54], ["lead compound", "SIMPLE_CHEMICAL", 58, 71], ["amino acids", "AMINO_ACID", 112, 123], ["antifungal activity", "TREATMENT", 12, 31], ["glycine of lead compound", "TREATMENT", 47, 71], ["natural and unnatural amino acids", "TREATMENT", 90, 123], ["new potent antifungal compounds", "TREATMENT", 128, 159], ["ANTIMICROBIAL PEPTIDES", "TREATMENT", 206, 228], ["antifungal activity", "OBSERVATION", 12, 31], ["potent", "OBSERVATION_MODIFIER", 132, 138], ["antifungal compounds", "OBSERVATION", 139, 159]]], ["Karbalaee-Mohammad, H. Naderi-manesh, H. Hossein nejad Ariani Tarbiat Modares University There is a wide range of antimicrobial peptide (AMPs) in nature.", [["antimicrobial peptide", "SIMPLE_CHEMICAL", 114, 135], ["Karbalaee", "TREATMENT", 0, 9], ["antimicrobial peptide", "TREATMENT", 114, 135], ["wide", "OBSERVATION_MODIFIER", 100, 104], ["range", "OBSERVATION_MODIFIER", 105, 110], ["antimicrobial peptide", "OBSERVATION", 114, 135]]], ["The activity of these peptide usually depends on several parameters such as: sequence, size, degree of structure formation, hydrophobicity , and Amphipathicity.", [["structure formation", "PROBLEM", 103, 122], ["hydrophobicity", "PROBLEM", 124, 138], ["Amphipathicity", "PROBLEM", 145, 159], ["size", "OBSERVATION_MODIFIER", 87, 91], ["structure formation", "OBSERVATION", 103, 122], ["hydrophobicity", "OBSERVATION_MODIFIER", 124, 138]]], ["In this work we plan to analysis these parameters in order to design a potent AMPcandidate.", [["AMPcandidate", "CHEMICAL", 78, 90], ["AMPcandidate", "CHEMICAL", 78, 90], ["AMPcandidate", "SIMPLE_CHEMICAL", 78, 90], ["these parameters", "TEST", 33, 49], ["a potent AMPcandidate", "TREATMENT", 69, 90]]], ["Although these parameters are infleuenced on activity but not directly correlated.AMPs due to their negative charge usually have anticancer activity.", [["anticancer", "ANATOMY", 129, 139], ["AMPs", "GENE_OR_GENE_PRODUCT", 82, 86], ["anticancer", "CANCER", 129, 139], ["AMPs", "TEST", 82, 86]]], ["In this work we focus on the group of peptides and choose aurein 1.2. which designed on it a target peptide.", [["aurein", "TEST", 58, 64], ["a target peptide", "TREATMENT", 91, 107]]], ["The designed peptide is synthesised and analysed conformation and the MIC test will be compared with aurein 1.2.", [["the MIC test", "TEST", 66, 78], ["aurein", "TEST", 101, 107]]], ["Dept. of Biochemistry, Institute of Chemistry; 2 Dept. of Cell and Developmental Biology, 3 Dept. of Parasitology, Institute of Biomedical Sciences; University of Sa\u02dco Paulo, 05508-900, Sa\u02dco Paulo, Brazil Glycine-rich proteins and peptides (GRP) are found in animals and plants.P 022 DESIGN AND SYNTHESIS OF ANTIMICROBIAL PEPTIDEAs little is known about their chemical synthesis, structure, structure-activity relationship and mode of action, we studied shepherin I (ShepI; an antimicrobial GRP with 67.9% of Gly and 28.6% of His) and analogues.", [["Cell", "ANATOMY", 58, 62], ["shepherin I", "CHEMICAL", 454, 465], ["Gly", "CHEMICAL", 509, 512], ["His", "CHEMICAL", 526, 529], ["Cell", "CELL", 58, 62], ["Glycine-rich proteins", "GENE_OR_GENE_PRODUCT", 205, 226], ["GRP", "GENE_OR_GENE_PRODUCT", 241, 244], ["shepherin I", "GENE_OR_GENE_PRODUCT", 454, 465], ["ShepI", "GENE_OR_GENE_PRODUCT", 467, 472], ["GRP", "GENE_OR_GENE_PRODUCT", 491, 494], ["GRP", "PROTEIN", 241, 244], ["shepherin I", "PROTEIN", 454, 465], ["ShepI", "PROTEIN", 467, 472], ["antimicrobial GRP", "PROTEIN", 477, 494], ["Brazil Glycine-rich proteins", "TREATMENT", 198, 226], ["ANTIMICROBIAL PEPTIDEAs", "TREATMENT", 308, 331], ["an antimicrobial GRP", "TEST", 474, 494], ["Gly", "TEST", 509, 512]]], ["Stepwise solid-phase synthesis at 608C and NIR-FT-Raman spectra of the growing peptide-resins indicated that Shep I is prone to aggregation.", [["aggregation", "DISEASE", 128, 139], ["608C", "SIMPLE_CHEMICAL", 34, 38], ["Shep I", "GENE_OR_GENE_PRODUCT", 109, 115], ["Shep I", "PROTEIN", 109, 115], ["Stepwise solid-phase synthesis", "TREATMENT", 0, 30], ["resins", "TREATMENT", 87, 93]]], ["Among the analogues studied, the C-terminally amidated Shep Ia, Shep I (3-28)a and Shep I (6-28)a showed to be the most attractive as they were as active as Shep I against C. albicans strains.", [["C", "CHEMICAL", 33, 34], ["Shep I (6-28)", "SIMPLE_CHEMICAL", 83, 96], ["Shep I", "GENE_OR_GENE_PRODUCT", 157, 163], ["C. albicans", "ORGANISM", 172, 183], ["C. albicans", "SPECIES", 172, 183], ["C. albicans", "SPECIES", 172, 183], ["C. albicans strains", "PROBLEM", 172, 191]]], ["Temporins, antimicrobial peptides (AMPs) isolated from the skin of Rana temporaria, are short, linear 10-14 residues long peptides, with a net charge positive and an amidate Cterminal.", [["skin", "ANATOMY", 59, 63], ["Temporins", "SIMPLE_CHEMICAL", 0, 9], ["antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 11, 33], ["AMPs", "GENE_OR_GENE_PRODUCT", 35, 39], ["skin", "ORGAN", 59, 63], ["Rana temporaria", "ORGANISM", 67, 82], ["amidate Cterminal", "PROTEIN", 166, 183], ["Rana temporaria", "SPECIES", 67, 82], ["Rana temporaria", "SPECIES", 67, 82], ["Temporins", "TREATMENT", 0, 9], ["antimicrobial peptides (AMPs)", "TREATMENT", 11, 40], ["Rana temporaria", "PROBLEM", 67, 82], ["a net charge positive", "PROBLEM", 137, 158], ["an amidate Cterminal", "TREATMENT", 163, 183], ["skin", "ANATOMY", 59, 63], ["Rana temporaria", "OBSERVATION", 67, 82]]], ["To get insight into mechanism of action and biological activity of these compounds, we have investigated two members of this family, temporin L (TL) and temporin A (TA).", [["temporin L", "GENE_OR_GENE_PRODUCT", 133, 143], ["TL", "GENE_OR_GENE_PRODUCT", 145, 147], ["temporin A", "GENE_OR_GENE_PRODUCT", 153, 163], ["TA", "GENE_OR_GENE_PRODUCT", 165, 167], ["temporin L", "PROTEIN", 133, 143], ["TL", "PROTEIN", 145, 147], ["temporin A", "PROTEIN", 153, 163], ["TA", "PROTEIN", 165, 167], ["temporin L (TL)", "TREATMENT", 133, 148], ["temporin A (TA)", "TREATMENT", 153, 168]]], ["The first (FLPLIGRVLSGIL-NH2) is preferentially active against Gram-positive bacterial strains and hasn't haemolytic activity.", [["FLPLIGRVLSGIL-NH2", "CHEMICAL", 11, 28], ["NH2", "CHEMICAL", 25, 28], ["FLPLIGRVLSGIL-NH2", "SIMPLE_CHEMICAL", 11, 28], ["Gram-", "GENE_OR_GENE_PRODUCT", 63, 68], ["NH2", "PROTEIN", 25, 28], ["Gram-positive bacterial strains", "PROBLEM", 63, 94], ["haemolytic activity", "PROBLEM", 106, 125], ["active", "OBSERVATION_MODIFIER", 48, 54], ["positive bacterial strains", "OBSERVATION", 68, 94], ["haemolytic activity", "OBSERVATION", 106, 125]]], ["The second (FVQWFSKFLGRIL-NH2) has the highest activity among all temporins but it shows a haemolytic activity at the concentrations required to kill bacteria.", [["haemolytic", "DISEASE", 91, 101], ["NH2", "CHEMICAL", 26, 29], ["FVQWFSKFLGRIL-NH2", "GENE_OR_GENE_PRODUCT", 12, 29], ["temporins", "SIMPLE_CHEMICAL", 66, 75], ["NH2", "PROTEIN", 26, 29], ["The second (FVQWFSKFLGRIL-NH2", "TREATMENT", 0, 29], ["a haemolytic activity", "PROBLEM", 89, 110], ["kill bacteria", "PROBLEM", 145, 158], ["haemolytic", "OBSERVATION", 91, 101]]], ["We have investigated the preferential conformation of TL and TA in SDS and DPC solutions.", [["TL", "SIMPLE_CHEMICAL", 54, 56], ["TA", "SIMPLE_CHEMICAL", 61, 63], ["DPC", "SIMPLE_CHEMICAL", 75, 78], ["TL and TA in SDS", "TREATMENT", 54, 70], ["DPC solutions", "TREATMENT", 75, 88]]], ["On the bases of the NMR and CD results, we have designed and synthesized new TA and TL analogues called Pro3TL and Gln3TA to understand the exact mechanism of the action.", [["Pro3TL", "CHEMICAL", 104, 110], ["Pro3TL", "CHEMICAL", 104, 110], ["Gln3TA", "CHEMICAL", 115, 121], ["TA", "SIMPLE_CHEMICAL", 77, 79], ["TL analogues", "SIMPLE_CHEMICAL", 84, 96], ["Pro3TL", "SIMPLE_CHEMICAL", 104, 110], ["Gln3TA", "SIMPLE_CHEMICAL", 115, 121], ["the NMR", "TEST", 16, 23], ["synthesized new TA and TL analogues", "TREATMENT", 61, 96], ["Pro3TL", "TREATMENT", 104, 110], ["Gln3TA", "TREATMENT", 115, 121], ["bases", "ANATOMY_MODIFIER", 7, 12]]], ["In addition, we have synthesized other compounds containing D-isomers and a Retro-TL analogue to define the structural characteristics for the design of the feature peptides.", [["D-isomers", "CHEMICAL", 60, 69], ["D-isomers", "SIMPLE_CHEMICAL", 60, 69], ["D-isomers", "TREATMENT", 60, 69], ["a Retro-TL analogue", "TREATMENT", 74, 93]]], ["Gomesin (Gm) is a potent antimicrobial peptide.", [["Gomesin", "CHEMICAL", 0, 7], ["Gm", "CHEMICAL", 9, 11], ["Gomesin", "CHEMICAL", 0, 7], ["Gomesin", "SIMPLE_CHEMICAL", 0, 7], ["Gm", "SIMPLE_CHEMICAL", 9, 11], ["a potent antimicrobial peptide", "TREATMENT", 16, 46]]], ["This molecule has two disulfide bridges (2/15 and 6/11), and adopts a -hairpinlike structure (pGlu-CRRLCYKQRCVTYCRGR-NH2).", [["disulfide", "CHEMICAL", 22, 31], ["NH2", "CHEMICAL", 117, 120], ["hairpinlike structure", "PROTEIN", 71, 92], ["pGlu", "PROTEIN", 94, 98], ["CRRLCYKQRCVTYCRGR", "PROTEIN", 99, 116], ["NH2", "PROTEIN", 117, 120], ["two disulfide bridges", "PROBLEM", 18, 39], ["a -hairpinlike structure", "PROBLEM", 68, 92], ["pGlu", "TEST", 94, 98], ["two", "OBSERVATION_MODIFIER", 18, 21], ["disulfide bridges", "OBSERVATION", 22, 39]]], ["Gm and its non active linear analogue, [Ser2,6,11,15]-Gm, were synthesized by solid-phase methodology.", [["Gm", "CHEMICAL", 0, 2], ["Ser2,6,11,15]-Gm", "CHEMICAL", 40, 56], ["[Ser2,6,11,15]-Gm", "CHEMICAL", 39, 56], ["Gm", "GENE_OR_GENE_PRODUCT", 0, 2], ["[Ser2,6,11,15]-Gm", "SIMPLE_CHEMICAL", 39, 56], ["Ser2,", "TEST", 40, 45], ["non active", "OBSERVATION_MODIFIER", 11, 21]]], ["We show here results obtained with optical and fluorescence microscopy of giant unilamellar vesicles (GUVs) composed of mixtures of a neutral (POPC) and a negatively charged (POPG) lipid.", [["giant unilamellar vesicles", "ANATOMY", 74, 100], ["GUVs", "ANATOMY", 102, 106], ["POPC", "CHEMICAL", 143, 147], ["POPC", "CHEMICAL", 143, 147], ["POPG", "CHEMICAL", 175, 179], ["unilamellar vesicles", "MULTI-TISSUE_STRUCTURE", 80, 100], ["POPC", "SIMPLE_CHEMICAL", 143, 147], ["POPG", "SIMPLE_CHEMICAL", 175, 179], ["fluorescence microscopy", "TEST", 47, 70], ["giant unilamellar vesicles", "TREATMENT", 74, 100], ["a neutral (POPC)", "TREATMENT", 132, 148], ["a negatively charged (POPG) lipid", "TREATMENT", 153, 186], ["giant", "OBSERVATION_MODIFIER", 74, 79], ["unilamellar vesicles", "OBSERVATION", 80, 100]]], ["Two different setups were used.", [["Two different setups", "TREATMENT", 0, 20]]], ["First we observed the effect of injecting a peptide solution with a micropipette placed at the vicinities of the GUVs.", [["GUVs", "ANATOMY", 113, 117], ["a peptide solution", "TREATMENT", 42, 60], ["a micropipette", "TREATMENT", 66, 80]]], ["As a result of peptide-lipid interaction, GUVs burst suddenly and stable pores were hardly ever observed.", [["lipid", "SIMPLE_CHEMICAL", 23, 28], ["GUVs", "SIMPLE_CHEMICAL", 42, 46], ["peptide-lipid interaction", "PROBLEM", 15, 40], ["GUVs burst", "PROBLEM", 42, 52], ["stable", "OBSERVATION_MODIFIER", 66, 72]]], ["As control, in the absence of peptide, the GUVs were never spontaneously disrupted.", [["GUVs", "GENE_OR_GENE_PRODUCT", 43, 47], ["the GUVs", "TEST", 39, 47]]], ["This fact leads us to speculate that gomesin disrupt the membrane via carpeting mode.", [["membrane", "ANATOMY", 57, 65], ["gomesin", "CHEMICAL", 37, 44], ["gomesin", "CHEMICAL", 37, 44], ["gomesin", "SIMPLE_CHEMICAL", 37, 44], ["membrane", "CELLULAR_COMPONENT", 57, 65]]], ["Injections of fluorescently labeled peptides show that Gm first accumulates on the vesicle surface, then domains are formed and eventually the vesicle burst.", [["vesicle surface", "ANATOMY", 83, 98], ["vesicle", "ANATOMY", 143, 150], ["Gm", "CHEMICAL", 55, 57], ["Gm", "GENE_OR_GENE_PRODUCT", 55, 57], ["vesicle surface", "CELLULAR_COMPONENT", 83, 98], ["vesicle", "CELLULAR_COMPONENT", 143, 150], ["Gm", "PROTEIN", 55, 57], ["fluorescently labeled peptides", "TEST", 14, 44], ["vesicle", "OBSERVATION_MODIFIER", 83, 90], ["surface", "OBSERVATION_MODIFIER", 91, 98], ["vesicle burst", "OBSERVATION", 143, 156]]], ["In the second setup, a GUV solution was mixed with increasing concentration of the peptides to quantify their lytic action against GUVs of different compositions.", [["GUV", "SIMPLE_CHEMICAL", 23, 26], ["GUVs", "SIMPLE_CHEMICAL", 131, 135], ["a GUV solution", "TREATMENT", 21, 35], ["increasing concentration of the peptides", "TREATMENT", 51, 91]]], ["The observed effect on the lytic activity were around 90% with 3 M gomesin and with 10 M of [Ser2,6,11,15]-Gm.", [["gomesin", "CHEMICAL", 67, 74], ["[Ser2,6,11,15]-Gm", "CHEMICAL", 92, 109], ["the lytic activity", "TEST", 23, 41], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["lytic", "OBSERVATION_MODIFIER", 27, 32]]], ["From our results we conclude that both peptides strongly interact with phospholipids vesicles and induce leakage of their content in a surface charge-dependent manner.", [["phospholipids vesicles", "ANATOMY", 71, 93], ["surface", "ANATOMY", 135, 142], ["phospholipids vesicles", "CELLULAR_COMPONENT", 71, 93], ["phospholipids vesicles", "TREATMENT", 71, 93], ["leakage of their content", "PROBLEM", 105, 129], ["leakage", "OBSERVATION", 105, 112]]], ["Bacillus polymyxa KT-8 strain, and exhibits promising activity against various kinds of fungi and Gram-positive bacteria, including methicillin-resistant S. aureus, In order to elucidate structural basis for its antibacterial activity we have synthesized fusaricidin A's analogues that differ in the lipid tail part, and its alanine-scanning library using standard Fmoc solid-phase methodology.", [["lipid tail", "ANATOMY", 300, 310], ["methicillin", "CHEMICAL", 132, 143], ["fusaricidin", "CHEMICAL", 255, 266], ["alanine", "CHEMICAL", 325, 332], ["methicillin", "CHEMICAL", 132, 143], ["fusaricidin A", "CHEMICAL", 255, 268], ["alanine", "CHEMICAL", 325, 332], ["Fmoc", "CHEMICAL", 365, 369], ["Bacillus polymyxa KT-8 strain", "ORGANISM", 0, 29], ["Gram-", "GENE_OR_GENE_PRODUCT", 98, 103], ["methicillin-resistant", "ORGANISM", 132, 153], ["S. aureus", "ORGANISM", 154, 163], ["fusaricidin A", "SIMPLE_CHEMICAL", 255, 268], ["alanine", "SIMPLE_CHEMICAL", 325, 332], ["Bacillus polymyxa", "SPECIES", 0, 17], ["S. aureus", "SPECIES", 154, 163], ["Bacillus polymyxa KT-8 strain", "SPECIES", 0, 29], ["S. aureus", "SPECIES", 154, 163], ["Bacillus polymyxa KT", "TEST", 0, 20], ["strain", "PROBLEM", 23, 29], ["various kinds of fungi", "PROBLEM", 71, 93], ["Gram-positive bacteria", "PROBLEM", 98, 120], ["methicillin", "TEST", 132, 143], ["resistant S. aureus", "PROBLEM", 144, 163], ["its antibacterial activity", "PROBLEM", 208, 234], ["synthesized fusaricidin A's analogues", "TREATMENT", 243, 280], ["its alanine", "TEST", 321, 332], ["8 strain", "OBSERVATION_MODIFIER", 21, 29], ["positive bacteria", "OBSERVATION", 103, 120], ["aureus", "OBSERVATION", 157, 163]]], ["Library screening assays revealed that lipophylic tail and amino acids involved in creation of an ester bond are crucial for peptides antibacterial activity.", [["amino acids", "CHEMICAL", 59, 70], ["ester", "CHEMICAL", 98, 103], ["amino acids", "CHEMICAL", 59, 70], ["ester", "CHEMICAL", 98, 103], ["amino acids", "AMINO_ACID", 59, 70], ["ester", "SIMPLE_CHEMICAL", 98, 103], ["lipophylic tail", "PROTEIN", 39, 54], ["Library screening assays", "TEST", 0, 24], ["lipophylic tail", "PROBLEM", 39, 54], ["amino acids", "TREATMENT", 59, 70], ["an ester bond", "TREATMENT", 95, 108], ["peptides antibacterial activity", "TREATMENT", 125, 156], ["ester bond", "OBSERVATION", 98, 108], ["antibacterial activity", "OBSERVATION", 134, 156]]], ["Complete loss of antibacterial activity was obtained for the depsipeptides without lipid tail and when peptide was cyclized via Lys side chain amino group instead of hydroxyl group found in the natural product.P 022 DESIGN AND SYNTHESIS OF ANTIMICROBIAL PEPTIDEP 027 NOVEL PLEUROCIDIN-AMP ANALOGS AND BIOASSAYS K. Tamminedi, B. Chaudhary, J. Sperry, R. LaCroix, and L. Martin* Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI 02881 USA Existing research shows that the C-terminal amide analog of pleurocidin is more active antibacterial agent than the native C-terminal acid.", [["Cell", "ANATOMY", 391, 395], ["Lys side chain amino", "CHEMICAL", 128, 148], ["hydroxyl", "CHEMICAL", 166, 174], ["C-terminal amide", "CHEMICAL", 503, 519], ["pleurocidin", "CHEMICAL", 530, 541], ["Lys", "CHEMICAL", 128, 131], ["amino", "CHEMICAL", 143, 148], ["hydroxyl", "CHEMICAL", 166, 174], ["C", "CHEMICAL", 503, 504], ["amide", "CHEMICAL", 514, 519], ["pleurocidin", "CHEMICAL", 530, 541], ["C", "CHEMICAL", 593, 594], ["depsipeptides", "SIMPLE_CHEMICAL", 61, 74], ["amino", "AMINO_ACID", 143, 148], ["hydroxyl", "SIMPLE_CHEMICAL", 166, 174], ["Cell", "CELL", 391, 395], ["C-terminal amide", "SIMPLE_CHEMICAL", 503, 519], ["pleurocidin", "SIMPLE_CHEMICAL", 530, 541], ["Complete loss of antibacterial activity", "PROBLEM", 0, 39], ["lipid tail", "PROBLEM", 83, 93], ["Lys side chain amino group", "TREATMENT", 128, 154], ["hydroxyl group", "TREATMENT", 166, 180], ["K", "TEST", 311, 312], ["the C-terminal amide analog of pleurocidin", "TREATMENT", 499, 541], ["antibacterial agent", "TREATMENT", 557, 576], ["loss", "OBSERVATION_MODIFIER", 9, 13], ["antibacterial activity", "OBSERVATION", 17, 39], ["natural product", "OBSERVATION", 194, 209], ["terminal acid", "ANATOMY_MODIFIER", 595, 608]]], ["Other evidence suggests that the amphipathic -helical structure is required for antibacterial activity and pleurocidin can assume an amphipathic alpha-helical conformation that is similar to other antimicrobial peptides (AMPs) in the presence of hexafluoroisopropanol.", [["pleurocidin", "CHEMICAL", 107, 118], ["hexafluoroisopropanol", "CHEMICAL", 246, 267], ["pleurocidin", "CHEMICAL", 107, 118], ["hexafluoroisopropanol", "CHEMICAL", 246, 267], ["pleurocidin", "SIMPLE_CHEMICAL", 107, 118], ["hexafluoroisopropanol", "SIMPLE_CHEMICAL", 246, 267], ["amphipathic -helical structure", "PROTEIN", 33, 63], ["pleurocidin", "PROTEIN", 107, 118], ["the amphipathic -helical structure", "PROBLEM", 29, 63], ["antibacterial activity", "TREATMENT", 80, 102], ["pleurocidin", "TREATMENT", 107, 118], ["an amphipathic alpha-helical conformation", "PROBLEM", 130, 171], ["other antimicrobial peptides", "TREATMENT", 191, 219], ["hexafluoroisopropanol", "TREATMENT", 246, 267], ["amphipathic", "OBSERVATION_MODIFIER", 33, 44], ["amphipathic", "OBSERVATION_MODIFIER", 133, 144], ["alpha-helical conformation", "OBSERVATION", 145, 171]]], ["Although the exact mechanism by which this antimicrobial peptide kills the bacterial cell is still unknown, it is believed that the cationic charge of the peptide is initially attracted to the negatively charged bacterial surface lipids.", [["cell", "ANATOMY", 85, 89], ["surface", "ANATOMY", 222, 229], ["bacterial cell", "CELL", 75, 89], ["surface lipids", "CELLULAR_COMPONENT", 222, 236], ["the bacterial cell", "PROBLEM", 71, 89], ["the cationic charge of the peptide", "TREATMENT", 128, 162], ["the negatively charged bacterial surface lipids", "TREATMENT", 189, 236], ["bacterial cell", "OBSERVATION", 75, 89]]], ["Our hypothesis is that specific alterations in the sequence of amino acids of native pleurocidin can increase the antimicrobial activity.", [["amino acids", "CHEMICAL", 63, 74], ["pleurocidin", "CHEMICAL", 85, 96], ["amino acids", "CHEMICAL", 63, 74], ["pleurocidin", "CHEMICAL", 85, 96], ["amino acids", "AMINO_ACID", 63, 74], ["pleurocidin", "GENE_OR_GENE_PRODUCT", 85, 96], ["native pleurocidin", "PROTEIN", 78, 96], ["specific alterations", "PROBLEM", 23, 43], ["amino acids", "TREATMENT", 63, 74], ["native pleurocidin", "TREATMENT", 78, 96], ["the antimicrobial activity", "TREATMENT", 110, 136], ["antimicrobial activity", "OBSERVATION", 114, 136]]], ["We have tested the effect of addition of N-terminal tryptophan to the pleurocidin C-terminal amide, and developed high-throughput bioassays that evaluated the effects of both AMP analogs on four diverse types of pathogenic bacteria.Washington UniversityA computational approach using virtual screening combined with consensus scoring revealed drug-like compounds that inhibit the function of the PhoP response regulator by disrupting formation to its active dimer state.", [["N-terminal tryptophan", "CHEMICAL", 41, 62], ["pleurocidin C-terminal amide", "CHEMICAL", 70, 98], ["AMP", "CHEMICAL", 175, 178], ["N", "CHEMICAL", 41, 42], ["tryptophan", "CHEMICAL", 52, 62], ["C", "CHEMICAL", 82, 83], ["amide", "CHEMICAL", 93, 98], ["AMP", "CHEMICAL", 175, 178], ["AMP", "SIMPLE_CHEMICAL", 175, 178], ["PhoP", "GENE_OR_GENE_PRODUCT", 396, 400], ["pleurocidin C", "PROTEIN", 70, 83], ["PhoP response regulator", "PROTEIN", 396, 419], ["N-terminal tryptophan", "TREATMENT", 41, 62], ["high-throughput bioassays", "PROBLEM", 114, 139], ["both AMP analogs", "TREATMENT", 170, 186], ["pathogenic bacteria", "PROBLEM", 212, 231], ["virtual screening", "TEST", 284, 301], ["consensus scoring", "TEST", 316, 333], ["drug-like compounds", "PROBLEM", 343, 362], ["pathogenic bacteria", "OBSERVATION", 212, 231]]], ["PhoP, the regulatory receiver of the PhoQ/PhoP two-component signal transduction system, senses and responds to extracellular Mg2\u00fe levels by controlling the transcription level of key virulence genes in Salmonella typhimurium, as well as a number of other pathogenic species including Yersinia pestis, the causative pathogen for plague.", [["extracellular", "ANATOMY", 112, 125], ["Mg2", "CHEMICAL", 126, 129], ["Yersinia pestis", "DISEASE", 285, 300], ["plague", "DISEASE", 329, 335], ["PhoP", "GENE_OR_GENE_PRODUCT", 0, 4], ["PhoQ", "GENE_OR_GENE_PRODUCT", 37, 41], ["PhoP", "GENE_OR_GENE_PRODUCT", 42, 46], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["Mg2", "GENE_OR_GENE_PRODUCT", 126, 129], ["Salmonella typhimurium", "ORGANISM", 203, 225], ["Yersinia pestis", "ORGANISM", 285, 300], ["PhoP", "PROTEIN", 0, 4], ["PhoQ", "PROTEIN", 37, 41], ["PhoP", "PROTEIN", 42, 46], ["Mg2", "PROTEIN", 126, 129], ["virulence genes", "DNA", 184, 199], ["Salmonella typhimurium", "SPECIES", 203, 225], ["Yersinia pestis", "SPECIES", 285, 300], ["Salmonella typhimurium", "SPECIES", 203, 225], ["Yersinia pestis", "SPECIES", 285, 300], ["the PhoQ/PhoP", "TREATMENT", 33, 46], ["extracellular Mg2\u00fe levels", "TEST", 112, 137], ["Salmonella typhimurium", "PROBLEM", 203, 225], ["other pathogenic species", "PROBLEM", 250, 274], ["Yersinia pestis", "PROBLEM", 285, 300], ["the causative pathogen", "PROBLEM", 302, 324], ["plague", "PROBLEM", 329, 335], ["virulence genes", "OBSERVATION", 184, 199], ["Salmonella typhimurium", "OBSERVATION", 203, 225], ["pathogenic species", "OBSERVATION", 256, 274], ["Yersinia pestis", "OBSERVATION", 285, 300]]], ["The monomeric state of PhoP is activated via phosphorylation by PhoQ, the sensor histidine kinase, at low extracellular Mg2\u00fe levels.", [["extracellular", "ANATOMY", 106, 119], ["histidine", "CHEMICAL", 81, 90], ["Mg2\u00fe", "CHEMICAL", 120, 124], ["PhoP", "GENE_OR_GENE_PRODUCT", 23, 27], ["PhoQ", "GENE_OR_GENE_PRODUCT", 64, 68], ["histidine", "AMINO_ACID", 81, 90], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["PhoP", "PROTEIN", 23, 27], ["PhoQ", "PROTEIN", 64, 68], ["sensor histidine kinase", "PROTEIN", 74, 97], ["Mg2", "PROTEIN", 120, 123], ["the sensor histidine kinase", "TEST", 70, 97]]], ["Phosphorylation leads to formation of its active PhoP dimer, that bind to its DNA promoter.", [["PhoP", "GENE_OR_GENE_PRODUCT", 49, 53], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["PhoP dimer", "PROTEIN", 49, 59], ["DNA promoter", "DNA", 78, 90], ["Phosphorylation", "TREATMENT", 0, 15], ["its active PhoP dimer", "PROBLEM", 38, 59], ["active", "OBSERVATION_MODIFIER", 42, 48], ["PhoP dimer", "OBSERVATION", 49, 59]]], ["Compounds that bind to the surface of the dimerization interface can disrupt its DNA-binding ability, and most importantly, interfere with its role as a transcription factor regulating virulence.", [["surface", "ANATOMY", 27, 34], ["surface", "CELLULAR_COMPONENT", 27, 34], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["transcription factor", "PROTEIN", 153, 173]]], ["Experimental methods including electrophoretic mobility-shift assays and gel-filtration chromatography were used to test the predictability of the computational approach and confirm the mechanism of action for the predicted inhibitors.", [["Experimental methods", "TREATMENT", 0, 20], ["electrophoretic mobility", "TEST", 31, 55], ["shift assays", "TEST", 56, 68], ["gel-filtration chromatography", "TEST", 73, 102], ["the predicted inhibitors", "TREATMENT", 210, 234]]], ["This study serves as a proof-of-principle for targeting the dimerization interface of a response regulator to inhibit its function and modulate gene regulation of the expression of virulence.", [["This study", "TEST", 0, 10], ["virulence", "PROBLEM", 181, 190]]], ["With the increasing resistance of pathogenic bacteria to current antibiotics, the success of this strategy suggests targeting two-component signal transduction as a promising approach for development of novel antibiotics.", [["pathogenic bacteria", "PROBLEM", 34, 53], ["current antibiotics", "TREATMENT", 57, 76], ["this strategy", "TREATMENT", 93, 106], ["two-component signal transduction", "TREATMENT", 126, 159], ["novel antibiotics", "TREATMENT", 203, 220], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["resistance", "OBSERVATION_MODIFIER", 20, 30], ["pathogenic bacteria", "OBSERVATION", 34, 53]]], ["Periodontal disease is an inflammatory disease that, while predominantly affecting the gums, has been linked to the onset of other severe systemic diseases.", [["Periodontal", "ANATOMY", 0, 11], ["gums", "ANATOMY", 87, 91], ["Periodontal disease", "DISEASE", 0, 19], ["systemic diseases", "DISEASE", 138, 155], ["gums", "ORGANISM_SUBDIVISION", 87, 91], ["Periodontal disease", "PROBLEM", 0, 19], ["an inflammatory disease", "PROBLEM", 23, 46], ["other severe systemic diseases", "PROBLEM", 125, 155], ["disease", "OBSERVATION", 12, 19], ["inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["predominantly", "OBSERVATION_MODIFIER", 59, 72], ["gums", "ANATOMY", 87, 91], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["systemic", "OBSERVATION_MODIFIER", 138, 146], ["diseases", "OBSERVATION", 147, 155]]], ["The disease is caused by the formation and accumulation of a bacterial biofilm in the sub-gingival pocket and in particular by presence of Porphyromonas gingivalis.", [["biofilm", "ANATOMY", 71, 78], ["gingival", "ANATOMY", 90, 98], ["gingival pocket", "TISSUE", 90, 105], ["Porphyromonas gingivalis", "GENE_OR_GENE_PRODUCT", 139, 163], ["Porphyromonas gingivalis", "SPECIES", 139, 163], ["Porphyromonas gingivalis", "SPECIES", 139, 163], ["The disease", "PROBLEM", 0, 11], ["a bacterial biofilm", "PROBLEM", 59, 78], ["the sub-gingival pocket", "PROBLEM", 82, 105], ["Porphyromonas gingivalis", "PROBLEM", 139, 163], ["disease", "OBSERVATION", 4, 11], ["accumulation", "OBSERVATION_MODIFIER", 43, 55], ["bacterial", "OBSERVATION_MODIFIER", 61, 70], ["biofilm", "OBSERVATION_MODIFIER", 71, 78], ["sub", "OBSERVATION_MODIFIER", 86, 89], ["gingival pocket", "OBSERVATION", 90, 105], ["Porphyromonas gingivalis", "OBSERVATION", 139, 163]]], ["P. gingivalis is an asaccharolytic, acid-intolerant, obligate anaerobe which interacts with specific bacterial species such as the oralis group streptococci to successfully colonize the oral cavity.", [["oral cavity", "ANATOMY", 186, 197], ["P. gingivalis", "DISEASE", 0, 13], ["P. gingivalis", "ORGANISM", 0, 13], ["oralis group streptococci", "ORGANISM", 131, 156], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 186, 197], ["P. gingivalis", "SPECIES", 0, 13], ["oralis group streptococci", "SPECIES", 131, 156], ["P. gingivalis", "SPECIES", 0, 13], ["an asaccharolytic, acid-intolerant", "PROBLEM", 17, 51], ["obligate anaerobe", "PROBLEM", 53, 70], ["specific bacterial species", "PROBLEM", 92, 118], ["the oralis group streptococci", "TREATMENT", 127, 156], ["oral cavity", "ANATOMY", 186, 197]]], ["The interaction between these bacteria is mediated through a species-specific protein-protein interaction occurring between the minor fimbrial protein Mfa1 of P. gingivalis and the SspB Adherence Region (BAR) of the antigen I/II protein (e.g., SspB) that is expressed by streptococci.", [["Mfa1", "GENE_OR_GENE_PRODUCT", 151, 155], ["P. gingivalis", "ORGANISM", 159, 172], ["SspB Adherence Region", "GENE_OR_GENE_PRODUCT", 181, 202], ["BAR", "GENE_OR_GENE_PRODUCT", 204, 207], ["antigen I/II", "GENE_OR_GENE_PRODUCT", 216, 228], ["SspB", "GENE_OR_GENE_PRODUCT", 244, 248], ["streptococci", "CELL", 271, 283], ["minor fimbrial protein", "PROTEIN", 128, 150], ["Mfa1", "PROTEIN", 151, 155], ["SspB Adherence Region", "PROTEIN", 181, 202], ["BAR", "PROTEIN", 204, 207], ["antigen I/II protein", "PROTEIN", 216, 236], ["SspB", "PROTEIN", 244, 248], ["P. gingivalis", "SPECIES", 159, 172], ["P. gingivalis", "SPECIES", 159, 172], ["these bacteria", "PROBLEM", 24, 38], ["a species", "TEST", 59, 68], ["protein interaction", "PROBLEM", 86, 105], ["P. gingivalis", "PROBLEM", 159, 172], ["the antigen I/II protein", "TEST", 212, 236], ["SspB", "TEST", 244, 248], ["streptococci", "PROBLEM", 271, 283], ["streptococci", "OBSERVATION", 271, 283]]], ["Our studies have shown that this inter-bacterial co-aggregation can be inhibited using a synthetic peptide based on BAR and that the amino acid motif, NITVK is essential for this interaction.", [["amino acid", "CHEMICAL", 133, 143], ["amino acid", "CHEMICAL", 133, 143], ["BAR", "GENE_OR_GENE_PRODUCT", 116, 119], ["amino acid", "AMINO_ACID", 133, 143], ["NITVK", "SIMPLE_CHEMICAL", 151, 156], ["BAR", "PROTEIN", 116, 119], ["amino acid motif", "PROTEIN", 133, 149], ["NITVK", "PROTEIN", 151, 156], ["Our studies", "TEST", 0, 11], ["this inter-bacterial co-aggregation", "PROBLEM", 28, 63], ["a synthetic peptide", "TREATMENT", 87, 106], ["the amino acid motif", "TREATMENT", 129, 149]]], ["Current studies have expanded the interacting interface between Mfa1 and show that a eukaryotic nuclear receptor co-activator-like motif, VXXLL, is also involved in facilitating the Mfa1/SspB (BAR) interaction.", [["nuclear", "ANATOMY", 96, 103], ["Mfa1", "GENE_OR_GENE_PRODUCT", 64, 68], ["VXXLL", "GENE_OR_GENE_PRODUCT", 138, 143], ["Mfa1", "GENE_OR_GENE_PRODUCT", 182, 186], ["SspB", "GENE_OR_GENE_PRODUCT", 187, 191], ["BAR", "GENE_OR_GENE_PRODUCT", 193, 196], ["Mfa1", "PROTEIN", 64, 68], ["eukaryotic nuclear receptor co-activator-like motif", "PROTEIN", 85, 136], ["VXXLL", "PROTEIN", 138, 143], ["Mfa1", "PROTEIN", 182, 186], ["SspB", "PROTEIN", 187, 191], ["BAR", "PROTEIN", 193, 196], ["Current studies", "TEST", 0, 15]]], ["Maintaining an amphipathic -helix through this region is important for the binding of Mfa1 to BAR.", [["Mfa1", "GENE_OR_GENE_PRODUCT", 86, 90], ["BAR", "GENE_OR_GENE_PRODUCT", 94, 97], ["amphipathic -helix", "PROTEIN", 15, 33], ["Mfa1", "PROTEIN", 86, 90], ["BAR", "PROTEIN", 94, 97], ["amphipathic", "OBSERVATION_MODIFIER", 15, 26], ["helix", "OBSERVATION_MODIFIER", 28, 33]]], ["In addition, positively charged lysine residues, Lys 1174, 1175, 1179, 1180 that flank VXXLL were shown to contribute to the interaction.", [["lysine", "CHEMICAL", 32, 38], ["lysine", "CHEMICAL", 32, 38], ["Lys", "CHEMICAL", 49, 52], ["VXXLL", "GENE_OR_GENE_PRODUCT", 87, 92], ["VXXLL", "PROTEIN", 87, 92], ["Lys", "TEST", 49, 52], ["lysine residues", "OBSERVATION", 32, 47], ["flank", "ANATOMY", 81, 86]]], ["Both the VXXLL and NITVK motifs are conserved among the oralis streptococci but these sequences have diverged in antigen I/II proteins expressed by streptococci that do not interact with P. gingivalis.", [["VXXLL", "GENE_OR_GENE_PRODUCT", 9, 14], ["NITVK", "GENE_OR_GENE_PRODUCT", 19, 24], ["oralis streptococci", "ORGANISM", 56, 75], ["antigen I/II", "GENE_OR_GENE_PRODUCT", 113, 125], ["P. gingivalis", "ORGANISM", 187, 200], ["VXXLL and NITVK motifs", "DNA", 9, 31], ["antigen I/II proteins", "PROTEIN", 113, 134], ["P. gingivalis", "SPECIES", 187, 200], ["P. gingivalis", "SPECIES", 187, 200], ["the VXXLL and NITVK motifs", "TREATMENT", 5, 31], ["the oralis streptococci", "PROBLEM", 52, 75], ["these sequences", "TEST", 80, 95], ["antigen I/II proteins", "PROBLEM", 113, 134], ["streptococci", "PROBLEM", 148, 160], ["P. gingivalis", "PROBLEM", 187, 200], ["streptococci", "OBSERVATION", 148, 160]]], ["These comparisons also identified a conserved proline residue upstream of VXXLL.", [["proline", "CHEMICAL", 46, 53], ["proline", "CHEMICAL", 46, 53], ["proline", "AMINO_ACID", 46, 53], ["VXXLL", "GENE_OR_GENE_PRODUCT", 74, 79], ["VXXLL", "PROTEIN", 74, 79], ["a conserved proline residue upstream of VXXLL", "PROBLEM", 34, 79], ["proline residue", "OBSERVATION", 46, 61]]], ["A Pro 1171 /Gln substitution resulted in the loss of the peptide's inhibitory activity, suggesting that Pro 1171 may also play an important structural role in the interaction of BAR with Mfa1.", [["Pro 1171 /Gln", "CHEMICAL", 2, 15], ["Pro 1171", "CHEMICAL", 104, 112], ["Pro 1171", "CHEMICAL", 2, 10], ["Gln", "CHEMICAL", 12, 15], ["Pro 1171", "CHEMICAL", 104, 112], ["Gln", "AMINO_ACID", 12, 15], ["Pro 1171", "GENE_OR_GENE_PRODUCT", 104, 112], ["BAR", "GENE_OR_GENE_PRODUCT", 178, 181], ["Mfa1", "GENE_OR_GENE_PRODUCT", 187, 191], ["BAR", "PROTEIN", 178, 181], ["Mfa1", "PROTEIN", 187, 191], ["A Pro 1171 /Gln substitution", "TREATMENT", 0, 28]]], ["Together, these studies have defined the protein-protein interaction that may drive the initial colonization of the oral cavity by P. gingivalis and may facilitate the development of targeted therapeutics to prevent colonization.", [["oral cavity", "ANATOMY", 116, 127], ["oral cavity", "ORGAN", 116, 127], ["P. gingivalis", "ORGANISM", 131, 144], ["P. gingivalis", "SPECIES", 131, 144], ["P. gingivalis", "SPECIES", 131, 144], ["these studies", "TEST", 10, 23], ["the protein-protein interaction", "PROBLEM", 37, 68], ["the initial colonization of the oral cavity", "PROBLEM", 84, 127], ["P. gingivalis", "PROBLEM", 131, 144], ["targeted therapeutics", "TREATMENT", 183, 204], ["colonization", "PROBLEM", 216, 228], ["oral cavity", "ANATOMY", 116, 127]]], ["It has been shown to induce analgesia in rat models of human neuropathic pain and has been reported to target the a9a10 nAChR, with low nM potency.", [["neuropathic pain", "DISEASE", 61, 77], ["rat", "ORGANISM", 41, 44], ["human", "ORGANISM", 55, 60], ["a9a10 nAChR", "GENE_OR_GENE_PRODUCT", 114, 125], ["a9a10 nAChR", "PROTEIN", 114, 125], ["rat", "SPECIES", 41, 44], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["analgesia", "TREATMENT", 28, 37], ["human neuropathic pain", "PROBLEM", 55, 77], ["low nM potency", "PROBLEM", 132, 146], ["neuropathic", "OBSERVATION_MODIFIER", 61, 72], ["low nM", "OBSERVATION_MODIFIER", 132, 138]]], ["We conducted mutational studies on Vc1.1, replacing individual residues with either an alanine, lysine or aspartic acid, except for the highly conserved cysteines.", [["alanine", "CHEMICAL", 87, 94], ["lysine", "CHEMICAL", 96, 102], ["aspartic acid", "CHEMICAL", 106, 119], ["alanine", "CHEMICAL", 87, 94], ["lysine", "CHEMICAL", 96, 102], ["aspartic acid", "CHEMICAL", 106, 119], ["cysteines", "CHEMICAL", 153, 162], ["alanine", "AMINO_ACID", 87, 94], ["lysine", "AMINO_ACID", 96, 102], ["aspartic acid", "AMINO_ACID", 106, 119], ["mutational studies", "TEST", 13, 31], ["Vc1.1", "TREATMENT", 35, 40], ["an alanine, lysine or aspartic acid", "TEST", 84, 119], ["cysteines", "OBSERVATION", 153, 162]]], ["Two key positions were identified, position 4 and position 9, which once mutated led to a significant increase in the potency of Vc1.1 at the a9a10 nAChR.", [["Vc1.1", "GENE_OR_GENE_PRODUCT", 129, 134], ["a9a10 nAChR", "GENE_OR_GENE_PRODUCT", 142, 153], ["position 4 and position 9", "DNA", 35, 60], ["Vc1.1", "PROTEIN", 129, 134], ["a9a10 nAChR", "PROTEIN", 142, 153], ["a significant increase", "PROBLEM", 88, 110], ["Vc", "TEST", 129, 131], ["positions", "OBSERVATION_MODIFIER", 8, 17], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["increase", "OBSERVATION_MODIFIER", 102, 110], ["potency", "OBSERVATION_MODIFIER", 118, 125]]], ["Subsequently, a second generation of analogues was synthesised, with further mutations at these positions, all of which were shown to be equally, if not more potent than Vc1.1 at the a9a10 nAChR.", [["a9a10 nAChR", "GENE_OR_GENE_PRODUCT", 183, 194], ["a9a10 nAChR", "PROTEIN", 183, 194], ["a second generation of analogues", "TREATMENT", 14, 46], ["further mutations", "PROBLEM", 69, 86], ["Vc", "TEST", 170, 172]]], ["The most potent mutants were also tested on a human a9 rat a10 hybrid clone.", [["clone", "ANATOMY", 70, 75], ["human", "ORGANISM", 46, 51], ["rat", "ORGANISM", 55, 58], ["a10 hybrid clone", "CELL", 59, 75], ["human a9 rat a10 hybrid clone", "CELL_LINE", 46, 75], ["human", "SPECIES", 46, 51], ["rat", "SPECIES", 55, 58], ["human", "SPECIES", 46, 51], ["rat", "SPECIES", 55, 58], ["most potent", "OBSERVATION_MODIFIER", 4, 15]]], ["For potential changes in the selectivity profile of Vc1.1, these potent mutants were also tested on other nAChR subtypes, namely a32, a34 and a7.", [["Vc1.1", "SIMPLE_CHEMICAL", 52, 57], ["nAChR", "GENE_OR_GENE_PRODUCT", 106, 111], ["a32", "GENE_OR_GENE_PRODUCT", 129, 132], ["a34", "GENE_OR_GENE_PRODUCT", 134, 137], ["a7", "GENE_OR_GENE_PRODUCT", 142, 144], ["Vc1.1", "PROTEIN", 52, 57], ["nAChR subtypes", "PROTEIN", 106, 120], ["a32", "PROTEIN", 129, 132], ["a34", "PROTEIN", 134, 137], ["a7", "PROTEIN", 142, 144]]], ["All the second generation analogues were more selective for the a9a10, with 4 out of the 7 analogues exclusively selective for a9a10 over the other nAChR subtypes screened.", [["a9a10", "SIMPLE_CHEMICAL", 64, 69], ["a9a10", "SIMPLE_CHEMICAL", 127, 132], ["a9a10", "PROTEIN", 127, 132], ["a9a10", "TREATMENT", 127, 132]]], ["This study has shown that the potency of Vc1.1 can be improved, whilst maintaining its selectivity, by strategic substitutions at key positions identified through mutational studies.", [["This study", "TEST", 0, 10], ["Vc", "TEST", 41, 43], ["mutational studies", "TEST", 163, 181], ["improved", "OBSERVATION_MODIFIER", 54, 62]]], ["Overall, the mutational studies have provided a great foundation for the design and synthesis of novel conotoxins with marked improvement in potency and selectivity towards the a9a10 nAChR.", [["conotoxins", "CHEMICAL", 103, 113], ["conotoxins", "SIMPLE_CHEMICAL", 103, 113], ["a9a10 nAChR", "GENE_OR_GENE_PRODUCT", 177, 188], ["a9a10 nAChR", "PROTEIN", 177, 188], ["the mutational studies", "TEST", 9, 31], ["novel conotoxins", "TREATMENT", 97, 113], ["marked", "OBSERVATION_MODIFIER", 119, 125], ["improvement", "OBSERVATION_MODIFIER", 126, 137]]], ["[1] combinatorial library method to identify ligands that target cancer cell surface molecule [2, 3] .", [["cancer cell surface", "ANATOMY", 65, 84], ["cancer", "DISEASE", 65, 71], ["cancer cell", "CELL", 65, 76], ["cancer cell surface molecule", "PROTEIN", 65, 93], ["combinatorial library method", "TREATMENT", 4, 32], ["target cancer cell surface molecule", "PROBLEM", 58, 93]]], ["We were able to demonstrate that these ligands can be used as effective optical and radioimaging agents for cancer.", [["cancer", "ANATOMY", 108, 114], ["cancer", "DISEASE", 108, 114], ["cancer", "CANCER", 108, 114], ["effective optical and radioimaging agents", "TREATMENT", 62, 103], ["cancer", "PROBLEM", 108, 114]]], ["Recently, we have developed a one-bead two-compounds (OBTC) combinatorial library method which can facilitate the discovery of ligands that affect cell function while interacting with specific receptors on the cell surface.", [["cell", "ANATOMY", 147, 151], ["cell surface", "ANATOMY", 210, 222], ["cell", "CELL", 147, 151], ["cell surface", "CELLULAR_COMPONENT", 210, 222], ["combinatorial library method", "TREATMENT", 60, 88], ["cell function", "PROBLEM", 147, 160]]], ["In this new method, we used topographically segregated bilayer bead methods [4] to generate chemical library beads with two distinct chemical molecules displayed on the bead surface and a coding tag in the bead interior.", [["bead surface", "ANATOMY", 169, 181], ["topographically segregated bilayer bead methods", "TREATMENT", 28, 75], ["chemical library beads", "TREATMENT", 92, 114], ["the bead surface", "TREATMENT", 165, 181], ["library beads", "OBSERVATION", 101, 114], ["distinct", "OBSERVATION_MODIFIER", 124, 132], ["chemical molecules", "OBSERVATION", 133, 151], ["bead", "ANATOMY_MODIFIER", 206, 210]]], ["One of these molecules could be a high affinity 41 integrin ligand such as LLP2A [3] that will bind strongly to both T-and B-lymphoid cancer cells.", [["T-", "ANATOMY", 117, 119], ["B-lymphoid cancer cells", "ANATOMY", 123, 146], ["cancer", "DISEASE", 134, 140], ["integrin", "GENE_OR_GENE_PRODUCT", 51, 59], ["LLP2A [3", "GENE_OR_GENE_PRODUCT", 75, 83], ["T", "CELL", 117, 118], ["B-lymphoid cancer cells", "CELL", 123, 146], ["high affinity 41 integrin ligand", "PROTEIN", 34, 66], ["LLP2A", "PROTEIN", 75, 80], ["T-and B-lymphoid cancer cells", "CELL_TYPE", 117, 146], ["a high affinity", "PROBLEM", 32, 47], ["T", "TEST", 117, 118], ["lymphoid cancer cells", "PROBLEM", 125, 146], ["lymphoid", "ANATOMY", 125, 133], ["cancer cells", "OBSERVATION", 134, 146]]], ["The other molecule (e.g. peptide or lipopeptide), however, is totally random, encoded by the coding tag in the bead interior, and unique on each bead.", [["coding tag", "DNA", 93, 103], ["bead", "OBSERVATION_MODIFIER", 111, 115]]], ["After incubation of beads displaying a random peptide or lipopeptide and LLP2A with live lymphoma cells (Molt-4, a T lymphoma cell line) for 30 minutes, the majority of these beads were coated with the added cells.", [["lymphoma cells", "ANATOMY", 89, 103], ["Molt-4", "ANATOMY", 105, 111], ["T lymphoma cell line", "ANATOMY", 115, 135], ["beads", "ANATOMY", 175, 180], ["cells", "ANATOMY", 208, 213], ["live lymphoma", "DISEASE", 84, 97], ["LLP2A", "SIMPLE_CHEMICAL", 73, 78], ["lymphoma cells", "CELL", 89, 103], ["Molt-4", "CELL", 105, 111], ["T lymphoma cell line", "CELL", 115, 135], ["cells", "CELL", 208, 213], ["LLP2A", "PROTEIN", 73, 78], ["live lymphoma cells", "CELL_TYPE", 84, 103], ["Molt-4", "CELL_LINE", 105, 111], ["T lymphoma cell line", "CELL_LINE", 115, 135], ["beads", "TREATMENT", 20, 25], ["a random peptide", "TREATMENT", 37, 53], ["lipopeptide", "TREATMENT", 57, 68], ["live lymphoma cells", "PROBLEM", 84, 103], ["Molt", "TEST", 105, 109], ["a T lymphoma cell line", "TREATMENT", 113, 135], ["these beads", "TREATMENT", 169, 180], ["lymphoma cells", "OBSERVATION", 89, 103]]], ["Upon adding (LAsp) 2 rhodamine 110 (D2R) 48 hours later, we detected rare beads that were covered entirely by apoptotic cells, indicating that the second ligand displayed on the bead surface has the capacity to induce apoptosis of lymphoid cancer cells.", [["cells", "ANATOMY", 120, 125], ["bead surface", "ANATOMY", 178, 190], ["lymphoid cancer cells", "ANATOMY", 231, 252], ["rhodamine 110", "CHEMICAL", 21, 34], ["lymphoid cancer", "DISEASE", 231, 246], ["(LAsp) 2 rhodamine 110", "CHEMICAL", 12, 34], ["rhodamine 110", "SIMPLE_CHEMICAL", 21, 34], ["D2R", "SIMPLE_CHEMICAL", 36, 39], ["cells", "CELL", 120, 125], ["lymphoid cancer cells", "CELL", 231, 252], ["apoptotic cells", "CELL_TYPE", 110, 125], ["lymphoid cancer cells", "CELL_TYPE", 231, 252], ["rare beads", "PROBLEM", 69, 79], ["the second ligand", "PROBLEM", 143, 160], ["the capacity", "PROBLEM", 195, 207], ["lymphoid cancer cells", "PROBLEM", 231, 252], ["apoptotic cells", "OBSERVATION", 110, 125], ["lymphoid cancer cells", "OBSERVATION", 231, 252]]], ["On-bead screening of one-bead-one-compound (OBOC) libraries provides a powerful method for the rapid identification of active compounds against biological targets.", [["one-bead-one-compound", "CHEMICAL", 21, 42], ["one-bead-one-compound", "SIMPLE_CHEMICAL", 21, 42], ["bead screening", "TEST", 3, 17], ["a powerful method", "TREATMENT", 69, 86]]], ["However, on-bead screening is susceptible to interference from nonspecific binding, which results in biased screening and false positives.", [["bead screening", "TEST", 12, 26], ["nonspecific binding", "PROBLEM", 63, 82], ["biased screening", "TEST", 101, 117], ["false positives", "PROBLEM", 122, 137], ["false positives", "OBSERVATION", 122, 137]]], ["In this work, we have found that a major source of nonspecific binding is derived from the high ligand loading on the library beads, which permits a macromolecular target (e.g. protein) to simultaneously interact with multiple ligands on the bead surface.", [["bead surface", "ANATOMY", 242, 254], ["bead surface", "CELLULAR_COMPONENT", 242, 254], ["nonspecific binding", "PROBLEM", 51, 70], ["the high ligand loading on the library beads", "PROBLEM", 87, 131], ["nonspecific", "OBSERVATION", 51, 62], ["high ligand loading", "OBSERVATION", 91, 110], ["multiple", "OBSERVATION_MODIFIER", 218, 226], ["ligands", "OBSERVATION", 227, 234], ["bead", "OBSERVATION_MODIFIER", 242, 246], ["surface", "OBSERVATION_MODIFIER", 247, 254]]], ["To circumvent this problem, we have synthesized a phosphotyrosyl (pY)-containing peptide library on spatially segregated Ten-taGel microbeads, which feature a 10-fold reduced peptide loading on the bead surface but a normal peptide loading in the bead interior.", [["bead surface", "ANATOMY", 198, 210], ["phosphotyrosyl", "CHEMICAL", 50, 64], ["phosphotyrosyl", "CHEMICAL", 50, 64], ["phosphotyrosyl", "SIMPLE_CHEMICAL", 50, 64], ["pY", "SIMPLE_CHEMICAL", 66, 68], ["Ten-taGel microbeads", "CELL_LINE", 121, 141], ["a phosphotyrosyl (pY)", "TREATMENT", 48, 69], ["peptide library", "TREATMENT", 81, 96], ["a 10-fold reduced peptide loading", "PROBLEM", 157, 190], ["the bead surface", "TREATMENT", 194, 210], ["normal", "OBSERVATION", 217, 223], ["peptide loading", "OBSERVATION", 224, 239], ["bead", "OBSERVATION_MODIFIER", 247, 251]]], ["The library was screened against 10 Src homology 2 (SH2) domains including Csk, Fyn and SLAP, and the specific recognition motif(s) was successfully identified for each domain.", [["Src homology 2", "GENE_OR_GENE_PRODUCT", 36, 50], ["SH2", "GENE_OR_GENE_PRODUCT", 52, 55], ["Csk", "GENE_OR_GENE_PRODUCT", 75, 78], ["Fyn", "GENE_OR_GENE_PRODUCT", 80, 83], ["SLAP", "GENE_OR_GENE_PRODUCT", 88, 92], ["Src homology 2 (SH2) domains", "PROTEIN", 36, 64], ["Csk", "PROTEIN", 75, 78], ["Fyn", "PROTEIN", 80, 83], ["SLAP", "PROTEIN", 88, 92], ["specific recognition motif", "PROTEIN", 102, 128], ["Csk", "TEST", 75, 78], ["SLAP", "TEST", 88, 92], ["SLAP", "OBSERVATION", 88, 92]]], ["In contrast, when the SH2 domains were screened against a control library that contained unaltered (high) ligand loading at the bead surface, six of them exhibited varying degrees of sequence biases.", [["bead surface", "ANATOMY", 128, 140], ["SH2", "GENE_OR_GENE_PRODUCT", 22, 25], ["bead surface", "CELLULAR_COMPONENT", 128, 140], ["SH2 domains", "PROTEIN", 22, 33], ["the SH2 domains", "TEST", 18, 33], ["a control library", "TREATMENT", 56, 73], ["unaltered (high) ligand loading", "PROBLEM", 89, 120], ["sequence biases", "TEST", 183, 198], ["unaltered", "OBSERVATION_MODIFIER", 89, 98], ["bead", "OBSERVATION_MODIFIER", 128, 132], ["surface", "OBSERVATION_MODIFIER", 133, 140], ["varying", "OBSERVATION_MODIFIER", 164, 171]]], ["The reduction of the ligand loading on the bead surface represents a simple, effective strategy to largely eliminate the interference from nonspecific binding, while preserving sufficient amounts of materials in the bead interior for compound identification.", [["bead surface", "ANATOMY", 43, 55], ["the ligand loading", "PROBLEM", 17, 35], ["the interference from nonspecific binding", "PROBLEM", 117, 158], ["compound identification", "TEST", 234, 257], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["ligand loading", "OBSERVATION", 21, 35], ["bead", "OBSERVATION_MODIFIER", 43, 47], ["surface", "OBSERVATION_MODIFIER", 48, 55], ["simple", "OBSERVATION_MODIFIER", 69, 75], ["nonspecific", "OBSERVATION_MODIFIER", 139, 150], ["amounts", "OBSERVATION_MODIFIER", 188, 195]]], ["This finding should further expand the utility of OBOC libraries in biomedical research.", [["OBOC libraries", "TREATMENT", 50, 64]]], ["In the one-bead-one-compound (OBOC) combinatorial method, compounds are constructed on bead resin via split-mix synthesis such that multiple copies of the library compound are displayed on each bead.", [["OBOC", "SIMPLE_CHEMICAL", 30, 34], ["combinatorial method", "TREATMENT", 36, 56], ["bead resin", "TREATMENT", 87, 97], ["split-mix synthesis", "TREATMENT", 102, 121], ["multiple", "OBSERVATION_MODIFIER", 132, 140], ["library compound", "OBSERVATION", 155, 171]]], ["These libraries are rapidly screened with ELISA, fluorescent, radiometric, or whole-cell binding assays.", [["cell", "ANATOMY", 84, 88], ["cell", "CELL", 84, 88], ["ELISA", "TEST", 42, 47], ["radiometric", "TEST", 62, 73], ["whole-cell binding assays", "TEST", 78, 103]]], ["While fluorescence-based probes are powerful tools in OBOC screening, their utility is greatly limited by the intrinsic fluorescence of many commonly used solid supports (e.g. Ten-taGel [TG] resin), residual coupling reagents, and library compounds.Washington UniversityTo overcome this problem, we topologically partitioned TG resin with a thin Fmoc-protected outer layer and an unprotected inner core.", [["outer layer", "ANATOMY", 361, 372], ["inner core", "ANATOMY", 392, 402], ["TG", "DISEASE", 325, 327], ["thin Fmoc", "CHEMICAL", 341, 350], ["Fmoc", "CHEMICAL", 346, 350], ["OBOC", "SIMPLE_CHEMICAL", 54, 58], ["Ten-taGel [TG] resin", "SIMPLE_CHEMICAL", 176, 196], ["OBOC screening", "TEST", 54, 68], ["solid supports", "TREATMENT", 155, 169], ["Ten-taGel [TG] resin", "TREATMENT", 176, 196], ["residual coupling reagents", "TREATMENT", 199, 225], ["topologically partitioned TG resin", "TREATMENT", 299, 333], ["a thin Fmoc-protected outer layer", "TREATMENT", 339, 372], ["an unprotected inner core", "TREATMENT", 377, 402], ["unprotected", "OBSERVATION", 380, 391]]], ["The inner core was derivatized with 3-nitrotyrosine, followed by random peptide library construction.", [["inner core", "ANATOMY", 4, 14], ["3-nitrotyrosine", "CHEMICAL", 36, 51], ["3-nitrotyrosine", "CHEMICAL", 36, 51], ["3-nitrotyrosine", "SIMPLE_CHEMICAL", 36, 51], ["nitrotyrosine", "TREATMENT", 38, 51], ["random peptide library construction", "TREATMENT", 65, 100]]], ["Spectral scans from a confocal microscope showed a dramatic decrease in the autofluorescence of blank beads and OBOC peptide libraries across a broad range of the optical spectrum.", [["Spectral scans", "TEST", 0, 14], ["a confocal microscope", "TEST", 20, 41], ["a dramatic decrease", "PROBLEM", 49, 68], ["blank beads", "TREATMENT", 96, 107], ["OBOC peptide libraries", "PROBLEM", 112, 134], ["dramatic", "OBSERVATION_MODIFIER", 51, 59], ["decrease", "OBSERVATION_MODIFIER", 60, 68], ["blank beads", "OBSERVATION", 96, 107], ["broad", "OBSERVATION_MODIFIER", 144, 149], ["optical spectrum", "OBSERVATION", 163, 179]]], ["The quenching capacity of 3-nitro-tyrosine was visualized in fluorescent micrographs for both bead samples.", [["bead samples", "ANATOMY", 94, 106], ["3-nitro-tyrosine", "CHEMICAL", 26, 42], ["3-nitro-tyrosine", "CHEMICAL", 26, 42], ["3-nitro-tyrosine", "SIMPLE_CHEMICAL", 26, 42], ["The quenching capacity", "TEST", 0, 22], ["nitro-tyrosine", "TREATMENT", 28, 42], ["both bead samples", "TEST", 89, 106]]], ["Using biotin/streptavidin as a model ligand/receptor system, we demonstrated a marked increase in visibility of multiple commercially available fluorescent probes binding to quenched beads, and increased feasibility of using a robust and efficient fluorescence-based, bead sorting platform known as COPAS 1 .", [["biotin", "CHEMICAL", 6, 12], ["biotin", "CHEMICAL", 6, 12], ["biotin", "SIMPLE_CHEMICAL", 6, 12], ["streptavidin", "SIMPLE_CHEMICAL", 13, 25], ["COPAS 1", "GENE_OR_GENE_PRODUCT", 299, 306], ["streptavidin", "PROTEIN", 13, 25], ["COPAS 1", "PROTEIN", 299, 306], ["biotin/streptavidin", "TREATMENT", 6, 25], ["a model ligand/receptor system", "TREATMENT", 29, 59], ["a robust and efficient fluorescence", "TREATMENT", 225, 260], ["marked", "OBSERVATION_MODIFIER", 79, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["multiple", "OBSERVATION_MODIFIER", 112, 120]]], ["These data show that using 3-nitro-tyrosine as an internal quencher greatly enhances the compatibility of fluorescence-based applications and OBOC combinatorial screening.Washington UniversityThe Ohio State University Pin1 is a peptidyl-prolyl isomerase which plays a significant role in cell-cycle regulation by altering the conformation, thus the function/ stability of targeted phosphoproteins.", [["cell", "ANATOMY", 288, 292], ["3-nitro-tyrosine", "CHEMICAL", 27, 43], ["3-nitro-tyrosine", "CHEMICAL", 27, 43], ["prolyl", "CHEMICAL", 237, 243], ["3-nitro-tyrosine", "SIMPLE_CHEMICAL", 27, 43], ["OBOC", "SIMPLE_CHEMICAL", 142, 146], ["Pin1", "GENE_OR_GENE_PRODUCT", 218, 222], ["peptidyl-prolyl isomerase", "GENE_OR_GENE_PRODUCT", 228, 253], ["cell", "CELL", 288, 292], ["Pin1", "PROTEIN", 218, 222], ["peptidyl-prolyl isomerase", "PROTEIN", 228, 253], ["targeted phosphoproteins", "PROTEIN", 372, 396], ["These data", "TEST", 0, 10], ["3-nitro-tyrosine", "TREATMENT", 27, 43], ["an internal quencher", "TREATMENT", 47, 67], ["fluorescence-based applications", "TREATMENT", 106, 137], ["OBOC combinatorial screening", "TEST", 142, 170], ["a peptidyl-prolyl isomerase", "TEST", 226, 253], ["cell-cycle regulation", "TREATMENT", 288, 309], ["targeted phosphoproteins", "PROBLEM", 372, 396], ["significant", "OBSERVATION_MODIFIER", 268, 279]]], ["Recent studies have suggested Pin1 as a potential target for anticancer drug design.", [["anticancer", "ANATOMY", 61, 71], ["Pin1", "GENE_OR_GENE_PRODUCT", 30, 34], ["anticancer", "CANCER", 61, 71], ["Pin1", "PROTEIN", 30, 34], ["Recent studies", "TEST", 0, 14], ["Pin1", "PROBLEM", 30, 34], ["anticancer drug design", "TREATMENT", 61, 83]]], ["A Dphosphoserine and D-phosphothreonine containing head-to-tail cyclic peptide library was built based on Pin1 structure and substrate specificity.", [["Dphosphoserine", "CHEMICAL", 2, 16], ["D-phosphothreonine", "CHEMICAL", 21, 39], ["Dphosphoserine", "CHEMICAL", 2, 16], ["D-phosphothreonine", "CHEMICAL", 21, 39], ["Dphosphoserine", "SIMPLE_CHEMICAL", 2, 16], ["D-phosphothreonine", "SIMPLE_CHEMICAL", 21, 39], ["Pin1", "GENE_OR_GENE_PRODUCT", 106, 110], ["Pin1", "PROTEIN", 106, 110], ["A Dphosphoserine and D-phosphothreonine", "TREATMENT", 0, 39], ["head-to-tail cyclic peptide library", "TREATMENT", 51, 86]]], ["After screening the library against Pin1, a few peptides were selected, individually synthesized and test for binding.", [["Pin1", "GENE_OR_GENE_PRODUCT", 36, 40], ["Pin1", "PROTEIN", 36, 40], ["Pin1", "PROBLEM", 36, 40], ["a few peptides", "TREATMENT", 42, 56]]], ["The peptides were shown to bind to Pin1 with a Kd ranging from 20nM -1.6uM by isothermal titration calorimetry.", [["Pin1", "GENE_OR_GENE_PRODUCT", 35, 39], ["Pin1", "PROTEIN", 35, 39], ["Pin1", "TEST", 35, 39], ["a Kd", "TEST", 45, 49], ["isothermal titration calorimetry", "TEST", 78, 110]]], ["To test whether Pin1 inhibitor is active in the cells, we examined the effects of one of the Pin1 inhibitor on the protein levels of two known Pin1 targets, PML and SMRT.", [["cells", "ANATOMY", 48, 53], ["Pin1", "GENE_OR_GENE_PRODUCT", 16, 20], ["cells", "CELL", 48, 53], ["Pin1", "GENE_OR_GENE_PRODUCT", 93, 97], ["Pin1", "GENE_OR_GENE_PRODUCT", 143, 147], ["PML", "GENE_OR_GENE_PRODUCT", 157, 160], ["SMRT", "GENE_OR_GENE_PRODUCT", 165, 169], ["Pin1", "PROTEIN", 16, 20], ["Pin1", "PROTEIN", 93, 97], ["Pin1 targets", "PROTEIN", 143, 155], ["PML", "PROTEIN", 157, 160], ["SMRT", "PROTEIN", 165, 169], ["Pin1 inhibitor", "TREATMENT", 16, 30], ["the Pin1 inhibitor", "TREATMENT", 89, 107], ["the protein levels", "TEST", 111, 129], ["PML", "PROBLEM", 157, 160], ["active", "OBSERVATION_MODIFIER", 34, 40], ["Pin1 targets", "OBSERVATION", 143, 155]]], ["Our data show that treatment of HeLa cells with the Pin1 inhibitor leads to increases in the protein levels of PML and SMRT.R. Hard and D. PeiThe Ohio State University Postsynaptic Density-95/Discs Large/Zona Occluden-1 (PDZ) domains bind to the free C-termini of target proteins to mediate protein interactions and display either unique or overlapping specificity.", [["HeLa cells", "ANATOMY", 32, 42], ["C", "CHEMICAL", 251, 252], ["HeLa cells", "CELL", 32, 42], ["Pin1", "GENE_OR_GENE_PRODUCT", 52, 56], ["PML", "GENE_OR_GENE_PRODUCT", 111, 114], ["SMRT", "GENE_OR_GENE_PRODUCT", 119, 123], ["Zona Occluden-1", "GENE_OR_GENE_PRODUCT", 204, 219], ["HeLa cells", "CELL_LINE", 32, 42], ["Pin1", "PROTEIN", 52, 56], ["PML", "PROTEIN", 111, 114], ["SMRT", "PROTEIN", 119, 123], ["Postsynaptic Density-95/Discs Large/Zona Occluden-1 (PDZ) domains", "PROTEIN", 168, 233], ["C-termini", "PROTEIN", 251, 260], ["target proteins", "PROTEIN", 264, 279], ["Our data", "TEST", 0, 8], ["HeLa cells", "PROBLEM", 32, 42], ["the Pin1 inhibitor", "TREATMENT", 48, 66], ["the protein levels", "TEST", 89, 107], ["PML", "PROBLEM", 111, 114], ["Postsynaptic Density", "TEST", 168, 188], ["Discs Large/Zona Occluden", "PROBLEM", 192, 217], ["HeLa cells", "OBSERVATION", 32, 42]]], ["The BUZ (binder of ubiquitin zinc-finger) domain binds to the free C-terminus of ubiquitin and therefore helps mediate ubiquitin-based signaling events.", [["BUZ", "CHEMICAL", 4, 7], ["zinc", "CHEMICAL", 29, 33], ["C", "CHEMICAL", 67, 68], ["BUZ", "GENE_OR_GENE_PRODUCT", 4, 7], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 81, 90], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 119, 128], ["BUZ", "PROTEIN", 4, 7], ["ubiquitin zinc-finger) domain", "PROTEIN", 19, 48], ["C-terminus", "PROTEIN", 67, 77], ["ubiquitin", "PROTEIN", 81, 90], ["ubiquitin", "PROTEIN", 119, 128], ["The BUZ (binder of ubiquitin zinc-finger)", "TREATMENT", 0, 41], ["based signaling events", "PROBLEM", 129, 151], ["finger", "ANATOMY", 34, 40]]], ["The BRCA1 C-terminal (BRCT) domain interacts with a variety of proteins involved in the DNA damage response and has been shown to associate with the C-termini of many proteins in a phosphorylation dependent manner.R. Hard and D. PeiThe one-bead one-compound (OBOC) combinatorial library approach allows for the determination of individual binding sequences to proteins of interest, which can be compiled and analyzed to determine the specificity of a particular protein domain.R. Hard and D. PeiA C-terminal OBOC library was used to define the sequence specificity of the PDZ domains of Tiam Aza-amino acids are amino acids in which the -carbon has been replaced by a nitrogen atom.", [["Aza-amino acids", "CHEMICAL", 592, 607], ["amino acids", "CHEMICAL", 612, 623], ["-carbon", "CHEMICAL", 637, 644], ["nitrogen", "CHEMICAL", 668, 676], ["C", "CHEMICAL", 497, 498], ["Aza-amino acids", "CHEMICAL", 592, 607], ["amino acids", "CHEMICAL", 612, 623], ["-carbon", "CHEMICAL", 637, 644], ["nitrogen", "CHEMICAL", 668, 676], ["BRCA1", "GENE_OR_GENE_PRODUCT", 4, 9], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["Tiam Aza-amino acids", "SIMPLE_CHEMICAL", 587, 607], ["amino acids", "AMINO_ACID", 612, 623], ["-carbon", "SIMPLE_CHEMICAL", 637, 644], ["nitrogen atom", "SIMPLE_CHEMICAL", 668, 681], ["BRCA1 C-terminal (BRCT) domain", "PROTEIN", 4, 34], ["C-termini", "PROTEIN", 149, 158], ["protein domain", "PROTEIN", 462, 476], ["Hard and D. PeiA C-terminal OBOC library", "DNA", 480, 520], ["PDZ domains", "PROTEIN", 572, 583], ["The BRCA1 C-terminal (BRCT) domain interacts", "PROBLEM", 0, 44], ["the DNA damage response", "PROBLEM", 84, 107], ["compound (OBOC) combinatorial library approach", "TREATMENT", 249, 295], ["C-terminal OBOC library", "TREATMENT", 497, 520], ["Tiam Aza-amino acids", "TREATMENT", 587, 607], ["amino acids", "TREATMENT", 612, 623], ["a nitrogen atom", "TREATMENT", 666, 681], ["BRCA1", "OBSERVATION", 4, 9], ["terminal", "OBSERVATION_MODIFIER", 12, 20]]], ["Lone pair repulsion between the adjacent nitrogens atoms in aza-amino acid residues have suggested to induce turn conformation as observed by X-ray diffraction, NMR spectroscopy and computational analysis.", [["aza-amino acid", "CHEMICAL", 60, 74], ["nitrogens", "CHEMICAL", 41, 50], ["aza-amino acid", "CHEMICAL", 60, 74], ["aza-amino acid", "SIMPLE_CHEMICAL", 60, 74], ["Lone pair repulsion", "PROBLEM", 0, 19], ["the adjacent nitrogens atoms", "TREATMENT", 28, 56], ["aza-amino acid residues", "TREATMENT", 60, 83], ["X-ray diffraction", "TEST", 142, 159], ["NMR spectroscopy", "TEST", 161, 177], ["computational analysis", "TEST", 182, 204], ["repulsion", "OBSERVATION_MODIFIER", 10, 19], ["nitrogens atoms", "OBSERVATION", 41, 56]]], ["Aza-peptide analogs of GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), a hexapeptide that exhibits dual affinity towards both the GHSR-1a and the CD36 receptors, were synthesized using solid-phase chemistry and split-and-mix protocols to make libraries i .", [["GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2", "CHEMICAL", 23, 62], ["GHRP-6", "CHEMICAL", 23, 29], ["His-D-Trp-Ala-Trp-D-Phe-Lys-NH2", "CHEMICAL", 31, 62], ["Aza-peptide", "SIMPLE_CHEMICAL", 0, 11], ["GHRP-6", "SIMPLE_CHEMICAL", 23, 29], ["His-D-Trp-Ala-Trp-D-Phe-Lys-NH2", "SIMPLE_CHEMICAL", 31, 62], ["GHSR-1a", "GENE_OR_GENE_PRODUCT", 124, 131], ["CD36", "GENE_OR_GENE_PRODUCT", 140, 144], ["NH2", "PROTEIN", 59, 62], ["GHSR-1a", "PROTEIN", 124, 131], ["CD36 receptors", "PROTEIN", 140, 154], ["GHRP", "TEST", 23, 27], ["His", "TEST", 31, 34], ["Trp", "TEST", 37, 40], ["Ala", "TEST", 41, 44], ["Trp", "TEST", 45, 48], ["Phe-Lys-NH2", "TREATMENT", 51, 62], ["a hexapeptide", "TREATMENT", 65, 78], ["dual affinity", "PROBLEM", 93, 106], ["the CD36 receptors", "TEST", 136, 154], ["solid-phase chemistry", "TREATMENT", 179, 200], ["split-and-mix protocols", "TREATMENT", 205, 228]]], ["Certain analogs exhibited selectivity to the CD36 receptor.", [["CD36 receptor", "GENE_OR_GENE_PRODUCT", 45, 58], ["CD36 receptor", "PROTEIN", 45, 58]]], ["Our presentation will describe the synthesis of GHRP-6 aza-peptides, binding affinity values for the GHS-R1a and CD36 receptors, as well as in vitro antiangiogenic properties of the best analogs.", [["GHRP-6 aza-peptides", "CHEMICAL", 48, 67], ["GHRP-6 aza-peptides", "CHEMICAL", 48, 67], ["GHRP-6 aza-peptides", "SIMPLE_CHEMICAL", 48, 67], ["GHS-R1a", "GENE_OR_GENE_PRODUCT", 101, 108], ["CD36 receptors", "GENE_OR_GENE_PRODUCT", 113, 127], ["GHRP", "PROTEIN", 48, 52], ["GHS", "PROTEIN", 101, 104], ["R1a", "PROTEIN", 105, 108], ["CD36 receptors", "PROTEIN", 113, 127], ["GHRP", "TEST", 48, 52], ["binding affinity values", "TEST", 69, 92], ["the GHS", "TEST", 97, 104], ["CD36 receptors", "TEST", 113, 127], ["vitro antiangiogenic properties", "TREATMENT", 143, 174]]], ["Cyclic peptides have the potential to mimic selection processes evolved by enzymes.", [["enzymes", "PROTEIN", 75, 82], ["Cyclic peptides", "PROBLEM", 0, 15], ["enzymes", "TEST", 75, 82]]], ["Linear peptides containing N-methylimidazole moiety have been established as catalysts for kinetic resolution of certain secondary alcohols.", [["N-methylimidazole", "CHEMICAL", 27, 44], ["N-methylimidazole", "CHEMICAL", 27, 44], ["secondary alcohols", "CHEMICAL", 121, 139], ["N-methylimidazole moiety", "SIMPLE_CHEMICAL", 27, 51], ["secondary alcohols", "SIMPLE_CHEMICAL", 121, 139], ["Linear peptides", "TREATMENT", 0, 15], ["N-methylimidazole moiety", "TREATMENT", 27, 51], ["catalysts", "TREATMENT", 77, 86], ["secondary alcohols", "OBSERVATION", 121, 139]]], ["However, cyclic peptides N-methylimidazole moiety have not been studied in catalytic reactions.", [["N-methylimidazole", "CHEMICAL", 25, 42], ["N-methylimidazole", "CHEMICAL", 25, 42], ["N-methylimidazole moiety", "SIMPLE_CHEMICAL", 25, 49], ["cyclic peptides", "PROBLEM", 9, 24], ["methylimidazole moiety", "TREATMENT", 27, 49]]], ["In this work, a new type of cyclic peptides is being developed as acyl transfer catalysts.", [["acyl", "CHEMICAL", 66, 70], ["cyclic peptides", "PROBLEM", 28, 43], ["acyl transfer catalysts", "TREATMENT", 66, 89], ["cyclic peptides", "OBSERVATION", 28, 43]]], ["A cyclic peptide library (2.15 million peptides) containing five random positions and N-methyl histidine was synthesized on PL-AMS resin on which fluorescent pH sensor and corresponding linear peptide were also employed.", [["N-methyl histidine", "CHEMICAL", 86, 104], ["N-methyl histidine", "CHEMICAL", 86, 104], ["N-methyl histidine", "SIMPLE_CHEMICAL", 86, 104], ["PL", "SIMPLE_CHEMICAL", 124, 126], ["A cyclic peptide library (2.15 million peptides)", "TREATMENT", 0, 48], ["five random positions", "TREATMENT", 60, 81], ["N-methyl histidine", "TREATMENT", 86, 104], ["PL-AMS resin", "TREATMENT", 124, 136], ["fluorescent pH sensor", "TEST", 146, 167]]], ["The library was then screened against several acylation reactions.", [["several acylation reactions", "PROBLEM", 38, 65]]], ["Selection of the brightest beads from the library identified the most active catalysts.", [["the brightest beads", "TREATMENT", 13, 32], ["brightest beads", "OBSERVATION", 17, 32], ["most", "OBSERVATION_MODIFIER", 65, 69], ["active", "OBSERVATION_MODIFIER", 70, 76], ["catalysts", "OBSERVATION", 77, 86]]], ["Resynthesis of these cyclic peptides were then carried out.", [["Resynthesis of these cyclic peptides", "PROBLEM", 0, 36]]], ["Preliminary results showed the selected cyclic peptides can catalyze acylation reactions.R. Nagarkar and J. SchneiderDepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE 19716 A responsive self-assembling peptide consisting of an amphiphilichairpin fused to a helical domain capable of forming coiled coils has been designed.", [["DE 19716", "CHEMICAL", 191, 199], ["amphiphilichairpin", "CHEMICAL", 254, 272], ["amphiphilichairpin", "SIMPLE_CHEMICAL", 254, 272], ["amphiphilichairpin", "PROTEIN", 254, 272], ["helical domain", "PROTEIN", 284, 298], ["coiled coils", "PROTEIN", 318, 330], ["the selected cyclic peptides", "PROBLEM", 27, 55], ["acylation reactions", "PROBLEM", 69, 88], ["A responsive self-assembling peptide", "PROBLEM", 200, 236], ["an amphiphilichairpin fused", "TREATMENT", 251, 278], ["a helical domain capable of forming coiled coils", "TREATMENT", 282, 330], ["coils", "OBSERVATION", 325, 330]]], ["This design allows the study of synergistic contributions to material formation from multiple distinct motifs within the selfassembling peptide.", [["material", "TISSUE", 61, 69], ["the study", "TEST", 19, 28], ["material formation", "PROBLEM", 61, 79], ["multiple distinct motifs", "PROBLEM", 85, 109]]], ["Folding of each domain (helical and -sheet) can be triggered by pH or temperature.", [["helical and -sheet", "PROTEIN", 24, 42]]], ["Aggregation state of the coiled coils appended to the -hairpin was investigated using AUC.", [["coiled coils", "PROTEIN", 25, 37], ["-hairpin", "PROTEIN", 54, 62], ["the coiled coils", "TREATMENT", 21, 37], ["AUC", "TEST", 86, 89], ["coiled", "OBSERVATION_MODIFIER", 25, 31], ["coils", "OBSERVATION", 32, 37]]], ["The fusion peptides form physically crosslinked hydrogels with fibrillar nanostructure.", [["The fusion peptides", "TREATMENT", 0, 19], ["physically crosslinked hydrogels", "PROBLEM", 25, 57], ["fibrillar nanostructure", "PROBLEM", 63, 86], ["fusion", "OBSERVATION", 4, 10], ["crosslinked hydrogels", "OBSERVATION", 36, 57], ["fibrillar nanostructure", "OBSERVATION", 63, 86]]], ["Fibril dimensions, as measured by TEM elucidate the underlying self-assembly mechanism.", [["Fibril", "ANATOMY", 0, 6]]], ["Rheological studies revealed that upon heating the 5 wt% peptide solutions at pH 9, viscoelastic gels formed from self-assembled -sheet rich fibrillar networks, which when cooled to room temperature exhibited increased mechanical rigidity concomitant with refolding of the helical domains.P 040 METAL-TRIGGERED SELF-ASSEMBLING COLLAGEN SCAFFOLDSD.", [["rigidity", "DISEASE", 230, 238], ["fibrillar networks", "MULTI-TISSUE_STRUCTURE", 141, 159], ["fibrillar networks", "PROTEIN", 141, 159], ["helical domains", "PROTEIN", 273, 288], ["TRIGGERED SELF", "DNA", 301, 315], ["SCAFFOLDSD", "DNA", 336, 346], ["Rheological studies", "TEST", 0, 19], ["heating the 5 wt% peptide solutions", "TREATMENT", 39, 74], ["pH", "TEST", 78, 80], ["viscoelastic gels", "TREATMENT", 84, 101], ["increased mechanical rigidity", "PROBLEM", 209, 238], ["increased", "OBSERVATION_MODIFIER", 209, 218], ["mechanical rigidity", "OBSERVATION", 219, 238]]], ["Przybyla and J. Chmielewski Department of Chemistry, Purdue University Self-assembling systems provide the unique bottom up approach for creating macro-sized objects from smaller fragments.", [["fragments", "ANATOMY", 179, 188], ["the unique bottom up approach", "TREATMENT", 103, 132], ["creating macro-sized objects", "PROBLEM", 137, 165], ["smaller fragments", "PROBLEM", 171, 188], ["macro-sized objects", "OBSERVATION", 146, 165], ["smaller", "OBSERVATION_MODIFIER", 171, 178], ["fragments", "OBSERVATION", 179, 188]]], ["These systems are of particular interest in the field of regenerative medicines, where self-assembling systems have successfully been used as scaffolds for cellular proliferation.", [["cellular", "ANATOMY", 156, 164], ["cellular", "CELL", 156, 164], ["regenerative medicines", "TREATMENT", 57, 79], ["scaffolds", "TREATMENT", 142, 151], ["cellular proliferation", "PROBLEM", 156, 178], ["cellular proliferation", "OBSERVATION", 156, 178]]], ["Specifically, collagen based scaffolds are particularly desirable because it is the major component of the extra cellular matrix.", [["cellular matrix", "ANATOMY", 113, 128], ["collagen", "GENE_OR_GENE_PRODUCT", 14, 22], ["extra cellular matrix", "CELLULAR_COMPONENT", 107, 128], ["collagen", "PROTEIN", 14, 22], ["collagen based scaffolds", "TREATMENT", 14, 38], ["collagen based", "OBSERVATION_MODIFIER", 14, 28], ["scaffolds", "OBSERVATION", 29, 38], ["extra cellular matrix", "OBSERVATION", 107, 128]]], ["To date, several groups have developed self-assembling collagen fibers by incorporating a variety of N-and C-terminal sticky ends that grow through a linear mechanism.", [["N", "CHEMICAL", 101, 102], ["C", "CHEMICAL", 107, 108], ["collagen", "GENE_OR_GENE_PRODUCT", 55, 63], ["N-and C-terminal sticky ends", "DNA", 101, 129], ["C-terminal sticky ends", "TREATMENT", 107, 129]]], ["However, these systems all generate similarly shaped structures, and provide no control over the 3dimensional architecture.", [["similarly", "OBSERVATION_MODIFIER", 36, 45], ["shaped", "OBSERVATION_MODIFIER", 46, 52]]], ["Consequently, we have successfully designed and synthesized three metal-triggered self-assembling peptides (H-byp, H-(byp)2, and H-(byp)3).", [["H-(byp)3", "CHEMICAL", 129, 137], ["H-byp", "SIMPLE_CHEMICAL", 108, 113], ["H-(byp)2", "SIMPLE_CHEMICAL", 115, 123], ["H-(byp)3", "SIMPLE_CHEMICAL", 129, 137]]], ["These collagen mimetic peptides are capable of assembling through a radial mechanism into a variety of unique structures, fibers, disks, and hollow spheres, and may provide enhanced biological properties to the current collagen based scaffolds.P 040 METAL-TRIGGERED SELF-ASSEMBLING COLLAGEN SCAFFOLDSDepartment of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, USA Collagen fibers are important components in skin, tendon, cartilage and blood vessel.", [["structures", "ANATOMY", 110, 120], ["fibers", "ANATOMY", 122, 128], ["disks", "ANATOMY", 130, 135], ["skin", "ANATOMY", 439, 443], ["tendon", "ANATOMY", 445, 451], ["cartilage", "ANATOMY", 453, 462], ["blood vessel", "ANATOMY", 467, 479], ["collagen", "GENE_OR_GENE_PRODUCT", 6, 14], ["fibers", "CELLULAR_COMPONENT", 122, 128], ["collagen", "GENE_OR_GENE_PRODUCT", 219, 227], ["Collagen fibers", "GENE_OR_GENE_PRODUCT", 395, 410], ["skin", "ORGAN", 439, 443], ["tendon", "TISSUE", 445, 451], ["cartilage", "TISSUE", 453, 462], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 467, 479], ["collagen", "PROTEIN", 219, 227], ["These collagen mimetic peptides", "TREATMENT", 0, 31], ["fibers, disks, and hollow spheres", "PROBLEM", 122, 155], ["the current collagen based scaffolds", "TREATMENT", 207, 243], ["USA Collagen fibers", "TREATMENT", 391, 410], ["disks", "OBSERVATION_MODIFIER", 130, 135], ["hollow spheres", "OBSERVATION", 141, 155], ["skin", "ANATOMY", 439, 443], ["tendon", "ANATOMY", 445, 451], ["cartilage", "ANATOMY", 453, 462], ["blood vessel", "ANATOMY", 467, 479]]], ["Controlling the self-assembly of collagen upon environmental condition is an essential feature for collagen-based biomaterial applications.", [["collagen", "GENE_OR_GENE_PRODUCT", 33, 41], ["collagen", "GENE_OR_GENE_PRODUCT", 99, 107], ["collagen", "PROTEIN", 33, 41], ["collagen", "PROTEIN", 99, 107], ["collagen upon environmental condition", "PROBLEM", 33, 70], ["collagen-based biomaterial applications", "TREATMENT", 99, 138]]], ["Electrostatic interactions have been one of the most popular strategies to promote self-assembly of the collagen peptides.", [["collagen", "GENE_OR_GENE_PRODUCT", 104, 112], ["the collagen peptides", "TREATMENT", 100, 121]]], ["Herein we disclose the self-assembly of the collagen peptides using positively and negatively charged collagen peptides.", [["collagen", "GENE_OR_GENE_PRODUCT", 44, 52], ["collagen", "GENE_OR_GENE_PRODUCT", 102, 110], ["the collagen peptides", "TREATMENT", 40, 61], ["negatively charged collagen peptides", "TREATMENT", 83, 119]]], ["Each positive and negative charge was introduced to the (POG)9 peptide by incorporation of Oalkylated hydroxyproline with carboxylate and amine functionalities.", [["hydroxyproline", "CHEMICAL", 102, 116], ["carboxylate", "CHEMICAL", 122, 133], ["amine", "CHEMICAL", 138, 143], ["(POG)9 peptide", "CHEMICAL", 56, 70], ["Oalkylated hydroxyproline", "CHEMICAL", 91, 116], ["carboxylate", "CHEMICAL", 122, 133], ["amine", "CHEMICAL", 138, 143], ["Oalkylated hydroxyproline", "SIMPLE_CHEMICAL", 91, 116], ["carboxylate", "SIMPLE_CHEMICAL", 122, 133], ["amine", "SIMPLE_CHEMICAL", 138, 143], ["the (POG)", "TREATMENT", 52, 61], ["Oalkylated hydroxyproline", "TREATMENT", 91, 116], ["carboxylate and amine functionalities", "TREATMENT", 122, 159], ["negative charge", "OBSERVATION", 18, 33]]], ["These collagen peptides display electronic charges that exposed to environmental conditions while stabilized as triple helix at neutral pH.", [["collagen", "GENE_OR_GENE_PRODUCT", 6, 14], ["These collagen peptides", "PROBLEM", 0, 23], ["electronic charges", "PROBLEM", 32, 50], ["triple helix at neutral pH", "PROBLEM", 112, 138]]], ["We successfully showed to control self-assembly of multiple homotrimers upon pH conditions through electrostatic interactions of displayed charges on the peptides.", [["homotrimers", "SIMPLE_CHEMICAL", 60, 71], ["multiple homotrimers upon pH conditions", "PROBLEM", 51, 90], ["the peptides", "TREATMENT", 150, 162]]], ["Our designs are distinct from the previous research in that thermal unfolding of the collagen peptide is the necessary process to promote self assembly of the peptides.", [["collagen", "GENE_OR_GENE_PRODUCT", 85, 93], ["the collagen peptide", "TREATMENT", 81, 101], ["distinct", "OBSERVATION_MODIFIER", 16, 24]]], ["The selfassembled peptides formed 200nm cone shaped structures that were confirmed by Dynamic Light Scattering and Atomic Force Microscopy.", [["The selfassembled peptides", "TREATMENT", 0, 26], ["Atomic Force Microscopy", "TEST", 115, 138], ["200nm", "OBSERVATION_MODIFIER", 34, 39]]], ["We anticipate that our design of self assembly of the collagen peptide can offer the new possibility of strategy for various collagen biomaterial applications.P 040 METAL-TRIGGERED SELF-ASSEMBLING COLLAGEN SCAFFOLDSThe hierarchical assembly of nanoscale building blocks into micronscaled functional materials is a powerful strategy for the design of devices for regenerative medicine and tissue engineering.", [["tissue", "ANATOMY", 388, 394], ["collagen", "GENE_OR_GENE_PRODUCT", 54, 62], ["collagen", "GENE_OR_GENE_PRODUCT", 125, 133], ["tissue", "TISSUE", 388, 394], ["the collagen peptide", "TREATMENT", 50, 70], ["strategy", "TREATMENT", 104, 112], ["various collagen biomaterial applications", "TREATMENT", 117, 158], ["the design of devices", "TREATMENT", 336, 357], ["regenerative medicine", "TREATMENT", 362, 383], ["tissue engineering", "TREATMENT", 388, 406]]], ["Essential features of successful tissue engineering, for instance, include the control of scaffold morphology at the nm to micro scale, along with the temporal and spatial release of specific growth factors to promote tissue growth and repair.", [["tissue", "ANATOMY", 33, 39], ["tissue", "ANATOMY", 218, 224], ["tissue", "TISSUE", 33, 39], ["tissue", "TISSUE", 218, 224], ["growth factors", "PROTEIN", 192, 206], ["successful tissue engineering", "TREATMENT", 22, 51], ["micro scale", "TEST", 123, 134], ["specific growth factors", "PROBLEM", 183, 206], ["tissue growth", "PROBLEM", 218, 231], ["repair", "TREATMENT", 236, 242], ["successful tissue engineering", "OBSERVATION", 22, 51], ["growth", "OBSERVATION_MODIFIER", 225, 231], ["repair", "OBSERVATION", 236, 242]]], ["Herein, we designed and synthesized a peptide composed of a core of (Pro-Hyp-Gly)9 flanked by the metal binding moieties nitrilotriacetic acid (NTA) and a di-histidine unit.", [["Pro-Hyp-Gly)9", "CHEMICAL", 69, 82], ["nitrilotriacetic acid", "CHEMICAL", 121, 142], ["NTA", "CHEMICAL", 144, 147], ["di-histidine", "CHEMICAL", 155, 167], ["(Pro-Hyp-Gly)9", "CHEMICAL", 68, 82], ["nitrilotriacetic acid", "CHEMICAL", 121, 142], ["NTA", "CHEMICAL", 144, 147], ["di-histidine", "CHEMICAL", 155, 167], ["Pro-Hyp-Gly", "SIMPLE_CHEMICAL", 69, 80], ["nitrilotriacetic acid", "SIMPLE_CHEMICAL", 121, 142], ["NTA", "SIMPLE_CHEMICAL", 144, 147], ["a core of (Pro-Hyp-Gly)", "TREATMENT", 58, 81], ["the metal binding moieties nitrilotriacetic acid (NTA", "TREATMENT", 94, 147], ["a di-histidine unit", "TREATMENT", 153, 172]]], ["We report that this peptide rapidly and reversibly assembles in the presence of metal ions to form microflorettes of reproducible size and shape.", [["metal ions", "SIMPLE_CHEMICAL", 80, 90], ["metal ions", "PROBLEM", 80, 90], ["metal ions", "OBSERVATION", 80, 90], ["reproducible", "OBSERVATION_MODIFIER", 117, 129], ["size", "OBSERVATION_MODIFIER", 130, 134], ["shape", "OBSERVATION_MODIFIER", 139, 144]]], ["In addition, we demonstrate that unsatisfied metal/ligands exist on the surface and within the microflorettes, and that these may be easily modified with His-tag functionalized molecules.", [["surface", "ANATOMY", 72, 79], ["His", "CHEMICAL", 154, 157], ["surface", "CELLULAR_COMPONENT", 72, 79], ["His-tag functionalized molecules", "PROTEIN", 154, 186], ["unsatisfied metal/ligands", "PROBLEM", 33, 58], ["His-tag functionalized molecules", "TREATMENT", 154, 186], ["ligands", "OBSERVATION", 51, 58]]], ["Two distinct His-tagged fluorescent proteins were used to demonstrate that these proteins could be incorporated within the structures with spatial control.", [["His", "CHEMICAL", 13, 16], ["His-tagged fluorescent proteins", "PROTEIN", 13, 44], ["tagged fluorescent proteins", "TEST", 17, 44], ["these proteins", "PROBLEM", 75, 89], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["spatial control", "OBSERVATION", 139, 154]]], ["Critical to their use in biomedical applications is their ability to associate with mammalians cells.", [["mammalians cells", "ANATOMY", 84, 100], ["mammalians cells", "CELL", 84, 100], ["mammalians cells", "CELL_TYPE", 84, 100], ["biomedical applications", "TREATMENT", 25, 48], ["mammalians cells", "PROBLEM", 84, 100], ["mammalians cells", "OBSERVATION", 84, 100]]], ["We show that the microflorettes are capable of avidly binding to various adherent and suspended cells.", [["cells", "ANATOMY", 96, 101], ["cells", "CELL", 96, 101], ["adherent and suspended cells", "CELL_TYPE", 73, 101], ["the microflorettes", "PROBLEM", 13, 31], ["suspended cells", "OBSERVATION", 86, 101]]], ["These unprecedented microscopic structures offer opportunities in many areas, including tissue engineering and regeneration.", [["tissue", "ANATOMY", 88, 94], ["tissue", "TISSUE", 88, 94], ["many", "OBSERVATION_MODIFIER", 66, 70], ["areas", "OBSERVATION_MODIFIER", 71, 76], ["tissue engineering", "OBSERVATION", 88, 106], ["regeneration", "OBSERVATION_MODIFIER", 111, 123]]], ["Advances in biotechnology techniques have led to the rapid development of small protein and antibody therapeutics.", [["small protein", "PROTEIN", 74, 87], ["biotechnology techniques", "TREATMENT", 12, 36], ["small protein", "PROBLEM", 74, 87], ["antibody therapeutics", "TREATMENT", 92, 113], ["small protein", "OBSERVATION", 74, 87]]], ["However, several limitations remain in the preparation and delivery of these drugs due to the susceptibility of proteins to degrade during storage and upon administration.", [["these drugs", "TREATMENT", 71, 82], ["the susceptibility of proteins", "PROBLEM", 90, 120]]], ["To address this problem, hydrogels have been used as delivery devices for these protein drugs.", [["this problem", "PROBLEM", 11, 23], ["hydrogels", "TREATMENT", 25, 34], ["delivery devices", "TREATMENT", 53, 69], ["these protein drugs", "TREATMENT", 74, 93]]], ["We have designed a class of self-assembling peptides that undergo triggered hydrogelation in response to physiological pH and salt conditions (pH 7.4, 150 mM NaCl).", [["NaCl", "CHEMICAL", 158, 162], ["NaCl", "CHEMICAL", 158, 162], ["self-assembling peptides", "PROBLEM", 28, 52], ["triggered hydrogelation", "PROBLEM", 66, 89], ["physiological pH", "TEST", 105, 121], ["salt conditions", "TEST", 126, 141], ["pH", "TEST", 143, 145]]], ["The peptides fold into a -hairpin, and subsequently, selfassemble to form a rigid hydrogel stabilized by non-covalent cross-links.", [["a rigid hydrogel", "TREATMENT", 74, 90]]], ["For these peptides, it is possible to control the folding and assembly kinetics to form hydrogels with different rigidities.", [["these peptides", "TEST", 4, 18], ["the folding", "PROBLEM", 46, 57], ["hydrogels", "PROBLEM", 88, 97], ["different rigidities", "PROBLEM", 103, 123]]], ["These changes affect the porous morphology within the hydrogel system, and subsequently influence the rate of macromolecular diffusion within the peptide fibrillar network.", [["macromolecular diffusion", "PROBLEM", 110, 134], ["porous", "OBSERVATION_MODIFIER", 25, 31], ["morphology", "OBSERVATION_MODIFIER", 32, 42], ["hydrogel system", "ANATOMY", 54, 69], ["macromolecular diffusion", "OBSERVATION", 110, 134], ["peptide fibrillar network", "OBSERVATION", 146, 171]]], ["This study focuses on determining the mass transport properties of model proteins from self-assembled MAX8 hydrogels.", [["MAX8 hydrogels", "SIMPLE_CHEMICAL", 102, 116], ["model proteins", "PROTEIN", 67, 81], ["This study", "TEST", 0, 10], ["model proteins", "PROBLEM", 67, 81], ["self-assembled MAX8 hydrogels", "TREATMENT", 87, 116], ["mass", "OBSERVATION", 38, 42]]], ["Proteins of varying molecular weights and pIs were chosen to assess the effect of fibrillar charge density and hydrogel mesh size on their release properties from these networks.", [["fibrillar", "ANATOMY", 82, 91], ["pIs", "SIMPLE_CHEMICAL", 42, 45], ["pIs", "TEST", 42, 45], ["fibrillar charge density", "TREATMENT", 82, 106], ["hydrogel mesh size", "TREATMENT", 111, 129], ["varying", "OBSERVATION_MODIFIER", 12, 19], ["hydrogel mesh", "OBSERVATION", 111, 124], ["size", "OBSERVATION_MODIFIER", 125, 129]]], ["Proteins are added into solution during folding and self-assembling, yielding gels with macromolecules directly encapsulated into the network.P 045 GOLD NANOPARTICLE SELF-ASSEMBLY PRO-MOTED BY A NON-COVALENT, CHARGE-COMPLE-MENTED COILED-COIL PEPTIDED.", [["COIL PEPTIDED", "DNA", 237, 250], ["Proteins", "TREATMENT", 0, 8], ["macromolecules", "TREATMENT", 88, 102]]], ["Numerous attempts to assemble gold nanoparticles (GNPs) to various biomolecules via covalent linkages are present in the literature; however non-covalent interactions have not been studied as extensively.", [["gold nanoparticles", "CHEMICAL", 30, 48], ["GNPs", "CHEMICAL", 50, 54], ["gold nanoparticles", "SIMPLE_CHEMICAL", 30, 48], ["GNPs", "SIMPLE_CHEMICAL", 50, 54], ["assemble gold nanoparticles (GNPs)", "TREATMENT", 21, 55], ["various biomolecules via covalent linkages", "TREATMENT", 59, 101], ["covalent linkages", "OBSERVATION", 84, 101]]], ["To this end, we have designed a system using cationic GNPs and anionic coiled-coil peptides to facilitate assembly via noncovalent interactions.", [["GNPs", "CHEMICAL", 54, 58], ["GNPs", "SIMPLE_CHEMICAL", 54, 58], ["cationic GNPs", "TREATMENT", 45, 58], ["anionic coiled-coil peptides", "TREATMENT", 63, 91]]], ["An anionic variant of the leucine zipper region of the transcription factor GCN4 was designed.", [["leucine", "CHEMICAL", 26, 33], ["leucine", "AMINO_ACID", 26, 33], ["GCN4", "GENE_OR_GENE_PRODUCT", 76, 80], ["leucine zipper region", "PROTEIN", 26, 47], ["transcription factor", "PROTEIN", 55, 75], ["GCN4", "PROTEIN", 76, 80], ["the transcription factor GCN4", "TEST", 51, 80], ["anionic variant", "OBSERVATION", 3, 18], ["leucine zipper", "OBSERVATION", 26, 40]]], ["The hydrophobic residues of the heptad repeat remained unaltered to facilitate the natural parallel, dimeric oligomerization of the peptide, but five solvent exposed residues were modified to Glu residues to yield GCN4-E.", [["Glu", "CHEMICAL", 192, 195], ["Glu", "CHEMICAL", 192, 195], ["GCN4-E.", "GENE_OR_GENE_PRODUCT", 214, 221], ["heptad repeat", "PROTEIN", 32, 45], ["GCN4", "PROTEIN", 214, 218], ["The hydrophobic residues", "PROBLEM", 0, 24], ["the heptad repeat", "TEST", 28, 45], ["dimeric oligomerization of the peptide", "TREATMENT", 101, 139], ["five solvent exposed residues", "TREATMENT", 145, 174], ["hydrophobic residues", "OBSERVATION", 4, 24]]], ["Circular dichroism (CD), UV-vis spectroscopy, dynamic light scattering (DLS) and transmission electron microscopy (TEM) were used to characterize and confirm the assembly and aggregation of GNPs in the presence of GCN4-E.", [["GNPs", "CHEMICAL", 190, 194], ["GNPs", "SIMPLE_CHEMICAL", 190, 194], ["GCN4", "PROTEIN", 214, 218], ["Circular dichroism", "TEST", 0, 18], ["UV-vis spectroscopy", "TEST", 25, 44], ["transmission electron microscopy", "TEST", 81, 113], ["aggregation of GNPs", "PROBLEM", 175, 194]]], ["To establish the importance of the hydrophobic face and the cofacial anionic face, two control peptides, GCN4-X, scrambled version of GCN4-E, and the native GCN4-p1 peptide were also tested.", [["GCN4-X", "GENE_OR_GENE_PRODUCT", 105, 111], ["GCN4-E", "GENE_OR_GENE_PRODUCT", 134, 140], ["GCN4-p1 peptide", "GENE_OR_GENE_PRODUCT", 157, 172], ["GCN4", "PROTEIN", 105, 109], ["X", "PROTEIN", 110, 111], ["GCN4", "PROTEIN", 134, 138], ["E", "PROTEIN", 139, 140], ["GCN4", "PROTEIN", 157, 161], ["the cofacial anionic face", "TREATMENT", 56, 81], ["GCN4", "TEST", 105, 109], ["GCN4", "TEST", 134, 138], ["the native GCN4", "TREATMENT", 146, 161]]], ["Neither showed any evidence of facilitating GNP aggregation.", [["GNP", "CHEMICAL", 44, 47], ["GNP", "SIMPLE_CHEMICAL", 44, 47], ["facilitating GNP aggregation", "PROBLEM", 31, 59], ["any evidence of", "UNCERTAINTY", 15, 30], ["GNP aggregation", "OBSERVATION", 44, 59]]], ["The designed system effectively shows that non-covalent interactions are responsible for the bottom-up self assembly of GNPs.", [["GNPs", "CHEMICAL", 120, 124], ["GNPs", "SIMPLE_CHEMICAL", 120, 124], ["non-covalent interactions", "PROBLEM", 43, 68], ["non-covalent", "OBSERVATION", 43, 55]]], ["Giano, D. Salick, J. Schneider University of Delaware Hydrogels have emerged as biomaterials to act as scaffolds for tissue regenerative therapies and drug delivery.", [["tissue", "ANATOMY", 117, 123], ["tissue", "TISSUE", 117, 123], ["Delaware Hydrogels", "TREATMENT", 45, 63], ["tissue regenerative therapies", "TREATMENT", 117, 146], ["drug delivery", "TREATMENT", 151, 164]]], ["The ability of the hydrogel scaffold to temporarily support the injured tissue, by providing mechanical properties consistent with the tissue during the wound healing process, allows for optimal tissue regeneration.", [["tissue", "ANATOMY", 72, 78], ["tissue", "ANATOMY", 135, 141], ["wound", "ANATOMY", 153, 158], ["tissue", "ANATOMY", 195, 201], ["tissue", "TISSUE", 72, 78], ["tissue", "TISSUE", 135, 141], ["wound", "PATHOLOGICAL_FORMATION", 153, 158], ["tissue", "TISSUE", 195, 201], ["the hydrogel scaffold", "TREATMENT", 15, 36], ["the injured tissue", "PROBLEM", 60, 78], ["the tissue", "PROBLEM", 131, 141], ["the wound healing process", "PROBLEM", 149, 174], ["optimal tissue regeneration", "PROBLEM", 187, 214], ["injured tissue", "OBSERVATION", 64, 78], ["wound", "ANATOMY", 153, 158], ["healing", "OBSERVATION", 159, 166], ["optimal tissue", "OBSERVATION_MODIFIER", 187, 201], ["regeneration", "OBSERVATION", 202, 214]]], ["Controlled degradation of the implanted material can aid the successful integration of the new tissue formed.", [["tissue", "ANATOMY", 95, 101], ["tissue", "TISSUE", 95, 101], ["the implanted material", "TREATMENT", 26, 48], ["new", "OBSERVATION_MODIFIER", 91, 94], ["tissue", "OBSERVATION", 95, 101]]], ["For many applications, the rate of degradation of the hydrogel scaffold should approximate the rate of new tissue formation.", [["tissue", "ANATOMY", 107, 113], ["tissue", "TISSUE", 107, 113], ["many applications", "TREATMENT", 4, 21], ["the hydrogel scaffold", "TREATMENT", 50, 71], ["new tissue formation", "PROBLEM", 103, 123], ["hydrogel scaffold", "OBSERVATION", 54, 71], ["new tissue", "OBSERVATION", 103, 113]]], ["If the hydrogel material is peptide-based, proteases, which hydrolyze amide bonds in a sequence specific manner, could provide a means of degrading the hydrogel with temporal resolution.", [["amide", "CHEMICAL", 70, 75], ["proteases", "PROTEIN", 43, 52], ["the hydrogel material", "TREATMENT", 3, 24], ["proteases", "PROBLEM", 43, 52], ["hydrolyze amide bonds", "TREATMENT", 60, 81]]], ["The degradation profile ofhairpin peptide hydrogels in vitro by trypsin, a model enzyme, was assessed by HPLC, mass spectrometry and rheology.", [["trypsin", "GENE_OR_GENE_PRODUCT", 64, 71], ["trypsin", "PROTEIN", 64, 71], ["The degradation profile ofhairpin peptide hydrogels", "TREATMENT", 0, 51], ["a model enzyme", "TEST", 73, 87], ["HPLC", "TEST", 105, 109], ["mass spectrometry", "TEST", 111, 128]]], ["Exogenous trypsin proteolysis studies were conducted on the peptide gels and respective fragments were separated by analytical HPLC and characterized utilizing electrospray ionization mass spectrometry.", [["fragments", "ANATOMY", 88, 97], ["trypsin", "GENE_OR_GENE_PRODUCT", 10, 17], ["trypsin", "PROTEIN", 10, 17], ["Exogenous trypsin proteolysis studies", "PROBLEM", 0, 37], ["the peptide gels", "TREATMENT", 56, 72], ["analytical HPLC", "TEST", 116, 131], ["electrospray ionization mass spectrometry", "TREATMENT", 160, 201]]], ["Bulk material properties were assessed with oscillatory shear rheology as a function of enzyme exposure time and were consistent with the rate of proteolysis measured by HPLC and mass spectrometry.", [["oscillatory shear rheology", "TEST", 44, 70], ["the rate of proteolysis", "PROBLEM", 134, 157], ["HPLC", "TEST", 170, 174], ["mass spectrometry", "PROBLEM", 179, 196], ["consistent with", "UNCERTAINTY", 118, 133], ["mass spectrometry", "OBSERVATION", 179, 196]]], ["Results demonstrated that tailoring the amino acid sequence towards the specificity of trypsin can be useful in tuning the degradation of the -hairpin peptide hydrogel.", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "AMINO_ACID", 40, 50], ["trypsin", "GENE_OR_GENE_PRODUCT", 87, 94], ["trypsin", "PROTEIN", 87, 94], ["the amino acid sequence", "TEST", 36, 59], ["trypsin", "TREATMENT", 87, 94], ["the -hairpin peptide hydrogel", "TREATMENT", 138, 167]]], ["The impact of nanotechnology on medicine and energy relies on the development and improvement of fabrication methods that produce highly pure nano-objects with novel structural features in a simple manner.", [["medicine", "TREATMENT", 32, 40], ["fabrication methods", "TREATMENT", 97, 116], ["novel structural features", "PROBLEM", 160, 185]]], ["One underlying goal of synthetic peptide science is to devise simple protocols that can program the assembly kinetics of synthetically facile peptides into desired sizes and shapes with necessary surface chemistries that lead the nanostructures to pack into hierarchically well-defined larger objects.", [["surface", "ANATOMY", 196, 203], ["synthetic peptide science", "TREATMENT", 23, 48], ["simple protocols", "TREATMENT", 62, 78], ["synthetically facile peptides", "TREATMENT", 121, 150], ["necessary surface chemistries", "TREATMENT", 186, 215], ["the nanostructures", "TREATMENT", 226, 244], ["sizes", "OBSERVATION_MODIFIER", 164, 169], ["-defined", "OBSERVATION_MODIFIER", 277, 285], ["larger", "OBSERVATION_MODIFIER", 286, 292], ["objects", "OBSERVATION", 293, 300]]], ["We report here our recent efforts to design and assemble small molecular peptides into discrete nanostructures, such as cylinders, belts, multi-walled tubes and ribbons, and their subsequent assembly at a larger length scale into highly ordered crystalline structures.", [["belts", "TREATMENT", 131, 136], ["multi-walled tubes and ribbons", "TREATMENT", 138, 168], ["a larger length scale", "TREATMENT", 203, 224], ["small", "OBSERVATION_MODIFIER", 57, 62], ["walled tubes", "OBSERVATION", 144, 156]]], ["The key feature of the designed molecular structural motif is the alternating hydrophobic and hydrophilic amino acid sequence that is covalently grafted onto hydrophobic tails, either a short alkyl tail or semiconducting oligomers.", [["amino acid", "CHEMICAL", 106, 116], ["alkyl", "CHEMICAL", 192, 197], ["amino acid", "CHEMICAL", 106, 116], ["amino acid", "AMINO_ACID", 106, 116], ["molecular structural motif", "PROTEIN", 32, 58], ["hydrophilic amino acid sequence", "PROTEIN", 94, 125], ["hydrophobic tails", "PROTEIN", 158, 175], ["alkyl tail", "PROTEIN", 192, 202], ["the alternating hydrophobic and hydrophilic amino acid sequence", "PROBLEM", 62, 125], ["a short alkyl tail", "PROBLEM", 184, 202], ["semiconducting oligomers", "PROBLEM", 206, 230], ["hydrophobic tails", "OBSERVATION", 158, 175], ["short alkyl tail", "OBSERVATION_MODIFIER", 186, 202], ["semiconducting oligomers", "OBSERVATION", 206, 230]]], ["We have explored their applications in regenerative medicine, cell signaling, and photoelectric energy conversion.", [["cell", "ANATOMY", 62, 66], ["cell", "CELL", 62, 66], ["regenerative medicine", "TREATMENT", 39, 60], ["cell signaling", "PROBLEM", 62, 76], ["photoelectric energy conversion", "TREATMENT", 82, 113]]], ["Chemical synthesis of proteins gives exquisite control over their covalent structure, enabling for example the incorporation of non-coded amino acids.", [["amino acids", "CHEMICAL", 138, 149], ["amino acids", "CHEMICAL", 138, 149], ["non-coded", "SIMPLE_CHEMICAL", 128, 137], ["amino acids", "AMINO_ACID", 138, 149], ["Chemical synthesis of proteins", "TREATMENT", 0, 30], ["non-coded amino acids", "TREATMENT", 128, 149]]], ["In this research, total syntheses of wild-type bovine pancreatic trypsin inhibitor (BPTI) and several chemical analogues (with appropriate controls) were undertaken by native chemical ligation of two unprotected peptide segments.", [["bovine", "ORGANISM", 47, 53], ["pancreatic trypsin", "GENE_OR_GENE_PRODUCT", 54, 72], ["BPTI", "GENE_OR_GENE_PRODUCT", 84, 88], ["bovine", "SPECIES", 47, 53], ["total syntheses", "TEST", 18, 33], ["wild-type bovine pancreatic trypsin inhibitor", "TREATMENT", 37, 82], ["several chemical analogues", "PROBLEM", 94, 120], ["pancreatic", "ANATOMY", 54, 64], ["ligation", "OBSERVATION", 184, 192]]], ["BPTI is the archetypal member of the Kunitz-type serine protease inhibitors, organized around a short ($50 amino acid) alpha/beta fold constrained by three disulfide bonds.", [["amino acid", "CHEMICAL", 107, 117], ["serine", "CHEMICAL", 49, 55], ["amino acid", "CHEMICAL", 107, 117], ["disulfide", "CHEMICAL", 156, 165], ["BPTI", "GENE_OR_GENE_PRODUCT", 0, 4], ["Kunitz", "GENE_OR_GENE_PRODUCT", 37, 43], ["BPTI", "PROTEIN", 0, 4], ["Kunitz", "PROTEIN", 37, 43], ["BPTI", "TEST", 0, 4], ["the Kunitz-type serine protease inhibitors", "TREATMENT", 33, 75], ["a short ($50 amino acid", "TREATMENT", 94, 117], ["alpha/beta fold", "TREATMENT", 119, 134]]], ["This fold occurs in a variety of mammalian proteins, some of which are implicated in cancer metastasis and tumor growth.", [["cancer", "ANATOMY", 85, 91], ["tumor", "ANATOMY", 107, 112], ["cancer", "DISEASE", 85, 91], ["tumor", "DISEASE", 107, 112], ["cancer", "CANCER", 85, 91], ["tumor", "CANCER", 107, 112], ["mammalian proteins", "PROTEIN", 33, 51], ["This fold", "PROBLEM", 0, 9], ["mammalian proteins", "PROBLEM", 33, 51], ["cancer metastasis", "PROBLEM", 85, 102], ["tumor growth", "PROBLEM", 107, 119], ["mammalian proteins", "OBSERVATION", 33, 51], ["cancer", "OBSERVATION_MODIFIER", 85, 91], ["metastasis", "OBSERVATION", 92, 102], ["tumor", "OBSERVATION", 107, 112]]], ["A [G37A]BPTI mutant reportedly destabilized the protein by 5 kcal/ mol, a surprisingly large destabilization thought to result from the disruption of an unusual NH-aromatic-NH network of interactions that involves the amide -NH-of Gly 37.", [["NH", "CHEMICAL", 161, 163], ["amide -NH-of Gly", "CHEMICAL", 218, 234], ["NH-aromatic-NH", "CHEMICAL", 161, 175], ["amide", "CHEMICAL", 218, 223], ["NH", "CHEMICAL", 225, 227], ["Gly", "CHEMICAL", 231, 234], ["Gly 37", "AMINO_ACID", 231, 237], ["[G37A]BPTI mutant", "PROTEIN", 2, 19], ["A [G37A]BPTI mutant", "TEST", 0, 19], ["a surprisingly large destabilization", "PROBLEM", 72, 108], ["large", "OBSERVATION_MODIFIER", 87, 92], ["destabilization", "OBSERVATION", 93, 108]]], ["We explored the effects of a [G37D-Ala] substitution at this position of BPTI, as this offered novel opportunities to look for damping effects on aromatic ring flipping and subglobal amide proton exchange.", [["G37D-Ala", "CHEMICAL", 30, 38], ["[G37D-Ala]", "CHEMICAL", 29, 39], ["amide", "CHEMICAL", 183, 188], ["[G37D-Ala", "SIMPLE_CHEMICAL", 29, 38], ["BPTI", "GENE_OR_GENE_PRODUCT", 73, 77], ["subglobal amide proton", "SIMPLE_CHEMICAL", 173, 195], ["a [G37D-Ala] substitution", "TREATMENT", 27, 52], ["this position of BPTI", "TREATMENT", 56, 77], ["damping effects", "PROBLEM", 127, 142], ["aromatic ring flipping", "TREATMENT", 146, 168], ["subglobal amide proton exchange", "TREATMENT", 173, 204], ["aromatic ring", "OBSERVATION", 146, 159]]], ["NMR properties of the unique chemical analogues and control molecules will be reported.", [["chemical analogues", "OBSERVATION", 29, 47]]], ["The convergent synthetic method has greatly facilitated the assembly of peptides/proteins.", [["peptides/proteins", "PROBLEM", 72, 89]]], ["However, a fundamental drawback of convergent synthesis is that epimerization at the C-terminal residue of an N-segment occurs during the condensation reaction with a C-segment, thereby limiting the N-segment to contain either a C-terminal Gly or Pro residue.", [["C", "CHEMICAL", 85, 86], ["C", "CHEMICAL", 229, 230], ["Gly", "CHEMICAL", 240, 243], ["Pro", "CHEMICAL", 247, 250], ["C-terminal residue", "PROTEIN", 85, 103], ["N-segment", "PROTEIN", 110, 119], ["C-segment", "PROTEIN", 167, 176], ["N-segment", "PROTEIN", 199, 208], ["convergent synthesis", "PROBLEM", 35, 55], ["epimerization", "PROBLEM", 64, 77], ["the C-terminal residue", "PROBLEM", 81, 103], ["the condensation reaction", "PROBLEM", 134, 159], ["a C-segment", "TREATMENT", 165, 176], ["a C-terminal Gly or Pro residue", "PROBLEM", 227, 258], ["terminal", "ANATOMY_MODIFIER", 87, 95], ["condensation reaction", "OBSERVATION", 138, 159]]], ["We herein report a racemization-free segment condensation based on the Oacyl isopeptide method with successful synthesis of bioactive peptides.", [["Oacyl", "CHEMICAL", 71, 76], ["Oacyl", "SIMPLE_CHEMICAL", 71, 76], ["a racemization-free segment condensation", "PROBLEM", 17, 57], ["the Oacyl isopeptide method", "TREATMENT", 67, 94], ["successful synthesis of bioactive peptides", "TREATMENT", 100, 142], ["bioactive peptides", "OBSERVATION", 124, 142]]], ["This method allows the use of an N-segment possessing a C-terminal Ser/Thr residue for segment condensation without any epimerization, because of a C-terminal urethane-protected Ser/Thr residue.", [["urethane", "CHEMICAL", 159, 167], ["N", "CHEMICAL", 33, 34], ["C", "CHEMICAL", 56, 57], ["Ser", "CHEMICAL", 67, 70], ["Thr", "CHEMICAL", 71, 74], ["C", "CHEMICAL", 148, 149], ["urethane", "CHEMICAL", 159, 167], ["Ser", "CHEMICAL", 178, 181], ["Thr", "CHEMICAL", 182, 185], ["Thr residue", "AMINO_ACID", 71, 82], ["urethane", "SIMPLE_CHEMICAL", 159, 167], ["Ser", "AMINO_ACID", 178, 181], ["Thr residue", "AMINO_ACID", 182, 193], ["N-segment", "PROTEIN", 33, 42], ["an N-segment", "TREATMENT", 30, 42], ["a C-terminal Ser/Thr residue", "TREATMENT", 54, 82], ["segment condensation", "PROBLEM", 87, 107], ["any epimerization", "TREATMENT", 116, 133], ["a C-terminal urethane-protected Ser/Thr residue", "PROBLEM", 146, 193], ["Thr residue", "OBSERVATION", 182, 193]]], ["Additionally, final deprotected peptides were effectively purified by HPLC, because an O-acyl structure remarkably changes the physicochemical properties of the native peptide.", [["O-acyl", "CHEMICAL", 87, 93], ["O-acyl", "CHEMICAL", 87, 93], ["O-acyl", "SIMPLE_CHEMICAL", 87, 93], ["final deprotected peptides", "TREATMENT", 14, 40], ["HPLC", "TEST", 70, 74], ["an O-acyl structure", "PROBLEM", 84, 103], ["physicochemical properties", "OBSERVATION", 127, 153]]], ["Finally, an O-to-N intramolecular acyl migration reaction triggers the native amide bond formation under neutral conditions [1] .", [["acyl", "CHEMICAL", 34, 38], ["O-to-N", "CHEMICAL", 12, 18], ["acyl", "CHEMICAL", 34, 38], ["amide", "CHEMICAL", 78, 83], ["acyl", "SIMPLE_CHEMICAL", 34, 38], ["N intramolecular acyl migration reaction", "TREATMENT", 17, 57], ["acyl migration", "OBSERVATION", 34, 48]]], ["Using this method, the segment condensation becomes possible at positions other than those bearing a C-terminal Gly or Pro residue at the N-segment, and suggesting that O-acyl isopeptide segment condensation as being advantageous for synthesizing larger peptides and proteins [2] .", [["C", "CHEMICAL", 101, 102], ["Gly", "CHEMICAL", 112, 115], ["Pro", "CHEMICAL", 119, 122], ["O-acyl", "CHEMICAL", 169, 175], ["O-acyl", "SIMPLE_CHEMICAL", 169, 175], ["N-segment", "PROTEIN", 138, 147], ["this method", "TREATMENT", 6, 17], ["the segment condensation", "PROBLEM", 19, 43], ["a C-terminal Gly", "PROBLEM", 99, 115], ["acyl isopeptide segment condensation", "PROBLEM", 171, 207], ["synthesizing larger peptides", "PROBLEM", 234, 262], ["segment", "ANATOMY_MODIFIER", 140, 147]]], ["Considering these features, the O-acyl isopeptide method-based segment condensation method would contribute to the field of chemical synthesis of peptides and proteins.", [["O-acyl", "CHEMICAL", 32, 38], ["O-acyl", "CHEMICAL", 32, 38], ["O-acyl", "SIMPLE_CHEMICAL", 32, 38], ["the O-acyl isopeptide method-based segment condensation method", "TREATMENT", 28, 90], ["chemical synthesis of peptides", "TREATMENT", 124, 154]]], ["Nowadays, peptides are gaining more and more importance in the treatment of various diseases.", [["various diseases", "PROBLEM", 76, 92], ["various", "OBSERVATION_MODIFIER", 76, 83], ["diseases", "OBSERVATION", 84, 92]]], ["They can be produced by solid phase synthe-sis or fermentation processes.", [["solid phase synthe-sis", "SIMPLE_CHEMICAL", 24, 46]]], ["Reversed-phase chromatography is one of the most important steps in the purification of peptides.", [["Reversed-phase chromatography", "TEST", 0, 29], ["the purification of peptides", "TREATMENT", 68, 96]]], ["Especially after a fermentation process, the downstream process and, therefore, the chromatographic steps, are responsible for the high cost of the peptide.", [["a fermentation process", "TREATMENT", 17, 39]]], ["Another important problem that is often seen in peptide purification is the progressive column performance dropping as a consequence of irreversibly adsorbing impurities.", [["peptide purification", "TREATMENT", 48, 68], ["the progressive column performance", "PROBLEM", 72, 106], ["irreversibly adsorbing impurities", "PROBLEM", 136, 169], ["progressive", "OBSERVATION_MODIFIER", 76, 87], ["column", "OBSERVATION_MODIFIER", 88, 94], ["irreversibly", "OBSERVATION_MODIFIER", 136, 148], ["adsorbing impurities", "OBSERVATION", 149, 169]]], ["This step involves washing the stationary phase with a high pH solution to remove the irreversibly adsorbing impurities.", [["a high pH solution", "TREATMENT", 53, 71], ["irreversibly", "OBSERVATION_MODIFIER", 86, 98], ["adsorbing impurities", "OBSERVATION", 99, 119]]], ["An undesired consequence of cleaning in place (seen especially on silica-based reversed-phase materials) is the progressive destruction of the stationary phase.P 046 CONTROLLING THE DEGRADATION OF b-HAIRPIN SELF ASSEMBLED HYDROGELS BY PROTEOLYSIS WITH TRYPSINIn this poster a crude peptide mixture will be studied.", [["silica", "CHEMICAL", 66, 72], ["silica", "CHEMICAL", 66, 72], ["cleaning", "TREATMENT", 28, 36], ["silica-based reversed-phase materials", "TREATMENT", 66, 103], ["the progressive destruction of the stationary phase", "PROBLEM", 108, 159], ["TRYPSINIn", "TREATMENT", 252, 261], ["a crude peptide mixture", "TREATMENT", 274, 297], ["cleaning", "OBSERVATION", 28, 36], ["progressive", "OBSERVATION_MODIFIER", 112, 123], ["destruction", "OBSERVATION", 124, 135], ["stationary phase", "OBSERVATION_MODIFIER", 143, 159]]], ["The reversed phase chromatographic purification step will be optimized leading to the best separation between the target peptide and the impurities.", [["The reversed phase chromatographic purification step", "TREATMENT", 0, 52]]], ["Moreover, the effect of cleaning in place will be studied.", [["cleaning", "TREATMENT", 24, 32]]], ["The deterioration and the purification performance change of the stationary phase will be followed after different cleaning in place steps.P 051 MOLECULAR DYNAMICS SIMULATIONS OF CHEMO-SELECTIVE BONDS IN BOVINE RIBONUCLEASE AC.E. Winsor, R.J. Broadbridge and B. Howlin University of Surrey Chemoselective ligation can be used to join peptide fragments together to create longer peptides than can be synthesised as a single chain, through the formation of non-amide linkages, and it is a possible tool in the production of synthetic proteins.", [["non-amide", "CHEMICAL", 455, 464], ["non-amide", "SIMPLE_CHEMICAL", 455, 464], ["synthetic proteins", "PROTEIN", 522, 540], ["The deterioration", "PROBLEM", 0, 17], ["the purification performance", "TEST", 22, 50], ["CHEMO", "TREATMENT", 179, 184], ["Surrey Chemoselective ligation", "TREATMENT", 283, 313], ["deterioration", "OBSERVATION", 4, 17], ["Chemoselective ligation", "OBSERVATION", 290, 313]]], ["For this to be used as a general method it is important to assess what impact these unnatural linkages may have on the structure and consequentially on the activity of biologically active molecules.", [["a general method", "TREATMENT", 23, 39]]], ["Chemoselective bonds formed from reaction of an aldehyde to hydrazine and amino-oxy groups have been used to assemble bovine ribonuclease A, masking the aldehyde as an amino alcohol to allow sequential ligation of several peptide fragments.", [["aldehyde", "CHEMICAL", 48, 56], ["hydrazine", "CHEMICAL", 60, 69], ["amino-oxy", "CHEMICAL", 74, 83], ["aldehyde", "CHEMICAL", 153, 161], ["amino alcohol", "CHEMICAL", 168, 181], ["aldehyde", "CHEMICAL", 48, 56], ["hydrazine", "CHEMICAL", 60, 69], ["amino-oxy", "CHEMICAL", 74, 83], ["aldehyde", "CHEMICAL", 153, 161], ["amino alcohol", "CHEMICAL", 168, 181], ["aldehyde", "SIMPLE_CHEMICAL", 48, 56], ["hydrazine", "SIMPLE_CHEMICAL", 60, 69], ["amino-oxy groups", "SIMPLE_CHEMICAL", 74, 90], ["bovine", "ORGANISM", 118, 124], ["ribonuclease A", "GENE_OR_GENE_PRODUCT", 125, 139], ["aldehyde", "SIMPLE_CHEMICAL", 153, 161], ["amino alcohol", "SIMPLE_CHEMICAL", 168, 181], ["bovine ribonuclease A", "PROTEIN", 118, 139], ["bovine", "SPECIES", 118, 124], ["Chemoselective bonds", "PROBLEM", 0, 20], ["an aldehyde to hydrazine", "TREATMENT", 45, 69], ["amino-oxy groups", "TREATMENT", 74, 90], ["masking the aldehyde", "TREATMENT", 141, 161], ["an amino alcohol", "TREATMENT", 165, 181], ["sequential ligation of several peptide fragments", "TREATMENT", 191, 239], ["bovine ribonuclease", "OBSERVATION", 118, 137], ["several", "OBSERVATION_MODIFIER", 214, 221], ["peptide fragments", "OBSERVATION", 222, 239]]], ["The structures of these non-amide bonds have been modeled within the structure of ribonuclease and molecular dynamics simulations have been run to allow theoretical predictions of the effect of these unnatural bonds to be compared to experimental results of the catalytic activity of the enzyme. inz@keyaki.cc.u-tokai.ac.jp Recently many kinds of self-assembly peptide have been reported.", [["inz@keyaki.cc.u-tokai.ac.jp", "CHEMICAL", 296, 323], ["non-amide", "CHEMICAL", 24, 33], ["non-amide bonds", "SIMPLE_CHEMICAL", 24, 39], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 82, 94], ["ribonuclease", "PROTEIN", 82, 94], ["enzyme", "PROTEIN", 288, 294], ["these unnatural bonds", "PROBLEM", 194, 215], ["the enzyme", "TEST", 284, 294], ["inz@keyaki.cc.u-tokai.ac.jp", "TREATMENT", 296, 323], ["self-assembly peptide", "PROBLEM", 347, 368], ["non-amide bonds", "OBSERVATION", 24, 39], ["structure", "OBSERVATION_MODIFIER", 69, 78], ["ribonuclease", "OBSERVATION_MODIFIER", 82, 94], ["unnatural bonds", "OBSERVATION", 200, 215]]], ["In this work synthesis of artificial lipopeptides and their supramolecular formation were studied.", [["artificial lipopeptides", "TREATMENT", 26, 49], ["artificial lipopeptides", "OBSERVATION", 26, 49], ["supramolecular formation", "OBSERVATION", 60, 84]]], ["First we synthesized Fmoc-Lys(Hdc)-OH and Fmoc-Glu(Hda)-OH with long alkyl chains.", [["Fmoc-Lys", "CHEMICAL", 21, 29], ["Hdc", "CHEMICAL", 30, 33], ["Fmoc-Glu", "CHEMICAL", 42, 50], ["Hda", "CHEMICAL", 51, 54], ["OH", "CHEMICAL", 56, 58], ["Fmoc-Lys(Hdc)-OH", "CHEMICAL", 21, 37], ["Fmoc-Glu(Hda)-OH", "CHEMICAL", 42, 58], ["Fmoc-Lys(Hdc)-OH", "SIMPLE_CHEMICAL", 21, 37], ["Fmoc-Glu(Hda)-OH", "SIMPLE_CHEMICAL", 42, 58], ["long alkyl chains", "SIMPLE_CHEMICAL", 64, 81], ["Fmoc", "TEST", 21, 25], ["Lys", "TEST", 26, 29], ["Hdc", "TEST", 30, 33], ["OH", "TEST", 35, 37], ["Fmoc", "TEST", 42, 46], ["Glu(Hda", "TEST", 47, 54], ["long alkyl chains", "TREATMENT", 64, 81], ["alkyl chains", "OBSERVATION", 69, 81]]], ["A long alkyl chain consists of hexaethleneglycol and decanoic acid or decanamine.", [["hexaethleneglycol", "CHEMICAL", 31, 48], ["decanoic acid", "CHEMICAL", 53, 66], ["decanamine", "CHEMICAL", 70, 80], ["hexaethleneglycol", "CHEMICAL", 31, 48], ["decanoic acid", "CHEMICAL", 53, 66], ["decanamine", "CHEMICAL", 70, 80], ["hexaethleneglycol", "SIMPLE_CHEMICAL", 31, 48], ["decanoic acid", "SIMPLE_CHEMICAL", 53, 66], ["decanamine", "SIMPLE_CHEMICAL", 70, 80], ["A long alkyl chain", "TREATMENT", 0, 18], ["hexaethleneglycol", "TREATMENT", 31, 48], ["decanoic acid", "TREATMENT", 53, 66], ["decanamine", "TREATMENT", 70, 80]]], ["Next we also synthesized lipopeptides (Ac-Tyr-Ser-Gln-Glu(Hda)-Gln-Ser-Ser-Ser-Ser-Gln-Glu(Hda)-Gln-Ser-Gly-NH2) using the artificial amino acid derivatives by the solid-phase method.", [["Ac-Tyr-Ser-Gln-Glu", "CHEMICAL", 39, 57], ["Hda", "CHEMICAL", 58, 61], ["Glu", "CHEMICAL", 87, 90], ["Hda)-Gln-Ser-Gly-NH2", "CHEMICAL", 91, 111], ["amino acid", "CHEMICAL", 134, 144], ["Ac-Tyr-Ser-Gln-Glu(Hda)-Gln-Ser-Ser-Ser-Ser-Gln-Glu(Hda)-Gln-Ser-Gly-NH2", "CHEMICAL", 39, 111], ["amino acid", "CHEMICAL", 134, 144], ["Ac-Tyr-Ser-Gln-Glu(Hda)-Gln-Ser-Ser-Ser-Ser-Gln-Glu(Hda)-Gln-Ser-Gly-NH2", "SIMPLE_CHEMICAL", 39, 111], ["amino acid", "AMINO_ACID", 134, 144], ["NH2", "PROTEIN", 108, 111], ["lipopeptides", "TEST", 25, 37], ["Ac", "TEST", 39, 41], ["Tyr", "TEST", 42, 45], ["Gln", "TEST", 50, 53], ["Glu", "TEST", 54, 57], ["Hda", "TEST", 58, 61], ["Gln-Ser-", "TEST", 63, 71], ["Hda", "TEST", 91, 94], ["Gln-Ser-Gly-NH2", "TREATMENT", 96, 111], ["the artificial amino acid derivatives", "TREATMENT", 119, 156], ["the solid-phase method", "TREATMENT", 160, 182]]], ["The synthesized lipopeptide was measured by AFM, and TEM.", [["The synthesized lipopeptide", "TREATMENT", 0, 27]]], ["From these results, we found the synthesized lipopeptide was formed a cylindrical micelle.", [["the synthesized lipopeptide", "TREATMENT", 29, 56], ["a cylindrical micelle", "TREATMENT", 68, 89], ["cylindrical micelle", "OBSERVATION", 70, 89]]], ["There are many naturally occurring monodehydro-2,5-diketopiperazines (monodehydroDKPs) possessing biological activity such as phenylahistin (PLH), which is a lead compound of NPI-2358 under Phase I/II clinical trial in the US as a vascular disrupting agent (VDA) [1] .", [["vascular", "ANATOMY", 231, 239], ["monodehydro-2,5-diketopiperazines", "CHEMICAL", 35, 68], ["monodehydroDKPs", "CHEMICAL", 70, 85], ["phenylahistin", "CHEMICAL", 126, 139], ["PLH", "CHEMICAL", 141, 144], ["NPI-2358", "CHEMICAL", 175, 183], ["monodehydro-2,5-diketopiperazines", "CHEMICAL", 35, 68], ["monodehydroDKPs", "CHEMICAL", 70, 85], ["phenylahistin", "CHEMICAL", 126, 139], ["PLH", "CHEMICAL", 141, 144], ["NPI-2358", "CHEMICAL", 175, 183], ["monodehydro-2,5-diketopiperazines", "SIMPLE_CHEMICAL", 35, 68], ["monodehydroDKPs", "SIMPLE_CHEMICAL", 70, 85], ["phenylahistin", "SIMPLE_CHEMICAL", 126, 139], ["PLH", "SIMPLE_CHEMICAL", 141, 144], ["NPI-2358", "SIMPLE_CHEMICAL", 175, 183], ["vascular", "MULTI-TISSUE_STRUCTURE", 231, 239], ["VDA", "SIMPLE_CHEMICAL", 258, 261], ["monodehydro", "TEST", 35, 46], ["diketopiperazines (monodehydroDKPs", "TREATMENT", 51, 85], ["phenylahistin (PLH", "TREATMENT", 126, 144], ["NPI", "TEST", 175, 178], ["a vascular disrupting agent", "TREATMENT", 229, 256], ["vascular", "ANATOMY", 231, 239]]], ["These cyclicdipeptides monodehydroDKPs are useful building blocks and templates for combinatorial chemistry.P 051 MOLECULAR DYNAMICS SIMULATIONS OF CHEMO-SELECTIVE BONDS IN BOVINE RIBONUCLEASE ATo develop an efficient synthetic route of monodehydroDKPs with no racemization for natural product synthesis, in our previous study, we focused our work on Gladiali et al.'s report [2] that the reaction ofketoester and Boc-NH2 in the presence of a catalytic amount of p-TsOH resulted in the formation of a dehydroamino acid, and successfully applied this method to N--ketoacyl-Phe-NH2 to synthesize monodehydroDKPs in a reasonable yield with no racemization.", [["cyclicdipeptides", "CHEMICAL", 6, 22], ["monodehydroDKPs", "CHEMICAL", 237, 252], ["ofketoester", "CHEMICAL", 398, 409], ["Boc-NH2", "CHEMICAL", 414, 421], ["p-TsOH", "CHEMICAL", 463, 469], ["dehydroamino acid", "CHEMICAL", 501, 518], ["N--ketoacyl-Phe-NH2", "CHEMICAL", 560, 579], ["monodehydroDKPs", "CHEMICAL", 594, 609], ["cyclicdipeptides", "CHEMICAL", 6, 22], ["monodehydroDKPs", "CHEMICAL", 237, 252], ["ofketoester", "CHEMICAL", 398, 409], ["Boc-NH2", "CHEMICAL", 414, 421], ["p-TsOH", "CHEMICAL", 463, 469], ["dehydroamino acid", "CHEMICAL", 501, 518], ["N--ketoacyl-Phe-NH2", "CHEMICAL", 560, 579], ["monodehydroDKPs", "CHEMICAL", 594, 609], ["cyclicdipeptides monodehydroDKPs", "SIMPLE_CHEMICAL", 6, 38], ["monodehydroDKPs", "SIMPLE_CHEMICAL", 237, 252], ["ofketoester", "SIMPLE_CHEMICAL", 398, 409], ["Boc-NH2", "SIMPLE_CHEMICAL", 414, 421], ["p-TsOH", "SIMPLE_CHEMICAL", 463, 469], ["dehydroamino acid", "SIMPLE_CHEMICAL", 501, 518], ["N--ketoacyl-Phe-NH2", "SIMPLE_CHEMICAL", 560, 579], ["monodehydroDKPs", "SIMPLE_CHEMICAL", 594, 609], ["NH2", "PROTEIN", 418, 421], ["NH2", "PROTEIN", 576, 579], ["These cyclicdipeptides monodehydroDKPs", "TREATMENT", 0, 38], ["building blocks", "TREATMENT", 50, 65], ["templates", "TREATMENT", 70, 79], ["combinatorial chemistry", "TEST", 84, 107], ["CHEMO", "TREATMENT", 148, 153], ["SELECTIVE BONDS IN BOVINE RIBONUCLEASE ATo", "TREATMENT", 154, 196], ["racemization", "PROBLEM", 261, 273], ["natural product synthesis", "PROBLEM", 278, 303], ["the reaction ofketoester", "PROBLEM", 385, 409], ["a dehydroamino acid", "TREATMENT", 499, 518], ["this method", "TREATMENT", 545, 556], ["ketoacyl", "TREATMENT", 563, 571], ["Phe-NH2 to synthesize monodehydroDKPs", "TREATMENT", 572, 609], ["racemization", "PROBLEM", 640, 652]]], ["In the present study, we have also successfully expanded this method to other amino acid residues such as Leu and Ser(Bzl) in case that -aliphatic--keto acid derivatives were used.", [["amino acid", "CHEMICAL", 78, 88], ["Leu", "CHEMICAL", 106, 109], ["Bzl", "CHEMICAL", 118, 121], ["aliphatic--keto acid", "CHEMICAL", 137, 157], ["amino acid", "CHEMICAL", 78, 88], ["Leu", "CHEMICAL", 106, 109], ["Ser", "CHEMICAL", 114, 117], ["Bzl", "CHEMICAL", 118, 121], ["aliphatic--keto acid", "CHEMICAL", 137, 157], ["amino acid", "AMINO_ACID", 78, 88], ["Leu", "AMINO_ACID", 106, 109], ["Ser", "AMINO_ACID", 114, 117], ["Bzl", "AMINO_ACID", 118, 121], ["-aliphatic--keto acid derivatives", "SIMPLE_CHEMICAL", 136, 169], ["amino acid residues", "TREATMENT", 78, 97], ["Leu and Ser(Bzl)", "TEST", 106, 122], ["aliphatic", "TEST", 137, 146], ["keto acid derivatives", "TREATMENT", 148, 169]]], ["Therefore, this method would be effective for the synthesis of natural products that contain -aliphatic- Chemical protein synthesis and X-ray crystallography were used to investigate the L and D forms of a recently discovered snow flea antifreeze protein (sfAFP) [1] [2] .", [["-aliphatic-", "CHEMICAL", 93, 104], ["-aliphatic-", "CHEMICAL", 93, 104], ["L and D forms", "PROTEIN", 187, 200], ["snow flea antifreeze protein", "PROTEIN", 226, 254], ["sfAFP", "PROTEIN", 256, 261], ["this method", "TREATMENT", 11, 22], ["the synthesis of natural products", "TREATMENT", 46, 79], ["Chemical protein synthesis", "TEST", 105, 131], ["X-ray crystallography", "TEST", 136, 157]]], ["This interesting glycine rich protein has no sequence homology with any known proteins and no experimental structure has been reported.", [["glycine", "CHEMICAL", 17, 24], ["glycine", "CHEMICAL", 17, 24], ["glycine", "AMINO_ACID", 17, 24], ["glycine rich protein", "PROTEIN", 17, 37], ["any known proteins", "PROBLEM", 68, 86], ["experimental structure", "PROBLEM", 94, 116]]], ["Chemically synthesized L and D-sfAFP were found to have the expected antifreeze activity in an ice recrystallization inhibition assay.", [["D-sfAFP", "CHEMICAL", 29, 36], ["D-sfAFP", "CHEMICAL", 29, 36], ["D-sfAFP", "SIMPLE_CHEMICAL", 29, 36], ["Chemically synthesized L and D-sfAFP", "PROBLEM", 0, 36], ["an ice recrystallization inhibition assay", "TREATMENT", 92, 133], ["antifreeze activity", "OBSERVATION", 69, 88]]], ["The X-ray structure was determined by an largely unexplored approach called racemic protein crystallization.", [["The X-ray structure", "TEST", 0, 19], ["racemic protein crystallization", "TREATMENT", 76, 107]]], ["It was found that crystal formation from a racemic solution containing equal amounts of the chemically synthesized proteins D-sfAFP and L-sfAFP occurred much more readily than for L-sfAFP alone.", [["racemic", "CHEMICAL", 43, 50], ["D-sfAFP", "CHEMICAL", 124, 131], ["L-sfAFP", "CHEMICAL", 136, 143], ["L-sfAFP", "CHEMICAL", 180, 187], ["L-sfAFP", "CHEMICAL", 180, 187], ["D-sfAFP", "SIMPLE_CHEMICAL", 124, 131], ["L-sfAFP", "SIMPLE_CHEMICAL", 136, 143], ["L-sfAFP", "SIMPLE_CHEMICAL", 180, 187], ["D-sfAFP", "PROTEIN", 124, 131], ["L-sfAFP", "PROTEIN", 136, 143], ["L-sfAFP", "PROTEIN", 180, 187], ["crystal formation", "PROBLEM", 18, 35], ["a racemic solution", "TREATMENT", 41, 59], ["the chemically synthesized proteins D-sfAFP", "PROBLEM", 88, 131], ["L-sfAFP", "PROBLEM", 136, 143], ["crystal formation", "OBSERVATION", 18, 35]]], ["More facile crystal formation also occurred from a quasi-racemic mixture of D-sfAFP and L-Se-sfAFP, where L-Se-sfAFP is an analogue.", [["D-sfAFP", "CHEMICAL", 76, 83], ["L-Se-sfAFP", "CHEMICAL", 88, 98], ["L-Se-sfAFP", "CHEMICAL", 106, 116], ["D-sfAFP", "CHEMICAL", 76, 83], ["L-Se-sfAFP", "CHEMICAL", 88, 98], ["L-Se-sfAFP", "CHEMICAL", 106, 116], ["D-sfAFP", "SIMPLE_CHEMICAL", 76, 83], ["L-Se-sfAFP", "SIMPLE_CHEMICAL", 88, 98], ["L-Se-sfAFP", "SIMPLE_CHEMICAL", 106, 116], ["More facile crystal formation", "PROBLEM", 0, 29], ["facile", "OBSERVATION", 5, 11], ["crystal formation", "OBSERVATION", 12, 29]]], ["The novel structure of sfAFP is made up of six antiparallel left-handed PPII helixes wrapped to form a compact bricklike structure with a hydrophilic and hydrophobic face.T. Tiefenbrunn and P. DawsonThe Scripps Research Institute The type 1 repeat domain from thrombospondin has potent antiangiogenic activity and a structurally interesting fold, making it an attractive target for protein engineering.", [["PPII", "CHEMICAL", 72, 76], ["sfAFP", "SIMPLE_CHEMICAL", 23, 28], ["PPII helixes", "SIMPLE_CHEMICAL", 72, 84], ["thrombospondin", "GENE_OR_GENE_PRODUCT", 260, 274], ["sfAFP", "PROTEIN", 23, 28], ["PPII helixes", "PROTEIN", 72, 84], ["bricklike structure", "PROTEIN", 111, 130], ["type 1 repeat domain", "PROTEIN", 234, 254], ["thrombospondin", "PROTEIN", 260, 274], ["six antiparallel left-handed PPII helixes", "TREATMENT", 43, 84], ["a hydrophilic and hydrophobic face", "PROBLEM", 136, 170], ["The type 1 repeat domain", "PROBLEM", 230, 254], ["potent antiangiogenic activity", "PROBLEM", 279, 309], ["a structurally interesting fold", "PROBLEM", 314, 345], ["protein engineering", "TREATMENT", 382, 401], ["left", "ANATOMY_MODIFIER", 60, 64], ["PPII helixes", "OBSERVATION", 72, 84], ["hydrophilic", "OBSERVATION_MODIFIER", 138, 149], ["hydrophobic face", "OBSERVATION", 154, 170], ["potent", "OBSERVATION_MODIFIER", 279, 285], ["antiangiogenic activity", "OBSERVATION", 286, 309]]], ["Chemical synthesis is an attractive approach for studying protein domains since it enables the use of unnatural amino acids for site-specific labeling and detailed structurefunction analysis.", [["amino acids", "CHEMICAL", 112, 123], ["amino acids", "CHEMICAL", 112, 123], ["amino acids", "AMINO_ACID", 112, 123], ["protein domains", "PROTEIN", 58, 73], ["studying protein domains", "PROBLEM", 49, 73], ["unnatural amino acids", "TREATMENT", 102, 123], ["detailed structurefunction analysis", "TEST", 155, 190]]], ["Here, we demonstrate the first total chemical synthesis of the thrombospondin type 1 repeat domain by native chemical ligation.", [["thrombospondin type 1", "GENE_OR_GENE_PRODUCT", 63, 84], ["thrombospondin type 1 repeat domain", "PROTEIN", 63, 98], ["the thrombospondin type 1 repeat domain", "TREATMENT", 59, 98], ["native chemical ligation", "TREATMENT", 102, 126], ["chemical ligation", "OBSERVATION", 109, 126]]], ["In addition to the natural domain, five sites for side chain modification were evaluated and two were found to be compatible with oxidative folding.", [["side chain modification", "TREATMENT", 50, 73], ["oxidative folding", "PROBLEM", 130, 147], ["compatible with", "UNCERTAINTY", 114, 129], ["oxidative folding", "OBSERVATION", 130, 147]]], ["Several challenges were encountered during peptide synthesis due to the functional complexity of the domain.", [["Several challenges", "TREATMENT", 0, 18], ["peptide synthesis", "TREATMENT", 43, 60]]], ["These challenges were overcome through the use of new solid supports, scavengers, and the testing of multiple ligation sites, as well as through utilizing a combination of Boc-and Fmoc-based SPPS for individual peptide segments.", [["Boc-and Fmoc", "CHEMICAL", 172, 184], ["Fmoc", "CHEMICAL", 180, 184], ["Boc-and", "SIMPLE_CHEMICAL", 172, 179], ["SPPS", "SIMPLE_CHEMICAL", 191, 195], ["SPPS", "PROTEIN", 191, 195], ["new solid supports", "TREATMENT", 50, 68], ["scavengers", "TREATMENT", 70, 80], ["the testing", "TEST", 86, 97], ["multiple ligation sites", "TREATMENT", 101, 124], ["Boc-and Fmoc", "TREATMENT", 172, 184], ["individual peptide segments", "TREATMENT", 200, 227], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["ligation", "OBSERVATION", 110, 118]]], ["Synthetic access to this domain has enabled the synthesis of a number of variants containing arginine or tryptophan analogs that modify the core cation-p stack of the TSR2 domain.", [["arginine", "CHEMICAL", 93, 101], ["tryptophan", "CHEMICAL", 105, 115], ["arginine", "CHEMICAL", 93, 101], ["tryptophan", "CHEMICAL", 105, 115], ["arginine", "SIMPLE_CHEMICAL", 93, 101], ["tryptophan analogs", "SIMPLE_CHEMICAL", 105, 123], ["TSR2 domain", "PROTEIN", 167, 178], ["arginine or tryptophan analogs", "TREATMENT", 93, 123], ["the core cation", "TREATMENT", 136, 151]]], ["The relative stabilities of these varaints, investigated via circular dichroism thermal melting and differential scanning calorimetry, provide insights into the stability afforded by cation-p interactions in the context of a native protein fold.", [["cation", "SIMPLE_CHEMICAL", 183, 189], ["circular dichroism thermal melting", "TREATMENT", 61, 95], ["differential scanning calorimetry", "TEST", 100, 133], ["a native protein fold", "PROBLEM", 223, 244], ["stabilities", "OBSERVATION_MODIFIER", 13, 24], ["protein fold", "OBSERVATION", 232, 244]]], ["Synthesized variants of TSR2 can be used to further our understanding of the biochemical interaction network of thrombospondin and provide insight into the structure and function of this important anti-tumorogenic protein domain.", [["TSR2", "GENE_OR_GENE_PRODUCT", 24, 28], ["thrombospondin", "GENE_OR_GENE_PRODUCT", 112, 126], ["TSR2", "PROTEIN", 24, 28], ["thrombospondin", "PROTEIN", 112, 126], ["anti-tumorogenic protein domain", "PROTEIN", 197, 228], ["TSR2", "TREATMENT", 24, 28], ["thrombospondin", "TREATMENT", 112, 126]]], ["Growing interest in developing and designing N-linked glycopeptidebased vaccines and therapeutics stimulates the study of the synthesis of N-glycopeptides.", [["N", "CHEMICAL", 45, 46], ["N-glycopeptides", "GENE_OR_GENE_PRODUCT", 139, 154], ["N-linked glycopeptidebased vaccines", "TREATMENT", 45, 80], ["therapeutics", "TREATMENT", 85, 97], ["the study", "TEST", 109, 118], ["N-glycopeptides", "TREATMENT", 139, 154]]], ["Although several strategies of in-solution glycopeptide synthesis have been developed, repetitive purification of intermediates is still a problem that lowers yields.", [["in-solution glycopeptide synthesis", "TREATMENT", 31, 65], ["repetitive purification of intermediates", "PROBLEM", 87, 127]]], ["Solid phase synthesis, on the other hand, has the advantage of automating the repetitive coupling steps and drives the coupling reactions to completion by using large excesses of building blocks.", [["Solid phase synthesis", "PROBLEM", 0, 21], ["the coupling reactions", "PROBLEM", 115, 137], ["building blocks", "TREATMENT", 179, 194], ["phase", "OBSERVATION_MODIFIER", 6, 11], ["synthesis", "OBSERVATION", 12, 21]]], ["Hence, solid phase synthesis of glycopeptides has many benefits, yet this strategy requires large amounts of N-oligosaccharides, which are extremely hard to obtain, thereby slowing down the development of solid phase synthesis of N-linked glycopeptide.", [["N-linked glycopeptide", "CHEMICAL", 230, 251], ["N-oligosaccharides", "CHEMICAL", 109, 127], ["N", "CHEMICAL", 230, 231], ["N-oligosaccharides", "SIMPLE_CHEMICAL", 109, 127], ["N-linked glycopeptide", "SIMPLE_CHEMICAL", 230, 251], ["solid phase synthesis of glycopeptides", "TREATMENT", 7, 45], ["large amounts of N-oligosaccharides", "PROBLEM", 92, 127], ["N-linked glycopeptide", "TREATMENT", 230, 251], ["solid phase", "OBSERVATION_MODIFIER", 7, 18], ["large", "OBSERVATION_MODIFIER", 92, 97], ["solid phase", "OBSERVATION_MODIFIER", 205, 216]]], ["In our lab, we have developed the capability of producing large amounts of N-linked oligosaccharides, and this allows the exploration of high-mannose glycopeptide synthesis on the solid phase.", [["N", "CHEMICAL", 75, 76], ["mannose", "CHEMICAL", 142, 149], ["high-mannose glycopeptide", "SIMPLE_CHEMICAL", 137, 162], ["N-linked oligosaccharides", "PROBLEM", 75, 100], ["the exploration", "TEST", 118, 133], ["high-mannose glycopeptide synthesis", "TREATMENT", 137, 172], ["large", "OBSERVATION_MODIFIER", 58, 63], ["amounts", "OBSERVATION_MODIFIER", 64, 71], ["mannose glycopeptide synthesis", "OBSERVATION", 142, 172], ["solid phase", "OBSERVATION_MODIFIER", 180, 191]]], ["Monosaccharide and oligosaccharide Fmoc-Asparagine building blocks have been synthesized and applied to glycopeptide synthesis on different resins to determine the effect of resin type on glycosylamino acid coupling.", [["Monosaccharide", "CHEMICAL", 0, 14], ["Fmoc", "CHEMICAL", 35, 39], ["Asparagine", "CHEMICAL", 40, 50], ["glycosylamino acid", "CHEMICAL", 188, 206], ["Monosaccharide", "CHEMICAL", 0, 14], ["Fmoc", "CHEMICAL", 35, 39], ["Asparagine", "CHEMICAL", 40, 50], ["glycosylamino acid", "CHEMICAL", 188, 206], ["Monosaccharide", "SIMPLE_CHEMICAL", 0, 14], ["oligosaccharide Fmoc", "SIMPLE_CHEMICAL", 19, 39], ["glycosylamino acid", "SIMPLE_CHEMICAL", 188, 206], ["Monosaccharide", "TREATMENT", 0, 14], ["oligosaccharide Fmoc", "TREATMENT", 19, 39], ["Asparagine building blocks", "TREATMENT", 40, 66], ["glycopeptide synthesis", "TREATMENT", 104, 126], ["different resins", "TREATMENT", 130, 146], ["resin type on glycosylamino acid coupling", "TREATMENT", 174, 215]]], ["In addition, on-resin glycosylamine coupling strategies have also been explored.", [["glycosylamine", "CHEMICAL", 22, 35], ["glycosylamine", "SIMPLE_CHEMICAL", 22, 35], ["resin glycosylamine coupling strategies", "TREATMENT", 16, 55]]], ["These strategies have been employed for a variety of biological relevant glycopeptides, such as HIV gp120 sequences.", [["HIV", "ORGANISM", 96, 99], ["gp120", "GENE_OR_GENE_PRODUCT", 100, 105], ["HIV gp120 sequences", "DNA", 96, 115], ["HIV", "SPECIES", 96, 99], ["HIV", "SPECIES", 96, 99], ["biological relevant glycopeptides", "TREATMENT", 53, 86], ["HIV gp120 sequences", "TEST", 96, 115]]], ["The extensive use of C-terminal peptide thioesters in protein chemistry, i.e. native chemical ligation or other chemoselective reactions, has provided the impetus for the search for optimal solid-phase strategies for their synthesis.", [["C", "CHEMICAL", 21, 22], ["thioesters", "CHEMICAL", 40, 50], ["C-terminal peptide thioesters", "TREATMENT", 21, 50], ["protein chemistry", "TEST", 54, 71], ["native chemical ligation", "TREATMENT", 78, 102], ["other chemoselective reactions", "PROBLEM", 106, 136], ["optimal solid-phase strategies", "TREATMENT", 182, 212], ["their synthesis", "PROBLEM", 217, 232], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["chemical ligation", "OBSERVATION", 85, 102]]], ["Numerous approaches for Fmoc based SPPS have been published; methods for reliable synthesis of peptide thioesters with a Cterminal glycine have been established.", [["Fmoc", "CHEMICAL", 24, 28], ["glycine", "CHEMICAL", 131, 138], ["Fmoc", "CHEMICAL", 24, 28], ["thioesters", "CHEMICAL", 103, 113], ["glycine", "CHEMICAL", 131, 138], ["SPPS", "SIMPLE_CHEMICAL", 35, 39], ["peptide thioesters", "SIMPLE_CHEMICAL", 95, 113], ["Cterminal glycine", "SIMPLE_CHEMICAL", 121, 138], ["Fmoc based SPPS", "TREATMENT", 24, 39], ["methods", "TREATMENT", 61, 68], ["reliable synthesis of peptide thioesters", "TREATMENT", 73, 113], ["a Cterminal glycine", "TREATMENT", 119, 138]]], ["However, Fmoc based methods for the syntheses of peptide thioesters with a C-terminal chiral amino acid are less reliable.", [["amino acid", "CHEMICAL", 93, 103], ["Fmoc", "CHEMICAL", 9, 13], ["thioesters", "CHEMICAL", 57, 67], ["C", "CHEMICAL", 75, 76], ["amino acid", "CHEMICAL", 93, 103], ["peptide thioesters", "SIMPLE_CHEMICAL", 49, 67], ["amino acid", "AMINO_ACID", 93, 103], ["Fmoc based methods", "TREATMENT", 9, 27], ["the syntheses of peptide thioesters", "TREATMENT", 32, 67], ["a C-terminal chiral amino acid", "TREATMENT", 73, 103]]], ["We have very recently introduced a novel method for the synthesis of C-terminal peptide thioesters.", [["C", "CHEMICAL", 69, 70], ["thioesters", "CHEMICAL", 88, 98], ["C-terminal peptide thioesters", "SIMPLE_CHEMICAL", 69, 98], ["a novel method", "TREATMENT", 33, 47], ["the synthesis", "TREATMENT", 52, 65], ["C-terminal peptide thioesters", "TREATMENT", 69, 98]]], ["A C-terminal glutamic acid residue with a highly labile side-chain protective group is first anchored to a solid support.", [["glutamic acid", "CHEMICAL", 13, 26], ["glutamic acid", "CHEMICAL", 13, 26], ["glutamic acid", "AMINO_ACID", 13, 26], ["A C-terminal glutamic acid residue", "PROBLEM", 0, 34], ["a highly labile side-chain protective group", "TREATMENT", 40, 83], ["a solid support", "TREATMENT", 105, 120], ["glutamic acid residue", "OBSERVATION", 13, 34]]], ["The desired peptide is then assembled on resin, followed by selective removal of the glutamic acid side-chain protecting group with dilute TFA.", [["glutamic acid", "CHEMICAL", 85, 98], ["TFA", "CHEMICAL", 139, 142], ["glutamic acid", "CHEMICAL", 85, 98], ["TFA", "CHEMICAL", 139, 142], ["glutamic acid", "SIMPLE_CHEMICAL", 85, 98], ["TFA", "SIMPLE_CHEMICAL", 139, 142], ["selective removal", "TREATMENT", 60, 77], ["the glutamic acid side-chain", "TREATMENT", 81, 109], ["dilute TFA", "TREATMENT", 132, 142]]], ["Strong activation, e.g. PyBrOP/DIEA in NMP, of the deprotected carboxylic acid results in formation of the pyroglutamyl imide moiety on-resin.", [["PyBrOP", "CHEMICAL", 24, 30], ["DIEA", "CHEMICAL", 31, 35], ["NMP", "CHEMICAL", 39, 42], ["carboxylic acid", "CHEMICAL", 63, 78], ["pyroglutamyl imide", "CHEMICAL", 107, 125], ["PyBrOP", "CHEMICAL", 24, 30], ["DIEA", "CHEMICAL", 31, 35], ["NMP", "CHEMICAL", 39, 42], ["carboxylic acid", "CHEMICAL", 63, 78], ["pyroglutamyl imide", "CHEMICAL", 107, 125], ["PyBrOP", "SIMPLE_CHEMICAL", 24, 30], ["DIEA", "SIMPLE_CHEMICAL", 31, 35], ["NMP", "SIMPLE_CHEMICAL", 39, 42], ["deprotected carboxylic acid", "SIMPLE_CHEMICAL", 51, 78], ["pyroglutamyl imide moiety", "SIMPLE_CHEMICAL", 107, 132], ["PyBrOP", "PROTEIN", 24, 30], ["DIEA", "PROTEIN", 31, 35], ["NMP", "TREATMENT", 39, 42], ["the deprotected carboxylic acid", "TREATMENT", 47, 78], ["the pyroglutamyl imide moiety", "TREATMENT", 103, 132]]], ["Nucleophilic displacement by treatment with thiol results in release of the thioester from the solid support.", [["thiol", "CHEMICAL", 44, 49], ["thiol", "CHEMICAL", 44, 49], ["thioester", "CHEMICAL", 76, 85], ["thiol", "SIMPLE_CHEMICAL", 44, 49], ["Nucleophilic displacement", "PROBLEM", 0, 25], ["the solid support", "TREATMENT", 91, 108], ["solid support", "OBSERVATION", 95, 108]]], ["Here we present optimized results where the overall yields have been improved and the epimerization problems have been addressed.F. Li and C. LiuSchool of Biological Sciences, Nanyang Technological University, Singapore 637551 Thioester-mediated peptide ligation at valine was reported recently [1] .", [["Li", "CHEMICAL", 132, 134], ["Singapore 637551 Thioester", "CHEMICAL", 210, 236], ["valine", "CHEMICAL", 266, 272], ["valine", "CHEMICAL", 266, 272], ["valine", "AMINO_ACID", 266, 272], ["the epimerization problems", "PROBLEM", 82, 108], ["Thioester-mediated peptide ligation at valine", "TREATMENT", 227, 272], ["improved", "OBSERVATION_MODIFIER", 69, 77]]], ["The method utilizes an N-terminal penicillinamine to mediate the ligation reaction, which is followed by desulfuration to give a Val residue at the ligation site.", [["penicillinamine", "CHEMICAL", 34, 49], ["Val", "CHEMICAL", 129, 132], ["N", "CHEMICAL", 23, 24], ["penicillinamine", "CHEMICAL", 34, 49], ["Val", "CHEMICAL", 129, 132], ["penicillinamine", "SIMPLE_CHEMICAL", 34, 49], ["N-terminal penicillinamine", "PROTEIN", 23, 49], ["The method", "TREATMENT", 0, 10], ["an N-terminal penicillinamine", "TREATMENT", 20, 49], ["the ligation reaction", "TREATMENT", 61, 82], ["a Val residue at the ligation site", "TREATMENT", 127, 161], ["ligation", "OBSERVATION", 65, 73]]], ["However, the slow kinetics of the ligation step severely limits the practical value of this method.", [["the ligation step", "TREATMENT", 30, 47], ["this method", "TREATMENT", 87, 98], ["ligation", "OBSERVATION", 34, 42]]], ["Herein, we report that thioacid capture ligation can overcome this problem and be used for ligation at Phe-Val, Leu-Val and even Pro-Val junctions.", [["Pro-Val junctions", "ANATOMY", 129, 146], ["thioacid", "CHEMICAL", 23, 31], ["thioacid", "CHEMICAL", 23, 31], ["Val", "CHEMICAL", 107, 110], ["Leu", "CHEMICAL", 112, 115], ["Val", "CHEMICAL", 116, 119], ["Val", "CHEMICAL", 133, 136], ["thioacid", "SIMPLE_CHEMICAL", 23, 31], ["Phe-Val", "SIMPLE_CHEMICAL", 103, 110], ["Leu-Val", "SIMPLE_CHEMICAL", 112, 119], ["thioacid capture ligation", "TREATMENT", 23, 48], ["ligation at Phe-Val", "TREATMENT", 91, 110], ["Leu-Val and even Pro-Val junctions", "TREATMENT", 112, 146]]], ["Comparative studies using small model peptides showed that thioacid capture liga-tion exhibited much faster reaction kinetics than native chemical ligation.", [["thioacid", "CHEMICAL", 59, 67], ["liga-tion", "CHEMICAL", 76, 85], ["thioacid", "CHEMICAL", 59, 67], ["thioacid", "SIMPLE_CHEMICAL", 59, 67], ["Comparative studies", "TEST", 0, 19], ["small model peptides", "TEST", 26, 46], ["thioacid capture liga-tion", "PROBLEM", 59, 85], ["much faster reaction kinetics", "PROBLEM", 96, 125], ["native chemical ligation", "TREATMENT", 131, 155], ["chemical ligation", "OBSERVATION", 138, 155]]], ["Using thioacid capture ligation, we successfully synthesized a histone protein H2B, whereas attempts to synthesize the protein using native chemical ligation at the same junction were not successful.", [["thioacid", "SIMPLE_CHEMICAL", 6, 14], ["histone", "GENE_OR_GENE_PRODUCT", 63, 70], ["H2B", "GENE_OR_GENE_PRODUCT", 79, 82], ["histone protein H2B", "PROTEIN", 63, 82], ["thioacid capture ligation", "TREATMENT", 6, 31], ["a histone protein H2B", "TREATMENT", 61, 82], ["native chemical ligation", "TREATMENT", 133, 157], ["chemical ligation", "OBSERVATION", 140, 157]]], ["[ The structural requirements for recognition of complex polysaccharides and the role of ligand-receptor interactions between different cells and organisms remain unsolved for many systems.", [["cells", "ANATOMY", 136, 141], ["cells", "CELL", 136, 141], ["complex polysaccharides", "PROBLEM", 49, 72], ["different cells", "PROBLEM", 126, 141], ["organisms", "PROBLEM", 146, 155]]], ["We are here focusing on the 'communication' between rhizobium and leguminous plants, which leads to symbiosis and nitrogen fixation.", [["nitrogen", "CHEMICAL", 114, 122], ["nitrogen", "CHEMICAL", 114, 122], ["nitrogen", "SIMPLE_CHEMICAL", 114, 122], ["rhizobium and leguminous plants", "TREATMENT", 52, 83], ["nitrogen fixation", "TREATMENT", 114, 131], ["leguminous plants", "OBSERVATION", 66, 83], ["nitrogen fixation", "OBSERVATION", 114, 131]]], ["The main focus is understanding the interaction between lipochitin oligosaccharide signal molecules and the plant receptors they are predicted to interact with.The LysM domain is a common protein moiety and may have a general peptidoglycan binding function.", [["lipochitin", "SIMPLE_CHEMICAL", 56, 66], ["LysM", "GENE_OR_GENE_PRODUCT", 164, 168], ["lipochitin oligosaccharide signal molecules", "PROTEIN", 56, 99], ["plant receptors", "PROTEIN", 108, 123], ["LysM domain", "PROTEIN", 164, 175], ["a common protein moiety", "PROBLEM", 179, 202], ["a general peptidoglycan binding function", "PROBLEM", 216, 256], ["main", "OBSERVATION_MODIFIER", 4, 8], ["peptidoglycan binding function", "OBSERVATION", 226, 256]]], ["The LysM domains are predicted to have a -\u00e1\u00e1-secondary structure with the two helices packing onto the same side of an anti-parallel beta sheet.", [["LysM", "GENE_OR_GENE_PRODUCT", 4, 8], ["LysM domains", "PROTEIN", 4, 16], ["anti-parallel beta sheet", "PROTEIN", 119, 143], ["a -\u00e1\u00e1-secondary structure", "PROBLEM", 39, 64], ["the two helices packing", "TREATMENT", 70, 93], ["secondary structure", "OBSERVATION", 45, 64]]], ["Here we present the linear solid-phase synthesis of LysM domains from the plant receptors in order to study their structure and the interaction with the lipochitin oligosaccharide signal molecules.", [["lipochitin", "SIMPLE_CHEMICAL", 153, 163], ["LysM domains", "PROTEIN", 52, 64], ["plant receptors", "PROTEIN", 74, 89], ["lipochitin oligosaccharide signal molecules", "PROTEIN", 153, 196], ["the linear solid-phase synthesis of LysM domains", "TREATMENT", 16, 64], ["the plant receptors", "TREATMENT", 70, 89], ["linear", "OBSERVATION_MODIFIER", 20, 26], ["solid-phase", "OBSERVATION_MODIFIER", 27, 38]]], ["The segments were the LysM 2 and LysM 3 domains of receptor kinase (NFR5) originating from Lotus japonicus filicaulis.", [["LysM 2", "GENE_OR_GENE_PRODUCT", 22, 28], ["LysM 3 domains of receptor kinase", "GENE_OR_GENE_PRODUCT", 33, 66], ["NFR5", "GENE_OR_GENE_PRODUCT", 68, 72], ["Lotus japonicus", "ORGANISM", 91, 106], ["filicaulis", "ORGANISM", 107, 117], ["LysM 2 and LysM 3 domains", "PROTEIN", 22, 47], ["receptor kinase", "PROTEIN", 51, 66], ["NFR5", "PROTEIN", 68, 72], ["Lotus", "SPECIES", 91, 96], ["japonicus filicaulis", "SPECIES", 97, 117], ["Lotus japonicus filicaulis", "SPECIES", 91, 117], ["receptor kinase (NFR5", "TREATMENT", 51, 72], ["segments", "ANATOMY_MODIFIER", 4, 12], ["LysM", "OBSERVATION", 22, 26], ["Lotus", "OBSERVATION_MODIFIER", 91, 96], ["japonicus filicaulis", "OBSERVATION", 97, 117]]], ["These small proteins ranged in size from 44 to 71 residues.", [["These small proteins", "TEST", 0, 20], ["small", "OBSERVATION_MODIFIER", 6, 11], ["proteins", "OBSERVATION", 12, 20], ["ranged", "OBSERVATION_MODIFIER", 21, 27], ["size", "OBSERVATION_MODIFIER", 31, 35], ["44 to 71", "OBSERVATION_MODIFIER", 41, 49], ["residues", "OBSERVATION", 50, 58]]], ["The synthesis was optimized, especially to overcome problems in the assembly of the C-and N-terminal ends.", [["C", "CHEMICAL", 84, 85], ["N", "CHEMICAL", 90, 91], ["C-and N-terminal ends", "DNA", 84, 105], ["overcome problems", "PROBLEM", 43, 60], ["the C", "TEST", 80, 85]]], ["Microwave heating using a custom-made semi-automated synthesizer was a key element in the improved protocol.", [["Microwave heating", "TREATMENT", 0, 17]]], ["Other aspects of the synthesis were also improved.", [["improved", "OBSERVATION_MODIFIER", 41, 49]]], ["These small proteins were subjected to various conditions for folding and disulfide bridge formation.", [["disulfide", "CHEMICAL", 74, 83], ["disulfide bridge", "SIMPLE_CHEMICAL", 74, 90], ["These small proteins", "PROBLEM", 0, 20], ["folding and disulfide bridge formation", "TREATMENT", 62, 100], ["small", "OBSERVATION_MODIFIER", 6, 11], ["proteins", "OBSERVATION", 12, 20], ["disulfide bridge", "OBSERVATION", 74, 90]]], ["Binding to lipochitin oligosaccharides was studied using a range of biophysical techniques.", [["lipochitin", "CHEMICAL", 11, 21], ["lipochitin oligosaccharides", "SIMPLE_CHEMICAL", 11, 38], ["Binding to lipochitin oligosaccharides", "PROBLEM", 0, 38]]], ["Both the homogeneity and yield of protected peptides are impediments to the cost-effective chemical synthesis of proteins by fragment condensation.", [["fragment", "CELLULAR_COMPONENT", 125, 133], ["protected peptides", "PROBLEM", 34, 52], ["fragment condensation", "PROBLEM", 125, 146], ["homogeneity", "OBSERVATION_MODIFIER", 9, 20], ["protected peptides", "OBSERVATION", 34, 52], ["fragment condensation", "OBSERVATION", 125, 146]]], ["Use of the EPG (Excluded Protecting Group) Method to overcome these issues is examined by synthesis of the 11peptide Fmoc-Leu-Lys(Boc)-Cys(Acm)-Ser(tBu)-Tyr(tBu)-Ala-Gln-Val-Glu(OtBu)-Phe-Gly.", [["Fmoc-Leu-Lys", "CHEMICAL", 117, 129], ["Boc)-Cys", "CHEMICAL", 130, 138], ["Glu", "CHEMICAL", 174, 177], ["OtBu", "CHEMICAL", 178, 182], ["Phe-Gly", "CHEMICAL", 184, 191], ["Fmoc-Leu-Lys(Boc)-Cys(Acm)-Ser(tBu)-Tyr(tBu)-Ala-Gln-Val-Glu(OtBu)-Phe-Gly", "CHEMICAL", 117, 191], ["11peptide Fmoc-Leu-Lys", "SIMPLE_CHEMICAL", 107, 129], ["tBu)-Ala-Gln-Val-Glu", "SIMPLE_CHEMICAL", 157, 177], ["OtBu)-Phe-Gly", "SIMPLE_CHEMICAL", 178, 191], ["the EPG", "TREATMENT", 7, 14], ["Cys", "TEST", 135, 138], ["Acm", "TEST", 139, 142], ["Ala-Gln-Val", "TEST", 162, 173]]], ["The C-terminal glycyl-residue was esterified to allocholesterol by wave irradiation and reacted with Fmoc-Phe-OPfp.", [["C-terminal glycyl-residue", "CHEMICAL", 4, 29], ["allocholesterol", "CHEMICAL", 48, 63], ["glycyl", "CHEMICAL", 15, 21], ["allocholesterol", "CHEMICAL", 48, 63], ["Fmoc-Phe-OPfp", "CHEMICAL", 101, 114], ["C-terminal glycyl-residue", "SIMPLE_CHEMICAL", 4, 29], ["allocholesterol", "SIMPLE_CHEMICAL", 48, 63], ["Fmoc-Phe-OPfp", "SIMPLE_CHEMICAL", 101, 114], ["The C-terminal glycyl-residue", "TREATMENT", 0, 29], ["wave irradiation", "TREATMENT", 67, 83], ["Fmoc-Phe-OPfp", "TREATMENT", 101, 114]]], ["The dipeptide product was deprotected and purified by gel permeation chromatography and the cycle repeated to produce the 11peptide.", [["dipeptide", "CHEMICAL", 4, 13], ["11peptide", "CHEMICAL", 122, 131], ["The dipeptide product", "TREATMENT", 0, 21], ["gel permeation chromatography", "TEST", 54, 83]]], ["Homogeneity of intermediates was determined both by measuring coupling reaction kinetics and mass spectrometry.", [["coupling reaction kinetics", "PROBLEM", 62, 88], ["mass spectrometry", "PROBLEM", 93, 110], ["intermediates", "OBSERVATION_MODIFIER", 15, 28], ["mass spectrometry", "OBSERVATION", 93, 110]]], ["Coupling reaction half-times were <2 minutes.", [["Coupling reaction", "PROBLEM", 0, 17]]], ["As little as 0.03% uncoupled amino component could be accurately measured at each step by ES-MS with deletion sequences comprising $0.26% of the 11peptide.", [["amino", "CHEMICAL", 29, 34], ["amino", "AMINO_ACID", 29, 34], ["deletion sequences", "DNA", 101, 119], ["uncoupled amino component", "PROBLEM", 19, 44], ["deletion sequences", "TEST", 101, 119]]], ["An approximately three-fold increase in the weight of the product is obtained over the course of synthesis.", [["An approximately three-fold increase", "PROBLEM", 0, 36], ["synthesis", "TREATMENT", 97, 106], ["approximately", "OBSERVATION_MODIFIER", 3, 16], ["three", "OBSERVATION_MODIFIER", 17, 22], ["-fold", "OBSERVATION_MODIFIER", 22, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36]]], ["Removal of the C-terminal allocholesterol group was readily effected by [ 3 P] 4 Pd8/SiMe 3 H. The high yield of an essentially homogeneous protected peptide should allow chemical synthesis by fragment condensation to become cost-competitive with biologic methods of protein production.", [["C", "CHEMICAL", 15, 16], ["allocholesterol", "CHEMICAL", 26, 41], ["[ 3 P] 4 Pd8", "CHEMICAL", 72, 84], ["C-terminal allocholesterol", "SIMPLE_CHEMICAL", 15, 41], ["[ 3 P] 4 Pd8", "SIMPLE_CHEMICAL", 72, 84], ["C-terminal allocholesterol group", "PROTEIN", 15, 47], ["Removal", "TREATMENT", 0, 7], ["the C-terminal allocholesterol group", "TREATMENT", 11, 47], ["an essentially homogeneous protected peptide", "PROBLEM", 113, 157], ["chemical synthesis", "TREATMENT", 171, 189], ["fragment condensation", "PROBLEM", 193, 214], ["protein production", "PROBLEM", 267, 285]]], ["Recently, several biologically active peptides and proteins have been successfully pegylated to improve their metabolic stabilities and increase their biological half-lives.", [["active", "OBSERVATION_MODIFIER", 31, 37], ["peptides", "OBSERVATION", 38, 46], ["metabolic stabilities", "OBSERVATION", 110, 131]]], ["These pegylated proteins have been shown to have improved biological profiles, require fewer injections than their non-pegylated counterparts, and some are being used as therapeutics.", [["pegylated proteins", "PROTEIN", 6, 24], ["These pegylated proteins", "TREATMENT", 0, 24], ["fewer injections", "TREATMENT", 87, 103], ["their non-pegylated counterparts", "TREATMENT", 109, 141]]], ["The goal of our work was to develop general conditions for the pegylation of small proteins e.g. thymosin a1, a naturally occurring thymic peptide consisting of 28-amino acids that possesses immunomodulatory activity.", [["thymic", "ANATOMY", 132, 138], ["28-amino acids", "CHEMICAL", 161, 175], ["28-amino acids", "CHEMICAL", 161, 175], ["thymosin a1", "GENE_OR_GENE_PRODUCT", 97, 108], ["28-amino acids", "SIMPLE_CHEMICAL", 161, 175], ["small proteins", "PROTEIN", 77, 91], ["thymosin a1", "PROTEIN", 97, 108], ["general conditions", "PROBLEM", 36, 54], ["small proteins e.g. thymosin a1", "PROBLEM", 77, 108], ["thymic peptide", "TREATMENT", 132, 146], ["28-amino acids", "TREATMENT", 161, 175], ["immunomodulatory activity", "OBSERVATION", 191, 216]]], ["Using a model pentapeptide, [H-Leu-Lys(Boc)-Lys(Boc)-Gly-Thr(tBu)-NH2], conditions were optimized for pegylation using an aminoalkylation procedure with PEG-aldehyde followed by reduction with NaCNBH3.", [["H-Leu-Lys", "CHEMICAL", 29, 38], ["Boc)-Lys", "CHEMICAL", 39, 47], ["Boc)-Gly-Thr", "CHEMICAL", 48, 60], ["PEG-aldehyde", "CHEMICAL", 153, 165], ["NaCNBH3", "CHEMICAL", 193, 200], ["pentapeptide", "CHEMICAL", 14, 26], ["[H-Leu-Lys(Boc)-Lys(Boc)-Gly-Thr(tBu)-NH2", "CHEMICAL", 28, 69], ["PEG-aldehyde", "CHEMICAL", 153, 165], ["NaCNBH3", "CHEMICAL", 193, 200], ["[H-Leu-Lys(Boc)-Lys", "SIMPLE_CHEMICAL", 28, 47], ["PEG-aldehyde", "SIMPLE_CHEMICAL", 153, 165], ["NaCNBH3", "SIMPLE_CHEMICAL", 193, 200], ["a model pentapeptide", "TREATMENT", 6, 26], ["H-Leu-Lys(Boc)", "TREATMENT", 29, 43], ["Lys(Boc)", "TREATMENT", 44, 52], ["pegylation", "TREATMENT", 102, 112], ["an aminoalkylation procedure", "TREATMENT", 119, 147], ["PEG-aldehyde", "TREATMENT", 153, 165], ["NaCNBH3", "TREATMENT", 193, 200]]], ["Purification of the crude pegylated pentapeptide was achieved by dialysis and lyophilization.", [["pegylated pentapeptide", "CHEMICAL", 26, 48], ["the crude pegylated pentapeptide", "TREATMENT", 16, 48], ["dialysis", "TREATMENT", 65, 73], ["lyophilization", "TREATMENT", 78, 92]]], ["Deprotection of the Boc/tBuprotecting groups resulted in the expected positive ninhydrin reaction.", [["Boc", "CHEMICAL", 20, 23], ["tBuprotecting", "CHEMICAL", 24, 37], ["Boc", "CHEMICAL", 20, 23], ["tBuprotecting", "CHEMICAL", 24, 37], ["ninhydrin", "CHEMICAL", 79, 88], ["ninhydrin", "SIMPLE_CHEMICAL", 79, 88], ["Deprotection", "TREATMENT", 0, 12], ["the Boc/tBuprotecting groups", "TREATMENT", 16, 44], ["the expected positive ninhydrin reaction", "PROBLEM", 57, 97], ["positive", "OBSERVATION_MODIFIER", 70, 78], ["ninhydrin reaction", "OBSERVATION", 79, 97]]], ["Thymosin a1 was then pegylated by coupling with either PEG2000aldehyde or PEG5000-aldehyde by the same aminoalkylation procedure using a novel H2O-trifluoroethanol solvent in place of methanol to maintain homogeneity.", [["pegylated", "CHEMICAL", 21, 30], ["PEG2000aldehyde", "CHEMICAL", 55, 70], ["PEG5000-aldehyde", "CHEMICAL", 74, 90], ["H2O-trifluoroethanol", "CHEMICAL", 143, 163], ["PEG2000aldehyde", "CHEMICAL", 55, 70], ["PEG5000-aldehyde", "CHEMICAL", 74, 90], ["H2O", "CHEMICAL", 143, 146], ["trifluoroethanol", "CHEMICAL", 147, 163], ["methanol", "CHEMICAL", 184, 192], ["Thymosin a1", "GENE_OR_GENE_PRODUCT", 0, 11], ["PEG2000aldehyde", "SIMPLE_CHEMICAL", 55, 70], ["PEG5000-aldehyde", "SIMPLE_CHEMICAL", 74, 90], ["H2O-trifluoroethanol solvent", "SIMPLE_CHEMICAL", 143, 171], ["methanol", "SIMPLE_CHEMICAL", 184, 192], ["Thymosin a1", "PROTEIN", 0, 11], ["Thymosin a1", "TREATMENT", 0, 11], ["PEG2000aldehyde", "TREATMENT", 55, 70], ["PEG5000", "TREATMENT", 74, 81], ["the same aminoalkylation procedure", "TREATMENT", 94, 128], ["a novel H2O-trifluoroethanol solvent", "TREATMENT", 135, 171], ["methanol", "TREATMENT", 184, 192]]], ["Confirmation of structure was provided by hydrolysis of the PEG-thymosin a1 followed by thin layer chromatography, which revealed the presence of amino acids present in thymosin a1.", [["PEG-thymosin", "CHEMICAL", 60, 72], ["amino acids", "CHEMICAL", 146, 157], ["PEG", "CHEMICAL", 60, 63], ["amino acids", "CHEMICAL", 146, 157], ["amino acids", "AMINO_ACID", 146, 157], ["thymosin a1", "GENE_OR_GENE_PRODUCT", 169, 180], ["thymosin a1", "PROTEIN", 64, 75], ["thymosin a1", "PROTEIN", 169, 180], ["the PEG", "TREATMENT", 56, 63], ["thymosin a1", "TREATMENT", 64, 75], ["thin layer chromatography", "TEST", 88, 113], ["amino acids", "PROBLEM", 146, 157], ["thymosin a1", "TREATMENT", 169, 180], ["PEG", "OBSERVATION", 60, 63], ["amino acids", "OBSERVATION", 146, 157], ["thymosin a1", "OBSERVATION", 169, 180]]], ["The aminoalkylation procedure has been extended to include pegylation of GRF(1-29)-NH2 and GRF(1-44)-NH2.", [["1-29)-NH2", "CHEMICAL", 77, 86], ["1-44)-NH2", "CHEMICAL", 95, 104], ["NH2", "CHEMICAL", 83, 86], ["NH2", "CHEMICAL", 101, 104], ["GRF(1-29)-NH2", "SIMPLE_CHEMICAL", 73, 86], ["GRF(1-44)-NH2", "SIMPLE_CHEMICAL", 91, 104], ["NH2", "PROTEIN", 83, 86], ["NH2", "PROTEIN", 101, 104], ["The aminoalkylation procedure", "TREATMENT", 0, 29], ["GRF", "TEST", 73, 76], ["GRF", "TEST", 91, 94]]], ["Biological studies of PEG-thymosin a1 are in progress.", [["PEG", "CHEMICAL", 22, 25], ["PEG", "CHEMICAL", 22, 25], ["PEG-thymosin a1", "GENE_OR_GENE_PRODUCT", 22, 37], ["thymosin a1", "PROTEIN", 26, 37], ["Biological studies", "TEST", 0, 18], ["PEG-thymosin a1", "TREATMENT", 22, 37], ["PEG", "OBSERVATION", 22, 25]]], ["The peptide sequence Arg-Gly-Asp (RGD) is by far the most prominent ligand to promote specific cell adhesion through integrin stimulation.F. Li and C. LiuRecently, it was shown that the mutation of the RGD sequence in Fibronectin to the RGE sequence still exhibits binding affinity, although RGE is known not to be recognized by integrins.", [["cell", "ANATOMY", 95, 99], ["Arg-Gly-Asp", "CHEMICAL", 21, 32], ["Arg-Gly-Asp", "CHEMICAL", 21, 32], ["Arg-Gly-Asp", "GENE_OR_GENE_PRODUCT", 21, 32], ["cell", "CELL", 95, 99], ["integrin", "GENE_OR_GENE_PRODUCT", 117, 125], ["Fibronectin", "GENE_OR_GENE_PRODUCT", 218, 229], ["RGE", "GENE_OR_GENE_PRODUCT", 292, 295], ["integrins", "GENE_OR_GENE_PRODUCT", 329, 338], ["integrin", "PROTEIN", 117, 125], ["RGD sequence", "DNA", 202, 214], ["Fibronectin", "PROTEIN", 218, 229], ["RGE sequence", "DNA", 237, 249], ["RGE", "PROTEIN", 292, 295], ["integrins", "PROTEIN", 329, 338], ["The peptide sequence Arg", "TEST", 0, 24], ["Asp (RGD)", "PROBLEM", 29, 38], ["specific cell adhesion", "TREATMENT", 86, 108], ["integrin stimulation", "TREATMENT", 117, 137], ["the RGD sequence", "TEST", 198, 214], ["the RGE sequence", "TEST", 233, 249], ["binding affinity", "PROBLEM", 265, 281], ["most prominent", "OBSERVATION_MODIFIER", 53, 67], ["specific cell adhesion", "OBSERVATION", 86, 108]]], ["However, these fibrils display a slightly different phenotype than wild-type Fibronectin.", [["fibrils", "ANATOMY", 15, 22], ["Fibronectin", "GENE_OR_GENE_PRODUCT", 77, 88], ["wild-type Fibronectin", "PROTEIN", 67, 88], ["a slightly different phenotype", "PROBLEM", 31, 61], ["slightly", "OBSERVATION_MODIFIER", 33, 41], ["different phenotype", "OBSERVATION_MODIFIER", 42, 61]]], ["The Asn-Gly-Arg sequence in fibronectin FN-I5 repeat is able to undergo a rearrangement to isoAsp-Gly-Arg, which shows activity on v3 and -with less potency -on 51.", [["Asn-Gly-Arg", "CHEMICAL", 4, 15], ["isoAsp-Gly-Arg", "CHEMICAL", 91, 105], ["Asn-Gly-Arg", "CHEMICAL", 4, 15], ["isoAsp-Gly-Arg", "CHEMICAL", 91, 105], ["fibronectin FN-I5", "GENE_OR_GENE_PRODUCT", 28, 45], ["isoAsp-Gly-Arg", "SIMPLE_CHEMICAL", 91, 105], ["Asn-Gly-Arg sequence", "DNA", 4, 24], ["fibronectin FN-I5 repeat", "DNA", 28, 52], ["The Asn-Gly-Arg sequence", "TEST", 0, 24], ["fibronectin FN", "TEST", 28, 42], ["activity on v3", "PROBLEM", 119, 133]]], ["The mechanism of Asndeamidation is already known for a long time and has widely been considered to be a process of degradation, acting as a biochemical clock that limits protein lifetimes in vivo.", [["Asndeamidation", "CHEMICAL", 17, 31]]], ["Curnis et al. were the first to show that the deamidation process increases protein function instead.", [["the deamidation process", "PROBLEM", 42, 65], ["protein function", "OBSERVATION", 76, 92]]], ["These findings stimulated us to create a library of cyclic peptides containing the isoDGR sequence.", [["isoDGR sequence", "DNA", 83, 98], ["cyclic peptides", "TREATMENT", 52, 67], ["the isoDGR sequence", "TEST", 79, 98]]], ["A screening of this library showed various new peptides with high activity towards the integrin receptor v3 or the receptor 51.F. Li and C. LiuFurther studies, including NMR-based structure determinations and docking experiments are currently in progress in order to elucidate the relationship between the three-dimensional arrangement of the isoDGR-sequence and the biological activity found in cellular assays.", [["cellular", "ANATOMY", 396, 404], ["Li", "CHEMICAL", 130, 132], ["integrin receptor v3", "GENE_OR_GENE_PRODUCT", 87, 107], ["cellular", "CELL", 396, 404], ["integrin receptor v3", "PROTEIN", 87, 107], ["receptor 51", "PROTEIN", 115, 126], ["isoDGR", "PROTEIN", 343, 349], ["F.", "SPECIES", 127, 129], ["A screening", "TEST", 0, 11], ["this library", "TEST", 15, 27], ["various new peptides", "PROBLEM", 35, 55], ["Li and C. LiuFurther studies", "TEST", 130, 158], ["NMR", "TEST", 170, 173], ["docking experiments", "TEST", 209, 228], ["cellular assays", "TEST", 396, 411], ["high activity", "OBSERVATION", 61, 74], ["cellular assays", "OBSERVATION", 396, 411]]], ["We previously generated selective regulator peptides derived from the C2 domain of individual PKC isozymes, since the C2 domain is the site of many PPIs.", [["PKC", "GENE_OR_GENE_PRODUCT", 94, 97], ["C2 domain", "PROTEIN", 70, 79], ["PKC isozymes", "PROTEIN", 94, 106], ["C2 domain", "PROTEIN", 118, 127], ["selective regulator peptides", "TREATMENT", 24, 52], ["individual PKC isozymes", "PROBLEM", 83, 106], ["many PPIs", "TREATMENT", 143, 152], ["PKC isozymes", "OBSERVATION", 94, 106], ["C2", "ANATOMY", 118, 120], ["many", "OBSERVATION_MODIFIER", 143, 147], ["PPIs", "OBSERVATION", 148, 152]]], ["The agonist and antagonist peptide regulators were used in vitro, in vivo and are currently being tested in humans.", [["humans", "ORGANISM", 108, 114], ["humans", "SPECIES", 108, 114], ["humans", "SPECIES", 108, 114], ["The agonist and antagonist peptide regulators", "TREATMENT", 0, 45]]], ["Selective antagonists inhibit PPI between a specific PKC and its RACK.", [["PKC", "GENE_OR_GENE_PRODUCT", 53, 56], ["RACK", "GENE_OR_GENE_PRODUCT", 65, 69], ["PKC", "PROTEIN", 53, 56], ["RACK", "PROTEIN", 65, 69], ["Selective antagonists inhibit PPI", "TREATMENT", 0, 33], ["a specific PKC", "TREATMENT", 42, 56], ["PPI", "OBSERVATION", 30, 33]]], ["The agonists interfere with intra-molecular inhibitory PPI within a given PKC isozyme and cause its activation.", [["PKC", "GENE_OR_GENE_PRODUCT", 74, 77], ["PKC isozyme", "PROTEIN", 74, 85], ["The agonists", "TREATMENT", 0, 12], ["intra-molecular inhibitory PPI", "TREATMENT", 28, 58], ["PKC isozyme", "TREATMENT", 74, 85]]], ["These isozyme-selective inhibitors and activators regulate all the cellular functions mediated by that isozyme.", [["cellular", "ANATOMY", 67, 75], ["cellular", "CELL", 67, 75], ["isozyme", "PROTEIN", 103, 110], ["These isozyme", "TREATMENT", 0, 13], ["selective inhibitors", "TREATMENT", 14, 34], ["activators regulate", "TREATMENT", 39, 58]]], ["For example, we showed that PKC induces apoptosis, inhibits ATP regeneration, induces endoplasmic reticulum stress and induces cell adhesion by phosphorylation of different substrates at each of those sub-cellular compartments.F. Li and C. LiuThe current PPI inhibitor of PKC, V1-1, inhibits all the above functions.", [["endoplasmic reticulum", "ANATOMY", 86, 107], ["cell", "ANATOMY", 127, 131], ["cellular compartments", "ANATOMY", 205, 226], ["ATP", "CHEMICAL", 60, 63], ["ATP", "CHEMICAL", 60, 63], ["PKC", "GENE_OR_GENE_PRODUCT", 28, 31], ["ATP", "SIMPLE_CHEMICAL", 60, 63], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 86, 107], ["cell", "CELL", 127, 131], ["cellular", "CELL", 205, 213], ["PKC", "GENE_OR_GENE_PRODUCT", 272, 275], ["V1-1", "GENE_OR_GENE_PRODUCT", 277, 281], ["PKC", "PROTEIN", 28, 31], ["PKC", "PROTEIN", 272, 275], ["V1", "PROTEIN", 277, 279], ["PKC induces apoptosis", "PROBLEM", 28, 49], ["ATP regeneration", "PROBLEM", 60, 76], ["endoplasmic reticulum stress", "PROBLEM", 86, 114], ["cell adhesion", "PROBLEM", 127, 140], ["phosphorylation of different substrates", "PROBLEM", 144, 183], ["The current PPI inhibitor", "TREATMENT", 243, 268], ["PKC", "TEST", 272, 275], ["ATP regeneration", "OBSERVATION", 60, 76], ["endoplasmic reticulum stress", "OBSERVATION", 86, 114], ["induces cell adhesion", "OBSERVATION", 119, 140], ["cellular compartments", "OBSERVATION", 205, 226]]], ["Here we sought to identify regulators of one of these PKC-mediated functions.", [["PKC", "GENE_OR_GENE_PRODUCT", 54, 57], ["PKC", "PROTEIN", 54, 57]]], ["Such regulators have the potential to affect only the PKC function that is associated with a particular pathology, without affecting other functions of these ubiquitous enzymes.", [["PKC", "GENE_OR_GENE_PRODUCT", 54, 57], ["PKC", "PROTEIN", 54, 57], ["ubiquitous enzymes", "PROTEIN", 158, 176], ["the PKC function", "TEST", 50, 66], ["a particular pathology", "PROBLEM", 91, 113], ["these ubiquitous enzymes", "TEST", 152, 176]]], ["Guided by the structure of the C2 domain, we developed a series of short peptide regulators of PKC.", [["PKC", "GENE_OR_GENE_PRODUCT", 95, 98], ["C2 domain", "PROTEIN", 31, 40], ["PKC", "PROTEIN", 95, 98], ["short peptide regulators of PKC", "TREATMENT", 67, 98], ["C2", "ANATOMY", 31, 33]]], ["One peptide, derived from a unique site in PKC induces PKC translocation to the mitochondria when using a myocardial infarction model, but not to other sub-cellular components and increases the phosphorylation of only a subset of PKC substrates.", [["mitochondria", "ANATOMY", 80, 92], ["myocardial", "ANATOMY", 106, 116], ["cellular", "ANATOMY", 156, 164], ["myocardial infarction", "DISEASE", 106, 127], ["PKC", "GENE_OR_GENE_PRODUCT", 43, 46], ["PKC", "GENE_OR_GENE_PRODUCT", 55, 58], ["mitochondria", "CELLULAR_COMPONENT", 80, 92], ["myocardial", "MULTI-TISSUE_STRUCTURE", 106, 116], ["cellular", "CELL", 156, 164], ["PKC", "GENE_OR_GENE_PRODUCT", 230, 233], ["PKC", "PROTEIN", 43, 46], ["PKC", "PROTEIN", 55, 58], ["PKC substrates", "PROTEIN", 230, 244], ["a unique site", "PROBLEM", 26, 39], ["PKC translocation", "PROBLEM", 55, 72], ["a myocardial infarction model", "PROBLEM", 104, 133], ["PKC substrates", "TREATMENT", 230, 244], ["myocardial", "ANATOMY", 106, 116], ["infarction", "OBSERVATION", 117, 127], ["cellular components", "OBSERVATION", 156, 175]]], ["In contrast, a previous PKC agonist, RACK, induces translocation of PKC to the mitochondria, plasma membrane and endoplasmic reticulum.", [["mitochondria", "ANATOMY", 79, 91], ["plasma membrane", "ANATOMY", 93, 108], ["endoplasmic reticulum", "ANATOMY", 113, 134], ["RACK", "CHEMICAL", 37, 41], ["PKC", "GENE_OR_GENE_PRODUCT", 24, 27], ["RACK", "GENE_OR_GENE_PRODUCT", 37, 41], ["PKC", "GENE_OR_GENE_PRODUCT", 68, 71], ["mitochondria", "CELLULAR_COMPONENT", 79, 91], ["plasma membrane", "CELLULAR_COMPONENT", 93, 108], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 113, 134], ["PKC", "PROTEIN", 24, 27], ["RACK", "PROTEIN", 37, 41], ["PKC", "PROTEIN", 68, 71], ["a previous PKC agonist", "TEST", 13, 35], ["endoplasmic reticulum", "PROBLEM", 113, 134], ["mitochondria", "ANATOMY", 79, 91], ["plasma membrane", "OBSERVATION", 93, 108], ["endoplasmic reticulum", "OBSERVATION", 113, 134]]], ["The characterization of the new selective PKC agonist will be provided.P 067 EXENATIDE COULD UPREGULATE SIRT1 PROTEIN IN RINM-5F CELLSX.", [["PKC", "GENE_OR_GENE_PRODUCT", 42, 45], ["PKC", "PROTEIN", 42, 45], ["P 067 EXENATIDE COULD UPREGULATE SIRT1 PROTEIN IN RINM-5F CELLSX", "DNA", 71, 135], ["the new selective PKC agonist", "TREATMENT", 24, 53], ["PROTEIN", "TEST", 110, 117]]], ["Wang, J. Yu, J. Wang, S. Yang, W. Li Jilin University Sirt1, a class III histone protein deacetylase,is essential in aging process.", [["Sirt1", "GENE_OR_GENE_PRODUCT", 54, 59], ["class III histone protein deacetylase", "GENE_OR_GENE_PRODUCT", 63, 100], ["Sirt1", "PROTEIN", 54, 59], ["class III histone protein deacetylase", "PROTEIN", 63, 100], ["a class III histone protein deacetylase", "TREATMENT", 61, 100], ["protein deacetylase", "OBSERVATION", 81, 100]]], ["It has been reported that Sirt1 is involved in glucose metabolism and can improve insulin sensitivity by repressing PTP1B [1] .", [["glucose", "CHEMICAL", 47, 54], ["glucose", "CHEMICAL", 47, 54], ["Sirt1", "GENE_OR_GENE_PRODUCT", 26, 31], ["glucose", "SIMPLE_CHEMICAL", 47, 54], ["insulin", "GENE_OR_GENE_PRODUCT", 82, 89], ["PTP1B", "GENE_OR_GENE_PRODUCT", 116, 121], ["Sirt1", "PROTEIN", 26, 31], ["PTP1B", "PROTEIN", 116, 121], ["glucose metabolism", "TEST", 47, 65], ["insulin sensitivity", "TEST", 82, 101]]], ["Furthermore,it has been testified by Laura Bordone that Sirt1 can regulate insulin secretion by repressing UCP2 in pancreatic cells [2] .", [["pancreatic cells", "ANATOMY", 115, 131], ["Sirt1", "GENE_OR_GENE_PRODUCT", 56, 61], ["insulin", "GENE_OR_GENE_PRODUCT", 75, 82], ["UCP2", "GENE_OR_GENE_PRODUCT", 107, 111], ["pancreatic cells", "CELL", 115, 131], ["Sirt1", "PROTEIN", 56, 61], ["UCP2", "PROTEIN", 107, 111], ["pancreatic cells", "CELL_TYPE", 115, 131], ["insulin secretion", "TREATMENT", 75, 92], ["pancreatic", "ANATOMY", 115, 125]]], ["Exenatide, which has been used to treat T2DM, is a 39 amino acid peptide.", [["Exenatide", "CHEMICAL", 0, 9], ["T2DM", "DISEASE", 40, 44], ["amino acid", "CHEMICAL", 54, 64], ["Exenatide", "CHEMICAL", 0, 9], ["amino acid", "CHEMICAL", 54, 64], ["Exenatide", "SIMPLE_CHEMICAL", 0, 9], ["Exenatide", "TREATMENT", 0, 9], ["T2DM", "PROBLEM", 40, 44], ["a 39 amino acid peptide", "TREATMENT", 49, 72]]], ["We have shown in our experiment that exenatide in RINm-5F cells could upregulate not only the protein level of sirt1 but also the gene expression.", [["RINm-5F cells", "ANATOMY", 50, 63], ["exenatide", "CHEMICAL", 37, 46], ["exenatide", "SIMPLE_CHEMICAL", 37, 46], ["RINm-5F cells", "CELL", 50, 63], ["sirt1", "GENE_OR_GENE_PRODUCT", 111, 116], ["RINm-5F cells", "CELL_LINE", 50, 63], ["sirt1", "PROTEIN", 111, 116], ["exenatide in RINm-5F cells", "TREATMENT", 37, 63]]], ["There may be some correlationship with the previous result we have got that exenatide could downregulate p53 protein level [3] .", [["exenatide", "CHEMICAL", 76, 85], ["exenatide", "SIMPLE_CHEMICAL", 76, 85], ["p53", "GENE_OR_GENE_PRODUCT", 105, 108], ["p53", "PROTEIN", 105, 108], ["exenatide", "TREATMENT", 76, 85], ["p53 protein level", "TEST", 105, 122]]], ["Chronic pain such as neuropathic pain can take place due to nerve injuries and is considered to be the most difficult to treat.", [["nerve", "ANATOMY", 60, 65], ["pain", "DISEASE", 8, 12], ["neuropathic pain", "DISEASE", 21, 37], ["nerve injuries", "DISEASE", 60, 74], ["nerve", "TISSUE", 60, 65], ["Chronic pain", "PROBLEM", 0, 12], ["neuropathic pain", "PROBLEM", 21, 37], ["nerve injuries", "PROBLEM", 60, 74], ["pain", "OBSERVATION", 8, 12], ["nerve", "ANATOMY", 60, 65], ["injuries", "OBSERVATION", 66, 74]]], ["Opioids often are the first line of treatment.", [["Opioids", "TREATMENT", 0, 7], ["treatment", "TREATMENT", 36, 45]]], ["Due to their side effects including tolerance, prolonged treatment with opioids is not feasible.", [["prolonged treatment", "TREATMENT", 47, 66], ["opioids", "TREATMENT", 72, 79]]], ["It has been found that the co-administeration of opioid mu agonist and delta antagonist or Neurokinin1 (NK1) antagonist reduces tolerance.", [["Neurokinin1", "CHEMICAL", 91, 102], ["NK1", "CHEMICAL", 104, 107], ["opioid mu agonist", "GENE_OR_GENE_PRODUCT", 49, 66], ["delta antagonist", "GENE_OR_GENE_PRODUCT", 71, 87], ["Neurokinin1", "GENE_OR_GENE_PRODUCT", 91, 102], ["NK1", "GENE_OR_GENE_PRODUCT", 104, 107], ["opioid mu agonist", "TREATMENT", 49, 66], ["delta antagonist", "TREATMENT", 71, 87], ["Neurokinin1 (NK1) antagonist", "TREATMENT", 91, 119]]], ["These observations prompted us to create a single peptide chimera which could act as an antagonist at the delta and NK1 receptors and an agonist at the mu receptor.", [["NK1 receptors", "GENE_OR_GENE_PRODUCT", 116, 129], ["mu receptor", "GENE_OR_GENE_PRODUCT", 152, 163], ["delta and NK1 receptors", "PROTEIN", 106, 129], ["mu receptor", "PROTEIN", 152, 163], ["a single peptide chimera", "TREATMENT", 41, 65], ["an antagonist at the delta", "TREATMENT", 85, 111], ["NK1 receptors", "TREATMENT", 116, 129]]], ["We made a series containing H2N-Dmt-Tic as an N terminal delta antagonist pharmacophore and Trp-CONHBzl(CF3)2 as a C terminal NK1 pharmacophore.", [["Trp", "CHEMICAL", 92, 95], ["H2N-Dmt-Tic", "CHEMICAL", 28, 39], ["N", "CHEMICAL", 46, 47], ["Trp-CONHBzl(CF3)2", "CHEMICAL", 92, 109], ["C", "CHEMICAL", 115, 116], ["H2N-Dmt-Tic", "SIMPLE_CHEMICAL", 28, 39], ["Trp-CONHBzl(CF3)2", "GENE_OR_GENE_PRODUCT", 92, 109], ["a series containing H2N", "TREATMENT", 8, 31], ["Dmt", "TREATMENT", 32, 35], ["Tic", "TREATMENT", 36, 39], ["an N terminal delta antagonist pharmacophore", "TREATMENT", 43, 87], ["Trp-CONHBzl(CF3)", "TREATMENT", 92, 108], ["a C terminal NK1 pharmacophore", "TREATMENT", 113, 143]]], ["We found that mu and delta affinities of the series increased when the length between these pharmacophore was decreased.", [["decreased", "OBSERVATION_MODIFIER", 110, 119]]], ["We found an optimized ligand that has good affinity constant (Ki) for both the mu and delta receptors 32.2 nM and 0.79 nM respectively.", [["delta receptors", "PROTEIN", 86, 101], ["delta receptors", "TEST", 86, 101], ["optimized ligand", "OBSERVATION", 12, 28]]], ["Hybrid molecules having mu agonist, delta and NK1 antagonist activities will be therapeutically advantageous for patients who do not show any response with current analgesics.", [["mu agonist", "GENE_OR_GENE_PRODUCT", 24, 34], ["delta", "GENE_OR_GENE_PRODUCT", 36, 41], ["NK1 antagonist", "GENE_OR_GENE_PRODUCT", 46, 60], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Hybrid molecules", "PROBLEM", 0, 16], ["mu agonist", "TREATMENT", 24, 34], ["delta and NK1 antagonist activities", "TREATMENT", 36, 71], ["current analgesics", "TREATMENT", 156, 174]]], ["We anticipate that these new molecules will show a high antinociceptive effect, less development of tolerance and less respiratory depression in animal assay models.P 067 EXENATIDE COULD UPREGULATE SIRT1 PROTEIN IN RINM-5F CELLSSupported by the grants from the US Public Health Service, National Institutes of Health.P 069 DEVELOPMENT OF COMPSTATIN-ALBUMIN BIND-ING PEPTIDE CONJUGATES FOR PROLONGED PEPTIDE HALF-LIFEH.", [["respiratory", "ANATOMY", 119, 130], ["respiratory depression", "DISEASE", 119, 141], ["SIRT1", "PROTEIN", 198, 203], ["LIFEH", "DNA", 412, 417], ["these new molecules", "PROBLEM", 19, 38], ["a high antinociceptive effect", "PROBLEM", 49, 78], ["less respiratory depression in animal assay models", "PROBLEM", 114, 164], ["COMPSTATIN-ALBUMIN BIND", "TREATMENT", 338, 361], ["high antinociceptive effect", "OBSERVATION_MODIFIER", 51, 78], ["less", "OBSERVATION_MODIFIER", 114, 118], ["respiratory depression", "OBSERVATION", 119, 141]]], ["Qu, P. Magotti, J. Lambris University of Pennsylvania Complement is the first line of defense against invading pathogens and a bridge to adaptive immunity.", [["invading pathogens", "PROBLEM", 102, 120], ["a bridge to adaptive immunity", "TREATMENT", 125, 154]]], ["However, inappropriate or excessive complement activation can cause host tissue damage and is implicated in many autoimmune diseases including Alzheimer's disease, rheumatoid arthritis, age-related macular degeneration (AMD), sepsis, ischemiareperfusion injuries, transplantation etc. Our lab has developed a 13-residue disulfide-bridged peptide named Compstatin that is able to selectively bind to complement component 3 and effectively inhibit complement activation.", [["tissue", "ANATOMY", 73, 79], ["macular", "ANATOMY", 198, 205], ["tissue damage", "DISEASE", 73, 86], ["autoimmune diseases", "DISEASE", 113, 132], ["Alzheimer's disease", "DISEASE", 143, 162], ["rheumatoid arthritis", "DISEASE", 164, 184], ["macular degeneration", "DISEASE", 198, 218], ["AMD", "DISEASE", 220, 223], ["sepsis", "DISEASE", 226, 232], ["ischemiareperfusion injuries", "DISEASE", 234, 262], ["Compstatin", "CHEMICAL", 352, 362], ["disulfide", "CHEMICAL", 320, 329], ["tissue", "TISSUE", 73, 79], ["macular", "TISSUE", 198, 205], ["Compstatin", "SIMPLE_CHEMICAL", 352, 362], ["complement component 3", "GENE_OR_GENE_PRODUCT", 399, 421], ["complement component 3", "PROTEIN", 399, 421], ["inappropriate or excessive complement activation", "PROBLEM", 9, 57], ["host tissue damage", "PROBLEM", 68, 86], ["many autoimmune diseases", "PROBLEM", 108, 132], ["Alzheimer's disease", "PROBLEM", 143, 162], ["rheumatoid arthritis", "PROBLEM", 164, 184], ["macular degeneration", "PROBLEM", 198, 218], ["AMD)", "PROBLEM", 220, 224], ["sepsis", "PROBLEM", 226, 232], ["ischemiareperfusion injuries", "PROBLEM", 234, 262], ["transplantation etc", "TREATMENT", 264, 283], ["a 13-residue disulfide", "TREATMENT", 307, 329], ["bridged peptide", "TREATMENT", 330, 345], ["host tissue", "OBSERVATION_MODIFIER", 68, 79], ["damage", "OBSERVATION", 80, 86], ["autoimmune", "OBSERVATION", 113, 123], ["rheumatoid arthritis", "OBSERVATION", 164, 184], ["macular degeneration", "OBSERVATION", 198, 218], ["sepsis", "OBSERVATION", 226, 232], ["transplantation", "OBSERVATION", 264, 279]]], ["A Compstatin analogue is currently in phase I clinically trials for the treatment of AMD.", [["Compstatin", "CHEMICAL", 2, 12], ["AMD", "DISEASE", 85, 88], ["Compstatin", "CHEMICAL", 2, 12], ["Compstatin", "SIMPLE_CHEMICAL", 2, 12], ["A Compstatin analogue", "TREATMENT", 0, 21], ["the treatment", "TREATMENT", 68, 81], ["AMD", "PROBLEM", 85, 88], ["AMD", "OBSERVATION", 85, 88]]], ["However, it has relatively short half-life in vivo due to its small size.", [["its small size", "PROBLEM", 58, 72], ["small", "OBSERVATION_MODIFIER", 62, 67], ["size", "OBSERVATION_MODIFIER", 68, 72]]], ["One of the ways to improve peptide in vivo half-life is by conjugation to a molecule that binds to human albumin, which has a long half-life of 19 days.", [["human", "ORGANISM", 99, 104], ["albumin", "GENE_OR_GENE_PRODUCT", 105, 112], ["human albumin", "PROTEIN", 99, 112], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["human albumin", "TEST", 99, 112]]], ["Therefore, we have designed chimeric peptides with a cyclic albumin binding peptide conjugated to either N-terminal or C-terminal of [W(Me)4]-Compstatin via a short PEG linker.", [["PEG", "CHEMICAL", 165, 168], ["N", "CHEMICAL", 105, 106], ["C", "CHEMICAL", 119, 120], ["[W(Me)4]-Compstatin", "CHEMICAL", 133, 152], ["PEG", "CHEMICAL", 165, 168], ["albumin", "GENE_OR_GENE_PRODUCT", 60, 67], ["[W(Me)4]-Compstatin", "SIMPLE_CHEMICAL", 133, 152], ["N-terminal or C-terminal", "PROTEIN", 105, 129], ["Compstatin", "PROTEIN", 142, 152], ["chimeric peptides", "TREATMENT", 28, 45], ["a cyclic albumin binding peptide", "TREATMENT", 51, 83], ["Compstatin", "TREATMENT", 142, 152], ["a short PEG linker", "TREATMENT", 157, 175]]], ["The peptides were synthesized by a combination of solid phase and solution phase chemistry to avoid crossing of the two disulfide bonds.", [["disulfide", "CHEMICAL", 120, 129], ["solid phase and solution phase chemistry", "TREATMENT", 50, 90], ["disulfide bonds", "OBSERVATION", 120, 135]]], ["In vitro assays show that those chimeric peptides are able to bind to albumin and C3 separately, and simultaneously.", [["albumin", "GENE_OR_GENE_PRODUCT", 70, 77], ["C3", "GENE_OR_GENE_PRODUCT", 82, 84], ["albumin", "PROTEIN", 70, 77], ["C3", "PROTEIN", 82, 84], ["vitro assays", "TEST", 3, 15], ["those chimeric peptides", "PROBLEM", 26, 49], ["albumin", "TEST", 70, 77]]], ["Thus, the chimeric peptides show great promise of having longer in vivo half-life and for the treatment of a broader range of complement associated diseases.University of CopenhagenThe prevalence of obesity is increasing with an alarming rate world wide and there is a need for anti-obesity drugs.", [["obesity", "DISEASE", 199, 206], ["the chimeric peptides", "TEST", 6, 27], ["the treatment", "TREATMENT", 90, 103], ["complement associated diseases", "PROBLEM", 126, 156], ["obesity", "PROBLEM", 199, 206], ["anti-obesity drugs", "TREATMENT", 278, 296], ["great", "OBSERVATION_MODIFIER", 33, 38], ["obesity", "OBSERVATION", 199, 206], ["increasing", "OBSERVATION_MODIFIER", 210, 220]]], ["PYY3-36 have been demonstrated to possess appetite suppressing potential thus novel analogs with high Y2R selectivity and potency have potential as drugs for the treatment of obesity.", [["PYY3-36", "CHEMICAL", 0, 7], ["obesity", "DISEASE", 175, 182], ["PYY3-36", "CHEMICAL", 0, 7], ["PYY3-36", "GENE_OR_GENE_PRODUCT", 0, 7], ["Y2R", "SIMPLE_CHEMICAL", 102, 105], ["high Y2R selectivity", "PROBLEM", 97, 117], ["drugs", "TREATMENT", 148, 153], ["obesity", "PROBLEM", 175, 182], ["obesity", "OBSERVATION", 175, 182]]], ["It has been hypothesized that PYY3-36 and possibly related peptide hormones bind to the membrane prior to interaction with the receptors.", [["membrane", "ANATOMY", 88, 96], ["PYY3-36", "GENE_OR_GENE_PRODUCT", 30, 37], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["PYY3", "PROTEIN", 30, 34]]], ["Based on this hypothesis, we have designed novel PYY3-36 analogs for increased membrane binding.", [["membrane", "ANATOMY", 79, 87], ["PYY3-36", "CHEMICAL", 49, 56], ["PYY3-36 analogs", "SIMPLE_CHEMICAL", 49, 64], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["novel PYY3-36 analogs", "TREATMENT", 43, 64], ["increased membrane binding", "PROBLEM", 69, 95], ["membrane binding", "OBSERVATION", 79, 95]]], ["The N-terminal segments (residue 1-12) of the PP fold family of peptides have proven very important for the Y receptor selectivity.", [["Y receptor", "GENE_OR_GENE_PRODUCT", 108, 118], ["N-terminal segments", "PROTEIN", 4, 23], ["PP fold family", "PROTEIN", 46, 60], ["Y receptor", "PROTEIN", 108, 118], ["The N-terminal segments (residue", "TEST", 0, 32], ["the PP fold family of peptides", "PROBLEM", 42, 72], ["N-terminal", "ANATOMY_MODIFIER", 4, 14], ["segments", "ANATOMY_MODIFIER", 15, 23]]], ["We have taken advantage of this phenomenon in the design of two classes of novel PYY3-36 analogs.", [["PYY3-36", "CHEMICAL", 81, 88], ["PYY3-36", "CHEMICAL", 81, 88], ["PYY3-36 analogs", "SIMPLE_CHEMICAL", 81, 96], ["this phenomenon", "TREATMENT", 27, 42], ["novel PYY3", "TREATMENT", 75, 85]]], ["First, the N-terminal segment was replaced with different amphiphatic heptad-repeat sequences which were designed to selfaggregate into protein-like structures.", [["N", "CHEMICAL", 11, 12], ["N-terminal segment", "DNA", 11, 29], ["amphiphatic heptad-repeat sequences", "DNA", 58, 93], ["the N-terminal segment", "TREATMENT", 7, 29], ["different amphiphatic heptad-repeat sequences", "TEST", 48, 93], ["terminal", "ANATOMY_MODIFIER", 13, 21], ["segment", "ANATOMY_MODIFIER", 22, 29]]], ["Binding experiments demonstrated high selectivity for the Y2R.", [["Y2R", "GENE_OR_GENE_PRODUCT", 58, 61], ["Y2R", "PROTEIN", 58, 61], ["Binding experiments", "TEST", 0, 19], ["high selectivity", "OBSERVATION", 33, 49]]], ["Second, different N-terminal segments derived from the PP fold family of peptides were introduced at an e amine of an additional Lys positioned before Ser-13 of the native sequence.", [["N", "CHEMICAL", 18, 19], ["amine", "CHEMICAL", 106, 111], ["Lys", "CHEMICAL", 129, 132], ["Ser", "CHEMICAL", 151, 154], ["Ser-13", "AMINO_ACID", 151, 157], ["N-terminal segments", "PROTEIN", 18, 37], ["PP fold family", "PROTEIN", 55, 69], ["Ser-13", "PROTEIN", 151, 157], ["the PP fold family of peptides", "TREATMENT", 51, 81], ["an additional Lys", "TREATMENT", 115, 132], ["terminal segments", "ANATOMY_MODIFIER", 20, 37]]], ["Our hypothesis is that this gives rise to a tighter back-folding, which consequently makes the N-terminal partly inaccessible for the receptors and also to some extent towards proteases.", [["N", "CHEMICAL", 95, 96], ["proteases", "PROTEIN", 176, 185], ["a tighter back-folding", "PROBLEM", 42, 64]]], ["Binding experiments back up the hypothesis by displaying interesting YR affinities and DIO mice studies show prolonged efficacy for at least one analog.", [["YR", "GENE_OR_GENE_PRODUCT", 69, 71], ["DIO mice", "ORGANISM", 87, 95], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["Binding experiments", "PROBLEM", 0, 19], ["DIO mice studies", "TEST", 87, 103]]], ["Virus like particles are one of the most exciting kind of nanoparticles that can be used for medicinal approaches, as they might serve as polyvalent building blocks that provide a stable and well characterized surface that can be used for many different chemical reactions.", [["surface", "ANATOMY", 210, 217], ["Virus", "ORGANISM", 0, 5], ["surface", "CELLULAR_COMPONENT", 210, 217], ["Virus like particles", "PROBLEM", 0, 20], ["medicinal approaches", "TREATMENT", 93, 113], ["polyvalent building blocks", "TREATMENT", 138, 164], ["many different chemical reactions", "PROBLEM", 239, 272], ["particles", "OBSERVATION_MODIFIER", 11, 20]]], ["So far, such particles have successfully been used for imaging purposes or to gain antibody responses.", [["imaging purposes", "TEST", 55, 71]]], ["However, they still suffer from unselectivity concerning internalization if only one specific cell has to be attacked or binding to cell surfaces.University of CopenhagenIntegrins constitute a family of heterodimeric, transmembrane cell adhesion receptors for a variety of extracellular matrix proteins, e.g. vitronectin or fibronectin.", [["cell", "ANATOMY", 94, 98], ["cell", "ANATOMY", 132, 136], ["transmembrane cell", "ANATOMY", 218, 236], ["extracellular matrix", "ANATOMY", 273, 293], ["cell", "CELL", 94, 98], ["cell", "CELL", 132, 136], ["transmembrane cell adhesion receptors", "GENE_OR_GENE_PRODUCT", 218, 255], ["extracellular matrix", "CELLULAR_COMPONENT", 273, 293], ["vitronectin", "GENE_OR_GENE_PRODUCT", 309, 320], ["fibronectin", "GENE_OR_GENE_PRODUCT", 324, 335], ["CopenhagenIntegrins", "PROTEIN", 160, 179], ["heterodimeric, transmembrane cell adhesion receptors", "PROTEIN", 203, 255], ["extracellular matrix proteins", "PROTEIN", 273, 302], ["vitronectin", "PROTEIN", 309, 320], ["fibronectin", "PROTEIN", 324, 335], ["one specific cell", "PROBLEM", 81, 98], ["heterodimeric, transmembrane cell adhesion receptors", "TREATMENT", 203, 255], ["extracellular matrix proteins", "TREATMENT", 273, 302], ["vitronectin", "TREATMENT", 309, 320], ["fibronectin", "TREATMENT", 324, 335]]], ["The pioneering observation that integrinsespecially v3 and 51 -are hallmarks of metastatic cancer and are seriously involved in the process of tumor angiogenesis turned them into attractive targets for cancer therapy.", [["metastatic cancer", "ANATOMY", 80, 97], ["tumor", "ANATOMY", 143, 148], ["cancer", "ANATOMY", 202, 208], ["cancer", "DISEASE", 91, 97], ["tumor", "DISEASE", 143, 148], ["cancer", "DISEASE", 202, 208], ["v3", "GENE_OR_GENE_PRODUCT", 52, 54], ["51", "GENE_OR_GENE_PRODUCT", 59, 61], ["metastatic cancer", "CANCER", 80, 97], ["tumor", "CANCER", 143, 148], ["cancer", "CANCER", 202, 208], ["metastatic cancer", "PROBLEM", 80, 97], ["tumor angiogenesis", "PROBLEM", 143, 161], ["cancer therapy", "TREATMENT", 202, 216], ["metastatic", "OBSERVATION_MODIFIER", 80, 90], ["cancer", "OBSERVATION", 91, 97], ["tumor", "OBSERVATION", 143, 148], ["cancer", "OBSERVATION", 202, 208]]], ["For more than two decades the RGD sequence is known to be recognized by several integrins, e.g. v3, v5 and 51.University of CopenhagenHere we report the successful surface coating of a virus like particle with a cyclic integrin binding peptide using click chemistry to gain selective binding towards cells presenting v3, v5 or 51 integrin receptors on their surface.", [["surface", "ANATOMY", 164, 171], ["cells", "ANATOMY", 300, 305], ["surface", "ANATOMY", 358, 365], ["integrins", "GENE_OR_GENE_PRODUCT", 80, 89], ["v3", "GENE_OR_GENE_PRODUCT", 96, 98], ["v5", "GENE_OR_GENE_PRODUCT", 100, 102], ["integrin", "GENE_OR_GENE_PRODUCT", 219, 227], ["cells", "CELL", 300, 305], ["v3", "GENE_OR_GENE_PRODUCT", 317, 319], ["v5", "GENE_OR_GENE_PRODUCT", 321, 323], ["integrin receptors", "GENE_OR_GENE_PRODUCT", 330, 348], ["surface", "CELLULAR_COMPONENT", 358, 365], ["integrins", "PROTEIN", 80, 89], ["v3", "PROTEIN", 96, 98], ["v5 and 51", "PROTEIN", 100, 109], ["v3, v5 or 51 integrin receptors", "PROTEIN", 317, 348], ["the RGD sequence", "TEST", 26, 42], ["a virus like particle", "PROBLEM", 183, 204], ["a cyclic integrin binding peptide", "TREATMENT", 210, 243], ["click chemistry", "TEST", 250, 265], ["virus", "OBSERVATION", 185, 190]]], ["The melanocortin receptors are involved in many physiological functions, including pigmentation, sexual function, feeding behavior, and energy homeostasis, making them potential targets to treat obesity, sexual dysfunction, etc. Understanding the basis of the ligand receptor interactions is crucial for the design of potent and selective ligands for these receptors.", [["obesity", "DISEASE", 195, 202], ["sexual dysfunction", "DISEASE", 204, 222], ["melanocortin receptors", "GENE_OR_GENE_PRODUCT", 4, 26], ["melanocortin receptors", "PROTEIN", 4, 26], ["The melanocortin receptors", "TREATMENT", 0, 26], ["pigmentation", "PROBLEM", 83, 95], ["obesity", "PROBLEM", 195, 202], ["sexual dysfunction", "PROBLEM", 204, 222], ["potent and selective ligands", "TREATMENT", 318, 346], ["these receptors", "TREATMENT", 351, 366]]], ["Cyclic melanocortin MTII and SHU9119 were investigated by solution NMR spectroscopy in aqueous solution of DPC (dodecylphosphocholine), used as a membrane mimetic environment.", [["membrane", "ANATOMY", 146, 154], ["SHU9119", "CHEMICAL", 29, 36], ["DPC", "CHEMICAL", 107, 110], ["dodecylphosphocholine", "CHEMICAL", 112, 133], ["DPC", "CHEMICAL", 107, 110], ["dodecylphosphocholine", "CHEMICAL", 112, 133], ["melanocortin MTII", "GENE_OR_GENE_PRODUCT", 7, 24], ["SHU9119", "SIMPLE_CHEMICAL", 29, 36], ["DPC", "SIMPLE_CHEMICAL", 107, 110], ["dodecylphosphocholine", "SIMPLE_CHEMICAL", 112, 133], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["Cyclic melanocortin MTII", "TREATMENT", 0, 24], ["NMR spectroscopy", "TEST", 67, 83], ["DPC (dodecylphosphocholine)", "TREATMENT", 107, 134], ["a membrane mimetic environment", "TREATMENT", 144, 174]]], ["NMR derived structures of these analogues were then docked within the hMC4 receptor, where they act as agonist and antagonist, respectively.", [["hMC4 receptor", "GENE_OR_GENE_PRODUCT", 70, 83], ["hMC4 receptor", "PROTEIN", 70, 83], ["NMR derived structures of these analogues", "PROBLEM", 0, 41], ["antagonist", "TEST", 115, 125]]], ["The detailed structural information on ligand-receptor complexes obtained in this study may assist future attempts to optimize the selectivity, potency, and efficacy of agonist and antagonist at MC4 receptor, which is involved in feeding.", [["MC4 receptor", "GENE_OR_GENE_PRODUCT", 195, 207], ["ligand-receptor complexes", "PROTEIN", 39, 64], ["MC4 receptor", "PROTEIN", 195, 207], ["this study", "TEST", 77, 87], ["agonist and antagonist at MC4 receptor", "TREATMENT", 169, 207]]], ["Alzheimer's disease (AD) is the most common neurodegenerative disease.", [["Alzheimer's disease", "DISEASE", 0, 19], ["AD", "DISEASE", 21, 23], ["neurodegenerative disease", "DISEASE", 44, 69], ["Alzheimer's disease", "PROBLEM", 0, 19], ["the most common neurodegenerative disease", "PROBLEM", 28, 69], ["most common", "OBSERVATION_MODIFIER", 32, 43], ["neurodegenerative", "OBSERVATION_MODIFIER", 44, 61], ["disease", "OBSERVATION", 62, 69]]], ["More than 20 million people suffer from it worldwide.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27]]], ["AD has been identified as a protein misfolding disease due to the accumulation of aggregated amyloid beta (A) proteins in the brains of the patients.", [["brains", "ANATOMY", 126, 132], ["AD", "DISEASE", 0, 2], ["misfolding disease", "DISEASE", 36, 54], ["amyloid beta (A) proteins", "GENE_OR_GENE_PRODUCT", 93, 118], ["brains", "ORGAN", 126, 132], ["patients", "ORGANISM", 140, 148], ["amyloid beta (A) proteins", "PROTEIN", 93, 118], ["patients", "SPECIES", 140, 148], ["a protein misfolding disease", "PROBLEM", 26, 54], ["aggregated amyloid beta (A) proteins in the brains", "PROBLEM", 82, 132], ["protein misfolding", "OBSERVATION", 28, 46], ["aggregated", "OBSERVATION_MODIFIER", 82, 92], ["amyloid", "OBSERVATION", 93, 100], ["brains", "ANATOMY", 126, 132]]], ["Therefore, compounds that can selectively interfere with A aggregation and accumulation are desperately needed.", [["A", "GENE_OR_GENE_PRODUCT", 57, 58], ["A aggregation", "PROBLEM", 57, 70]]], ["Previous studies have demonstrtaed that the hydrophobic core of A, KLVFF, is an essentional sequence for the self-assembly of A. It binds the homologous sequence in A, prevents its aggregation and reduces its toxicity, in vitro.", [["toxicity", "DISEASE", 209, 217], ["A", "GENE_OR_GENE_PRODUCT", 64, 65], ["KLVFF", "GENE_OR_GENE_PRODUCT", 67, 72], ["KLVFF", "PROTEIN", 67, 72], ["Previous studies", "TEST", 0, 16], ["its aggregation", "PROBLEM", 177, 192], ["its toxicity", "PROBLEM", 205, 217]]], ["Using a multivalent variant of KLVFF, Scheper and coworkers have demonstrated that the affinity and specifity to A can be significantly improved.", [["KLVFF", "PROTEIN", 31, 36]]], ["This strategy was found to be more effective in preventing A aggregation than the native KLVFF.", [["KLVFF", "GENE_OR_GENE_PRODUCT", 89, 94], ["KLVFF", "PROTEIN", 89, 94], ["A aggregation", "PROBLEM", 59, 72], ["the native KLVFF", "TREATMENT", 78, 94], ["aggregation", "OBSERVATION", 61, 72]]], ["Here we describe how proteinous microsphares containing different copies of KLVFF fragments on their surface can potently prevent A aggregation and reduce its toxicity to the cells.", [["KLVFF fragments", "ANATOMY", 76, 91], ["surface", "ANATOMY", 101, 108], ["cells", "ANATOMY", 175, 180], ["toxicity", "DISEASE", 159, 167], ["KLVFF", "GENE_OR_GENE_PRODUCT", 76, 81], ["surface", "CELLULAR_COMPONENT", 101, 108], ["cells", "CELL", 175, 180], ["KLVFF fragments", "DNA", 76, 91], ["proteinous microsphares", "PROBLEM", 21, 44], ["KLVFF fragments", "PROBLEM", 76, 91], ["A aggregation", "PROBLEM", 130, 143], ["its toxicity to the cells", "PROBLEM", 155, 180], ["KLVFF fragments", "OBSERVATION", 76, 91], ["aggregation", "OBSERVATION", 132, 143]]], ["These microsphares are prepared from ultrasonic irradiation of various proteins, such as bovine serum albumin, with the presence of different amounts of KLVFF analogs.", [["serum", "ANATOMY", 96, 101], ["KLVFF", "CHEMICAL", 153, 158], ["bovine", "ORGANISM", 89, 95], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["albumin", "GENE_OR_GENE_PRODUCT", 102, 109], ["KLVFF", "SIMPLE_CHEMICAL", 153, 158], ["bovine", "SPECIES", 89, 95], ["ultrasonic irradiation of various proteins", "TREATMENT", 37, 79], ["bovine serum albumin", "TEST", 89, 109], ["KLVFF analogs", "TREATMENT", 153, 166]]], ["We demonstrate that these microspheres have a narrow size distribution (1-5 m) and are highly stable in different conditions.", [["microspheres", "OBSERVATION_MODIFIER", 26, 38], ["narrow", "OBSERVATION_MODIFIER", 46, 52], ["size", "OBSERVATION_MODIFIER", 53, 57], ["distribution", "OBSERVATION_MODIFIER", 58, 70], ["1-5 m", "OBSERVATION_MODIFIER", 72, 77], ["highly", "OBSERVATION_MODIFIER", 87, 93], ["stable", "OBSERVATION_MODIFIER", 94, 100], ["different conditions", "OBSERVATION", 104, 124]]], ["Moreover, using confocal microscopy and fluorescently labeled KLVFF analog, we show that the peptide is presented mainly on the surface of the microsphares, while the internal volume can be filled with different contrasting agents.P 076 COMBINATION TREATMENT WITH HER-2 AND VEGF PEPTIDE MIMICS INDUCES POTENT ANTI-TUMOR AND ANTI-ANGIOGENIC RESPONSES IN VITRO AND IN VIVOK.", [["surface", "ANATOMY", 128, 135], ["microsphares", "ANATOMY", 143, 155], ["KLVFF", "SIMPLE_CHEMICAL", 62, 67], ["surface", "CELLULAR_COMPONENT", 128, 135], ["confocal microscopy", "TEST", 16, 35], ["fluorescently labeled KLVFF analog", "TEST", 40, 74], ["the peptide", "PROBLEM", 89, 100], ["different contrasting agents", "TREATMENT", 202, 230], ["TUMOR", "OBSERVATION", 314, 319]]], ["Foy, 1, 2 S. Rawale, 2 P.T.P. Kaumaya 1, 2, 3 1 Department of Microbiology, 2 Department of Obstetrics and Gynecology, and the 3 Arthur G. James Comprehensive Cancer Center, The Ohio State University HER-2 is a member of the EGFR family and is overexpressed in 20-30% of breast cancer patients.VEGF is a glycoprotein containing an anti-parallel structure with inter and intra chain disulfide bonds .It belongs to the cysteine-knot family and is a ligand for class III tyrosine kinase growth receptors.", [["breast cancer", "ANATOMY", 271, 284], ["Cancer", "DISEASE", 159, 165], ["breast cancer", "DISEASE", 271, 284], ["tyrosine", "CHEMICAL", 468, 476], ["disulfide", "CHEMICAL", 382, 391], ["cysteine", "CHEMICAL", 417, 425], ["tyrosine", "CHEMICAL", 468, 476], ["HER-2", "GENE_OR_GENE_PRODUCT", 200, 205], ["EGFR", "GENE_OR_GENE_PRODUCT", 225, 229], ["breast cancer", "CANCER", 271, 284], ["patients", "ORGANISM", 285, 293], ["VEGF", "GENE_OR_GENE_PRODUCT", 294, 298], ["class III tyrosine kinase growth receptors", "GENE_OR_GENE_PRODUCT", 458, 500], ["HER", "PROTEIN", 200, 203], ["EGFR family", "PROTEIN", 225, 236], ["VEGF", "PROTEIN", 294, 298], ["glycoprotein", "PROTEIN", 304, 316], ["cysteine-knot family", "PROTEIN", 417, 437], ["class III tyrosine kinase growth receptors", "PROTEIN", 458, 500], ["patients", "SPECIES", 285, 293], ["breast cancer", "PROBLEM", 271, 284], ["a glycoprotein", "TREATMENT", 302, 316], ["an anti-parallel structure", "TREATMENT", 328, 354], ["inter and intra chain disulfide bonds", "TREATMENT", 360, 397], ["class III tyrosine kinase growth receptors", "TREATMENT", 458, 500], ["breast", "ANATOMY", 271, 277], ["cancer", "OBSERVATION", 278, 284], ["disulfide bonds", "OBSERVATION", 382, 397]]], ["Both HER-2 and VEGF are good targets for cancer treatments.", [["cancer", "ANATOMY", 41, 47], ["cancer", "DISEASE", 41, 47], ["HER-2", "GENE_OR_GENE_PRODUCT", 5, 10], ["VEGF", "GENE_OR_GENE_PRODUCT", 15, 19], ["cancer", "CANCER", 41, 47], ["HER-2", "PROTEIN", 5, 10], ["VEGF", "PROTEIN", 15, 19], ["cancer treatments", "TREATMENT", 41, 58], ["cancer", "OBSERVATION", 41, 47]]], ["Pertuzumab and Bevacizumab are two humanized monoclonal antibodies (mAb) that target HER-2 and VEGF respectively.", [["Pertuzumab", "CHEMICAL", 0, 10], ["Bevacizumab", "CHEMICAL", 15, 26], ["Pertuzumab", "CHEMICAL", 0, 10], ["Bevacizumab", "CHEMICAL", 15, 26], ["Pertuzumab", "SIMPLE_CHEMICAL", 0, 10], ["Bevacizumab", "SIMPLE_CHEMICAL", 15, 26], ["HER-2", "GENE_OR_GENE_PRODUCT", 85, 90], ["VEGF", "GENE_OR_GENE_PRODUCT", 95, 99], ["humanized monoclonal antibodies", "PROTEIN", 35, 66], ["mAb", "PROTEIN", 68, 71], ["HER-2", "PROTEIN", 85, 90], ["VEGF", "PROTEIN", 95, 99], ["Pertuzumab", "TREATMENT", 0, 10], ["Bevacizumab", "TREATMENT", 15, 26]]], ["The overexpression of HER-2 is associated with increased expression of VEGF at both the RNA and protein level in human breast cancer cells [1] and exposure of HER-2 overexpressing cells to trastuzumab significantly decreases VEGF expression.", [["breast cancer cells", "ANATOMY", 119, 138], ["HER-2 overexpressing cells", "ANATOMY", 159, 185], ["breast cancer", "DISEASE", 119, 132], ["trastuzumab", "CHEMICAL", 189, 200], ["HER-2", "GENE_OR_GENE_PRODUCT", 22, 27], ["VEGF", "GENE_OR_GENE_PRODUCT", 71, 75], ["human", "ORGANISM", 113, 118], ["breast cancer cells", "CELL", 119, 138], ["HER-2", "GENE_OR_GENE_PRODUCT", 159, 164], ["cells", "CELL", 180, 185], ["trastuzumab", "SIMPLE_CHEMICAL", 189, 200], ["VEGF", "GENE_OR_GENE_PRODUCT", 225, 229], ["HER-2", "PROTEIN", 22, 27], ["VEGF", "PROTEIN", 71, 75], ["human breast cancer cells", "CELL_TYPE", 113, 138], ["HER-2 overexpressing cells", "CELL_LINE", 159, 185], ["VEGF", "PROTEIN", 225, 229], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["increased expression of VEGF", "PROBLEM", 47, 75], ["protein level", "TEST", 96, 109], ["human breast cancer cells", "PROBLEM", 113, 138], ["HER", "TEST", 159, 162], ["overexpressing cells", "PROBLEM", 165, 185], ["trastuzumab", "TREATMENT", 189, 200], ["breast", "ANATOMY", 119, 125], ["cancer", "OBSERVATION", 126, 132]]], ["Furthermore, a positive association between HER-2 and VEGF expression in breast cancer patients has been identified [2] .", [["breast cancer", "ANATOMY", 73, 86], ["breast cancer", "DISEASE", 73, 86], ["HER-2", "GENE_OR_GENE_PRODUCT", 44, 49], ["VEGF", "GENE_OR_GENE_PRODUCT", 54, 58], ["breast cancer", "CANCER", 73, 86], ["patients", "ORGANISM", 87, 95], ["HER", "PROTEIN", 44, 47], ["VEGF", "PROTEIN", 54, 58], ["patients", "SPECIES", 87, 95], ["VEGF expression in breast cancer", "PROBLEM", 54, 86], ["breast", "ANATOMY", 73, 79], ["cancer", "OBSERVATION", 80, 86]]], ["We have created novel peptide molecules based on the known crystal structures of HER-2 in complex with pertuzumab, and VEGF with Avastin and VEGFR2.", [["Avastin", "CHEMICAL", 129, 136], ["pertuzumab", "CHEMICAL", 103, 113], ["HER-2", "GENE_OR_GENE_PRODUCT", 81, 86], ["pertuzumab", "SIMPLE_CHEMICAL", 103, 113], ["VEGF", "GENE_OR_GENE_PRODUCT", 119, 123], ["Avastin", "SIMPLE_CHEMICAL", 129, 136], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 141, 147], ["HER-2", "PROTEIN", 81, 86], ["pertuzumab", "PROTEIN", 103, 113], ["VEGF", "PROTEIN", 119, 123], ["VEGFR2", "PROTEIN", 141, 147], ["novel peptide molecules", "TREATMENT", 16, 39], ["pertuzumab", "TREATMENT", 103, 113], ["Avastin", "TREATMENT", 129, 136], ["VEGF", "ANATOMY", 119, 123], ["Avastin", "OBSERVATION", 129, 136]]], ["Because of the potential synergy between HER-2 and VEGF inhibitors, we want to test if combination therapy interacts in a synergistic or additive manner, killing tumor cells or retarding tumor development.", [["tumor cells", "ANATOMY", 162, 173], ["tumor", "ANATOMY", 187, 192], ["tumor", "DISEASE", 162, 167], ["tumor", "DISEASE", 187, 192], ["HER-2", "GENE_OR_GENE_PRODUCT", 41, 46], ["VEGF", "GENE_OR_GENE_PRODUCT", 51, 55], ["tumor cells", "CELL", 162, 173], ["tumor", "CANCER", 187, 192], ["HER", "PROTEIN", 41, 44], ["VEGF", "PROTEIN", 51, 55], ["tumor cells", "CELL_TYPE", 162, 173], ["HER-2 and VEGF inhibitors", "TREATMENT", 41, 66], ["combination therapy", "TREATMENT", 87, 106], ["killing tumor cells", "PROBLEM", 154, 173], ["retarding tumor development", "PROBLEM", 177, 204], ["tumor", "OBSERVATION", 187, 192]]], ["[1] Liang, Y., and Hyder M, Endocrinology 146:3632 (2005 Alzheimer's disease (AD) likely is caused by neurotoxic oligomers of amyloid -protein (A).", [["Alzheimer's disease", "DISEASE", 57, 76], ["AD", "DISEASE", 78, 80], ["neurotoxic", "DISEASE", 102, 112], ["amyloid -protein", "GENE_OR_GENE_PRODUCT", 126, 142], ["amyloid -protein", "PROTEIN", 126, 142], ["Alzheimer's disease", "PROBLEM", 57, 76]]], ["Disruption of A oligomerization is a promising approach for developing therapeutics for AD.", [["AD", "DISEASE", 88, 90], ["A", "GENE_OR_GENE_PRODUCT", 14, 15], ["A oligomerization", "PROBLEM", 14, 31], ["AD", "PROBLEM", 88, 90], ["oligomerization", "OBSERVATION", 16, 31]]], ["We have prepared a series of A42 C-terminal fragments (CTFs), evaluated their bioactivity, and identified lead inhibitors of A42 assembly and neurotoxicity (Fradinger et al., Proc.", [["neurotoxicity", "DISEASE", 142, 155], ["A42 C", "CHEMICAL", 29, 34], ["A42 C-terminal fragments", "SIMPLE_CHEMICAL", 29, 53], ["CTFs", "SIMPLE_CHEMICAL", 55, 59], ["A42", "SIMPLE_CHEMICAL", 125, 128], ["A42 C-terminal fragments", "DNA", 29, 53], ["a series of A42 C-terminal fragments (CTFs", "TREATMENT", 17, 59], ["lead inhibitors", "TREATMENT", 106, 121], ["neurotoxicity", "PROBLEM", 142, 155]]], ["Natl.", [["Natl", "CHEMICAL", 0, 4]]], ["To decipher the mechanisms by which CTFs affect A assembly and neurotoxicity, we investigated the solubility, secondary structure, morphology, self-assembly, and interaction with full-length A42 of CTFs and of control A-derived fragments.", [["fragments", "ANATOMY", 228, 237], ["neurotoxicity", "DISEASE", 63, 76], ["CTFs", "GENE_OR_GENE_PRODUCT", 36, 40], ["A", "GENE_OR_GENE_PRODUCT", 48, 49], ["CTFs", "CANCER", 198, 202], ["A42", "PROTEIN", 191, 194], ["CTFs", "PROTEIN", 198, 202], ["control A-derived fragments", "DNA", 210, 237], ["neurotoxicity", "PROBLEM", 63, 76], ["CTFs", "TREATMENT", 198, 202], ["control A-derived fragments", "PROBLEM", 210, 237]]], ["The results demonstrated that the biophysical properties of CTFs were roughly length-dependent.", [["CTFs", "SIMPLE_CHEMICAL", 60, 64], ["CTFs", "TEST", 60, 64], ["length", "OBSERVATION_MODIFIER", 78, 84]]], ["In contrast, inhibition of A42 assembly and neurotoxicity correlated poorly with CTF length and was sequence-specific.", [["neurotoxicity", "DISEASE", 44, 57], ["A42", "GENE_OR_GENE_PRODUCT", 27, 30], ["CTF", "GENE_OR_GENE_PRODUCT", 81, 84], ["A42", "PROTEIN", 27, 30], ["CTF", "PROTEIN", 81, 84], ["neurotoxicity", "PROBLEM", 44, 57], ["CTF length", "TEST", 81, 91]]], ["Understanding the relationship between CTF sequence and biophysical/biological properties provides insight into their mechanism of action and will be used for design and testing of improved peptidomimetic inhibitors of A42 toxicity as drug candidates for AD.P 079 SYNTHESIS AND CHARACTERIZATION OF PEP-TIDE HORMONE-BASED PRODRUGSA.", [["toxicity", "DISEASE", 223, 231], ["AD", "DISEASE", 255, 257], ["CTF", "GENE_OR_GENE_PRODUCT", 39, 42], ["A42", "SIMPLE_CHEMICAL", 219, 222], ["CTF", "PROTEIN", 39, 42], ["CTF sequence", "TEST", 39, 51], ["design and testing", "TEST", 159, 177], ["improved peptidomimetic inhibitors", "TREATMENT", 181, 215], ["A42 toxicity", "PROBLEM", 219, 231], ["PEP", "TEST", 298, 301]]], ["De and R. DiMarchi* Department of Chemistry, Indiana University, Bloomington, Indiana 47405, USA *rdimarch@indiana.edu Peptides represent a rich natural source of potential medicines with a notable pharmaceutical limitation being their relatively short duration of action.", [["potential medicines", "TREATMENT", 163, 182], ["a notable pharmaceutical limitation", "PROBLEM", 188, 223]]], ["A particularly good example of this phenomenon is glucagon-like peptide 1 (GLP).", [["glucagon-like peptide 1", "CHEMICAL", 50, 73], ["glucagon-like peptide 1", "GENE_OR_GENE_PRODUCT", 50, 73], ["GLP", "GENE_OR_GENE_PRODUCT", 75, 78], ["this phenomenon", "PROBLEM", 31, 46], ["glucagon", "TEST", 50, 58]]], ["In the native form GLP demonstrates an extremely short half-life in plasma and a relatively narrow therapeutic index with notable adverse gastrointestinal pharmacology.", [["plasma", "ANATOMY", 68, 74], ["gastrointestinal", "ANATOMY", 138, 154], ["plasma", "ORGANISM_SUBSTANCE", 68, 74], ["gastrointestinal", "ORGANISM_SUBDIVISION", 138, 154], ["an extremely short half-life in plasma", "PROBLEM", 36, 74], ["a relatively narrow therapeutic index", "PROBLEM", 79, 116], ["extremely", "OBSERVATION_MODIFIER", 39, 48], ["short", "OBSERVATION_MODIFIER", 49, 54]]], ["We explored a set of GLP-based prodrugs as a means to extend the duration of action and broaden the therapeutic index of the native hormone.", [["GLP-based prodrugs", "TREATMENT", 21, 39], ["native hormone", "OBSERVATION", 125, 139]]], ["A set of Nterminal dipeptideextended hormone analogs was synthesized and characterized by chemical and biochemical methods.", [["Nterminal dipeptideextended hormone analogs", "TREATMENT", 9, 52]]], ["GLP-analogs with amide-based dipeptide extensions demonstrated much reduced in vitro potency relative to the native hormone, but little propensity to generate diketopiperazines (DKP) or diketomorpholines (DMP), under physiological conditions.", [["amide", "CHEMICAL", 17, 22], ["diketopiperazines", "CHEMICAL", 159, 176], ["DKP", "CHEMICAL", 178, 181], ["diketomorpholines", "CHEMICAL", 186, 203], ["DMP", "CHEMICAL", 205, 208], ["amide", "CHEMICAL", 17, 22], ["dipeptide", "CHEMICAL", 29, 38], ["diketopiperazines", "CHEMICAL", 159, 176], ["DKP", "CHEMICAL", 178, 181], ["diketomorpholines", "CHEMICAL", 186, 203], ["DMP", "CHEMICAL", 205, 208], ["GLP-analogs", "SIMPLE_CHEMICAL", 0, 11], ["amide-based dipeptide", "SIMPLE_CHEMICAL", 17, 38], ["diketopiperazines", "SIMPLE_CHEMICAL", 159, 176], ["DKP", "SIMPLE_CHEMICAL", 178, 181], ["diketomorpholines", "SIMPLE_CHEMICAL", 186, 203], ["DMP", "SIMPLE_CHEMICAL", 205, 208], ["GLP", "TEST", 0, 3], ["amide-based dipeptide extensions", "TREATMENT", 17, 49], ["much reduced in vitro potency", "PROBLEM", 63, 92], ["reduced", "OBSERVATION_MODIFIER", 68, 75]]], ["Analogous ester-based prodrugs of GLP were observed to generate the parent peptide and a cyclized dipeptide when incubated at physiological pH and temperature.", [["ester", "CHEMICAL", 10, 15], ["ester", "CHEMICAL", 10, 15], ["dipeptide", "CHEMICAL", 98, 107], ["ester", "SIMPLE_CHEMICAL", 10, 15], ["GLP", "SIMPLE_CHEMICAL", 34, 37], ["Analogous ester-based prodrugs of GLP", "TREATMENT", 0, 37], ["the parent peptide", "TREATMENT", 64, 82], ["a cyclized dipeptide", "TREATMENT", 87, 107]]], ["The relative rate of DKP and DMP formation with simultaneous formation of a highly active and otherwise chemically stable GLP was optimized for pharmacological use.", [["DKP", "CHEMICAL", 21, 24], ["DMP", "CHEMICAL", 29, 32], ["DKP", "CHEMICAL", 21, 24], ["DMP", "CHEMICAL", 29, 32], ["DKP", "SIMPLE_CHEMICAL", 21, 24], ["DMP", "SIMPLE_CHEMICAL", 29, 32], ["DKP", "PROBLEM", 21, 24], ["DMP formation", "PROBLEM", 29, 42], ["active", "OBSERVATION_MODIFIER", 83, 89]]], ["The speed of cleavage was observed to be a function of the conformational propensity of the dipeptide extension to reside in a cisconfiguration coupled with the relative strength of the cyclization nucleophile.", [["dipeptide", "CHEMICAL", 92, 101], ["the dipeptide extension", "TREATMENT", 88, 111], ["the cyclization nucleophile", "TREATMENT", 182, 209]]], ["A set of GLP ester-based prodrugs of variable half-live has been identified and biochemically characterized.", [["GLP ester", "CHEMICAL", 9, 18], ["ester", "CHEMICAL", 13, 18], ["GLP ester", "SIMPLE_CHEMICAL", 9, 18], ["GLP ester", "TEST", 9, 18], ["ester", "OBSERVATION_MODIFIER", 13, 18], ["prodrugs", "OBSERVATION_MODIFIER", 25, 33], ["variable", "OBSERVATION_MODIFIER", 37, 45], ["half", "OBSERVATION_MODIFIER", 46, 50], ["biochemically characterized", "OBSERVATION_MODIFIER", 80, 107]]], ["The central -helix of the insulin B-chain formed by residues 9-19 is crucial for the structural stability of the hormone and its biological activity.", [["residues 9-19", "CHEMICAL", 52, 65], ["insulin", "GENE_OR_GENE_PRODUCT", 26, 33], ["insulin B-chain", "PROTEIN", 26, 41], ["the insulin B-chain", "TREATMENT", 22, 41], ["central", "ANATOMY_MODIFIER", 4, 11], ["-helix", "ANATOMY_MODIFIER", 12, 18], ["insulin", "ANATOMY", 26, 33], ["stability", "OBSERVATION", 96, 105]]], ["Previous studies have investigated numerous amino acid changes with a particular emphasis on natural amino acids.", [["amino acid", "CHEMICAL", 44, 54], ["amino acids", "CHEMICAL", 101, 112], ["amino acid", "CHEMICAL", 44, 54], ["amino acids", "CHEMICAL", 101, 112], ["amino acid", "AMINO_ACID", 44, 54], ["amino acids", "AMINO_ACID", 101, 112], ["Previous studies", "TEST", 0, 16], ["numerous amino acid changes", "PROBLEM", 35, 62], ["natural amino acids", "TREATMENT", 93, 112], ["numerous", "OBSERVATION_MODIFIER", 35, 43], ["amino acid", "OBSERVATION", 44, 54]]], ["The reported results while informative are highly restrictive in the depth and breath of secondary structural change explored given the limited structural diversity of natural amino acids.", [["amino acids", "CHEMICAL", 176, 187], ["amino acids", "CHEMICAL", 176, 187], ["amino acids", "AMINO_ACID", 176, 187], ["secondary structural change", "PROBLEM", 89, 116], ["natural amino acids", "TREATMENT", 168, 187], ["restrictive", "OBSERVATION_MODIFIER", 50, 61]]], ["However, these analogs are easier to obtain since the vast majority can be prepared by rDNA methods where the native conformation is directed by biosynthesis of the native three disulfides.", [["disulfides", "CHEMICAL", 178, 188]]], ["We report here the synthesis and biological analysis of insulin analogs with select helix stabilizing elements such as substitution with an Aib residue, salt bridge insertion and backbone lactam cyclization.", [["lactam", "CHEMICAL", 188, 194], ["lactam", "CHEMICAL", 188, 194], ["insulin", "GENE_OR_GENE_PRODUCT", 56, 63], ["salt", "SIMPLE_CHEMICAL", 153, 157], ["backbone lactam", "SIMPLE_CHEMICAL", 179, 194], ["the synthesis", "TREATMENT", 15, 28], ["biological analysis", "TEST", 33, 52], ["insulin analogs", "TREATMENT", 56, 71], ["select helix stabilizing elements", "TREATMENT", 77, 110], ["substitution", "TREATMENT", 119, 131], ["an Aib residue", "TREATMENT", 137, 151], ["salt bridge insertion", "TREATMENT", 153, 174], ["backbone lactam cyclization", "TREATMENT", 179, 206], ["lactam cyclization", "OBSERVATION", 188, 206]]], ["L-Lysine or L-Ornithine was introduced at position B9 or B10 to facilitate salt bridge formation or lactam cyclization with the native GluB13 residue of insulin.", [["L-Lysine", "CHEMICAL", 0, 8], ["L-Ornithine", "CHEMICAL", 12, 23], ["lactam", "CHEMICAL", 100, 106], ["L-Lysine", "CHEMICAL", 0, 8], ["L-Ornithine", "CHEMICAL", 12, 23], ["lactam", "CHEMICAL", 100, 106], ["GluB13", "CHEMICAL", 135, 141], ["L-Lysine", "SIMPLE_CHEMICAL", 0, 8], ["L-Ornithine", "SIMPLE_CHEMICAL", 12, 23], ["salt bridge", "SIMPLE_CHEMICAL", 75, 86], ["lactam", "SIMPLE_CHEMICAL", 100, 106], ["GluB13", "SIMPLE_CHEMICAL", 135, 141], ["insulin", "GENE_OR_GENE_PRODUCT", 153, 160], ["insulin", "PROTEIN", 153, 160], ["L-Lysine", "TREATMENT", 0, 8], ["L-Ornithine", "TREATMENT", 12, 23], ["position B9", "TREATMENT", 42, 53], ["B10", "TREATMENT", 57, 60], ["salt bridge formation", "TREATMENT", 75, 96], ["lactam cyclization", "TREATMENT", 100, 118], ["the native GluB13 residue of insulin", "TREATMENT", 124, 160], ["Lysine", "OBSERVATION", 2, 8], ["L-Ornithine", "OBSERVATION", 12, 23], ["salt bridge", "OBSERVATION", 75, 86]]], ["The analogs were synthesized via a 1\u00fe2 chain combination procedure developed by Dr. Jie Han and reported elsewhere in this meeting.", [["The analogs", "TREATMENT", 0, 11], ["a 1\u00fe2 chain combination procedure", "TREATMENT", 33, 66]]], ["Sequence dependent, synthetic difficulties were encountered in the lactam cyclization step.", [["lactam", "CHEMICAL", 67, 73], ["lactam", "CHEMICAL", 67, 73], ["Sequence dependent", "PROBLEM", 0, 18], ["synthetic difficulties", "PROBLEM", 20, 42], ["the lactam cyclization step", "TREATMENT", 63, 90]]], ["Most of the insulin analogs demonstrated increased helical content.", [["insulin", "GENE_OR_GENE_PRODUCT", 12, 19], ["the insulin analogs", "TREATMENT", 8, 27], ["increased helical content", "PROBLEM", 41, 66], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["helical content", "OBSERVATION", 51, 66]]], ["Significant decreases in insulin receptor binding and in vitro biochemical signaling were observed for all analogs in this series.", [["insulin receptor", "GENE_OR_GENE_PRODUCT", 25, 41], ["insulin receptor", "PROTEIN", 25, 41], ["Significant decreases", "PROBLEM", 0, 21], ["insulin receptor binding", "TREATMENT", 25, 49], ["decreases", "OBSERVATION_MODIFIER", 12, 21], ["insulin receptor binding", "OBSERVATION", 25, 49]]], ["One of the conclusions from this set of analogs is that secondary structure alteration at the specific sites studied had a negative effect on bioactivity and appears to result from more than local alterations in conformation. in the quest to find a receptor superagonist.", [["analogs", "TREATMENT", 40, 47], ["secondary structure alteration", "PROBLEM", 56, 86], ["local alterations in conformation", "PROBLEM", 191, 224], ["a receptor superagonist", "TREATMENT", 247, 270], ["negative effect", "OBSERVATION_MODIFIER", 123, 138]]], ["The structural series included all three natural aromatic amino acid residues (phenylalanine, tryptophan and tyrosine) and leucine at positions 6, 10 and 13 for both peptides.", [["amino acid", "CHEMICAL", 58, 68], ["phenylalanine", "CHEMICAL", 79, 92], ["tryptophan", "CHEMICAL", 94, 104], ["tyrosine", "CHEMICAL", 109, 117], ["leucine", "CHEMICAL", 123, 130], ["amino acid", "CHEMICAL", 58, 68], ["phenylalanine", "CHEMICAL", 79, 92], ["tryptophan", "CHEMICAL", 94, 104], ["tyrosine", "CHEMICAL", 109, 117], ["leucine", "CHEMICAL", 123, 130], ["amino acid", "AMINO_ACID", 58, 68], ["phenylalanine", "AMINO_ACID", 79, 92], ["tryptophan", "AMINO_ACID", 94, 104], ["tyrosine", "AMINO_ACID", 109, 117], ["leucine", "AMINO_ACID", 123, 130], ["The structural series", "TEST", 0, 21], ["natural aromatic amino acid residues", "TREATMENT", 41, 77], ["phenylalanine, tryptophan and tyrosine)", "TREATMENT", 79, 118], ["leucine at positions", "TREATMENT", 123, 143], ["aromatic amino", "OBSERVATION", 49, 63], ["acid residues", "OBSERVATION", 64, 77]]], ["Our results illustrate that in contrast to calcitonin, glucagon and GLP-1 do not tolerate simultaneous replacement of all aromatic character with leucine in the N-terminal region.", [["calcitonin", "CHEMICAL", 43, 53], ["glucagon", "CHEMICAL", 55, 63], ["leucine", "CHEMICAL", 146, 153], ["leucine", "CHEMICAL", 146, 153], ["N", "CHEMICAL", 161, 162], ["calcitonin", "GENE_OR_GENE_PRODUCT", 43, 53], ["glucagon", "GENE_OR_GENE_PRODUCT", 55, 63], ["GLP-1", "GENE_OR_GENE_PRODUCT", 68, 73], ["leucine", "AMINO_ACID", 146, 153], ["N-terminal region", "PROTEIN", 161, 178], ["calcitonin", "TEST", 43, 53], ["glucagon", "TEST", 55, 63], ["GLP", "TEST", 68, 71], ["simultaneous replacement", "TREATMENT", 90, 114], ["replacement", "OBSERVATION", 103, 114], ["aromatic character", "OBSERVATION", 122, 140], ["terminal", "ANATOMY_MODIFIER", 163, 171], ["region", "ANATOMY_MODIFIER", 172, 178]]], ["Position 10 in each of the glucagon-based peptides was observed to be more permissive to substitution where observed bioactivity changes were more subtle relative to the native hormones.", [["glucagon", "CHEMICAL", 27, 35], ["glucagon", "GENE_OR_GENE_PRODUCT", 27, 35], ["the glucagon", "TREATMENT", 23, 35], ["observed bioactivity changes", "PROBLEM", 108, 136]]], ["These results warrant additional study to explain the clear difference in recognition of peptide ligands by the calcitonin and glucagon receptors, as well as additional investigation pertaining to the degree of structural change that can be tolerated at residue 10.", [["calcitonin", "CHEMICAL", 112, 122], ["glucagon", "CHEMICAL", 127, 135], ["calcitonin", "GENE_OR_GENE_PRODUCT", 112, 122], ["glucagon receptors", "GENE_OR_GENE_PRODUCT", 127, 145], ["calcitonin and glucagon receptors", "PROTEIN", 112, 145], ["additional study", "TEST", 22, 38], ["peptide ligands", "TREATMENT", 89, 104], ["the calcitonin and glucagon receptors", "TREATMENT", 108, 145], ["additional investigation", "TEST", 158, 182], ["structural change", "PROBLEM", 211, 228], ["structural change", "OBSERVATION", 211, 228]]], ["Glucagon and glucagon-like peptide-1 (GLP-1) are two highly homologous hormones involved in the maintenance of glucose homeostasis and of sizable importance to the clinical management of diabetes.", [["Glucagon", "CHEMICAL", 0, 8], ["glucose", "CHEMICAL", 111, 118], ["diabetes", "DISEASE", 187, 195], ["glucose", "CHEMICAL", 111, 118], ["Glucagon", "GENE_OR_GENE_PRODUCT", 0, 8], ["glucagon-like peptide-1", "GENE_OR_GENE_PRODUCT", 13, 36], ["GLP-1", "GENE_OR_GENE_PRODUCT", 38, 43], ["glucose", "SIMPLE_CHEMICAL", 111, 118], ["Glucagon", "TEST", 0, 8], ["glucagon", "TEST", 13, 21], ["peptide", "TEST", 27, 34], ["GLP", "TEST", 38, 41], ["two highly homologous hormones", "PROBLEM", 49, 79], ["glucose homeostasis", "TREATMENT", 111, 130], ["diabetes", "PROBLEM", 187, 195], ["glucose homeostasis", "OBSERVATION", 111, 130], ["sizable", "OBSERVATION_MODIFIER", 138, 145], ["diabetes", "OBSERVATION", 187, 195]]], ["These two peptides are highly specific in association with their native receptors through structural elements within different regions of their sequences that confer biological specificity.", [["native receptors", "PROTEIN", 65, 81]]], ["We explored the structureactivity relationship of these two hormones through the use of single residue substitutions and hybrid peptides.", [["single residue substitutions", "TREATMENT", 88, 116], ["hybrid peptides", "TREATMENT", 121, 136], ["residue substitutions", "OBSERVATION", 95, 116]]], ["We have identified a set of novel 29-residue peptides which exhibit high potency and balanced coagonism at the glucagon and GLP-1 receptors.", [["coagonism", "SIMPLE_CHEMICAL", 94, 103], ["glucagon", "SIMPLE_CHEMICAL", 111, 119], ["GLP-1 receptors", "GENE_OR_GENE_PRODUCT", 124, 139], ["glucagon and GLP-1 receptors", "PROTEIN", 111, 139], ["novel 29-residue peptides", "PROBLEM", 28, 53], ["high potency and balanced coagonism", "PROBLEM", 68, 103], ["high potency", "OBSERVATION_MODIFIER", 68, 80]]], ["Modifications to the glucagon C-terminal sequence resulted in a nearly complete loss of specificity, with minimal change to inherent activity.", [["glucagon", "CHEMICAL", 21, 29], ["C", "CHEMICAL", 30, 31], ["glucagon", "GENE_OR_GENE_PRODUCT", 21, 29], ["glucagon C-terminal sequence", "DNA", 21, 49], ["the glucagon C-terminal sequence", "TEST", 17, 49], ["a nearly complete loss of specificity", "PROBLEM", 62, 99], ["loss", "OBSERVATION", 80, 84], ["minimal", "OBSERVATION_MODIFIER", 106, 113], ["change", "OBSERVATION_MODIFIER", 114, 120], ["activity", "OBSERVATION_MODIFIER", 133, 141]]], ["Three modifications to native glucagon and addition of a C-terminal amide produced a peptide with a 100-fold increase in potency at the GLP-1 receptor and potency equivalent to glucagon.", [["glucagon", "CHEMICAL", 30, 38], ["C-terminal amide", "CHEMICAL", 57, 73], ["glucagon", "CHEMICAL", 177, 185], ["C", "CHEMICAL", 57, 58], ["amide", "CHEMICAL", 68, 73], ["glucagon", "GENE_OR_GENE_PRODUCT", 30, 38], ["C-terminal amide", "SIMPLE_CHEMICAL", 57, 73], ["GLP-1 receptor", "GENE_OR_GENE_PRODUCT", 136, 150], ["glucagon", "GENE_OR_GENE_PRODUCT", 177, 185], ["GLP-1 receptor", "PROTEIN", 136, 150], ["native glucagon", "TREATMENT", 23, 38], ["a C-terminal amide", "TREATMENT", 55, 73], ["a peptide", "TREATMENT", 83, 92], ["the GLP", "TEST", 132, 139], ["glucagon", "TREATMENT", 177, 185]]], ["The significant increase in potency at the GLP-1 receptor can be attributed to an increase in alpha helicity as well as enhanced positional interactions at the receptor.", [["GLP-1 receptor", "GENE_OR_GENE_PRODUCT", 43, 57], ["alpha helicity", "GENE_OR_GENE_PRODUCT", 94, 108], ["GLP-1 receptor", "PROTEIN", 43, 57], ["an increase in alpha helicity", "PROBLEM", 79, 108], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["potency", "OBSERVATION_MODIFIER", 28, 35], ["can be attributed to", "UNCERTAINTY", 58, 78], ["increase", "OBSERVATION_MODIFIER", 82, 90], ["alpha helicity", "OBSERVATION", 94, 108], ["positional interactions", "OBSERVATION", 129, 152]]], ["These high potency glucagon-based co-agonists represent a refined set of peptides that vary in selectivity within a dynamic range that spans a ten-fold preference for one or the other receptor while maintaining full potency at a one of the two receptors.", [["glucagon", "CHEMICAL", 19, 27], ["glucagon", "SIMPLE_CHEMICAL", 19, 27], ["a refined set of peptides", "PROBLEM", 56, 81]]], ["The analogs identified provide the basis for investigating through in vivo studies the relative efficacy and safety obtainable at each receptor for purposes of optimizing metabolism and body weight.P 083 SOLID PHASE SYNTHESIS OF LIPIDATED PEPTIDO-TRIAZOLES AS BISUBSTRATE INHIBITORS OF PRO-TEIN GERANYLGERANYLTRANSFERASE-IA.", [["body", "ANATOMY", 186, 190], ["body", "ORGANISM_SUBDIVISION", 186, 190], ["The analogs", "TREATMENT", 0, 11], ["body weight", "TEST", 186, 197], ["LIPIDATED PEPTIDO", "TREATMENT", 229, 246]]], ["Aditya, R.A. Gibbs School of Pharmacy, Purdue University, West Lafayette, IN Protein prenylation is an important post-translational modification that controls the subcellular localization and membrane trafficking of more than hundred human proteins, particularly G-proteins belonging to the Ras and Rho families.", [["subcellular", "ANATOMY", 163, 174], ["membrane", "ANATOMY", 192, 200], ["membrane", "CELLULAR_COMPONENT", 192, 200], ["human", "ORGANISM", 234, 239], ["G-proteins", "GENE_OR_GENE_PRODUCT", 263, 273], ["Ras", "GENE_OR_GENE_PRODUCT", 291, 294], ["Rho", "GENE_OR_GENE_PRODUCT", 299, 302], ["human proteins", "PROTEIN", 234, 248], ["G-proteins", "PROTEIN", 263, 273], ["Ras", "PROTEIN", 291, 294], ["Rho families", "PROTEIN", 299, 311], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 234, 239], ["Protein prenylation", "TREATMENT", 77, 96], ["-translational modification", "TREATMENT", 117, 144]]], ["Prenylation is executed by three protein prenyltransferases -Farnesyltransferase (FTase) and Geranylgeranyl-transferase-I & II (GGTase) that catalyze the transfer of a C 15 or C 20 isoprenoid to the cysteine thiol present close to the C-terminal of the protein.P 083 SOLID PHASE SYNTHESIS OF LIPIDATED PEPTIDO-TRIAZOLES AS BISUBSTRATE INHIBITORS OF PRO-TEIN GERANYLGERANYLTRANSFERASE-IFTase and GGTase-I have been established as effective targets for development of cancer therapeutics.", [["cancer", "ANATOMY", 466, 472], ["isoprenoid", "CHEMICAL", 181, 191], ["thiol", "CHEMICAL", 208, 213], ["cancer", "DISEASE", 466, 472], ["Geranylgeranyl", "CHEMICAL", 93, 107], ["C 15 or C 20 isoprenoid", "CHEMICAL", 168, 191], ["cysteine", "CHEMICAL", 199, 207], ["thiol", "CHEMICAL", 208, 213], ["C", "CHEMICAL", 235, 236], ["Farnesyltransferase", "GENE_OR_GENE_PRODUCT", 61, 80], ["FTase", "GENE_OR_GENE_PRODUCT", 82, 87], ["Geranylgeranyl-transferase-I & II", "GENE_OR_GENE_PRODUCT", 93, 126], ["GGTase", "GENE_OR_GENE_PRODUCT", 128, 134], ["C 15", "SIMPLE_CHEMICAL", 168, 172], ["C 20 isoprenoid", "SIMPLE_CHEMICAL", 176, 191], ["cysteine", "AMINO_ACID", 199, 207], ["thiol", "SIMPLE_CHEMICAL", 208, 213], ["GGTase-I", "GENE_OR_GENE_PRODUCT", 395, 403], ["cancer", "CANCER", 466, 472], ["protein prenyltransferases", "PROTEIN", 33, 59], ["Farnesyltransferase", "PROTEIN", 61, 80], ["FTase", "PROTEIN", 82, 87], ["Geranylgeranyl-transferase", "PROTEIN", 93, 119], ["I & II", "PROTEIN", 120, 126], ["GGTase", "PROTEIN", 128, 134], ["C-terminal", "PROTEIN", 235, 245], ["IFTase", "PROTEIN", 384, 390], ["GGTase-I", "DNA", 395, 403], ["Prenylation", "TREATMENT", 0, 11], ["three protein prenyltransferases", "TEST", 27, 59], ["Farnesyltransferase (FTase", "TREATMENT", 61, 87], ["Geranylgeranyl", "TEST", 93, 107], ["a C 15", "TREATMENT", 166, 172], ["the cysteine thiol", "TREATMENT", 195, 213], ["LIPIDATED PEPTIDO", "TREATMENT", 292, 309], ["PRO-TEIN GERANYLGERANYLTRANSFERASE", "TEST", 349, 383], ["cancer therapeutics", "TREATMENT", 466, 485], ["cancer", "OBSERVATION", 466, 472]]], ["These bisubstrate enzymes utilize their protein substrates (or peptides containing a C-terminal CaaXmotif) along with the respective isoprenoid pyrophosphates for their catalytic turnover.", [["C", "CHEMICAL", 85, 86], ["isoprenoid pyrophosphates", "CHEMICAL", 133, 158], ["isoprenoid pyrophosphates", "SIMPLE_CHEMICAL", 133, 158], ["bisubstrate enzymes", "PROTEIN", 6, 25], ["C-terminal CaaXmotif", "PROTEIN", 85, 105], ["These bisubstrate enzymes", "TEST", 0, 25], ["their protein substrates", "TREATMENT", 34, 58], ["a C-terminal CaaXmotif)", "TREATMENT", 83, 106], ["the respective isoprenoid pyrophosphates", "TREATMENT", 118, 158], ["isoprenoid pyrophosphates", "OBSERVATION", 133, 158]]], ["Our bisubstrate inhibitor design involves the conjunction of the peptide and the isoprenoid fragments by utilizing Cu-catalyzed H\u00fcisgen cycloaddition of isoprenoid alkynes with the N-terminal azide of the peptide moiety.", [["isoprenoid", "CHEMICAL", 81, 91], ["H\u00fcisgen", "CHEMICAL", 128, 135], ["isoprenoid alkynes", "CHEMICAL", 153, 171], ["N-terminal azide", "CHEMICAL", 181, 197], ["isoprenoid", "CHEMICAL", 81, 91], ["isoprenoid alkynes", "CHEMICAL", 153, 171], ["N", "CHEMICAL", 181, 182], ["azide", "CHEMICAL", 192, 197], ["H\u00fcisgen", "SIMPLE_CHEMICAL", 128, 135], ["isoprenoid alkynes", "SIMPLE_CHEMICAL", 153, 171], ["azide", "SIMPLE_CHEMICAL", 192, 197], ["Our bisubstrate inhibitor", "TREATMENT", 0, 25], ["the peptide", "TREATMENT", 61, 72], ["the isoprenoid fragments", "PROBLEM", 77, 101], ["Cu-catalyzed H\u00fcisgen cycloaddition of isoprenoid alkynes", "TREATMENT", 115, 171], ["the N-terminal azide of the peptide moiety", "TREATMENT", 177, 219], ["isoprenoid fragments", "OBSERVATION", 81, 101], ["isoprenoid alkynes", "OBSERVATION", 153, 171]]], ["These peptidotriazoles were assembled on chlorotrityl resin by sequential on-resin diazo transfer and click chemistry.", [["peptidotriazoles", "CHEMICAL", 6, 22], ["chlorotrityl resin", "CHEMICAL", 41, 59], ["peptidotriazoles", "CHEMICAL", 6, 22], ["chlorotrityl", "CHEMICAL", 41, 53], ["diazo", "CHEMICAL", 83, 88], ["peptidotriazoles", "SIMPLE_CHEMICAL", 6, 22], ["chlorotrityl resin", "SIMPLE_CHEMICAL", 41, 59], ["These peptidotriazoles", "TREATMENT", 0, 22], ["chlorotrityl resin", "TREATMENT", 41, 59], ["click chemistry", "TEST", 102, 117]]], ["The potency of these inhibitors was fine-tuned by systematically modifying the diversity elements such as the ''aaX'' motif, the linker length between the peptide and triazole, and length of the isoprenoid chain.", [["triazole", "CHEMICAL", 167, 175], ["isoprenoid", "CHEMICAL", 195, 205], ["triazole", "CHEMICAL", 167, 175], ["isoprenoid", "CHEMICAL", 195, 205], ["triazole", "SIMPLE_CHEMICAL", 167, 175], ["''aaX'' motif", "DNA", 110, 123], ["isoprenoid chain", "PROTEIN", 195, 211], ["these inhibitors", "TREATMENT", 15, 31], ["the diversity elements", "TREATMENT", 75, 97], ["the ''aaX'' motif", "TREATMENT", 106, 123], ["the linker length between the peptide and triazole", "TREATMENT", 125, 175], ["isoprenoid chain", "OBSERVATION", 195, 211]]], ["This approach has led to the discovery of potent and highly selective bisubstrate inhibitors of GGTase-I with IC 50 values ranging from 500 nM to 5 M.P 084 SYNTHESIS AND BIOLOGICAL EVALUATION OF CONSTRAINED V3-PEPTIDE ANTI HIV-1 IMMUNO-GENS CONJUGATED TO A T-CELL EPITOPES.", [["GGTase-I", "GENE_OR_GENE_PRODUCT", 96, 104], ["GGTase", "PROTEIN", 96, 102], ["SYNTHESIS", "TEST", 156, 165], ["BIOLOGICAL EVALUATION", "TEST", 170, 191], ["CONSTRAINED V3-PEPTIDE ANTI HIV", "TEST", 195, 226], ["A T-CELL EPITOPES", "PROBLEM", 255, 272]]], ["Tantry, 1 A. Moseri, 2 B. Arshava, 1 F. Naider 1 and J. Anglister 2 1 Department of Chemistry, College of Staten Island, CUNY, NY 10314, USA; 2 Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel Human immunodeficiency virus type 1 (HIV-1) is responsible for a pandemic which has infected $1% of the world's adult population.", [["Human immunodeficiency virus type 1 (HIV-1", "CHEMICAL", 225, 267], ["Israel", "ORGANISM", 218, 224], ["Human immunodeficiency virus type 1", "ORGANISM", 225, 260], ["HIV-1", "ORGANISM", 262, 267], ["Human immunodeficiency virus type 1", "SPECIES", 225, 260], ["HIV-1", "SPECIES", 262, 267], ["Human immunodeficiency virus type 1", "SPECIES", 225, 260], ["HIV-1", "SPECIES", 262, 267], ["a pandemic", "PROBLEM", 288, 298]]], ["Two envelope glycoproteins, gp41 and gp120 play critical roles in facilitating the entry of the retroviral genome into macrophages and Tcells.", [["macrophages", "ANATOMY", 119, 130], ["Tcells", "ANATOMY", 135, 141], ["gp41", "GENE_OR_GENE_PRODUCT", 28, 32], ["gp120", "GENE_OR_GENE_PRODUCT", 37, 42], ["retroviral", "ORGANISM", 96, 106], ["macrophages", "CELL", 119, 130], ["Tcells", "CELL", 135, 141], ["envelope glycoproteins", "PROTEIN", 4, 26], ["gp41", "PROTEIN", 28, 32], ["gp120", "PROTEIN", 37, 42], ["retroviral genome", "DNA", 96, 113], ["macrophages", "CELL_TYPE", 119, 130], ["Tcells", "CELL_TYPE", 135, 141], ["Two envelope glycoproteins", "TREATMENT", 0, 26], ["gp41 and gp120", "TREATMENT", 28, 42], ["glycoproteins", "OBSERVATION", 13, 26], ["retroviral genome", "OBSERVATION", 96, 113]]], ["The third variable loop V3 of gp120, consisting of $35 amino acids plays a critical role in the binding of gp120 to CXCR4 or CCR5 co-receptors and is a dominant antigenic determinant.", [["amino acids", "CHEMICAL", 55, 66], ["amino acids", "CHEMICAL", 55, 66], ["gp120", "GENE_OR_GENE_PRODUCT", 30, 35], ["amino acids", "AMINO_ACID", 55, 66], ["gp120", "GENE_OR_GENE_PRODUCT", 107, 112], ["CXCR4", "GENE_OR_GENE_PRODUCT", 116, 121], ["CCR5", "GENE_OR_GENE_PRODUCT", 125, 129], ["gp120", "PROTEIN", 30, 35], ["gp120", "PROTEIN", 107, 112], ["CXCR4", "PROTEIN", 116, 121], ["CCR5 co-receptors", "PROTEIN", 125, 142], ["The third variable loop V3 of gp120", "PROBLEM", 0, 35], ["$35 amino acids", "TREATMENT", 51, 66], ["CCR5 co-receptors", "TEST", 125, 142], ["loop V3", "OBSERVATION", 19, 26], ["dominant", "OBSERVATION_MODIFIER", 152, 160], ["antigenic", "OBSERVATION", 161, 170]]], ["Based on NMR structures of bound peptide antigens we designed and synthesized, three constrained V3-loop analogues conjugated to a T-Cell epitope.", [["V3", "PROTEIN", 97, 99], ["T-Cell epitope", "PROTEIN", 131, 145], ["NMR structures of bound peptide antigens", "TEST", 9, 49], ["V3-loop analogues", "TREATMENT", 97, 114], ["a T-Cell epitope", "TREATMENT", 129, 145]]], ["(P 1 ) KQIINMWQEVGKAMYA-RPNNNTRKSIHIGPGRAFYTTGEI, a conserved V3 loop T-cell epitope conjugate, (P 2 ) KQIINMWQEVGKA MYA-RPNNN-cyclo[CRKSIHIGPGRAFYTTGEC], a T?C and I?C mutant of P 1 and (P 3 ) KQIINMWQEVGKAMYA-RPNNNTR-cyclo [CSIHIGPGRAFYTC]GEI, a K?C and T?C mutant of P 1 .", [["V3 loop T-cell epitope conjugate", "PROTEIN", 62, 94], ["P 1", "PROTEIN", 179, 182], ["K?C", "PROTEIN", 248, 251], ["P 1", "PROTEIN", 270, 273], ["a conserved V3 loop T-cell epitope conjugate", "TREATMENT", 50, 94], ["a T?C", "TEST", 155, 160], ["KQIINMWQEVGKAMYA-RPNNNTR", "TEST", 194, 218], ["a K?C", "TEST", 246, 251]]], ["Cystine replacement enabled cyclization through disulfide bonds and stabilized the conserved V 3 -loop region of the gp120 in a -hairpin like structure.", [["Cystine", "CHEMICAL", 0, 7], ["Cystine", "CHEMICAL", 0, 7], ["disulfide", "CHEMICAL", 48, 57], ["Cystine", "SIMPLE_CHEMICAL", 0, 7], ["disulfide bonds", "SIMPLE_CHEMICAL", 48, 63], ["gp120", "GENE_OR_GENE_PRODUCT", 117, 122], ["V 3 -loop region", "PROTEIN", 93, 109], ["gp120", "PROTEIN", 117, 122], ["-hairpin like structure", "PROTEIN", 128, 151], ["Cystine replacement", "TREATMENT", 0, 19], ["cyclization through disulfide bonds", "TREATMENT", 28, 63], ["replacement", "OBSERVATION", 8, 19], ["loop", "ANATOMY_MODIFIER", 98, 102], ["region", "ANATOMY_MODIFIER", 103, 109], ["gp120", "ANATOMY_MODIFIER", 117, 122]]], ["These 41-residue peptides were synthesized using standard solid phase Fmoc-chemistry on an Applied biosystems 433A peptide synthesizer.", [["an Applied biosystems 433A peptide synthesizer", "TREATMENT", 88, 134]]], ["Cyclization of the HPLC-purified linear peptide was performed using a glutathione (GSSG/GSH) oxidation of the linear peptide.", [["glutathione", "CHEMICAL", 70, 81], ["GSSG", "CHEMICAL", 83, 87], ["GSH", "CHEMICAL", 88, 91], ["glutathione", "CHEMICAL", 70, 81], ["GSSG", "CHEMICAL", 83, 87], ["GSH", "CHEMICAL", 88, 91], ["glutathione", "SIMPLE_CHEMICAL", 70, 81], ["GSSG", "SIMPLE_CHEMICAL", 83, 87], ["GSH", "SIMPLE_CHEMICAL", 88, 91], ["the HPLC", "TEST", 15, 23], ["a glutathione (GSSG/GSH) oxidation", "TREATMENT", 68, 102], ["the linear peptide", "TREATMENT", 106, 124]]], ["Final peptides were recovered in >95% homogeneity with the expected molecular weights.", [["Final peptides", "TEST", 0, 14]]], ["Constrained V3 peptides analogous to P2 and P3 exhibited strong binding to 447-52D, a broadly neutralizing human anti-HIV-1 antibody, and the P2 and P3 immunogens elicited stronger immune responses than P1.", [["447-52D", "CHEMICAL", 75, 82], ["447-52D", "SIMPLE_CHEMICAL", 75, 82], ["human", "ORGANISM", 107, 112], ["anti-HIV-1 antibody", "GENE_OR_GENE_PRODUCT", 113, 132], ["P2", "DNA", 37, 39], ["P3", "DNA", 44, 46], ["human anti-HIV-1 antibody", "PROTEIN", 107, 132], ["human", "SPECIES", 107, 112], ["human anti-HIV-1", "SPECIES", 107, 123], ["P2", "TEST", 37, 39], ["strong binding", "PROBLEM", 57, 71], ["a broadly neutralizing human anti-HIV", "TEST", 84, 121], ["the P2 and P3 immunogens", "TEST", 138, 162]]], ["In addition the P2 elicited antibody response was more effective in neutralizing HIV-1 primary isolates.", [["HIV-1", "ORGANISM", 81, 86], ["P2", "DNA", 16, 18], ["HIV-1", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 81, 86], ["the P2 elicited antibody response", "TEST", 12, 45], ["neutralizing HIV", "PROBLEM", 68, 84], ["antibody response", "OBSERVATION", 28, 45]]], ["These results indicate that constrained V3 peptides will be a useful component of an anti-HIV-1 vaccine.", [["anti-HIV-1", "ORGANISM", 85, 95], ["anti-HIV-1", "SPECIES", 85, 95], ["constrained V3 peptides", "PROBLEM", 28, 51], ["an anti-HIV-1 vaccine", "TREATMENT", 82, 103]]], ["The membrane proximal external region (MPER) of the HIV surface glycoprotein gp41 is the binding site for several broadly neutralizing antibodies.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["membrane proximal external region", "PROTEIN", 4, 37], ["MPER", "PROTEIN", 39, 43], ["HIV surface glycoprotein gp41", "PROTEIN", 52, 81], ["neutralizing antibodies", "PROTEIN", 122, 145], ["HIV", "SPECIES", 52, 55], ["the HIV surface glycoprotein gp41", "TREATMENT", 48, 81], ["the binding site", "PROBLEM", 85, 101], ["several broadly neutralizing antibodies", "PROBLEM", 106, 145], ["membrane", "ANATOMY_MODIFIER", 4, 12], ["proximal", "ANATOMY_MODIFIER", 13, 21], ["external", "ANATOMY_MODIFIER", 22, 30], ["region", "ANATOMY_MODIFIER", 31, 37], ["neutralizing antibodies", "OBSERVATION", 122, 145]]], ["Antigens derived from this region have the potential to be an important components of a vaccine directed against HIV-1.1 Peptide epitopes for these antibodies are highly conserved but sterically obscured from the immune system by an intimate association with the viral membrane and by the presence of a large trimeric glycoprotein spike.", [["immune system", "ANATOMY", 213, 226], ["membrane", "ANATOMY", 269, 277], ["HIV-1.1", "ORGANISM", 113, 120], ["immune system", "ANATOMICAL_SYSTEM", 213, 226], ["membrane", "CELLULAR_COMPONENT", 269, 277], ["antibodies", "PROTEIN", 148, 158], ["trimeric glycoprotein spike", "PROTEIN", 309, 336], ["HIV", "SPECIES", 113, 116], ["HIV", "SPECIES", 113, 116], ["a vaccine", "TREATMENT", 86, 95], ["HIV", "TEST", 113, 116], ["Peptide epitopes", "TREATMENT", 121, 137], ["these antibodies", "TEST", 142, 158], ["the viral membrane", "TREATMENT", 259, 277], ["a large trimeric glycoprotein spike", "PROBLEM", 301, 336], ["viral membrane", "OBSERVATION", 263, 277], ["large", "OBSERVATION_MODIFIER", 303, 308], ["trimeric glycoprotein spike", "OBSERVATION", 309, 336]]], ["In order to better mimic the structural features of the MPER domain with an eye towards better understanding of epitope-antibody interactions near membranes, peptide mimics derived from HIV gp41 have been synthesized with a variety of structural changes affecting characteristics such as helicity, orientation, and positioning of the epitope with respect to the membrane.", [["eye", "ANATOMY", 76, 79], ["membranes", "ANATOMY", 147, 156], ["membrane", "ANATOMY", 362, 370], ["eye", "ORGAN", 76, 79], ["membranes", "CELLULAR_COMPONENT", 147, 156], ["HIV gp41", "ORGANISM", 186, 194], ["membrane", "CELLULAR_COMPONENT", 362, 370], ["MPER domain", "PROTEIN", 56, 67], ["epitope", "PROTEIN", 112, 119], ["HIV gp41", "PROTEIN", 186, 194], ["epitope", "PROTEIN", 334, 341], ["HIV", "SPECIES", 186, 189], ["HIV", "SPECIES", 186, 189], ["epitope-antibody interactions near membranes", "PROBLEM", 112, 156], ["HIV gp41", "PROBLEM", 186, 194], ["eye", "ANATOMY", 76, 79]]], ["These peptide mimics have been incorporated into membrane bilayer mimics called ''Nanodiscs''.", [["membrane bilayer", "ANATOMY", 49, 65], ["membrane bilayer", "CELLULAR_COMPONENT", 49, 65]]], ["These Nanodiscs are $10 nm-diameter structures composed of a phospholipid bilayer ringed by an apolipoprotein-derived scaffold protein.", [["Nanodiscs", "CANCER", 6, 15], ["phospholipid bilayer", "SIMPLE_CHEMICAL", 61, 81], ["apolipoprotein-derived scaffold protein", "PROTEIN", 95, 134], ["a phospholipid bilayer ringed", "TREATMENT", 59, 88], ["an apolipoprotein-derived scaffold protein", "TREATMENT", 92, 134]]], ["2 We have examined the affinity of HIV-1 neutralizing antibodies to these membrane-bound peptides to better understand the binding of these neutralizing antibodies to epitopes on or near a membrane.", [["membrane", "ANATOMY", 74, 82], ["membrane", "ANATOMY", 189, 197], ["HIV-1", "ORGANISM", 35, 40], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["membrane", "CELLULAR_COMPONENT", 189, 197], ["HIV-1 neutralizing antibodies", "PROTEIN", 35, 64], ["neutralizing antibodies", "PROTEIN", 140, 163], ["epitopes", "PROTEIN", 167, 175], ["HIV-1", "SPECIES", 35, 40], ["HIV-1", "SPECIES", 35, 40], ["HIV-1 neutralizing antibodies", "TREATMENT", 35, 64], ["these neutralizing antibodies", "TREATMENT", 134, 163]]], ["These constructs will enable both immunization studies to give insight into the affects of membrane proximity on immune response as well as the design of simple peptides that are capable of self-assembly into stable Nanodiscs.", [["membrane", "ANATOMY", 91, 99], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["Nanodiscs", "CANCER", 216, 225], ["Nanodiscs", "PROTEIN", 216, 225], ["both immunization studies", "TEST", 29, 54], ["simple peptides", "TREATMENT", 154, 169]]], ["The assessment of the receptor binding affinity of analogues of INSL3 typically requires the use of 125I-labelled INSL3 which has a number of disadvantages including its short half-life, high cost, the need to be prepared prior to use, and radioactivity safety issues.", [["INSL3", "GENE_OR_GENE_PRODUCT", 64, 69], ["INSL3", "GENE_OR_GENE_PRODUCT", 114, 119], ["INSL3", "PROTEIN", 64, 69], ["INSL3", "PROTEIN", 114, 119], ["The assessment", "TEST", 0, 14], ["analogues of INSL3", "PROBLEM", 51, 69], ["125I-labelled INSL3", "TREATMENT", 100, 119]]], ["To overcome these problems, we have developed a fluorescent-lanthanide receptor binding assay.", [["lanthanide", "CHEMICAL", 60, 70], ["these problems", "PROBLEM", 12, 26], ["a fluorescent-lanthanide receptor binding assay", "TREATMENT", 46, 93]]], ["Initially, INSL3 was labelled post-synthesis with a europium chelate at free amino groups.", [["europium chelate", "CHEMICAL", 52, 68], ["amino", "CHEMICAL", 77, 82], ["europium", "CHEMICAL", 52, 60], ["amino", "CHEMICAL", 77, 82], ["INSL3", "GENE_OR_GENE_PRODUCT", 11, 16], ["europium chelate", "SIMPLE_CHEMICAL", 52, 68], ["free amino groups", "SIMPLE_CHEMICAL", 72, 89], ["INSL3", "PROTEIN", 11, 16], ["a europium chelate at free amino groups", "TREATMENT", 50, 89]]], ["This method of labelling gave a mixture of mono-and multi-labelled peptide which was difficult to purify.", [["a mixture of mono", "TREATMENT", 30, 47], ["multi-labelled peptide", "TREATMENT", 52, 74]]], ["Consequently we have developed an efficient solid phase synthesis technique to prepare specifically mono-labelled peptide using DTPA chelate.", [["DTPA chelate", "CHEMICAL", 128, 140], ["DTPA", "CHEMICAL", 128, 132], ["DTPA chelate", "SIMPLE_CHEMICAL", 128, 140], ["an efficient solid phase synthesis technique", "TREATMENT", 31, 75], ["DTPA chelate", "TREATMENT", 128, 140], ["efficient", "OBSERVATION_MODIFIER", 34, 43], ["solid phase", "OBSERVATION", 44, 55]]], ["Eu-DTPA-labelled INSL3 had receptor binding affinity (9.05 6 0.03, n=3) similar to 125I-labelled INSL3 (9.59 6 0.09, n=3).", [["Eu-DTPA", "CHEMICAL", 0, 7], ["Eu-DTPA", "CHEMICAL", 0, 7], ["Eu-DTPA", "SIMPLE_CHEMICAL", 0, 7], ["INSL3", "GENE_OR_GENE_PRODUCT", 17, 22], ["INSL3", "GENE_OR_GENE_PRODUCT", 97, 102], ["Eu-DTPA", "PROTEIN", 0, 7], ["INSL3", "PROTEIN", 17, 22], ["INSL3", "PROTEIN", 97, 102], ["Eu-DTPA", "TEST", 0, 7], ["receptor binding affinity", "TEST", 27, 52], ["INSL3", "TEST", 97, 102]]], ["The receptor binding affinity (pKi) of INSL3 was determined to be 9.27 6 0.06, n=3 using Eu-DTPA-INSL3 as a labelled ligand, which again is similar to that obtained when 125I-INSL3 was used as labelled ligand (9.34 6 0.02, n=4).", [["INSL3", "GENE_OR_GENE_PRODUCT", 39, 44], ["Eu-DTPA-INSL3", "GENE_OR_GENE_PRODUCT", 89, 102], ["125I-INSL3", "GENE_OR_GENE_PRODUCT", 170, 180], ["INSL3", "PROTEIN", 39, 44], ["Eu-DTPA", "PROTEIN", 89, 96], ["INSL3", "PROTEIN", 97, 102], ["INSL3", "PROTEIN", 175, 180], ["INSL3", "TEST", 39, 44], ["Eu-DTPA", "TEST", 89, 96], ["labelled ligand", "TEST", 193, 208]]], ["The lanthanide-based binding assay has a very low background and is highly reproducible.Leipzig UniversityAlzheimer's disease (AD) is characterized by two major hallmarks, the intracellular aggregation of hyperphosphorylated protein into paired helical filaments (PHF-) and the extra cellular deposition of A-peptides.", [["intracellular", "ANATOMY", 176, 189], ["cellular", "ANATOMY", 284, 292], ["lanthanide", "CHEMICAL", 4, 14], ["UniversityAlzheimer's disease", "DISEASE", 96, 125], ["AD", "DISEASE", 127, 129], ["lanthanide", "CHEMICAL", 4, 14], ["lanthanide", "SIMPLE_CHEMICAL", 4, 14], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 176, 189], ["hyperphosphorylated protein into paired helical filaments", "GENE_OR_GENE_PRODUCT", 205, 262], ["cellular", "CELL", 284, 292], ["A-peptides", "GENE_OR_GENE_PRODUCT", 307, 317], ["hyperphosphorylated protein", "PROTEIN", 205, 232], ["paired helical filaments", "PROTEIN", 238, 262], ["PHF", "PROTEIN", 264, 267], ["A-peptides", "PROTEIN", 307, 317], ["The lanthanide-based binding assay", "TEST", 0, 34], ["a very low background", "PROBLEM", 39, 60], ["Leipzig UniversityAlzheimer's disease", "PROBLEM", 88, 125], ["the intracellular aggregation of hyperphosphorylated protein into paired helical filaments (PHF", "PROBLEM", 172, 267], ["the extra cellular deposition of A-peptides", "PROBLEM", 274, 317], ["reproducible", "OBSERVATION_MODIFIER", 75, 87], ["helical filaments", "OBSERVATION_MODIFIER", 245, 262], ["extra", "OBSERVATION_MODIFIER", 278, 283], ["cellular deposition", "OBSERVATION", 284, 303]]], ["Several lines of evidence suggest that the analysis of A, totaland especially phospho-might be favorable for early and specific AD diagnosis.", [["AD", "DISEASE", 128, 130], ["phospho", "CHEMICAL", 78, 85], ["A", "GENE_OR_GENE_PRODUCT", 55, 56], ["totaland", "GENE_OR_GENE_PRODUCT", 58, 66], ["phospho", "GENE_OR_GENE_PRODUCT", 78, 85], ["phospho", "PROTEIN", 78, 85], ["the analysis", "TEST", 39, 51], ["phospho", "TEST", 78, 85], ["lines", "OBSERVATION", 8, 13]]], ["To establish a sensitive, AD-specific Immuno-PCR (polymerase chain reaction) based Sandwich-ELISA, the peptides 207-219[p212/p214] and 226-240[p231/p235] containing two PHF--specific phosphoepitopes were used for immunization.", [["p212", "GENE_OR_GENE_PRODUCT", 120, 124], ["p214", "GENE_OR_GENE_PRODUCT", 125, 129], ["226-240", "GENE_OR_GENE_PRODUCT", 135, 142], ["p231", "GENE_OR_GENE_PRODUCT", 143, 147], ["p235", "GENE_OR_GENE_PRODUCT", 148, 152], ["PHF", "GENE_OR_GENE_PRODUCT", 169, 172], ["PHF", "PROTEIN", 169, 172], ["polymerase chain reaction", "TEST", 50, 75], ["the peptides", "TEST", 99, 111], ["two PHF", "PROBLEM", 165, 172], ["specific phosphoepitopes", "TREATMENT", 174, 198], ["immunization", "TREATMENT", 213, 225]]], ["The obtained monoclonal antibodies (mAb) HPT-1 and HPT-101/HPT-103 were specific for the doubly phosphorylated epitopes p212/p214 and p231/p235 respectively.", [["HPT-101", "SIMPLE_CHEMICAL", 51, 58], ["HPT-103", "CELL", 59, 66], ["p212/p214", "GENE_OR_GENE_PRODUCT", 120, 129], ["p231/p235", "GENE_OR_GENE_PRODUCT", 134, 143], ["monoclonal antibodies", "PROTEIN", 13, 34], ["mAb", "PROTEIN", 36, 39], ["doubly phosphorylated epitopes", "PROTEIN", 89, 119], ["p212/p214", "PROTEIN", 120, 129], ["p231/p235", "PROTEIN", 134, 143], ["The obtained monoclonal antibodies", "TEST", 0, 34], ["mAb", "TEST", 36, 39], ["HPT", "TEST", 41, 44], ["HPT", "TEST", 51, 54], ["HPT", "TEST", 59, 62], ["the doubly phosphorylated epitopes", "TEST", 85, 119]]], ["HPT-104 and HPT-110 were specific for monophosphorylated Thr231 or Ser235.", [["HPT-104", "CHEMICAL", 0, 7], ["HPT-110", "CHEMICAL", 12, 19], ["Thr", "CHEMICAL", 57, 60], ["Ser235", "CHEMICAL", 67, 73], ["HPT-110", "SIMPLE_CHEMICAL", 12, 19], ["Thr231", "AMINO_ACID", 57, 63], ["Ser235", "AMINO_ACID", 67, 73], ["HPT", "TEST", 0, 3], ["HPT", "TEST", 12, 15], ["monophosphorylated Thr", "TEST", 38, 60]]], ["The PHF--specificity of the mAbs was confirmed by ELISA, immunoblotting and histochemical analysis of brain tissue from AD patients.", [["brain tissue", "ANATOMY", 102, 114], ["AD", "DISEASE", 120, 122], ["PHF", "SIMPLE_CHEMICAL", 4, 7], ["mAbs", "GENE_OR_GENE_PRODUCT", 28, 32], ["brain tissue", "TISSUE", 102, 114], ["patients", "ORGANISM", 123, 131], ["PHF", "PROTEIN", 4, 7], ["mAbs", "PROTEIN", 28, 32], ["patients", "SPECIES", 123, 131], ["The PHF", "PROBLEM", 0, 7], ["the mAbs", "TEST", 24, 32], ["ELISA", "TEST", 50, 55], ["immunoblotting", "TEST", 57, 71], ["histochemical analysis", "TEST", 76, 98], ["brain tissue", "PROBLEM", 102, 114], ["brain", "ANATOMY", 102, 107]]], ["Thus, PHF-specific mAbs HTP-1 and HPT-101 were combined in a Sandwich-ELISA to detect phospho-in CSF at the low pg/mL range.", [["HPT-101", "CHEMICAL", 34, 41], ["PHF", "SIMPLE_CHEMICAL", 6, 9], ["HTP-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["HPT-101", "SIMPLE_CHEMICAL", 34, 41], ["phospho-in CSF", "GENE_OR_GENE_PRODUCT", 86, 100], ["PHF", "PROTEIN", 6, 9], ["phospho-in CSF", "PROTEIN", 86, 100], ["PHF", "TEST", 6, 9], ["specific mAbs HTP", "TEST", 10, 27], ["HPT", "TEST", 34, 37], ["a Sandwich-ELISA", "TEST", 59, 75], ["phospho-in CSF", "TEST", 86, 100]]], ["After digoxigenin labeling of the detector mAb and assay optimization a detection limit of 2 pg/mL PHF--in buffer and spiked in CSF from healthy individuals was achieved.", [["digoxigenin", "SIMPLE_CHEMICAL", 6, 17], ["PHF", "SIMPLE_CHEMICAL", 99, 102], ["CSF", "ORGANISM_SUBSTANCE", 128, 131], ["detector mAb", "PROTEIN", 34, 46], ["CSF", "PROTEIN", 128, 131], ["the detector mAb", "TREATMENT", 30, 46], ["PHF", "PROBLEM", 99, 102], ["buffer", "TREATMENT", 107, 113]]], ["In combination with mAbs specific for p231 and unphosphorylated-protein, a quantification of the fourfold phosphoepitope p212/p214/p231/p235, the single phosphorylation at Thr231 and total-in post mortem CSF samples was accomplished.University of ArizonaLanthanide-based luminescent ligand binding assays are superior to traditional radiolabel assays due to improved sensitivity and affordability in high throughput screening while eliminating the use of radioactivity.", [["CSF samples", "ANATOMY", 204, 215], ["ArizonaLanthanide", "CHEMICAL", 247, 264], ["p231", "GENE_OR_GENE_PRODUCT", 38, 42], ["p212", "GENE_OR_GENE_PRODUCT", 121, 125], ["p214", "GENE_OR_GENE_PRODUCT", 126, 130], ["p231/p235", "GENE_OR_GENE_PRODUCT", 131, 140], ["Thr231", "GENE_OR_GENE_PRODUCT", 172, 178], ["ArizonaLanthanide", "SIMPLE_CHEMICAL", 247, 264], ["mAbs", "PROTEIN", 20, 24], ["p231", "PROTEIN", 38, 42], ["unphosphorylated-protein", "PROTEIN", 47, 71], ["p212", "PROTEIN", 121, 125], ["p214", "PROTEIN", 126, 130], ["p231/p235", "PROTEIN", 131, 140], ["Thr231", "PROTEIN", 172, 178], ["the fourfold phosphoepitope", "TEST", 93, 120], ["the single phosphorylation", "TEST", 142, 168], ["post mortem CSF samples", "TEST", 192, 215], ["ArizonaLanthanide", "TREATMENT", 247, 264], ["luminescent ligand binding assays", "TEST", 271, 304], ["traditional radiolabel assays", "TEST", 321, 350], ["improved sensitivity", "PROBLEM", 358, 378]]], ["Accordingly, dissociation enhanced lanthanide fluoroimmunoassay (DELFIA) technology is rapidly emerging as a bioanalytical tool using Eu(III)-coordinated chelators such as DTPA (diethylenetriaminepentaacetic acid).", [["lanthanide", "CHEMICAL", 35, 45], ["Eu", "CHEMICAL", 134, 136], ["DTPA", "CHEMICAL", 172, 176], ["diethylenetriaminepentaacetic acid", "CHEMICAL", 178, 212], ["lanthanide", "CHEMICAL", 35, 45], ["Eu(III)", "CHEMICAL", 134, 141], ["DTPA", "CHEMICAL", 172, 176], ["diethylenetriaminepentaacetic acid", "CHEMICAL", 178, 212], ["lanthanide fluoroimmunoassay", "SIMPLE_CHEMICAL", 35, 63], ["Eu(III)", "SIMPLE_CHEMICAL", 134, 141], ["chelators", "SIMPLE_CHEMICAL", 154, 163], ["DTPA", "SIMPLE_CHEMICAL", 172, 176], ["diethylenetriaminepentaacetic acid", "SIMPLE_CHEMICAL", 178, 212], ["dissociation enhanced lanthanide fluoroimmunoassay", "TREATMENT", 13, 63], ["Eu(III)", "TREATMENT", 134, 141], ["coordinated chelators", "TREATMENT", 142, 163], ["DTPA (diethylenetriaminepentaacetic acid)", "TREATMENT", 172, 213]]], ["However, DELFIA has not been successfully used with more stable chelators such as DOTA (1,4,7,10-tetraaza-1,4,7 ,10-tetrakis(carboxymethyl)-cyclododecane) due to the incomplete release of Eu(III).", [["DELFIA", "CHEMICAL", 9, 15], ["DOTA", "CHEMICAL", 82, 86], ["1,4,7,10-tetraaza-1,4,7 ,10-tetrakis(carboxymethyl)-cyclododecane", "CHEMICAL", 88, 153], ["Eu", "CHEMICAL", 188, 190], ["DELFIA", "CHEMICAL", 9, 15], ["DOTA", "CHEMICAL", 82, 86], ["1,4,7,10-tetraaza-1,4,7 ,10-tetrakis(carboxymethyl)-cyclododecane", "CHEMICAL", 88, 153], ["Eu(III)", "CHEMICAL", 188, 195], ["DELFIA", "SIMPLE_CHEMICAL", 9, 15], ["chelators", "SIMPLE_CHEMICAL", 64, 73], ["DOTA (1,4,7,10-tetraaza-1,4,7 ,10-tetrakis(carboxymethyl)-cyclododecane", "SIMPLE_CHEMICAL", 82, 153], ["Eu(III", "SIMPLE_CHEMICAL", 188, 194], ["DELFIA", "PROBLEM", 9, 15], ["DOTA", "TEST", 82, 86], ["tetraaza", "TREATMENT", 97, 105], ["tetrakis(carboxymethyl)", "TREATMENT", 116, 139], ["cyclododecane", "TREATMENT", 140, 153]]], ["Here we report a modified and optimized DELFIA procedure for the use of Eu(III)-DOTA labeled peptides to study the ligand-receptor interactions.", [["Eu(III)-DOTA", "CHEMICAL", 72, 84], ["Eu(III)", "CHEMICAL", 72, 79], ["DOTA", "CHEMICAL", 80, 84], ["Eu(III)-DOTA", "SIMPLE_CHEMICAL", 72, 84], ["a modified and optimized DELFIA procedure", "TREATMENT", 15, 56], ["Eu(III)", "TREATMENT", 72, 79]]], ["NDP-a-MSH (melanocyte stimulating hormone) ligand labeled with Eu(III)-DOTA was synthesized and the binding affinity of this peptide to cells overexpressing human melanocortin-4 receptors was evaluated using an acid treatment protocol.", [["cells", "ANATOMY", 136, 141], ["Eu(III)-DOTA", "CHEMICAL", 63, 75], ["Eu(III)", "CHEMICAL", 63, 70], ["DOTA", "CHEMICAL", 71, 75], ["NDP-a-MSH", "GENE_OR_GENE_PRODUCT", 0, 9], ["melanocyte stimulating hormone", "GENE_OR_GENE_PRODUCT", 11, 41], ["Eu(III)-DOTA", "SIMPLE_CHEMICAL", 63, 75], ["cells", "CELL", 136, 141], ["human", "ORGANISM", 157, 162], ["melanocortin-4 receptors", "GENE_OR_GENE_PRODUCT", 163, 187], ["NDP", "PROTEIN", 0, 3], ["human melanocortin-4 receptors", "PROTEIN", 157, 187], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["NDP", "TEST", 0, 3], ["a-MSH (melanocyte stimulating hormone", "TEST", 4, 41], ["DOTA", "TREATMENT", 71, 75], ["the binding affinity", "PROBLEM", 96, 116], ["this peptide to cells overexpressing human melanocortin", "TREATMENT", 120, 175], ["an acid treatment protocol", "TREATMENT", 208, 234]]], ["Complete release of Eu(III) from the DOTA chelate was observed using HCl acid (2M) prior to the luminescent enhancement step.", [["Eu", "CHEMICAL", 20, 22], ["DOTA chelate", "CHEMICAL", 37, 49], ["HCl acid", "CHEMICAL", 69, 77], ["Eu(III)", "CHEMICAL", 20, 27], ["DOTA", "CHEMICAL", 37, 41], ["HCl acid", "CHEMICAL", 69, 77], ["Eu(III)", "SIMPLE_CHEMICAL", 20, 27], ["DOTA chelate", "SIMPLE_CHEMICAL", 37, 49], ["HCl acid", "SIMPLE_CHEMICAL", 69, 77], ["the DOTA chelate", "TREATMENT", 33, 49], ["HCl acid (2M", "TREATMENT", 69, 81], ["the luminescent enhancement step", "TREATMENT", 92, 124]]], ["Saturation binding data indicate that the Eu(III)-DOTA linked peptide binds to these cells with an affinity similar to its DTPA analogue.", [["cells", "ANATOMY", 85, 90], ["Eu", "CHEMICAL", 42, 44], ["DOTA", "CHEMICAL", 50, 54], ["DTPA", "CHEMICAL", 123, 127], ["Eu(III)", "CHEMICAL", 42, 49], ["DOTA", "CHEMICAL", 50, 54], ["DTPA", "CHEMICAL", 123, 127], ["Eu(III)-DOTA", "SIMPLE_CHEMICAL", 42, 54], ["cells", "CELL", 85, 90], ["DTPA", "SIMPLE_CHEMICAL", 123, 127], ["Saturation binding data", "TEST", 0, 23], ["an affinity", "PROBLEM", 96, 107]]], ["Modified DELFIA procedure will be used to monitor the binding of heterobivalent peptides to the cells expressing both MSH and CCK (Cholecystokinin) receptors.", [["cells", "ANATOMY", 96, 101], ["cells", "CELL", 96, 101], ["MSH", "GENE_OR_GENE_PRODUCT", 118, 121], ["CCK (Cholecystokinin) receptors", "GENE_OR_GENE_PRODUCT", 126, 157], ["MSH and CCK (Cholecystokinin) receptors", "PROTEIN", 118, 157], ["Modified DELFIA procedure", "TREATMENT", 0, 25], ["heterobivalent peptides", "TREATMENT", 65, 88]]], ["Peptide-based radioligands have become an important tool in the diagnosis and treatment of malignant tumors.", [["malignant tumors", "ANATOMY", 91, 107], ["malignant tumors", "DISEASE", 91, 107], ["malignant tumors", "CANCER", 91, 107], ["Peptide-based radioligands", "PROBLEM", 0, 26], ["malignant tumors", "PROBLEM", 91, 107], ["malignant", "OBSERVATION_MODIFIER", 91, 100], ["tumors", "OBSERVATION", 101, 107]]], ["Many types of tumors overexpress G-protein coupled receptors for regulatory peptides making them an excellent target for cancer diagnosis and therapy.", [["tumors", "ANATOMY", 14, 20], ["cancer", "ANATOMY", 121, 127], ["tumors", "DISEASE", 14, 20], ["cancer", "DISEASE", 121, 127], ["tumors", "CANCER", 14, 20], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 33, 60], ["cancer", "CANCER", 121, 127], ["G-protein coupled receptors", "PROTEIN", 33, 60], ["tumors overexpress G-protein coupled receptors", "TREATMENT", 14, 60], ["regulatory peptides", "TREATMENT", 65, 84], ["therapy", "TREATMENT", 142, 149], ["tumors", "OBSERVATION", 14, 20]]], ["Vasoactive intestinal peptide (VIP) is a 28 amino acid neuropeptide with high affinity for VPAC1 and VPAC2 receptors.", [["amino acid", "CHEMICAL", 44, 54], ["amino acid", "CHEMICAL", 44, 54], ["Vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 0, 29], ["VIP", "GENE_OR_GENE_PRODUCT", 31, 34], ["VPAC1", "GENE_OR_GENE_PRODUCT", 91, 96], ["VPAC2 receptors", "GENE_OR_GENE_PRODUCT", 101, 116], ["VPAC1", "PROTEIN", 91, 96], ["VPAC2 receptors", "PROTEIN", 101, 116], ["Vasoactive intestinal peptide", "TREATMENT", 0, 29], ["a 28 amino acid neuropeptide", "TREATMENT", 39, 67], ["VPAC1 and VPAC2 receptors", "TREATMENT", 91, 116], ["intestinal", "ANATOMY", 11, 21]]], ["VIP has potential as a radiopeptide imaging agent because several of the most frequently occurring human tumors, including breast, ovarian, prostate, bladder, pancreatic, colonic, and esophageal carcinoma, have been found to express VIP receptors.", [["tumors", "ANATOMY", 105, 111], ["breast", "ANATOMY", 123, 129], ["ovarian", "ANATOMY", 131, 138], ["prostate", "ANATOMY", 140, 148], ["bladder", "ANATOMY", 150, 157], ["pancreatic", "ANATOMY", 159, 169], ["colonic", "ANATOMY", 171, 178], ["esophageal carcinoma", "ANATOMY", 184, 204], ["tumors", "DISEASE", 105, 111], ["breast, ovarian, prostate, bladder, pancreatic, colonic, and esophageal carcinoma", "DISEASE", 123, 204], ["VIP", "GENE_OR_GENE_PRODUCT", 0, 3], ["human", "ORGANISM", 99, 104], ["tumors", "CANCER", 105, 111], ["breast", "CANCER", 123, 129], ["ovarian", "CANCER", 131, 138], ["prostate", "CANCER", 140, 148], ["bladder", "CANCER", 150, 157], ["pancreatic", "CANCER", 159, 169], ["colonic", "CANCER", 171, 178], ["esophageal carcinoma", "CANCER", 184, 204], ["VIP receptors", "GENE_OR_GENE_PRODUCT", 233, 246], ["VIP receptors", "PROTEIN", 233, 246], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["a radiopeptide imaging agent", "TREATMENT", 21, 49], ["human tumors", "PROBLEM", 99, 111], ["breast, ovarian, prostate, bladder", "PROBLEM", 123, 157], ["pancreatic, colonic, and esophageal carcinoma", "PROBLEM", 159, 204], ["tumors", "OBSERVATION", 105, 111], ["breast", "ANATOMY", 123, 129], ["ovarian", "ANATOMY", 131, 138], ["prostate", "ANATOMY", 140, 148], ["bladder", "ANATOMY", 150, 157], ["pancreatic", "ANATOMY", 159, 169], ["colonic", "ANATOMY", 171, 178], ["esophageal", "ANATOMY", 184, 194], ["carcinoma", "OBSERVATION", 195, 204]]], ["For use as an imaging agent, a radionuclide chelator needs to be incorporated into the peptide sequence to stably complex the radiometal ion.", [["chelator", "SIMPLE_CHEMICAL", 44, 52], ["an imaging agent", "TEST", 11, 27], ["a radionuclide chelator", "TREATMENT", 29, 52], ["the peptide sequence", "TEST", 83, 103]]], ["DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) is often used for this purpose as it is able to form stable complexes with trivalent metal ions in biological systems.", [["DOTA", "CHEMICAL", 0, 4], ["1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid", "CHEMICAL", 6, 62], ["DOTA", "CHEMICAL", 0, 4], ["1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid", "CHEMICAL", 6, 62], ["DOTA", "SIMPLE_CHEMICAL", 0, 4], ["1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid", "SIMPLE_CHEMICAL", 6, 62], ["trivalent metal ions", "SIMPLE_CHEMICAL", 139, 159], ["DOTA", "TEST", 0, 4], ["tetraazacyclododecane", "TREATMENT", 15, 36], ["tetraacetic acid)", "TREATMENT", 46, 63], ["trivalent metal ions", "TREATMENT", 139, 159]]], ["However, the key residues for receptor affinity and biological activity of VIP are distributed throughout the entire 28-amino acid peptide sequence.", [["amino acid", "CHEMICAL", 120, 130], ["amino acid", "CHEMICAL", 120, 130], ["VIP", "GENE_OR_GENE_PRODUCT", 75, 78], ["amino acid", "AMINO_ACID", 120, 130], ["VIP", "PROTEIN", 75, 78], ["28-amino acid peptide sequence", "PROTEIN", 117, 147], ["receptor affinity", "PROBLEM", 30, 47]]], ["Because of this, DOTA will need to be conjugated to the peptide in a position where it will not interfere with either receptor binding or activity.", [["DOTA", "CHEMICAL", 17, 21], ["DOTA", "CHEMICAL", 17, 21], ["DOTA", "SIMPLE_CHEMICAL", 17, 21], ["DOTA", "TREATMENT", 17, 21]]], ["In this study, we have conjugated DOTA to multiple positions within the VIP sequence to determine the optimal placement of the metal chelator to preserve receptor binding affinity.", [["DOTA", "CHEMICAL", 34, 38], ["DOTA", "CHEMICAL", 34, 38], ["DOTA", "SIMPLE_CHEMICAL", 34, 38], ["metal chelator", "SIMPLE_CHEMICAL", 127, 141], ["VIP sequence", "DNA", 72, 84], ["this study", "TEST", 3, 13], ["conjugated DOTA", "TREATMENT", 23, 38], ["the VIP sequence", "TEST", 68, 84], ["the metal chelator", "TREATMENT", 123, 141], ["receptor binding affinity", "TREATMENT", 154, 179]]], ["We have also studied the effect of DOTA conjugation on peptide stability and stimulation of cAMP generation as compared to VIP.University of British ColumbiaThe bicyclic octapeptide -amanitin is a potent inhibitor of eukaryotic transcription.", [["DOTA", "CHEMICAL", 35, 39], ["cAMP", "CHEMICAL", 92, 96], ["-amanitin", "CHEMICAL", 182, 191], ["DOTA", "CHEMICAL", 35, 39], ["cAMP", "CHEMICAL", 92, 96], ["-amanitin", "CHEMICAL", 182, 191], ["DOTA", "SIMPLE_CHEMICAL", 35, 39], ["cAMP", "SIMPLE_CHEMICAL", 92, 96], ["VIP", "GENE_OR_GENE_PRODUCT", 123, 126], ["bicyclic octapeptide -amanitin", "SIMPLE_CHEMICAL", 161, 191], ["DOTA conjugation", "TREATMENT", 35, 51], ["peptide stability", "TREATMENT", 55, 72], ["cAMP generation", "TREATMENT", 92, 107], ["The bicyclic octapeptide -amanitin", "TREATMENT", 157, 191], ["a potent inhibitor", "TREATMENT", 195, 213], ["eukaryotic transcription", "TREATMENT", 217, 241], ["British Columbia", "OBSERVATION", 141, 157]]], ["It binds tightly to RNA Pol II (KD$10-9) with high selectivity over other polymerases.", [["Pol II", "GENE_OR_GENE_PRODUCT", 24, 30], ["RNA Pol II", "PROTEIN", 20, 30], ["high selectivity", "OBSERVATION_MODIFIER", 46, 62]]], ["This exceptional binding occurs at the bridge-helix site of the polymerase.", [["bridge-helix site", "PROTEIN", 39, 56], ["polymerase", "PROTEIN", 64, 74], ["This exceptional binding", "PROBLEM", 0, 24]]], ["We have chosen to use this octapeptide scaffold to create a series of probes that could be used to aid in the elucidation of various transcriptionally related processes.", [["this octapeptide scaffold", "TREATMENT", 22, 47], ["a series of probes", "TREATMENT", 58, 76], ["various transcriptionally related processes", "PROBLEM", 125, 168]]], ["Specifically, we prepared fluorescent and photo-activatible probes that provide the ability to visualize peptide localization as well as enable control of transcription in a spatio-temporal manner.", [["photo-activatible probes", "TREATMENT", 42, 66], ["peptide localization", "TEST", 105, 125]]], ["Unfortunately, poor cellular uptake (as demonstrated by fluorescent microscopy) rendered these probes unsuitable to transcription studies.", [["cellular", "ANATOMY", 20, 28], ["cellular", "CELL", 20, 28], ["poor cellular uptake", "PROBLEM", 15, 35], ["fluorescent microscopy", "TEST", 56, 78], ["these probes", "TEST", 89, 101], ["transcription studies", "TEST", 116, 137], ["poor", "OBSERVATION_MODIFIER", 15, 19], ["cellular uptake", "OBSERVATION", 20, 35]]], ["It was hypothesized that our mutation of (1S, 2R, 3R) .,d-dihydroxyisoleucine for isoleucine directly led to this poor uptake.", [["d-dihydroxyisoleucine", "CHEMICAL", 56, 77], ["isoleucine", "CHEMICAL", 82, 92], ["d-dihydroxyisoleucine", "CHEMICAL", 56, 77], ["isoleucine", "CHEMICAL", 82, 92], ["(1S, 2R, 3R", "SIMPLE_CHEMICAL", 41, 52], ["d-dihydroxyisoleucine", "SIMPLE_CHEMICAL", 56, 77], ["isoleucine", "AMINO_ACID", 82, 92], ["d-dihydroxyisoleucine", "TREATMENT", 56, 77], ["isoleucine directly", "PROBLEM", 82, 101], ["this poor uptake", "PROBLEM", 109, 125]]], ["Following the stereoselective synthesis of this monomer, we prepared a small library of our amanitin probes varying the identity at this amino acid, and studied its effects on cellular penetration.", [["cellular", "ANATOMY", 176, 184], ["amanitin", "CHEMICAL", 92, 100], ["amino acid", "CHEMICAL", 137, 147], ["amanitin", "CHEMICAL", 92, 100], ["amino acid", "CHEMICAL", 137, 147], ["amanitin", "SIMPLE_CHEMICAL", 92, 100], ["amino acid", "AMINO_ACID", 137, 147], ["cellular", "CELL", 176, 184], ["the stereoselective synthesis", "TREATMENT", 10, 39], ["our amanitin probes", "TREATMENT", 88, 107], ["this amino acid", "TREATMENT", 132, 147], ["cellular penetration", "PROBLEM", 176, 196], ["cellular penetration", "OBSERVATION", 176, 196]]], ["The results of the synthesis of these probes, as well as their cellular uptake will be discussed here.P 091 SPECIFIC TARGETING OF CELLS BY HETEROMUL-TIVALENT LIGANDS & ITS IMPLICATIONS IN CANCERJ.", [["cellular", "ANATOMY", 63, 71], ["cellular", "CELL", 63, 71], ["these probes", "TEST", 32, 44], ["TIVALENT LIGANDS", "OBSERVATION", 149, 165]]], ["Josan, L. Xu, J. Vagner, R. Gillies, V. Hruby Bio5 Institute, University of Arizona Current cancer therapies exploit either differential metabolism or overexpression of specific individual gene products in aberrant cells.", [["cancer", "ANATOMY", 92, 98], ["cells", "ANATOMY", 215, 220], ["cancer", "DISEASE", 92, 98], ["cancer", "CANCER", 92, 98], ["cells", "CELL", 215, 220], ["aberrant cells", "CELL_TYPE", 206, 220], ["Arizona Current cancer therapies", "TREATMENT", 76, 108], ["differential metabolism", "PROBLEM", 124, 147], ["aberrant cells", "PROBLEM", 206, 220], ["cancer", "OBSERVATION", 92, 98], ["aberrant cells", "OBSERVATION", 206, 220]]], ["We propose an alternative approach -to specifically target combinations of cellsurface receptors using heteromultivalent ligands (htMVLs).", [["cellsurface receptors", "GENE_OR_GENE_PRODUCT", 75, 96], ["cellsurface receptors", "PROTEIN", 75, 96], ["heteromultivalent ligands", "PROTEIN", 103, 128], ["htMVLs", "PROTEIN", 130, 136], ["an alternative approach", "TREATMENT", 11, 34], ["cellsurface receptors", "TREATMENT", 75, 96], ["heteromultivalent ligands", "TREATMENT", 103, 128]]], ["For proofof-concept, heterobivalent ligands (htBVLs) were constructed with binding motifs as melanocortin peptide ligand combined with either a cholecystokinin peptide ligand or the delta-opioid specific ligand.", [["heterobivalent ligands", "SIMPLE_CHEMICAL", 21, 43], ["htBVLs", "SIMPLE_CHEMICAL", 45, 51], ["cholecystokinin", "GENE_OR_GENE_PRODUCT", 144, 159], ["heterobivalent ligands", "PROTEIN", 21, 43], ["htBVLs", "PROTEIN", 45, 51], ["proofof", "TREATMENT", 4, 11], ["binding motifs", "TREATMENT", 75, 89], ["melanocortin peptide ligand", "TREATMENT", 93, 120], ["a cholecystokinin peptide ligand", "TREATMENT", 142, 174]]], ["The two ligands were tethered with linkers of varying rigidity and length and constructed from natural and/or synthetic building blocks.", [["rigidity", "DISEASE", 54, 62], ["varying rigidity and length", "PROBLEM", 46, 73], ["natural and/or synthetic building blocks", "TREATMENT", 95, 135], ["varying", "OBSERVATION_MODIFIER", 46, 53], ["rigidity", "OBSERVATION_MODIFIER", 54, 62]]], ["Using lanthanide based competitive binding assay, the htBVLs were found to bind with higher affinity (apparent cooperativity) to their cognate receptors compared to their monovalent binding, in cell lines transiently co-expressing hMC4R/CCK-2R and hMC4R/OR receptors.", [["cell lines", "ANATOMY", 194, 204], ["lanthanide", "CHEMICAL", 6, 16], ["lanthanide", "CHEMICAL", 6, 16], ["htBVLs", "SIMPLE_CHEMICAL", 54, 60], ["cell lines", "CELL", 194, 204], ["hMC4R", "GENE_OR_GENE_PRODUCT", 231, 236], ["CCK-2R", "GENE_OR_GENE_PRODUCT", 237, 243], ["hMC4R/OR receptors", "GENE_OR_GENE_PRODUCT", 248, 266], ["htBVLs", "PROTEIN", 54, 60], ["cognate receptors", "PROTEIN", 135, 152], ["cell lines", "CELL_LINE", 194, 204], ["hMC4R", "PROTEIN", 231, 236], ["CCK-2R and hMC4R/OR receptors", "PROTEIN", 237, 266], ["lanthanide", "TREATMENT", 6, 16], ["CCK", "TEST", 237, 240], ["cell lines", "OBSERVATION", 194, 204]]], ["There is up to a 80-fold decrease in IC 50 for CCK-6 ligand in hMC4R/CCK-2R system and up to a 50-fold decrease for MSH-7 ligand hMC4R/OR system in the bivalent binding mode.", [["CCK-6", "GENE_OR_GENE_PRODUCT", 47, 52], ["hMC4R", "CELL", 63, 68], ["CCK-2R", "GENE_OR_GENE_PRODUCT", 69, 75], ["MSH-7", "GENE_OR_GENE_PRODUCT", 116, 121], ["hMC4R", "GENE_OR_GENE_PRODUCT", 129, 134], ["CCK-6 ligand", "PROTEIN", 47, 59], ["CCK", "PROTEIN", 69, 72], ["MSH", "PROTEIN", 116, 119], ["hMC4R", "PROTEIN", 129, 134], ["IC", "TEST", 37, 39], ["CCK", "TEST", 47, 50], ["hMC4R", "TEST", 63, 68], ["CCK", "TEST", 69, 72], ["MSH", "TEST", 116, 119], ["ligand hMC4R", "TEST", 122, 134]]], ["Cell-surface labeling demonstrated the high avidity and specificity of heteromultivalent targeting and validity of the receptor combination approach.", [["Cell", "ANATOMY", 0, 4], ["surface", "ANATOMY", 5, 12], ["Cell", "CELL", 0, 4], ["Cell-surface labeling", "TEST", 0, 21], ["the high avidity", "PROBLEM", 35, 51], ["the receptor combination approach", "TREATMENT", 115, 148], ["high avidity", "OBSERVATION", 39, 51]]], ["This approach to non-covalently crosslink heterologous receptors and target individual cells opens up new possibilities for specific targeting in vivo for theragnostic purposes.P 091 SPECIFIC TARGETING OF CELLS BY HETEROMUL-TIVALENT LIGANDS & ITS IMPLICATIONS IN CANCERSupported by grants from the U.S. Public Health Service, NCI P 092 ENGINEERING HETEROCHIRAL PEPTIDES J. Kulp, T. Clark Naval Research Laboratory Heterochiral peptides promise new routes to important compounds for use in sensors, smart materials, and catalysts.", [["cells", "ANATOMY", 87, 92], ["cells", "CELL", 87, 92], ["non-covalently crosslink heterologous receptors", "PROTEIN", 17, 64], ["target individual cells", "CELL_TYPE", 69, 92], ["non-covalently crosslink heterologous receptors", "TREATMENT", 17, 64], ["target individual cells", "PROBLEM", 69, 92], ["theragnostic purposes", "TEST", 155, 176], ["Heterochiral peptides", "TREATMENT", 414, 435]]], ["These peptides, which contain amino acids with periodic alternating chirality, exist in Nature: gramicidin, polytheonamide, and feglymycin.", [["amino acids", "CHEMICAL", 30, 41], ["gramicidin", "CHEMICAL", 96, 106], ["polytheonamide", "CHEMICAL", 108, 122], ["feglymycin", "CHEMICAL", 128, 138], ["amino acids", "CHEMICAL", 30, 41], ["polytheonamide", "CHEMICAL", 108, 122], ["feglymycin", "CHEMICAL", 128, 138], ["amino acids", "AMINO_ACID", 30, 41], ["gramicidin", "SIMPLE_CHEMICAL", 96, 106], ["polytheonamide", "SIMPLE_CHEMICAL", 108, 122], ["feglymycin", "SIMPLE_CHEMICAL", 128, 138], ["These peptides", "TEST", 0, 14], ["amino acids", "TREATMENT", 30, 41], ["periodic alternating chirality", "PROBLEM", 47, 77], ["gramicidin", "TREATMENT", 96, 106], ["polytheonamide", "TREATMENT", 108, 122], ["feglymycin", "TREATMENT", 128, 138], ["amino acids", "OBSERVATION", 30, 41], ["alternating chirality", "OBSERVATION_MODIFIER", 56, 77]]], ["These few peptides all reside in membrane environments, so are heterochiral peptides limited to hydrophobic conditions for proper folding?", [["membrane", "ANATOMY", 33, 41], ["membrane", "CELLULAR_COMPONENT", 33, 41], ["heterochiral peptides", "PROBLEM", 63, 84], ["hydrophobic conditions", "PROBLEM", 96, 118], ["few", "OBSERVATION_MODIFIER", 6, 9], ["peptides", "OBSERVATION", 10, 18], ["membrane environments", "OBSERVATION", 33, 54]]], ["When compared to peptides containing all alpha-amino acids, heterochiral peptides differ not only in structural space-these peptides fold into single-and doublestranded helices stabilized by beta-sheet-type hydrogen bonding-but also differ in stabilizing mechanisms.", [["alpha-amino acids", "CHEMICAL", 41, 58], ["alpha-amino acids", "CHEMICAL", 41, 58], ["hydrogen", "CHEMICAL", 207, 215], ["alpha-amino acids", "SIMPLE_CHEMICAL", 41, 58], ["all alpha-amino acids", "TREATMENT", 37, 58], ["heterochiral peptides", "PROBLEM", 60, 81], ["single-and doublestranded helices", "TREATMENT", 143, 176], ["type hydrogen bonding", "PROBLEM", 202, 223], ["alpha-amino acids", "OBSERVATION", 41, 58]]], ["For instance, the alternating updown configuration of the amide carbonyl groups along the backbone results in a smaller, or absent, macrodipole; all L-peptide helices have an overall dipole moment.", [["amide carbonyl", "CHEMICAL", 58, 72], ["amide carbonyl", "CHEMICAL", 58, 72], ["amide carbonyl", "SIMPLE_CHEMICAL", 58, 72], ["L-peptide helices", "PROTEIN", 149, 166], ["the amide carbonyl groups", "TREATMENT", 54, 79], ["a smaller, or absent, macrodipole", "PROBLEM", 110, 143], ["all L-peptide helices", "TREATMENT", 145, 166], ["smaller", "OBSERVATION_MODIFIER", 112, 119], ["overall", "OBSERVATION_MODIFIER", 175, 182], ["dipole moment", "OBSERVATION", 183, 196]]], ["This talk will communicate general synthetic and structural principles for heterochiral peptides by presenting the design, synthesis, and biophysical characterization of a set of hydrophobic-and hydrophilic-heterochiral peptides.University of MichiganThe serine protease thrombin is the main clotting enzyme in the hemostatic system, in addition to being an effective platelet activator.", [["platelet", "ANATOMY", 368, 376], ["serine", "CHEMICAL", 255, 261], ["thrombin", "GENE_OR_GENE_PRODUCT", 271, 279], ["platelet", "CELL", 368, 376], ["serine protease", "PROTEIN", 255, 270], ["thrombin", "PROTEIN", 271, 279], ["clotting enzyme", "PROTEIN", 292, 307], ["platelet activator", "PROTEIN", 368, 386], ["heterochiral peptides", "PROBLEM", 75, 96], ["biophysical characterization", "TEST", 138, 166], ["hydrophilic-heterochiral peptides", "TREATMENT", 195, 228], ["The serine protease thrombin", "TREATMENT", 251, 279], ["an effective platelet activator", "TREATMENT", 355, 386], ["heterochiral peptides", "OBSERVATION", 207, 228], ["hemostatic system", "ANATOMY", 315, 332], ["effective platelet activator", "OBSERVATION", 358, 386]]], ["Thrombin has two substrates that are G-protein coupled receptors, protease-activated receptors 1 and 4 (PAR1 and PAR4).", [["Thrombin", "GENE_OR_GENE_PRODUCT", 0, 8], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 37, 64], ["protease-activated receptors 1", "GENE_OR_GENE_PRODUCT", 66, 96], ["4", "GENE_OR_GENE_PRODUCT", 101, 102], ["PAR1", "GENE_OR_GENE_PRODUCT", 104, 108], ["PAR4", "GENE_OR_GENE_PRODUCT", 113, 117], ["Thrombin", "PROTEIN", 0, 8], ["G-protein coupled receptors", "PROTEIN", 37, 64], ["protease-activated receptors 1 and 4", "PROTEIN", 66, 102], ["PAR1", "PROTEIN", 104, 108], ["PAR4", "PROTEIN", 113, 117], ["Thrombin", "TREATMENT", 0, 8], ["two substrates", "TREATMENT", 13, 27], ["G-protein coupled receptors", "TREATMENT", 37, 64], ["protease-activated receptors", "TREATMENT", 66, 94], ["PAR4", "TEST", 113, 117]]], ["The PARs carry their own cryptic ligand, and thrombin cleaves a fragment of the N-terminus to reveal this ligand, as the neo-Nterminus, which then binds intramolecularly to activate platelet aggregation.", [["platelet", "ANATOMY", 182, 190], ["platelet aggregation", "DISEASE", 182, 202], ["N", "CHEMICAL", 80, 81], ["PARs", "GENE_OR_GENE_PRODUCT", 4, 8], ["thrombin", "GENE_OR_GENE_PRODUCT", 45, 53], ["neo-Nterminus", "SIMPLE_CHEMICAL", 121, 134], ["platelet", "CELL", 182, 190], ["PARs", "PROTEIN", 4, 8], ["cryptic ligand", "PROTEIN", 25, 39], ["thrombin", "PROTEIN", 45, 53], ["N-terminus", "PROTEIN", 80, 90], ["neo-Nterminus", "PROTEIN", 121, 134], ["thrombin", "TREATMENT", 45, 53], ["platelet aggregation", "PROBLEM", 182, 202], ["cryptic ligand", "OBSERVATION", 25, 39], ["fragment", "OBSERVATION_MODIFIER", 64, 72], ["platelet aggregation", "OBSERVATION", 182, 202]]], ["Thus, the development of a direct thrombin inhibitor offers an approach for the treatment of myocardial infarctions and other acute coronary syndromes through a two-prong modulation of the hemostatic system: blocking thrombus formation by inhibiting both clotting and platelet aggregation.", [["myocardial", "ANATOMY", 93, 103], ["coronary", "ANATOMY", 132, 140], ["thrombus", "ANATOMY", 217, 225], ["platelet", "ANATOMY", 268, 276], ["myocardial infarctions", "DISEASE", 93, 115], ["acute coronary syndromes", "DISEASE", 126, 150], ["thrombus", "DISEASE", 217, 225], ["platelet aggregation", "DISEASE", 268, 288], ["thrombin", "GENE_OR_GENE_PRODUCT", 34, 42], ["myocardial", "MULTI-TISSUE_STRUCTURE", 93, 103], ["thrombus", "PATHOLOGICAL_FORMATION", 217, 225], ["platelet", "CELL", 268, 276], ["thrombin", "PROTEIN", 34, 42], ["a direct thrombin inhibitor", "TREATMENT", 25, 52], ["an approach", "TREATMENT", 60, 71], ["myocardial infarctions", "PROBLEM", 93, 115], ["other acute coronary syndromes", "PROBLEM", 120, 150], ["a two-prong modulation", "TREATMENT", 159, 181], ["the hemostatic system", "TREATMENT", 185, 206], ["blocking thrombus formation", "PROBLEM", 208, 235], ["both clotting", "PROBLEM", 250, 263], ["platelet aggregation", "PROBLEM", 268, 288], ["myocardial", "ANATOMY", 93, 103], ["infarctions", "OBSERVATION", 104, 115], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["coronary", "ANATOMY", 132, 140], ["syndromes", "OBSERVATION", 141, 150], ["thrombus", "OBSERVATION", 217, 225], ["both", "OBSERVATION_MODIFIER", 250, 254], ["clotting", "OBSERVATION", 255, 263], ["platelet aggregation", "OBSERVATION", 268, 288]]], ["Previous studies have shown that the pentapeptide Arg-Pro-Pro-Gly-Phe, a bradykinin breakdown product, inhibits the function of thrombin by interacting with its active site in a retro-binding fashion, as well as binding to PAR1 to prevent cleavage by thrombin.", [["Arg-", "CHEMICAL", 50, 54], ["Pro-", "CHEMICAL", 58, 62], ["Gly-Phe", "CHEMICAL", 62, 69], ["bradykinin", "CHEMICAL", 73, 83], ["Gly-Phe", "CHEMICAL", 62, 69], ["bradykinin", "CHEMICAL", 73, 83], ["Arg-Pro-Pro-Gly-Phe", "SIMPLE_CHEMICAL", 50, 69], ["bradykinin", "SIMPLE_CHEMICAL", 73, 83], ["thrombin", "GENE_OR_GENE_PRODUCT", 128, 136], ["PAR1", "GENE_OR_GENE_PRODUCT", 223, 227], ["thrombin", "GENE_OR_GENE_PRODUCT", 251, 259], ["thrombin", "PROTEIN", 128, 136], ["PAR1", "PROTEIN", 223, 227], ["thrombin", "PROTEIN", 251, 259], ["Previous studies", "TEST", 0, 16], ["the pentapeptide Arg-", "TEST", 33, 54], ["Pro-Gly", "TEST", 58, 65], ["a bradykinin breakdown product", "PROBLEM", 71, 101], ["thrombin", "TREATMENT", 128, 136], ["PAR1", "TREATMENT", 223, 227], ["thrombin", "PROBLEM", 251, 259], ["bradykinin breakdown", "OBSERVATION", 73, 93], ["thrombin", "OBSERVATION", 251, 259]]], ["Structure-activity studies led to the development of a lead compound, FM 19, with the sequence D-Arg-Octahydroindole-2-carboxylic acid-Pro-D-Ala-Phe(p-Me)-NH2.", [["D-Arg-Octahydroindole-2-carboxylic acid-Pro-D-Ala-Phe", "CHEMICAL", 95, 148], ["p-Me", "CHEMICAL", 149, 153], ["D-Arg-Octahydroindole-2-carboxylic acid-Pro-D-Ala-Phe", "CHEMICAL", 95, 148], ["p-Me)-NH2", "CHEMICAL", 149, 158], ["FM 19", "SIMPLE_CHEMICAL", 70, 75], ["D-Arg-Octahydroindole-2-carboxylic acid-Pro-D-Ala-Phe(p-Me)-NH2", "SIMPLE_CHEMICAL", 95, 158], ["NH2", "PROTEIN", 155, 158], ["a lead compound", "PROBLEM", 53, 68], ["FM", "TEST", 70, 72], ["the sequence D", "TEST", 82, 96], ["Arg", "TEST", 97, 100], ["Octahydroindole", "TEST", 101, 116], ["carboxylic acid-Pro", "TEST", 119, 138]]], ["The recently determined x-ray structure of FM 19 in the active site of thrombin has revealed potential modifications to improve binding, resulting in two analogs, BG 5 and BG 6, which each show an over 30- Structural studies of integral membrane proteins (IMPs) are often hampered by difficulties in crystallizing them in a lipid-like environment.", [["membrane", "ANATOMY", 237, 245], ["FM 19", "GENE_OR_GENE_PRODUCT", 43, 48], ["thrombin", "GENE_OR_GENE_PRODUCT", 71, 79], ["integral membrane proteins", "GENE_OR_GENE_PRODUCT", 228, 254], ["IMPs", "CELLULAR_COMPONENT", 256, 260], ["lipid", "SIMPLE_CHEMICAL", 324, 329], ["FM 19", "PROTEIN", 43, 48], ["thrombin", "PROTEIN", 71, 79], ["integral membrane proteins", "PROTEIN", 228, 254], ["IMPs", "PROTEIN", 256, 260], ["x-ray structure of FM", "TEST", 24, 45], ["thrombin", "PROBLEM", 71, 79], ["potential modifications", "PROBLEM", 93, 116], ["BG", "TEST", 163, 165], ["BG", "TEST", 172, 174], ["thrombin", "OBSERVATION", 71, 79], ["membrane proteins", "OBSERVATION", 237, 254]]], ["Alternatively, NMR has been applied and most detailed results have been so far obtained from the analysis of fragments containing one or two TM domains.", [["TM domains", "PROTEIN", 141, 151], ["NMR", "TEST", 15, 18], ["the analysis", "TEST", 93, 105], ["fragments", "OBSERVATION", 109, 118]]], ["In this study, the structure and dynamic properties of an 80-residue fragment of Ste2p, the G protein-coupled receptor for the -mating factor of S. cerevisiae, was studied in lyso-palmitoylphosphatidylglycerol (LPPG) micelles and trifluoroethanol:water using solution NMR.", [["lyso-palmitoylphosphatidylglycerol", "CHEMICAL", 175, 209], ["LPPG", "CHEMICAL", 211, 215], ["trifluoroethanol", "CHEMICAL", 230, 246], ["lyso-palmitoylphosphatidylglycerol", "CHEMICAL", 175, 209], ["LPPG", "CHEMICAL", 211, 215], ["trifluoroethanol", "CHEMICAL", 230, 246], ["Ste2p", "GENE_OR_GENE_PRODUCT", 81, 86], ["G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 92, 118], ["S. cerevisiae", "ORGANISM", 145, 158], ["lyso-palmitoylphosphatidylglycerol", "SIMPLE_CHEMICAL", 175, 209], ["LPPG) micelles", "SIMPLE_CHEMICAL", 211, 225], ["trifluoroethanol:water", "SIMPLE_CHEMICAL", 230, 252], ["80-residue fragment", "PROTEIN", 58, 77], ["Ste2p", "PROTEIN", 81, 86], ["G protein-coupled receptor", "PROTEIN", 92, 118], ["-mating factor", "PROTEIN", 127, 141], ["S. cerevisiae", "SPECIES", 145, 158], ["S. cerevisiae", "SPECIES", 145, 158], ["this study", "TEST", 3, 13], ["Ste2p", "TEST", 81, 86], ["the G protein-coupled receptor", "TREATMENT", 88, 118], ["lyso-palmitoylphosphatidylglycerol (LPPG) micelles", "TREATMENT", 175, 225]]], ["The fragment, Ste2p (G31-T110; TM1-TM2), consisted of 19 residues from the N-terminal domain, the first transmembrane helix (TM1), the first cytoplasmic loop, the second transmembrane helix (TM2) and 7 residues from the first extracellular loop.", [["cytoplasmic", "ANATOMY", 141, 152], ["extracellular loop", "ANATOMY", 226, 244], ["N", "CHEMICAL", 75, 76], ["cytoplasmic", "ORGANISM_SUBSTANCE", 141, 152], ["extracellular loop", "CELLULAR_COMPONENT", 226, 244], ["Ste2p", "PROTEIN", 14, 19], ["G31", "PROTEIN", 21, 24], ["T110", "PROTEIN", 25, 29], ["TM1", "PROTEIN", 31, 34], ["TM2", "PROTEIN", 35, 38], ["N-terminal domain", "PROTEIN", 75, 92], ["transmembrane helix", "PROTEIN", 104, 123], ["TM1", "PROTEIN", 125, 128], ["cytoplasmic loop", "PROTEIN", 141, 157], ["transmembrane helix", "PROTEIN", 170, 189], ["TM2", "PROTEIN", 191, 194], ["first extracellular loop", "PROTEIN", 220, 244], ["The fragment", "TEST", 0, 12], ["Ste2p", "TEST", 14, 19], ["G31", "TEST", 21, 24], ["fragment", "OBSERVATION_MODIFIER", 4, 12], ["terminal", "ANATOMY_MODIFIER", 77, 85], ["helix", "ANATOMY_MODIFIER", 118, 123], ["cytoplasmic loop", "OBSERVATION", 141, 157], ["helix", "ANATOMY_MODIFIER", 184, 189], ["extracellular loop", "OBSERVATION", 226, 244]]], ["Multi-dimensional NMR experiments on [15N], [15N,13C] , [15N,13C,2H]-labeled TM1-TM2 and this fragment selectively labeled at specific amino acids or protonated at selected methyl groups resulted in >95% assignment of backbone and side chain nuclei in both media.", [["[15N], [15N,13C] , [15N,13C,2H", "CHEMICAL", 37, 67], ["amino acids", "CHEMICAL", 135, 146], ["methyl", "CHEMICAL", 173, 179], ["[15N]", "CHEMICAL", 37, 42], ["15N", "CHEMICAL", 45, 48], ["13C", "CHEMICAL", 49, 52], ["15N", "CHEMICAL", 57, 60], ["13C", "CHEMICAL", 61, 64], ["2H", "CHEMICAL", 65, 67], ["TM1-TM2", "CHEMICAL", 77, 84], ["amino acids", "CHEMICAL", 135, 146], ["methyl", "CHEMICAL", 173, 179], ["[15N]", "SIMPLE_CHEMICAL", 37, 42], ["[15N,13C]", "SIMPLE_CHEMICAL", 44, 53], ["[15N,13C,2H]-labeled TM1-TM2", "SIMPLE_CHEMICAL", 56, 84], ["amino acids", "AMINO_ACID", 135, 146], ["Multi-dimensional NMR experiments", "TEST", 0, 33], ["TM1", "TEST", 77, 80], ["TM2", "TEST", 81, 84], ["this fragment", "PROBLEM", 89, 102], ["specific amino acids", "TEST", 126, 146], ["backbone and side chain nuclei", "PROBLEM", 218, 248], ["backbone", "ANATOMY_MODIFIER", 218, 226], ["chain nuclei", "OBSERVATION", 236, 248], ["both", "ANATOMY_MODIFIER", 252, 256], ["media", "ANATOMY", 257, 262]]], ["The NMR investigation revealed the secondary structure of specific residues of TM1-TM2 and a -hairpin like structure in LPPG.", [["TM1", "AMINO_ACID", 79, 82], ["TM2", "AMINO_ACID", 83, 86], ["LPPG", "SIMPLE_CHEMICAL", 120, 124], ["TM1", "PROTEIN", 79, 82], ["TM2", "PROTEIN", 83, 86], ["-hairpin like structure", "PROTEIN", 93, 116], ["LPPG", "PROTEIN", 120, 124], ["The NMR investigation", "TEST", 0, 21], ["a -hairpin like structure in LPPG", "PROBLEM", 91, 124], ["secondary structure", "OBSERVATION", 35, 54], ["specific residues", "OBSERVATION", 58, 75], ["TM2", "ANATOMY", 83, 86]]], ["The LPPG structure is consistent with the results of biochemical experiments that identified the ligand binding site within this region.", [["LPPG structure", "PROTEIN", 4, 18], ["biochemical experiments", "TREATMENT", 53, 76], ["consistent with", "UNCERTAINTY", 22, 37], ["biochemical experiments", "OBSERVATION", 53, 76], ["ligand binding", "OBSERVATION", 97, 111]]], ["Furthermore, superposition of the backbone atoms of TM1-TM2 with a rhodopsin-templated model of Ste2p yielded an RMSD of 1.8\u00c5 justifying the fragment approach towards determination of the full length structure of GPCRs.", [["TM1-TM2", "CHEMICAL", 52, 59], ["TM1-TM2", "AMINO_ACID", 52, 59], ["GPCRs", "GENE_OR_GENE_PRODUCT", 213, 218], ["TM1", "PROTEIN", 52, 55], ["TM2", "PROTEIN", 56, 59], ["rhodopsin", "PROTEIN", 67, 76], ["Ste2p", "PROTEIN", 96, 101], ["GPCRs", "PROTEIN", 213, 218], ["a rhodopsin", "TREATMENT", 65, 76], ["an RMSD", "TEST", 110, 117], ["the fragment approach", "TREATMENT", 137, 158], ["backbone", "ANATOMY_MODIFIER", 34, 42], ["atoms", "ANATOMY_MODIFIER", 43, 48], ["TM1", "ANATOMY", 52, 55], ["RMSD", "OBSERVATION", 113, 117], ["fragment", "OBSERVATION", 141, 149], ["full length", "OBSERVATION_MODIFIER", 188, 199], ["GPCRs", "OBSERVATION_MODIFIER", 213, 218]]], ["The study of the insulin analogues may help provide a better understanding of the structure-function relationship of insulin and its receptor.", [["insulin", "GENE_OR_GENE_PRODUCT", 17, 24], ["insulin", "GENE_OR_GENE_PRODUCT", 117, 124], ["insulin", "PROTEIN", 117, 124], ["The study", "TEST", 0, 9], ["the insulin analogues", "TREATMENT", 13, 34], ["insulin", "TREATMENT", 117, 124]]], ["The amino acids in the C-terminus of the B-chain of insulin, especially PheB24, PheB25 and TyrB26, are involved in the recognition of insulin receptor.", [["amino acids", "CHEMICAL", 4, 15], ["amino acids", "CHEMICAL", 4, 15], ["amino acids", "AMINO_ACID", 4, 15], ["B-chain", "GENE_OR_GENE_PRODUCT", 41, 48], ["insulin", "GENE_OR_GENE_PRODUCT", 52, 59], ["PheB24", "GENE_OR_GENE_PRODUCT", 72, 78], ["PheB25", "GENE_OR_GENE_PRODUCT", 80, 86], ["TyrB26", "GENE_OR_GENE_PRODUCT", 91, 97], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 134, 150], ["C-terminus", "PROTEIN", 23, 33], ["B-chain", "PROTEIN", 41, 48], ["insulin", "PROTEIN", 52, 59], ["PheB24", "PROTEIN", 72, 78], ["PheB25", "PROTEIN", 80, 86], ["TyrB26", "PROTEIN", 91, 97], ["insulin receptor", "PROTEIN", 134, 150], ["The amino acids", "TEST", 0, 15], ["insulin", "TREATMENT", 52, 59], ["PheB24", "TREATMENT", 72, 78], ["PheB25", "TREATMENT", 80, 86], ["TyrB26", "TREATMENT", 91, 97], ["insulin receptor", "TREATMENT", 134, 150], ["amino acids", "OBSERVATION", 4, 15]]], ["The C-terminus of the B-chain, and in particular residues B24 and B26-B28, are also essential for insulin dimer formation.", [["C-terminus", "GENE_OR_GENE_PRODUCT", 4, 14], ["B-chain", "GENE_OR_GENE_PRODUCT", 22, 29], ["B24", "GENE_OR_GENE_PRODUCT", 58, 61], ["B26-B28", "GENE_OR_GENE_PRODUCT", 66, 73], ["insulin", "GENE_OR_GENE_PRODUCT", 98, 105], ["C-terminus", "PROTEIN", 4, 14], ["B-chain", "PROTEIN", 22, 29], ["B26", "PROTEIN", 66, 69], ["B28", "PROTEIN", 70, 73], ["insulin dimer", "PROTEIN", 98, 111], ["B26", "TEST", 66, 69], ["insulin dimer formation", "PROBLEM", 98, 121], ["chain", "ANATOMY_MODIFIER", 24, 29], ["insulin dimer", "OBSERVATION", 98, 111]]], ["Dimerization of insulin has an important role in the delivery of the hormone from the pancreas to the circulation or in the administration of insulin to diabetic patients.", [["pancreas", "ANATOMY", 86, 94], ["diabetic", "DISEASE", 153, 161], ["insulin", "GENE_OR_GENE_PRODUCT", 16, 23], ["pancreas", "ORGAN", 86, 94], ["insulin", "GENE_OR_GENE_PRODUCT", 142, 149], ["patients", "ORGANISM", 162, 170], ["insulin", "PROTEIN", 16, 23], ["insulin", "PROTEIN", 142, 149], ["patients", "SPECIES", 162, 170], ["Dimerization of insulin", "TREATMENT", 0, 23], ["insulin", "TREATMENT", 142, 149], ["pancreas", "ANATOMY", 86, 94], ["circulation", "ANATOMY", 102, 113]]], ["The N-methylation of particular peptide bonds of insulin may result in the elimination of the ability to form intermolecular or intramolecular hydrogen bonds, which are important for stability and correct folding of the insulin monomer, dimer formation, and interaction with its receptor.", [["N", "CHEMICAL", 4, 5], ["hydrogen", "CHEMICAL", 143, 151], ["insulin", "GENE_OR_GENE_PRODUCT", 49, 56], ["insulin", "GENE_OR_GENE_PRODUCT", 220, 227], ["insulin", "PROTEIN", 49, 56], ["insulin monomer", "PROTEIN", 220, 235], ["The N-methylation of particular peptide bonds of insulin", "TREATMENT", 0, 56], ["intermolecular or intramolecular hydrogen bonds", "PROBLEM", 110, 157], ["the insulin monomer", "TREATMENT", 216, 235], ["intramolecular", "OBSERVATION", 128, 142], ["hydrogen bonds", "OBSERVATION", 143, 157]]], ["Here we present several novel full-length insulin analogues with the N-methylation of the peptide bond at position B24, B25 or B26.", [["N", "CHEMICAL", 69, 70], ["insulin", "GENE_OR_GENE_PRODUCT", 42, 49], ["B25", "SIMPLE_CHEMICAL", 120, 123], ["B26", "SIMPLE_CHEMICAL", 127, 130], ["B26", "PROTEIN", 127, 130], ["novel full-length insulin analogues", "TREATMENT", 24, 59], ["the N-methylation of the peptide bond at position B24", "TREATMENT", 65, 118], ["B26", "TREATMENT", 127, 130]]], ["We determined the binding affinities of the analogues for insulin receptor in rat adipose membranes.", [["adipose membranes", "ANATOMY", 82, 99], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 58, 74], ["rat", "ORGANISM", 78, 81], ["adipose membranes", "TISSUE", 82, 99], ["insulin receptor", "PROTEIN", 58, 74], ["rat", "SPECIES", 78, 81], ["rat", "SPECIES", 78, 81], ["the analogues", "TREATMENT", 40, 53], ["insulin receptor in rat adipose membranes", "TREATMENT", 58, 99]]], ["We used the isothermal microcalorimetry method to compare the energetics of dissociation of the analogues with the wild-type insulin (which forms dimers) and with des(B23-B30)octapeptide insulin (which does not form dimers).", [["insulin", "GENE_OR_GENE_PRODUCT", 125, 132], ["insulin", "GENE_OR_GENE_PRODUCT", 187, 194], ["wild-type insulin", "PROTEIN", 115, 132], ["B23", "PROTEIN", 167, 170], ["B30", "PROTEIN", 171, 174], ["the isothermal microcalorimetry method", "TREATMENT", 8, 46], ["the analogues", "TREATMENT", 92, 105], ["the wild-type insulin", "TREATMENT", 111, 132], ["des(B23-B30)octapeptide insulin", "TREATMENT", 163, 194]]], ["This method allowed us to deduce several clear conclusions about the role of individual peptide bond amides for the dimerization and binding affinity of insulin.", [["amides", "CHEMICAL", 101, 107], ["insulin", "GENE_OR_GENE_PRODUCT", 153, 160], ["insulin", "PROTEIN", 153, 160], ["individual peptide bond amides", "TREATMENT", 77, 107], ["the dimerization", "TREATMENT", 112, 128], ["insulin", "TREATMENT", 153, 160]]], ["In Alzheimer's disease (AD) research, low water-solubility and uncontrolled aggregation of amyloid peptide (A) 1-42 are known to cause difficulties in preparing monomer A1-42, resulting in irreproducible or discrepant outcomes in toxicological studies.", [["Alzheimer's disease", "DISEASE", 3, 22], ["AD", "DISEASE", 24, 26], ["amyloid peptide (A) 1-42", "CHEMICAL", 91, 115], ["monomer A1-42", "CHEMICAL", 161, 174], ["amyloid peptide (A) 1-42", "GENE_OR_GENE_PRODUCT", 91, 115], ["Alzheimer's disease", "PROBLEM", 3, 22], ["low water-solubility", "TREATMENT", 38, 58], ["uncontrolled aggregation of amyloid peptide", "PROBLEM", 63, 106], ["toxicological studies", "TEST", 230, 251], ["Alzheimer", "OBSERVATION", 3, 12]]], ["To solve these problems, we disclosed water-soluble \"click peptides\" [1] based on an \"Oacyl isopeptide method\" [2] .", [["Oacyl", "CHEMICAL", 86, 91], ["Oacyl isopeptide", "SIMPLE_CHEMICAL", 86, 102], ["water-soluble \"click peptides", "TREATMENT", 38, 67], ["an \"Oacyl isopeptide method", "TREATMENT", 82, 109]]], ["The peptide had no self-assembling nature due to an O-acyl isopeptide structure at Gly25-Ser26.", [["O-acyl", "CHEMICAL", 52, 58], ["O-acyl isopeptide", "SIMPLE_CHEMICAL", 52, 69], ["Gly25-Ser26", "SIMPLE_CHEMICAL", 83, 94], ["Gly25", "PROTEIN", 83, 88], ["Ser26", "PROTEIN", 89, 94], ["an O-acyl isopeptide structure", "TREATMENT", 49, 79]]], ["The peptide converted to intact A1-42 under physiological conditions via an O-to-N intramolecular acyl migration upon being triggered by \"click\" (e.g. pHchange or photo-irradiation).", [["A1-42", "CHEMICAL", 32, 37], ["O", "CHEMICAL", 76, 77], ["N", "CHEMICAL", 81, 82], ["acyl", "CHEMICAL", 98, 102], ["acyl", "SIMPLE_CHEMICAL", 98, 102], ["A1", "PROTEIN", 32, 34], ["The peptide", "TEST", 0, 11], ["intramolecular acyl migration", "PROBLEM", 83, 112], ["photo-irradiation", "TREATMENT", 163, 180], ["acyl migration", "OBSERVATION", 98, 112]]], ["The produced A1-42 underwent selfassembling events starting from a monomeric random coil structure.", [["A1-42", "CHEMICAL", 13, 18], ["A1", "PROTEIN", 13, 15], ["monomeric random coil structure", "PROTEIN", 67, 98], ["selfassembling events", "PROBLEM", 29, 50], ["a monomeric random coil structure", "TREATMENT", 65, 98]]], ["These results indicated that in situ production of monomer A1-42 from click peptides can be used to establish a reliable experimental system to investigate the pathological functions of A1-42 in AD.", [["monomer A1-42", "CHEMICAL", 51, 64], ["A1-42", "CHEMICAL", 186, 191], ["AD", "DISEASE", 195, 197], ["A1-42", "GENE_OR_GENE_PRODUCT", 59, 64], ["A1-42", "GENE_OR_GENE_PRODUCT", 186, 191], ["A1", "PROTEIN", 186, 188], ["click peptides", "TREATMENT", 70, 84]]], ["The human islet amyloid polypeptide, also known as hIAPP or amylin, is a 37-residue peptide that is the major component of the amyloid deposits frequently found in patients suffering from diabetes mellitus type 2.", [["diabetes mellitus", "DISEASE", 188, 205], ["human", "ORGANISM", 4, 9], ["islet amyloid polypeptide", "GENE_OR_GENE_PRODUCT", 10, 35], ["hIAPP", "GENE_OR_GENE_PRODUCT", 51, 56], ["amylin", "GENE_OR_GENE_PRODUCT", 60, 66], ["amyloid", "GENE_OR_GENE_PRODUCT", 127, 134], ["patients", "ORGANISM", 164, 172], ["hIAPP", "PROTEIN", 51, 56], ["human", "SPECIES", 4, 9], ["patients", "SPECIES", 164, 172], ["human", "SPECIES", 4, 9], ["The human islet amyloid polypeptide", "TREATMENT", 0, 35], ["amylin", "TREATMENT", 60, 66], ["a 37-residue peptide", "PROBLEM", 71, 91], ["the amyloid deposits", "PROBLEM", 123, 143], ["diabetes mellitus type 2", "PROBLEM", 188, 212], ["major", "OBSERVATION_MODIFIER", 104, 109], ["component", "OBSERVATION_MODIFIER", 110, 119], ["amyloid deposits", "OBSERVATION", 127, 143], ["diabetes mellitus", "OBSERVATION", 188, 205]]], ["Although it is not yet clear whether these amyloid deposits are a cause, consequence or side effect of the disease, it is hypothesized that the interaction between hIAPP and cellular membranes is a cause of IAPP cytotoxicity, leading to -cell death.University of MichiganTo provide further insights in the interaction between cell membranes and IAPP, we chemically synthesized human (h) and murine (m) ProIAPP, ProIAPP1-48 as well as mature IAPP. mIAPP differs at only 6 residues from hIAPP but is known not to aggregate into amyloid deposits.", [["cellular membranes", "ANATOMY", 174, 192], ["cell", "ANATOMY", 238, 242], ["cell membranes", "ANATOMY", 326, 340], ["amyloid deposits", "DISEASE", 43, 59], ["death", "DISEASE", 243, 248], ["amyloid", "GENE_OR_GENE_PRODUCT", 43, 50], ["hIAPP", "GENE_OR_GENE_PRODUCT", 164, 169], ["cellular membranes", "CELLULAR_COMPONENT", 174, 192], ["IAPP", "GENE_OR_GENE_PRODUCT", 207, 211], ["cell", "CELL", 238, 242], ["cell membranes", "CELLULAR_COMPONENT", 326, 340], ["IAPP", "GENE_OR_GENE_PRODUCT", 345, 349], ["human", "ORGANISM", 377, 382], ["murine", "ORGANISM", 391, 397], ["ProIAPP", "GENE_OR_GENE_PRODUCT", 402, 409], ["ProIAPP1-48", "GENE_OR_GENE_PRODUCT", 411, 422], ["IAPP", "GENE_OR_GENE_PRODUCT", 441, 445], ["mIAPP", "SIMPLE_CHEMICAL", 447, 452], ["hIAPP", "GENE_OR_GENE_PRODUCT", 485, 490], ["amyloid", "GENE_OR_GENE_PRODUCT", 526, 533], ["IAPP", "PROTEIN", 207, 211], ["IAPP", "PROTEIN", 345, 349], ["ProIAPP1", "PROTEIN", 411, 419], ["mature IAPP", "PROTEIN", 434, 445], ["mIAPP", "PROTEIN", 447, 452], ["hIAPP", "PROTEIN", 485, 490], ["human", "SPECIES", 377, 382], ["murine", "SPECIES", 391, 397], ["human", "SPECIES", 377, 382], ["these amyloid deposits", "PROBLEM", 37, 59], ["the disease", "PROBLEM", 103, 114], ["hIAPP and cellular membranes", "PROBLEM", 164, 192], ["IAPP cytotoxicity", "PROBLEM", 207, 224], ["cell death", "PROBLEM", 238, 248], ["ProIAPP", "TEST", 402, 409], ["ProIAPP1", "TEST", 411, 419], ["mIAPP", "TREATMENT", 447, 452], ["amyloid deposits", "PROBLEM", 526, 542], ["amyloid deposits", "OBSERVATION", 43, 59], ["disease", "OBSERVATION", 107, 114], ["cellular membranes", "OBSERVATION", 174, 192], ["cell death", "OBSERVATION", 238, 248], ["known not to", "UNCERTAINTY", 498, 510], ["amyloid deposits", "OBSERVATION", 526, 542]]], ["IAPP and its precursors were synthesized by manual Boc-SPPS.", [["IAPP", "GENE_OR_GENE_PRODUCT", 0, 4], ["IAPP", "PROTEIN", 0, 4], ["IAPP", "TEST", 0, 4]]], ["ProIAPP and ProIAPP1-48 were prepared by native chemical ligation of N-terminal fragments with mercaptopropionyl-leucine functionalized C-termini and C-terminal fragments starting with cysteine.", [["ProIAPP", "CHEMICAL", 0, 7], ["ProIAPP1-48", "CHEMICAL", 12, 23], ["mercaptopropionyl-leucine", "CHEMICAL", 95, 120], ["cysteine", "CHEMICAL", 185, 193], ["ProIAPP", "CHEMICAL", 0, 7], ["ProIAPP1-48", "CHEMICAL", 12, 23], ["N", "CHEMICAL", 69, 70], ["mercaptopropionyl-leucine", "CHEMICAL", 95, 120], ["C", "CHEMICAL", 150, 151], ["cysteine", "CHEMICAL", 185, 193], ["ProIAPP", "SIMPLE_CHEMICAL", 0, 7], ["ProIAPP1-48", "GENE_OR_GENE_PRODUCT", 12, 23], ["mercaptopropionyl-leucine functionalized C-termini", "SIMPLE_CHEMICAL", 95, 145], ["cysteine", "AMINO_ACID", 185, 193], ["ProIAPP and ProIAPP1-48", "DNA", 0, 23], ["N-terminal fragments", "PROTEIN", 69, 89], ["mercaptopropionyl-leucine functionalized C-termini and C-terminal fragments", "PROTEIN", 95, 170], ["ProIAPP and ProIAPP1", "TREATMENT", 0, 20], ["native chemical ligation", "TREATMENT", 41, 65], ["terminal fragments", "PROBLEM", 71, 89], ["mercaptopropionyl-leucine functionalized C-termini", "TREATMENT", 95, 145], ["C-terminal fragments", "PROBLEM", 150, 170], ["cysteine", "TREATMENT", 185, 193], ["ligation", "OBSERVATION", 57, 65], ["terminal fragments", "OBSERVATION", 71, 89], ["leucine functionalized", "OBSERVATION", 113, 135], ["terminal", "OBSERVATION_MODIFIER", 152, 160], ["fragments", "OBSERVATION", 161, 170]]], ["Oxidative folding and purification yielded IAPP and IAPP precursors.", [["IAPP", "GENE_OR_GENE_PRODUCT", 43, 47], ["IAPP", "GENE_OR_GENE_PRODUCT", 52, 56], ["IAPP", "PROTEIN", 43, 47], ["Oxidative folding", "TREATMENT", 0, 17], ["IAPP", "TEST", 43, 47]]], ["Amyloid fibril formation of IAPP, IAPP-precursors and combinations thereof was studied in synthetic membranes as well as in cells, and a model was developed describing (protective) effects of IAPPprecursors on IAPP fibril formation.", [["fibril", "ANATOMY", 8, 14], ["membranes", "ANATOMY", 100, 109], ["cells", "ANATOMY", 124, 129], ["fibril", "ANATOMY", 215, 221], ["Amyloid fibril", "CELLULAR_COMPONENT", 0, 14], ["IAPP", "GENE_OR_GENE_PRODUCT", 28, 32], ["IAPP", "GENE_OR_GENE_PRODUCT", 34, 38], ["membranes", "CELLULAR_COMPONENT", 100, 109], ["cells", "CELL", 124, 129], ["IAPPprecursors", "SIMPLE_CHEMICAL", 192, 206], ["IAPP", "GENE_OR_GENE_PRODUCT", 210, 214], ["fibril", "CELLULAR_COMPONENT", 215, 221], ["IAPP", "PROTEIN", 28, 32], ["IAPP", "PROTEIN", 34, 38], ["Amyloid fibril formation of IAPP", "PROBLEM", 0, 32], ["IAPP", "TEST", 34, 38], ["IAPPprecursors", "TREATMENT", 192, 206], ["IAPP fibril formation", "TREATMENT", 210, 231], ["fibril formation", "OBSERVATION", 8, 24], ["fibril formation", "OBSERVATION", 215, 231]]], ["We are interested in preparing novel probes to study receptor-ligand interactions of delta opioid receptors (DOR).", [["delta opioid receptors", "GENE_OR_GENE_PRODUCT", 85, 107], ["DOR", "GENE_OR_GENE_PRODUCT", 109, 112], ["delta opioid receptors", "PROTEIN", 85, 107], ["DOR", "PROTEIN", 109, 112], ["delta opioid receptors", "TREATMENT", 85, 107]]], ["Our approach utilizes a multilabeled peptide containing a fluorescent moiety along with isolation tags and an electrophilic affinity label to aid in the elucidation of the specific DOR amino acids that bind these peptides.", [["amino acids", "CHEMICAL", 185, 196], ["amino acids", "CHEMICAL", 185, 196], ["DOR", "SIMPLE_CHEMICAL", 181, 184], ["amino acids", "AMINO_ACID", 185, 196], ["a multilabeled peptide", "TREATMENT", 22, 44], ["a fluorescent moiety", "TREATMENT", 56, 76], ["isolation tags", "TREATMENT", 88, 102], ["an electrophilic affinity label", "TREATMENT", 107, 138], ["the specific DOR amino acids", "TREATMENT", 168, 196]]], ["The multifunctional peptide is a derivative of the high affinity, DOR selective antagonist TIPP (Tyr-Tic-Phe-Phe, Tic =1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid).", [["TIPP", "CHEMICAL", 91, 95], ["Tyr-Tic-Phe-Phe", "CHEMICAL", 97, 112], ["Tic =1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid", "CHEMICAL", 114, 167], ["TIPP", "CHEMICAL", 91, 95], ["Tyr-Tic-Phe-Phe", "CHEMICAL", 97, 112], ["Tic", "CHEMICAL", 114, 117], ["1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid", "CHEMICAL", 119, 167], ["DOR", "SIMPLE_CHEMICAL", 66, 69], ["TIPP", "SIMPLE_CHEMICAL", 91, 95], ["Tyr-Tic-Phe-Phe", "SIMPLE_CHEMICAL", 97, 112], ["Tic =1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid", "SIMPLE_CHEMICAL", 114, 167], ["the high affinity", "PROBLEM", 47, 64], ["DOR selective antagonist TIPP", "TREATMENT", 66, 95], ["Tic", "TEST", 101, 104], ["Phe", "TEST", 105, 108], ["Phe", "TEST", 109, 112], ["Tic", "TEST", 114, 117], ["tetrahydroisoquinoline", "TREATMENT", 127, 149], ["carboxylic acid", "TREATMENT", 152, 167]]], ["The multifunctional peptide was successfully prepared by Fmoc solid phase peptide synthesis using an aldehyde-functionalized resin.", [["aldehyde", "CHEMICAL", 101, 109], ["Fmoc", "CHEMICAL", 57, 61], ["aldehyde", "CHEMICAL", 101, 109], ["aldehyde", "SIMPLE_CHEMICAL", 101, 109], ["The multifunctional peptide", "TREATMENT", 0, 27], ["Fmoc solid phase peptide synthesis", "TREATMENT", 57, 91], ["an aldehyde-functionalized resin", "TREATMENT", 98, 130], ["functionalized resin", "OBSERVATION", 110, 130]]], ["Multiple lysine residues bearing different side chain protecting groups were employed to allow for selective deprotection and subsequent functionalization of the side chain amines with the various labels during peptide synthesis.", [["lysine", "CHEMICAL", 9, 15], ["amines", "CHEMICAL", 173, 179], ["lysine", "CHEMICAL", 9, 15], ["amines", "CHEMICAL", 173, 179], ["side chain amines", "SIMPLE_CHEMICAL", 162, 179], ["Multiple lysine residues bearing different side chain protecting groups", "TREATMENT", 0, 71], ["selective deprotection", "TREATMENT", 99, 121], ["subsequent functionalization of the side chain amines", "TREATMENT", 126, 179], ["peptide synthesis", "TREATMENT", 211, 228], ["lysine residues", "OBSERVATION", 9, 24], ["bearing", "OBSERVATION_MODIFIER", 25, 32], ["different", "OBSERVATION_MODIFIER", 33, 42]]], ["PEG (poly(ethylene glycol))-like linkers were included to enhance water solubility and to separate the TIPP portion of the peptide from the various labels incorporated at the C-terminus.", [["PEG", "CHEMICAL", 0, 3], ["poly(ethylene glycol", "CHEMICAL", 5, 25], ["PEG (poly(ethylene glycol)", "CHEMICAL", 0, 26], ["PEG", "SIMPLE_CHEMICAL", 0, 3], ["poly(ethylene glycol))-like linkers", "SIMPLE_CHEMICAL", 5, 40], ["water", "SIMPLE_CHEMICAL", 66, 71], ["TIPP portion", "PROTEIN", 103, 115], ["C-terminus", "PROTEIN", 175, 185], ["PEG (poly(ethylene glycol))-like linkers", "TREATMENT", 0, 40], ["water solubility", "TREATMENT", 66, 82]]], ["The interaction of this peptide with Chinese hamster ovary (CHO) cells expressing DOR was assessed using fluorescence microscopy.", [["hamster ovary (CHO) cells", "ANATOMY", 45, 70], ["hamster ovary (CHO) cells", "CELL", 45, 70], ["DOR", "GENE_OR_GENE_PRODUCT", 82, 85], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 37, 70], ["DOR", "PROTEIN", 82, 85], ["Chinese hamster", "SPECIES", 37, 52], ["this peptide", "TREATMENT", 19, 31], ["Chinese hamster ovary (CHO) cells", "TREATMENT", 37, 70], ["fluorescence microscopy", "TEST", 105, 128], ["ovary", "ANATOMY", 53, 58]]], ["These experiments provide evidence that this novel peptide binds covalently and specifically to DOR and demonstrates its utility to visualize DOR.", [["DOR", "GENE_OR_GENE_PRODUCT", 96, 99], ["DOR", "GENE_OR_GENE_PRODUCT", 142, 145], ["DOR", "PROTEIN", 96, 99], ["DOR", "PROTEIN", 142, 145], ["this novel peptide binds", "PROBLEM", 40, 64]]], ["This research was supported by NIDA grant DA010035.", [["DA010035", "CHEMICAL", 42, 50]]], ["It has long been recognized that 13 C and 13 C chemical shift deviations (CSDs) from random coil values have different characteristics for residues in -helical versus -sheet regions of proteins; CSDs of 13 C (and 13 C') are positive and those of 13 C are negative in -helices, while these are reversed in -sheets.", [["C", "CHEMICAL", 36, 37], ["C", "CHEMICAL", 45, 46], ["-helical versus -sheet regions", "PROTEIN", 151, 181], ["CSDs", "PROTEIN", 195, 199], ["13 C", "PROTEIN", 203, 207], ["13 C", "PROTEIN", 246, 250], ["13 C chemical shift deviations (CSDs)", "PROBLEM", 42, 79], ["random coil values", "TEST", 85, 103], ["residues in -helical versus -sheet regions of proteins", "PROBLEM", 139, 193], ["CSDs", "TEST", 195, 199], ["13 C", "OBSERVATION_MODIFIER", 33, 37]]], ["Although Rico and co-workers were early advocates of using the 13 C and 13 C shifts qualitatively (and even quantitatively) as a means for assessing -hairpin fold populations, unlike the case of H and HN shifts, the more detailed pattern of the 13C CSDs along the -strands does not appear to have been recognized in literature yet.", [["H", "CHEMICAL", 195, 196], ["13C", "CHEMICAL", 245, 248], ["13C", "SIMPLE_CHEMICAL", 245, 248], ["assessing -hairpin fold populations", "PROBLEM", 139, 174], ["the 13C CSDs", "TREATMENT", 241, 253]]], ["In protein -sheets, many amide units have Hbonds with two strands and the range of 13 C CSDs occurring in -sheets overlaps with the narrower range for -helices.", [["amide", "CHEMICAL", 25, 30], ["C", "CHEMICAL", 86, 87], ["Hbonds", "SIMPLE_CHEMICAL", 42, 48], ["many amide units", "TREATMENT", 20, 36]]], ["There also appears to be a discrepancy in the prediction of H-bonding effects on 13 C shifts in helices versus hairpins.", [["H", "CHEMICAL", 60, 61], ["a discrepancy", "PROBLEM", 25, 38], ["H-bonding effects", "TREATMENT", 60, 77], ["13 C shifts in helices versus hairpins", "TREATMENT", 81, 119], ["appears to be", "UNCERTAINTY", 11, 24], ["discrepancy", "OBSERVATION", 27, 38]]], ["To answer these questions, 13 C structuring shifts have been determined for a series of designed hairpins of varying fold stability.", [["varying fold stability", "PROBLEM", 109, 131], ["varying fold", "OBSERVATION_MODIFIER", 109, 121], ["stability", "OBSERVATION_MODIFIER", 122, 131]]], ["Our study reveals that the diagnostic 13 C shifts forstructuring are associated, almost exclusively, with the cross-strand Hbonded residues, and instances in which aromatic ring current effects on 13 C CSDs can be as large as the secondary structure shifts.", [["C", "CHEMICAL", 200, 201], ["13 C CSDs", "SIMPLE_CHEMICAL", 197, 206], ["Our study", "TEST", 0, 9], ["the diagnostic 13 C shifts forstructuring", "PROBLEM", 23, 64], ["13 C CSDs", "TREATMENT", 197, 206], ["aromatic ring", "OBSERVATION", 164, 177], ["large", "OBSERVATION_MODIFIER", 217, 222], ["secondary structure shifts", "OBSERVATION", 230, 256]]], ["Results from a further search of 13 C shifts in -structures of proteins will also be reported as a test of the generality of the conclusions based on the model hairpins.", [["a further search", "TEST", 13, 29], ["13 C shifts in -structures of proteins", "PROBLEM", 33, 71], ["the model hairpins", "TREATMENT", 150, 168]]], ["Out of 26 different types of MMPs, matrix metalloproteinase-9 (MMP-9) is ubiquitously over expressed in almost every type of tumor cells undergoing metastasis.", [["tumor cells", "ANATOMY", 125, 136], ["tumor", "DISEASE", 125, 130], ["MMPs", "GENE_OR_GENE_PRODUCT", 29, 33], ["matrix metalloproteinase-9", "GENE_OR_GENE_PRODUCT", 35, 61], ["MMP-9", "GENE_OR_GENE_PRODUCT", 63, 68], ["tumor cells", "CELL", 125, 136], ["MMPs", "PROTEIN", 29, 33], ["matrix metalloproteinase-9 (MMP-9", "PROTEIN", 35, 68], ["tumor cells", "CELL_TYPE", 125, 136], ["MMPs, matrix metalloproteinase", "TEST", 29, 59], ["MMP", "TEST", 63, 66], ["tumor cells", "PROBLEM", 125, 136], ["metastasis", "PROBLEM", 148, 158], ["26 different", "OBSERVATION_MODIFIER", 7, 19], ["types", "OBSERVATION_MODIFIER", 20, 25], ["MMPs", "ANATOMY", 29, 33], ["tumor cells", "OBSERVATION", 125, 136], ["metastasis", "OBSERVATION", 148, 158]]], ["Our objective was to develop and optimized a novel methodology for releasing liposomal contents triggered by human recombinant and cancer cell secreted MMP-9.", [["cancer cell", "ANATOMY", 131, 142], ["liposomal", "SIMPLE_CHEMICAL", 77, 86], ["human", "ORGANISM", 109, 114], ["cancer cell", "CELL", 131, 142], ["MMP-9", "GENE_OR_GENE_PRODUCT", 152, 157], ["human recombinant", "PROTEIN", 109, 126], ["MMP-9", "PROTEIN", 152, 157], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["a novel methodology", "TREATMENT", 43, 62], ["releasing liposomal contents", "PROBLEM", 67, 95], ["cancer cell secreted MMP", "TEST", 131, 155]]], ["For this purpose we formulated liposomes by incorporating commercially available phosphatidylcholines as the major component and a synthesized MMP-9 cleavable lipid-peptide conjugate of varying triple helicity as the minor component.", [["phosphatidylcholines", "CHEMICAL", 81, 101], ["phosphatidylcholines", "CHEMICAL", 81, 101], ["liposomes", "SIMPLE_CHEMICAL", 31, 40], ["phosphatidylcholines", "SIMPLE_CHEMICAL", 81, 101], ["MMP", "PROTEIN", 143, 146], ["liposomes", "TREATMENT", 31, 40], ["phosphatidylcholines", "TREATMENT", 81, 101], ["a synthesized MMP", "TEST", 129, 146], ["varying triple helicity", "TREATMENT", 186, 209], ["minor", "OBSERVATION_MODIFIER", 217, 222], ["component", "OBSERVATION_MODIFIER", 223, 232]]], ["The liposomes were encapsulated with a self quenching dye carboxyfluorescein.", [["liposomes", "ANATOMY", 4, 13], ["dye carboxyfluorescein", "CHEMICAL", 54, 76], ["carboxyfluorescein", "CHEMICAL", 58, 76], ["liposomes", "SIMPLE_CHEMICAL", 4, 13], ["dye carboxyfluorescein", "SIMPLE_CHEMICAL", 54, 76], ["a self quenching dye carboxyfluorescein", "TREATMENT", 37, 76], ["liposomes", "ANATOMY", 4, 13]]], ["Experimental Methods: The lipopeptides were synthesized by employing a microwave peptide synthesizer (Liberty from CEM Inc.).", [["The lipopeptides", "TREATMENT", 22, 38], ["a microwave peptide synthesizer", "TREATMENT", 69, 100]]], ["The triple helical peptides were purified and characterized by reverse phase HPLC, mass spectrometry (MALDI-ToF) and circular dichroism (CD) spectrometry.", [["The triple helical peptides", "TEST", 0, 27], ["reverse phase HPLC", "TEST", 63, 81], ["mass spectrometry", "TEST", 83, 100], ["MALDI", "TEST", 102, 107], ["circular dichroism (CD) spectrometry", "PROBLEM", 117, 153]]], ["The fluorescence emission of carboxyfluorescein from liposomes was recorded with a spectrophotometer (Spectramax, Molecular Devices).", [["carboxyfluorescein", "CHEMICAL", 29, 47], ["carboxyfluorescein", "CHEMICAL", 29, 47], ["carboxyfluorescein", "SIMPLE_CHEMICAL", 29, 47], ["liposomes", "SIMPLE_CHEMICAL", 53, 62], ["carboxyfluorescein from liposomes", "TREATMENT", 29, 62], ["a spectrophotometer (Spectramax, Molecular Devices", "TREATMENT", 81, 131]]], ["Cell based studies were done using optimized liposomal formulations with human breast adenocarcinoma MCF-7 and human colorectal HT-29 cultured cell lines.", [["Cell", "ANATOMY", 0, 4], ["breast adenocarcinoma MCF-7", "ANATOMY", 79, 106], ["colorectal HT-29 cultured cell lines", "ANATOMY", 117, 153], ["breast adenocarcinoma", "DISEASE", 79, 100], ["Cell", "CELL", 0, 4], ["human", "ORGANISM", 73, 78], ["breast adenocarcinoma MCF-7", "CELL", 79, 106], ["human", "ORGANISM", 111, 116], ["colorectal HT-29 cultured cell lines", "CELL", 117, 153], ["human breast adenocarcinoma MCF-7", "CELL_LINE", 73, 106], ["human colorectal HT-29 cultured cell lines", "CELL_LINE", 111, 153], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 73, 78], ["MCF-7", "SPECIES", 101, 106], ["human", "SPECIES", 111, 116], ["Cell based studies", "TEST", 0, 18], ["optimized liposomal formulations", "TREATMENT", 35, 67], ["human breast adenocarcinoma MCF", "TREATMENT", 73, 104], ["human colorectal HT", "TEST", 111, 130], ["cultured cell lines", "TREATMENT", 134, 153], ["breast", "ANATOMY", 79, 85], ["adenocarcinoma", "OBSERVATION", 86, 100], ["cell lines", "OBSERVATION", 143, 153]]], ["Results and Discussion: The lipopeptides synthesized have the general sequence : St-GPQGIAGQR(GPO) n GG.", [["The lipopeptides", "TREATMENT", 24, 40]]], ["The peptides contain a Stearic acid (St) at the N-terminal of Gly, a MMP-9 sessile bond (underlined) and varying GPO units from n =3 to n =5.", [["Stearic acid", "CHEMICAL", 23, 35], ["Stearic acid", "CHEMICAL", 23, 35], ["Gly", "CHEMICAL", 62, 65], ["Stearic acid", "SIMPLE_CHEMICAL", 23, 35], ["Gly", "AMINO_ACID", 62, 65], ["MMP", "PROTEIN", 69, 72], ["The peptides", "TEST", 0, 12], ["a Stearic acid", "TEST", 21, 35], ["a MMP", "TEST", 67, 72], ["varying GPO units", "TREATMENT", 105, 122], ["Stearic acid", "OBSERVATION", 23, 35]]], ["An optimized liposome formulation was obtained for POPC (70 mole %) and lipopetide (30 mole%) with 4 units of GPO (n=4) .", [["liposome", "ANATOMY", 13, 21], ["POPC", "CHEMICAL", 51, 55], ["lipopetide", "CHEMICAL", 72, 82], ["POPC", "CHEMICAL", 51, 55], ["lipopetide", "CHEMICAL", 72, 82], ["GPO", "CHEMICAL", 110, 113], ["liposome", "SIMPLE_CHEMICAL", 13, 21], ["POPC", "SIMPLE_CHEMICAL", 51, 55], ["lipopetide", "SIMPLE_CHEMICAL", 72, 82], ["GPO", "SIMPLE_CHEMICAL", 110, 113], ["An optimized liposome formulation", "TREATMENT", 0, 33], ["POPC", "TREATMENT", 51, 55], ["lipopetide", "TREATMENT", 72, 82], ["GPO", "TREATMENT", 110, 113]]], ["This formulation releases about 50% of the dye at caner associated concentration of recombinant human MMP-9.", [["human", "ORGANISM", 96, 101], ["MMP-9", "GENE_OR_GENE_PRODUCT", 102, 107], ["recombinant human MMP-9", "PROTEIN", 84, 107], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["recombinant human MMP", "TEST", 84, 105]]], ["When tested against cultured cell lines we found that while metastatic MCF-7 cells secreting active MMP-9 was able to release the encapsulated dye, HT-29 cells which do not secrete much of active MMP-9 was unable to show any significant release of the dye over the same time period.", [["cell lines", "ANATOMY", 29, 39], ["metastatic MCF-7 cells", "ANATOMY", 60, 82], ["HT-29 cells", "ANATOMY", 148, 159], ["cell lines", "CELL", 29, 39], ["MCF-7 cells", "CELL", 71, 82], ["MMP-9", "GENE_OR_GENE_PRODUCT", 100, 105], ["HT-29 cells", "CELL", 148, 159], ["MMP-9", "GENE_OR_GENE_PRODUCT", 196, 201], ["cultured cell lines", "CELL_LINE", 20, 39], ["metastatic MCF-7 cells", "CELL_LINE", 60, 82], ["MMP-9", "PROTEIN", 100, 105], ["HT-29 cells", "CELL_LINE", 148, 159], ["MMP", "PROTEIN", 196, 199], ["MCF-7", "SPECIES", 71, 76], ["cultured cell lines", "TEST", 20, 39], ["metastatic MCF", "TEST", 60, 74], ["secreting active MMP", "TEST", 83, 103], ["the encapsulated dye", "TEST", 126, 146], ["HT", "TEST", 148, 150], ["active MMP", "TEST", 189, 199], ["the dye", "PROBLEM", 248, 255], ["metastatic", "OBSERVATION_MODIFIER", 60, 70]]], ["Conclusions: The triggered release methodology showed significant promise in in-vitro release experiments in cancer cells.", [["cancer cells", "ANATOMY", 109, 121], ["cancer", "DISEASE", 109, 115], ["cancer cells", "CELL", 109, 121], ["cancer cells", "CELL_TYPE", 109, 121], ["The triggered release methodology", "TEST", 13, 46], ["significant promise in in-vitro release experiments in cancer cells", "PROBLEM", 54, 121], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["promise", "OBSERVATION_MODIFIER", 66, 73], ["cancer cells", "OBSERVATION", 109, 121]]], ["This methodology can be next applied on an animal model for in-vivo studies and in future can be fine tuned to act as a drug delivery vehicle for inhibition of MMP-9 over expressed under various pathological conditions.", [["MMP-9", "GENE_OR_GENE_PRODUCT", 160, 165], ["MMP-9", "PROTEIN", 160, 165], ["a drug delivery vehicle", "TREATMENT", 118, 141], ["MMP", "TEST", 160, 163]]], ["We investigated if GRP plays a role in compulsive, hindleg scratching of the neck in mice by the kappa opioid antagonist, 5-guanidinonaltrindole (GNTI), or in the antipruritic activity of the kappa agonist, nalfurafine.", [["neck", "ANATOMY", 77, 81], ["5-guanidinonaltrindole", "CHEMICAL", 122, 144], ["GNTI", "CHEMICAL", 146, 150], ["nalfurafine", "CHEMICAL", 207, 218], ["5-guanidinonaltrindole", "CHEMICAL", 122, 144], ["GNTI", "CHEMICAL", 146, 150], ["nalfurafine", "CHEMICAL", 207, 218], ["GRP", "GENE_OR_GENE_PRODUCT", 19, 22], ["neck", "ORGANISM_SUBDIVISION", 77, 81], ["mice", "ORGANISM", 85, 89], ["5-guanidinonaltrindole", "SIMPLE_CHEMICAL", 122, 144], ["GNTI", "SIMPLE_CHEMICAL", 146, 150], ["kappa", "GENE_OR_GENE_PRODUCT", 192, 197], ["nalfurafine", "SIMPLE_CHEMICAL", 207, 218], ["GRP", "PROTEIN", 19, 22], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["GRP", "PROBLEM", 19, 22], ["the kappa opioid antagonist", "TREATMENT", 93, 120], ["guanidinonaltrindole (GNTI)", "TREATMENT", 124, 151], ["the kappa agonist", "TREATMENT", 188, 205], ["nalfurafine", "TREATMENT", 207, 218], ["hindleg", "ANATOMY", 51, 58], ["neck", "ANATOMY", 77, 81]]], ["We showed that GNTI (0.03-1 mg/kg, s.c. behind the neck) elicits dose-related scratching and that nalfurafine (0.001-0.02 mg/kg, s.c.) inhibits this stereotyped behavior.", [["neck", "ANATOMY", 51, 55], ["GNTI", "CHEMICAL", 15, 19], ["nalfurafine", "CHEMICAL", 98, 109], ["GNTI", "CHEMICAL", 15, 19], ["nalfurafine", "CHEMICAL", 98, 109], ["GNTI", "SIMPLE_CHEMICAL", 15, 19], ["neck", "ORGANISM_SUBDIVISION", 51, 55], ["nalfurafine", "SIMPLE_CHEMICAL", 98, 109], ["GNTI", "TEST", 15, 19], ["scratching", "PROBLEM", 78, 88], ["nalfurafine", "TREATMENT", 98, 109], ["this stereotyped behavior", "PROBLEM", 144, 169], ["neck", "ANATOMY", 51, 55]]], ["Utilizing immunohistochemistry, we located GRP positive nerve fibers in the epidermis and dermis of mouse skin and superficial layer of the dorsal horn of the spinal cord as well as GRP positive small and medium sized cells in the dorsal root ganglion.", [["nerve fibers", "ANATOMY", 56, 68], ["epidermis", "ANATOMY", 76, 85], ["dermis", "ANATOMY", 90, 96], ["skin", "ANATOMY", 106, 110], ["superficial layer", "ANATOMY", 115, 132], ["dorsal horn", "ANATOMY", 140, 151], ["spinal cord", "ANATOMY", 159, 170], ["cells", "ANATOMY", 218, 223], ["dorsal root ganglion", "ANATOMY", 231, 251], ["GRP", "GENE_OR_GENE_PRODUCT", 43, 46], ["epidermis", "TISSUE", 76, 85], ["dermis", "TISSUE", 90, 96], ["mouse", "ORGANISM", 100, 105], ["skin", "ORGAN", 106, 110], ["superficial layer", "TISSUE", 115, 132], ["dorsal horn", "ORGAN", 140, 151], ["spinal cord", "ORGAN", 159, 170], ["GRP", "GENE_OR_GENE_PRODUCT", 182, 185], ["cells", "CELL", 218, 223], ["dorsal root ganglion", "TISSUE", 231, 251], ["GRP", "PROTEIN", 43, 46], ["GRP positive small and medium sized cells", "CELL_TYPE", 182, 223], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 100, 105], ["immunohistochemistry", "TEST", 10, 30], ["GRP positive small and medium sized cells", "PROBLEM", 182, 223], ["positive nerve fibers", "OBSERVATION", 47, 68], ["epidermis", "ANATOMY", 76, 85], ["dermis", "ANATOMY_MODIFIER", 90, 96], ["mouse", "ANATOMY_MODIFIER", 100, 105], ["skin", "ANATOMY", 106, 110], ["superficial", "ANATOMY_MODIFIER", 115, 126], ["layer", "ANATOMY_MODIFIER", 127, 132], ["dorsal", "ANATOMY_MODIFIER", 140, 146], ["horn", "ANATOMY_MODIFIER", 147, 151], ["spinal cord", "ANATOMY", 159, 170], ["positive", "OBSERVATION_MODIFIER", 186, 194], ["small", "OBSERVATION_MODIFIER", 195, 200], ["medium sized", "OBSERVATION_MODIFIER", 205, 217], ["cells", "OBSERVATION", 218, 223], ["dorsal", "ANATOMY_MODIFIER", 231, 237], ["root ganglion", "ANATOMY", 238, 251]]], ["In a double staining study, GRP positive nerve fibers were near the cells expressing c-fos in response to GNTI injection, located on the lateral aspect of the superficial layer of the dorsal horn.", [["nerve fibers", "ANATOMY", 41, 53], ["cells", "ANATOMY", 68, 73], ["lateral aspect", "ANATOMY", 137, 151], ["superficial layer", "ANATOMY", 159, 176], ["dorsal horn", "ANATOMY", 184, 195], ["GNTI", "CHEMICAL", 106, 110], ["GNTI", "CHEMICAL", 106, 110], ["GRP", "GENE_OR_GENE_PRODUCT", 28, 31], ["cells", "CELL", 68, 73], ["c-fos", "GENE_OR_GENE_PRODUCT", 85, 90], ["GNTI", "GENE_OR_GENE_PRODUCT", 106, 110], ["superficial layer", "TISSUE", 159, 176], ["dorsal horn", "ORGAN", 184, 195], ["GRP", "PROTEIN", 28, 31], ["c-fos", "DNA", 85, 90], ["a double staining study", "TEST", 3, 26], ["GRP positive nerve fibers", "PROBLEM", 28, 53], ["GNTI injection", "TREATMENT", 106, 120], ["nerve fibers", "ANATOMY", 41, 53], ["lateral", "ANATOMY_MODIFIER", 137, 144], ["superficial", "ANATOMY_MODIFIER", 159, 170], ["layer", "ANATOMY_MODIFIER", 171, 176], ["dorsal horn", "ANATOMY", 184, 195]]], ["Cervical spinal cord GRP mRNA levels were similar in mice treated with saline-saline, saline-GNTI, nalfurafine-saline or nalfurafine-GNTI.", [["Cervical spinal cord", "ANATOMY", 0, 20], ["GNTI", "CHEMICAL", 93, 97], ["nalfurafine", "CHEMICAL", 99, 110], ["nalfurafine", "CHEMICAL", 121, 132], ["GNTI", "CHEMICAL", 133, 137], ["nalfurafine", "CHEMICAL", 99, 110], ["nalfurafine", "CHEMICAL", 121, 132], ["Cervical", "ORGAN", 0, 8], ["spinal cord", "ORGAN", 9, 20], ["GRP", "GENE_OR_GENE_PRODUCT", 21, 24], ["mice", "ORGANISM", 53, 57], ["saline-saline", "SIMPLE_CHEMICAL", 71, 84], ["saline-GNTI", "SIMPLE_CHEMICAL", 86, 97], ["nalfurafine-saline", "SIMPLE_CHEMICAL", 99, 117], ["nalfurafine-GNTI", "SIMPLE_CHEMICAL", 121, 137], ["Cervical spinal cord GRP mRNA", "RNA", 0, 29], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["Cervical spinal cord GRP mRNA levels", "TEST", 0, 36], ["saline-saline", "TREATMENT", 71, 84], ["saline", "TREATMENT", 86, 92], ["GNTI", "TREATMENT", 93, 97], ["nalfurafine", "TREATMENT", 99, 110], ["saline", "TREATMENT", 111, 117], ["nalfurafine", "TREATMENT", 121, 132], ["GNTI", "TREATMENT", 133, 137], ["spinal cord", "ANATOMY", 9, 20]]], ["Pretreating mice with RC-3095 (10 mg/kg, s.c.), a GRP receptor antagonist, did not markedly suppress GNTI-induced scratching.", [["RC-3095", "CHEMICAL", 22, 29], ["GNTI", "CHEMICAL", 101, 105], ["RC-3095", "CHEMICAL", 22, 29], ["mice", "ORGANISM", 12, 16], ["RC-3095", "SIMPLE_CHEMICAL", 22, 29], ["GRP receptor", "GENE_OR_GENE_PRODUCT", 50, 62], ["GNTI", "SIMPLE_CHEMICAL", 101, 105], ["GNTI", "PROTEIN", 101, 105], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["a GRP receptor antagonist", "TREATMENT", 48, 73], ["induced scratching", "PROBLEM", 106, 124], ["scratching", "OBSERVATION", 114, 124]]], ["We conclude that GRP mediates neither GNTI-induced scratching nor the antipruritic activity of nalfurafine in mice.", [["GNTI", "CHEMICAL", 38, 42], ["nalfurafine", "CHEMICAL", 95, 106], ["nalfurafine", "CHEMICAL", 95, 106], ["GRP", "GENE_OR_GENE_PRODUCT", 17, 20], ["GNTI", "SIMPLE_CHEMICAL", 38, 42], ["nalfurafine", "SIMPLE_CHEMICAL", 95, 106], ["mice", "ORGANISM", 110, 114], ["GRP", "PROTEIN", 17, 20], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["GRP mediates", "TEST", 17, 29], ["GNTI", "PROBLEM", 38, 42], ["scratching", "PROBLEM", 51, 61], ["nalfurafine", "TREATMENT", 95, 106]]], ["(P30DA013429 and NS18710).", [["NS18710", "CHEMICAL", 17, 24], ["NS", "TREATMENT", 17, 19]]], ["Incorporation of amino lactams into biologically active peptides may restrict conformational mobility, enhance selectivity and increase potency.", [["amino lactams", "CHEMICAL", 17, 30], ["amino lactams", "CHEMICAL", 17, 30], ["amino lactams", "SIMPLE_CHEMICAL", 17, 30], ["amino lactams", "TREATMENT", 17, 30], ["active peptides", "TREATMENT", 49, 64]]], ["Fmoc-protection has been used in a novel strategy for the solid-phase synthesis of peptides containing <and 1amino -lactams.", [["Fmoc-protection", "DISEASE", 0, 15], ["1amino -lactams", "CHEMICAL", 108, 123], ["<and 1amino -lactams", "CHEMICAL", 103, 123], ["1amino -lactams", "SIMPLE_CHEMICAL", 108, 123], ["Fmoc-protection", "TREATMENT", 0, 15], ["a novel strategy", "TREATMENT", 33, 49], ["the solid-phase synthesis of peptides", "TREATMENT", 54, 91]]], ["Lactams were introduced into the peptide chain by Nalkylation using five-and six-membered cyclic sulfamidates and lactam annulation under microwave heating.", [["Lactams", "CHEMICAL", 0, 7], ["Nalkylation", "CHEMICAL", 50, 61], ["lactam", "CHEMICAL", 114, 120], ["Lactams", "CHEMICAL", 0, 7], ["cyclic sulfamidates", "CHEMICAL", 90, 109], ["lactam", "CHEMICAL", 114, 120], ["Lactams", "SIMPLE_CHEMICAL", 0, 7], ["Nalkylation", "SIMPLE_CHEMICAL", 50, 61], ["six-membered cyclic sulfamidates", "SIMPLE_CHEMICAL", 77, 109], ["lactam annulation", "SIMPLE_CHEMICAL", 114, 131], ["Lactams", "TREATMENT", 0, 7], ["Nalkylation", "TREATMENT", 50, 61], ["six-membered cyclic sulfamidates", "TREATMENT", 77, 109], ["lactam annulation", "TREATMENT", 114, 131], ["microwave heating", "TREATMENT", 138, 155]]], ["Employing this solidphase protocol on the growth hormone secretagogue GHRP-6 as well as on the allosteric modulator of the IL1 receptor 101.10 has furnished lactam peptides for biological studies.", [["GHRP-6", "CHEMICAL", 70, 76], ["GHRP-6", "GENE_OR_GENE_PRODUCT", 70, 76], ["IL1", "GENE_OR_GENE_PRODUCT", 123, 126], ["growth hormone secretagogue GHRP-6", "PROTEIN", 42, 76], ["IL1 receptor 101.10", "PROTEIN", 123, 142], ["this solidphase protocol", "TREATMENT", 10, 34], ["the growth hormone secretagogue GHRP", "TEST", 38, 74], ["the IL1 receptor", "TEST", 119, 135], ["lactam peptides", "TREATMENT", 157, 172], ["biological studies", "TEST", 177, 195]]], ["The binding affinity IC50 values of the GHRP-6 lactam analogs on both GHS-R1a and CD36 are reported as well as inhibition of thymocyte proliferation measurements for the 101.10 lactam analogs.", [["thymocyte", "ANATOMY", 125, 134], ["GHRP-6 lactam", "CHEMICAL", 40, 53], ["101.10 lactam", "CHEMICAL", 170, 183], ["GHRP-6 lactam", "CHEMICAL", 40, 53], ["lactam", "CHEMICAL", 177, 183], ["GHRP-6 lactam", "SIMPLE_CHEMICAL", 40, 53], ["GHS-R1a", "GENE_OR_GENE_PRODUCT", 70, 77], ["CD36", "GENE_OR_GENE_PRODUCT", 82, 86], ["thymocyte", "CELL", 125, 134], ["101.10 lactam analogs", "SIMPLE_CHEMICAL", 170, 191], ["GHS", "PROTEIN", 70, 73], ["R1a", "PROTEIN", 74, 77], ["CD36", "PROTEIN", 82, 86], ["thymocyte", "CELL_TYPE", 125, 134], ["The binding affinity IC50 values", "TEST", 0, 32], ["the GHRP", "TEST", 36, 44], ["lactam analogs", "TEST", 47, 61], ["CD36", "TEST", 82, 86], ["thymocyte proliferation measurements", "TEST", 125, 161], ["lactam analogs", "TREATMENT", 177, 191], ["thymocyte proliferation", "OBSERVATION", 125, 148]]], ["In these cases, lactam analogs were prepared exhibiting similar and improved properties compared with the parent peptide.", [["lactam", "CHEMICAL", 16, 22], ["lactam", "CHEMICAL", 16, 22], ["lactam analogs", "SIMPLE_CHEMICAL", 16, 30], ["lactam analogs", "TREATMENT", 16, 30], ["the parent peptide", "TREATMENT", 102, 120], ["improved", "OBSERVATION_MODIFIER", 68, 76]]], ["The presence of lactams in natural products, such as penicillin, as well as in peptide analogs with enhanced potency and greater receptor selec-tivity [1] , underline their importance as synthetic tools in drug discovery.", [["penicillin", "CHEMICAL", 53, 63], ["penicillin", "CHEMICAL", 53, 63], ["lactams", "SIMPLE_CHEMICAL", 16, 23], ["penicillin", "SIMPLE_CHEMICAL", 53, 63], ["lactams in natural products", "TREATMENT", 16, 43], ["penicillin", "TREATMENT", 53, 63], ["enhanced potency", "TREATMENT", 100, 116], ["lactams", "OBSERVATION", 16, 23]]], ["In particular, the insertion of lactam motif in linear peptides limits conformational freedom stabilizing -turn structures with potential bioactivity [2] .", [["lactam", "CHEMICAL", 32, 38], ["lactam", "CHEMICAL", 32, 38], ["lactam motif", "PROTEIN", 32, 44], ["the insertion of lactam motif in linear peptides", "TREATMENT", 15, 63], ["conformational freedom stabilizing", "TREATMENT", 71, 105]]], ["Here, we present the synthesis of lactam-bridged peptide sequences performed by a solidphase approach on SynPhase lanterns [3] using cyclic sulfamidate to annulate the amino lactam residue onto the peptide chain.", [["lactam", "CHEMICAL", 34, 40], ["cyclic sulfamidate", "CHEMICAL", 133, 151], ["amino lactam", "CHEMICAL", 168, 180], ["lactam", "CHEMICAL", 34, 40], ["cyclic sulfamidate", "CHEMICAL", 133, 151], ["amino lactam", "CHEMICAL", 168, 180], ["lactam", "SIMPLE_CHEMICAL", 34, 40], ["cyclic sulfamidate", "SIMPLE_CHEMICAL", 133, 151], ["amino", "AMINO_ACID", 168, 173], ["lactam-bridged peptide sequences", "TREATMENT", 34, 66], ["a solidphase approach", "TREATMENT", 80, 101], ["SynPhase lanterns", "TREATMENT", 105, 122], ["cyclic sulfamidate", "TREATMENT", 133, 151], ["the amino lactam residue", "TREATMENT", 164, 188]]], ["Parallel synthesis of -amino -lactam (Agl) analogs of the allosteric modulator of IL-1 receptor 101.10 (rytvela) [4] was performed by split and mix chemistry on the lanterns.", [["-amino -lactam", "CHEMICAL", 22, 36], ["Agl", "CHEMICAL", 38, 41], ["-amino -lactam", "CHEMICAL", 22, 36], ["Agl", "CHEMICAL", 38, 41], ["-amino -lactam", "SIMPLE_CHEMICAL", 22, 36], ["Agl) analogs", "SIMPLE_CHEMICAL", 38, 50], ["IL-1 receptor 101.10", "SIMPLE_CHEMICAL", 82, 102], ["rytvela) [4]", "SIMPLE_CHEMICAL", 104, 116], ["Parallel synthesis of -amino -lactam (Agl) analogs", "TREATMENT", 0, 50], ["the allosteric modulator of IL", "TREATMENT", 54, 84]]], ["In particular, the double insertion of -amino -lactams in the same peptide sequence has been accomplished by this effective method for the solid-supported combinatorial synthesis of lactam-bridged peptides.", [["-amino -lactams", "CHEMICAL", 39, 54], ["lactam", "CHEMICAL", 182, 188], ["-amino -lactams", "CHEMICAL", 39, 54], ["lactam", "CHEMICAL", 182, 188], ["-amino -lactams", "SIMPLE_CHEMICAL", 39, 54], ["lactam-bridged peptides", "SIMPLE_CHEMICAL", 182, 205], ["the double insertion of -amino -lactams", "TREATMENT", 15, 54], ["combinatorial synthesis of lactam", "TREATMENT", 155, 188], ["bridged peptides", "TREATMENT", 189, 205]]], ["[ The replication of the type 1 human immunodeficiency virus (HIV) is regulated by its viral mRNA expression.", [["human immunodeficiency virus", "DISEASE", 32, 60], ["type 1", "ORGANISM", 25, 31], ["human immunodeficiency virus", "ORGANISM", 32, 60], ["HIV", "ORGANISM", 62, 65], ["viral mRNA", "RNA", 87, 97], ["human immunodeficiency virus (HIV", "SPECIES", 32, 65], ["human immunodeficiency virus", "SPECIES", 32, 60], ["HIV", "SPECIES", 62, 65], ["the type 1 human immunodeficiency virus", "PROBLEM", 21, 60], ["HIV", "PROBLEM", 62, 65], ["immunodeficiency virus", "OBSERVATION", 38, 60], ["viral mRNA expression", "OBSERVATION", 87, 108]]], ["Control of HIV RNA expression is complex and involves the interplay of viral transactivators and several cellular proteins.", [["cellular", "ANATOMY", 105, 113], ["HIV", "ORGANISM", 11, 14], ["cellular", "CELL", 105, 113], ["HIV RNA", "RNA", 11, 18], ["viral transactivators", "PROTEIN", 71, 92], ["cellular proteins", "PROTEIN", 105, 122], ["HIV", "SPECIES", 11, 14], ["HIV RNA expression", "PROBLEM", 11, 29], ["viral transactivators", "PROBLEM", 71, 92], ["several cellular proteins", "PROBLEM", 97, 122], ["HIV RNA", "OBSERVATION", 11, 18], ["cellular proteins", "OBSERVATION", 105, 122]]], ["Rev is one of these proteins.", [["Rev", "GENE_OR_GENE_PRODUCT", 0, 3], ["Rev", "PROTEIN", 0, 3], ["these proteins", "TREATMENT", 14, 28]]], ["The HIV-1 Rev protein is an essential regulator of the HIV-1 mRNA expression, through multimerization Rev molecules bind throughout the Revresponsive element RRE and promotes the export of unspliced and partially spliced mRNA.", [["HIV-1", "ORGANISM", 4, 9], ["Rev", "GENE_OR_GENE_PRODUCT", 10, 13], ["HIV-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["HIV-1 Rev protein", "PROTEIN", 4, 21], ["Rev molecules", "PROTEIN", 102, 115], ["Revresponsive element RRE", "DNA", 136, 161], ["unspliced and partially spliced mRNA", "RNA", 189, 225], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 55, 60], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 55, 60], ["The HIV", "TEST", 0, 7], ["the HIV", "TEST", 51, 58], ["Rev molecules bind", "PROBLEM", 102, 120], ["partially spliced mRNA", "PROBLEM", 203, 225], ["molecules bind", "OBSERVATION", 106, 120], ["spliced mRNA", "OBSERVATION", 213, 225]]], ["It is suggested that the multimerization regions of Rev are two separate -helices comprising residues 9-24 and 34-62.", [["Rev", "GENE_OR_GENE_PRODUCT", 52, 55], ["multimerization regions", "PROTEIN", 25, 48], ["Rev", "PROTEIN", 52, 55], ["residues 9-24 and 34-62", "PROTEIN", 93, 116]]], ["Here we report the synthesis of an -helix mimic of the Rev protein domain located between amino acid 10 and 24 which is responsible for Rev multimerization.", [["amino acid", "CHEMICAL", 90, 100], ["amino acid", "CHEMICAL", 90, 100], ["amino acid 10", "AMINO_ACID", 90, 103], ["Rev", "GENE_OR_GENE_PRODUCT", 136, 139], ["Rev protein domain", "PROTEIN", 55, 73], ["amino acid 10 and 24", "PROTEIN", 90, 110], ["Rev", "PROTEIN", 136, 139], ["the Rev protein domain", "PROBLEM", 51, 73], ["amino acid", "TEST", 90, 100], ["Rev multimerization", "TREATMENT", 136, 155], ["responsible for", "UNCERTAINTY", 120, 135], ["Rev multimerization", "OBSERVATION", 136, 155]]], ["Synthesis of several -helical, cyclic peptides of the Rev protein domain mimics was carried out by SPPS, using Fmoc strategy.", [["Fmoc", "CHEMICAL", 111, 115], ["SPPS", "SIMPLE_CHEMICAL", 99, 103], ["Rev protein domain", "PROTEIN", 54, 72], ["Synthesis", "TREATMENT", 0, 9], ["the Rev protein domain mimics", "PROBLEM", 50, 79], ["Fmoc strategy", "TREATMENT", 111, 124]]], ["The a helical nature of these peptides has shown by Circular Dichroism (CD) and NMR spectroscopy.", [["NMR spectroscopy", "TEST", 80, 96], ["Circular Dichroism", "OBSERVATION", 52, 70]]], ["The Fluorescence Resonance Energy Transfer (FRET) assay for inhibition of Rev-multimerization, will also be discussed.", [["Rev-multimerization", "TREATMENT", 74, 93]]], ["The use of peptides as drugs in pharmaceutical application is hindered by their susceptibility to enzymatic degradation (proteolysis) and so low bioavailability.", [["peptides", "TREATMENT", 11, 19], ["drugs", "TREATMENT", 23, 28], ["pharmaceutical application", "TREATMENT", 32, 58], ["enzymatic degradation (proteolysis", "PROBLEM", 98, 132]]], ["Peptidomimetic oligomers, such as -peptides with an additional methylene group in the backbone, are gaining recognition from biological and pharmaceutical stand points as they are considerably more resilient to proteolysis and metabolism.", [["methylene", "CHEMICAL", 63, 72], ["methylene", "CHEMICAL", 63, 72], ["methylene", "SIMPLE_CHEMICAL", 63, 72], ["Peptidomimetic oligomers", "PROBLEM", 0, 24], ["an additional methylene group in the backbone", "TREATMENT", 49, 94]]], ["Recently we have reported two new classes of -peptides, 3 -and 2 -peptides derived from L-aspartic acid and L-diaminopropionic acid, respectively.", [["L-aspartic acid", "CHEMICAL", 88, 103], ["L-diaminopropionic acid", "CHEMICAL", 108, 131], ["L-aspartic acid", "CHEMICAL", 88, 103], ["L-diaminopropionic acid", "CHEMICAL", 108, 131], ["3 -and 2 -peptides", "SIMPLE_CHEMICAL", 56, 74], ["L-aspartic acid", "SIMPLE_CHEMICAL", 88, 103], ["L-diaminopropionic acid", "SIMPLE_CHEMICAL", 108, 131], ["peptides", "TEST", 46, 54], ["L-aspartic acid and L-diaminopropionic acid", "TREATMENT", 88, 131], ["new", "OBSERVATION_MODIFIER", 30, 33]]], ["Here we studied the proteolytic stability of these -peptides, and a mixed a/ -peptide against three proteolytic enzymes (pronase, trypsin, and elastase) as well as human serum.", [["serum", "ANATOMY", 170, 175], ["pronase", "SIMPLE_CHEMICAL", 121, 128], ["trypsin", "GENE_OR_GENE_PRODUCT", 130, 137], ["elastase", "GENE_OR_GENE_PRODUCT", 143, 151], ["human", "ORGANISM", 164, 169], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["proteolytic enzymes", "PROTEIN", 100, 119], ["pronase", "PROTEIN", 121, 128], ["trypsin", "PROTEIN", 130, 137], ["elastase", "PROTEIN", 143, 151], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 164, 169], ["three proteolytic enzymes", "TEST", 94, 119], ["pronase", "TEST", 121, 128], ["trypsin", "TEST", 130, 137], ["elastase", "TEST", 143, 151], ["human serum", "TEST", 164, 175]]], ["The stability of these peptides was compared to an -peptide, to evaluate their potential as peptidomimetics.University of MichiganPeptides containing -linkages were resistant to all conditions, whereas, the mixed /-peptide exhibited proteolysis in the presence of trypsin and pronase but not elastase.", [["MichiganPeptides", "CHEMICAL", 122, 138], ["MichiganPeptides", "SIMPLE_CHEMICAL", 122, 138], ["trypsin", "GENE_OR_GENE_PRODUCT", 264, 271], ["pronase", "SIMPLE_CHEMICAL", 276, 283], ["elastase", "GENE_OR_GENE_PRODUCT", 292, 300], ["trypsin", "PROTEIN", 264, 271], ["pronase", "PROTEIN", 276, 283], ["elastase", "PROTEIN", 292, 300], ["an -peptide", "TEST", 48, 59], ["proteolysis", "PROBLEM", 233, 244], ["trypsin and pronase", "TREATMENT", 264, 283], ["elastase", "PROBLEM", 292, 300], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["elastase", "OBSERVATION", 292, 300]]], ["The rate of degradation of the mixed /peptide was slower than that would be expected for an -peptide, a feature important for drug design.", [["the mixed /peptide", "PROBLEM", 27, 45]]], ["The toxicity profile and application of these oligomers in the design of biological active peptides will be highlighted.University of MichiganP 111 EFFICIENT SOLID-PHASE SYNTHESIS OF TRIS-BENZAMIDES FOR A RAPID PRODUCTION OF ALPHA-HELIX MIMETICS T. Lee, J. Ahn University of Texas at Dallas -Helix involves widely in protein-protein interaction and modulation of this key process would be of great interest in studying many fundamental biochemical pathways.", [["toxicity", "DISEASE", 4, 12], ["The toxicity profile", "PROBLEM", 0, 20], ["these oligomers", "TREATMENT", 40, 55], ["biological active peptides", "TREATMENT", 73, 99], ["MichiganP", "TEST", 134, 143]]], ["However, developing non-peptidic small molecules for this goal is still a challenging area of research.", [["developing non-peptidic small molecules", "PROBLEM", 9, 48], ["non-peptidic", "OBSERVATION_MODIFIER", 20, 32], ["small molecules", "OBSERVATION", 33, 48]]], ["Suitable -helix mimetics should be able to hold a structure to properly place functional groups as presented in a helix and also to be easily synthesized for a production of a number of compounds for efficient biochemical studies.", [["Suitable -helix mimetics", "TREATMENT", 0, 24], ["efficient biochemical studies", "TEST", 200, 229]]], ["Recently, we have reported a tris-benzamide as a scaffold to mimic the side chains of amino acids found at the i, i\u00fe4, and i\u00fe7 positions of an -helix.", [["tris-benzamide", "CHEMICAL", 29, 43], ["amino acids", "CHEMICAL", 86, 97], ["tris-benzamide", "CHEMICAL", 29, 43], ["amino acids", "CHEMICAL", 86, 97], ["tris-benzamide", "SIMPLE_CHEMICAL", 29, 43], ["amino acids", "AMINO_ACID", 86, 97], ["i\u00fe7 positions", "PROTEIN", 123, 136], ["-helix", "PROTEIN", 143, 149], ["a tris-benzamide", "TREATMENT", 27, 43], ["a scaffold", "TREATMENT", 47, 57], ["amino acids", "TREATMENT", 86, 97], ["-helix", "OBSERVATION", 143, 149]]], ["Its simple and straightforward synthesis uses conventional and high-yielding reactions that can be readily amenable to solid-phase combinatorial synthesis.", [["solid-phase combinatorial synthesis", "TREATMENT", 119, 154], ["simple", "OBSERVATION_MODIFIER", 4, 10]]], ["Thus, we report herein an efficient solid-phase strategy to synthesize a number of tris-benzamides.", [["tris-benzamides", "CHEMICAL", 83, 98], ["tris-benzamides", "CHEMICAL", 83, 98], ["tris-benzamides", "SIMPLE_CHEMICAL", 83, 98]]], ["The library construction involved several repeating reactions including removal of an allyl ester, an amidebond formation via O-N acyl migration, and an O-alkylation on a solid support, and each step was carried out with high synthetic yield.", [["allyl ester", "CHEMICAL", 86, 97], ["O-N acyl", "CHEMICAL", 126, 134], ["allyl ester", "CHEMICAL", 86, 97], ["O-N acyl", "CHEMICAL", 126, 134], ["O", "CHEMICAL", 153, 154], ["allyl ester", "SIMPLE_CHEMICAL", 86, 97], ["amidebond", "SIMPLE_CHEMICAL", 102, 111], ["O-N acyl", "SIMPLE_CHEMICAL", 126, 134], ["The library construction", "TREATMENT", 0, 24], ["several repeating reactions", "PROBLEM", 34, 61], ["removal", "TREATMENT", 72, 79], ["an allyl ester", "TREATMENT", 83, 97], ["an amidebond formation", "TREATMENT", 99, 121], ["N acyl migration", "TREATMENT", 128, 144], ["an O-alkylation", "TREATMENT", 150, 165], ["a solid support", "TREATMENT", 169, 184], ["acyl migration", "OBSERVATION", 130, 144]]], ["This facile and efficient approach allowed the production of tris-benzamides containing functional groups that represent hydrophobic (e.g., Ala, Val, Leu, Phe, Trp) and hydrophilic (e.g., Glu, Lys) amino acids, in high overall yield and purity.", [["tris-benzamides", "CHEMICAL", 61, 76], ["Val, Leu, Phe, Trp", "CHEMICAL", 145, 163], ["Glu", "CHEMICAL", 188, 191], ["Lys", "CHEMICAL", 193, 196], ["amino acids", "CHEMICAL", 198, 209], ["tris-benzamides", "CHEMICAL", 61, 76], ["Ala", "CHEMICAL", 140, 143], ["Val", "CHEMICAL", 145, 148], ["Leu", "CHEMICAL", 150, 153], ["Phe", "CHEMICAL", 155, 158], ["Trp", "CHEMICAL", 160, 163], ["Glu", "CHEMICAL", 188, 191], ["Lys", "CHEMICAL", 193, 196], ["amino acids", "CHEMICAL", 198, 209], ["tris-benzamides", "SIMPLE_CHEMICAL", 61, 76], ["Leu", "AMINO_ACID", 150, 153], ["Phe", "AMINO_ACID", 155, 158], ["Trp", "AMINO_ACID", 160, 163], ["Glu, Lys)", "SIMPLE_CHEMICAL", 188, 197], ["amino acids", "AMINO_ACID", 198, 209], ["This facile", "TREATMENT", 0, 11], ["the production of tris-benzamides", "TREATMENT", 43, 76], ["Ala", "TEST", 140, 143], ["Leu", "TEST", 150, 153], ["Phe", "TEST", 155, 158], ["Trp", "TEST", 160, 163], ["hydrophilic (e.g., Glu, Lys)", "PROBLEM", 169, 197], ["amino acids", "TEST", 198, 209]]], ["Preterm labor is a significant medical and social burden, estimated at $ 9 billion per year in the USA (the highest per patient cost of any disorder).", [["Preterm labor", "DISEASE", 0, 13], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["Preterm labor", "PROBLEM", 0, 13], ["any disorder", "PROBLEM", 136, 148], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["Furthermore, preterm labor has steadily increased over the last thirty years.", [["preterm labor", "DISEASE", 13, 26], ["preterm labor", "PROBLEM", 13, 26], ["preterm", "OBSERVATION_MODIFIER", 13, 20], ["labor", "OBSERVATION", 21, 26], ["steadily", "OBSERVATION_MODIFIER", 31, 39], ["increased", "OBSERVATION_MODIFIER", 40, 49]]], ["A member of the G-protein coupled receptor family, the prostaglandin F2a (FP) receptor is a valid target for the development of a method to prevent preterm labor, because it is directly involved in uterine contractions and over-expressed at onset and during labor.", [["uterine", "ANATOMY", 198, 205], ["prostaglandin F2a", "CHEMICAL", 55, 72], ["preterm labor", "DISEASE", 148, 161], ["prostaglandin F2a", "CHEMICAL", 55, 72], ["G-protein coupled receptor", "GENE_OR_GENE_PRODUCT", 16, 42], ["prostaglandin F2a", "GENE_OR_GENE_PRODUCT", 55, 72], ["FP) receptor", "GENE_OR_GENE_PRODUCT", 74, 86], ["uterine", "ORGAN", 198, 205], ["G-protein coupled receptor family", "PROTEIN", 16, 49], ["prostaglandin F2a (FP) receptor", "PROTEIN", 55, 86], ["the prostaglandin F2a (FP) receptor", "TREATMENT", 51, 86], ["a method", "TREATMENT", 128, 136], ["preterm labor", "PROBLEM", 148, 161], ["uterine contractions", "PROBLEM", 198, 218], ["labor", "PROBLEM", 258, 263], ["uterine contractions", "ANATOMY", 198, 218]]], ["Potent allosteric modulators of the FP receptor have been developed, which feature an indolizidinone dipeptide mimic as a type II' -turn surrogate (Fig.1 ).1 In addition to delaying labor and stopping uterine contractions in vivo, the mimic THG113.824 has been used in vitro as a tool for studying secondary messenger signalling on FP binding to its receptor.", [["uterine", "ANATOMY", 201, 208], ["indolizidinone", "CHEMICAL", 86, 100], ["THG113.824", "CHEMICAL", 241, 251], ["indolizidinone dipeptide", "CHEMICAL", 86, 110], ["FP receptor", "GENE_OR_GENE_PRODUCT", 36, 47], ["indolizidinone dipeptide", "SIMPLE_CHEMICAL", 86, 110], ["uterine", "ORGAN", 201, 208], ["FP", "SIMPLE_CHEMICAL", 332, 334], ["FP receptor", "PROTEIN", 36, 47], ["an indolizidinone dipeptide mimic", "TREATMENT", 83, 116], ["delaying labor", "PROBLEM", 173, 187], ["uterine contractions", "PROBLEM", 201, 221]]], ["Isotopically labelled and photo-reactive analogs of THG113.824 are being pursued to better understand its mechanism of action.", [["THG113.824", "CHEMICAL", 52, 62], ["THG113.824", "CHEMICAL", 52, 62], ["THG113.824", "SIMPLE_CHEMICAL", 52, 62]]], ["Our presentation will discuss the synthesis, biological activity and determination of the binding site of these novel allosteric modulators of FP receptor activity.University of South FloridaThe overall balance of pro and anti-apoptotic protein interactions controls the susceptibility of a cell towards programmed cell death.", [["cell", "ANATOMY", 291, 295], ["cell", "ANATOMY", 315, 319], ["death", "DISEASE", 320, 325], ["FP receptor", "GENE_OR_GENE_PRODUCT", 143, 154], ["cell", "CELL", 291, 295], ["cell", "CELL", 315, 319], ["FP receptor", "PROTEIN", 143, 154], ["the synthesis", "TREATMENT", 30, 43], ["the binding site", "PROBLEM", 86, 102], ["pro and anti-apoptotic protein interactions", "TREATMENT", 214, 257], ["programmed cell death", "PROBLEM", 304, 325], ["cell death", "OBSERVATION", 315, 325]]], ["Overexpression of the anti-apoptotic proteins, MDM2 and MDMX, is associated with chemo and radiation therapy resistance.", [["MDM2", "GENE_OR_GENE_PRODUCT", 47, 51], ["MDMX", "GENE_OR_GENE_PRODUCT", 56, 60], ["anti-apoptotic proteins", "PROTEIN", 22, 45], ["MDM2", "PROTEIN", 47, 51], ["MDMX", "PROTEIN", 56, 60], ["the anti-apoptotic proteins", "TREATMENT", 18, 45], ["MDM2", "PROBLEM", 47, 51], ["MDMX", "PROBLEM", 56, 60], ["chemo", "TREATMENT", 81, 86], ["radiation therapy resistance", "TREATMENT", 91, 119]]], ["NMR studies have shown that the tumor suppressor p53 protein, forms an amphipathichelix in the NH2 terminal that directly interacts (binds) with a hydrophobic groove on the globular MDM2 and MDMX domains; resulting in inhibition of apoptosis, allowing the continuation of tumor growth.", [["tumor", "ANATOMY", 32, 37], ["globular", "ANATOMY", 173, 181], ["tumor", "ANATOMY", 272, 277], ["tumor", "DISEASE", 32, 37], ["tumor", "DISEASE", 272, 277], ["NH2", "CHEMICAL", 95, 98], ["tumor", "CANCER", 32, 37], ["p53", "GENE_OR_GENE_PRODUCT", 49, 52], ["MDM2", "GENE_OR_GENE_PRODUCT", 182, 186], ["tumor", "CANCER", 272, 277], ["tumor suppressor p53 protein", "PROTEIN", 32, 60], ["amphipathichelix", "PROTEIN", 71, 87], ["NH2 terminal", "PROTEIN", 95, 107], ["globular MDM2 and MDMX domains", "PROTEIN", 173, 203], ["NMR studies", "TEST", 0, 11], ["the tumor suppressor p53 protein", "TEST", 28, 60], ["an amphipathichelix in the NH2 terminal", "PROBLEM", 68, 107], ["MDMX domains", "TEST", 191, 203], ["apoptosis", "PROBLEM", 232, 241], ["tumor growth", "PROBLEM", 272, 284], ["tumor", "OBSERVATION", 32, 37], ["globular", "OBSERVATION_MODIFIER", 173, 181], ["MDM2", "OBSERVATION", 182, 186], ["MDMX domains", "OBSERVATION", 191, 203], ["apoptosis", "OBSERVATION", 232, 241], ["tumor", "OBSERVATION", 272, 277]]], ["Synthesis of derivatives that mimic the -helix portion of p53's NH2 activation site, capable of disrupting the p53/MDM2 and p53/MDMX interactions, could represent a great potential for medicinal chemistry studies.", [["NH2", "CHEMICAL", 64, 67], ["p53's NH2", "GENE_OR_GENE_PRODUCT", 58, 67], ["p53", "GENE_OR_GENE_PRODUCT", 111, 114], ["MDM2", "GENE_OR_GENE_PRODUCT", 115, 119], ["p53", "GENE_OR_GENE_PRODUCT", 124, 127], ["MDMX", "GENE_OR_GENE_PRODUCT", 128, 132], ["-helix portion", "PROTEIN", 40, 54], ["p53's", "PROTEIN", 58, 63], ["NH2", "PROTEIN", 64, 67], ["p53", "PROTEIN", 111, 114], ["MDM2", "PROTEIN", 115, 119], ["p53", "PROTEIN", 124, 127], ["MDMX", "PROTEIN", 128, 132], ["Synthesis of derivatives", "TREATMENT", 0, 24], ["NH2 activation site", "PROBLEM", 64, 83], ["medicinal chemistry studies", "TEST", 185, 212]]], ["There have been documented syntheses of various potent alpha helix mimics that successfully bind to NH2 activation site of the p53 protein.", [["NH2", "CHEMICAL", 100, 103], ["NH2", "GENE_OR_GENE_PRODUCT", 100, 103], ["p53", "GENE_OR_GENE_PRODUCT", 127, 130], ["NH2", "PROTEIN", 100, 103], ["p53 protein", "PROTEIN", 127, 138], ["various potent alpha helix mimics", "TREATMENT", 40, 73], ["the p53 protein", "TEST", 123, 138]]], ["However, these compounds have hydrophobic scaffolds that limit their usefulness as drugs.", [["hydrophobic scaffolds", "TREATMENT", 30, 51], ["hydrophobic scaffolds", "OBSERVATION", 30, 51]]], ["Presented, is the design and synthesis of a new family of -helical mimics based on a functionalized hybrid scaffold containing both piperazine and pyrimidine based repeat units, holding amino acid-like side chain residues in positions that mimic the ith, ith\u00fe4, and ith\u00fe7 positions of an alpha helix.", [["piperazine", "CHEMICAL", 132, 142], ["pyrimidine", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 186, 196], ["piperazine", "CHEMICAL", 132, 142], ["pyrimidine", "CHEMICAL", 147, 157], ["amino acid", "CHEMICAL", 186, 196], ["piperazine", "SIMPLE_CHEMICAL", 132, 142], ["pyrimidine", "SIMPLE_CHEMICAL", 147, 157], ["amino acid", "AMINO_ACID", 186, 196], ["ith\u00fe4", "PROTEIN", 255, 260], ["ith\u00fe7 positions", "PROTEIN", 266, 281], ["alpha helix", "PROTEIN", 288, 299], ["-helical mimics", "TREATMENT", 58, 73], ["a functionalized hybrid scaffold", "TREATMENT", 83, 115], ["both piperazine", "TREATMENT", 127, 142], ["pyrimidine based repeat units", "TREATMENT", 147, 176], ["amino acid", "TREATMENT", 186, 196], ["side chain residues", "TREATMENT", 202, 221], ["an alpha helix", "TREATMENT", 285, 299], ["alpha helix", "OBSERVATION", 288, 299]]], ["This novel scaffold has a high degree of polarity therefore increasing its degree of solubility and potential as a novel therapeutic when compared to previous -helix mimics.P 114 EFFECT OF HELIX-PROMOTING STRATEGIES ON THE BIOLOGICAL ACTIVITY OF NOVEL ANA-LOGUES OF THE B-CHAIN OF INSL3F.", [["INSL3F", "DNA", 281, 287], ["high degree", "OBSERVATION_MODIFIER", 26, 37], ["polarity", "OBSERVATION_MODIFIER", 41, 49], ["increasing", "OBSERVATION_MODIFIER", 60, 70], ["degree", "OBSERVATION_MODIFIER", 75, 81], ["solubility", "OBSERVATION_MODIFIER", 85, 95]]], ["Shabanpoor, R. Hughes, R. Bathgate, F. Separovic, J. Wade Howard Florey Institute, University of Melbourne Insulin-like 3 (INSL3) is a novel circulating peptide hormone that is produced by testicular Leydig cells and ovarian thecal and luteal cells.", [["testicular Leydig cells", "ANATOMY", 189, 212], ["ovarian thecal", "ANATOMY", 217, 231], ["luteal cells", "ANATOMY", 236, 248], ["Insulin-like 3", "GENE_OR_GENE_PRODUCT", 107, 121], ["INSL3", "GENE_OR_GENE_PRODUCT", 123, 128], ["testicular Leydig cells", "CELL", 189, 212], ["ovarian thecal", "CELL", 217, 231], ["luteal cells", "CELL", 236, 248], ["INSL3", "PROTEIN", 123, 128], ["testicular Leydig cells", "CELL_TYPE", 189, 212], ["ovarian thecal and luteal cells", "CELL_TYPE", 217, 248], ["Melbourne Insulin", "TREATMENT", 97, 114], ["a novel circulating peptide hormone", "TREATMENT", 133, 168], ["testicular Leydig cells", "PROBLEM", 189, 212], ["ovarian thecal and luteal cells", "PROBLEM", 217, 248], ["R. Hughes", "ANATOMY", 12, 21], ["testicular", "ANATOMY", 189, 199], ["Leydig cells", "OBSERVATION", 200, 212], ["ovarian", "ANATOMY", 217, 224], ["thecal", "ANATOMY_MODIFIER", 225, 231], ["luteal cells", "OBSERVATION", 236, 248]]], ["In males, INSL3 is responsible for testicular descent during foetal life and suppresses germ cell apoptosis in adult males, whereas in females, it causes oocyte maturation.", [["testicular", "ANATOMY", 35, 45], ["foetal", "ANATOMY", 61, 67], ["germ cell", "ANATOMY", 88, 97], ["oocyte", "ANATOMY", 154, 160], ["INSL3", "GENE_OR_GENE_PRODUCT", 10, 15], ["testicular", "ORGAN", 35, 45], ["foetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 61, 67], ["germ cell", "CELL", 88, 97], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 154, 160], ["INSL3", "PROTEIN", 10, 15], ["testicular descent", "PROBLEM", 35, 53], ["foetal life", "TREATMENT", 61, 72], ["germ cell apoptosis", "PROBLEM", 88, 107], ["oocyte maturation", "PROBLEM", 154, 171], ["germ cell apoptosis", "OBSERVATION", 88, 107], ["oocyte maturation", "OBSERVATION", 154, 171]]], ["Antagonists of INSL3 thus have significant potential clinical application as contraceptives in both males and females.", [["INSL3", "GENE_OR_GENE_PRODUCT", 15, 20], ["INSL3", "PROTEIN", 15, 20], ["INSL3", "PROBLEM", 15, 20]]], ["Previous work has shown that the INSL3 receptor binding region is largely confined to the B-chain central -helicity of this peptide in order to better present the key receptor binding residues and increase its affinity for the receptor.", [["INSL3", "GENE_OR_GENE_PRODUCT", 33, 38], ["INSL3 receptor binding region", "PROTEIN", 33, 62], ["the INSL3 receptor binding region", "PROBLEM", 29, 62], ["this peptide", "TREATMENT", 119, 131]]], ["Analogues of INSL3 with higher _-helicity generally had higher receptor binding affinity although other structural considerations limit their effectiveness.P 115 HIGH-THROUGHPUT SEQUENCING OF PEPTOIDS AND PEPTIDE-PEPTOID HYBRIDS BY PARTIAL EDMAN DEGRADATION AND MASS SPECTROMETRYA.", [["INSL3", "GENE_OR_GENE_PRODUCT", 13, 18], ["INSL3", "PROTEIN", 13, 18], ["Analogues of INSL3", "PROBLEM", 0, 18], ["higher _-helicity", "PROBLEM", 24, 41], ["higher receptor binding affinity", "PROBLEM", 56, 88], ["P", "TEST", 156, 157], ["PEPTOIDS", "PROBLEM", 192, 200], ["PARTIAL EDMAN DEGRADATION", "PROBLEM", 232, 257], ["MASS", "OBSERVATION", 262, 266]]], ["Thakkar and D. Pei Department of Chemistry, The Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210 A method for the rapid sequence determination of peptoids [oligo(Nsubstituted glycines)] and peptide-peptoid hybrids selected from onebead-one-compound combinatorial libraries has been developed.", [["oligo(Nsubstituted glycines", "CHEMICAL", 173, 200], ["peptoids", "SIMPLE_CHEMICAL", 163, 171], ["oligo(Nsubstituted glycines", "SIMPLE_CHEMICAL", 173, 200], ["the rapid sequence determination", "TEST", 127, 159], ["peptoids", "PROBLEM", 163, 171], ["oligo(Nsubstituted glycines)", "TREATMENT", 173, 201], ["peptide", "TREATMENT", 207, 214], ["peptoid hybrids", "TREATMENT", 215, 230], ["compound combinatorial libraries", "PROBLEM", 257, 289], ["combinatorial libraries", "OBSERVATION", 266, 289]]], ["In this method, beads carrying unique peptoid (or peptide-peptoid) sequences were subjected to multiple cycles of partial Edman degradation (PED) by the treatment with a 1:3 (mol/mol) mixture of phenyl isothiocyanate (PITC) and 9-fluorenylmethyl chloroformate (Fmoc-Cl) to generate a series of N-terminal truncation products for each resin-bound peptoid.", [["phenyl isothiocyanate", "CHEMICAL", 195, 216], ["PITC", "CHEMICAL", 218, 222], ["9-fluorenylmethyl chloroformate", "CHEMICAL", 228, 259], ["Fmoc-Cl", "CHEMICAL", 261, 268], ["phenyl isothiocyanate", "CHEMICAL", 195, 216], ["PITC", "CHEMICAL", 218, 222], ["9-fluorenylmethyl chloroformate", "CHEMICAL", 228, 259], ["Fmoc-Cl", "CHEMICAL", 261, 268], ["N", "CHEMICAL", 294, 295], ["peptoid", "SIMPLE_CHEMICAL", 38, 45], ["phenyl isothiocyanate", "SIMPLE_CHEMICAL", 195, 216], ["PITC", "SIMPLE_CHEMICAL", 218, 222], ["9-fluorenylmethyl chloroformate", "SIMPLE_CHEMICAL", 228, 259], ["Fmoc-Cl", "SIMPLE_CHEMICAL", 261, 268], ["peptoid", "SIMPLE_CHEMICAL", 346, 353], ["peptoid (or peptide-peptoid) sequences", "DNA", 38, 76], ["N-terminal truncation products", "PROTEIN", 294, 324], ["resin-bound peptoid", "PROTEIN", 334, 353], ["peptide-peptoid) sequences", "TREATMENT", 50, 76], ["partial Edman degradation", "PROBLEM", 114, 139], ["a 1:3 (mol/mol)", "TREATMENT", 168, 183], ["phenyl isothiocyanate (PITC", "TREATMENT", 195, 222], ["9-fluorenylmethyl chloroformate (Fmoc-Cl", "TREATMENT", 228, 268], ["N-terminal truncation products", "TREATMENT", 294, 324], ["each resin-bound peptoid", "TREATMENT", 329, 353], ["bound peptoid", "OBSERVATION", 340, 353]]], ["After PED, the Fmoc group was removed from the N-terminus and any reacted side chains via piperidine treatment.", [["Fmoc", "CHEMICAL", 15, 19], ["piperidine", "CHEMICAL", 90, 100], ["Fmoc", "CHEMICAL", 15, 19], ["N", "CHEMICAL", 47, 48], ["piperidine", "CHEMICAL", 90, 100], ["piperidine", "SIMPLE_CHEMICAL", 90, 100], ["N-terminus", "PROTEIN", 47, 57], ["the Fmoc group", "TREATMENT", 11, 25], ["the N-terminus", "TREATMENT", 43, 57], ["any reacted side chains", "TREATMENT", 62, 85], ["piperidine treatment", "TREATMENT", 90, 110], ["piperidine treatment", "OBSERVATION", 90, 110]]], ["The resulting mixture of the full-length peptoid and its truncation products was analyzed by matrix-assisted laser desorption ionization (MALDI) mass spectrometry, to reveal the sequence of the full-length peptoid.", [["peptoid", "SIMPLE_CHEMICAL", 41, 48], ["truncation products", "PROTEIN", 57, 76], ["full-length peptoid", "DNA", 194, 213], ["the full-length peptoid", "TREATMENT", 25, 48], ["its truncation products", "TREATMENT", 53, 76], ["matrix-assisted laser desorption ionization", "TREATMENT", 93, 136], ["mass spectrometry", "TEST", 145, 162], ["mixture", "OBSERVATION_MODIFIER", 14, 21]]], ["This rapid, highthroughput, sensitive, and inexpensive sequencing method should greatly expand the utility of combinatorial peptoid libraries in biomedical and materials research.P 116 SELF-PEPTIDOMIC REPERTOIRE OF THE HUMAN PRE-NODAL LYMPHC.", [["NODAL LYMPHC", "DNA", 229, 241], ["inexpensive sequencing method", "TEST", 43, 72], ["combinatorial peptoid libraries", "TREATMENT", 110, 141], ["P", "TEST", 179, 180], ["peptoid libraries", "OBSERVATION", 124, 141], ["NODAL LYMPHC", "OBSERVATION", 229, 241]]], ["Clement, R. Maitra, R. Sahu, L. Santambrogio Pathology, Albert Einstein College of Medicine, Bronx, NY The reticular network within the lymph node is a conduit system forming the infrastructure for the fast delivery of soluble substances from the afferent lymph to the lumen of high endothelial venules (HEVs).", [["reticular network", "ANATOMY", 107, 124], ["lymph node", "ANATOMY", 136, 146], ["conduit system", "ANATOMY", 152, 166], ["afferent lymph", "ANATOMY", 247, 261], ["lumen", "ANATOMY", 269, 274], ["high endothelial venules", "ANATOMY", 278, 302], ["HEVs", "ANATOMY", 304, 308], ["reticular network", "MULTI-TISSUE_STRUCTURE", 107, 124], ["lymph node", "MULTI-TISSUE_STRUCTURE", 136, 146], ["afferent lymph", "MULTI-TISSUE_STRUCTURE", 247, 261], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 269, 274], ["endothelial venules", "TISSUE", 283, 302], ["HEVs", "CELL", 304, 308], ["high endothelial venules", "CELL_TYPE", 278, 302], ["HEVs", "CELL_TYPE", 304, 308], ["The reticular network within the lymph node", "PROBLEM", 103, 146], ["a conduit system", "TREATMENT", 150, 166], ["the fast delivery of soluble substances", "TREATMENT", 198, 237], ["reticular", "OBSERVATION_MODIFIER", 107, 116], ["lymph node", "OBSERVATION", 136, 146], ["conduit system", "OBSERVATION", 152, 166], ["fast", "OBSERVATION_MODIFIER", 202, 206], ["soluble substances", "OBSERVATION", 219, 237], ["afferent lymph", "OBSERVATION", 247, 261], ["lumen", "ANATOMY_MODIFIER", 269, 274], ["high endothelial venules", "OBSERVATION", 278, 302]]], ["Conduit associated dendritic cells (DC) are capable of taking up and processing soluble antigens by directly fishing into the nanometer size conduits transporting the afferent lymph.", [["Conduit", "ANATOMY", 0, 7], ["dendritic cells", "ANATOMY", 19, 34], ["DC", "ANATOMY", 36, 38], ["afferent lymph", "ANATOMY", 167, 181], ["dendritic cells", "CELL", 19, 34], ["DC", "CELL", 36, 38], ["afferent lymph", "MULTI-TISSUE_STRUCTURE", 167, 181], ["Conduit associated dendritic cells", "CELL_TYPE", 0, 34], ["DC", "CELL_TYPE", 36, 38], ["soluble antigens", "PROTEIN", 80, 96], ["Conduit associated dendritic cells", "PROBLEM", 0, 34], ["processing soluble antigens", "TREATMENT", 69, 96], ["the nanometer size conduits", "TREATMENT", 122, 149], ["dendritic cells", "OBSERVATION", 19, 34], ["nanometer", "OBSERVATION_MODIFIER", 126, 135], ["size", "OBSERVATION_MODIFIER", 136, 140], ["afferent lymph", "OBSERVATION", 167, 181]]], ["No data are currently available on the antigenic composition of the human lymph available to the resident dendritic cells, which constantly sample the self-antigenic repertoire.", [["lymph", "ANATOMY", 74, 79], ["dendritic cells", "ANATOMY", 106, 121], ["human", "ORGANISM", 68, 73], ["lymph", "ORGAN", 74, 79], ["dendritic cells", "CELL", 106, 121], ["resident dendritic cells", "CELL_TYPE", 97, 121], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["dendritic cells", "OBSERVATION", 106, 121]]], ["In this study we are reporting important sequence information of peptides from the human lymph of healthy donors.", [["lymph", "ANATOMY", 89, 94], ["human", "ORGANISM", 83, 88], ["lymph", "ORGAN", 89, 94], ["donors", "ORGANISM", 106, 112], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["this study", "TEST", 3, 13]]], ["Using advanced proteomics approaches, such as high resolution electrospray ionization mass spectroscopy sequencing (LTQ-MS/MS) together with proteins MS/MS database search using Mascot and SEQUEST algorithms we were able to sequence more than three hundred peptides present in the pre-nodal lymph.", [["pre-nodal lymph", "ANATOMY", 281, 296], ["lymph", "MULTI-TISSUE_STRUCTURE", 291, 296], ["advanced proteomics approaches", "TREATMENT", 6, 36], ["high resolution electrospray ionization mass", "TREATMENT", 46, 90], ["spectroscopy sequencing", "TEST", 91, 114], ["LTQ", "TEST", 116, 119], ["proteins MS", "PROBLEM", 141, 152], ["MS database search", "TEST", 153, 171], ["Mascot and SEQUEST algorithms", "TEST", 178, 207], ["lymph", "ANATOMY", 291, 296]]], ["A significant majority of these peptides derived from the in vivo processing and turnover of extracellular matrix proteins such as collagens, laminins, fibronectins, mucins.", [["extracellular matrix", "ANATOMY", 93, 113], ["extracellular matrix", "CELLULAR_COMPONENT", 93, 113], ["collagens", "GENE_OR_GENE_PRODUCT", 131, 140], ["laminins", "GENE_OR_GENE_PRODUCT", 142, 150], ["fibronectins", "GENE_OR_GENE_PRODUCT", 152, 164], ["mucins", "GENE_OR_GENE_PRODUCT", 166, 172], ["extracellular matrix proteins", "PROTEIN", 93, 122], ["collagens", "PROTEIN", 131, 140], ["laminins", "PROTEIN", 142, 150], ["fibronectins", "PROTEIN", 152, 164], ["mucins", "PROTEIN", 166, 172], ["these peptides", "PROBLEM", 26, 40], ["extracellular matrix proteins", "TREATMENT", 93, 122], ["collagens, laminins", "TREATMENT", 131, 150], ["fibronectins", "TREATMENT", 152, 164], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["Sequenced peptides were then screened for their potential affinity for HLA-DR1 and HLA-DR4 MHC class II proteins using the Syf-P9 algorithm.", [["HLA-DR1", "GENE_OR_GENE_PRODUCT", 71, 78], ["HLA-DR4", "GENE_OR_GENE_PRODUCT", 83, 90], ["HLA", "PROTEIN", 71, 74], ["DR1", "PROTEIN", 75, 78], ["HLA", "PROTEIN", 83, 86], ["DR4 MHC class II proteins", "PROTEIN", 87, 112], ["Syf-P9 algorithm", "DNA", 123, 139], ["Sequenced peptides", "TEST", 0, 18], ["HLA", "TEST", 71, 74], ["the Syf-P9 algorithm", "TREATMENT", 119, 139]]], ["The best hit candidates were further screened and found to have high binding affinity for either HLA-DR1 or HLA-DR4.P 117 b-AMINO ACID SYNTHESIS AND THE TOTAL SOLID-PHASE SYNTHESIS OF MIXIRINS A AND BG.", [["HLA-DR1", "GENE_OR_GENE_PRODUCT", 97, 104], ["HLA-DR4", "GENE_OR_GENE_PRODUCT", 108, 115], ["HLA", "PROTEIN", 97, 100], ["DR1", "PROTEIN", 101, 104], ["HLA", "PROTEIN", 108, 111], ["DR4", "PROTEIN", 112, 115], ["high binding affinity", "PROBLEM", 64, 85], ["DR4", "PROBLEM", 112, 115], ["P", "TEST", 116, 117], ["b-AMINO ACID SYNTHESIS", "TEST", 122, 144], ["BG", "TEST", 199, 201]]], ["KempDepartment of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London, 29-39 Brunswick Square, London WC1N 1AX, UK gary.kemp@pharmacy.ac.uk Mixirins A, B and C were recently isolated from a marine Bacillus sp. bacterium and have shown cytotoxic activity against human colon tumor cells.", [["colon tumor cells", "ANATOMY", 298, 315], ["Mixirins", "CHEMICAL", 170, 178], ["colon tumor", "DISEASE", 298, 309], ["Mixirins", "CHEMICAL", 170, 178], ["A, B and C", "CHEMICAL", 179, 189], ["B", "GENE_OR_GENE_PRODUCT", 182, 183], ["C", "GENE_OR_GENE_PRODUCT", 188, 189], ["Bacillus sp", "ORGANISM", 227, 238], ["human", "ORGANISM", 292, 297], ["colon tumor cells", "CELL", 298, 315], ["human colon tumor cells", "CELL_TYPE", 292, 315], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 292, 297], ["Mixirins", "TREATMENT", 170, 178], ["a marine Bacillus sp", "PROBLEM", 218, 238], ["bacterium", "PROBLEM", 240, 249], ["cytotoxic activity against human colon tumor cells", "PROBLEM", 265, 315], ["cytotoxic activity", "OBSERVATION", 265, 283], ["colon", "ANATOMY", 298, 303], ["tumor cells", "OBSERVATION", 304, 315]]], ["The mixirins were subsequently identified as a mixture of cyclic lipopeptides belonging to the iturin class of compounds.", [["mixirins", "CHEMICAL", 4, 12], ["mixirins", "CHEMICAL", 4, 12], ["iturin", "CHEMICAL", 95, 101], ["mixirins", "SIMPLE_CHEMICAL", 4, 12], ["iturin", "SIMPLE_CHEMICAL", 95, 101], ["The mixirins", "TREATMENT", 0, 12], ["cyclic lipopeptides", "TREATMENT", 58, 77]]], ["The iturins contain 7 proteinogenic -amino acid residues and one unusual lipophilic -amino acid residue of undetermined absolute stereochemistry.", [["-amino acid", "CHEMICAL", 36, 47], ["amino acid", "CHEMICAL", 85, 95], ["-amino acid", "CHEMICAL", 36, 47], ["amino acid", "CHEMICAL", 85, 95], ["iturins", "GENE_OR_GENE_PRODUCT", 4, 11], ["amino acid", "AMINO_ACID", 85, 95], ["iturins", "PROTEIN", 4, 11], ["7 proteinogenic -amino acid residues", "TREATMENT", 20, 56], ["unusual lipophilic -amino acid residue", "PROBLEM", 65, 103], ["7 proteinogenic", "OBSERVATION_MODIFIER", 20, 35], ["-amino acid residues", "OBSERVATION", 36, 56], ["lipophilic", "OBSERVATION_MODIFIER", 73, 83], ["amino acid residue", "OBSERVATION", 85, 103], ["undetermined", "UNCERTAINTY", 107, 119], ["absolute stereochemistry", "OBSERVATION", 120, 144]]], ["The -amino acid moieties of mixirins A and B were synthesised enantioselectively by a novel -amino acid homologation procedure, yielding both enantiomers of the -amino acid residue.", [["-amino acid", "CHEMICAL", 4, 15], ["mixirins A and B", "CHEMICAL", 28, 44], ["-amino acid", "CHEMICAL", 92, 103], ["-amino acid", "CHEMICAL", 161, 172], ["-amino acid", "CHEMICAL", 4, 15], ["mixirins A and B", "CHEMICAL", 28, 44], ["-amino acid", "CHEMICAL", 92, 103], ["-amino acid", "CHEMICAL", 161, 172], ["-amino acid", "SIMPLE_CHEMICAL", 4, 15], ["mixirins A", "SIMPLE_CHEMICAL", 28, 38], ["B", "SIMPLE_CHEMICAL", 43, 44], ["-amino acid", "SIMPLE_CHEMICAL", 92, 103], ["-amino acid", "SIMPLE_CHEMICAL", 161, 172], ["The -amino acid moieties", "TREATMENT", 0, 24], ["mixirins A and B", "TREATMENT", 28, 44], ["a novel -amino acid homologation procedure", "TREATMENT", 84, 126], ["the -amino acid residue", "TREATMENT", 157, 180], ["-amino acid residue", "OBSERVATION", 161, 180]]], ["The lipophilicamino acids were then suitably protected for subsequent Fmoc SPPS.", [["lipophilicamino acids", "CHEMICAL", 4, 25], ["Fmoc", "CHEMICAL", 70, 74], ["lipophilicamino acids", "CHEMICAL", 4, 25], ["Fmoc", "CHEMICAL", 70, 74], ["lipophilicamino acids", "SIMPLE_CHEMICAL", 4, 25], ["The lipophilicamino acids", "TREATMENT", 0, 25], ["subsequent Fmoc SPPS", "TREATMENT", 59, 79]]], ["Four novel potential anticancer compounds have been synthesised by solid-phase techniques: mixirin A and its -amino acid epimer, and mixirin B and its -amino acid epimer.", [["anticancer", "ANATOMY", 21, 31], ["mixirin A", "CHEMICAL", 91, 100], ["mixirin B", "CHEMICAL", 133, 142], ["-amino acid", "CHEMICAL", 151, 162], ["mixirin A", "CHEMICAL", 91, 100], ["-amino acid", "CHEMICAL", 109, 120], ["mixirin B", "CHEMICAL", 133, 142], ["-amino acid", "CHEMICAL", 151, 162], ["anticancer", "CANCER", 21, 31], ["mixirin A", "SIMPLE_CHEMICAL", 91, 100], ["-amino acid epimer", "SIMPLE_CHEMICAL", 109, 127], ["mixirin B", "SIMPLE_CHEMICAL", 133, 142], ["-amino acid epimer", "SIMPLE_CHEMICAL", 151, 169], ["mixirin A", "TREATMENT", 91, 100], ["its -amino acid epimer", "TREATMENT", 105, 127], ["mixirin B", "TREATMENT", 133, 142], ["its -amino acid epimer", "TREATMENT", 147, 169], ["anticancer compounds", "OBSERVATION", 21, 41]]], ["Their synthesis and evaluation will be reported.", [["evaluation", "TEST", 20, 30]]], ["Department of Biochemistry and Molecular Biology, 2 Department of Chemistry, 3 Institute for Biophysical Dynamics, The University of Chicago, *Email: kmandal@uchicago.edu Crambin possesses an important salt bridge between the Arg 10 side chain and the -carboxylate of Asn 46 that guides the formation of correct disulfide bonds and contributes to the tightly folded overall structure.", [["Crambin", "CHEMICAL", 171, 178], ["Arg 10 side", "CHEMICAL", 226, 237], ["Asn 46", "CHEMICAL", 268, 274], ["Crambin", "CHEMICAL", 171, 178], ["Arg", "CHEMICAL", 226, 229], ["carboxylate", "CHEMICAL", 253, 264], ["Asn", "CHEMICAL", 268, 271], ["disulfide", "CHEMICAL", 312, 321], ["Crambin", "SIMPLE_CHEMICAL", 171, 178], ["salt", "SIMPLE_CHEMICAL", 202, 206], ["Asn 46", "AMINO_ACID", 268, 274], ["Arg 10 side chain", "PROTEIN", 226, 243], ["Crambin", "TREATMENT", 171, 178], ["the Arg 10 side chain", "TREATMENT", 222, 243], ["the -carboxylate of Asn", "TREATMENT", 248, 271], ["correct disulfide bonds", "TREATMENT", 304, 327], ["the tightly folded overall structure", "PROBLEM", 347, 383], ["salt bridge", "OBSERVATION", 202, 213], ["disulfide bonds", "OBSERVATION", 312, 327], ["tightly folded", "OBSERVATION_MODIFIER", 351, 365], ["overall structure", "OBSERVATION", 366, 383]]], ["1 We set out to use chemistry to replace the salt bridge by a covalent bond.", [["chemistry", "TREATMENT", 20, 29], ["the salt bridge", "TREATMENT", 41, 56]]], ["This led us to ask: will the artificial covalent bond allow the molecule to fold with correct disulfide bond formation?", [["disulfide", "CHEMICAL", 94, 103], ["the artificial covalent bond", "TREATMENT", 25, 53], ["correct disulfide bond formation", "TREATMENT", 86, 118]]], ["Replacement of a salt bridge by amide bond has never been done for a protein and is only possible by total chemical synthesis.", [["amide", "CHEMICAL", 32, 37], ["a salt bridge by amide bond", "TREATMENT", 15, 42], ["a protein", "TEST", 67, 76], ["total chemical synthesis", "TREATMENT", 101, 125], ["only possible", "UNCERTAINTY", 84, 97], ["chemical synthesis", "OBSERVATION", 107, 125]]], ["The resulting novel topology is fascinating because the polypeptide chain will have a start (N-termianl) but no end (C-terimanl).", [["polypeptide chain", "PROTEIN", 56, 73], ["the polypeptide chain", "PROBLEM", 52, 73]]], ["This novel topology is reminiscent of but not identical to the naturally occurring cyclotides and lasso proteins.P 117 b-AMINO ACID SYNTHESIS AND THE TOTAL SOLID-PHASE SYNTHESIS OF MIXIRINS A AND BChemical synthesis of such a unique topological analogue is highly challenging.", [["cyclotides", "CHEMICAL", 83, 93], ["cyclotides", "SIMPLE_CHEMICAL", 83, 93], ["cyclotides and lasso proteins", "PROTEIN", 83, 112], ["cyclotides", "TREATMENT", 83, 93], ["P", "TEST", 113, 114], ["b-AMINO ACID SYNTHESIS", "TEST", 119, 141], ["THE TOTAL SOLID-PHASE SYNTHESIS", "TREATMENT", 146, 177], ["MIXIRINS A AND BChemical synthesis", "TREATMENT", 181, 215], ["a unique topological analogue", "TREATMENT", 224, 253]]], ["We have devised an efficient convergent synthetic route to the crambin-derived protein of novel topology.", [["crambin", "CHEMICAL", 63, 70], ["crambin", "SIMPLE_CHEMICAL", 63, 70], ["crambin", "PROTEIN", 63, 70]]], ["The synthetic challenge represented by this protein molecule of novel topology has led to the development of 'kinetically controlled ligation'.", [["protein molecule", "PROTEIN", 44, 60], ["The synthetic challenge", "TREATMENT", 0, 23], ["'kinetically controlled ligation'", "TREATMENT", 109, 142], ["kinetically controlled ligation", "OBSERVATION", 110, 141]]], ["2 We have used a novel quasi-racemic crystallization technique 3 to crystallize the synthetic", [["a novel quasi-racemic crystallization technique", "TREATMENT", 15, 62]]]], "496b549a2327f4d55ee0f0efc2085516b8e79e6b": [["IntroductionSialic acids are a diverse family of monosaccharides widely expressed on all cell surfaces of vertebrates and higher invertebrates (such as starfish and sea urchin), and on some bacteria that interact with vertebrates [1] .", [["cell surfaces", "ANATOMY", 89, 102], ["starfish", "ANATOMY", 152, 160], ["IntroductionSialic acids", "CHEMICAL", 0, 24], ["monosaccharides", "CHEMICAL", 49, 64], ["IntroductionSialic acids", "SIMPLE_CHEMICAL", 0, 24], ["monosaccharides", "SIMPLE_CHEMICAL", 49, 64], ["cell surfaces", "CELLULAR_COMPONENT", 89, 102], ["starfish", "ORGANISM_SUBDIVISION", 152, 160], ["sea urchin", "ORGANISM", 165, 175], ["sea urchin", "SPECIES", 165, 175], ["IntroductionSialic acids", "TREATMENT", 0, 24], ["monosaccharides", "TREATMENT", 49, 64], ["higher invertebrates", "PROBLEM", 122, 142], ["some bacteria", "PROBLEM", 185, 198]]], ["The expression of sialic acids is highly conserved in deuterostomes, i.e., from echinoderms to humans [2] .", [["sialic acids", "CHEMICAL", 18, 30], ["sialic acids", "CHEMICAL", 18, 30], ["sialic acids", "AMINO_ACID", 18, 30], ["humans", "ORGANISM", 95, 101], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 95, 101], ["sialic acids", "PROBLEM", 18, 30], ["sialic acids", "OBSERVATION", 18, 30]]], ["Sialic acids are biosynthesized by almost all organisms as a 9-carbon carboxylated monosaccharide and found most frequently as the terminal sugars of cell surface glycolipids and glycoproteins [3e6] .", [["cell surface", "ANATOMY", 150, 162], ["Sialic acids", "CHEMICAL", 0, 12], ["9-carbon carboxylated", "CHEMICAL", 61, 82], ["Sialic acids", "CHEMICAL", 0, 12], ["9-carbon", "CHEMICAL", 61, 69], ["monosaccharide", "CHEMICAL", 83, 97], ["sugars", "CHEMICAL", 140, 146], ["Sialic acids", "SIMPLE_CHEMICAL", 0, 12], ["9-carbon carboxylated monosaccharide", "SIMPLE_CHEMICAL", 61, 97], ["cell surface glycolipids", "CELLULAR_COMPONENT", 150, 174], ["Sialic acids", "TREATMENT", 0, 12], ["a 9-carbon carboxylated monosaccharide", "TREATMENT", 59, 97], ["cell surface glycolipids", "TREATMENT", 150, 174]]], ["Because of their terminal location and negative charge, sialic acids have numerous roles in many aspect of immunity [1] .", [["sialic acids", "CHEMICAL", 56, 68], ["sialic acids", "CHEMICAL", 56, 68], ["sialic acids", "SIMPLE_CHEMICAL", 56, 68], ["sialic acids", "TREATMENT", 56, 68]]], ["These monosaccharides have the potential to contribute or inhibit many intermolecular and intercellular interactions [4, 7] .", [["intercellular", "ANATOMY", 90, 103], ["monosaccharides", "CHEMICAL", 6, 21], ["monosaccharides", "SIMPLE_CHEMICAL", 6, 21], ["many intermolecular and intercellular interactions", "PROBLEM", 66, 116]]], ["Sialic acids also contribute to many features of the cell surface and frequently serve as ligands for receptor-mediated intercellular interactions, host cell-pathogen recognition processes and lymphocyte-endothelial cell interactions [8, 9] .", [["cell surface", "ANATOMY", 53, 65], ["intercellular", "ANATOMY", 120, 133], ["cell", "ANATOMY", 153, 157], ["lymphocyte", "ANATOMY", 193, 203], ["endothelial cell", "ANATOMY", 204, 220], ["Sialic acids", "CHEMICAL", 0, 12], ["Sialic acids", "CHEMICAL", 0, 12], ["Sialic acids", "SIMPLE_CHEMICAL", 0, 12], ["cell surface", "CELLULAR_COMPONENT", 53, 65], ["intercellular", "CELL", 120, 133], ["cell", "CELL", 153, 157], ["lymphocyte", "CELL", 193, 203], ["endothelial cell", "CELL", 204, 220], ["Sialic acids", "TREATMENT", 0, 12], ["the cell surface", "TREATMENT", 49, 65], ["receptor-mediated intercellular interactions", "PROBLEM", 102, 146], ["lymphocyte", "TEST", 193, 203], ["cell surface", "OBSERVATION", 53, 65], ["host cell", "OBSERVATION", 148, 157], ["endothelial cell", "OBSERVATION", 204, 220]]], ["Many earlier studies removed sialic acids from immune cell surfaces using sialidases and observed changes in behavior of such cells [1] .", [["immune cell surfaces", "ANATOMY", 47, 67], ["cells", "ANATOMY", 126, 131], ["sialic acids", "CHEMICAL", 29, 41], ["sialic acids", "CHEMICAL", 29, 41], ["sialic acids", "SIMPLE_CHEMICAL", 29, 41], ["immune cell", "CELL", 47, 58], ["sialidases", "SIMPLE_CHEMICAL", 74, 84], ["cells", "CELL", 126, 131], ["sialic acids", "TREATMENT", 29, 41], ["immune cell surfaces", "TREATMENT", 47, 67], ["sialidases", "TREATMENT", 74, 84], ["observed changes in behavior of such cells", "PROBLEM", 89, 131], ["immune cell", "OBSERVATION", 47, 58]]], ["Sialic acids are crucial in the development of vertebrates, as observed that mouse embryos engineered to deficiency of sialic acid expression die after they birth [10] .", [["embryos", "ANATOMY", 83, 90], ["Sialic acids", "CHEMICAL", 0, 12], ["sialic acid", "CHEMICAL", 119, 130], ["Sialic acids", "CHEMICAL", 0, 12], ["sialic acid", "CHEMICAL", 119, 130], ["Sialic acids", "AMINO_ACID", 0, 12], ["mouse", "ORGANISM", 77, 82], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 83, 90], ["sialic acid", "AMINO_ACID", 119, 130], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 77, 82], ["Sialic acids", "TREATMENT", 0, 12], ["mouse embryos", "PROBLEM", 77, 90], ["deficiency of sialic acid expression die", "PROBLEM", 105, 145]]], ["In pathogenic diseases, including some inflammations, particular microbes recognize cell surface sialic acids when invading host cells [11, 12] .", [["cell surface", "ANATOMY", 84, 96], ["cells", "ANATOMY", 129, 134], ["inflammations", "DISEASE", 39, 52], ["sialic acids", "CHEMICAL", 97, 109], ["sialic acids", "CHEMICAL", 97, 109], ["cell", "CELL", 84, 88], ["sialic acids", "AMINO_ACID", 97, 109], ["host cells", "CELL", 124, 134], ["invading host cells", "CELL_TYPE", 115, 134], ["pathogenic diseases", "PROBLEM", 3, 22], ["some inflammations", "PROBLEM", 34, 52], ["cell surface sialic acids", "TREATMENT", 84, 109], ["pathogenic", "OBSERVATION_MODIFIER", 3, 13], ["diseases", "OBSERVATION", 14, 22], ["some", "OBSERVATION_MODIFIER", 34, 38], ["inflammations", "OBSERVATION", 39, 52]]], ["For example, binding of influenza A and B viruses to host cell is accomplished by the specific recognition of the host sialic acid linkage by the virus.", [["cell", "ANATOMY", 58, 62], ["sialic acid", "CHEMICAL", 119, 130], ["sialic acid", "CHEMICAL", 119, 130], ["influenza A", "ORGANISM", 24, 35], ["B viruses", "ORGANISM", 40, 49], ["host cell", "CELL", 53, 62], ["sialic acid", "SIMPLE_CHEMICAL", 119, 130], ["influenza A", "SPECIES", 24, 35], ["influenza A", "PROBLEM", 24, 35], ["B viruses to host cell", "PROBLEM", 40, 62], ["the host sialic acid linkage", "TREATMENT", 110, 138], ["the virus", "PROBLEM", 142, 151], ["influenza", "OBSERVATION", 24, 33], ["host cell", "OBSERVATION", 53, 62]]], ["Sialylated molecules on Aspergillus fumigatus conidia (fungal pathogen) are recognized by cultured mouse macrophages and lung epithelial cell lines and enhance the uptake of conidia into the endosomal system of the host cell [13] .", [["macrophages", "ANATOMY", 105, 116], ["lung epithelial cell lines", "ANATOMY", 121, 147], ["conidia", "ANATOMY", 174, 181], ["endosomal system", "ANATOMY", 191, 207], ["cell", "ANATOMY", 220, 224], ["Aspergillus fumigatus conidia", "ORGANISM", 24, 53], ["fungal pathogen", "ORGANISM", 55, 70], ["mouse", "ORGANISM", 99, 104], ["macrophages", "CELL", 105, 116], ["lung epithelial cell lines", "CELL", 121, 147], ["endosomal", "CELLULAR_COMPONENT", 191, 200], ["host cell", "CELL", 215, 224], ["cultured mouse macrophages", "CELL_LINE", 90, 116], ["lung epithelial cell lines", "CELL_LINE", 121, 147], ["Aspergillus fumigatus", "SPECIES", 24, 45], ["mouse", "SPECIES", 99, 104], ["Aspergillus fumigatus", "SPECIES", 24, 45], ["mouse", "SPECIES", 99, 104], ["Sialylated molecules", "PROBLEM", 0, 20], ["Aspergillus fumigatus conidia (fungal pathogen", "PROBLEM", 24, 70], ["lung epithelial cell lines", "PROBLEM", 121, 147], ["Aspergillus fumigatus conidia", "OBSERVATION", 24, 53], ["fungal", "OBSERVATION_MODIFIER", 55, 61], ["mouse macrophages", "OBSERVATION", 99, 116], ["lung", "ANATOMY", 121, 125], ["epithelial cell lines", "OBSERVATION", 126, 147], ["uptake", "OBSERVATION_MODIFIER", 164, 170], ["endosomal system", "ANATOMY_MODIFIER", 191, 207], ["host cell", "OBSERVATION", 215, 224]]], ["Sialic acid residues can also mask recognition sites such as galactose residues on glycoproteins to prevent their in vivo removal by asiaologlycoprotein receptors [14] .", [["Sialic acid", "CHEMICAL", 0, 11], ["galactose", "CHEMICAL", 61, 70], ["Sialic acid", "CHEMICAL", 0, 11], ["galactose", "CHEMICAL", 61, 70], ["Sialic acid", "SIMPLE_CHEMICAL", 0, 11], ["galactose", "SIMPLE_CHEMICAL", 61, 70], ["asiaologlycoprotein receptors", "PROTEIN", 133, 162], ["Sialic acid residues", "TREATMENT", 0, 20], ["mask recognition sites", "TREATMENT", 30, 52], ["galactose residues on glycoproteins", "TREATMENT", 61, 96], ["acid residues", "OBSERVATION", 7, 20]]], ["In certain cancers, changes in sialic acid amounts, types and linkages have been associated with tumorigenesis and cancer metastasis [12] .", [["cancers", "ANATOMY", 11, 18], ["cancer", "ANATOMY", 115, 121], ["cancers", "DISEASE", 11, 18], ["sialic acid", "CHEMICAL", 31, 42], ["cancer", "DISEASE", 115, 121], ["sialic acid", "CHEMICAL", 31, 42], ["cancers", "CANCER", 11, 18], ["sialic acid", "SIMPLE_CHEMICAL", 31, 42], ["cancer", "CANCER", 115, 121], ["certain cancers", "PROBLEM", 3, 18], ["changes in sialic acid amounts", "PROBLEM", 20, 50], ["tumorigenesis", "PROBLEM", 97, 110], ["cancer metastasis", "PROBLEM", 115, 132], ["certain", "OBSERVATION_MODIFIER", 3, 10], ["cancers", "OBSERVATION", 11, 18], ["sialic acid", "OBSERVATION_MODIFIER", 31, 42], ["associated with", "UNCERTAINTY", 81, 96], ["tumorigenesis", "OBSERVATION", 97, 110], ["cancer", "OBSERVATION", 115, 121]]], ["More than 50 naturally occurring sialic acid [15e 17] derivatives of the three main forms, N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc) and 2-keto-3deoxy-nonulosonic acid (KDN) were identified [6, 18] .", [["sialic acid", "CHEMICAL", 33, 44], ["15e 17] derivatives", "CHEMICAL", 46, 65], ["N-acetylneuraminic acid", "CHEMICAL", 91, 114], ["Neu5Ac", "CHEMICAL", 116, 122], ["N-glycolylneuraminic acid", "CHEMICAL", 125, 150], ["Neu5Gc", "CHEMICAL", 152, 158], ["2-keto-3deoxy-nonulosonic acid", "CHEMICAL", 164, 194], ["KDN", "CHEMICAL", 196, 199], ["sialic acid", "CHEMICAL", 33, 44], ["N-acetylneuraminic acid", "CHEMICAL", 91, 114], ["Neu5Ac", "CHEMICAL", 116, 122], ["N-glycolylneuraminic acid", "CHEMICAL", 125, 150], ["Neu5Gc", "CHEMICAL", 152, 158], ["2-keto-3deoxy-nonulosonic acid", "CHEMICAL", 164, 194], ["KDN", "CHEMICAL", 196, 199], ["sialic acid", "SIMPLE_CHEMICAL", 33, 44], ["15e 17] derivatives", "SIMPLE_CHEMICAL", 46, 65], ["N-acetylneuraminic acid", "SIMPLE_CHEMICAL", 91, 114], ["Neu5Ac", "SIMPLE_CHEMICAL", 116, 122], ["N-glycolylneuraminic acid", "SIMPLE_CHEMICAL", 125, 150], ["Neu5Gc", "SIMPLE_CHEMICAL", 152, 158], ["2-keto-3deoxy-nonulosonic acid", "SIMPLE_CHEMICAL", 164, 194], ["KDN", "SIMPLE_CHEMICAL", 196, 199], ["sialic acid", "TEST", 33, 44], ["N-acetylneuraminic acid", "TEST", 91, 114], ["Neu5Ac", "TEST", 116, 122], ["glycolylneuraminic acid", "TEST", 127, 150], ["Neu5Gc", "TEST", 152, 158], ["keto", "TEST", 166, 170]]], ["The great structural diversity in the sialic acids originates from different substitutions on the amino group at carbon 5 and hydroxyl groups at carbons 4, 7, 8 and 9 by acetyl groups (O-acetylation) [3, 19, 20] .IntroductionThere have been many reports concerning the analysis of specific sialic acids in animals.", [["sialic acids", "CHEMICAL", 38, 50], ["amino", "CHEMICAL", 98, 103], ["carbon 5 and hydroxyl", "CHEMICAL", 113, 134], ["carbons 4, 7, 8 and 9", "CHEMICAL", 145, 166], ["acetyl", "CHEMICAL", 170, 176], ["sialic acids", "CHEMICAL", 290, 302], ["sialic acids", "CHEMICAL", 38, 50], ["amino", "CHEMICAL", 98, 103], ["carbon", "CHEMICAL", 113, 119], ["hydroxyl", "CHEMICAL", 126, 134], ["carbons", "CHEMICAL", 145, 152], ["acetyl", "CHEMICAL", 170, 176], ["sialic acids", "CHEMICAL", 290, 302], ["sialic acids", "AMINO_ACID", 38, 50], ["amino", "AMINO_ACID", 98, 103], ["carbon 5", "SIMPLE_CHEMICAL", 113, 121], ["hydroxyl", "SIMPLE_CHEMICAL", 126, 134], ["acetyl groups", "SIMPLE_CHEMICAL", 170, 183], ["O-acetylation", "SIMPLE_CHEMICAL", 185, 198], ["sialic acids", "SIMPLE_CHEMICAL", 290, 302], ["carbons 4, 7, 8 and 9", "PROTEIN", 145, 166], ["the sialic acids", "TREATMENT", 34, 50], ["different substitutions", "PROBLEM", 67, 90], ["the amino group at carbon 5 and hydroxyl groups at carbons", "TREATMENT", 94, 152], ["the analysis", "TEST", 265, 277], ["specific sialic acids", "TREATMENT", 281, 302], ["great", "OBSERVATION_MODIFIER", 4, 9], ["structural", "OBSERVATION_MODIFIER", 10, 20], ["diversity", "OBSERVATION_MODIFIER", 21, 30], ["sialic acids", "OBSERVATION", 38, 50], ["different substitutions", "OBSERVATION", 67, 90]]], ["Although small amounts of glycoconjugates with sialic acids have been reported in certain protostome animals such as insect [21e24], these sugars are found in largest amount and exhibit greatest structural variability in deuterostomia, predominantly in the echinodermata and hemichordata [25] .IntroductionEchinoderms have a potential immune system for their survival [26] .", [["echinodermata", "ANATOMY", 257, 270], ["Echinoderms", "ANATOMY", 306, 317], ["immune system", "ANATOMY", 335, 348], ["sialic acids", "CHEMICAL", 47, 59], ["deuterostomia", "DISEASE", 221, 234], ["sialic acids", "CHEMICAL", 47, 59], ["sugars", "CHEMICAL", 139, 145], ["sialic acids", "SIMPLE_CHEMICAL", 47, 59], ["sugars", "SIMPLE_CHEMICAL", 139, 145], ["echinodermata", "CANCER", 257, 270], ["Echinoderms", "CANCER", 306, 317], ["small amounts of glycoconjugates", "PROBLEM", 9, 41], ["sialic acids", "TREATMENT", 47, 59], ["these sugars", "TEST", 133, 145], ["greatest structural variability in deuterostomia", "PROBLEM", 186, 234], ["small", "OBSERVATION_MODIFIER", 9, 14], ["amounts", "OBSERVATION_MODIFIER", 15, 22], ["largest", "OBSERVATION_MODIFIER", 159, 166], ["greatest", "OBSERVATION_MODIFIER", 186, 194], ["structural variability", "OBSERVATION", 195, 217], ["deuterostomia", "OBSERVATION_MODIFIER", 221, 234], ["predominantly", "OBSERVATION_MODIFIER", 236, 249]]], ["Many species, living in coastal and estuarine waters, are directly exposed to potentially pathogenic microorganisms and have developed defence responses mainly based on immunocytes (coelomocytes) and humoral factors contained in the coelomic fluid [27e30].", [["immunocytes", "ANATOMY", 169, 180], ["coelomocytes", "ANATOMY", 182, 194], ["coelomic fluid", "ANATOMY", 233, 247], ["immunocytes", "CELL", 169, 180], ["coelomocytes", "CELL", 182, 194], ["coelomic fluid", "ORGANISM_SUBSTANCE", 233, 247], ["immunocytes", "CELL_TYPE", 169, 180], ["coelomocytes", "CELL_TYPE", 182, 194], ["humoral factors", "PROTEIN", 200, 215], ["Many species", "PROBLEM", 0, 12], ["pathogenic microorganisms", "PROBLEM", 90, 115], ["defence responses", "PROBLEM", 135, 152], ["immunocytes (coelomocytes", "PROBLEM", 169, 194], ["humoral factors", "PROBLEM", 200, 215], ["the coelomic fluid", "TEST", 229, 247], ["coelomic", "ANATOMY", 233, 241], ["fluid", "OBSERVATION", 242, 247]]], ["In echinoids, sea urchin, Paracentrotus lividus, at least four main coelomocyte types including a subpopulation of macrophagelike cell, phagocytic cells that circulate in the coelomic fluid have been described: amoebocytes, vibratile cells, red and uncolored spherulocytes [26,30e35] .", [["echinoids", "ANATOMY", 3, 12], ["coelomocyte", "ANATOMY", 68, 79], ["macrophagelike cell", "ANATOMY", 115, 134], ["phagocytic cells", "ANATOMY", 136, 152], ["coelomic fluid", "ANATOMY", 175, 189], ["amoebocytes", "ANATOMY", 211, 222], ["vibratile cells", "ANATOMY", 224, 239], ["sea urchin", "ORGANISM", 14, 24], ["Paracentrotus lividus", "ORGANISM", 26, 47], ["coelomocyte", "CANCER", 68, 79], ["macrophagelike cell", "CELL", 115, 134], ["phagocytic cells", "CELL", 136, 152], ["coelomic fluid", "ORGANISM_SUBSTANCE", 175, 189], ["amoebocytes", "CELL", 211, 222], ["vibratile cells", "CELL", 224, 239], ["red", "CELL", 241, 244], ["macrophagelike cell", "CELL_TYPE", 115, 134], ["phagocytic cells", "CELL_TYPE", 136, 152], ["amoebocytes", "CELL_TYPE", 211, 222], ["vibratile cells", "CELL_TYPE", 224, 239], ["red and uncolored spherulocytes", "CELL_TYPE", 241, 272], ["sea urchin", "SPECIES", 14, 24], ["Paracentrotus lividus", "SPECIES", 26, 47], ["sea urchin", "SPECIES", 14, 24], ["Paracentrotus lividus", "SPECIES", 26, 47], ["Paracentrotus lividus", "PROBLEM", 26, 47], ["macrophagelike cell", "PROBLEM", 115, 134], ["phagocytic cells", "PROBLEM", 136, 152], ["the coelomic fluid", "TEST", 171, 189], ["amoebocytes", "PROBLEM", 211, 222], ["vibratile cells", "PROBLEM", 224, 239], ["red and uncolored spherulocytes", "PROBLEM", 241, 272], ["sea urchin", "OBSERVATION", 14, 24], ["Paracentrotus lividus", "OBSERVATION", 26, 47], ["main", "OBSERVATION_MODIFIER", 63, 67], ["coelomocyte types", "OBSERVATION", 68, 85], ["subpopulation", "OBSERVATION_MODIFIER", 98, 111], ["macrophagelike cell", "OBSERVATION", 115, 134], ["phagocytic cells", "OBSERVATION", 136, 152], ["coelomic", "ANATOMY", 175, 183], ["fluid", "OBSERVATION", 184, 189], ["vibratile cells", "OBSERVATION", 224, 239]]], ["Cell-based immunity is carried by the coelomocytes, a morphologically heterogeneous population of free roaming cells that are capable of recognizing and neutralizing pathogens.", [["Cell", "ANATOMY", 0, 4], ["coelomocytes", "ANATOMY", 38, 50], ["cells", "ANATOMY", 111, 116], ["Cell", "CELL", 0, 4], ["coelomocytes", "CANCER", 38, 50], ["cells", "CELL", 111, 116], ["roaming cells", "CELL_TYPE", 103, 116], ["free roaming cells", "PROBLEM", 98, 116], ["neutralizing pathogens", "PROBLEM", 153, 175], ["coelomocytes", "ANATOMY", 38, 50], ["morphologically", "OBSERVATION_MODIFIER", 54, 69], ["heterogeneous", "OBSERVATION_MODIFIER", 70, 83], ["population", "OBSERVATION_MODIFIER", 84, 94], ["free roaming cells", "OBSERVATION", 98, 116], ["neutralizing pathogens", "OBSERVATION", 153, 175]]], ["Coelomocytes present diverse functions which include phagocytosis, encapsulation, clotting, cytotoxicity and wound healing [31, 35] .IntroductionThe cell-based immunity system is able to distinguish between self and non-self by oversialylation and undersialylation of their cell surface (but so far not examined in echinoids) [36] .", [["Coelomocytes", "ANATOMY", 0, 12], ["wound", "ANATOMY", 109, 114], ["cell", "ANATOMY", 149, 153], ["cell surface", "ANATOMY", 274, 286], ["Coelomocytes", "CELL", 0, 12], ["wound", "PATHOLOGICAL_FORMATION", 109, 114], ["cell", "CELL", 149, 153], ["cell surface", "CELLULAR_COMPONENT", 274, 286], ["Coelomocytes", "CELL_TYPE", 0, 12], ["Coelomocytes present diverse functions", "PROBLEM", 0, 38], ["phagocytosis", "PROBLEM", 53, 65], ["encapsulation", "TREATMENT", 67, 80], ["clotting", "PROBLEM", 82, 90], ["cytotoxicity", "PROBLEM", 92, 104], ["wound healing", "PROBLEM", 109, 122], ["The cell-based immunity system", "TREATMENT", 145, 175], ["diverse functions", "OBSERVATION", 21, 38], ["phagocytosis", "OBSERVATION_MODIFIER", 53, 65], ["encapsulation", "OBSERVATION_MODIFIER", 67, 80], ["clotting", "OBSERVATION_MODIFIER", 82, 90], ["cytotoxicity", "OBSERVATION_MODIFIER", 92, 104], ["wound", "ANATOMY", 109, 114], ["healing", "OBSERVATION_MODIFIER", 115, 122]]], ["In terms of their immune systems, echinoderms represent the same basic types of responses that most multicellular (including vertebrates) animals do.", [["immune systems", "OBSERVATION", 18, 32]]], ["The coelomocytes of echinoderms can recognize self from non-self and, if a foreign material (e.g., microorganism/pathogen) enters the body cavity, they can readily neutralize it and dispose of it [32, 34, 35] .", [["coelomocytes", "ANATOMY", 4, 16], ["echinoderms", "ANATOMY", 20, 31], ["body cavity", "ANATOMY", 134, 145], ["coelomocytes", "CANCER", 4, 16], ["body cavity", "ORGANISM_SUBDIVISION", 134, 145], ["a foreign material (e.g., microorganism/pathogen) enters the body cavity", "PROBLEM", 73, 145], ["body cavity", "ANATOMY", 134, 145]]], ["Due to multifarious roles of sialic acids in immunity [1] , sialic acid is an ideal points of investigation in coelomocytes of echinoids.", [["coelomocytes", "ANATOMY", 111, 123], ["echinoids", "ANATOMY", 127, 136], ["sialic acids", "CHEMICAL", 29, 41], ["sialic acid", "CHEMICAL", 60, 71], ["sialic acids", "CHEMICAL", 29, 41], ["sialic acid", "CHEMICAL", 60, 71], ["sialic acids", "AMINO_ACID", 29, 41], ["sialic acid", "SIMPLE_CHEMICAL", 60, 71], ["coelomocytes", "CANCER", 111, 123], ["echinoids", "CANCER", 127, 136], ["sialic acids", "TREATMENT", 29, 41], ["sialic acid", "TEST", 60, 71], ["coelomocytes of echinoids", "PROBLEM", 111, 136]]], ["Until recently, there has been no study on the determination and function of sialic acid and their types in immune system cells, particularly in the echinoderm coelomocytes.Sea urchinsSea urchins of the species P. lividus were collected from the nearshore waters of the northern Izmir coastline, Fo\u00e7a, Turkey.Coelomocyte collection for sialic acid analysisNecessary quantities of the coelomic fluid with coelomocytes were immediately taken from the coelomic cavity without feeding sea urchins.", [["immune system cells", "ANATOMY", 108, 127], ["echinoderm coelomocytes", "ANATOMY", 149, 172], ["Coelomocyte", "ANATOMY", 309, 320], ["coelomic fluid", "ANATOMY", 384, 398], ["coelomocytes", "ANATOMY", 404, 416], ["coelomic cavity", "ANATOMY", 449, 464], ["sialic acid", "CHEMICAL", 77, 88], ["sialic acid", "CHEMICAL", 336, 347], ["sialic acid", "CHEMICAL", 77, 88], ["sialic acid", "CHEMICAL", 336, 347], ["sialic acid", "SIMPLE_CHEMICAL", 77, 88], ["immune system cells", "CELL", 108, 127], ["echinoderm coelomocytes", "CELL", 149, 172], ["Sea urchinsSea urchins", "ORGANISM", 173, 195], ["P. lividus", "ORGANISM", 211, 221], ["Coelomocyte", "CELL", 309, 320], ["sialic acid", "SIMPLE_CHEMICAL", 336, 347], ["coelomic fluid", "ORGANISM_SUBSTANCE", 384, 398], ["coelomocytes", "CANCER", 404, 416], ["coelomic cavity", "MULTI-TISSUE_STRUCTURE", 449, 464], ["immune system cells", "CELL_TYPE", 108, 127], ["echinoderm coelomocytes", "CELL_TYPE", 149, 172], ["Sea urchinsSea urchins", "SPECIES", 173, 195], ["P. lividus", "SPECIES", 211, 221], ["Sea urchinsSea urchins", "SPECIES", 173, 195], ["P. lividus", "SPECIES", 211, 221], ["study", "TEST", 34, 39], ["the determination", "TEST", 43, 60], ["sialic acid", "TEST", 77, 88], ["immune system cells", "PROBLEM", 108, 127], ["the echinoderm coelomocytes", "PROBLEM", 145, 172], ["P. lividus", "PROBLEM", 211, 221], ["Coelomocyte collection", "TEST", 309, 331], ["sialic acid analysis", "TEST", 336, 356], ["the coelomic fluid with coelomocytes", "TREATMENT", 380, 416], ["echinoderm coelomocytes", "OBSERVATION", 149, 172], ["lividus", "OBSERVATION_MODIFIER", 214, 221], ["coelomic", "ANATOMY", 384, 392], ["fluid", "OBSERVATION", 393, 398], ["coelomic cavity", "ANATOMY", 449, 464], ["sea urchins", "OBSERVATION", 481, 492]]], ["As previously described [37, 38] , the coelomic fluid from each animal was collected by removing Aristotle's lantern, or the mouth structure, and aliquoted into 3 ml volumes and then diluted with isosmotic anticoagulant solution (20 mM Tris, 0.5 M NaCl, 70 mM EDTA pH 7.5) (ISO-EDTA).", [["coelomic fluid", "ANATOMY", 39, 53], ["mouth", "ANATOMY", 125, 130], ["NaCl", "CHEMICAL", 248, 252], ["ISO-EDTA", "CHEMICAL", 274, 282], ["Tris", "CHEMICAL", 236, 240], ["NaCl", "CHEMICAL", 248, 252], ["EDTA", "CHEMICAL", 260, 264], ["ISO-EDTA", "CHEMICAL", 274, 282], ["coelomic fluid", "ORGANISM_SUBSTANCE", 39, 53], ["mouth", "ORGANISM_SUBDIVISION", 125, 130], ["ISO-EDTA", "SIMPLE_CHEMICAL", 274, 282], ["the coelomic fluid", "TEST", 35, 53], ["Aristotle's lantern", "TREATMENT", 97, 116], ["isosmotic anticoagulant solution", "TREATMENT", 196, 228], ["NaCl", "TEST", 248, 252], ["mM EDTA pH", "TEST", 257, 267], ["coelomic", "ANATOMY", 39, 47], ["fluid", "OBSERVATION", 48, 53], ["mouth", "ANATOMY", 125, 130]]], ["After centrifugation (1000 \u00c2 g for 10 min at 4 C), coelomocytes were washed three times in ISO-EDTA and then fixed in methanol either at \u00c020 C or \u00c080 C.Coelomocyte preparation for microscopyCoelomocytes were suspended in coelomocyte culture (CCM: 0.5 M NaCl, 5 mM MgCl 2 , 1 mM EGTA, 20 mM HEPES, pH 7.4).", [["coelomocytes", "ANATOMY", 51, 63], ["Coelomocytes", "ANATOMY", 190, 202], ["ISO-EDTA", "CHEMICAL", 91, 99], ["CCM", "CHEMICAL", 242, 245], ["NaCl", "CHEMICAL", 253, 257], ["EGTA", "CHEMICAL", 278, 282], ["ISO", "CHEMICAL", 91, 94], ["EDTA", "CHEMICAL", 95, 99], ["methanol", "CHEMICAL", 118, 126], ["CCM", "CHEMICAL", 242, 245], ["NaCl", "CHEMICAL", 253, 257], ["MgCl 2", "CHEMICAL", 264, 270], ["EGTA", "CHEMICAL", 278, 282], ["HEPES", "CHEMICAL", 290, 295], ["coelomocytes", "CELL", 51, 63], ["methanol", "SIMPLE_CHEMICAL", 118, 126], ["EGTA", "SIMPLE_CHEMICAL", 278, 282], ["coelomocyte culture", "CELL_LINE", 221, 240], ["centrifugation", "TREATMENT", 6, 20], ["EDTA", "TREATMENT", 95, 99], ["methanol", "TREATMENT", 118, 126], ["microscopyCoelomocytes", "TEST", 180, 202], ["coelomocyte culture", "TEST", 221, 240], ["NaCl", "TREATMENT", 253, 257], ["5 mM MgCl", "TREATMENT", 259, 268], ["1 mM EGTA", "TREATMENT", 273, 282], ["20 mM HEPES", "TREATMENT", 284, 295], ["pH", "TEST", 297, 299], ["coelomocytes", "ANATOMY", 51, 63]]], ["Cell suspensions (100 ml) were settled onto glass coverslips.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell suspensions", "TREATMENT", 0, 16]]], ["Cells in fresh preparations were viewed on a Leica DM 4000B microscope using a 63\u00c2 NA 1.4 apochromatic objective lens coupled to a DP71 camera (Olympus).MaterialsAll chemicals and solvents were of the highest grade commercially available (LC-MS grade).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Standart sialic acids; Neu5Ac, Neu5Gc and KDN (A9646, G9793 and 60714) were purchased from Sigma (Sigma-Aldrich Chemie GmbH Riedstrasse 2 D-89555 STEINHEIM).", [["sialic acids", "CHEMICAL", 9, 21], ["Neu5Ac", "CHEMICAL", 23, 29], ["Neu5Gc", "CHEMICAL", 31, 37], ["A9646, G9793 and 60714", "CHEMICAL", 47, 69], ["Riedstrasse 2 D-89555", "CHEMICAL", 124, 145], ["sialic acids", "CHEMICAL", 9, 21], ["Neu5Ac", "CHEMICAL", 23, 29], ["Neu5Gc", "CHEMICAL", 31, 37], ["KDN", "CHEMICAL", 42, 45], ["A9646, G9793 and 60714", "CHEMICAL", 47, 69], ["D-89555", "CHEMICAL", 138, 145], ["Standart sialic acids", "SIMPLE_CHEMICAL", 0, 21], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 23, 29], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 31, 37], ["Neu5Ac", "TREATMENT", 23, 29], ["Neu5Gc", "TEST", 31, 37], ["KDN", "TEST", 42, 45]]], ["DMB (1,2-diamino-4,5-methylenediaoxy-benzene dihydrochloride) was obtained from Sigma (D4784).", [["DMB", "CHEMICAL", 0, 3], ["1,2-diamino-4,5-methylenediaoxy-benzene dihydrochloride", "CHEMICAL", 5, 60], ["DMB", "CHEMICAL", 0, 3], ["1,2-diamino-4,5-methylenediaoxy-benzene dihydrochloride", "CHEMICAL", 5, 60], ["DMB", "SIMPLE_CHEMICAL", 0, 3], ["1,2-diamino-4,5-methylenediaoxy-benzene dihydrochloride", "SIMPLE_CHEMICAL", 5, 60], ["DMB", "TEST", 0, 3], ["diamino", "TEST", 9, 16], ["methylenediaoxy-benzene dihydrochloride", "TREATMENT", 21, 60]]], ["Sialic acids were determined by labeling with DMB.", [["Sialic acids", "CHEMICAL", 0, 12], ["DMB", "CHEMICAL", 46, 49], ["Sialic acids", "CHEMICAL", 0, 12], ["DMB", "CHEMICAL", 46, 49], ["Sialic acids", "SIMPLE_CHEMICAL", 0, 12], ["DMB", "SIMPLE_CHEMICAL", 46, 49], ["Sialic acids", "TREATMENT", 0, 12]]], ["Mucin (purchased from Sigma-M-3895 Bovine Submaxillary Gland) was used in the present study as a model for sialic acid compounds.", [["sialic acid", "CHEMICAL", 107, 118], ["sialic acid", "CHEMICAL", 107, 118], ["Mucin", "GENE_OR_GENE_PRODUCT", 0, 5], ["sialic acid", "SIMPLE_CHEMICAL", 107, 118], ["Bovine", "SPECIES", 35, 41], ["Mucin", "TEST", 0, 5], ["sialic acid compounds", "TREATMENT", 107, 128], ["Submaxillary Gland", "ANATOMY", 42, 60]]], ["Salivary mucin is a collection of proteins that contain large amounts of O-glycosidically linked carbohydrate chains.", [["O", "CHEMICAL", 73, 74], ["carbohydrate", "CHEMICAL", 97, 109], ["Salivary mucin", "GENE_OR_GENE_PRODUCT", 0, 14], ["O-glycosidically", "SIMPLE_CHEMICAL", 73, 89], ["O-glycosidically linked carbohydrate chains", "PROTEIN", 73, 116], ["a collection of proteins", "PROBLEM", 18, 42], ["large", "OBSERVATION_MODIFIER", 56, 61], ["amounts", "OBSERVATION_MODIFIER", 62, 69], ["carbohydrate chains", "OBSERVATION", 97, 116]]], ["Mucin isolated from bovine submaxillary gland using as a standard compound contains most members of sialic acid family [4, 39] .", [["submaxillary gland", "ANATOMY", 27, 45], ["sialic acid", "CHEMICAL", 100, 111], ["sialic acid", "CHEMICAL", 100, 111], ["Mucin", "GENE_OR_GENE_PRODUCT", 0, 5], ["bovine", "ORGANISM", 20, 26], ["submaxillary gland", "ORGAN", 27, 45], ["sialic acid", "SIMPLE_CHEMICAL", 100, 111], ["Mucin", "PROTEIN", 0, 5], ["sialic acid family", "PROTEIN", 100, 118], ["bovine", "SPECIES", 20, 26], ["Mucin", "TEST", 0, 5], ["submaxillary gland", "ANATOMY", 27, 45]]], ["The amino group of sialic acids in mucin is usually substituted with acetyl or glycolyl groups.", [["amino", "CHEMICAL", 4, 9], ["sialic acids", "CHEMICAL", 19, 31], ["acetyl", "CHEMICAL", 69, 75], ["glycolyl", "CHEMICAL", 79, 87], ["amino", "CHEMICAL", 4, 9], ["sialic acids", "CHEMICAL", 19, 31], ["acetyl", "CHEMICAL", 69, 75], ["glycolyl", "CHEMICAL", 79, 87], ["amino", "AMINO_ACID", 4, 9], ["sialic acids", "AMINO_ACID", 19, 31], ["mucin", "GENE_OR_GENE_PRODUCT", 35, 40], ["acetyl", "SIMPLE_CHEMICAL", 69, 75], ["glycolyl", "SIMPLE_CHEMICAL", 79, 87], ["The amino group of sialic acids in mucin", "TREATMENT", 0, 40], ["acetyl or glycolyl groups", "TREATMENT", 69, 94], ["sialic acids", "OBSERVATION", 19, 31]]], ["Hydroxyl groups of sialic acids are also sometimes substituted with acetyl, lactyl and other groups [40] .Liberation and derivatization of sialic acids from coelomocytesCoelomocytes were homogenized by sonication (Bandelin-Sonorex) at 4 C in 2 M aqueous acetic acid solution (1 mg of cells/ 5 mL).", [["coelomocytes", "ANATOMY", 157, 169], ["cells", "ANATOMY", 284, 289], ["Hydroxyl", "CHEMICAL", 0, 8], ["sialic acids", "CHEMICAL", 19, 31], ["acetyl", "CHEMICAL", 68, 74], ["lactyl", "CHEMICAL", 76, 82], ["sialic acids", "CHEMICAL", 139, 151], ["Bandelin-Sonorex", "CHEMICAL", 214, 230], ["acetic acid", "CHEMICAL", 254, 265], ["Hydroxyl", "CHEMICAL", 0, 8], ["sialic acids", "CHEMICAL", 19, 31], ["acetyl", "CHEMICAL", 68, 74], ["lactyl", "CHEMICAL", 76, 82], ["sialic acids", "CHEMICAL", 139, 151], ["acetic acid", "CHEMICAL", 254, 265], ["Hydroxyl", "SIMPLE_CHEMICAL", 0, 8], ["sialic acids", "SIMPLE_CHEMICAL", 19, 31], ["acetyl", "SIMPLE_CHEMICAL", 68, 74], ["lactyl", "SIMPLE_CHEMICAL", 76, 82], ["sialic acids", "SIMPLE_CHEMICAL", 139, 151], ["Coelomocytes", "SIMPLE_CHEMICAL", 169, 181], ["aqueous acetic acid", "SIMPLE_CHEMICAL", 246, 265], ["cells", "CELL", 284, 289], ["Hydroxyl groups of sialic acids", "TREATMENT", 0, 31], ["acetyl", "TREATMENT", 68, 74], ["lactyl", "TREATMENT", 76, 82], ["Liberation", "TREATMENT", 106, 116], ["derivatization of sialic acids", "TREATMENT", 121, 151], ["coelomocytesCoelomocytes", "PROBLEM", 157, 181], ["Bandelin-Sonorex)", "TREATMENT", 214, 231], ["2 M aqueous acetic acid solution", "TREATMENT", 242, 274], ["sialic acids", "OBSERVATION", 139, 151]]], ["The solution was used for sialic acid analysis.", [["sialic acid", "CHEMICAL", 26, 37], ["sialic acid", "CHEMICAL", 26, 37], ["sialic acid", "SIMPLE_CHEMICAL", 26, 37], ["The solution", "TREATMENT", 0, 12], ["sialic acid analysis", "TEST", 26, 46]]], ["Homogenizated 40 mL sample solutions (1 mg/5 mL) were kept for 3 h at 80 C. After hydrolysis, the mixtures were derivatized with DMB in the same manner as above.", [["sample", "ANATOMY", 20, 26], ["DMB", "CHEMICAL", 129, 132], ["DMB", "CHEMICAL", 129, 132], ["DMB", "SIMPLE_CHEMICAL", 129, 132], ["Homogenizated 40 mL sample solutions", "TREATMENT", 0, 36], ["the mixtures", "TREATMENT", 94, 106], ["DMB", "TREATMENT", 129, 132]]], ["The mixtures were centrifuged at 16,300 rpm for 10 min at 4 C. Supernatant solution containing the derivatizated sialic acids was pipetted to HPLC vial insert (250 mL).", [["sialic acids", "CHEMICAL", 113, 125], ["sialic acids", "CHEMICAL", 113, 125], ["sialic acids", "SIMPLE_CHEMICAL", 113, 125], ["Supernatant solution", "TREATMENT", 63, 83], ["the derivatizated sialic acids", "TREATMENT", 95, 125], ["HPLC vial insert", "TREATMENT", 142, 158]]], ["The injection volumes of both samples were 0.5 mL for analyzing by CapLC-ESI-MS/MS with ion trap.Capillary LC-ESI-MS/MS/Ion trap parametersLC was performed using an Agilent 1200 Capillary HPLC system with an ODS capillary column (Agilent ZORBAX SB-C18 150 \u00c2 0.5 mm, 5 mm, USA) delivering 20 mL/min of the eluent.Capillary LC-ESI-MS/MS/Ion trap parametersElution was performed by isocratic mode using mixture of methanoleacetonitrileewater (7.5:5:87.5, v/v).", [["samples", "ANATOMY", 30, 37], ["methanoleacetonitrileewater", "CHEMICAL", 411, 438], ["methanoleacetonitrileewater", "CHEMICAL", 411, 438], ["methanoleacetonitrileewater", "SIMPLE_CHEMICAL", 411, 438], ["The injection volumes of both samples", "TREATMENT", 0, 37], ["CapLC", "TEST", 67, 72], ["MS", "PROBLEM", 80, 82], ["ion trap", "TREATMENT", 88, 96], ["Capillary LC", "TEST", 97, 109], ["ESI", "TEST", 110, 113], ["MS", "PROBLEM", 114, 116], ["MS", "PROBLEM", 117, 119], ["Ion trap parametersLC", "TEST", 120, 141], ["an Agilent 1200 Capillary HPLC system", "TREATMENT", 162, 199], ["an ODS capillary column", "TREATMENT", 205, 228], ["Agilent ZORBAX SB", "TREATMENT", 230, 247], ["Capillary LC", "TEST", 312, 324], ["ESI", "TEST", 325, 328], ["MS", "PROBLEM", 329, 331], ["MS", "PROBLEM", 332, 334], ["Ion trap parameters", "TEST", 335, 354], ["methanoleacetonitrileewater", "TREATMENT", 411, 438], ["capillary column", "OBSERVATION", 212, 228]]], ["The column was kept at 30 C during the analysis.", [["The column", "TREATMENT", 0, 10], ["the analysis", "TEST", 35, 47], ["column", "OBSERVATION_MODIFIER", 4, 10]]], ["The samples were stored at 5 C in temperature controlled autosampler board (Agilent G1377A).", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["The column of LC system was connected to an electrospray ion source (ESI positive).", [["column", "OBSERVATION_MODIFIER", 4, 10]]], ["All mass spectrometric measurements were performed on a HCT Ultra ion trap mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray ionization (ESI) source.", [["All mass spectrometric measurements", "TEST", 0, 35], ["a HCT Ultra ion trap mass spectrometer", "TREATMENT", 54, 92], ["an electrospray ionization", "TREATMENT", 143, 169], ["mass", "OBSERVATION", 4, 8]]], ["Spectrometric conditions such as the ion optics voltages, nebulizer gas and dry gas flow rates, and the dry gas temperature were controlled by EsquireControl software 6.1.", [["Spectrometric conditions", "PROBLEM", 0, 24], ["the ion optics voltages", "TEST", 33, 56], ["nebulizer gas", "TEST", 58, 71], ["dry gas flow rates", "TEST", 76, 94], ["the dry gas temperature", "TEST", 100, 123], ["EsquireControl software", "TEST", 143, 166], ["dry", "OBSERVATION_MODIFIER", 76, 79], ["gas flow", "OBSERVATION", 80, 88]]], ["Both the nebulizer gas and the dry gas were nitrogen, and helium (He) (99.9%) was used as the collision gas in the ion trap.", [["nitrogen", "CHEMICAL", 44, 52], ["helium", "CHEMICAL", 58, 64], ["He", "CHEMICAL", 66, 68], ["nitrogen", "CHEMICAL", 44, 52], ["helium", "CHEMICAL", 58, 64], ["He", "CHEMICAL", 66, 68], ["nitrogen", "SIMPLE_CHEMICAL", 44, 52], ["the nebulizer gas", "TEST", 5, 22], ["the dry gas", "TEST", 27, 38], ["helium", "TEST", 58, 64], ["the collision gas", "TEST", 90, 107], ["nebulizer", "ANATOMY", 9, 18]]], ["The ion source parameters were set as follows: dry temperature 310 C, nebulizer pressure 15.0 psi, and dry gas flow 5 l/min.", [["dry temperature", "TEST", 47, 62], ["nebulizer pressure", "TEST", 70, 88], ["dry gas flow", "TEST", 103, 115]]], ["MS/MS spectra were carried out by collision-induced dissociation (CID).", [["MS/MS spectra", "PROBLEM", 0, 13]]], ["All mass spectra were acquired in the mass range 200e600 m/z, with a scan speed of 26,000 m/z per second.", [["All mass spectra", "TEST", 0, 16], ["a scan speed", "TEST", 67, 79], ["mass", "OBSERVATION", 4, 8], ["mass", "ANATOMY", 38, 42]]], ["Data analysis was carried out using Data Analysis software (v.3.4, Bruker Daltonics).ResultsTo determine whether substituted sialic acids exists on the circulating coelomocytes, 2 M acetic acid treatment was used to release sialic acids from glycoconjugates without destroying the substitutions that may be present on the sialic acid molecule.", [["coelomocytes", "ANATOMY", 164, 176], ["sialic acids", "CHEMICAL", 125, 137], ["acetic acid", "CHEMICAL", 182, 193], ["sialic acids", "CHEMICAL", 224, 236], ["sialic acid", "CHEMICAL", 322, 333], ["sialic acids", "CHEMICAL", 125, 137], ["acetic acid", "CHEMICAL", 182, 193], ["sialic acids", "CHEMICAL", 224, 236], ["sialic acid", "CHEMICAL", 322, 333], ["sialic acids", "SIMPLE_CHEMICAL", 125, 137], ["coelomocytes", "CELL", 164, 176], ["acetic acid", "SIMPLE_CHEMICAL", 182, 193], ["sialic acids", "SIMPLE_CHEMICAL", 224, 236], ["sialic acid", "SIMPLE_CHEMICAL", 322, 333], ["sialic acid molecule", "PROTEIN", 322, 342], ["Data analysis", "TEST", 0, 13], ["Data Analysis software", "TEST", 36, 58], ["substituted sialic acids", "PROBLEM", 113, 137], ["the circulating coelomocytes", "TREATMENT", 148, 176], ["acetic acid treatment", "TREATMENT", 182, 203], ["sialic acids", "TEST", 224, 236], ["glycoconjugates", "TREATMENT", 242, 257], ["the substitutions", "PROBLEM", 277, 294], ["the sialic acid molecule", "PROBLEM", 318, 342], ["may be", "UNCERTAINTY", 300, 306], ["sialic", "ANATOMY_MODIFIER", 322, 328], ["acid molecule", "OBSERVATION", 329, 342]]], ["Released sialic acids were then derivatized with 1,2-diamino-4,5methylenedioxybenzene dihydrochloride (DMB) and separated by CapLC-ESI-MS/MS and retention times-CID fragments were compared with standards: an acid hydrolysate of bovine submaxillary mucin (BSM) which is a rich source of sialic acids and Oacetylated sialic acids [4] and other standard sialic acids (Neu5Ac, Neu5Gc and KDN).", [["submaxillary mucin", "ANATOMY", 235, 253], ["sialic acids", "CHEMICAL", 9, 21], ["1,2-diamino-4,5methylenedioxybenzene dihydrochloride", "CHEMICAL", 49, 101], ["DMB", "CHEMICAL", 103, 106], ["sialic acids", "CHEMICAL", 286, 298], ["sialic acids", "CHEMICAL", 315, 327], ["sialic acids", "CHEMICAL", 351, 363], ["sialic acids", "CHEMICAL", 9, 21], ["1,2-diamino-4,5methylenedioxybenzene dihydrochloride", "CHEMICAL", 49, 101], ["DMB", "CHEMICAL", 103, 106], ["sialic acids", "CHEMICAL", 286, 298], ["Oacetylated sialic acids", "CHEMICAL", 303, 327], ["sialic acids", "CHEMICAL", 351, 363], ["Neu5Ac", "CHEMICAL", 365, 371], ["Neu5Gc", "CHEMICAL", 373, 379], ["KDN", "CHEMICAL", 384, 387], ["sialic acids", "SIMPLE_CHEMICAL", 9, 21], ["1,2-diamino-4,5methylenedioxybenzene dihydrochloride", "SIMPLE_CHEMICAL", 49, 101], ["DMB", "SIMPLE_CHEMICAL", 103, 106], ["CapLC", "SIMPLE_CHEMICAL", 125, 130], ["bovine", "ORGANISM", 228, 234], ["submaxillary mucin", "ORGANISM_SUBSTANCE", 235, 253], ["BSM", "MULTI-TISSUE_STRUCTURE", 255, 258], ["sialic acids", "SIMPLE_CHEMICAL", 286, 298], ["Oacetylated sialic acids", "SIMPLE_CHEMICAL", 303, 327], ["sialic acids", "SIMPLE_CHEMICAL", 351, 363], ["Neu5Ac", "SIMPLE_CHEMICAL", 365, 371], ["Neu5Gc", "SIMPLE_CHEMICAL", 373, 379], ["KDN", "GENE_OR_GENE_PRODUCT", 384, 387], ["Neu5Gc", "PROTEIN", 373, 379], ["KDN", "PROTEIN", 384, 387], ["bovine", "SPECIES", 228, 234], ["Released sialic acids", "TREATMENT", 0, 21], ["diamino", "TREATMENT", 53, 60], ["4,5methylenedioxybenzene dihydrochloride (DMB", "TREATMENT", 61, 106], ["MS", "PROBLEM", 138, 140], ["retention times-CID fragments", "TREATMENT", 145, 174], ["an acid hydrolysate of bovine submaxillary mucin (BSM", "TREATMENT", 205, 258], ["sialic acids", "TREATMENT", 286, 298], ["Oacetylated sialic acids", "TREATMENT", 303, 327], ["other standard sialic acids (Neu5Ac", "TREATMENT", 336, 371], ["Neu5Gc and KDN", "TREATMENT", 373, 387]]], ["Sialic acids derivatized with DMB ( Fig. 1) analysis also provides useful information regarding the identity and location substituents of sialic acids, even without knowing the relative retention times of standard sialic acid derivatives [4] .", [["Sialic acids", "CHEMICAL", 0, 12], ["DMB", "CHEMICAL", 30, 33], ["sialic acids", "CHEMICAL", 138, 150], ["sialic acid", "CHEMICAL", 214, 225], ["Sialic acids", "CHEMICAL", 0, 12], ["DMB", "CHEMICAL", 30, 33], ["sialic acids", "CHEMICAL", 138, 150], ["sialic acid", "CHEMICAL", 214, 225], ["Sialic acids", "SIMPLE_CHEMICAL", 0, 12], ["DMB", "SIMPLE_CHEMICAL", 30, 33], ["sialic acids", "SIMPLE_CHEMICAL", 138, 150], ["sialic acid", "SIMPLE_CHEMICAL", 214, 225], ["Sialic acids", "TREATMENT", 0, 12], ["sialic acids", "TREATMENT", 138, 150], ["standard sialic acid derivatives", "TREATMENT", 205, 237]]], ["But, this approach is limited in ion trap systems due to an inherently low mass cutoff (LMCO) derived from CID.", [["an inherently low mass cutoff", "PROBLEM", 57, 86], ["low", "OBSERVATION_MODIFIER", 71, 74], ["mass", "OBSERVATION", 75, 79]]], ["The ion trap fails to trap the ions at lower end of the m/z range when using CID for tandem mass spectrometry (MS/MS) [41] .", [["The ion trap", "TREATMENT", 0, 12], ["tandem mass spectrometry", "TEST", 85, 109], ["ion trap", "OBSERVATION", 4, 12]]], ["Therefore, [M \u00fe H-18] \u00fe ions obtained from MRM of sialic acids are very useful for screening the chromatogram and the spectrum in MS/MS system [15] .ResultsTwelve different sialic acids were detected in BSM by DMB derivatization-CapLC-ESI-MS/MS (data not shown).", [["sialic acids", "CHEMICAL", 50, 62], ["sialic acids", "CHEMICAL", 173, 185], ["DMB", "CHEMICAL", 210, 213], ["CapLC", "CHEMICAL", 229, 234], ["sialic acids", "CHEMICAL", 50, 62], ["sialic acids", "CHEMICAL", 173, 185], ["[M \u00fe H-18] \u00fe ions", "SIMPLE_CHEMICAL", 11, 28], ["sialic acids", "SIMPLE_CHEMICAL", 50, 62], ["sialic acids", "SIMPLE_CHEMICAL", 173, 185], ["BSM", "SIMPLE_CHEMICAL", 203, 206], ["DMB", "SIMPLE_CHEMICAL", 210, 213], ["MRM of sialic acids", "TEST", 43, 62], ["screening the chromatogram", "TEST", 83, 109], ["Twelve different sialic acids", "TEST", 156, 185], ["DMB derivatization", "TEST", 210, 228], ["CapLC", "TEST", 229, 234], ["MS", "PROBLEM", 242, 244]]], ["The peaks for Neu5Ac, Neu5Gc, Neu5,9Ac 2 along with additional sialic acid peaks were assigned by comparison of the elution times and CID fragments ([M \u00fe H-18] \u00fe ions and others (m/z)) as reported by Refs.", [["sialic acid", "CHEMICAL", 63, 74], ["Neu5Ac", "CHEMICAL", 14, 20], ["Neu5Gc", "CHEMICAL", 22, 28], ["Neu5,9Ac 2", "CHEMICAL", 30, 40], ["sialic acid", "CHEMICAL", 63, 74], ["H", "CHEMICAL", 154, 155], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 14, 20], ["Neu5Gc", "SIMPLE_CHEMICAL", 22, 28], ["Neu5", "SIMPLE_CHEMICAL", 30, 34], ["9Ac 2", "SIMPLE_CHEMICAL", 35, 40], ["sialic acid", "SIMPLE_CHEMICAL", 63, 74], ["Neu5Ac", "TREATMENT", 14, 20], ["Neu5Gc", "TEST", 22, 28], ["Neu5", "TREATMENT", 30, 34], ["9Ac", "TREATMENT", 35, 38], ["additional sialic acid peaks", "TREATMENT", 52, 80], ["CID fragments", "PROBLEM", 134, 147], ["H", "TEST", 154, 155], ["ions", "TEST", 162, 166]]], ["[4, 15] using bovine submaxillary mucin and other sialic acidcontaining glycoconjugates.ResultsWe found the presence of ten different types of sialic acids (Neu5Gc, Neu5Ac, Neu5Gc7Ac, Neu5Gc8Ac, Neu5,7Ac 2 , Neu5-Gc9Ac, Neu5,8Ac 2 , Neu5,9Ac 2 , Neu5Gc7,9Ac 2 , Neu5,7,9Ac 3 ) isolated in limited amounts of total coelomocyte population (Fig. 2) by comparison with the data obtained for the analysis of sialic acids of BSM (data not shown) and standard sialic acids (KDN, Neu5Gc and Neu5Ac) (Fig. 3) .", [["submaxillary mucin", "ANATOMY", 21, 39], ["coelomocyte", "ANATOMY", 314, 325], ["sialic acids", "CHEMICAL", 143, 155], ["Neu5Gc, Neu5Ac, Neu5Gc7Ac, Neu5Gc8Ac, Neu5,7Ac 2 , Neu5-Gc9Ac, Neu5,8Ac 2 , Neu5,9Ac 2 , Neu5Gc7,9Ac 2 , Neu5,7,9Ac 3", "CHEMICAL", 157, 274], ["sialic acids", "CHEMICAL", 403, 415], ["sialic acids", "CHEMICAL", 453, 465], ["sialic acids", "CHEMICAL", 143, 155], ["Neu5Gc", "CHEMICAL", 157, 163], ["Neu5Ac", "CHEMICAL", 165, 171], ["Neu5Gc7Ac", "CHEMICAL", 173, 182], ["Neu5Gc8Ac", "CHEMICAL", 184, 193], ["Neu5", "CHEMICAL", 195, 199], ["7Ac 2 , Neu5-Gc9Ac, Neu5,8Ac 2 , Neu5,9Ac 2 , Neu5Gc7,9Ac 2 , Neu5,7,9Ac 3", "CHEMICAL", 200, 274], ["sialic acids", "CHEMICAL", 403, 415], ["sialic acids", "CHEMICAL", 453, 465], ["KDN", "CHEMICAL", 467, 470], ["Neu5Gc", "CHEMICAL", 472, 478], ["Neu5Ac", "CHEMICAL", 483, 489], ["bovine", "ORGANISM", 14, 20], ["submaxillary", "ORGAN", 21, 33], ["mucin", "GENE_OR_GENE_PRODUCT", 34, 39], ["sialic acidcontaining glycoconjugates", "SIMPLE_CHEMICAL", 50, 87], ["sialic acids", "SIMPLE_CHEMICAL", 143, 155], ["Neu5Gc", "SIMPLE_CHEMICAL", 157, 163], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 165, 171], ["Neu5Gc7Ac", "GENE_OR_GENE_PRODUCT", 173, 182], ["Neu5Gc8Ac", "GENE_OR_GENE_PRODUCT", 184, 193], ["Neu5,7Ac 2", "SIMPLE_CHEMICAL", 195, 205], ["Neu5-Gc9Ac", "SIMPLE_CHEMICAL", 208, 218], ["Neu5,8Ac 2", "SIMPLE_CHEMICAL", 220, 230], ["Neu5,9Ac 2", "SIMPLE_CHEMICAL", 233, 243], ["Neu5Gc7", "SIMPLE_CHEMICAL", 246, 253], ["9Ac 2", "SIMPLE_CHEMICAL", 254, 259], ["Neu5", "GENE_OR_GENE_PRODUCT", 262, 266], ["7,9Ac 3", "GENE_OR_GENE_PRODUCT", 267, 274], ["sialic acids", "SIMPLE_CHEMICAL", 403, 415], ["sialic acids", "SIMPLE_CHEMICAL", 453, 465], ["KDN", "SIMPLE_CHEMICAL", 467, 470], ["Neu5", "PROTEIN", 208, 212], ["Gc9Ac", "PROTEIN", 213, 218], ["Neu5", "PROTEIN", 233, 237], ["Neu5", "PROTEIN", 262, 266], ["7,9Ac 3", "PROTEIN", 267, 274], ["coelomocyte population", "CELL_TYPE", 314, 336], ["KDN", "PROTEIN", 467, 470], ["bovine", "SPECIES", 14, 20], ["bovine submaxillary mucin", "TREATMENT", 14, 39], ["sialic acids", "TEST", 143, 155], ["Neu5Gc", "TEST", 157, 163], ["Neu5Ac", "TEST", 165, 171], ["Neu5Gc7Ac", "TEST", 173, 182], ["Neu5Gc8Ac", "TEST", 184, 193], ["Neu5", "TEST", 195, 199], ["Neu5", "TEST", 208, 212], ["Neu5", "TEST", 220, 224], ["Neu5", "TEST", 233, 237], ["Neu5", "TEST", 262, 266], ["total coelomocyte population", "TREATMENT", 308, 336], ["the data", "TEST", 365, 373], ["the analysis", "TEST", 387, 399], ["sialic acids", "TEST", 403, 415], ["standard sialic acids", "TEST", 444, 465], ["KDN", "TEST", 467, 470], ["Neu5Gc", "TEST", 472, 478], ["sialic acids", "OBSERVATION", 143, 155]]], ["The peaks were identified by extracted ion chromatogram.", [["extracted ion chromatogram", "TEST", 29, 55]]], ["The highly abundant fragment ions were used for quantification and others used for confirmation of sialic acid derivatives.", [["sialic acid", "CHEMICAL", 99, 110], ["sialic acid", "CHEMICAL", 99, 110], ["sialic acid derivatives", "SIMPLE_CHEMICAL", 99, 122], ["The highly abundant fragment ions", "PROBLEM", 0, 33], ["quantification", "TEST", 48, 62], ["sialic acid derivatives", "TREATMENT", 99, 122], ["highly", "OBSERVATION_MODIFIER", 4, 10], ["abundant", "OBSERVATION_MODIFIER", 11, 19], ["fragment ions", "OBSERVATION", 20, 33]]], ["All DMB derivatives of sialic acids in our samples show clear molecular ions at [M \u00fe H] \u00fe and [M \u00fe H-18] \u00fe .", [["samples", "ANATOMY", 43, 50], ["DMB", "CHEMICAL", 4, 7], ["sialic acids", "CHEMICAL", 23, 35], ["DMB", "CHEMICAL", 4, 7], ["sialic acids", "CHEMICAL", 23, 35], ["H", "CHEMICAL", 85, 86], ["DMB derivatives", "SIMPLE_CHEMICAL", 4, 19], ["sialic acids", "SIMPLE_CHEMICAL", 23, 35], ["[M \u00fe H] \u00fe", "SIMPLE_CHEMICAL", 80, 89], ["[M \u00fe H-18] \u00fe", "SIMPLE_CHEMICAL", 94, 106], ["All DMB derivatives", "TREATMENT", 0, 19], ["sialic acids", "TREATMENT", 23, 35], ["\u00fe", "TEST", 88, 89]]], ["The fragment pattern of the MS/MS spectrum of sialic acids in total coelomocyte population (see Table 1 ) was consistent with that of DMB derivatives of sialic acids in mucin and the previous reports [4, 20] .ResultsThe most abundant sialic acids were determined as Neu5Gc in coelomocytes.", [["coelomocyte", "ANATOMY", 68, 79], ["coelomocytes", "ANATOMY", 276, 288], ["sialic acids", "CHEMICAL", 46, 58], ["DMB", "CHEMICAL", 134, 137], ["sialic acids", "CHEMICAL", 153, 165], ["sialic acids", "CHEMICAL", 234, 246], ["sialic acids", "CHEMICAL", 46, 58], ["DMB", "CHEMICAL", 134, 137], ["sialic acids", "CHEMICAL", 153, 165], ["sialic acids", "CHEMICAL", 234, 246], ["sialic acids", "SIMPLE_CHEMICAL", 46, 58], ["DMB derivatives", "SIMPLE_CHEMICAL", 134, 149], ["sialic acids", "SIMPLE_CHEMICAL", 153, 165], ["mucin", "GENE_OR_GENE_PRODUCT", 169, 174], ["sialic acids", "SIMPLE_CHEMICAL", 234, 246], ["Neu5Gc", "SIMPLE_CHEMICAL", 266, 272], ["coelomocytes", "CANCER", 276, 288], ["Neu5Gc", "PROTEIN", 266, 272], ["coelomocytes", "CELL_TYPE", 276, 288], ["The fragment pattern", "PROBLEM", 0, 20], ["sialic acids", "TREATMENT", 46, 58], ["total coelomocyte population", "TREATMENT", 62, 90], ["DMB derivatives", "TREATMENT", 134, 149], ["sialic acids", "TREATMENT", 153, 165], ["sialic acids", "TEST", 234, 246], ["Neu5Gc", "TEST", 266, 272], ["fragment", "OBSERVATION_MODIFIER", 4, 12], ["pattern", "OBSERVATION_MODIFIER", 13, 20], ["consistent with", "UNCERTAINTY", 110, 125]]], ["Mass spectral data revealed that the peaks of Neu5Ac and O-acetylated sialic acids were lower mass than Neu5Gc.", [["sialic acids", "CHEMICAL", 70, 82], ["Neu5Ac", "CHEMICAL", 46, 52], ["O-acetylated sialic acids", "CHEMICAL", 57, 82], ["Neu5Gc", "CHEMICAL", 104, 110], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 46, 52], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 57, 82], ["Neu5Gc", "PROTEIN", 104, 110], ["Mass spectral data", "TEST", 0, 18], ["Neu5Ac", "TEST", 46, 52], ["O-acetylated sialic acids", "TREATMENT", 57, 82], ["lower mass", "PROBLEM", 88, 98], ["Neu5Gc", "TEST", 104, 110], ["mass", "OBSERVATION", 94, 98]]], ["Di-O-acetyl derivatives of Neu5Gc (Neu5Gc7,9Ac 2 ) and Neu5Ac (Neu5,7,9Ac 3 ) were observed respectively at m/z \u00bc 526 -18] \u00fe in the mass chromatogram on total coelomocyte population.", [["Di-O-acetyl", "CHEMICAL", 0, 11], ["Neu5Gc", "CHEMICAL", 27, 33], ["Di-O-acetyl", "CHEMICAL", 0, 11], ["Neu5Gc", "CHEMICAL", 27, 33], ["Neu5Gc7,9Ac 2 )", "CHEMICAL", 35, 50], ["Neu5Ac", "CHEMICAL", 55, 61], ["Neu5,7,9Ac 3 )", "CHEMICAL", 63, 77], ["Di-O-acetyl derivatives", "SIMPLE_CHEMICAL", 0, 23], ["Neu5Gc", "SIMPLE_CHEMICAL", 27, 33], ["Neu5Gc7,9Ac 2 )", "SIMPLE_CHEMICAL", 35, 50], ["Neu5Ac (Neu5,7,9Ac 3 )", "SIMPLE_CHEMICAL", 55, 77], ["Di-O-acetyl derivatives", "TREATMENT", 0, 23], ["Neu5Gc (Neu5Gc7,9Ac", "TREATMENT", 27, 46], ["Neu5Ac (Neu5,7,9Ac", "TREATMENT", 55, 73], ["the mass chromatogram", "TEST", 128, 149], ["total coelomocyte population", "TREATMENT", 153, 181]]], ["7, 8, 9-O-acetylated of Neu5Ac was obtained atResultsAlso, Neu5Gc type of sialic acids and its acetylated compounds (Neu5Gc7Ac, Neu5Gc8Ac and Neu5Gc9Ac) were identified at m/z \u00bc 484ResultsThe distributions of sialic acids in total coelomocyte population were shown Fig. 4 .", [["coelomocyte", "ANATOMY", 231, 242], ["7, 8, 9-O", "CHEMICAL", 0, 9], ["sialic acids", "CHEMICAL", 74, 86], ["Neu5Gc7Ac", "CHEMICAL", 117, 126], ["sialic acids", "CHEMICAL", 209, 221], ["7, 8, 9-O-acetylated", "CHEMICAL", 0, 20], ["Neu5Ac", "CHEMICAL", 24, 30], ["sialic acids", "CHEMICAL", 74, 86], ["Neu5Gc7Ac", "CHEMICAL", 117, 126], ["Neu5Gc8Ac", "CHEMICAL", 128, 137], ["Neu5Gc9Ac", "CHEMICAL", 142, 151], ["sialic acids", "CHEMICAL", 209, 221], ["8, 9-O-acetylated of Neu5Ac", "SIMPLE_CHEMICAL", 3, 30], ["sialic acids", "SIMPLE_CHEMICAL", 74, 86], ["Neu5Gc7Ac", "SIMPLE_CHEMICAL", 117, 126], ["Neu5Gc8Ac", "SIMPLE_CHEMICAL", 128, 137], ["Neu5Gc9Ac", "SIMPLE_CHEMICAL", 142, 151], ["sialic acids", "SIMPLE_CHEMICAL", 209, 221], ["Neu5Ac", "TREATMENT", 24, 30], ["sialic acids", "TEST", 74, 86], ["its acetylated compounds", "TREATMENT", 91, 115], ["sialic acids", "TEST", 209, 221], ["total coelomocyte population", "TREATMENT", 225, 253], ["sialic acids", "OBSERVATION", 74, 86], ["acetylated compounds", "OBSERVATION", 95, 115], ["sialic acids", "OBSERVATION", 209, 221]]], ["KDN is a structurally related a-keto acid that is also found in glycoconjugates [13] .", [["KDN", "CHEMICAL", 0, 3], ["a-keto acid", "CHEMICAL", 30, 41], ["a-keto acid", "CHEMICAL", 30, 41], ["KDN", "SIMPLE_CHEMICAL", 0, 3], ["a-keto acid", "SIMPLE_CHEMICAL", 30, 41], ["a structurally related a-keto acid", "PROBLEM", 7, 41], ["structurally related", "OBSERVATION_MODIFIER", 9, 29], ["a-keto acid", "OBSERVATION", 30, 41]]], ["However, under the conditions used in this study, KDN was not found both coelomocytes and BSM.", [["coelomocytes", "ANATOMY", 73, 85], ["KDN", "SIMPLE_CHEMICAL", 50, 53], ["coelomocytes", "CELL", 73, 85], ["BSM", "CELL", 90, 93], ["this study", "TEST", 38, 48]]], ["Hence, Neu5Gc was established as the predominant sialic acid on circulating coelomocytes of P. lividus.DiscussionAlthough small amounts of sialic acid have been reported in insects [21e23] and a gastropod [24] , they are not found generally in glycoconjugates of protostome animals [42] .", [["coelomocytes", "ANATOMY", 76, 88], ["Neu5Gc", "CHEMICAL", 7, 13], ["sialic acid", "CHEMICAL", 49, 60], ["sialic acid", "CHEMICAL", 139, 150], ["sialic acid", "CHEMICAL", 49, 60], ["sialic acid", "CHEMICAL", 139, 150], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 7, 13], ["sialic acid", "SIMPLE_CHEMICAL", 49, 60], ["P. lividus", "ORGANISM", 92, 102], ["sialic acid", "SIMPLE_CHEMICAL", 139, 150], ["Neu5Gc", "PROTEIN", 7, 13], ["P. lividus", "SPECIES", 92, 102], ["P. lividus", "SPECIES", 92, 102], ["Neu5Gc", "TEST", 7, 13], ["the predominant sialic acid", "PROBLEM", 33, 60], ["P. lividus", "PROBLEM", 92, 102], ["small amounts of sialic acid", "PROBLEM", 122, 150], ["sialic acid", "OBSERVATION", 49, 60], ["P. lividus", "OBSERVATION", 92, 102], ["small", "OBSERVATION_MODIFIER", 122, 127], ["amounts", "OBSERVATION_MODIFIER", 128, 135]]], ["However, within the deuterostomate lineage of the animal kingdom, both the echinoderms and vertebrates possess significant amounts of sialylated glycoconjugates and frequently display a considerable number of sialic acid types.", [["echinoderms", "ANATOMY", 75, 86], ["sialic acid", "CHEMICAL", 209, 220], ["sialic acid", "CHEMICAL", 209, 220], ["sialic acid", "SIMPLE_CHEMICAL", 209, 220], ["deuterostomate lineage", "CELL_TYPE", 20, 42], ["sialylated glycoconjugates", "PROBLEM", 134, 160], ["lineage", "OBSERVATION_MODIFIER", 35, 42], ["animal kingdom", "OBSERVATION", 50, 64], ["echinoderms", "OBSERVATION", 75, 86], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["amounts", "OBSERVATION_MODIFIER", 123, 130], ["sialylated glycoconjugates", "OBSERVATION", 134, 160], ["considerable", "OBSERVATION_MODIFIER", 186, 198], ["number", "OBSERVATION_MODIFIER", 199, 205], ["sialic acid types", "OBSERVATION", 209, 226]]], ["The structural variety among the sialic acids results from a number of enzyme-catalyzed modifications of N-acetylneuraminic acid occurring at different stages of glycoconjugate biosynthesis [43] .", [["sialic acids", "CHEMICAL", 33, 45], ["N-acetylneuraminic acid", "CHEMICAL", 105, 128], ["sialic acids", "CHEMICAL", 33, 45], ["N-acetylneuraminic acid", "CHEMICAL", 105, 128], ["sialic acids", "SIMPLE_CHEMICAL", 33, 45], ["N-acetylneuraminic acid", "SIMPLE_CHEMICAL", 105, 128], ["glycoconjugate", "SIMPLE_CHEMICAL", 162, 176], ["enzyme", "PROTEIN", 71, 77], ["the sialic acids", "TEST", 29, 45], ["enzyme", "TEST", 71, 77], ["N-acetylneuraminic acid", "PROBLEM", 105, 128], ["glycoconjugate biosynthesis", "PROBLEM", 162, 189], ["variety", "OBSERVATION_MODIFIER", 15, 22], ["N-acetylneuraminic acid", "OBSERVATION", 105, 128]]], ["N-Glycolylneuraminic acid (Neu5Gc) is one of the most common sialic acids and formally results from the hydroxylation of the methyl group of the 5-N-acetyl moiety of Neu5Ac.", [["N-Glycolylneuraminic acid", "CHEMICAL", 0, 25], ["Neu5Gc", "CHEMICAL", 27, 33], ["sialic acids", "CHEMICAL", 61, 73], ["methyl", "CHEMICAL", 125, 131], ["5-N-acetyl", "CHEMICAL", 145, 155], ["Neu5Ac", "CHEMICAL", 166, 172], ["N-Glycolylneuraminic acid", "CHEMICAL", 0, 25], ["Neu5Gc", "CHEMICAL", 27, 33], ["sialic acids", "CHEMICAL", 61, 73], ["methyl", "CHEMICAL", 125, 131], ["5-N-acetyl", "CHEMICAL", 145, 155], ["Neu5Ac", "CHEMICAL", 166, 172], ["N-Glycolylneuraminic acid", "SIMPLE_CHEMICAL", 0, 25], ["Neu5Gc", "SIMPLE_CHEMICAL", 27, 33], ["sialic acids", "SIMPLE_CHEMICAL", 61, 73], ["methyl", "SIMPLE_CHEMICAL", 125, 131], ["5-N-acetyl moiety", "SIMPLE_CHEMICAL", 145, 162], ["Neu5Ac", "SIMPLE_CHEMICAL", 166, 172], ["Glycolylneuraminic acid (Neu5Gc", "TREATMENT", 2, 33], ["the 5-N-acetyl moiety of Neu5Ac", "TREATMENT", 141, 172]]], ["Interestingly, no Neu5Gc has been found in human and chicken tissues, although small amounts have been detected in tumors [9] .", [["tissues", "ANATOMY", 61, 68], ["tumors", "ANATOMY", 115, 121], ["Neu5Gc", "CHEMICAL", 18, 24], ["tumors", "DISEASE", 115, 121], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 18, 24], ["human", "ORGANISM", 43, 48], ["chicken", "ORGANISM", 53, 60], ["tissues", "TISSUE", 61, 68], ["tumors", "CANCER", 115, 121], ["Neu5Gc", "PROTEIN", 18, 24], ["human", "SPECIES", 43, 48], ["chicken", "SPECIES", 53, 60], ["human", "SPECIES", 43, 48], ["chicken", "SPECIES", 53, 60], ["Neu5Gc", "PROBLEM", 18, 24], ["small amounts", "PROBLEM", 79, 92], ["tumors", "PROBLEM", 115, 121], ["no", "UNCERTAINTY", 15, 17], ["chicken tissues", "OBSERVATION_MODIFIER", 53, 68], ["small", "OBSERVATION_MODIFIER", 79, 84], ["amounts", "OBSERVATION_MODIFIER", 85, 92], ["tumors", "OBSERVATION", 115, 121]]], ["In the marine deuterostomes, including sea urchins and starfish, Neu5Gc is often main and predominant sialic acid and is widely distributed in glycoproteins and gangliosides of especially oocyte and sperm cells, suggesting that it is involved in a number of important biological functions in these marine invertebrates [9, 25, 44, 45] .", [["oocyte", "ANATOMY", 188, 194], ["sperm cells", "ANATOMY", 199, 210], ["sialic acid", "CHEMICAL", 102, 113], ["sialic acid", "CHEMICAL", 102, 113], ["sea urchins", "ORGANISM", 39, 50], ["starfish", "ORGANISM_SUBSTANCE", 55, 63], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 65, 71], ["sialic acid", "SIMPLE_CHEMICAL", 102, 113], ["gangliosides", "GENE_OR_GENE_PRODUCT", 161, 173], ["oocyte", "CELL", 188, 194], ["sperm cells", "CELL", 199, 210], ["glycoproteins", "PROTEIN", 143, 156], ["oocyte and sperm cells", "CELL_TYPE", 188, 210], ["sea urchins", "PROBLEM", 39, 50], ["predominant sialic acid", "PROBLEM", 90, 113], ["especially oocyte and sperm cells", "PROBLEM", 177, 210], ["marine deuterostomes", "OBSERVATION", 7, 27], ["predominant", "OBSERVATION_MODIFIER", 90, 101], ["sialic acid", "OBSERVATION", 102, 113], ["widely", "OBSERVATION_MODIFIER", 121, 127]]], ["In immune cells of sea urchin, P. lividus, Neu5Gc was the most abundant type sialic acid when compared with other found sialic acid types.", [["immune cells", "ANATOMY", 3, 15], ["sialic acid", "CHEMICAL", 77, 88], ["sialic acid", "CHEMICAL", 120, 131], ["sialic acid", "CHEMICAL", 77, 88], ["sialic acid", "CHEMICAL", 120, 131], ["immune cells", "CELL", 3, 15], ["sea urchin", "ORGANISM", 19, 29], ["P. lividus", "ORGANISM", 31, 41], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 43, 49], ["sialic acid", "SIMPLE_CHEMICAL", 77, 88], ["sialic acid", "SIMPLE_CHEMICAL", 120, 131], ["immune cells", "CELL_TYPE", 3, 15], ["sea urchin", "SPECIES", 19, 29], ["P. lividus", "SPECIES", 31, 41], ["sea urchin", "SPECIES", 19, 29], ["P. lividus", "SPECIES", 31, 41], ["sea urchin", "TREATMENT", 19, 29], ["P. lividus", "PROBLEM", 31, 41], ["Neu5Gc", "TEST", 43, 49], ["immune cells", "OBSERVATION", 3, 15], ["sea urchin", "OBSERVATION", 19, 29]]], ["Cell surface glycoconjugates which include Neu5Gc may help to protect tissues from attack by certain pathogen-derived toxic enzymes.", [["Cell surface", "ANATOMY", 0, 12], ["tissues", "ANATOMY", 70, 77], ["Neu5Gc", "CHEMICAL", 43, 49], ["Cell", "CELL", 0, 4], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 43, 49], ["tissues", "TISSUE", 70, 77], ["Neu5Gc", "PROTEIN", 43, 49], ["pathogen-derived toxic enzymes", "PROTEIN", 101, 131], ["Cell surface glycoconjugates", "TREATMENT", 0, 28], ["Neu5Gc", "TREATMENT", 43, 49], ["toxic enzymes", "TEST", 118, 131]]], ["In order to aid the digestion of the cell surface glycoconjugates, several microorganisms secrete sialidase, which may facilitate bacterial infection.", [["cell surface", "ANATOMY", 37, 49], ["bacterial infection", "DISEASE", 130, 149], ["cell", "CELL", 37, 41], ["sialidase", "GENE_OR_GENE_PRODUCT", 98, 107], ["sialidase", "PROTEIN", 98, 107], ["the cell surface glycoconjugates", "TREATMENT", 33, 65], ["several microorganisms secrete sialidase", "PROBLEM", 67, 107], ["bacterial infection", "PROBLEM", 130, 149], ["bacterial", "OBSERVATION_MODIFIER", 130, 139], ["infection", "OBSERVATION", 140, 149]]], ["Since the cleavage rate of Neu5Gc by bacterial and viral sialidases is generally lower than that of Neu5Ac, the expression of Neu5Gc may be an adaptation to retard the effects of sialidases [46] .", [["Neu5Gc", "CHEMICAL", 27, 33], ["Neu5Gc", "CHEMICAL", 126, 132], ["Neu5Ac", "CHEMICAL", 100, 106], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 27, 33], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 100, 106], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 126, 132], ["Neu5Gc", "PROTEIN", 27, 33], ["Neu5Ac", "PROTEIN", 100, 106], ["Neu5Gc", "PROTEIN", 126, 132], ["the cleavage rate of Neu5Gc", "TREATMENT", 6, 33], ["bacterial and viral sialidases", "PROBLEM", 37, 67], ["Neu5Ac", "TREATMENT", 100, 106], ["Neu5Gc", "TREATMENT", 126, 132], ["viral sialidases", "OBSERVATION", 51, 67]]], ["Neu5Ac is the most common ligand for virus binding but Neu5Gc and O-acetylated sialic acids were also found to be specific ligands, for example for influenza C and corona viruses [16] .", [["Neu5Ac", "CHEMICAL", 0, 6], ["sialic acids", "CHEMICAL", 79, 91], ["Neu5Ac", "CHEMICAL", 0, 6], ["Neu5Gc", "CHEMICAL", 55, 61], ["O-acetylated sialic acids", "CHEMICAL", 66, 91], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 0, 6], ["Neu5Gc", "GENE_OR_GENE_PRODUCT", 55, 61], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 66, 91], ["influenza C", "ORGANISM", 148, 159], ["corona viruses", "ORGANISM", 164, 178], ["Neu5Gc", "PROTEIN", 55, 61], ["Neu5Ac", "TREATMENT", 0, 6], ["virus binding", "PROBLEM", 37, 50], ["Neu5Gc", "TEST", 55, 61], ["O-acetylated sialic acids", "TREATMENT", 66, 91], ["influenza C and corona viruses", "PROBLEM", 148, 178]]], ["The presence of Neu5Gc and its derivatives with O-acetyl groups in immune system cells of sea urchin may be related to their habitat, providing a first line of defense against sialidase-containing microorganisms.", [["immune system cells", "ANATOMY", 67, 86], ["Neu5Gc", "CHEMICAL", 16, 22], ["-acetyl", "CHEMICAL", 49, 56], ["Neu5Gc", "CHEMICAL", 16, 22], ["O-acetyl", "CHEMICAL", 48, 56], ["Neu5Gc", "SIMPLE_CHEMICAL", 16, 22], ["O-acetyl", "SIMPLE_CHEMICAL", 48, 56], ["immune system cells", "CELL", 67, 86], ["sea urchin", "ORGANISM", 90, 100], ["sialidase", "GENE_OR_GENE_PRODUCT", 176, 185], ["immune system cells", "CELL_TYPE", 67, 86], ["sialidase", "PROTEIN", 176, 185], ["Neu5Gc", "TREATMENT", 16, 22], ["its derivatives", "TREATMENT", 27, 42], ["O-acetyl groups", "TREATMENT", 48, 63], ["sialidase", "PROBLEM", 176, 185], ["microorganisms", "PROBLEM", 197, 211], ["Neu5Gc", "OBSERVATION", 16, 22]]], ["According to the results, our data may provide an explanation of why 9-O-acetylated Neu5Gc (Neu5Gc9Ac) was found more than other O-acetylated sialic acids in immune cells of P. lividus (Fig. 4) .", [["immune cells", "ANATOMY", 158, 170], ["9-O", "CHEMICAL", 69, 72], ["Neu5Gc9Ac", "CHEMICAL", 92, 101], ["sialic acids", "CHEMICAL", 142, 154], ["9-O-acetylated Neu5Gc", "CHEMICAL", 69, 90], ["Neu5Gc9Ac", "CHEMICAL", 92, 101], ["O-acetylated sialic acids", "CHEMICAL", 129, 154], ["9-O-acetylated Neu5Gc", "SIMPLE_CHEMICAL", 69, 90], ["Neu5Gc9Ac", "SIMPLE_CHEMICAL", 92, 101], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 129, 154], ["immune cells", "CELL", 158, 170], ["P. lividus", "ORGANISM", 174, 184], ["Fig. 4", "ORGANISM", 186, 192], ["immune cells", "CELL_TYPE", 158, 170], ["P. lividus", "SPECIES", 174, 184], ["P. lividus", "SPECIES", 174, 184], ["O-acetylated sialic acids", "TREATMENT", 129, 154], ["P. lividus", "PROBLEM", 174, 184]]], ["Naturally occurring sialic acids can be O-acetylated at all their hydroxyl groups at positions C4, C7, C8 and C9 of these carboxylated sugars [47] .", [["sialic acids", "CHEMICAL", 20, 32], ["hydroxyl", "CHEMICAL", 66, 74], ["carboxylated sugars", "CHEMICAL", 122, 141], ["sialic acids", "CHEMICAL", 20, 32], ["hydroxyl", "CHEMICAL", 66, 74], ["sugars", "CHEMICAL", 135, 141], ["sialic acids", "SIMPLE_CHEMICAL", 20, 32], ["O-acetylated", "SIMPLE_CHEMICAL", 40, 52], ["carboxylated sugars [47]", "SIMPLE_CHEMICAL", 122, 146], ["sialic acids", "TREATMENT", 20, 32], ["these carboxylated sugars", "TEST", 116, 141], ["sialic acids", "OBSERVATION", 20, 32], ["C7", "ANATOMY_MODIFIER", 99, 101], ["C8", "ANATOMY_MODIFIER", 103, 105]]], ["One sialic acid molecule may carry one or several, up to there, O-acetyl groups but they mostly are mono-O-acetylated derivatives.", [["sialic acid", "CHEMICAL", 4, 15], ["O-acetyl", "CHEMICAL", 64, 72], ["sialic acid", "CHEMICAL", 4, 15], ["O-acetyl", "CHEMICAL", 64, 72], ["sialic acid", "SIMPLE_CHEMICAL", 4, 15], ["O-acetyl groups", "SIMPLE_CHEMICAL", 64, 79], ["mono-O-acetylated derivatives", "SIMPLE_CHEMICAL", 100, 129], ["One sialic acid molecule", "PROBLEM", 0, 24], ["O-acetyl groups", "TREATMENT", 64, 79], ["mono-O-acetylated derivatives", "TREATMENT", 100, 129], ["sialic", "ANATOMY_MODIFIER", 4, 10], ["acid molecule", "OBSERVATION", 11, 24], ["acetylated derivatives", "OBSERVATION", 107, 129]]], ["Biological effect depends on the position relative to the 9-carbon scaffold and whether it is the Neu5Ac or Neu5Gc [2, 47] .", [["9-carbon", "CHEMICAL", 58, 66], ["9-carbon", "CHEMICAL", 58, 66], ["Neu5Ac", "CHEMICAL", 98, 104], ["Neu5Gc", "CHEMICAL", 108, 114], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 98, 104], ["the 9-carbon scaffold", "TREATMENT", 54, 75]]], ["O-acetylated sialic acids seem to be involved in many biological phenomena [2] .", [["sialic acids", "CHEMICAL", 13, 25], ["O-acetylated sialic acids", "CHEMICAL", 0, 25], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 0, 25], ["acetylated sialic acids", "TREATMENT", 2, 25]]], ["Given variable expression of O-acetyl groups on sialic acids and their diverse effects in all immune reactions [1] .", [["sialic acids", "CHEMICAL", 48, 60], ["O-acetyl", "CHEMICAL", 29, 37], ["sialic acids", "CHEMICAL", 48, 60], ["O-acetyl", "SIMPLE_CHEMICAL", 29, 37], ["sialic acids", "AMINO_ACID", 48, 60], ["O-acetyl groups", "PROTEIN", 29, 44], ["O-acetyl groups", "TREATMENT", 29, 44], ["sialic acids", "TREATMENT", 48, 60], ["all immune reactions", "PROBLEM", 90, 110]]], ["O-acetylation of sialic acids can be developmentally regulated in immune systems or create new biological functions [3, 6] .", [["immune systems", "ANATOMY", 66, 80], ["sialic acids", "CHEMICAL", 17, 29], ["O", "CHEMICAL", 0, 1], ["sialic acids", "CHEMICAL", 17, 29], ["sialic acids", "SIMPLE_CHEMICAL", 17, 29], ["acetylation of sialic acids", "TREATMENT", 2, 29]]], ["They therefore revealed to be important in cell differentiation, neural development, non-immunogenic protection and immuno reactivity [47] .", [["cell", "ANATOMY", 43, 47], ["neural", "ANATOMY", 65, 71], ["cell", "CELL", 43, 47], ["immuno reactivity", "TEST", 116, 133], ["cell differentiation", "OBSERVATION", 43, 63]]], ["However, high levels of 9-O-acetylated sialic acids were detected on developing and peripheral resting and activated T-cells [48] .", [["T-cells", "ANATOMY", 117, 124], ["9-O", "CHEMICAL", 24, 27], ["sialic acids", "CHEMICAL", 39, 51], ["9-O-acetylated sialic acids", "CHEMICAL", 24, 51], ["9-O-acetylated sialic acids", "SIMPLE_CHEMICAL", 24, 51], ["T-cells", "CELL", 117, 124], ["peripheral resting and activated T-cells", "CELL_TYPE", 84, 124], ["acetylated sialic acids", "TREATMENT", 28, 51], ["peripheral", "ANATOMY_MODIFIER", 84, 94]]], ["As another example, side chain O-acetylated sialic acids are also expressed human leukocytes, where they can be used as markers for specific subsets of T-helper cell.", [["leukocytes", "ANATOMY", 82, 92], ["T-helper cell", "ANATOMY", 152, 165], ["sialic acids", "CHEMICAL", 44, 56], ["O-acetylated sialic acids", "CHEMICAL", 31, 56], ["side chain O-acetylated sialic acids", "SIMPLE_CHEMICAL", 20, 56], ["human", "ORGANISM", 76, 81], ["leukocytes", "CELL", 82, 92], ["T-helper cell", "CELL", 152, 165], ["human leukocytes", "CELL_TYPE", 76, 92], ["T-helper cell", "CELL_TYPE", 152, 165], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["side chain O-acetylated sialic acids", "TEST", 20, 56]]], ["For several subsets of T-lymphocytes O-acetylation of sialic acids is known to be a differentiation and maturation marker [47, 48] .", [["T-lymphocytes", "ANATOMY", 23, 36], ["sialic acids", "CHEMICAL", 54, 66], ["sialic acids", "CHEMICAL", 54, 66], ["T-lymphocytes", "CELL", 23, 36], ["sialic acids", "AMINO_ACID", 54, 66], ["T-lymphocytes", "CELL_TYPE", 23, 36], ["T-lymphocytes O-acetylation of sialic acids", "TREATMENT", 23, 66], ["lymphocytes O-acetylation", "OBSERVATION", 25, 50], ["sialic acids", "OBSERVATION", 54, 66]]], ["This may be one of reasons why immune cells, circulating coelomocytes, contain such a wide variety of O-acetylated sialic acids (Neu5Gc9Ac, Neu5Gc8Ac, Neu5,9Ac 2 , Neu5,7Ac 2 , Neu5,8Ac 2 , Neu5,7,9Ac 3 , Neu5Gc7,9Ac 2 , Neu5Gc7Ac).", [["immune cells", "ANATOMY", 31, 43], ["coelomocytes", "ANATOMY", 57, 69], ["sialic acids", "CHEMICAL", 115, 127], ["sialic acids", "CHEMICAL", 115, 127], ["Neu5Gc9Ac", "CHEMICAL", 129, 138], ["Neu5Gc8Ac", "CHEMICAL", 140, 149], ["Neu5", "CHEMICAL", 151, 155], ["9Ac", "CHEMICAL", 156, 159], ["Neu5", "CHEMICAL", 164, 168], ["7Ac 2 , Neu5,8Ac 2 , Neu5,7,9Ac 3 , Neu5Gc7,9Ac 2 , Neu5Gc7Ac", "CHEMICAL", 169, 230], ["immune cells", "CELL", 31, 43], ["coelomocytes", "CELL", 57, 69], ["O-acetylated sialic acids", "SIMPLE_CHEMICAL", 102, 127], ["Neu5Gc9Ac", "SIMPLE_CHEMICAL", 129, 138], ["9Ac 2", "GENE_OR_GENE_PRODUCT", 156, 161], ["Neu5", "GENE_OR_GENE_PRODUCT", 164, 168], ["7Ac 2", "GENE_OR_GENE_PRODUCT", 169, 174], ["Neu5", "GENE_OR_GENE_PRODUCT", 177, 181], ["8Ac 2", "GENE_OR_GENE_PRODUCT", 182, 187], ["Neu5", "GENE_OR_GENE_PRODUCT", 190, 194], ["Neu5Gc7,9Ac 2", "GENE_OR_GENE_PRODUCT", 205, 218], ["Neu5Gc7Ac", "GENE_OR_GENE_PRODUCT", 221, 230], ["immune cells", "CELL_TYPE", 31, 43], ["circulating coelomocytes", "CELL_TYPE", 45, 69], ["O-acetylated sialic acids", "PROTEIN", 102, 127], ["Neu5Gc9Ac", "PROTEIN", 129, 138], ["Neu5Gc8Ac", "PROTEIN", 140, 149], ["Neu5", "PROTEIN", 151, 155], ["Neu5", "PROTEIN", 164, 168], ["Neu5", "PROTEIN", 177, 181], ["Neu5", "PROTEIN", 190, 194], ["7,9Ac 3", "PROTEIN", 195, 202], ["Neu5Gc7,9Ac 2", "PROTEIN", 205, 218], ["Neu5Gc7Ac", "PROTEIN", 221, 230], ["immune cells", "PROBLEM", 31, 43], ["circulating coelomocytes", "PROBLEM", 45, 69], ["O-acetylated sialic acids", "TREATMENT", 102, 127], ["Neu5Gc9Ac", "TEST", 129, 138], ["Neu5Gc8Ac", "TEST", 140, 149], ["Neu5", "TREATMENT", 177, 181], ["Neu5", "TREATMENT", 190, 194], ["Neu5Gc", "TREATMENT", 205, 211], ["immune cells", "OBSERVATION", 31, 43], ["sialic acids", "OBSERVATION", 115, 127]]], ["And also, O-acetylation of sialic acids may be a novel marker for finding subsets of coelomocytes like T-cells.DiscussionIn conclusion, the investigation of the immune system of echinoderms should help in understanding the cellular and humoral interactions that control host defense in this group of marine animals and mammals.", [["coelomocytes", "ANATOMY", 85, 97], ["T-cells", "ANATOMY", 103, 110], ["immune system", "ANATOMY", 161, 174], ["cellular", "ANATOMY", 223, 231], ["sialic acids", "CHEMICAL", 27, 39], ["sialic acids", "CHEMICAL", 27, 39], ["sialic acids", "SIMPLE_CHEMICAL", 27, 39], ["coelomocytes", "CELL", 85, 97], ["T-cells", "CELL", 103, 110], ["cellular", "CELL", 223, 231], ["coelomocytes", "CELL_TYPE", 85, 97], ["T-cells", "CELL_TYPE", 103, 110], ["O-acetylation of sialic acids", "TREATMENT", 10, 39], ["coelomocytes like T-cells", "PROBLEM", 85, 110]]], ["Moreover, they may lead to possible analogies or homologies with immune reactions in vertebrates.", [["immune reactions in vertebrates", "PROBLEM", 65, 96]]]], "9bb1ae59f89f6a69e843425e4c5846cfa5be4f1d": [["Author ContributionsConceptualization: Lee Third, although the authors have acknowledged selection bias, they should recognize that the patient group had more of health-related issues compared with general population, resulting limited generalizability of the study.", [["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["the study", "TEST", 256, 265]]], ["The generalization of the prevalence obtained from patient group should be cautious.", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["A recent systematic review found that 89% of antibody test evaluation results had selection bias.", [["A recent systematic review", "TEST", 0, 26], ["antibody test evaluation", "TEST", 45, 69]]], ["4 In addition, the PCR-negative specimens collected during COVID-19 pandemic period are inadequate for the evaluation of specificity, as the convalescent patients may show positive results in antibody assay, but negative results in PCR.", [["specimens", "ANATOMY", 32, 41], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["the PCR", "TEST", 15, 22], ["COVID", "TEST", 59, 64], ["the evaluation", "TEST", 103, 117], ["specificity", "TEST", 121, 132], ["antibody assay", "TEST", 192, 206], ["PCR", "TEST", 232, 235]]], ["7 If the authors claimed the high seroprevalence in the population, then authors should not use the PCR-negative samples from the population as negative control group.", [["the PCR", "TEST", 96, 103]]], ["Moreover, given only small specimens have been included (60 positive and 30 negative), providing the confidence intervals for distribution would be more informative.", [["specimens", "ANATOMY", 27, 36], ["specimens", "CANCER", 27, 36], ["small specimens", "PROBLEM", 21, 36]]], ["The confidence interval of the specificity seems to be 88.4%-100.0%, based on Clopper-Pearson Interval. https://jkms.org https://doi.org/10.3346/jkms.2020.35.e339Author ContributionsDr.", [["the specificity", "TEST", 27, 42]]], ["Lee and colleagues 1 raised several issues related to our study, 2 which can be summarized into two categories: 1) the possibility of low specificity of rapid test kit and 2) selection bias of study subjects.", [["our study", "TEST", 54, 63], ["rapid test kit", "TEST", 153, 167]]], ["They stated that 92% specificity of the assay was a study limitation.", [["the assay", "TEST", 36, 45]]], ["However, the truth is that the specificity was 100% but sensitivity was 92%.", [["the specificity", "TEST", 27, 42], ["sensitivity", "TEST", 56, 67]]], ["It was a simple typo which occurred during manuscript revision.Author ContributionsThe authors criticized that the seroprevalence of 7.6% of our study can be totally attributed to false-positive cases due to 92% specificity.", [["a simple typo", "PROBLEM", 7, 20], ["manuscript revision", "TREATMENT", 43, 62], ["our study", "TEST", 141, 150], ["false-positive cases", "PROBLEM", 180, 200], ["simple", "OBSERVATION_MODIFIER", 9, 15], ["typo", "OBSERVATION", 16, 20], ["revision", "OBSERVATION", 54, 62]]], ["However, it is more accurate to state that even the value of 7.6% was an underestimation of the true figure because the sensitivity was 92%.", [["the sensitivity", "TEST", 116, 131]]], ["In addition, recent findings, which demonstrated the disappearance of antibodies among coronavirus disease 2019 (COVID19) patients in months, 3 suggested an additional reason to justify our speculation; the epidemic peak of Daegu was late February, while the collection of blood was performed from late May to early June.", [["blood", "ANATOMY", 273, 278], ["coronavirus disease", "DISEASE", 87, 106], ["coronavirus", "ORGANISM", 87, 98], ["patients", "ORGANISM", 122, 130], ["blood", "ORGANISM_SUBSTANCE", 273, 278], ["antibodies", "PROTEIN", 70, 80], ["patients", "SPECIES", 122, 130], ["the disappearance of antibodies", "PROBLEM", 49, 80], ["coronavirus disease", "PROBLEM", 87, 106], ["coronavirus disease", "OBSERVATION", 87, 106]]], ["In particular, a rapid decline in antibodies was observed in mild cases 4 ; the majority of COVID19 patients in Daegu only had mild symptoms or were asymptomatic.Author ContributionsIn fact, many details raised by the authors relate to the accuracy of rapid test kit, especially the possible low specificity.", [["patients", "ORGANISM", 100, 108], ["antibodies", "PROTEIN", 34, 44], ["patients", "SPECIES", 100, 108], ["a rapid decline in antibodies", "PROBLEM", 15, 44], ["mild cases 4", "PROBLEM", 61, 73], ["mild symptoms", "PROBLEM", 127, 140], ["asymptomatic", "PROBLEM", 149, 161], ["rapid test kit", "TEST", 252, 266], ["rapid", "OBSERVATION_MODIFIER", 17, 22], ["decline", "OBSERVATION", 23, 30], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["mild", "OBSERVATION_MODIFIER", 127, 131], ["symptoms", "OBSERVATION", 132, 140]]], ["Although 92% specificity is not relevant anymore as explained above, the authors' perspective on accuracy of antibody testing requires further discussion because the importance of this issue differs substantially depending on the purpose of the test.", [["antibody testing", "TEST", 109, 125], ["the test", "TEST", 241, 249]]], ["5 If the results of antibody test are applied to individuals, such as immunity passports, the accuracy of the test is crucial to avoid risks due to false-positive and false-negative cases.", [["antibody test", "TEST", 20, 33], ["the test", "TEST", 106, 114], ["false-positive and false-negative cases", "PROBLEM", 148, 187]]], ["However, when an antibody test is performed to estimate seroprevalence at the population level, even a serological test with moderate sensitivity and specificity is acceptable 5 because of the tradeoff between false-positive and false-negative cases.", [["an antibody test", "TEST", 14, 30], ["a serological test", "TEST", 101, 119], ["moderate sensitivity", "PROBLEM", 125, 145], ["specificity", "TEST", 150, 161], ["negative cases", "OBSERVATION", 235, 249]]], ["A recent nationwide population-based study in Spain, reporting 5.0% seroprevalence, clearly demonstrated that the performance of the rapid test was satisfactory compared with that of immunoassay.", [["based study", "TEST", 31, 42], ["the rapid test", "TEST", 129, 143], ["immunoassay", "TEST", 183, 194]]], ["6 4/4 https://jkms.org https://doi.org/10.3346/jkms.2020.35.e339COVID-19 Seroprevalencebetween patients and guardians, and given that all of the positive cases belonged to different households, the selection bias may not be as serious as the authors have suspected.COVID-19 SeroprevalenceMoreover, despite the possibility of selection bias, we believe that the size of missing undiagnosed cases in Daegu should be estimated because it is one of most important reasons underlying any seroprevalence study during the epidemic.", [["https://doi.org/10.3346/jkms.2020.35.e339COVID-19", "CHEMICAL", 23, 72], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["the positive cases", "PROBLEM", 141, 159], ["COVID", "TEST", 265, 270], ["SeroprevalenceMoreover", "TREATMENT", 274, 296], ["missing undiagnosed cases", "PROBLEM", 369, 394], ["any seroprevalence study", "TEST", 479, 503], ["size", "OBSERVATION_MODIFIER", 361, 365]]], ["This estimation is more important for infectious diseases with a high proportion of asymptomatic or mild cases, such as COVID 19, to determine the optimal public health strategy.COVID-19 SeroprevalenceSometimes, information with limitation would be better than at least no information.", [["infectious diseases", "PROBLEM", 38, 57], ["asymptomatic or mild cases", "PROBLEM", 84, 110], ["more important", "UNCERTAINTY", 19, 33], ["mild", "OBSERVATION_MODIFIER", 100, 104]]], ["The estimated size of missing undiagnosed cases during any epidemics may be a case in point.", [["missing undiagnosed cases", "PROBLEM", 22, 47], ["any epidemics", "PROBLEM", 55, 68], ["size", "OBSERVATION_MODIFIER", 14, 18]]], ["Currently, however, even a population-based seroprevalence survey with a perfect serological assay may not validly estimate the size of missing undiagnosed cases in Daegu because of antibody loss in many previously infected cases.", [["antibody loss", "DISEASE", 182, 195], ["a perfect serological assay", "TEST", 71, 98], ["missing undiagnosed cases", "PROBLEM", 136, 161], ["antibody loss", "PROBLEM", 182, 195], ["size", "OBSERVATION_MODIFIER", 128, 132], ["antibody loss", "OBSERVATION", 182, 195], ["infected", "OBSERVATION", 215, 223]]], ["3,4", [["3,4", "CHEMICAL", 0, 3]]]], "PMC5893201": [["IntroductionThe genus Ebolavirus of the family Filoviridae (Order: Mononegavirales) is comprised of five recognized species, with Zaire ebolavirus (ZEBOV) representing the prototype species.", [["Order: Mononegavirales", "ORGANISM", 60, 82], ["Zaire ebolavirus", "ORGANISM", 130, 146], ["ZEBOV", "ORGANISM", 148, 153], ["Zaire ebolavirus", "SPECIES", 130, 146], ["ZEBOV", "SPECIES", 148, 153], ["Zaire ebolavirus", "PROBLEM", 130, 146], ["the prototype species", "PROBLEM", 168, 189], ["genus Ebolavirus", "OBSERVATION", 16, 32]]], ["ZEBOV is a significant human pathogen with case fatality rates often reaching 90%.", [["ZEBOV", "ORGANISM", 0, 5], ["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["ZEBOV", "SPECIES", 0, 5], ["human", "SPECIES", 23, 28], ["a significant human pathogen", "PROBLEM", 9, 37], ["significant", "OBSERVATION_MODIFIER", 11, 22]]], ["To date there have been numerous outbreaks of ZEBOV,1 the largest of which occurred in West Africa in 2014 and resulted in >28,000 human cases and >11,000 deaths.2,3 The high case fatality rate and magnitude of the 2014 outbreak in West Africa illustrates the pressing need for the development of a safe and efficacious vaccine to prevent future ZEBOV outbreaks.IntroductionZEBOV particles are filamentous and enveloped.4 The ZEBOV genome consists of a non-segmented, negative-sense, single-stranded RNA molecule which is approximately 19kb and encodes eight proteins: nucleoprotein (NP), virion protein (VP) 35, VP40, glycoprotein (GP), secreted glycoprotein (sGP), VP30, VP24, and an RNA-dependent RNA polymerase (L).5,6 Notably, GP mediates attachment and fusion of the virion to affected cells.5,7 Previous studies have shown immunization against GP to be an effective means of eliciting a protective immune response against a lethal ZEBOV challenge due to GP containing important neutralization or other functional epitopes.8,9IntroductionVesicular stomatitis virus (VSV) (Order: Mononegavirales; Family: Rhabdoviridae; Genus: Vesiculovirus) is an enveloped virus containing a non-segmented, single-stranded, negative-sense RNA genome.", [["virion", "ANATOMY", 773, 779], ["cells", "ANATOMY", 792, 797], ["deaths", "DISEASE", 155, 161], ["2,3", "CHEMICAL", 162, 165], ["Vesicular stomatitis", "DISEASE", 1044, 1064], ["ZEBOV", "ORGANISM", 46, 51], ["human", "ORGANISM", 131, 136], ["2,3", "SIMPLE_CHEMICAL", 162, 165], ["ZEBOV", "ORGANISM", 346, 351], ["ZEBOV", "ORGANISM", 426, 431], ["nucleoprotein (NP), virion protein (VP) 35", "GENE_OR_GENE_PRODUCT", 569, 611], ["VP40", "GENE_OR_GENE_PRODUCT", 613, 617], ["glycoprotein (GP), secreted glycoprotein", "GENE_OR_GENE_PRODUCT", 619, 659], ["sGP", "GENE_OR_GENE_PRODUCT", 661, 664], ["VP30", "GENE_OR_GENE_PRODUCT", 667, 671], ["VP24", "GENE_OR_GENE_PRODUCT", 673, 677], ["GP", "GENE_OR_GENE_PRODUCT", 732, 734], ["cells", "CELL", 792, 797], ["ZEBOV", "ORGANISM", 938, 943], ["8,9Introduction", "ORGANISM", 1029, 1044], ["Vesicular stomatitis virus", "ORGANISM", 1044, 1070], ["VSV", "ORGANISM", 1072, 1075], ["Vesiculovirus", "GENE_OR_GENE_PRODUCT", 1132, 1145], ["ZEBOV genome", "DNA", 426, 438], ["non-segmented, negative-sense, single-stranded RNA molecule", "RNA", 453, 512], ["19kb", "PROTEIN", 536, 540], ["nucleoprotein", "PROTEIN", 569, 582], ["NP", "PROTEIN", 584, 586], ["virion protein (VP) 35", "PROTEIN", 589, 611], ["VP40", "PROTEIN", 613, 617], ["glycoprotein", "PROTEIN", 619, 631], ["GP", "PROTEIN", 633, 635], ["secreted glycoprotein", "PROTEIN", 638, 659], ["sGP", "PROTEIN", 661, 664], ["VP30", "PROTEIN", 667, 671], ["VP24", "PROTEIN", 673, 677], ["RNA-dependent RNA polymerase (L).5,6", "PROTEIN", 686, 722], ["GP", "PROTEIN", 732, 734], ["non-segmented, single-stranded, negative-sense RNA genome", "DNA", 1182, 1239], ["human", "SPECIES", 131, 136], ["Vesicular stomatitis virus", "SPECIES", 1044, 1070], ["ZEBOV", "SPECIES", 46, 51], ["human", "SPECIES", 131, 136], ["ZEBOV", "SPECIES", 346, 351], ["ZEBOV", "SPECIES", 426, 431], ["ZEBOV", "SPECIES", 938, 943], ["Vesicular stomatitis virus", "SPECIES", 1044, 1070], ["VSV", "SPECIES", 1072, 1075], ["numerous outbreaks of ZEBOV", "PROBLEM", 24, 51], ["a safe and efficacious vaccine", "TREATMENT", 297, 327], ["future ZEBOV outbreaks", "PROBLEM", 339, 361], ["IntroductionZEBOV particles", "TREATMENT", 362, 389], ["The ZEBOV genome", "TEST", 422, 438], ["nucleoprotein (NP", "TEST", 569, 586], ["virion protein", "TEST", 589, 603], ["VP", "TEST", 605, 607], ["VP40", "TEST", 613, 617], ["secreted glycoprotein", "TEST", 638, 659], ["sGP", "TEST", 661, 664], ["VP30", "TEST", 667, 671], ["VP24", "TEST", 673, 677], ["an RNA", "TEST", 683, 689], ["RNA polymerase", "TEST", 700, 714], ["GP mediates attachment", "PROBLEM", 732, 754], ["affected cells", "PROBLEM", 783, 797], ["Previous studies", "TEST", 802, 818], ["immunization", "TREATMENT", 830, 842], ["a lethal ZEBOV challenge", "TREATMENT", 929, 953], ["GP containing important neutralization", "PROBLEM", 961, 999], ["other functional epitopes", "PROBLEM", 1003, 1028], ["Vesicular stomatitis virus", "PROBLEM", 1044, 1070], ["an enveloped virus", "PROBLEM", 1150, 1168], ["numerous", "OBSERVATION_MODIFIER", 24, 32], ["outbreaks", "OBSERVATION", 33, 42], ["largest", "OBSERVATION_MODIFIER", 58, 65], ["high", "OBSERVATION_MODIFIER", 170, 174], ["filamentous", "OBSERVATION_MODIFIER", 394, 405], ["enveloped", "OBSERVATION_MODIFIER", 410, 419], ["Vesicular stomatitis virus", "OBSERVATION", 1044, 1070], ["RNA genome", "OBSERVATION", 1229, 1239]]], ["This approximately 11kb genome encodes five viral proteins: the nucleoprotein (N), phosphoprotein (P), matrix (M), glycoprotein (G), and the large protein (L).10 The epidemiology and ecology of naturally-circulating vesiculoviruses remains poorly understood, but VS viruses and/or serological evidence of exposure to VSV have been found in a diversity of domestic and wild vertebrate species.10-12 The two serotypes of VSV, VSV-Indiana and VSV-New Jersey are both transmitted to mammals by hematophagous insects as well as through direct contact via the transcutaneous or transmucosal route.10,12 Transmission competent insect vectors of VSV include biting midges (Culicoides spp.) phlebotomine sand flies (Lutzomyia and Phlebotomus spp.), black flies (Simulium spp.), and mosquitoes.13-19 Clinical illness in cattle, horses, and pigs as a result of VSV infection includes vesiculation, ulceration, and erosion of the oral and nasal mucosa and epithelial surface of the tongue, coronary bands, and teats.11,12 The prevalence of clinical cases in cattle herds is generally low (10%-20%), but seroprevalence within the herd may approach 100%.11IntroductionVSV has proven to be a successful vector in the development of several live-attenuated vaccine candidates due to its ability to accept and stably express foreign gene products from heterologous viruses.20-26 To develop a safe and efficacious single-dose vaccine against ZEBOV, the G gene of VSV was replaced with the immunogenic glycoprotein (GP) gene of ZEBOV, resulting in VSV virion particles expressing ZEBOV GP as the surface antigen.27-30 The resulting rVSV\u0394G-ZEBOV-GP construct, also referred to as V920, is a replication competent, live-attenuated vaccine that has attenuated replication and a narrower host-cell tropism in vitro than wild-type VSV.27 The resulting rVSV\u0394G-ZEBOV-GP construct has been tested in several animal models, including mice and non-human primates (NHPs), and has been shown to be safe and to elicit a robust, protective immune response.29,31-34 This vaccine has been tested in several clinical trials and has been shown to have an acceptable safety profile, to be immunogenic, and to be highly effective in preventing ebola virus disease (EVD) induced by ZEBOV in humans.35-38 A viremia is detectable, generally in the first few days after vaccination, but at low levels, as will be discussed below.39IntroductionHowever, due to the vector-borne potential of wild-type VSV, certain environmental concerns must be addressed.", [["transcutaneous", "ANATOMY", 554, 568], ["transmucosal", "ANATOMY", 572, 584], ["oral", "ANATOMY", 918, 922], ["nasal mucosa", "ANATOMY", 927, 939], ["epithelial surface", "ANATOMY", 944, 962], ["tongue", "ANATOMY", 970, 976], ["coronary", "ANATOMY", 978, 986], ["teats", "ANATOMY", 998, 1003], ["surface", "ANATOMY", 1577, 1584], ["cell", "ANATOMY", 1770, 1774], ["illness", "DISEASE", 799, 806], ["VSV infection", "DISEASE", 850, 863], ["ulceration", "DISEASE", 887, 897], ["IntroductionVSV", "CHEMICAL", 1142, 1157], ["29,31-34", "CHEMICAL", 2023, 2031], ["ebola virus disease", "DISEASE", 2205, 2224], ["EVD", "DISEASE", 2226, 2229], ["viremia", "DISEASE", 2266, 2273], ["matrix", "CELLULAR_COMPONENT", 103, 109], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 115, 131], ["large protein (L)", "GENE_OR_GENE_PRODUCT", 141, 158], ["vesiculoviruses", "CANCER", 216, 231], ["VS viruses", "ORGANISM", 263, 273], ["VSV", "ORGANISM", 317, 320], ["VSV", "ORGANISM", 419, 422], ["VSV-Indiana", "ORGANISM", 424, 435], ["VSV-New Jersey", "ORGANISM", 440, 454], ["VSV", "ORGANISM", 638, 641], ["Culicoides spp.", "ORGANISM", 665, 680], ["phlebotomine", "ORGANISM", 682, 694], ["sand flies", "ORGANISM", 695, 705], ["Lutzomyia", "ORGANISM", 707, 716], ["Phlebotomus spp.", "ORGANISM", 721, 737], ["black flies", "ORGANISM", 740, 751], ["Simulium spp.", "ORGANISM", 753, 766], ["cattle", "ORGANISM", 810, 816], ["horses", "ORGANISM_SUBDIVISION", 818, 824], ["pigs", "ORGANISM", 830, 834], ["VSV", "ORGANISM", 850, 853], ["oral", "ORGANISM_SUBDIVISION", 918, 922], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 927, 939], ["epithelial surface", "TISSUE", 944, 962], ["tongue", "ORGAN", 970, 976], ["cattle", "ORGANISM", 1046, 1052], ["ZEBOV", "ORGANISM", 1424, 1429], ["G", "GENE_OR_GENE_PRODUCT", 1435, 1436], ["VSV", "ORGANISM", 1445, 1448], ["GP", "GENE_OR_GENE_PRODUCT", 1497, 1499], ["ZEBOV", "ORGANISM", 1509, 1514], ["VSV", "ORGANISM", 1529, 1532], ["ZEBOV", "ORGANISM", 1561, 1566], ["GP", "ORGANISM", 1567, 1569], ["rVSV\u0394G", "GENE_OR_GENE_PRODUCT", 1613, 1619], ["cell", "CELL", 1770, 1774], ["wild-type VSV", "ORGANISM", 1797, 1810], ["rVSV\u0394G", "GENE_OR_GENE_PRODUCT", 1828, 1834], ["ZEBOV", "ORGANISM", 1835, 1840], ["mice", "ORGANISM", 1906, 1910], ["non-human primates", "ORGANISM", 1915, 1933], ["NHPs", "ORGANISM", 1935, 1939], ["ebola virus", "ORGANISM", 2205, 2216], ["ZEBOV", "ORGANISM", 2242, 2247], ["humans", "ORGANISM", 2251, 2257], ["VSV", "ORGANISM", 2456, 2459], ["11kb genome", "DNA", 19, 30], ["viral proteins", "PROTEIN", 44, 58], ["nucleoprotein (N)", "PROTEIN", 64, 81], ["phosphoprotein", "PROTEIN", 83, 97], ["P", "PROTEIN", 99, 100], ["matrix (M)", "PROTEIN", 103, 113], ["glycoprotein", "PROTEIN", 115, 127], ["G", "PROTEIN", 129, 130], ["large protein (L)", "PROTEIN", 141, 158], ["foreign gene products", "PROTEIN", 1308, 1329], ["G gene", "DNA", 1435, 1441], ["immunogenic glycoprotein (GP) gene", "DNA", 1471, 1505], ["ZEBOV GP", "PROTEIN", 1561, 1569], ["surface antigen", "PROTEIN", 1577, 1592], ["rVSV\u0394G-ZEBOV-GP construct", "DNA", 1613, 1638], ["V920", "CELL_LINE", 1660, 1664], ["rVSV\u0394G-ZEBOV-GP construct", "DNA", 1828, 1853], ["VSV", "SPECIES", 419, 422], ["VSV", "SPECIES", 424, 427], ["VSV", "SPECIES", 440, 443], ["VSV", "SPECIES", 638, 641], ["Culicoides spp.", "SPECIES", 665, 680], ["Phlebotomus spp.", "SPECIES", 721, 737], ["flies", "SPECIES", 746, 751], ["Simulium spp.", "SPECIES", 753, 766], ["cattle", "SPECIES", 810, 816], ["horses", "SPECIES", 818, 824], ["pigs", "SPECIES", 830, 834], ["cattle", "SPECIES", 1046, 1052], ["mice", "SPECIES", 1906, 1910], ["humans", "SPECIES", 2251, 2257], ["VSV", "SPECIES", 317, 320], ["VSV", "SPECIES", 419, 422], ["VSV", "SPECIES", 424, 427], ["VSV", "SPECIES", 440, 443], ["VSV", "SPECIES", 638, 641], ["Culicoides spp.", "SPECIES", 665, 680], ["Phlebotomus spp.", "SPECIES", 721, 737], ["black flies", "SPECIES", 740, 751], ["Simulium spp.", "SPECIES", 753, 766], ["cattle", "SPECIES", 810, 816], ["horses", "SPECIES", 818, 824], ["pigs", "SPECIES", 830, 834], ["VSV", "SPECIES", 850, 853], ["cattle", "SPECIES", 1046, 1052], ["ZEBOV", "SPECIES", 1424, 1429], ["VSV", "SPECIES", 1445, 1448], ["ZEBOV", "SPECIES", 1509, 1514], ["VSV", "SPECIES", 1529, 1532], ["ZEBOV", "SPECIES", 1561, 1566], ["VSV", "SPECIES", 1807, 1810], ["mice", "SPECIES", 1906, 1910], ["ebola virus", "SPECIES", 2205, 2216], ["ZEBOV", "SPECIES", 2242, 2247], ["humans", "SPECIES", 2251, 2257], ["VSV", "SPECIES", 2456, 2459], ["viral proteins", "TEST", 44, 58], ["the nucleoprotein", "TEST", 60, 77], ["phosphoprotein (P), matrix (M), glycoprotein (G)", "TREATMENT", 83, 131], ["circulating vesiculoviruses", "PROBLEM", 204, 231], ["VS viruses", "PROBLEM", 263, 273], ["exposure to VSV", "PROBLEM", 305, 320], ["wild vertebrate species", "PROBLEM", 368, 391], ["the transcutaneous or transmucosal route", "TREATMENT", 550, 590], ["biting midges (Culicoides spp.", "TREATMENT", 650, 680], ["pigs", "TREATMENT", 830, 834], ["VSV infection", "PROBLEM", 850, 863], ["vesiculation", "PROBLEM", 873, 885], ["ulceration", "PROBLEM", 887, 897], ["erosion of the oral and nasal mucosa and epithelial surface of the tongue", "PROBLEM", 903, 976], ["a successful vector", "TREATMENT", 1175, 1194], ["attenuated vaccine candidates", "TREATMENT", 1230, 1259], ["foreign gene products", "TREATMENT", 1308, 1329], ["heterologous viruses", "PROBLEM", 1335, 1355], ["a safe and efficacious single-dose vaccine", "TREATMENT", 1373, 1415], ["ZEBOV", "TREATMENT", 1424, 1429], ["the G gene of VSV", "TREATMENT", 1431, 1448], ["the immunogenic glycoprotein", "TREATMENT", 1467, 1495], ["ZEBOV", "TREATMENT", 1509, 1514], ["VSV virion particles", "PROBLEM", 1529, 1549], ["the surface antigen", "TEST", 1573, 1592], ["live-attenuated vaccine", "TREATMENT", 1694, 1717], ["attenuated replication", "PROBLEM", 1727, 1749], ["a narrower host", "PROBLEM", 1754, 1769], ["The resulting rVSV\u0394G", "TEST", 1814, 1834], ["This vaccine", "TREATMENT", 2032, 2044], ["immunogenic", "PROBLEM", 2151, 2162], ["ebola virus disease", "PROBLEM", 2205, 2224], ["EVD", "TREATMENT", 2226, 2229], ["A viremia", "PROBLEM", 2264, 2273], ["vaccination", "TREATMENT", 2327, 2338], ["wild-type VSV", "PROBLEM", 2446, 2459], ["vertebrate species", "OBSERVATION", 373, 391], ["serotypes", "OBSERVATION_MODIFIER", 406, 415], ["VSV", "OBSERVATION", 419, 422], ["New", "OBSERVATION_MODIFIER", 444, 447], ["Jersey", "OBSERVATION_MODIFIER", 448, 454], ["VSV", "OBSERVATION_MODIFIER", 850, 853], ["infection", "OBSERVATION", 854, 863], ["vesiculation", "OBSERVATION_MODIFIER", 873, 885], ["ulceration", "OBSERVATION", 887, 897], ["erosion", "OBSERVATION", 903, 910], ["oral", "ANATOMY", 918, 922], ["nasal mucosa", "ANATOMY", 927, 939], ["epithelial", "ANATOMY_MODIFIER", 944, 954], ["surface", "ANATOMY_MODIFIER", 955, 962], ["tongue", "ANATOMY", 970, 976], ["coronary bands", "ANATOMY", 978, 992], ["low", "OBSERVATION_MODIFIER", 1072, 1075], ["heterologous viruses", "OBSERVATION", 1335, 1355], ["VSV virion particles", "OBSERVATION", 1529, 1549], ["cell tropism", "OBSERVATION", 1770, 1782], ["ebola virus", "OBSERVATION", 2205, 2216], ["viremia", "OBSERVATION", 2266, 2273]]], ["Development of live attenuated vaccines using an arbovirus as a vaccine vector introduces the risk that an immunized person might develop a viremia high enough for a susceptible insect to become infected with and potentially transmit the vaccine.", [["viremia", "DISEASE", 140, 147], ["person", "SPECIES", 117, 123], ["live attenuated vaccines", "TREATMENT", 15, 39], ["an arbovirus", "TREATMENT", 46, 58], ["a vaccine vector", "TREATMENT", 62, 78], ["a viremia", "PROBLEM", 138, 147], ["the vaccine", "TREATMENT", 234, 245], ["viremia", "OBSERVATION", 140, 147]]], ["This phenomenon was documented with the Venezuelan equine encephalitis virus vaccine TC-83, when TC-83 was isolated from mosquitoes in Louisiana following its use in horses to stop the 1969\u201372 epidemic in Texas.40 In the case of V920, while the backbone is an arbovirus, prior experimental evidence demonstrated that Ebola Reston virus was incapable of replication in arthropods.41 Therefore, we hypothesized that the V920 rVSV\u0394G-ZEBOV-GP vaccine would not replicate in arthropod cells or live mosquitoes.", [["cells", "ANATOMY", 480, 485], ["Venezuelan equine encephalitis", "DISEASE", 40, 70], ["TC-83", "CHEMICAL", 85, 90], ["TC-83", "CHEMICAL", 97, 102], ["Ebola", "DISEASE", 317, 322], ["Venezuelan equine encephalitis virus", "ORGANISM", 40, 76], ["TC-83", "ORGANISM", 85, 90], ["TC-83", "CELL", 97, 102], ["V920", "CANCER", 229, 233], ["Ebola Reston virus", "ORGANISM", 317, 335], ["V920", "ORGANISM", 418, 422], ["rVSV\u0394G", "GENE_OR_GENE_PRODUCT", 423, 429], ["ZEBOV", "ORGANISM", 430, 435], ["arthropod cells", "CELL", 470, 485], ["arthropod cells", "CELL_TYPE", 470, 485], ["equine encephalitis virus vaccine", "SPECIES", 51, 84], ["Ebola Reston virus", "SPECIES", 317, 335], ["Venezuelan equine encephalitis virus vaccine TC-83", "SPECIES", 40, 90], ["TC-83", "SPECIES", 97, 102], ["Ebola Reston virus", "SPECIES", 317, 335], ["This phenomenon", "PROBLEM", 0, 15], ["the Venezuelan equine encephalitis virus", "TREATMENT", 36, 76], ["TC", "TEST", 85, 87], ["TC", "TEST", 97, 99], ["an arbovirus", "PROBLEM", 257, 269], ["Ebola Reston virus", "PROBLEM", 317, 335], ["the V920 rVSV\u0394G", "TREATMENT", 414, 429], ["ZEBOV", "TREATMENT", 430, 435], ["GP vaccine", "TREATMENT", 436, 446], ["arbovirus", "OBSERVATION", 260, 269]]], ["Furthermore, in addition to our inclusion of a wild-type VSV-Indiana strain (VSV-I) control throughout the study, we included another VSV construct with the G gene of VSV replaced with the structural cassette, sans capsid, of Semliki Forest virus (SFV), termed rVSV-SFV, as a control.", [["wild-type", "ORGANISM", 47, 56], ["VSV-Indiana strain", "ORGANISM", 57, 75], ["VSV-I", "ORGANISM", 77, 82], ["VSV", "ORGANISM", 134, 137], ["G", "GENE_OR_GENE_PRODUCT", 157, 158], ["VSV", "ORGANISM", 167, 170], ["Semliki Forest virus", "ORGANISM", 226, 246], ["SFV", "ORGANISM", 248, 251], ["rVSV-SFV", "ORGANISM", 261, 269], ["G gene", "DNA", 157, 163], ["structural cassette", "DNA", 189, 208], ["Semliki Forest virus", "SPECIES", 226, 246], ["VSV-Indiana strain (VSV-I", "SPECIES", 57, 82], ["VSV", "SPECIES", 134, 137], ["VSV", "SPECIES", 167, 170], ["Semliki Forest virus", "SPECIES", 226, 246], ["SFV", "SPECIES", 248, 251], ["SFV", "SPECIES", 266, 269], ["a wild-type VSV", "PROBLEM", 45, 60], ["the study", "TEST", 103, 112], ["another VSV construct", "TREATMENT", 126, 147], ["the G gene of VSV", "TREATMENT", 153, 170], ["the structural cassette", "TREATMENT", 185, 208], ["Semliki Forest virus (SFV", "TREATMENT", 226, 251], ["SFV", "TREATMENT", 266, 269], ["SFV", "OBSERVATION", 266, 269]]], ["The rationale for including rVSV-SFV, which we hypothesized would replicate in arthropods due to the natural transmission of SFV by mosquitoes, was to demonstrate that the inability of V920 to replicate in arthropod (in vitro and in vivo) was due to the replacement of the arbovirus envelope cassette with the ZEBOV GP gene.", [["rVSV-SFV", "ORGANISM", 28, 36], ["SFV", "ORGANISM", 125, 128], ["V920", "GENE_OR_GENE_PRODUCT", 185, 189], ["arbovirus", "ORGANISM", 273, 282], ["ZEBOV", "ORGANISM", 310, 315], ["GP", "GENE_OR_GENE_PRODUCT", 316, 318], ["rVSV", "PROTEIN", 28, 32], ["arbovirus envelope cassette", "DNA", 273, 300], ["ZEBOV GP gene", "DNA", 310, 323], ["SFV", "SPECIES", 33, 36], ["SFV", "SPECIES", 125, 128], ["ZEBOV", "SPECIES", 310, 315], ["rVSV", "TEST", 28, 32], ["SFV", "PROBLEM", 33, 36], ["the replacement of the arbovirus envelope cassette", "TREATMENT", 250, 300], ["SFV", "ANATOMY", 33, 36], ["SFV", "ANATOMY", 125, 128]]], ["An experiment was conducted to determine whether V920 replicated in arthropod cells.", [["cells", "ANATOMY", 78, 83], ["arthropod cells", "CELL", 68, 83], ["V920", "PROTEIN", 49, 53], ["arthropod cells", "CELL_TYPE", 68, 83], ["arthropod cells", "OBSERVATION", 68, 83]]], ["We evaluated the replication kinetics of all three viruses in several relevant insect vector cell lines derived from mosquitoes (Genera: Aedes and Anopheles), biting midges (Genus: Culicoides), and sand flies (Genus: Lutzomyia).", [["cell lines", "ANATOMY", 93, 103], ["cell lines", "CELL", 93, 103], ["Anopheles", "ORGANISM", 147, 156], ["Culicoides", "ORGANISM", 181, 191], ["sand flies", "ORGANISM", 198, 208], ["insect vector cell lines", "CELL_LINE", 79, 103], ["all three viruses", "PROBLEM", 41, 58], ["vector cell lines", "OBSERVATION", 86, 103]]], ["We also assessed the replication potential of V920 in live Aedes and Culex mosquitoes exposed via an infectious blood meal and intrathoracic (IT) inoculation.", [["blood", "ANATOMY", 112, 117], ["V920", "CHEMICAL", 46, 50], ["V920", "SIMPLE_CHEMICAL", 46, 50], ["Culex mosquitoes", "ORGANISM", 69, 85], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["Culex mosquitoes", "SPECIES", 69, 85], ["an infectious blood meal", "TREATMENT", 98, 122], ["intrathoracic (IT) inoculation", "TREATMENT", 127, 157], ["infectious", "OBSERVATION_MODIFIER", 101, 111], ["intrathoracic", "ANATOMY", 127, 140]]], ["Through this study, we confirmed the inability of V920 to replicate in arthropods in vitro and in vivo, interestingly we also found that rVSV-SFV was also unable to replicate in arthropods in vitro and in vivo.Growth curves in cell cultures ::: ResultsVirus replication was assessed in multiple arthropod cell lines (Figure 1), representing taxa that serve as actual or potential vectors of VSV in the field.", [["cell cultures", "ANATOMY", 227, 240], ["cell lines", "ANATOMY", 305, 315], ["V920", "SIMPLE_CHEMICAL", 50, 54], ["rVSV-SFV", "ORGANISM", 137, 145], ["cell cultures", "CELL", 227, 240], ["arthropod cell lines", "CELL", 295, 315], ["Figure 1", "CELL", 317, 325], ["VSV", "ORGANISM", 391, 394], ["rVSV", "PROTEIN", 137, 141], ["cell cultures", "CELL_LINE", 227, 240], ["multiple arthropod cell lines", "CELL_LINE", 286, 315], ["SFV", "SPECIES", 142, 145], ["VSV", "SPECIES", 391, 394], ["this study", "TEST", 8, 18], ["SFV", "PROBLEM", 142, 145], ["Growth curves", "TEST", 210, 223], ["cell cultures", "TEST", 227, 240], ["multiple arthropod cell lines", "TREATMENT", 286, 315], ["SFV", "OBSERVATION", 142, 145], ["arthropod cell lines", "OBSERVATION", 295, 315]]], ["All growth curves were conducted in triplicate at a multiplicity of infection (MOI) of 0.01.", [["infection", "DISEASE", 68, 77], ["All growth curves", "TEST", 0, 17], ["infection", "PROBLEM", 68, 77], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["curves", "OBSERVATION_MODIFIER", 11, 17], ["infection", "OBSERVATION", 68, 77]]], ["Back titrations were conducted for each inoculum and confirmed to be within two-fold of the desired inoculum titer.", [["Back titrations", "TREATMENT", 0, 15]]], ["Each virus replicated to a high titer in Vero cells and caused significant cytopathic effect (CPE), confirming the utility of this cell line for virus quantification purposes (Figure 1A).", [["Vero cells", "ANATOMY", 41, 51], ["cell line", "ANATOMY", 131, 140], ["Vero cells", "CELL", 41, 51], ["cell line", "CELL", 131, 140], ["Vero cells", "CELL_LINE", 41, 51], ["Each virus", "PROBLEM", 0, 10], ["a high titer in Vero cells", "PROBLEM", 25, 51], ["significant cytopathic effect (CPE", "PROBLEM", 63, 97], ["this cell line", "TREATMENT", 126, 140], ["virus quantification purposes", "TEST", 145, 174], ["virus", "OBSERVATION", 5, 10], ["high titer", "OBSERVATION_MODIFIER", 27, 37], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["cytopathic", "OBSERVATION_MODIFIER", 75, 85], ["cell line", "OBSERVATION", 131, 140]]], ["In Anopheline (4a3b), Aedes (C6/36), biting midge (CuVa), and sand fly (LL-5) cell lines replication was observed for VSV-I but not for either V920 or rVSV-SFV (Figure 1B-E).", [["LL-5) cell lines", "ANATOMY", 72, 88], ["C6/36", "ORGANISM", 29, 34], ["biting midge", "ORGANISM", 37, 49], ["CuVa", "CELL", 51, 55], ["LL-5) cell lines", "CELL", 72, 88], ["VSV-I", "ORGANISM", 118, 123], ["rVSV-SFV", "ORGANISM", 151, 159], ["sand fly (LL-5) cell lines", "CELL_LINE", 62, 88], ["rVSV", "PROTEIN", 151, 155], ["VSV-I", "SPECIES", 118, 123], ["rVSV-SFV", "SPECIES", 151, 159], ["biting midge (CuVa)", "TREATMENT", 37, 56], ["sand fly (LL-5) cell lines replication", "TREATMENT", 62, 100], ["VSV", "PROBLEM", 118, 121], ["rVSV", "TEST", 151, 155], ["cell lines", "OBSERVATION", 78, 88], ["SFV", "ANATOMY", 156, 159]]], ["For each cell line, virus titers of VSV-I were significantly higher (p-value < 0.05) than V920 and rVSV-SFV as determined by a two-way ANOVA with a Tukey's correction at each timepoint (Figure 1).", [["cell line", "ANATOMY", 9, 18], ["cell line", "CELL", 9, 18], ["VSV-I", "ORGANISM", 36, 41], ["rVSV-SFV", "ORGANISM", 99, 107], ["VSV-I", "SPECIES", 36, 41], ["rVSV-SFV", "SPECIES", 99, 107], ["each cell line", "TREATMENT", 4, 18], ["virus titers", "TEST", 20, 32], ["VSV", "TEST", 36, 39], ["p-value", "TEST", 69, 76], ["rVSV", "TEST", 99, 103], ["a Tukey's correction", "TREATMENT", 146, 166], ["cell line", "OBSERVATION", 9, 18]]]], "d674cbef00936a6b54bc59ed041aa8e55c94d1dd": [["IntroductionHepatitis C virus (HCV) is a major pathogen that causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) with 170 million people infected worldwide (Saito et al., 1990; Di Bishceglie, 1997) .", [["liver", "ANATOMY", 87, 92], ["hepatocellular carcinoma", "ANATOMY", 108, 132], ["HCC", "ANATOMY", 134, 137], ["IntroductionHepatitis C", "DISEASE", 0, 23], ["chronic hepatitis", "DISEASE", 68, 85], ["liver cirrhosis", "DISEASE", 87, 102], ["hepatocellular carcinoma", "DISEASE", 108, 132], ["HCC", "DISEASE", 134, 137], ["IntroductionHepatitis C virus", "ORGANISM", 0, 29], ["HCV", "ORGANISM", 31, 34], ["liver", "ORGAN", 87, 92], ["hepatocellular carcinoma", "CANCER", 108, 132], ["HCC", "CANCER", 134, 137], ["people", "ORGANISM", 156, 162], ["C virus", "SPECIES", 22, 29], ["people", "SPECIES", 156, 162], ["HCV", "SPECIES", 31, 34], ["IntroductionHepatitis C virus (HCV)", "PROBLEM", 0, 35], ["a major pathogen", "PROBLEM", 39, 55], ["chronic hepatitis", "PROBLEM", 68, 85], ["liver cirrhosis", "PROBLEM", 87, 102], ["hepatocellular carcinoma", "PROBLEM", 108, 132], ["HCC", "PROBLEM", 134, 137], ["virus", "OBSERVATION", 24, 29], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["hepatitis", "OBSERVATION", 76, 85], ["liver", "ANATOMY", 87, 92], ["cirrhosis", "OBSERVATION", 93, 102], ["hepatocellular", "ANATOMY", 108, 122], ["carcinoma", "OBSERVATION", 123, 132]]], ["However, the exact mechanisms of HCV-associated pathogenesis and carcinogenesis are largely unknown.IntroductionHCV is a member of the flaviviridae family with a singlestranded and positive-sense RNA genome of approximately 9.6 kb in length (Choo et al., 1989; Rice et al., 1996) .", [["carcinogenesis", "DISEASE", 65, 79], ["HCV", "ORGANISM", 33, 36], ["flaviviridae", "CANCER", 135, 147], ["flaviviridae family", "PROTEIN", 135, 154], ["singlestranded and positive-sense RNA genome", "DNA", 162, 206], ["HCV", "SPECIES", 33, 36], ["HCV", "PROBLEM", 33, 36], ["associated pathogenesis", "PROBLEM", 37, 60], ["carcinogenesis", "PROBLEM", 65, 79], ["HCV", "OBSERVATION", 33, 36], ["carcinogenesis", "OBSERVATION", 65, 79]]], ["The viral RNA genome contains a single open reading frame flanked by un-translated regions (UTR) at both 5\u2032 and 3\u2032 ends.", [["viral RNA genome", "DNA", 4, 20], ["open reading frame", "DNA", 39, 57], ["UTR", "DNA", 92, 95], ["5\u2032 and 3\u2032 ends", "DNA", 105, 119], ["The viral RNA genome", "PROBLEM", 0, 20], ["viral RNA genome", "OBSERVATION", 4, 20]]], ["A large viral polyprotein precursor of about 3010 amino acids is translated and sequentially cleaved by cellular and viral proteases into at least 10 different proteins, including structural proteins (C, E1, E2, and p7) and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Reed and Rice, 2000; Luo and Colacino, 2004) .", [["cellular", "ANATOMY", 104, 112], ["amino acids", "CHEMICAL", 50, 61], ["amino acids", "CHEMICAL", 50, 61], ["amino acids", "AMINO_ACID", 50, 61], ["cellular", "CELL", 104, 112], ["C", "GENE_OR_GENE_PRODUCT", 201, 202], ["E1", "GENE_OR_GENE_PRODUCT", 204, 206], ["E2", "GENE_OR_GENE_PRODUCT", 208, 210], ["p7", "GENE_OR_GENE_PRODUCT", 216, 218], ["NS2", "GENE_OR_GENE_PRODUCT", 249, 252], ["NS3", "GENE_OR_GENE_PRODUCT", 254, 257], ["NS4A", "GENE_OR_GENE_PRODUCT", 259, 263], ["NS4B", "GENE_OR_GENE_PRODUCT", 265, 269], ["NS5A", "GENE_OR_GENE_PRODUCT", 271, 275], ["NS5B", "GENE_OR_GENE_PRODUCT", 281, 285], ["cellular and viral proteases", "PROTEIN", 104, 132], ["structural proteins", "PROTEIN", 180, 199], ["C", "PROTEIN", 201, 202], ["E1", "PROTEIN", 204, 206], ["E2", "PROTEIN", 208, 210], ["p7", "PROTEIN", 216, 218], ["non-structural proteins", "PROTEIN", 224, 247], ["NS2", "PROTEIN", 249, 252], ["NS3", "PROTEIN", 254, 257], ["NS4A", "PROTEIN", 259, 263], ["NS4B", "PROTEIN", 265, 269], ["NS5A", "PROTEIN", 271, 275], ["NS5B", "PROTEIN", 281, 285], ["A large viral polyprotein precursor", "TEST", 0, 35], ["amino acids", "TEST", 50, 61], ["viral proteases", "TEST", 117, 132], ["structural proteins", "TEST", 180, 199], ["E1", "TEST", 204, 206], ["E2", "TEST", 208, 210], ["non-structural proteins", "TEST", 224, 247], ["NS2", "TEST", 249, 252], ["NS3", "TEST", 254, 257], ["NS4A", "TREATMENT", 259, 263], ["NS4B", "TREATMENT", 265, 269], ["NS5A", "TREATMENT", 271, 275], ["NS5B", "TEST", 281, 285], ["large", "OBSERVATION_MODIFIER", 2, 7], ["viral polyprotein", "OBSERVATION", 8, 25]]], ["Replication of HCV RNA occurs in the cytoplasmic membrane-bound multiple-protein complex containing the HCV RNA and non-structural proteins NS3 to NS5B (Di Bishceglie, 1997; Luo and Colacino, 2004) .", [["cytoplasmic membrane", "ANATOMY", 37, 57], ["HCV", "ORGANISM", 15, 18], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 37, 57], ["NS3", "GENE_OR_GENE_PRODUCT", 140, 143], ["HCV RNA", "RNA", 15, 22], ["cytoplasmic membrane-bound multiple-protein complex", "PROTEIN", 37, 88], ["HCV RNA", "RNA", 104, 111], ["non-structural proteins", "PROTEIN", 116, 139], ["NS3", "PROTEIN", 140, 143], ["NS5B", "PROTEIN", 147, 151], ["HCV", "SPECIES", 15, 18], ["HCV", "SPECIES", 104, 107], ["HCV RNA", "PROBLEM", 15, 22], ["the cytoplasmic membrane", "TEST", 33, 57], ["bound multiple-protein complex", "PROBLEM", 58, 88], ["the HCV RNA", "PROBLEM", 100, 111], ["non-structural proteins NS3", "TREATMENT", 116, 143], ["NS5B", "TEST", 147, 151], ["HCV RNA", "OBSERVATION", 15, 22], ["HCV RNA", "OBSERVATION", 104, 111]]], ["Based on genome sequence similarity, HCV is grouped into six major genotypes and numerous subtypes (Tanaka et al., 1995) .IntroductionNS3 is one of the viral serine proteases that is essential for virus replication and would be a good target for antiviral drugs.", [["serine", "CHEMICAL", 158, 164], ["HCV", "ORGANISM", 37, 40], ["viral serine proteases", "PROTEIN", 152, 174], ["HCV", "SPECIES", 37, 40], ["HCV", "PROBLEM", 37, 40], ["IntroductionNS3", "TREATMENT", 122, 137], ["the viral serine proteases", "TREATMENT", 148, 174], ["virus replication", "TREATMENT", 197, 214], ["antiviral drugs", "TREATMENT", 246, 261], ["numerous", "OBSERVATION_MODIFIER", 81, 89], ["subtypes", "OBSERVATION_MODIFIER", 90, 98]]], ["The serine protease is located in the N-terminal portion of NS3, which is responsible for cleavage at the NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B junctions.", [["serine", "CHEMICAL", 4, 10], ["N", "CHEMICAL", 38, 39], ["serine", "AMINO_ACID", 4, 10], ["NS3", "GENE_OR_GENE_PRODUCT", 60, 63], ["NS3/4A", "GENE_OR_GENE_PRODUCT", 106, 112], ["NS4A/4B", "GENE_OR_GENE_PRODUCT", 114, 121], ["NS4B", "GENE_OR_GENE_PRODUCT", 123, 127], ["NS5A/5B", "GENE_OR_GENE_PRODUCT", 136, 143], ["serine protease", "PROTEIN", 4, 19], ["N-terminal portion", "PROTEIN", 38, 56], ["NS3", "PROTEIN", 60, 63], ["NS3", "PROTEIN", 106, 109], ["NS4A", "PROTEIN", 114, 118], ["4B", "PROTEIN", 119, 121], ["NS4B", "PROTEIN", 123, 127], ["5A", "PROTEIN", 128, 130], ["NS5A", "PROTEIN", 136, 140], ["The serine protease", "TREATMENT", 0, 19], ["NS3", "PROBLEM", 60, 63], ["cleavage", "PROBLEM", 90, 98], ["NS4A/4B", "TREATMENT", 114, 121], ["NS4B/5A", "TREATMENT", 123, 130], ["NS5A/5B junctions", "TREATMENT", 136, 153], ["terminal", "ANATOMY_MODIFIER", 40, 48], ["NS3", "OBSERVATION", 60, 63], ["responsible for", "UNCERTAINTY", 74, 89], ["NS5A", "ANATOMY", 136, 140], ["5B junctions", "OBSERVATION", 141, 153]]], ["NS4A, a cofactor for NS3, stabilizes it to augment its serine protease activity and is essential for complete cleavage of the HCV polyprotein (Reed and Rice, 2000) .", [["serine", "CHEMICAL", 55, 61], ["NS4A", "GENE_OR_GENE_PRODUCT", 0, 4], ["NS3", "GENE_OR_GENE_PRODUCT", 21, 24], ["HCV", "ORGANISM", 126, 129], ["NS4A", "PROTEIN", 0, 4], ["NS3", "PROTEIN", 21, 24], ["serine protease", "PROTEIN", 55, 70], ["HCV polyprotein", "PROTEIN", 126, 141], ["HCV", "SPECIES", 126, 129], ["NS4A", "TREATMENT", 0, 4], ["a cofactor", "TREATMENT", 6, 16], ["NS3", "TREATMENT", 21, 24], ["its serine protease activity", "TREATMENT", 51, 79], ["the HCV polyprotein", "PROBLEM", 122, 141]]], ["The C-terminal portion of NS3 possesses the NTPase/ helicase activity, which is essential for viral RNA replication (Kim et al., 1995) .IntroductionIn addition to its key role in the life cycle of HCV, NS3 is also involved in viral persistence and hepatocarcinogenesis.", [["hepatocarcinogenesis", "DISEASE", 248, 268], ["NS3", "GENE_OR_GENE_PRODUCT", 26, 29], ["NTPase", "GENE_OR_GENE_PRODUCT", 44, 50], ["HCV", "ORGANISM", 197, 200], ["NS3", "GENE_OR_GENE_PRODUCT", 202, 205], ["C-terminal portion", "PROTEIN", 4, 22], ["NS3", "PROTEIN", 26, 29], ["NTPase", "PROTEIN", 44, 50], ["helicase", "PROTEIN", 52, 60], ["NS3", "PROTEIN", 202, 205], ["HCV", "SPECIES", 197, 200], ["The C-terminal portion of NS3", "TREATMENT", 0, 29], ["the NTPase/ helicase activity", "TREATMENT", 40, 69], ["viral RNA replication", "TREATMENT", 94, 115], ["HCV", "PROBLEM", 197, 200], ["NS3", "TREATMENT", 202, 205], ["hepatocarcinogenesis", "PROBLEM", 248, 268], ["NS3", "OBSERVATION", 26, 29], ["helicase activity", "OBSERVATION", 52, 69], ["HCV", "OBSERVATION", 197, 200], ["viral persistence", "OBSERVATION", 226, 243], ["hepatocarcinogenesis", "OBSERVATION", 248, 268]]], ["NS3 could transform NIH3T3 cells (Sakamuro et al., 1995) and rat fibroblasts (Zemel et al., 2001) .", [["NIH3T3 cells", "ANATOMY", 20, 32], ["fibroblasts", "ANATOMY", 65, 76], ["NS3", "GENE_OR_GENE_PRODUCT", 0, 3], ["NIH3T3 cells", "CELL", 20, 32], ["rat", "ORGANISM", 61, 64], ["fibroblasts", "CELL", 65, 76], ["NS3", "PROTEIN", 0, 3], ["NIH3T3 cells", "CELL_LINE", 20, 32], ["rat fibroblasts", "CELL_TYPE", 61, 76], ["rat", "SPECIES", 61, 64], ["rat", "SPECIES", 61, 64], ["NS3", "TREATMENT", 0, 3], ["NIH3T3 cells", "OBSERVATION", 20, 32]]], ["NIH3T3 cells constitutively expressing truncated NS3 (aa 1-433) were more resistant to Actinomycin D-induced apoptosis (Fujita et al., 1996) .", [["NIH3T3 cells", "ANATOMY", 0, 12], ["aa 1-433", "CHEMICAL", 54, 62], ["Actinomycin D", "CHEMICAL", 87, 100], ["Actinomycin D", "CHEMICAL", 87, 100], ["NIH3T3 cells", "CELL", 0, 12], ["Actinomycin D", "SIMPLE_CHEMICAL", 87, 100], ["NIH3T3 cells", "CELL_LINE", 0, 12], ["NS3", "PROTEIN", 49, 52], ["NIH3T3 cells", "TEST", 0, 12], ["truncated NS3", "TEST", 39, 52], ["aa", "TEST", 54, 56], ["Actinomycin D-induced apoptosis", "PROBLEM", 87, 118]]], ["NS3 could also block transforming growth factor-\u03b1/Smad3-mediated apoptosis (Cheng et al., 2004) .", [["NS3", "ORGANISM", 0, 3], ["transforming growth factor-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 49], ["Smad3", "GENE_OR_GENE_PRODUCT", 50, 55], ["NS3", "PROTEIN", 0, 3], ["transforming growth factor-\u03b1", "PROTEIN", 21, 49], ["Smad3", "PROTEIN", 50, 55], ["NS3", "TREATMENT", 0, 3], ["growth factor", "TEST", 34, 47], ["Smad3", "PROBLEM", 50, 55], ["growth", "OBSERVATION_MODIFIER", 34, 40]]], ["In addition, NS3-NS4A complex suppresses beta interferon (IFN-\u03b2) induction by inhibiting retinoic acid-inducible gene I-mediated activation of IFN regulatory factor 3 to help establish persistent HCV infection (Foy et al., 2003; Breiman et al., 2005; Foy et al., 2005) .IntroductionRecently it was reported that NS3 could inhibit the function of tumor suppressor p53 in a sequence-dependent manner, which partly interprets the different degree of oncogenic capacity of different HCV isolates (Lin et al., 2006) .", [["tumor", "ANATOMY", 346, 351], ["HCV infection", "DISEASE", 196, 209], ["tumor", "DISEASE", 346, 351], ["NS3", "GENE_OR_GENE_PRODUCT", 13, 16], ["beta interferon", "GENE_OR_GENE_PRODUCT", 41, 56], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["retinoic acid-inducible gene I", "GENE_OR_GENE_PRODUCT", 89, 119], ["IFN regulatory factor 3", "GENE_OR_GENE_PRODUCT", 143, 166], ["HCV", "ORGANISM", 196, 199], ["NS3", "GENE_OR_GENE_PRODUCT", 312, 315], ["tumor", "CANCER", 346, 351], ["p53", "GENE_OR_GENE_PRODUCT", 363, 366], ["HCV", "ORGANISM", 479, 482], ["NS3", "PROTEIN", 13, 16], ["NS4A complex", "PROTEIN", 17, 29], ["beta interferon", "PROTEIN", 41, 56], ["IFN-\u03b2", "PROTEIN", 58, 63], ["retinoic acid-inducible gene I", "DNA", 89, 119], ["IFN regulatory factor 3", "PROTEIN", 143, 166], ["NS3", "PROTEIN", 312, 315], ["tumor suppressor p53", "PROTEIN", 346, 366], ["HCV", "SPECIES", 196, 199], ["HCV", "SPECIES", 479, 482], ["NS3", "TREATMENT", 13, 16], ["NS4A complex", "TREATMENT", 17, 29], ["beta interferon (IFN-\u03b2) induction", "TREATMENT", 41, 74], ["retinoic acid-inducible gene I-mediated activation of IFN regulatory factor", "TREATMENT", 89, 164], ["persistent HCV infection", "PROBLEM", 185, 209], ["NS3", "TREATMENT", 312, 315], ["tumor suppressor p53", "TREATMENT", 346, 366], ["oncogenic capacity", "PROBLEM", 447, 465], ["different HCV isolates", "PROBLEM", 469, 491], ["persistent", "OBSERVATION_MODIFIER", 185, 195], ["HCV", "OBSERVATION_MODIFIER", 196, 199], ["infection", "OBSERVATION", 200, 209], ["tumor", "OBSERVATION", 346, 351], ["different degree", "OBSERVATION_MODIFIER", 427, 443], ["oncogenic capacity", "OBSERVATION", 447, 465]]], ["Cyclooxygenases (COX), including constitutively expressed COX-1 and inducible COX-2, are the rate-limiting enzymes for production of prostanoids (prostaglandins and thromboxanes) from arachidonic acid.", [["prostanoids", "CHEMICAL", 133, 144], ["prostaglandins", "CHEMICAL", 146, 160], ["thromboxanes", "CHEMICAL", 165, 177], ["arachidonic acid", "CHEMICAL", 184, 200], ["prostanoids", "CHEMICAL", 133, 144], ["prostaglandins", "CHEMICAL", 146, 160], ["thromboxanes", "CHEMICAL", 165, 177], ["arachidonic acid", "CHEMICAL", 184, 200], ["Cyclooxygenases", "GENE_OR_GENE_PRODUCT", 0, 15], ["COX", "GENE_OR_GENE_PRODUCT", 17, 20], ["COX-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["COX-2", "GENE_OR_GENE_PRODUCT", 78, 83], ["prostanoids", "SIMPLE_CHEMICAL", 133, 144], ["prostaglandins", "SIMPLE_CHEMICAL", 146, 160], ["thromboxanes", "SIMPLE_CHEMICAL", 165, 177], ["arachidonic acid", "SIMPLE_CHEMICAL", 184, 200], ["Cyclooxygenases", "PROTEIN", 0, 15], ["COX", "PROTEIN", 17, 20], ["COX-1", "PROTEIN", 58, 63], ["COX-2", "PROTEIN", 78, 83], ["Cyclooxygenases (COX)", "TREATMENT", 0, 21], ["COX", "TEST", 58, 61], ["inducible COX", "PROBLEM", 68, 81], ["the rate", "TEST", 89, 97], ["prostanoids (prostaglandins", "TREATMENT", 133, 160], ["thromboxanes", "TREATMENT", 165, 177], ["arachidonic acid", "TREATMENT", 184, 200], ["arachidonic acid", "OBSERVATION", 184, 200]]], ["COX-2 has been categorized as a cellular factor associated with inflammation (McAdam et al., 2000) , cellular growth (Williams et al., 2000) , prevention of apoptosis (McGinty et al., 2000) , and tumorigenesis (Ambs et al., 1998) .", [["cellular", "ANATOMY", 32, 40], ["cellular", "ANATOMY", 101, 109], ["inflammation", "DISEASE", 64, 76], ["COX-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 32, 40], ["cellular", "CELL", 101, 109], ["COX-2", "PROTEIN", 0, 5], ["cellular factor", "PROTEIN", 32, 47], ["COX", "TEST", 0, 3], ["a cellular factor", "PROBLEM", 30, 47], ["inflammation", "PROBLEM", 64, 76], ["apoptosis", "PROBLEM", 157, 166], ["inflammation", "OBSERVATION", 64, 76]]], ["It has also reported that COX-2 induces angiogenesis and is essential for tumor growth (Tsujii et al., 1998) .", [["tumor", "ANATOMY", 74, 79], ["tumor", "DISEASE", 74, 79], ["COX-2", "GENE_OR_GENE_PRODUCT", 26, 31], ["tumor", "CANCER", 74, 79], ["COX-2", "PROTEIN", 26, 31], ["COX", "TEST", 26, 29], ["angiogenesis", "PROBLEM", 40, 52], ["tumor growth", "PROBLEM", 74, 86], ["essential for", "UNCERTAINTY", 60, 73], ["tumor", "OBSERVATION", 74, 79]]], ["Increased prostaglandin production and enhanced release of angiogenic growth factor by COX-2 may induce neovascularization (Ambs et al., 1998; Williams et al., 2000) .IntroductionA number of investigations have demonstrated that viral proteins can stimulate COX-2 expression.", [["prostaglandin", "CHEMICAL", 10, 23], ["neovascularization", "DISEASE", 104, 122], ["prostaglandin", "CHEMICAL", 10, 23], ["prostaglandin", "SIMPLE_CHEMICAL", 10, 23], ["COX-2", "GENE_OR_GENE_PRODUCT", 87, 92], ["COX-2", "GENE_OR_GENE_PRODUCT", 258, 263], ["angiogenic growth factor", "PROTEIN", 59, 83], ["COX-2", "PROTEIN", 87, 92], ["viral proteins", "PROTEIN", 229, 243], ["COX", "PROTEIN", 258, 261], ["Increased prostaglandin production", "PROBLEM", 0, 34], ["angiogenic growth factor", "PROBLEM", 59, 83], ["COX", "TEST", 87, 90], ["neovascularization", "PROBLEM", 104, 122], ["investigations", "TEST", 191, 205], ["viral proteins", "PROBLEM", 229, 243], ["COX", "TEST", 258, 261], ["prostaglandin production", "OBSERVATION", 10, 34], ["neovascularization", "OBSERVATION", 104, 122]]], ["For examples, latent membrane protein 1 of Epstein-Barr virus (EBV) (Murono et al., 2001) , X protein of hepatitis B virus (HBV) (Lara-Pezzi et al., 2002) , gp120 and Tat proteins of human immunodeficiency virus (HIV) (Bagetta et al., 1998) , and core and NS5A proteins of HCV (Nunez et al., 2004) have been reported to be able to activate COX-2 expression.", [["hepatitis B", "DISEASE", 105, 116], ["human immunodeficiency virus (HIV)", "DISEASE", 183, 217], ["latent membrane protein 1", "GENE_OR_GENE_PRODUCT", 14, 39], ["Epstein-Barr virus", "ORGANISM", 43, 61], ["EBV", "ORGANISM", 63, 66], ["hepatitis B virus", "ORGANISM", 105, 122], ["HBV", "ORGANISM", 124, 127], ["gp120", "GENE_OR_GENE_PRODUCT", 157, 162], ["Tat", "GENE_OR_GENE_PRODUCT", 167, 170], ["human immunodeficiency virus", "ORGANISM", 183, 211], ["HIV", "ORGANISM", 213, 216], ["NS5A", "GENE_OR_GENE_PRODUCT", 256, 260], ["HCV", "ORGANISM", 273, 276], ["COX-2", "GENE_OR_GENE_PRODUCT", 340, 345], ["latent membrane protein 1", "PROTEIN", 14, 39], ["gp120", "PROTEIN", 157, 162], ["Tat proteins", "PROTEIN", 167, 179], ["NS5A proteins", "PROTEIN", 256, 269], ["COX", "PROTEIN", 340, 343], ["hepatitis B virus", "SPECIES", 105, 122], ["human immunodeficiency virus", "SPECIES", 183, 211], ["HIV", "SPECIES", 213, 216], ["Epstein-Barr virus", "SPECIES", 43, 61], ["EBV", "SPECIES", 63, 66], ["hepatitis B virus", "SPECIES", 105, 122], ["HBV", "SPECIES", 124, 127], ["human immunodeficiency virus", "SPECIES", 183, 211], ["HIV", "SPECIES", 213, 216], ["HCV", "SPECIES", 273, 276], ["latent membrane protein", "TEST", 14, 37], ["Epstein", "TEST", 43, 50], ["Barr virus", "PROBLEM", 51, 61], ["Murono et al.", "TEST", 69, 82], ["X protein", "TEST", 92, 101], ["hepatitis B virus", "PROBLEM", 105, 122], ["HBV", "TEST", 124, 127], ["Lara", "TEST", 130, 134], ["gp120", "TEST", 157, 162], ["Tat proteins", "TEST", 167, 179], ["human immunodeficiency virus", "PROBLEM", 183, 211], ["HCV", "PROBLEM", 273, 276], ["COX", "TEST", 340, 343]]], ["We have previously demonstrated that nucleocapsid protein (Yan et al., 2006) and spike protein (Liu et al., 2006; 2007) of SARSassociated coronavirus (SARS-CoV) were able to activate COX-2 expression.", [["SARSassociated coronavirus", "ORGANISM", 123, 149], ["SARS-CoV", "ORGANISM", 151, 159], ["COX-2", "GENE_OR_GENE_PRODUCT", 183, 188], ["nucleocapsid protein", "PROTEIN", 37, 57], ["spike protein", "PROTEIN", 81, 94], ["COX", "PROTEIN", 183, 186], ["SARSassociated coronavirus", "SPECIES", 123, 149], ["SARSassociated coronavirus", "SPECIES", 123, 149], ["SARS-CoV", "SPECIES", 151, 159], ["nucleocapsid protein", "TEST", 37, 57], ["Yan et al.", "TEST", 59, 69], ["spike protein", "TEST", 81, 94], ["SARSassociated coronavirus", "PROBLEM", 123, 149], ["COX", "TEST", 183, 186]]], ["However, the effects of other proteins of HCV on the regulation of COX-2 protein expression and inflammation are still unclear.IntroductionIn this study, we investigated the roles of NS3 protein of HCV in the activation of COX-2 expression and the mechanisms involved in such regulation.", [["inflammation", "DISEASE", 96, 108], ["HCV", "ORGANISM", 42, 45], ["COX-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["NS3", "GENE_OR_GENE_PRODUCT", 183, 186], ["HCV", "ORGANISM", 198, 201], ["COX-2", "GENE_OR_GENE_PRODUCT", 223, 228], ["COX-2", "PROTEIN", 67, 72], ["NS3 protein", "PROTEIN", 183, 194], ["COX", "PROTEIN", 223, 226], ["HCV", "SPECIES", 42, 45], ["HCV", "SPECIES", 198, 201], ["HCV", "PROBLEM", 42, 45], ["COX", "TEST", 67, 70], ["inflammation", "PROBLEM", 96, 108], ["this study", "TEST", 142, 152], ["NS3 protein", "TREATMENT", 183, 194], ["HCV", "PROBLEM", 198, 201], ["HCV", "OBSERVATION", 42, 45], ["inflammation", "OBSERVATION", 96, 108]]], ["The effects of NS3 on COX-2 gene promoter activity, COX-2 mRNA expression, COX-2 protein production, and PGE2 release are determined.", [["PGE2", "CHEMICAL", 105, 109], ["PGE2", "CHEMICAL", 105, 109], ["NS3", "GENE_OR_GENE_PRODUCT", 15, 18], ["COX-2", "GENE_OR_GENE_PRODUCT", 22, 27], ["COX-2", "GENE_OR_GENE_PRODUCT", 52, 57], ["COX-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["PGE2", "SIMPLE_CHEMICAL", 105, 109], ["NS3", "PROTEIN", 15, 18], ["COX-2 gene promoter", "DNA", 22, 41], ["COX-2 mRNA", "RNA", 52, 62], ["COX", "PROTEIN", 75, 78], ["NS3 on COX", "TREATMENT", 15, 25], ["COX", "TEST", 52, 55], ["mRNA expression", "TEST", 58, 73], ["COX", "TEST", 75, 78], ["protein production", "TEST", 81, 99], ["PGE2 release", "TREATMENT", 105, 117]]], ["The roles of transcription factor NF-\u03baB and multiple signaling pathways in NS3-activated COX-2 expression are also investigated and discussed.NS3 of HCV activates COX-2 expression in HepG2 cellsIt has been reported that HCV could induce the expression of cyclooxygenase-2 in both clinic samples and in cell culture system (Waris and Siddiqui, 2005) and that both core and NS5A of HCV are required for the induction of COX-2 expression (Nunez et al., 2004) .", [["HepG2 cells", "ANATOMY", 183, 194], ["samples", "ANATOMY", 287, 294], ["cell culture system", "ANATOMY", 302, 321], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 34, 39], ["NS3", "GENE_OR_GENE_PRODUCT", 75, 78], ["COX-2", "GENE_OR_GENE_PRODUCT", 89, 94], ["HCV", "ORGANISM", 149, 152], ["COX-2", "GENE_OR_GENE_PRODUCT", 163, 168], ["HepG2 cells", "CELL", 183, 194], ["HCV", "ORGANISM", 220, 223], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 255, 271], ["cell culture system", "CELL", 302, 321], ["NS5A", "GENE_OR_GENE_PRODUCT", 372, 376], ["HCV", "ORGANISM", 380, 383], ["COX-2", "GENE_OR_GENE_PRODUCT", 418, 423], ["transcription factor NF-\u03baB", "PROTEIN", 13, 39], ["NS3", "PROTEIN", 75, 78], ["COX", "PROTEIN", 89, 92], ["NS3", "PROTEIN", 142, 145], ["COX-2", "PROTEIN", 163, 168], ["HepG2 cells", "CELL_LINE", 183, 194], ["cyclooxygenase-2", "PROTEIN", 255, 271], ["NS5A", "PROTEIN", 372, 376], ["COX", "PROTEIN", 418, 421], ["HCV", "SPECIES", 149, 152], ["HCV", "SPECIES", 220, 223], ["HCV", "SPECIES", 380, 383], ["transcription factor NF", "TEST", 13, 36], ["HCV activates COX", "TREATMENT", 149, 166], ["HepG2 cells", "TEST", 183, 194], ["HCV", "PROBLEM", 220, 223], ["cyclooxygenase", "TEST", 255, 269], ["cell culture system", "TEST", 302, 321], ["NS5A of HCV", "TREATMENT", 372, 383], ["COX", "TEST", 418, 421], ["HCV", "OBSERVATION", 149, 152], ["HepG2", "ANATOMY", 183, 188], ["cells", "OBSERVATION", 189, 194], ["HCV", "OBSERVATION", 220, 223]]], ["Here we investigated whether the rest proteins of HCV play roles, if any, in the regulation of COX-2 expression.", [["HCV", "ORGANISM", 50, 53], ["COX-2", "GENE_OR_GENE_PRODUCT", 95, 100], ["COX", "PROTEIN", 95, 98], ["HCV", "SPECIES", 50, 53], ["HCV", "OBSERVATION", 50, 53]]], ["HepG2 cells were co-transfected with plasmid (pCOX-2-Luc) carrying the reporter fusion gene, in which luciferase gene is under the control of COX-2 promoter and plasmids pCMV-Core, pCMV-E1, pCMV-E2, pCMV-P7, pCMV-NS2, pCMV-NS3, pCMV-NS4A, pCMV-NS4B, pCMV-NS5A, and pCMV-NS5B, carrying each of HCV genes, core, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B, respectively.", [["HepG2 cells", "ANATOMY", 0, 11], ["plasmid", "ANATOMY", 37, 44], ["HepG2 cells", "CELL", 0, 11], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 46, 52], ["Luc", "GENE_OR_GENE_PRODUCT", 53, 56], ["luciferase", "GENE_OR_GENE_PRODUCT", 102, 112], ["COX-2", "GENE_OR_GENE_PRODUCT", 142, 147], ["pCMV", "GENE_OR_GENE_PRODUCT", 170, 174], ["pCMV-E1", "GENE_OR_GENE_PRODUCT", 181, 188], ["pCMV-E2", "ORGANISM", 190, 197], ["pCMV-P7", "ORGANISM", 199, 206], ["pCMV-NS2", "ORGANISM", 208, 216], ["pCMV-NS3", "ORGANISM", 218, 226], ["pCMV-NS4A", "ORGANISM", 228, 237], ["pCMV-NS4B", "ORGANISM", 239, 248], ["pCMV-NS5A", "GENE_OR_GENE_PRODUCT", 250, 259], ["pCMV-NS5B", "GENE_OR_GENE_PRODUCT", 265, 274], ["HCV", "ORGANISM", 293, 296], ["E1", "GENE_OR_GENE_PRODUCT", 310, 312], ["E2", "GENE_OR_GENE_PRODUCT", 314, 316], ["P7", "GENE_OR_GENE_PRODUCT", 318, 320], ["NS2", "GENE_OR_GENE_PRODUCT", 322, 325], ["NS3", "GENE_OR_GENE_PRODUCT", 327, 330], ["NS4A", "GENE_OR_GENE_PRODUCT", 332, 336], ["NS4B", "GENE_OR_GENE_PRODUCT", 338, 342], ["NS5A", "GENE_OR_GENE_PRODUCT", 344, 348], ["NS5B", "GENE_OR_GENE_PRODUCT", 354, 358], ["HepG2 cells", "CELL_LINE", 0, 11], ["plasmid", "DNA", 37, 44], ["pCOX", "DNA", 46, 50], ["Luc", "DNA", 53, 56], ["reporter fusion gene", "DNA", 71, 91], ["luciferase gene", "DNA", 102, 117], ["COX-2 promoter", "DNA", 142, 156], ["plasmids", "DNA", 161, 169], ["pCMV", "DNA", 170, 174], ["pCMV", "DNA", 181, 185], ["E1", "DNA", 186, 188], ["pCMV", "DNA", 190, 194], ["E2", "DNA", 195, 197], ["pCMV", "DNA", 199, 203], ["P7", "DNA", 204, 206], ["pCMV", "DNA", 208, 212], ["NS2", "DNA", 213, 216], ["pCMV", "DNA", 218, 222], ["NS3", "DNA", 223, 226], ["pCMV", "DNA", 228, 232], ["NS4A", "DNA", 233, 237], ["pCMV", "DNA", 239, 243], ["NS4B", "DNA", 244, 248], ["pCMV", "DNA", 250, 254], ["NS5A", "DNA", 255, 259], ["pCMV", "DNA", 265, 269], ["NS5B", "DNA", 270, 274], ["HCV genes", "DNA", 293, 302], ["E1", "DNA", 310, 312], ["E2", "DNA", 314, 316], ["P7", "DNA", 318, 320], ["NS2", "DNA", 322, 325], ["NS3", "DNA", 327, 330], ["NS4A", "DNA", 332, 336], ["NS4B", "DNA", 338, 342], ["NS5A", "DNA", 344, 348], ["NS5B", "DNA", 354, 358], ["pCMV", "SPECIES", 265, 269], ["HCV", "SPECIES", 293, 296], ["HepG2 cells", "PROBLEM", 0, 11], ["plasmid (pCOX", "TREATMENT", 37, 50], ["the reporter fusion gene", "TREATMENT", 67, 91], ["COX", "TEST", 142, 145], ["plasmids pCMV", "TREATMENT", 161, 174], ["Core", "TEST", 175, 179], ["pCMV", "TEST", 181, 185], ["E1", "TEST", 186, 188], ["pCMV", "TEST", 190, 194], ["E2", "TEST", 195, 197], ["pCMV", "TEST", 199, 203], ["pCMV", "TEST", 208, 212], ["NS2", "TEST", 213, 216], ["pCMV", "TEST", 218, 222], ["NS3", "TREATMENT", 223, 226], ["pCMV", "TEST", 228, 232], ["NS4A", "TREATMENT", 233, 237], ["pCMV", "TREATMENT", 239, 243], ["NS4B", "TREATMENT", 244, 248], ["pCMV", "TREATMENT", 250, 254], ["NS5A", "TREATMENT", 255, 259], ["pCMV", "TREATMENT", 265, 269], ["NS5B", "TREATMENT", 270, 274], ["E2", "TEST", 314, 316], ["NS2", "TEST", 322, 325], ["NS3", "TEST", 327, 330], ["NS4A", "TREATMENT", 332, 336], ["NS4B", "TREATMENT", 338, 342], ["NS5A", "TREATMENT", 344, 348], ["NS5B", "TEST", 354, 358], ["NS2", "ANATOMY", 322, 325], ["NS3", "ANATOMY", 327, 330], ["NS4B", "ANATOMY", 338, 342], ["NS5A", "ANATOMY", 344, 348], ["NS5B", "ANATOMY", 354, 358]]], ["Results from luciferase activity assay showed that NS3 and Core proteins of HCV significantly enhanced the expression of luciferase, while the rest of HCV proteins tested in this study had no significant effect on the fusion gene expression in HepG2 cells (Fig. 1A) .NS3 of HCV activates COX-2 expression in HepG2 cellsConsidering the fact that NS4A protein always functions as a cofactor in NS3 protease function including cellular signaling pathways, we further checked whether NS4A plays a role in NS3-regulated COX-2 expression.", [["HepG2 cells", "ANATOMY", 244, 255], ["HepG2 cells", "ANATOMY", 308, 319], ["cellular", "ANATOMY", 424, 432], ["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["NS3", "GENE_OR_GENE_PRODUCT", 51, 54], ["HCV", "ORGANISM", 76, 79], ["luciferase", "GENE_OR_GENE_PRODUCT", 121, 131], ["HCV", "ORGANISM", 151, 154], ["HepG2 cells", "CELL", 244, 255], ["HCV", "ORGANISM", 274, 277], ["COX-2", "GENE_OR_GENE_PRODUCT", 288, 293], ["HepG2 cells", "CELL", 308, 319], ["NS3 protease", "GENE_OR_GENE_PRODUCT", 392, 404], ["cellular", "CELL", 424, 432], ["NS4A", "GENE_OR_GENE_PRODUCT", 480, 484], ["NS3", "GENE_OR_GENE_PRODUCT", 501, 504], ["COX-2", "GENE_OR_GENE_PRODUCT", 515, 520], ["luciferase", "PROTEIN", 13, 23], ["NS3", "PROTEIN", 51, 54], ["Core proteins", "PROTEIN", 59, 72], ["luciferase", "PROTEIN", 121, 131], ["HCV proteins", "PROTEIN", 151, 163], ["HepG2 cells", "CELL_LINE", 244, 255], ["NS3", "PROTEIN", 267, 270], ["COX-2", "PROTEIN", 288, 293], ["HepG2 cells", "CELL_LINE", 308, 319], ["NS4A protein", "PROTEIN", 345, 357], ["NS3 protease", "PROTEIN", 392, 404], ["NS4A", "PROTEIN", 480, 484], ["NS3", "PROTEIN", 501, 504], ["COX-2", "PROTEIN", 515, 520], ["HCV", "SPECIES", 76, 79], ["HCV", "SPECIES", 151, 154], ["HCV", "SPECIES", 274, 277], ["luciferase activity assay", "TEST", 13, 38], ["NS3", "PROBLEM", 51, 54], ["HCV", "PROBLEM", 76, 79], ["HCV proteins", "TEST", 151, 163], ["this study", "TEST", 174, 184], ["significant effect", "PROBLEM", 192, 210], ["the fusion gene expression in HepG2 cells", "PROBLEM", 214, 255], ["HCV activates COX", "TREATMENT", 274, 291], ["HepG2 cells", "TEST", 308, 319], ["NS4A protein", "TREATMENT", 345, 357], ["a cofactor in NS3 protease function", "TREATMENT", 378, 413], ["NS3-regulated COX", "TREATMENT", 501, 518], ["HCV", "OBSERVATION", 76, 79], ["HCV", "OBSERVATION", 274, 277], ["HepG2", "ANATOMY", 308, 313], ["cells", "OBSERVATION", 314, 319]]], ["Cells were cotransfected with plasmids carrying the NS3 gene and/or the NS4A gene, respectively, along with pCOX-2-Luc.", [["Cells", "ANATOMY", 0, 5], ["plasmids", "ANATOMY", 30, 38], ["Cells", "CELL", 0, 5], ["NS3", "GENE_OR_GENE_PRODUCT", 52, 55], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 108, 114], ["Luc", "GENE_OR_GENE_PRODUCT", 115, 118], ["plasmids", "DNA", 30, 38], ["NS3 gene", "DNA", 52, 60], ["NS4A gene", "DNA", 72, 81], ["pCOX-2-Luc", "DNA", 108, 118], ["plasmids", "TREATMENT", 30, 38], ["the NS3 gene", "TREATMENT", 48, 60], ["the NS4A gene", "TREATMENT", 68, 81], ["pCOX", "TEST", 108, 112]]], ["Results from luciferase activity assay showed that the level of COX-2 promoter activity in the presence of NS3 was almost the same as that in the presence of both NS3 and NS4A (Fig. 1B) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["COX-2", "GENE_OR_GENE_PRODUCT", 64, 69], ["NS3", "GENE_OR_GENE_PRODUCT", 107, 110], ["NS3", "GENE_OR_GENE_PRODUCT", 163, 166], ["NS4A", "GENE_OR_GENE_PRODUCT", 171, 175], ["luciferase", "PROTEIN", 13, 23], ["COX-2 promoter", "DNA", 64, 78], ["NS3", "PROTEIN", 107, 110], ["NS3", "PROTEIN", 163, 166], ["NS4A", "PROTEIN", 171, 175], ["luciferase activity assay", "TEST", 13, 38], ["COX", "TEST", 64, 67], ["NS3", "TREATMENT", 107, 110], ["both NS3", "TREATMENT", 158, 166], ["NS4A (Fig", "TREATMENT", 171, 180]]], ["These results suggested that NS3 alone could activate the expression COX-2 promoter in HepG2 cells without the cooperation of NS4A.", [["HepG2 cells", "ANATOMY", 87, 98], ["NS3", "GENE_OR_GENE_PRODUCT", 29, 32], ["COX-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["HepG2 cells", "CELL", 87, 98], ["NS4A", "GENE_OR_GENE_PRODUCT", 126, 130], ["NS3", "PROTEIN", 29, 32], ["COX-2 promoter", "DNA", 69, 83], ["HepG2 cells", "CELL_LINE", 87, 98], ["NS4A", "PROTEIN", 126, 130], ["NS3", "PROBLEM", 29, 32], ["the expression COX", "TREATMENT", 54, 72], ["HepG2 cells", "TREATMENT", 87, 98], ["NS4A", "TREATMENT", 126, 130]]], ["Roles of HCV proteins in the activation of COX-2 promoter.", [["HCV", "ORGANISM", 9, 12], ["COX-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["HCV proteins", "PROTEIN", 9, 21], ["COX-2 promoter", "DNA", 43, 57], ["HCV", "SPECIES", 9, 12], ["HCV proteins", "PROBLEM", 9, 21], ["HCV", "OBSERVATION", 9, 12]]], ["(A) HepG2 cells were co-transfected with 0.2 \u03bcg reporter plasmid pCOX-2-Luc containing the luciferase gene under the control of COX-2 promoter and 0.4 \u03bcg plasmids, pCMV-flag, pCMV-flag-Core, pCMV-flag-E1, pCMV-flag-E2, pCMV-flag-P7, pCMV-flag-NS2, pCMV-flag-NS3, pCMV-flag-NS4A, pCMV-flag-NS4B, pCMV-flag-NS5A, and pCMV-flag-NS5B, carrying individual genes of HCV, respectively.", [["HepG2 cells", "ANATOMY", 4, 15], ["plasmids", "ANATOMY", 154, 162], ["HepG2 cells", "CELL", 4, 15], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 65, 71], ["Luc", "GENE_OR_GENE_PRODUCT", 72, 75], ["luciferase", "GENE_OR_GENE_PRODUCT", 91, 101], ["COX-2", "GENE_OR_GENE_PRODUCT", 128, 133], ["pCMV", "GENE_OR_GENE_PRODUCT", 164, 168], ["pCMV-flag-Core", "ORGANISM", 175, 189], ["pCMV-flag-E1", "ORGANISM", 191, 203], ["pCMV", "ORGANISM", 205, 209], ["-flag-E2", "ORGANISM", 209, 217], ["pCMV-flag-P7", "ORGANISM", 219, 231], ["pCMV-flag-NS2", "ORGANISM", 233, 246], ["pCMV-flag-NS3", "ORGANISM", 248, 261], ["pCMV-flag-NS4A", "ORGANISM", 263, 277], ["pCMV-flag-NS4B", "ORGANISM", 279, 293], ["pCMV-flag-NS5A", "GENE_OR_GENE_PRODUCT", 295, 309], ["pCMV-flag-NS5B", "GENE_OR_GENE_PRODUCT", 315, 329], ["HCV", "ORGANISM", 360, 363], ["HepG2 cells", "CELL_LINE", 4, 15], ["pCOX-2-Luc", "DNA", 65, 75], ["luciferase gene", "DNA", 91, 106], ["COX-2 promoter", "DNA", 128, 142], ["0.4 \u03bcg plasmids", "DNA", 147, 162], ["pCMV", "DNA", 164, 168], ["pCMV", "DNA", 175, 179], ["pCMV", "DNA", 191, 195], ["E1", "DNA", 201, 203], ["pCMV", "DNA", 205, 209], ["E2", "DNA", 215, 217], ["pCMV", "DNA", 219, 223], ["P7", "DNA", 229, 231], ["pCMV", "DNA", 233, 237], ["NS2", "DNA", 243, 246], ["pCMV", "DNA", 248, 252], ["flag", "DNA", 253, 257], ["NS3", "DNA", 258, 261], ["pCMV", "DNA", 263, 267], ["flag", "DNA", 268, 272], ["NS4A", "DNA", 273, 277], ["pCMV", "DNA", 279, 283], ["flag", "DNA", 284, 288], ["NS4B", "DNA", 289, 293], ["pCMV", "DNA", 295, 299], ["flag", "DNA", 300, 304], ["NS5A", "DNA", 305, 309], ["pCMV", "DNA", 315, 319], ["flag", "DNA", 320, 324], ["NS5B", "DNA", 325, 329], ["HCV", "SPECIES", 360, 363], ["A) HepG2 cells", "TREATMENT", 1, 15], ["reporter plasmid pCOX", "TREATMENT", 48, 69], ["COX", "TEST", 128, 131], ["pCMV", "TEST", 164, 168], ["pCMV", "TEST", 191, 195], ["pCMV", "TEST", 205, 209], ["E2", "TREATMENT", 215, 217], ["pCMV", "TEST", 219, 223], ["pCMV", "TEST", 233, 237], ["NS2", "TREATMENT", 243, 246], ["pCMV", "TREATMENT", 248, 252], ["NS3", "TREATMENT", 258, 261], ["pCMV", "TREATMENT", 263, 267], ["NS4A", "TREATMENT", 273, 277], ["pCMV", "TREATMENT", 279, 283], ["flag", "TREATMENT", 284, 288], ["NS4B", "TREATMENT", 289, 293], ["pCMV", "TREATMENT", 295, 299], ["flag", "TREATMENT", 300, 304], ["NS5A", "TREATMENT", 305, 309], ["pCMV", "TREATMENT", 315, 319], ["flag", "TREATMENT", 320, 324], ["NS5B", "TREATMENT", 325, 329], ["HCV", "PROBLEM", 360, 363]]], ["Luciferase activity was measured as described in the Materials and methods section.", [["Luciferase", "GENE_OR_GENE_PRODUCT", 0, 10], ["Luciferase activity", "TEST", 0, 19]]], ["Results are expressed as the mean \u00b1 sd of three independent experiments performed in triplicate and normalized by \u03b2-galactosidase assay.", [["\u03b2-galactosidase", "PROTEIN", 114, 129]]], ["(B) Equal amount of pCMV-NS3 and pCMV-NS4A was transfected or cotransfected, respectively, into HepG2 cells with reporter plasmid pCOX-2-Luc.", [["HepG2 cells", "ANATOMY", 96, 107], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 20, 28], ["pCMV-NS4A", "GENE_OR_GENE_PRODUCT", 33, 42], ["HepG2 cells", "CELL", 96, 107], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 130, 136], ["Luc", "GENE_OR_GENE_PRODUCT", 137, 140], ["pCMV", "PROTEIN", 20, 24], ["NS3", "PROTEIN", 25, 28], ["pCMV", "PROTEIN", 33, 37], ["NS4A", "PROTEIN", 38, 42], ["HepG2 cells", "CELL_LINE", 96, 107], ["reporter plasmid pCOX-2-Luc", "DNA", 113, 140], ["pCMV", "TREATMENT", 20, 24], ["NS3", "TREATMENT", 25, 28], ["pCMV", "TREATMENT", 33, 37], ["NS4A", "TREATMENT", 38, 42], ["reporter plasmid pCOX", "TEST", 113, 134]]], ["Results are expressed as the mean \u00b1 sd of three independent experiments performed in triplicate and normalized by \u03b2-galactosidase assay. \u204e , p b 0.05 versus pCMV-flag.NS3 activates COX-2 expression in a dose-dependent mannerTo further confirm the role of NS3 in the activation of COX-2 expression, we determined the effects of different concentrations of NS3 on the activation of COX-2 promoter.", [["NS3", "ORGANISM", 167, 170], ["COX-2", "GENE_OR_GENE_PRODUCT", 181, 186], ["NS3", "GENE_OR_GENE_PRODUCT", 255, 258], ["COX-2", "GENE_OR_GENE_PRODUCT", 280, 285], ["NS3", "GENE_OR_GENE_PRODUCT", 355, 358], ["COX-2", "GENE_OR_GENE_PRODUCT", 380, 385], ["\u03b2-galactosidase", "PROTEIN", 114, 129], ["pCMV", "PROTEIN", 157, 161], ["NS3", "PROTEIN", 167, 170], ["COX-2", "PROTEIN", 181, 186], ["NS3", "PROTEIN", 255, 258], ["COX", "PROTEIN", 280, 283], ["NS3", "PROTEIN", 355, 358], ["COX-2 promoter", "DNA", 380, 394], ["NS3", "TREATMENT", 255, 258], ["NS3", "TREATMENT", 355, 358], ["the activation of COX", "TREATMENT", 362, 383]]], ["HepG2 cells were co-transfected with the report plasmid pCOX-2-luc and different concentrations of plasmid pCMV-NS3.", [["HepG2 cells", "ANATOMY", 0, 11], ["plasmid", "ANATOMY", 48, 55], ["HepG2 cells", "CELL", 0, 11], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 56, 62], ["luc", "GENE_OR_GENE_PRODUCT", 63, 66], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 107, 115], ["HepG2 cells", "CELL_LINE", 0, 11], ["plasmid pCOX-2-luc", "DNA", 48, 66], ["pCMV", "DNA", 107, 111], ["NS3", "PROTEIN", 112, 115], ["HepG2 cells", "PROBLEM", 0, 11], ["plasmid pCOX", "TREATMENT", 48, 60], ["plasmid pCMV", "TREATMENT", 99, 111], ["NS3", "PROBLEM", 112, 115]]], ["Results from luciferase activity assay showed that the level of COX-2 promoter activity increased as the concentration of NS3 increased, indicting NS3 stimulates COX-2 promoter in a concentration-dependent fashion ( Fig. 2A) .NS3 activates COX-2 expression in a dose-dependent mannerTo determine the effects of NS3 on the activation of COX-2 mRNA expression, COX-2 protein production, and prostaglandin E2 (PGE2) generation, HepG2 cells were transfected with different concentrations of pCMV-NS3.", [["HepG2 cells", "ANATOMY", 425, 436], ["prostaglandin E2", "CHEMICAL", 389, 405], ["PGE2", "CHEMICAL", 407, 411], ["prostaglandin E2", "CHEMICAL", 389, 405], ["PGE2", "CHEMICAL", 407, 411], ["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["COX-2", "GENE_OR_GENE_PRODUCT", 64, 69], ["NS3", "GENE_OR_GENE_PRODUCT", 122, 125], ["NS3", "GENE_OR_GENE_PRODUCT", 147, 150], ["COX-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["NS3", "ORGANISM", 226, 229], ["COX-2", "GENE_OR_GENE_PRODUCT", 240, 245], ["NS3", "GENE_OR_GENE_PRODUCT", 311, 314], ["COX-2", "GENE_OR_GENE_PRODUCT", 336, 341], ["COX-2", "GENE_OR_GENE_PRODUCT", 359, 364], ["prostaglandin E2", "SIMPLE_CHEMICAL", 389, 405], ["PGE2", "SIMPLE_CHEMICAL", 407, 411], ["HepG2 cells", "CELL", 425, 436], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 487, 495], ["luciferase", "PROTEIN", 13, 23], ["COX-2 promoter", "DNA", 64, 78], ["NS3", "PROTEIN", 122, 125], ["NS3", "PROTEIN", 147, 150], ["COX-2 promoter", "DNA", 162, 176], ["NS3", "PROTEIN", 226, 229], ["COX-2", "PROTEIN", 240, 245], ["NS3", "PROTEIN", 311, 314], ["COX-2 mRNA", "RNA", 336, 346], ["COX", "PROTEIN", 359, 362], ["HepG2 cells", "CELL_LINE", 425, 436], ["pCMV", "PROTEIN", 487, 491], ["NS3", "PROTEIN", 492, 495], ["luciferase activity assay", "TEST", 13, 38], ["COX", "TEST", 64, 67], ["NS3", "TREATMENT", 122, 125], ["NS3 stimulates COX", "TREATMENT", 147, 165], ["NS3", "TREATMENT", 311, 314], ["COX", "TEST", 336, 339], ["COX", "TEST", 359, 362], ["protein production", "TEST", 365, 383], ["prostaglandin E2 (PGE2) generation, HepG2 cells", "TREATMENT", 389, 436], ["pCMV", "TREATMENT", 487, 491], ["NS3", "TREATMENT", 492, 495]]], ["Results from RT-PCR using COX-2-specific or \u03b2-actin-specific primers showed that the levels of COX-2 mRNA were increased as the concentration of pCMV-NS3 increased, but the levels of \u03b2-actin mRNA remained relatively constant (Fig. 2B ).", [["COX-2", "GENE_OR_GENE_PRODUCT", 26, 31], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 44, 51], ["COX-2", "GENE_OR_GENE_PRODUCT", 95, 100], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 145, 153], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 183, 190], ["COX", "PROTEIN", 26, 29], ["\u03b2-actin", "PROTEIN", 44, 51], ["COX-2 mRNA", "RNA", 95, 105], ["pCMV", "PROTEIN", 145, 149], ["NS3", "PROTEIN", 150, 153], ["\u03b2-actin mRNA", "RNA", 183, 195], ["RT-PCR", "TEST", 13, 19], ["COX", "TEST", 26, 29], ["\u03b2-actin", "TEST", 44, 51], ["specific primers", "TEST", 52, 68], ["the levels", "TEST", 81, 91], ["COX", "TEST", 95, 98], ["mRNA", "TEST", 101, 105], ["pCMV", "TEST", 145, 149], ["NS3", "PROBLEM", 150, 153], ["the levels", "TEST", 169, 179], ["\u03b2-actin mRNA", "PROBLEM", 183, 195], ["increased", "OBSERVATION_MODIFIER", 154, 163]]], ["Results from western blot analysis using antibody to COX-2 protein or to \u03b2-actin protein revealed that the levels of COX-2 protein were increased as pCMV-NS3 concentration increased, while \u03b2actin protein level was remained relatively unchanged (Fig. 2C ).", [["COX-2", "GENE_OR_GENE_PRODUCT", 53, 58], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 73, 80], ["COX-2", "GENE_OR_GENE_PRODUCT", 117, 122], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 149, 157], ["\u03b2actin", "GENE_OR_GENE_PRODUCT", 189, 195], ["COX-2 protein", "PROTEIN", 53, 66], ["\u03b2-actin protein", "PROTEIN", 73, 88], ["COX-2 protein", "PROTEIN", 117, 130], ["pCMV", "PROTEIN", 149, 153], ["NS3", "PROTEIN", 154, 157], ["\u03b2actin", "PROTEIN", 189, 195], ["western blot analysis", "TEST", 13, 34], ["antibody", "TEST", 41, 49], ["COX", "TEST", 53, 56], ["\u03b2-actin protein", "TEST", 73, 88], ["the levels", "TEST", 103, 113], ["COX", "TEST", 117, 120], ["protein", "TEST", 123, 130], ["pCMV", "TEST", 149, 153], ["NS3 concentration", "TREATMENT", 154, 171], ["\u03b2actin protein level", "TEST", 189, 209], ["unchanged", "OBSERVATION_MODIFIER", 234, 243]]], ["The production of PGE2 was assayed with the Biotrak Prostaglandin E2 Enzyme Immunoassay system and results indicated that the level of PGE2 was increased as the concentration of pCMV-NS3 increased (Fig. 2D ).", [["PGE2", "CHEMICAL", 18, 22], ["Prostaglandin E2", "CHEMICAL", 52, 68], ["PGE2", "CHEMICAL", 135, 139], ["PGE2", "CHEMICAL", 18, 22], ["Prostaglandin E2", "CHEMICAL", 52, 68], ["PGE2", "CHEMICAL", 135, 139], ["PGE2", "SIMPLE_CHEMICAL", 18, 22], ["Prostaglandin E2", "GENE_OR_GENE_PRODUCT", 52, 68], ["PGE2", "SIMPLE_CHEMICAL", 135, 139], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 178, 186], ["pCMV", "PROTEIN", 178, 182], ["NS3", "PROTEIN", 183, 186], ["the Biotrak Prostaglandin E2 Enzyme Immunoassay system", "TEST", 40, 94], ["PGE2", "TREATMENT", 135, 139], ["pCMV", "TEST", 178, 182], ["NS3", "TREATMENT", 183, 186]]], ["Taken together, these results demonstrated that NS3 protein of HCV induces COX-2 expression and PGE2 production in a dose-dependent manner in HepG2 cells.NS3 activates COX-2 expression in a dose-dependent mannerNF-\u03baB is required for the activation of COX-2 gene regulated by NS3NS3 activates COX-2 expression in a dose-dependent mannerActivation of COX-2 gene relies on many consensus cisregulatory elements on its promoter, including two NF-\u03baB binding sites (Jijon et al., 2002) (Fig. 3A) .", [["HepG2 cells", "ANATOMY", 142, 153], ["PGE2", "CHEMICAL", 96, 100], ["PGE2", "CHEMICAL", 96, 100], ["NS3", "GENE_OR_GENE_PRODUCT", 48, 51], ["HCV", "ORGANISM", 63, 66], ["COX-2", "GENE_OR_GENE_PRODUCT", 75, 80], ["PGE2", "SIMPLE_CHEMICAL", 96, 100], ["HepG2 cells", "CELL", 142, 153], ["NS3", "ORGANISM", 154, 157], ["COX-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["mannerNF-\u03baB", "GENE_OR_GENE_PRODUCT", 205, 216], ["COX-2", "GENE_OR_GENE_PRODUCT", 251, 256], ["NS3NS3", "GENE_OR_GENE_PRODUCT", 275, 281], ["COX-2", "GENE_OR_GENE_PRODUCT", 292, 297], ["COX-2", "GENE_OR_GENE_PRODUCT", 349, 354], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 439, 444], ["NS3 protein", "PROTEIN", 48, 59], ["COX", "PROTEIN", 75, 78], ["HepG2 cells", "CELL_LINE", 142, 153], ["NS3", "PROTEIN", 154, 157], ["COX-2", "PROTEIN", 168, 173], ["mannerNF", "PROTEIN", 205, 213], ["-\u03baB", "PROTEIN", 213, 216], ["COX-2 gene", "DNA", 251, 261], ["NS3NS3", "PROTEIN", 275, 281], ["COX-2", "PROTEIN", 292, 297], ["COX-2 gene", "DNA", 349, 359], ["consensus cisregulatory elements", "DNA", 375, 407], ["NF-\u03baB binding sites", "DNA", 439, 458], ["HCV", "SPECIES", 63, 66], ["NS3 protein", "TEST", 48, 59], ["HCV", "PROBLEM", 63, 66], ["COX", "TEST", 75, 78], ["PGE2 production", "TREATMENT", 96, 111], ["a dose-dependent manner in HepG2 cells", "TREATMENT", 115, 153], ["the activation of COX", "TREATMENT", 233, 254], ["a dose-dependent mannerActivation of COX", "TREATMENT", 312, 352], ["HepG2 cells", "OBSERVATION", 142, 153]]], ["To define the role of NF-\u03baB recognition elements in the activation of COX-2 regulated by NS3, three mutants (Mut1, Mut2, and Mut3) of NF-\u03baB binding site were generated by site specific mutagenesis ( Fig. 3A ).", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 22, 27], ["COX-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["NS3", "GENE_OR_GENE_PRODUCT", 89, 92], ["Mut1", "GENE_OR_GENE_PRODUCT", 109, 113], ["Mut2", "GENE_OR_GENE_PRODUCT", 115, 119], ["Mut3", "GENE_OR_GENE_PRODUCT", 125, 129], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["NF-\u03baB recognition elements", "DNA", 22, 48], ["COX-2", "PROTEIN", 70, 75], ["NS3", "PROTEIN", 89, 92], ["Mut1", "PROTEIN", 109, 113], ["Mut2", "PROTEIN", 115, 119], ["Mut3", "PROTEIN", 125, 129], ["NF-\u03baB binding site", "DNA", 134, 152], ["COX", "TEST", 70, 73], ["NF", "TREATMENT", 134, 136]]], ["Reporter plasmids were constructed, in which the luciferase gene was under the control of Mut1, Mut2, and Mut3 promoter, respectively.NS3 activates COX-2 expression in a dose-dependent mannerPlasmids carrying these mutant COX-2 promoters were then co-transfected with pCMV-NS3 into HepG2 cells, respectively.", [["plasmids", "ANATOMY", 9, 17], ["HepG2 cells", "ANATOMY", 282, 293], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["Mut1", "GENE_OR_GENE_PRODUCT", 90, 94], ["Mut2", "GENE_OR_GENE_PRODUCT", 96, 100], ["Mut3", "GENE_OR_GENE_PRODUCT", 106, 110], ["NS3", "ORGANISM", 134, 137], ["COX-2", "GENE_OR_GENE_PRODUCT", 148, 153], ["COX-2", "GENE_OR_GENE_PRODUCT", 222, 227], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 268, 276], ["HepG2 cells", "CELL", 282, 293], ["Reporter plasmids", "DNA", 0, 17], ["luciferase gene", "DNA", 49, 64], ["Mut1", "DNA", 90, 94], ["Mut2", "DNA", 96, 100], ["Mut3 promoter", "DNA", 106, 119], ["NS3", "PROTEIN", 134, 137], ["COX-2", "PROTEIN", 148, 153], ["mutant COX-2 promoters", "DNA", 215, 237], ["pCMV", "PROTEIN", 268, 272], ["NS3", "PROTEIN", 273, 276], ["HepG2 cells", "CELL_LINE", 282, 293], ["Reporter plasmids", "TREATMENT", 0, 17], ["Plasmids", "TREATMENT", 191, 199], ["pCMV", "TREATMENT", 268, 272], ["NS3 into HepG2 cells", "TREATMENT", 273, 293]]], ["Results from luciferase assay showed that the two single mutations (Mut1 and Mut2) reduced the level of COX-2 promoter activation regulated by NS3 and the double mutation (Mut3) eliminated NS3-regulated COX-2 activation (Fig. 3B) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["Mut1", "GENE_OR_GENE_PRODUCT", 68, 72], ["Mut2", "GENE_OR_GENE_PRODUCT", 77, 81], ["COX-2", "GENE_OR_GENE_PRODUCT", 104, 109], ["NS3", "GENE_OR_GENE_PRODUCT", 143, 146], ["NS3", "GENE_OR_GENE_PRODUCT", 189, 192], ["COX-2", "GENE_OR_GENE_PRODUCT", 203, 208], ["luciferase", "PROTEIN", 13, 23], ["Mut1", "DNA", 68, 72], ["Mut2", "DNA", 77, 81], ["COX-2 promoter", "DNA", 104, 118], ["NS3", "PROTEIN", 143, 146], ["NS3", "PROTEIN", 189, 192], ["COX-2", "PROTEIN", 203, 208], ["luciferase assay", "TEST", 13, 29], ["the two single mutations", "PROBLEM", 42, 66], ["COX", "TEST", 104, 107], ["NS3", "TREATMENT", 143, 146], ["the double mutation", "TREATMENT", 151, 170], ["NS3", "PROBLEM", 189, 192]]], ["These results suggested that NF-\u03baB was involved in the regulation of COX-2 gene expression.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 29, 34], ["COX-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["NF-\u03baB", "PROTEIN", 29, 34], ["COX-2 gene", "DNA", 69, 79]]], ["In subsequent experiment, cells were transiently transfected with reporter plasmid, in which the expression of luciferase gene is under the control of NF-\u03baBbinding element.", [["cells", "ANATOMY", 26, 31], ["plasmid", "ANATOMY", 75, 82], ["cells", "CELL", 26, 31], ["luciferase", "GENE_OR_GENE_PRODUCT", 111, 121], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 151, 155], ["reporter plasmid", "DNA", 66, 82], ["luciferase gene", "DNA", 111, 126], ["NF-\u03baBbinding element", "DNA", 151, 171], ["reporter plasmid", "TREATMENT", 66, 82], ["luciferase gene", "TREATMENT", 111, 126]]], ["Results showed that NS3 stimulated the NF-\u03baB-binding element activity in a dose-dependent manner (Fig. 3C ).", [["NS3", "GENE_OR_GENE_PRODUCT", 20, 23], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 39, 44], ["NS3", "PROTEIN", 20, 23], ["NF-\u03baB", "PROTEIN", 39, 44], ["NS3", "PROBLEM", 20, 23], ["the NF", "TEST", 35, 41], ["activity", "OBSERVATION_MODIFIER", 61, 69]]], ["This result demonstrated that NF-\u03baB was sufficient for the activation of COX-2 expression regulated by NS3 protein.NS3 activates COX-2 expression in a dose-dependent mannerNF-\u03baB is a ubiquitously expressed transcription factor that regulates the induction of genes involved in cellular immune response and inflammatory function.", [["cellular", "ANATOMY", 277, 285], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 30, 35], ["COX-2", "GENE_OR_GENE_PRODUCT", 73, 78], ["NS3", "GENE_OR_GENE_PRODUCT", 103, 106], ["NS3", "ORGANISM", 115, 118], ["COX-2", "GENE_OR_GENE_PRODUCT", 129, 134], ["mannerNF-\u03baB", "GENE_OR_GENE_PRODUCT", 166, 177], ["cellular", "CELL", 277, 285], ["NF-\u03baB", "PROTEIN", 30, 35], ["COX-2", "PROTEIN", 73, 78], ["NS3 protein", "PROTEIN", 103, 114], ["NS3", "PROTEIN", 115, 118], ["COX-2", "PROTEIN", 129, 134], ["mannerNF", "PROTEIN", 166, 174], ["-\u03baB", "PROTEIN", 174, 177], ["transcription factor", "PROTEIN", 206, 226], ["NF", "TEST", 30, 32], ["COX", "TEST", 73, 76], ["inflammatory function", "PROBLEM", 306, 327], ["cellular immune response", "OBSERVATION", 277, 301], ["inflammatory", "OBSERVATION_MODIFIER", 306, 318]]], ["To further confirm the involvement of NF-\u03baB in the activation of COX-2 regulated by NS3, HepG2 cells were transfected with pCMV-NS3 and treated with or without NF-\u03baB inhibitor, MG132.", [["HepG2 cells", "ANATOMY", 89, 100], ["MG132", "CHEMICAL", 177, 182], ["MG132", "CHEMICAL", 177, 182], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 38, 43], ["COX-2", "GENE_OR_GENE_PRODUCT", 65, 70], ["NS3", "GENE_OR_GENE_PRODUCT", 84, 87], ["HepG2 cells", "CELL", 89, 100], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 123, 131], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 160, 165], ["MG132", "SIMPLE_CHEMICAL", 177, 182], ["NF-\u03baB", "PROTEIN", 38, 43], ["COX-2", "PROTEIN", 65, 70], ["NS3", "PROTEIN", 84, 87], ["HepG2 cells", "CELL_LINE", 89, 100], ["pCMV", "PROTEIN", 123, 127], ["NS3", "PROTEIN", 128, 131], ["NF", "PROBLEM", 38, 40], ["COX", "TEST", 65, 68], ["HepG2 cells", "TREATMENT", 89, 100], ["pCMV", "TREATMENT", 123, 127], ["NS3", "TREATMENT", 128, 131], ["NF", "TREATMENT", 160, 162], ["B inhibitor", "TREATMENT", 164, 175], ["MG132", "TREATMENT", 177, 182]]], ["Results from RT-PCR analysis showed that MG132 significantly decreased the level of COX-2 mRNA activated by NS3 (Fig. 3D ).", [["MG132", "CHEMICAL", 41, 46], ["MG132", "CHEMICAL", 41, 46], ["MG132", "SIMPLE_CHEMICAL", 41, 46], ["COX-2", "GENE_OR_GENE_PRODUCT", 84, 89], ["NS3", "GENE_OR_GENE_PRODUCT", 108, 111], ["COX-2 mRNA", "RNA", 84, 94], ["NS3", "PROTEIN", 108, 111], ["RT-PCR analysis", "TEST", 13, 28], ["MG132", "PROBLEM", 41, 46], ["COX", "TEST", 84, 87]]], ["Similar results were obtained when western blot analysis was carried out, which indicated that MG132 significantly reduced the level of COX-2 protein activated by NS3 (Fig. 3E) .", [["MG132", "CHEMICAL", 95, 100], ["MG132", "CHEMICAL", 95, 100], ["MG132", "SIMPLE_CHEMICAL", 95, 100], ["COX-2", "GENE_OR_GENE_PRODUCT", 136, 141], ["NS3", "GENE_OR_GENE_PRODUCT", 163, 166], ["COX-2 protein", "PROTEIN", 136, 149], ["NS3", "PROTEIN", 163, 166], ["Fig. 3E", "PROTEIN", 168, 175], ["western blot analysis", "TEST", 35, 56], ["MG132", "TEST", 95, 100], ["COX", "TEST", 136, 139]]], ["These results demonstrated that transcription factor NF-\u03baB was required for the activation of COX-2 expression regulated by NS3 protein.Multiple signal transduction pathways are involved in the activation of COX-2 expression regulated by NS3Given the critical roles of COX-2 in liver inflammation and carcinogenesis, it is important to understand the key signaling pathways involved in the regulation of COX-2 expression in human liver cell line.", [["liver", "ANATOMY", 278, 283], ["liver cell line", "ANATOMY", 430, 445], ["liver inflammation", "DISEASE", 278, 296], ["carcinogenesis", "DISEASE", 301, 315], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 53, 58], ["COX-2", "GENE_OR_GENE_PRODUCT", 94, 99], ["NS3", "GENE_OR_GENE_PRODUCT", 124, 127], ["COX-2", "GENE_OR_GENE_PRODUCT", 208, 213], ["NS3Given", "GENE_OR_GENE_PRODUCT", 238, 246], ["COX-2", "GENE_OR_GENE_PRODUCT", 269, 274], ["liver", "ORGAN", 278, 283], ["COX-2", "GENE_OR_GENE_PRODUCT", 404, 409], ["human", "ORGANISM", 424, 429], ["liver cell line", "CELL", 430, 445], ["transcription factor", "PROTEIN", 32, 52], ["NF-\u03baB", "PROTEIN", 53, 58], ["COX-2", "PROTEIN", 94, 99], ["NS3 protein", "PROTEIN", 124, 135], ["COX", "PROTEIN", 208, 211], ["COX-2", "PROTEIN", 269, 274], ["COX", "PROTEIN", 404, 407], ["human liver cell line", "CELL_LINE", 424, 445], ["human", "SPECIES", 424, 429], ["human", "SPECIES", 424, 429], ["transcription factor NF", "TEST", 32, 55], ["COX", "TEST", 94, 97], ["Multiple signal transduction pathways", "PROBLEM", 136, 173], ["COX", "TEST", 269, 272], ["liver inflammation", "PROBLEM", 278, 296], ["carcinogenesis", "PROBLEM", 301, 315], ["human liver cell line", "TREATMENT", 424, 445], ["transduction pathways", "OBSERVATION", 152, 173], ["liver", "ANATOMY", 278, 283], ["inflammation", "OBSERVATION", 284, 296], ["carcinogenesis", "OBSERVATION", 301, 315], ["liver", "ANATOMY", 430, 435], ["cell line", "OBSERVATION", 436, 445]]], ["To delineate the signaling cascades involved, HepG2 cells were transfected with pCMV-NS3 and then treated with inhibitors of individual components of signaling pathways.Multiple signal transduction pathways are involved in the activation of COX-2 expression regulated by NS3Results from RT-PCR analyses showed that the level of COX-2 mRNA activated by NS3 was suppressed by SP600125 (c-Jun inhibitor), GF109203 (PKC inhibitor), and PD98059 (MEK1/2 inhibitor), respectively, but not by LY294002 (PI3K inhibitor), H89 (protein kinase A inhibitor), or SB203580 (SAPK2\u03b1/\u03b2/p38\u03b1/\u03b2 MAPK inhibitor) (Fig. 4A ).", [["HepG2 cells", "ANATOMY", 46, 57], ["SP600125", "CHEMICAL", 374, 382], ["GF109203", "CHEMICAL", 402, 410], ["PD98059", "CHEMICAL", 432, 439], ["LY294002", "CHEMICAL", 485, 493], ["H89", "CHEMICAL", 512, 515], ["SB203580", "CHEMICAL", 549, 557], ["SP600125", "CHEMICAL", 374, 382], ["GF109203", "CHEMICAL", 402, 410], ["PD98059", "CHEMICAL", 432, 439], ["LY294002", "CHEMICAL", 485, 493], ["H89", "CHEMICAL", 512, 515], ["SB203580", "CHEMICAL", 549, 557], ["HepG2 cells", "CELL", 46, 57], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 80, 88], ["COX-2", "GENE_OR_GENE_PRODUCT", 241, 246], ["NS3Results", "GENE_OR_GENE_PRODUCT", 271, 281], ["COX-2", "GENE_OR_GENE_PRODUCT", 328, 333], ["NS3", "GENE_OR_GENE_PRODUCT", 352, 355], ["SP600125", "SIMPLE_CHEMICAL", 374, 382], ["c-Jun", "GENE_OR_GENE_PRODUCT", 384, 389], ["GF109203", "SIMPLE_CHEMICAL", 402, 410], ["PKC", "GENE_OR_GENE_PRODUCT", 412, 415], ["PD98059", "SIMPLE_CHEMICAL", 432, 439], ["MEK1/2", "GENE_OR_GENE_PRODUCT", 441, 447], ["LY294002", "SIMPLE_CHEMICAL", 485, 493], ["PI3K", "GENE_OR_GENE_PRODUCT", 495, 499], ["H89", "SIMPLE_CHEMICAL", 512, 515], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 517, 533], ["SB203580", "SIMPLE_CHEMICAL", 549, 557], ["SAPK2\u03b1/\u03b2", "GENE_OR_GENE_PRODUCT", 559, 567], ["p38\u03b1", "GENE_OR_GENE_PRODUCT", 568, 572], ["\u03b2 MAPK", "GENE_OR_GENE_PRODUCT", 573, 579], ["HepG2 cells", "CELL_LINE", 46, 57], ["pCMV", "PROTEIN", 80, 84], ["NS3", "PROTEIN", 85, 88], ["COX", "PROTEIN", 241, 244], ["NS3Results", "PROTEIN", 271, 281], ["COX-2 mRNA", "RNA", 328, 338], ["NS3", "PROTEIN", 352, 355], ["PKC", "PROTEIN", 412, 415], ["MEK1", "PROTEIN", 441, 445], ["PI3K", "PROTEIN", 495, 499], ["protein kinase A", "PROTEIN", 517, 533], ["\u03b2", "PROTEIN", 566, 567], ["p38\u03b1", "PROTEIN", 568, 572], ["MAPK", "PROTEIN", 575, 579], ["the signaling cascades", "PROBLEM", 13, 35], ["HepG2 cells", "PROBLEM", 46, 57], ["pCMV", "TREATMENT", 80, 84], ["NS3", "TREATMENT", 85, 88], ["inhibitors", "TREATMENT", 111, 121], ["signaling pathways", "PROBLEM", 150, 168], ["Multiple signal transduction pathways", "PROBLEM", 169, 206], ["COX", "TEST", 241, 244], ["RT-PCR analyses", "TEST", 287, 302], ["COX", "TEST", 328, 331], ["NS3", "TEST", 352, 355], ["SP600125", "TEST", 374, 382], ["c-Jun inhibitor", "TEST", 384, 399], ["PKC inhibitor", "TEST", 412, 425], ["PD98059", "TEST", 432, 439], ["MEK1", "TEST", 441, 445], ["PI3K inhibitor", "TEST", 495, 509], ["H89", "TEST", 512, 515], ["protein kinase A inhibitor", "TEST", 517, 543], ["SB203580", "TEST", 549, 557], ["SAPK2\u03b1", "TEST", 559, 565], ["p38", "TEST", 568, 571], ["MAPK inhibitor", "TEST", 575, 589], ["transduction pathways", "OBSERVATION", 185, 206]]], ["Similar results were observed when western blot analysis was performed, which showed that the level of COX-2 protein expression regulated by NS3 was inhibited by SP600125, GF109203, and PD98059, respectively, but not by LY294002, H89, or SB203580 (Fig. 4B) .Multiple signal transduction pathways are involved in the activation of COX-2 expression regulated by NS3The roles of ERK and JNK in the activation of COX-2 mediated by NS3 protein were further determined by introducing three dominant kinase-inactive mutants, mERK1, mERK2, and mJNK, which can block corresponding kinase activities by competing with endogenous kinases (Werlen et al., 1998; Khoo et al., 2003) .", [["SP600125", "CHEMICAL", 162, 170], ["GF109203", "CHEMICAL", 172, 180], ["PD98059", "CHEMICAL", 186, 193], ["LY294002", "CHEMICAL", 220, 228], ["H89", "CHEMICAL", 230, 233], ["SB203580", "CHEMICAL", 238, 246], ["SP600125", "CHEMICAL", 162, 170], ["GF109203", "CHEMICAL", 172, 180], ["PD98059", "CHEMICAL", 186, 193], ["LY294002", "CHEMICAL", 220, 228], ["H89", "CHEMICAL", 230, 233], ["SB203580", "CHEMICAL", 238, 246], ["COX-2", "GENE_OR_GENE_PRODUCT", 103, 108], ["NS3", "GENE_OR_GENE_PRODUCT", 141, 144], ["SP600125", "SIMPLE_CHEMICAL", 162, 170], ["GF109203", "SIMPLE_CHEMICAL", 172, 180], ["PD98059", "SIMPLE_CHEMICAL", 186, 193], ["LY294002", "SIMPLE_CHEMICAL", 220, 228], ["H89", "SIMPLE_CHEMICAL", 230, 233], ["SB203580", "SIMPLE_CHEMICAL", 238, 246], ["COX-2", "GENE_OR_GENE_PRODUCT", 330, 335], ["NS3", "ORGANISM", 360, 363], ["ERK", "GENE_OR_GENE_PRODUCT", 376, 379], ["JNK", "GENE_OR_GENE_PRODUCT", 384, 387], ["COX-2", "GENE_OR_GENE_PRODUCT", 409, 414], ["NS3", "GENE_OR_GENE_PRODUCT", 427, 430], ["mERK1", "GENE_OR_GENE_PRODUCT", 518, 523], ["mERK2", "GENE_OR_GENE_PRODUCT", 525, 530], ["mJNK", "GENE_OR_GENE_PRODUCT", 536, 540], ["COX", "PROTEIN", 103, 106], ["NS3", "PROTEIN", 141, 144], ["COX", "PROTEIN", 330, 333], ["NS3", "PROTEIN", 360, 363], ["ERK", "PROTEIN", 376, 379], ["JNK", "PROTEIN", 384, 387], ["COX-2", "PROTEIN", 409, 414], ["NS3 protein", "PROTEIN", 427, 438], ["dominant kinase-inactive mutants", "PROTEIN", 484, 516], ["mERK1", "PROTEIN", 518, 523], ["mERK2", "PROTEIN", 525, 530], ["mJNK", "PROTEIN", 536, 540], ["endogenous kinases", "PROTEIN", 608, 626], ["NS3", "SPECIES", 360, 363], ["western blot analysis", "TEST", 35, 56], ["COX", "TEST", 103, 106], ["NS3", "PROBLEM", 141, 144], ["SP600125", "TEST", 162, 170], ["PD98059", "TEST", 186, 193], ["LY294002", "TEST", 220, 228], ["H89", "TEST", 230, 233], ["SB203580", "TEST", 238, 246], ["Multiple signal transduction pathways", "PROBLEM", 258, 295], ["COX", "TEST", 330, 333], ["ERK", "TEST", 376, 379], ["JNK", "TEST", 384, 387], ["COX", "TEST", 409, 412], ["NS3 protein", "TEST", 427, 438], ["mJNK", "TREATMENT", 536, 540], ["transduction pathways", "OBSERVATION", 274, 295]]], ["Cells were co-transfected with pCMV-NS3, pCOX-2-Luc reporter, and each of these three kinase mutants, respectively.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 31, 39], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 41, 47], ["Luc", "GENE_OR_GENE_PRODUCT", 48, 51], ["pCMV-NS3, pCOX-2-Luc reporter", "DNA", 31, 60], ["kinase mutants", "PROTEIN", 86, 100], ["Cells", "TEST", 0, 5], ["pCMV", "TEST", 31, 35], ["NS3", "TEST", 36, 39], ["pCOX", "TEST", 41, 45]]], ["Results from luciferase activity assays showed that all three mutants reduced COX-2 promoter activity in a dose-dependent manner, especially mERK2 and mJNK (Fig. 4C) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["COX-2", "GENE_OR_GENE_PRODUCT", 78, 83], ["mERK2", "GENE_OR_GENE_PRODUCT", 141, 146], ["mJNK", "GENE_OR_GENE_PRODUCT", 151, 155], ["luciferase", "PROTEIN", 13, 23], ["COX-2 promoter", "DNA", 78, 92], ["mERK2", "PROTEIN", 141, 146], ["mJNK", "PROTEIN", 151, 155], ["luciferase activity assays", "TEST", 13, 39], ["all three mutants reduced COX", "PROBLEM", 52, 81]]], ["Taken together, these data suggested that ERK, JNK, and PKC were involved in NS3-regulated COX-2 activation.NS3 protein of HCV activates JNK and ERK signaling pathwaysTo evaluate the effects of NS3 protein of HCV on the activation of JNK and ERK signaling cascades, we used antibodies specific to the phosphorylated forms of the two mitogen-activated protein kinases ERK1/2 and JNK.", [["ERK", "GENE_OR_GENE_PRODUCT", 42, 45], ["JNK", "GENE_OR_GENE_PRODUCT", 47, 50], ["PKC", "GENE_OR_GENE_PRODUCT", 56, 59], ["NS3", "GENE_OR_GENE_PRODUCT", 77, 80], ["COX-2", "GENE_OR_GENE_PRODUCT", 91, 96], ["NS3", "GENE_OR_GENE_PRODUCT", 108, 111], ["HCV", "ORGANISM", 123, 126], ["JNK", "GENE_OR_GENE_PRODUCT", 137, 140], ["ERK", "GENE_OR_GENE_PRODUCT", 145, 148], ["NS3", "GENE_OR_GENE_PRODUCT", 194, 197], ["HCV", "ORGANISM", 209, 212], ["JNK", "GENE_OR_GENE_PRODUCT", 234, 237], ["ERK", "GENE_OR_GENE_PRODUCT", 242, 245], ["mitogen-activated protein kinases ERK1/2", "GENE_OR_GENE_PRODUCT", 333, 373], ["JNK", "GENE_OR_GENE_PRODUCT", 378, 381], ["ERK", "PROTEIN", 42, 45], ["JNK", "PROTEIN", 47, 50], ["PKC", "PROTEIN", 56, 59], ["NS3", "PROTEIN", 77, 80], ["COX-2", "PROTEIN", 91, 96], ["NS3 protein", "PROTEIN", 108, 119], ["JNK", "PROTEIN", 137, 140], ["ERK", "PROTEIN", 145, 148], ["NS3 protein", "PROTEIN", 194, 205], ["JNK", "PROTEIN", 234, 237], ["ERK", "PROTEIN", 242, 245], ["mitogen-activated protein kinases", "PROTEIN", 333, 366], ["ERK1/2", "PROTEIN", 367, 373], ["JNK", "PROTEIN", 378, 381], ["HCV", "SPECIES", 123, 126], ["HCV", "SPECIES", 209, 212], ["these data", "TEST", 16, 26], ["ERK", "TEST", 42, 45], ["JNK", "TEST", 47, 50], ["PKC", "TEST", 56, 59], ["NS3", "TEST", 77, 80], ["HCV", "PROBLEM", 123, 126], ["JNK", "TEST", 137, 140], ["ERK signaling pathways", "TEST", 145, 167], ["NS3 protein", "TREATMENT", 194, 205], ["HCV", "PROBLEM", 209, 212], ["ERK signaling cascades", "PROBLEM", 242, 264], ["antibodies", "TREATMENT", 274, 284], ["the two mitogen", "TEST", 325, 340], ["activated protein kinases ERK1", "TEST", 341, 371], ["JNK", "TEST", 378, 381], ["HCV", "OBSERVATION", 123, 126], ["JNK", "ANATOMY", 378, 381]]], ["Results from western blot and densitometry analyses showed that the levels of phosphorylation of both JNK (Fig. 5A ) and ERK1/2 (Fig. 5B) were significantly increased when NS3 protein was present.", [["JNK", "GENE_OR_GENE_PRODUCT", 102, 105], ["Fig. 5A", "GENE_OR_GENE_PRODUCT", 107, 114], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 121, 127], ["Fig. 5B", "GENE_OR_GENE_PRODUCT", 129, 136], ["NS3", "GENE_OR_GENE_PRODUCT", 172, 175], ["JNK", "PROTEIN", 102, 105], ["Fig. 5A", "PROTEIN", 107, 114], ["ERK1/2", "PROTEIN", 121, 127], ["Fig. 5B", "PROTEIN", 129, 136], ["NS3 protein", "PROTEIN", 172, 183], ["western blot", "TEST", 13, 25], ["densitometry analyses", "TEST", 30, 51], ["JNK", "TEST", 102, 105], ["ERK1/2 (Fig. 5B)", "TEST", 121, 137], ["NS3 protein", "TEST", 172, 183]]], ["These results suggested that NS3 plays a role in the activation of JNK and ERK signaling pathways through phosphorylation of these two protein kinases.NS3-activated COX-2 expression is calcium-independent and involves PKD2 kinaseIt is known that PKCs comprise a family of intracellular serine/threonine-specific kinases.", [["intracellular", "ANATOMY", 272, 285], ["calcium", "CHEMICAL", 185, 192], ["calcium", "CHEMICAL", 185, 192], ["serine", "CHEMICAL", 286, 292], ["threonine", "CHEMICAL", 293, 302], ["NS3", "GENE_OR_GENE_PRODUCT", 29, 32], ["JNK", "GENE_OR_GENE_PRODUCT", 67, 70], ["ERK", "GENE_OR_GENE_PRODUCT", 75, 78], ["NS3", "GENE_OR_GENE_PRODUCT", 151, 154], ["COX-2", "GENE_OR_GENE_PRODUCT", 165, 170], ["calcium", "SIMPLE_CHEMICAL", 185, 192], ["PKD2", "GENE_OR_GENE_PRODUCT", 218, 222], ["PKCs", "GENE_OR_GENE_PRODUCT", 246, 250], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 272, 285], ["serine", "AMINO_ACID", 286, 292], ["threonine", "AMINO_ACID", 293, 302], ["NS3", "PROTEIN", 29, 32], ["JNK", "PROTEIN", 67, 70], ["ERK", "PROTEIN", 75, 78], ["protein kinases", "PROTEIN", 135, 150], ["NS3", "PROTEIN", 151, 154], ["COX", "PROTEIN", 165, 168], ["PKD2 kinase", "PROTEIN", 218, 229], ["PKCs", "PROTEIN", 246, 250], ["intracellular serine/threonine-specific kinases", "PROTEIN", 272, 319], ["NS3", "PROBLEM", 29, 32], ["ERK signaling pathways", "TEST", 75, 97], ["these two protein kinases", "TEST", 125, 150], ["NS3", "TREATMENT", 151, 154], ["calcium", "TEST", 185, 192], ["PKD2 kinase", "TEST", 218, 229], ["intracellular serine/threonine", "TREATMENT", 272, 302], ["NS3", "OBSERVATION", 29, 32]]], ["Depending on the type of isoforms, activation of PKCs is typically initiated by Ca 2+ , lipid second messengers, and/or protein activators.", [["Ca", "CHEMICAL", 80, 82], ["Ca 2+", "CHEMICAL", 80, 85], ["PKCs", "GENE_OR_GENE_PRODUCT", 49, 53], ["Ca 2+", "SIMPLE_CHEMICAL", 80, 85], ["lipid", "SIMPLE_CHEMICAL", 88, 93], ["PKCs", "PROTEIN", 49, 53], ["lipid second messengers", "PROTEIN", 88, 111], ["protein activators", "PROTEIN", 120, 138], ["PKCs", "PROBLEM", 49, 53], ["Ca", "TEST", 80, 82]]], ["To elucidate whether Ca 2+ is involved in the expression of COX-2 regulated by NS3, HepG2 cells were co-transfected with pCMV-NS3 and pCOX-2-Luc and then treated with BAPAT/AM or EGTA at different concentrations.", [["HepG2 cells", "ANATOMY", 84, 95], ["Ca", "CHEMICAL", 21, 23], ["BAPAT", "CHEMICAL", 167, 172], ["EGTA", "CHEMICAL", 179, 183], ["Ca 2+", "CHEMICAL", 21, 26], ["BAPAT", "CHEMICAL", 167, 172], ["EGTA", "CHEMICAL", 179, 183], ["Ca 2", "GENE_OR_GENE_PRODUCT", 21, 25], ["COX-2", "GENE_OR_GENE_PRODUCT", 60, 65], ["NS3", "GENE_OR_GENE_PRODUCT", 79, 82], ["HepG2 cells", "CELL", 84, 95], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 121, 129], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 134, 140], ["Luc", "GENE_OR_GENE_PRODUCT", 141, 144], ["BAPAT", "SIMPLE_CHEMICAL", 167, 172], ["AM", "SIMPLE_CHEMICAL", 173, 175], ["EGTA", "SIMPLE_CHEMICAL", 179, 183], ["COX-2", "PROTEIN", 60, 65], ["NS3", "PROTEIN", 79, 82], ["HepG2 cells", "CELL_LINE", 84, 95], ["pCMV", "PROTEIN", 121, 125], ["NS3 and pCOX-2-Luc", "DNA", 126, 144], ["Ca", "TEST", 21, 23], ["COX", "TEST", 60, 63], ["HepG2 cells", "TREATMENT", 84, 95], ["pCMV", "TREATMENT", 121, 125], ["NS3", "TREATMENT", 126, 129], ["pCOX", "TREATMENT", 134, 138], ["BAPAT", "TREATMENT", 167, 172], ["EGTA", "TREATMENT", 179, 183]]], ["Results from luciferase assays showed that BAPAT/AM (Fig. 6A) and EGTA (Fig. 6B ) had no significant effect on the activity of COX-2 promoter regulated by NS3, suggesting that Ca 2+ was not involved in the induction of COX-2 regulated by NS3.NS3-activated COX-2 expression is calcium-independent and involves PKD2 kinaseWe then extended our study to identify the specific isozymes of PKC involved in NS3-regulated activation of COX-2 using RNA interference (RNAi) approach.", [["EGTA", "CHEMICAL", 66, 70], ["Ca", "CHEMICAL", 176, 178], ["calcium", "CHEMICAL", 276, 283], ["EGTA", "CHEMICAL", 66, 70], ["Ca 2+", "CHEMICAL", 176, 181], ["calcium", "CHEMICAL", 276, 283], ["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["BAPAT/AM", "GENE_OR_GENE_PRODUCT", 43, 51], ["Fig. 6A", "GENE_OR_GENE_PRODUCT", 53, 60], ["EGTA", "SIMPLE_CHEMICAL", 66, 70], ["Fig. 6B", "ORGANISM", 72, 79], ["COX-2", "GENE_OR_GENE_PRODUCT", 127, 132], ["NS3", "GENE_OR_GENE_PRODUCT", 155, 158], ["Ca 2", "GENE_OR_GENE_PRODUCT", 176, 180], ["COX-2", "GENE_OR_GENE_PRODUCT", 219, 224], ["NS3", "GENE_OR_GENE_PRODUCT", 238, 241], ["NS3", "GENE_OR_GENE_PRODUCT", 242, 245], ["COX-2", "GENE_OR_GENE_PRODUCT", 256, 261], ["calcium", "SIMPLE_CHEMICAL", 276, 283], ["PKD2", "GENE_OR_GENE_PRODUCT", 309, 313], ["PKC", "GENE_OR_GENE_PRODUCT", 384, 387], ["NS3", "GENE_OR_GENE_PRODUCT", 400, 403], ["COX-2", "GENE_OR_GENE_PRODUCT", 428, 433], ["luciferase", "PROTEIN", 13, 23], ["COX-2 promoter", "DNA", 127, 141], ["NS3", "PROTEIN", 155, 158], ["COX-2", "PROTEIN", 219, 224], ["NS3", "PROTEIN", 238, 241], ["NS3", "PROTEIN", 242, 245], ["COX", "PROTEIN", 256, 259], ["PKD2 kinaseWe", "PROTEIN", 309, 322], ["PKC", "PROTEIN", 384, 387], ["NS3", "PROTEIN", 400, 403], ["COX-2", "PROTEIN", 428, 433], ["luciferase assays", "TEST", 13, 30], ["BAPAT", "TEST", 43, 48], ["EGTA (Fig. 6B", "TEST", 66, 79], ["significant effect", "PROBLEM", 89, 107], ["COX", "TEST", 127, 130], ["Ca", "TEST", 176, 178], ["COX", "TEST", 219, 222], ["NS3", "TREATMENT", 242, 245], ["calcium", "TEST", 276, 283], ["our study", "TEST", 337, 346], ["NS3", "TREATMENT", 400, 403], ["activation of COX", "TREATMENT", 414, 431], ["RNA interference (RNAi) approach", "TREATMENT", 440, 472], ["no", "UNCERTAINTY", 86, 88], ["significant", "OBSERVATION_MODIFIER", 89, 100]]], ["Small interfering RNA (siRNA) molecules that specifically knock down genes encoding for each PKC isozymes were used to study the function of PKC based on previous studies (Storz et al., 2004; Liu et al., 2007) .", [["PKC", "GENE_OR_GENE_PRODUCT", 93, 96], ["PKC", "GENE_OR_GENE_PRODUCT", 141, 144], ["Small interfering RNA", "RNA", 0, 21], ["PKC isozymes", "PROTEIN", 93, 105], ["PKC", "PROTEIN", 141, 144], ["Small interfering RNA (siRNA) molecules", "PROBLEM", 0, 39], ["each PKC isozymes", "TREATMENT", 88, 105], ["previous studies", "TEST", 154, 170], ["interfering RNA", "OBSERVATION", 6, 21]]], ["HepG2 cells were transfected with pCMV-NS3 and then treated with siRNAs, including siPKC\u03b4, siPKC\u03b6, siPKC\u03b1, siPKC\u03b21, siPKD1, and siPKD2, respectively.", [["HepG2 cells", "ANATOMY", 0, 11], ["HepG2 cells", "CELL", 0, 11], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 34, 42], ["siPKC\u03b4", "GENE_OR_GENE_PRODUCT", 83, 89], ["siPKC\u03b6", "GENE_OR_GENE_PRODUCT", 91, 97], ["siPKC\u03b1", "GENE_OR_GENE_PRODUCT", 99, 105], ["siPKC\u03b21", "GENE_OR_GENE_PRODUCT", 107, 114], ["siPKD1", "GENE_OR_GENE_PRODUCT", 116, 122], ["siPKD2", "GENE_OR_GENE_PRODUCT", 128, 134], ["HepG2 cells", "CELL_LINE", 0, 11], ["pCMV", "PROTEIN", 34, 38], ["NS3", "PROTEIN", 39, 42], ["siPKC\u03b4", "PROTEIN", 83, 89], ["siPKC\u03b6", "PROTEIN", 91, 97], ["siPKC\u03b1", "PROTEIN", 99, 105], ["siPKC\u03b21", "DNA", 107, 114], ["siPKD1", "DNA", 116, 122], ["siPKD2", "DNA", 128, 134], ["HepG2 cells", "TEST", 0, 11], ["pCMV", "TEST", 34, 38], ["NS3", "TREATMENT", 39, 42], ["siRNAs", "TREATMENT", 65, 71], ["siPKC\u03b4", "TEST", 83, 89], ["siPKC\u03b6", "TREATMENT", 91, 97], ["siPKC\u03b1", "TREATMENT", 99, 105]]], ["Results from western blot analysis using antibody to COX-2 protein showed that siPKD2, but not other siRNAs tested, had a significant effect on the activation of COX-2 protein expression regulated by NS3 (Fig. 6C) .", [["COX-2", "GENE_OR_GENE_PRODUCT", 53, 58], ["siPKD2", "GENE_OR_GENE_PRODUCT", 79, 85], ["COX-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["NS3", "GENE_OR_GENE_PRODUCT", 200, 203], ["COX-2 protein", "PROTEIN", 53, 66], ["siPKD2", "PROTEIN", 79, 85], ["COX", "PROTEIN", 162, 165], ["NS3", "PROTEIN", 200, 203], ["western blot analysis", "TEST", 13, 34], ["antibody", "TEST", 41, 49], ["COX", "TEST", 53, 56], ["protein", "TEST", 59, 66], ["siPKD2", "TEST", 79, 85], ["other siRNAs", "PROBLEM", 95, 107], ["COX", "TEST", 162, 165], ["NS3 (Fig", "TREATMENT", 200, 208], ["significant", "OBSERVATION_MODIFIER", 122, 133]]], ["These results suggested that PKD2 signaling pathway was involved in the activation of COX-2 regulated by NS3 protein.NS3-activated COX-2 expression is calcium-independent and involves PKD2 kinaseExpression of PKD2 (Fig. 6D) , PKC\u03b1 (Fig. 6E) , and PKC\u03b6 (Fig. 6F ) mRNA was also determined before and after knock down by specific siRNA using RT-PCR analyses.", [["calcium", "CHEMICAL", 151, 158], ["calcium", "CHEMICAL", 151, 158], ["PKD2", "GENE_OR_GENE_PRODUCT", 29, 33], ["COX-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["NS3", "GENE_OR_GENE_PRODUCT", 105, 108], ["NS3", "GENE_OR_GENE_PRODUCT", 117, 120], ["COX-2", "GENE_OR_GENE_PRODUCT", 131, 136], ["calcium", "SIMPLE_CHEMICAL", 151, 158], ["PKD2", "GENE_OR_GENE_PRODUCT", 184, 188], ["PKD2", "GENE_OR_GENE_PRODUCT", 209, 213], ["Fig. 6D", "GENE_OR_GENE_PRODUCT", 215, 222], ["PKC\u03b1 (Fig. 6E", "GENE_OR_GENE_PRODUCT", 226, 239], ["PKC\u03b6", "GENE_OR_GENE_PRODUCT", 247, 251], ["Fig. 6F", "GENE_OR_GENE_PRODUCT", 253, 260], ["PKD2", "PROTEIN", 29, 33], ["COX-2", "PROTEIN", 86, 91], ["NS3 protein", "PROTEIN", 105, 116], ["NS3", "PROTEIN", 117, 120], ["COX", "PROTEIN", 131, 134], ["PKD2", "PROTEIN", 184, 188], ["PKD2", "PROTEIN", 209, 213], ["Fig. 6D) , PKC\u03b1 (Fig. 6E) , and PKC\u03b6 (Fig. 6F ) mRNA", "RNA", 215, 267], ["PKD2 signaling pathway", "PROBLEM", 29, 51], ["COX", "TEST", 86, 89], ["NS3", "TREATMENT", 117, 120], ["calcium", "TEST", 151, 158], ["PKD2", "PROBLEM", 209, 213], ["PKC", "TEST", 247, 250], ["RT-PCR analyses", "TEST", 340, 355]]], ["Results showed that expression of different PKC isoforms was decreased significantly in the presence of PKC isoform-specific siRNAs (siPKC\u03b1, siPKC\u03b6, and siPKD2), but siCtrl (a control siRNA containing an irrelevant sequence to PKCs and no homology to any human gene sequence) had no significant effect on the expression of PKCs (Figs.", [["PKC", "GENE_OR_GENE_PRODUCT", 44, 47], ["PKC", "GENE_OR_GENE_PRODUCT", 104, 107], ["siPKC\u03b1", "GENE_OR_GENE_PRODUCT", 133, 139], ["siPKC\u03b6", "GENE_OR_GENE_PRODUCT", 141, 147], ["siPKD2", "GENE_OR_GENE_PRODUCT", 153, 159], ["siCtrl", "GENE_OR_GENE_PRODUCT", 166, 172], ["PKCs", "GENE_OR_GENE_PRODUCT", 227, 231], ["human", "ORGANISM", 255, 260], ["PKCs", "GENE_OR_GENE_PRODUCT", 323, 327], ["PKC isoforms", "PROTEIN", 44, 56], ["PKC isoform", "PROTEIN", 104, 115], ["siPKC\u03b1", "PROTEIN", 133, 139], ["siPKC\u03b6", "PROTEIN", 141, 147], ["siPKD2", "PROTEIN", 153, 159], ["siCtrl", "PROTEIN", 166, 172], ["PKCs", "PROTEIN", 227, 231], ["human gene sequence", "DNA", 255, 274], ["PKCs", "PROTEIN", 323, 327], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 255, 260], ["different PKC isoforms", "PROBLEM", 34, 56], ["PKC isoform", "PROBLEM", 104, 115], ["specific siRNAs (siPKC\u03b1, siPKC\u03b6, and siPKD2)", "PROBLEM", 116, 160], ["a control siRNA", "TREATMENT", 174, 189], ["PKCs", "TEST", 227, 231], ["any human gene sequence", "TEST", 251, 274]]], ["These results indicated that various PKC isoform-specific siRNAs worked efficiently in the assays and that among PKCs, only PKD2 was involved in the activation of COX-2 regulated by NS3 protein.DiscussionCOX-2 was reported to be highly expressed in liver inflammation and carcinogenesis, thus representing a potential target for drug intervention during these processes (Rahman et al., 2001; Nunez et al., 2004; Aggarwal et al., 2006) .", [["liver", "ANATOMY", 249, 254], ["liver inflammation", "DISEASE", 249, 267], ["carcinogenesis", "DISEASE", 272, 286], ["PKC", "GENE_OR_GENE_PRODUCT", 37, 40], ["PKCs", "GENE_OR_GENE_PRODUCT", 113, 117], ["PKD2", "GENE_OR_GENE_PRODUCT", 124, 128], ["COX-2", "GENE_OR_GENE_PRODUCT", 163, 168], ["NS3", "GENE_OR_GENE_PRODUCT", 182, 185], ["DiscussionCOX-2", "GENE_OR_GENE_PRODUCT", 194, 209], ["liver", "ORGAN", 249, 254], ["PKC isoform", "PROTEIN", 37, 48], ["PKCs", "PROTEIN", 113, 117], ["PKD2", "PROTEIN", 124, 128], ["COX-2", "PROTEIN", 163, 168], ["NS3 protein", "PROTEIN", 182, 193], ["various PKC isoform", "PROBLEM", 29, 48], ["the assays", "TEST", 87, 97], ["liver inflammation", "PROBLEM", 249, 267], ["drug intervention", "TREATMENT", 329, 346], ["liver", "ANATOMY", 249, 254], ["inflammation", "OBSERVATION", 255, 267]]], ["Recent study provided evidence that COX-2 is over-expressed in the liver tissues of patients with chronic HCV infection, implying a positive correlation with the fibrotic stage of liver disease.", [["liver tissues", "ANATOMY", 67, 80], ["liver", "ANATOMY", 180, 185], ["HCV infection", "DISEASE", 106, 119], ["liver disease", "DISEASE", 180, 193], ["COX-2", "GENE_OR_GENE_PRODUCT", 36, 41], ["liver tissues", "TISSUE", 67, 80], ["patients", "ORGANISM", 84, 92], ["liver", "ORGAN", 180, 185], ["COX-2", "PROTEIN", 36, 41], ["patients", "SPECIES", 84, 92], ["HCV", "SPECIES", 106, 109], ["Recent study", "TEST", 0, 12], ["COX", "TEST", 36, 39], ["chronic HCV infection", "PROBLEM", 98, 119], ["liver disease", "PROBLEM", 180, 193], ["liver", "ANATOMY", 67, 72], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["HCV", "OBSERVATION_MODIFIER", 106, 109], ["infection", "OBSERVATION", 110, 119], ["fibrotic", "OBSERVATION", 162, 170], ["liver", "ANATOMY", 180, 185], ["disease", "OBSERVATION", 186, 193]]], ["Although the molecular basis for hepatocellular COX-2 expression in patients with chronic HCV infection remains to be defined, there is evidence that core and NS5A proteins of HCV can function as transcriptional transactivators for many cellular genes (Kato et al., 2000; Reyes, 2002; Nunez et al., 2004) .DiscussionIn the process of investigating the roles of additional proteins of HCV in COX-2 expression during HCV infection, we found that NS3 protein could induce COX-2 promoter activity, COX-2 mRNA expression, COX-2 protein production, and PGE 2 generation in human liver cell line HepG2 in a concentrationdependent fashion.", [["hepatocellular", "ANATOMY", 33, 47], ["cellular", "ANATOMY", 237, 245], ["liver cell line HepG2", "ANATOMY", 573, 594], ["HCV infection", "DISEASE", 90, 103], ["HCV infection", "DISEASE", 415, 428], ["PGE 2", "CHEMICAL", 547, 552], ["hepatocellular", "GENE_OR_GENE_PRODUCT", 33, 47], ["COX-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["patients", "ORGANISM", 68, 76], ["HCV", "ORGANISM", 90, 93], ["NS5A", "GENE_OR_GENE_PRODUCT", 159, 163], ["HCV", "ORGANISM", 176, 179], ["cellular", "CELL", 237, 245], ["HCV", "ORGANISM", 384, 387], ["COX-2", "GENE_OR_GENE_PRODUCT", 391, 396], ["HCV", "ORGANISM", 415, 418], ["NS3", "GENE_OR_GENE_PRODUCT", 444, 447], ["COX-2", "GENE_OR_GENE_PRODUCT", 469, 474], ["COX-2", "GENE_OR_GENE_PRODUCT", 494, 499], ["COX-2", "GENE_OR_GENE_PRODUCT", 517, 522], ["PGE 2", "GENE_OR_GENE_PRODUCT", 547, 552], ["human", "ORGANISM", 567, 572], ["liver cell line HepG2", "CELL", 573, 594], ["hepatocellular COX-2", "PROTEIN", 33, 53], ["NS5A proteins", "PROTEIN", 159, 172], ["transcriptional transactivators", "PROTEIN", 196, 227], ["cellular genes", "DNA", 237, 251], ["COX", "PROTEIN", 391, 394], ["NS3 protein", "PROTEIN", 444, 455], ["COX", "PROTEIN", 469, 472], ["COX", "PROTEIN", 517, 520], ["PGE 2", "PROTEIN", 547, 552], ["human liver cell line HepG2", "CELL_LINE", 567, 594], ["patients", "SPECIES", 68, 76], ["human", "SPECIES", 567, 572], ["HCV", "SPECIES", 90, 93], ["HCV", "SPECIES", 176, 179], ["HCV", "SPECIES", 384, 387], ["HCV", "SPECIES", 415, 418], ["human", "SPECIES", 567, 572], ["hepatocellular COX", "PROBLEM", 33, 51], ["chronic HCV infection", "PROBLEM", 82, 103], ["core and NS5A proteins of HCV", "PROBLEM", 150, 179], ["transcriptional transactivators", "TREATMENT", 196, 227], ["HCV in COX", "PROBLEM", 384, 394], ["HCV infection", "PROBLEM", 415, 428], ["NS3 protein", "TEST", 444, 455], ["COX", "TEST", 469, 472], ["COX", "TEST", 494, 497], ["mRNA expression", "TEST", 500, 515], ["COX", "TEST", 517, 520], ["protein production", "TEST", 523, 541], ["PGE 2 generation in human liver cell line HepG2", "TREATMENT", 547, 594], ["hepatocellular", "ANATOMY", 33, 47], ["chronic", "OBSERVATION_MODIFIER", 82, 89], ["HCV", "OBSERVATION_MODIFIER", 90, 93], ["infection", "OBSERVATION", 94, 103], ["NS5A", "OBSERVATION", 159, 163], ["liver", "ANATOMY", 573, 578], ["cell line", "OBSERVATION", 579, 588]]], ["These results suggested that NS3 protein of HCV can also function as transcriptional transactivator for cellular genes.DiscussionNF-\u03baB has been reported to mediate COX-2 activation induced by diverse stimulating agents.", [["cellular", "ANATOMY", 104, 112], ["DiscussionNF-\u03baB", "CHEMICAL", 119, 134], ["NS3", "GENE_OR_GENE_PRODUCT", 29, 32], ["HCV", "ORGANISM", 44, 47], ["cellular", "CELL", 104, 112], ["DiscussionNF-\u03baB", "GENE_OR_GENE_PRODUCT", 119, 134], ["COX-2", "GENE_OR_GENE_PRODUCT", 164, 169], ["NS3 protein", "PROTEIN", 29, 40], ["transcriptional transactivator", "PROTEIN", 69, 99], ["cellular genes", "DNA", 104, 118], ["DiscussionNF", "PROTEIN", 119, 131], ["\u03baB", "PROTEIN", 132, 134], ["COX-2", "PROTEIN", 164, 169], ["HCV", "SPECIES", 44, 47], ["NS3 protein of HCV", "PROBLEM", 29, 47], ["transcriptional transactivator", "TREATMENT", 69, 99], ["diverse stimulating agents", "TREATMENT", 192, 218]]], ["We demonstrated in this study that NF-\u03baB is also essential for NS3 protein-induced COX-2 expression since mutations of binding sites for NF-\u03baB and the inhibitor of NF-\u03baB could eliminate NS3 function in the activation of COX-2.DiscussionBased on the findings that NS3 protein activates COX-2 expression and NF-\u03baB is involved in such regulation, we further investigated the roles of different MAP kinases on the activation of COX-2 regulated by NS3.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 35, 40], ["NS3", "GENE_OR_GENE_PRODUCT", 63, 66], ["COX-2", "GENE_OR_GENE_PRODUCT", 83, 88], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 137, 142], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 164, 169], ["NS3", "GENE_OR_GENE_PRODUCT", 186, 189], ["COX-2", "GENE_OR_GENE_PRODUCT", 220, 225], ["NS3", "ORGANISM", 263, 266], ["COX-2", "GENE_OR_GENE_PRODUCT", 285, 290], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 306, 311], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 391, 402], ["COX-2", "GENE_OR_GENE_PRODUCT", 424, 429], ["NS3", "GENE_OR_GENE_PRODUCT", 443, 446], ["NF-\u03baB", "PROTEIN", 35, 40], ["NS3 protein", "PROTEIN", 63, 74], ["COX", "PROTEIN", 83, 86], ["binding sites", "DNA", 119, 132], ["NF-\u03baB", "PROTEIN", 137, 142], ["NF-\u03baB", "PROTEIN", 164, 169], ["NS3", "PROTEIN", 186, 189], ["COX-2", "PROTEIN", 220, 225], ["NS3 protein", "PROTEIN", 263, 274], ["COX", "PROTEIN", 285, 288], ["NF-\u03baB", "PROTEIN", 306, 311], ["MAP kinases", "PROTEIN", 391, 402], ["COX-2", "PROTEIN", 424, 429], ["NS3", "PROTEIN", 443, 446], ["this study", "TEST", 19, 29], ["NF", "TEST", 35, 37], ["NS3 protein", "TREATMENT", 63, 74], ["induced COX", "PROBLEM", 75, 86], ["mutations of binding sites", "PROBLEM", 106, 132], ["NF", "TEST", 137, 139], ["\u03baB", "TREATMENT", 140, 142], ["the inhibitor of NF", "TREATMENT", 147, 166], ["\u03baB", "TREATMENT", 167, 169], ["NS3 function", "PROBLEM", 186, 198], ["COX", "TEST", 220, 223], ["NS3 protein", "TEST", 263, 274], ["COX", "TEST", 285, 288], ["different MAP kinases", "TREATMENT", 381, 402], ["COX", "TEST", 424, 427]]], ["Our results demonstrated that ERK, JNK, and PKC were involved in the activation of COX-2 regulated by NS3 since inhibition of each of those kinases abolished the expression of COX-2 activated by NS3.", [["ERK", "GENE_OR_GENE_PRODUCT", 30, 33], ["JNK", "GENE_OR_GENE_PRODUCT", 35, 38], ["PKC", "GENE_OR_GENE_PRODUCT", 44, 47], ["COX-2", "GENE_OR_GENE_PRODUCT", 83, 88], ["NS3", "GENE_OR_GENE_PRODUCT", 102, 105], ["COX-2", "GENE_OR_GENE_PRODUCT", 176, 181], ["NS3", "GENE_OR_GENE_PRODUCT", 195, 198], ["ERK", "PROTEIN", 30, 33], ["JNK", "PROTEIN", 35, 38], ["PKC", "PROTEIN", 44, 47], ["COX-2", "PROTEIN", 83, 88], ["NS3", "PROTEIN", 102, 105], ["COX-2", "PROTEIN", 176, 181], ["NS3", "PROTEIN", 195, 198], ["ERK", "TEST", 30, 33], ["JNK", "TEST", 35, 38], ["PKC", "TEST", 44, 47], ["COX", "TEST", 83, 86], ["those kinases", "TREATMENT", 134, 147], ["COX", "TEST", 176, 179]]], ["We also observed that inhibitors of PI3K, protein kinase A, and SAPK2\u03b1/\u03b2/p38\u03b1/\u03b2MAPK had no effect on NS3-activated COX-2 expression.", [["PI3K", "GENE_OR_GENE_PRODUCT", 36, 40], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 42, 58], ["SAPK2\u03b1", "GENE_OR_GENE_PRODUCT", 64, 70], ["\u03b2", "GENE_OR_GENE_PRODUCT", 71, 72], ["p38\u03b1", "GENE_OR_GENE_PRODUCT", 73, 77], ["\u03b2MAPK", "GENE_OR_GENE_PRODUCT", 78, 83], ["NS3", "GENE_OR_GENE_PRODUCT", 101, 104], ["COX-2", "GENE_OR_GENE_PRODUCT", 115, 120], ["PI3K", "PROTEIN", 36, 40], ["protein kinase A", "PROTEIN", 42, 58], ["SAPK2\u03b1", "PROTEIN", 64, 70], ["\u03b2", "PROTEIN", 71, 72], ["p38\u03b1", "PROTEIN", 73, 77], ["\u03b2MAPK", "PROTEIN", 78, 83], ["NS3", "PROTEIN", 101, 104], ["COX", "PROTEIN", 115, 118], ["inhibitors", "TEST", 22, 32], ["PI3K", "TEST", 36, 40], ["protein kinase A", "TEST", 42, 58], ["SAPK2\u03b1", "TEST", 64, 70], ["p38", "TEST", 73, 76], ["MAPK", "TEST", 79, 83], ["effect", "PROBLEM", 91, 97], ["NS3", "TEST", 101, 104], ["activated COX", "TEST", 105, 118]]], ["Using RNA interference approach, we further found that the induction of COX-2 by NS3 required the atypical isoform PKD2 since PKD2 specific siRNA inhibited COX-2 protein expression activated by NS3 and siRNA specific to other PKC isoforms had no effect on NS3-induced COX-2 expression.DiscussionMany viral proteins can induce multiple signaling pathways, which may crosstalk with each other or converge on common downstream effectors (Chen et al., 2003) .", [["COX-2", "GENE_OR_GENE_PRODUCT", 72, 77], ["NS3", "GENE_OR_GENE_PRODUCT", 81, 84], ["PKD2", "GENE_OR_GENE_PRODUCT", 115, 119], ["PKD2", "GENE_OR_GENE_PRODUCT", 126, 130], ["COX-2", "GENE_OR_GENE_PRODUCT", 156, 161], ["NS3", "GENE_OR_GENE_PRODUCT", 194, 197], ["PKC", "GENE_OR_GENE_PRODUCT", 226, 229], ["NS3", "GENE_OR_GENE_PRODUCT", 256, 259], ["COX-2", "GENE_OR_GENE_PRODUCT", 268, 273], ["COX-2", "PROTEIN", 72, 77], ["NS3", "PROTEIN", 81, 84], ["atypical isoform PKD2", "PROTEIN", 98, 119], ["PKD2", "PROTEIN", 126, 130], ["COX-2", "PROTEIN", 156, 161], ["NS3", "PROTEIN", 194, 197], ["PKC isoforms", "PROTEIN", 226, 238], ["NS3", "PROTEIN", 256, 259], ["COX", "PROTEIN", 268, 271], ["viral proteins", "PROTEIN", 300, 314], ["RNA interference approach", "TREATMENT", 6, 31], ["the induction of COX", "TREATMENT", 55, 75], ["NS3", "TREATMENT", 81, 84], ["the atypical isoform PKD2", "PROBLEM", 94, 119], ["PKD2 specific siRNA", "TREATMENT", 126, 145], ["COX", "TEST", 156, 159], ["protein expression", "TEST", 162, 180], ["NS3 and siRNA", "TREATMENT", 194, 207], ["other PKC isoforms", "TEST", 220, 238], ["NS3", "TEST", 256, 259], ["multiple signaling pathways", "PROBLEM", 326, 353]]], ["In embryonic kidney cells, the latent membrane protein-1 of EBV induced COX-2 expression through MAPK, JNK/AP-1, and JAK/STAT signaling pathways and required the transcription factor NF-\u03baB (Saunders et al., 2001) .DiscussionOur results in this study suggested that the NS3 of HCV regulates multiple signaling pathways, such as ERK, JNK, and PKD2, to control the activity of transcription factor NF-\u03baB, which in turn to activate the expression of COX-2 that may induce host inflammatory response and, perhaps, carcinogenesis.", [["embryonic kidney cells", "ANATOMY", 3, 25], ["carcinogenesis", "DISEASE", 509, 523], ["embryonic kidney cells", "CELL", 3, 25], ["latent membrane protein-1", "GENE_OR_GENE_PRODUCT", 31, 56], ["EBV", "ORGANISM", 60, 63], ["COX-2", "GENE_OR_GENE_PRODUCT", 72, 77], ["MAPK", "GENE_OR_GENE_PRODUCT", 97, 101], ["JNK", "GENE_OR_GENE_PRODUCT", 103, 106], ["AP-1", "GENE_OR_GENE_PRODUCT", 107, 111], ["JAK", "GENE_OR_GENE_PRODUCT", 117, 120], ["STAT", "GENE_OR_GENE_PRODUCT", 121, 125], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 183, 188], ["NS3", "GENE_OR_GENE_PRODUCT", 269, 272], ["HCV", "ORGANISM", 276, 279], ["ERK", "GENE_OR_GENE_PRODUCT", 327, 330], ["JNK", "GENE_OR_GENE_PRODUCT", 332, 335], ["PKD2", "GENE_OR_GENE_PRODUCT", 341, 345], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 395, 400], ["COX-2", "GENE_OR_GENE_PRODUCT", 446, 451], ["embryonic kidney cells", "CELL_TYPE", 3, 25], ["latent membrane protein-1", "PROTEIN", 31, 56], ["COX", "PROTEIN", 72, 75], ["MAPK", "PROTEIN", 97, 101], ["JNK", "PROTEIN", 103, 106], ["AP", "PROTEIN", 107, 109], ["JAK", "PROTEIN", 117, 120], ["STAT", "PROTEIN", 121, 125], ["transcription factor", "PROTEIN", 162, 182], ["NF-\u03baB", "PROTEIN", 183, 188], ["NS3", "PROTEIN", 269, 272], ["ERK", "PROTEIN", 327, 330], ["JNK", "PROTEIN", 332, 335], ["PKD2", "PROTEIN", 341, 345], ["transcription factor NF-\u03baB", "PROTEIN", 374, 400], ["COX-2", "PROTEIN", 446, 451], ["HCV", "SPECIES", 276, 279], ["embryonic kidney cells", "PROBLEM", 3, 25], ["the latent membrane protein", "TEST", 27, 54], ["EBV", "PROBLEM", 60, 63], ["COX", "TEST", 72, 75], ["MAPK", "TEST", 97, 101], ["JNK", "TEST", 103, 106], ["AP", "TEST", 107, 109], ["JAK", "TEST", 117, 120], ["this study", "TEST", 239, 249], ["the NS3 of HCV regulates", "PROBLEM", 265, 289], ["ERK", "TEST", 327, 330], ["JNK", "TEST", 332, 335], ["PKD2", "PROBLEM", 341, 345], ["host inflammatory response", "PROBLEM", 468, 494], ["embryonic kidney cells", "OBSERVATION", 3, 25]]], ["A thorough understanding of COX-2 gene expression regulated by the NS3 protein of HCV would provide insights into the development of novel therapeutics and into our understanding of liver inflammation and cancer development caused by HCV infection.Materials and methodsPlasmids, antibodies, and reagents SB203580, PD98059, LY294002, SP600125, GF109203, H89, EGTA, MG132, DTT, fura-2/acetoxymethyl ester (AM), and pluronic-F127 were purchased from Sigma Chemical Co (St. Louis, MO, USA).", [["liver", "ANATOMY", 182, 187], ["cancer", "ANATOMY", 205, 211], ["liver inflammation", "DISEASE", 182, 200], ["cancer", "DISEASE", 205, 211], ["HCV infection", "DISEASE", 234, 247], ["SB203580", "CHEMICAL", 304, 312], ["PD98059", "CHEMICAL", 314, 321], ["LY294002", "CHEMICAL", 323, 331], ["SP600125", "CHEMICAL", 333, 341], ["GF109203", "CHEMICAL", 343, 351], ["H89", "CHEMICAL", 353, 356], ["EGTA", "CHEMICAL", 358, 362], ["MG132", "CHEMICAL", 364, 369], ["DTT", "CHEMICAL", 371, 374], ["fura-2/acetoxymethyl ester", "CHEMICAL", 376, 402], ["AM", "CHEMICAL", 404, 406], ["pluronic-F127", "CHEMICAL", 413, 426], ["SB203580", "CHEMICAL", 304, 312], ["PD98059", "CHEMICAL", 314, 321], ["LY294002", "CHEMICAL", 323, 331], ["SP600125", "CHEMICAL", 333, 341], ["GF109203", "CHEMICAL", 343, 351], ["H89", "CHEMICAL", 353, 356], ["EGTA", "CHEMICAL", 358, 362], ["MG132", "CHEMICAL", 364, 369], ["DTT", "CHEMICAL", 371, 374], ["fura-2", "CHEMICAL", 376, 382], ["acetoxymethyl ester", "CHEMICAL", 383, 402], ["pluronic-F127", "CHEMICAL", 413, 426], ["COX-2", "GENE_OR_GENE_PRODUCT", 28, 33], ["NS3", "GENE_OR_GENE_PRODUCT", 67, 70], ["HCV", "ORGANISM", 82, 85], ["liver", "ORGAN", 182, 187], ["cancer", "CANCER", 205, 211], ["HCV", "ORGANISM", 234, 237], ["SB203580", "SIMPLE_CHEMICAL", 304, 312], ["PD98059", "SIMPLE_CHEMICAL", 314, 321], ["LY294002", "SIMPLE_CHEMICAL", 323, 331], ["SP600125", "SIMPLE_CHEMICAL", 333, 341], ["GF109203", "SIMPLE_CHEMICAL", 343, 351], ["H89", "SIMPLE_CHEMICAL", 353, 356], ["EGTA", "SIMPLE_CHEMICAL", 358, 362], ["MG132", "SIMPLE_CHEMICAL", 364, 369], ["DTT", "SIMPLE_CHEMICAL", 371, 374], ["fura-2/acetoxymethyl ester", "SIMPLE_CHEMICAL", 376, 402], ["AM", "SIMPLE_CHEMICAL", 404, 406], ["pluronic-F127", "SIMPLE_CHEMICAL", 413, 426], ["St. Louis", "ORGANISM", 466, 475], ["COX-2 gene", "DNA", 28, 38], ["NS3 protein", "PROTEIN", 67, 78], ["antibodies", "PROTEIN", 279, 289], ["HCV", "SPECIES", 82, 85], ["HCV", "SPECIES", 234, 237], ["COX-2 gene expression", "TREATMENT", 28, 49], ["the NS3 protein of HCV", "TREATMENT", 63, 85], ["novel therapeutics", "TREATMENT", 133, 151], ["liver inflammation", "PROBLEM", 182, 200], ["cancer development", "PROBLEM", 205, 223], ["HCV infection", "PROBLEM", 234, 247], ["methodsPlasmids", "TREATMENT", 262, 277], ["antibodies", "TEST", 279, 289], ["SB203580", "TEST", 304, 312], ["PD98059", "TEST", 314, 321], ["LY294002", "TEST", 323, 331], ["SP600125", "TEST", 333, 341], ["GF109203", "TEST", 343, 351], ["H89", "TEST", 353, 356], ["EGTA", "TEST", 358, 362], ["MG132", "TEST", 364, 369], ["DTT", "TEST", 371, 374], ["fura", "TEST", 376, 380], ["acetoxymethyl ester", "TEST", 383, 402], ["liver", "ANATOMY", 182, 187], ["inflammation", "OBSERVATION", 188, 200], ["cancer", "OBSERVATION", 205, 211], ["HCV", "OBSERVATION_MODIFIER", 234, 237], ["infection", "OBSERVATION", 238, 247]]], ["All protein kinase inhibitors were dissolved in DMSO and used at a final concentration of 50 \u03bcM for PD98059, 10 \u03bcM for SB203580, 50 \u03bcM for GF109203, 30 \u03bcM for SP600125, 25 \u03bcM for LY294002, 10 \u03bcM for H89, and 10 \u03bcM for MG132.", [["DMSO", "CHEMICAL", 48, 52], ["PD98059", "CHEMICAL", 100, 107], ["SB203580", "CHEMICAL", 119, 127], ["GF109203", "CHEMICAL", 139, 147], ["SP600125", "CHEMICAL", 159, 167], ["LY294002", "CHEMICAL", 179, 187], ["H89", "CHEMICAL", 199, 202], ["MG132", "CHEMICAL", 218, 223], ["DMSO", "CHEMICAL", 48, 52], ["PD98059", "CHEMICAL", 100, 107], ["SB203580", "CHEMICAL", 119, 127], ["GF109203", "CHEMICAL", 139, 147], ["SP600125", "CHEMICAL", 159, 167], ["LY294002", "CHEMICAL", 179, 187], ["H89", "CHEMICAL", 199, 202], ["MG132", "CHEMICAL", 218, 223], ["DMSO", "SIMPLE_CHEMICAL", 48, 52], ["PD98059", "SIMPLE_CHEMICAL", 100, 107], ["SB203580", "SIMPLE_CHEMICAL", 119, 127], ["GF109203", "SIMPLE_CHEMICAL", 139, 147], ["SP600125", "SIMPLE_CHEMICAL", 159, 167], ["LY294002", "SIMPLE_CHEMICAL", 179, 187], ["H89", "SIMPLE_CHEMICAL", 199, 202], ["MG132", "SIMPLE_CHEMICAL", 218, 223], ["All protein kinase inhibitors", "TREATMENT", 0, 29], ["DMSO", "TREATMENT", 48, 52], ["PD98059", "TEST", 100, 107], ["SB203580", "TEST", 119, 127], ["SP600125", "TEST", 159, 167], ["LY294002", "TEST", 179, 187], ["H89", "TEST", 199, 202], ["MG132", "PROBLEM", 218, 223]]], ["Antibody against COX-2 was from Cayman Chemical Company (Ann Arbor, MI, USA).", [["COX-2", "GENE_OR_GENE_PRODUCT", 17, 22], ["COX", "PROTEIN", 17, 20], ["Antibody", "TEST", 0, 8], ["COX", "TEST", 17, 20]]], ["Antibodies specific for ERK, phospho-ERK, JNK, and phospho-JNK were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).Materials and methodsLuciferase reporter vector (pGL3) containing a COX-2 promoter region (\u2212 891/+ 9), its truncation mutants, and site specific mutants were constructed previously (Zhu et al., 2002) .", [["ERK", "GENE_OR_GENE_PRODUCT", 24, 27], ["phospho-ERK", "GENE_OR_GENE_PRODUCT", 29, 40], ["JNK", "GENE_OR_GENE_PRODUCT", 42, 45], ["phospho-JNK", "GENE_OR_GENE_PRODUCT", 51, 62], ["Luciferase reporter vector", "GENE_OR_GENE_PRODUCT", 156, 182], ["pGL3", "GENE_OR_GENE_PRODUCT", 184, 188], ["COX-2", "GENE_OR_GENE_PRODUCT", 203, 208], ["ERK", "PROTEIN", 24, 27], ["phospho", "PROTEIN", 29, 36], ["ERK", "PROTEIN", 37, 40], ["JNK", "PROTEIN", 42, 45], ["phospho-JNK", "PROTEIN", 51, 62], ["Luciferase reporter vector", "DNA", 156, 182], ["pGL3", "DNA", 184, 188], ["COX-2 promoter region", "DNA", 203, 224], ["\u2212 891", "DNA", 226, 231], ["truncation mutants", "DNA", 242, 260], ["Antibodies", "TEST", 0, 10], ["ERK", "TEST", 24, 27], ["phospho", "TEST", 29, 36], ["ERK", "TEST", 37, 40], ["JNK", "TEST", 42, 45], ["phospho-JNK", "TEST", 51, 62], ["a COX-2 promoter region", "TREATMENT", 201, 224], ["its truncation mutants", "PROBLEM", 238, 260]]], ["A NS3 construct was created by RT-polymerase chain reaction (RT-PCR) amplification of the open reading frame from HCV 2b.", [["NS3", "ORGANISM", 2, 5], ["HCV 2b", "ORGANISM", 114, 120], ["NS3 construct", "DNA", 2, 15], ["open reading frame", "DNA", 90, 108], ["HCV 2b", "SPECIES", 114, 120], ["A NS3 construct", "TREATMENT", 0, 15], ["RT-polymerase chain reaction", "TREATMENT", 31, 59], ["RT-PCR", "TREATMENT", 61, 67], ["NS3 construct", "OBSERVATION", 2, 15]]], ["To create NS3-encoding vectors, the NS3 gene was amplified using the following primers: 5\u2032-AAAGGATC-CATGGCGCCCATCACG-3\u2032 (sense) 5\u2032-CCCGAATTCC-TAAGTGACGACCTCTAGGTC-3\u2032 (antisense), in which BamHI and EcoRI sites were introduced, respectively.", [["NS3", "GENE_OR_GENE_PRODUCT", 10, 13], ["NS3", "GENE_OR_GENE_PRODUCT", 36, 39], ["BamHI", "GENE_OR_GENE_PRODUCT", 188, 193], ["EcoRI", "GENE_OR_GENE_PRODUCT", 198, 203], ["NS3-encoding vectors", "DNA", 10, 30], ["NS3 gene", "DNA", 36, 44], ["antisense", "DNA", 167, 176], ["BamHI and EcoRI sites", "DNA", 188, 209], ["NS3-encoding vectors", "TREATMENT", 10, 30], ["the NS3 gene", "TREATMENT", 32, 44], ["AAAGGATC", "TEST", 91, 99], ["CATGGCGCCCATCACG-3\u2032 (sense)", "TREATMENT", 100, 127], ["CCCGAATTCC-TAAGTGACGACCTCTAGGTC", "TREATMENT", 131, 162], ["BamHI and EcoRI sites", "TREATMENT", 188, 209], ["NS3", "OBSERVATION", 10, 13]]], ["The polymerase chain reaction (PCR) product was cloned into BamHI and EcoRI sites of pCMV-tag2B to generate plasmid pCMV-NS3, in which NS3 protein was tagged by FLAG.", [["BamHI", "GENE_OR_GENE_PRODUCT", 60, 65], ["EcoRI", "GENE_OR_GENE_PRODUCT", 70, 75], ["pCMV-tag2B", "GENE_OR_GENE_PRODUCT", 85, 95], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 116, 124], ["NS3", "GENE_OR_GENE_PRODUCT", 135, 138], ["FLAG", "GENE_OR_GENE_PRODUCT", 161, 165], ["BamHI and EcoRI sites", "DNA", 60, 81], ["pCMV", "DNA", 85, 89], ["tag2B", "DNA", 90, 95], ["pCMV", "DNA", 116, 120], ["NS3", "PROTEIN", 121, 124], ["NS3 protein", "PROTEIN", 135, 146], ["FLAG", "PROTEIN", 161, 165], ["The polymerase chain reaction", "PROBLEM", 0, 29], ["pCMV", "TREATMENT", 85, 89], ["tag2B", "TREATMENT", 90, 95], ["plasmid pCMV", "TREATMENT", 108, 120], ["NS3", "TREATMENT", 121, 124], ["NS3 protein", "TEST", 135, 146]]], ["The resulting construct was confirmed by DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["DNA sequencing", "TEST", 41, 55]]], ["Mutants of ERK1 and ERK2 were gifts from Dr. Cobb (University of Texas Southwestern Medical Center) and a mutant of JNK was a gift from Dr. Karin (University of California at San Diego, San Diego, CA, USA).", [["ERK1", "GENE_OR_GENE_PRODUCT", 11, 15], ["ERK2", "GENE_OR_GENE_PRODUCT", 20, 24], ["JNK", "GENE_OR_GENE_PRODUCT", 116, 119], ["ERK1", "PROTEIN", 11, 15], ["ERK2", "PROTEIN", 20, 24], ["JNK", "PROTEIN", 116, 119], ["ERK1", "TEST", 11, 15], ["ERK1", "ANATOMY", 11, 15]]], ["PKC siRNA vectors were constructed by ligating the corresponding pairs of oligonucleotide to pSilencer 2.0 (Ambion, Inc., Augustin, TX, USA) based on the sequences described previously (Storz et al., 2004) .Cell cultureThe human hepatoma cell line HepG2 was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 \u03bcg/ml streptomycin sulfate at 37\u00b0C in a 5% CO 2 incubator.Transient transfection and luciferase reporter gene assaysCells were plated at density of 4.0 \u00d7 10 5 cells per 24-well plate or 6-well plate and grown to the confluence reaching about 80% at the time of transfection.", [["Cell", "ANATOMY", 207, 211], ["hepatoma cell line HepG2", "ANATOMY", 229, 253], ["fetal calf serum", "ANATOMY", 324, 340], ["Cells", "ANATOMY", 487, 492], ["cells", "ANATOMY", 530, 535], ["penicillin", "CHEMICAL", 351, 361], ["streptomycin sulfate", "CHEMICAL", 377, 397], ["penicillin", "CHEMICAL", 351, 361], ["streptomycin sulfate", "CHEMICAL", 377, 397], ["CO 2", "CHEMICAL", 414, 418], ["PKC", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cell", "CELL", 207, 211], ["human", "ORGANISM", 223, 228], ["hepatoma cell line HepG2", "CELL", 229, 253], ["fetal calf", "ORGANISM_SUBSTANCE", 324, 334], ["serum", "ORGANISM_SUBSTANCE", 335, 340], ["penicillin", "SIMPLE_CHEMICAL", 351, 361], ["streptomycin sulfate", "SIMPLE_CHEMICAL", 377, 397], ["luciferase", "GENE_OR_GENE_PRODUCT", 456, 466], ["Cells", "CELL", 487, 492], ["cells", "CELL", 530, 535], ["PKC siRNA vectors", "DNA", 0, 17], ["human hepatoma cell line HepG2", "CELL_LINE", 223, 253], ["luciferase reporter gene", "DNA", 456, 480], ["human", "SPECIES", 223, 228], ["calf", "SPECIES", 330, 334], ["human", "SPECIES", 223, 228], ["PKC siRNA vectors", "TREATMENT", 0, 17], ["pSilencer", "TEST", 93, 102], ["TX", "TREATMENT", 132, 134], ["Cell culture", "TEST", 207, 219], ["The human hepatoma cell line HepG2", "TREATMENT", 219, 253], ["10% fetal calf serum", "TREATMENT", 320, 340], ["penicillin", "TREATMENT", 351, 361], ["streptomycin sulfate", "TREATMENT", 377, 397], ["Transient transfection and luciferase reporter gene assays", "PROBLEM", 429, 487], ["Cells", "TEST", 487, 492], ["density", "TEST", 508, 515], ["cells", "TEST", 530, 535], ["hepatoma", "ANATOMY", 229, 237], ["cell line", "OBSERVATION", 238, 247], ["transfection", "OBSERVATION", 439, 451], ["confluence", "OBSERVATION_MODIFIER", 587, 597], ["transfection", "OBSERVATION", 632, 644]]], ["Cells were co-transfected with 0.4 \u03bcg of plasmid pCMV-NS3 together with 0.2 \u03bcg plasmid containing luciferase reporter and 0.2 \u03bcg of the pCMV-\u03b2-galactosidase plasmid, using Sofast\u2122 transfection reagent (Xiamen Sunma Biotechnology Co. Ltd., China) according to the protocol provided by the manufacturer.", [["Cells", "ANATOMY", 0, 5], ["Sofast\u2122", "CHEMICAL", 172, 179], ["Cells", "CELL", 0, 5], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 49, 57], ["luciferase", "GENE_OR_GENE_PRODUCT", 98, 108], ["pCMV-\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 136, 156], ["Sofast\u2122", "SIMPLE_CHEMICAL", 172, 179], ["pCMV", "DNA", 49, 53], ["NS3", "DNA", 54, 57], ["0.2 \u03bcg plasmid", "DNA", 72, 86], ["luciferase reporter", "DNA", 98, 117], ["pCMV-\u03b2-galactosidase plasmid", "DNA", 136, 164], ["Cells", "TEST", 0, 5], ["plasmid pCMV", "TREATMENT", 41, 53], ["NS3", "TREATMENT", 54, 57], ["luciferase reporter", "TEST", 98, 117], ["the pCMV", "TEST", 132, 140], ["galactosidase plasmid", "TREATMENT", 143, 164], ["Sofast\u2122 transfection reagent", "TREATMENT", 172, 200]]], ["In all co-transfection experiments, appropriate vector DNA was used to ensure similar DNA concentrations in all conditions.", [["DNA", "CELLULAR_COMPONENT", 55, 58], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["vector DNA", "DNA", 48, 58], ["all co-transfection experiments", "TREATMENT", 3, 34], ["appropriate vector DNA", "TREATMENT", 36, 58], ["co-transfection experiments", "OBSERVATION", 7, 34]]], ["Twenty-four hours post-transfection, cells were serum-starved for another 24 h before being harvested.", [["cells", "ANATOMY", 37, 42], ["serum", "ANATOMY", 48, 53], ["cells", "CELL", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["serum", "TEST", 48, 53], ["harvested", "OBSERVATION", 92, 101]]], ["Harvested cells were lysed with luciferase assay cell culture lysis reagent (Promega, Madison, WI, USA).", [["cells", "ANATOMY", 10, 15], ["cell", "ANATOMY", 49, 53], ["cells", "CELL", 10, 15], ["luciferase", "GENE_OR_GENE_PRODUCT", 32, 42], ["cell", "CELL", 49, 53], ["luciferase", "PROTEIN", 32, 42], ["Harvested cells", "PROBLEM", 0, 15], ["luciferase assay", "TEST", 32, 48], ["lysis reagent", "TEST", 62, 75]]], ["Cell lysates and luciferase assay substrate (Promega) were mixed and light intensity was detected by the luminometer (Turner T20/20).", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "CELL", 0, 12], ["luciferase", "GENE_OR_GENE_PRODUCT", 17, 27], ["luciferase", "PROTEIN", 17, 27], ["Cell lysates", "TEST", 0, 12], ["luciferase assay substrate (Promega)", "TREATMENT", 17, 53], ["light intensity", "OBSERVATION_MODIFIER", 69, 84]]], ["Assays were performed in triplicate and expressed as means \u00b1 sd.", [["Assays", "TEST", 0, 6]]], ["All transfections included a \u03b2-galactosidase expression vector to serve as an internal control.Semiquantitative RT-PCR analysisTotal RNA was isolated using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed with oligo(dT) primer.", [["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 29, 44], ["\u03b2-galactosidase expression vector", "DNA", 29, 62], ["oligo(dT) primer", "DNA", 234, 250], ["All transfections", "TREATMENT", 0, 17], ["a \u03b2-galactosidase expression vector", "TREATMENT", 27, 62], ["an internal control", "TREATMENT", 75, 94], ["Semiquantitative RT-PCR analysisTotal RNA", "TEST", 95, 136], ["a TRIzol reagent", "TREATMENT", 156, 172], ["Invitrogen", "TREATMENT", 174, 184], ["oligo(dT) primer", "TREATMENT", 234, 250]]], ["PCR was performed in 25 \u03bcl reactions with the primer pairs (20 \u03bcM) described in Table 1 . \u03b2-Actin specific primers were run in all reactions as an internal control.", [["\u03b2-Actin", "GENE_OR_GENE_PRODUCT", 90, 97], ["primer pairs", "DNA", 46, 58], ["\u03b2-Actin specific primers", "DNA", 90, 114], ["PCR", "TEST", 0, 3], ["the primer pairs", "TEST", 42, 58], ["Actin specific primers", "TREATMENT", 92, 114], ["an internal control", "TREATMENT", 144, 163]]], ["The PCR products were amplified for 28 cycles.", [["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16]]], ["The selected cycle number was chosen to stop the PCR reaction during its log phase to ensure availability of all reagents.", [["the PCR reaction", "PROBLEM", 45, 61], ["all reagents", "TREATMENT", 109, 121]]], ["Additional RT-PCR related information is summarized in Table 1 .", [["Additional RT-PCR", "TEST", 0, 17]]], ["PCR products were analyzed by electrophoresis on 1% agarose gel containing ethidium bromide.Western blot analysisWhole-cell lysates were prepared by lysing HepG2 with radioimmune precipitation buffer (50 mM Tris, pH7.5, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1 mM sodium formate, 1 mM phenylmethylsulfonyl fluoride, and 10% cocktail protease inhibitor [Roche]).", [["analysisWhole-cell lysates", "ANATOMY", 105, 131], ["HepG2", "ANATOMY", 156, 161], ["ethidium bromide", "CHEMICAL", 75, 91], ["NaCl", "CHEMICAL", 227, 231], ["Triton X-100", "CHEMICAL", 236, 248], ["sodium deoxycholate", "CHEMICAL", 253, 272], ["sodium dodecyl sulfate", "CHEMICAL", 279, 301], ["sodium formate", "CHEMICAL", 314, 328], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 335, 364], ["ethidium bromide", "CHEMICAL", 75, 91], ["Tris", "CHEMICAL", 207, 211], ["NaCl", "CHEMICAL", 227, 231], ["sodium deoxycholate", "CHEMICAL", 253, 272], ["sodium dodecyl sulfate", "CHEMICAL", 279, 301], ["SDS", "CHEMICAL", 303, 306], ["sodium formate", "CHEMICAL", 314, 328], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 335, 364], ["agarose", "SIMPLE_CHEMICAL", 52, 59], ["ethidium bromide", "SIMPLE_CHEMICAL", 75, 91], ["cell lysates", "ORGANISM_SUBSTANCE", 119, 131], ["HepG2", "CELL", 156, 161], ["Triton X-100", "SIMPLE_CHEMICAL", 236, 248], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 253, 272], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 279, 301], ["sodium formate", "SIMPLE_CHEMICAL", 314, 328], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 335, 364], ["PCR products", "TREATMENT", 0, 12], ["electrophoresis", "TEST", 30, 45], ["1% agarose gel", "TREATMENT", 49, 63], ["ethidium bromide", "TREATMENT", 75, 91], ["Western blot analysisWhole-cell lysates", "TREATMENT", 92, 131], ["radioimmune precipitation buffer", "TREATMENT", 167, 199], ["mM NaCl", "TREATMENT", 224, 231], ["sodium deoxycholate", "TREATMENT", 253, 272], ["sodium dodecyl sulfate", "TREATMENT", 279, 301], ["1 mM sodium formate", "TREATMENT", 309, 328], ["1 mM phenylmethylsulfonyl fluoride", "TREATMENT", 330, 364]]], ["Cells were washed with ice-cold PBS, collected by centrifugation, and pellets were resuspended in RIPA buffer described above for 30 min on ice and vortexed for 10 s.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ice-cold PBS", "TREATMENT", 23, 35], ["pellets", "TREATMENT", 70, 77], ["RIPA buffer", "TREATMENT", 98, 109]]], ["Lysates were centrifuged at 12,000 rpm for 10 min.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Lysates", "TEST", 0, 7]]], ["The supernatants were boiled for 5 min in SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer.", [["supernatants", "ANATOMY", 4, 16], ["SDS-polyacrylamide gel", "CHEMICAL", 42, 64], ["SDS", "CHEMICAL", 42, 45], ["polyacrylamide", "CHEMICAL", 46, 60], ["The supernatants", "TREATMENT", 0, 16], ["polyacrylamide gel electrophoresis", "TREATMENT", 46, 80]]], ["One hundred micrograms of cultured cell lysates was subjected to 12% SDS-PAGE gel.", [["cell lysates", "ANATOMY", 35, 47], ["cell lysates", "CELL", 35, 47], ["cultured cell lysates", "TEST", 26, 47]]], ["Gels were electroblotted onto a nitrocellulose membrane in 25 mM Tris, 192 mM glycine, and 20% methanol by electrophoresis.", [["membrane", "ANATOMY", 47, 55], ["glycine", "CHEMICAL", 78, 85], ["nitrocellulose", "CHEMICAL", 32, 46], ["Tris", "CHEMICAL", 65, 69], ["glycine", "CHEMICAL", 78, 85], ["methanol", "CHEMICAL", 95, 103], ["Gels", "SIMPLE_CHEMICAL", 0, 4], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["glycine", "SIMPLE_CHEMICAL", 78, 85], ["methanol", "SIMPLE_CHEMICAL", 95, 103], ["a nitrocellulose membrane", "TREATMENT", 30, 55], ["mM glycine", "TEST", 75, 85], ["20% methanol", "TREATMENT", 91, 103]]], ["Nonspecific IgGs were blocked with 5% nonfat dried milk before being probed with antibodies used inIntracellular PGE2 measurementsSubconfluent HepG2 cells were transiently transfected various amounts of pCMV-NS3.", [["milk", "ANATOMY", 51, 55], ["HepG2 cells", "ANATOMY", 143, 154], ["PGE2", "CHEMICAL", 113, 117], ["PGE2", "CHEMICAL", 113, 117], ["IgGs", "GENE_OR_GENE_PRODUCT", 12, 16], ["milk", "ORGANISM_SUBSTANCE", 51, 55], ["HepG2 cells", "CELL", 143, 154], ["pCMV-NS3", "GENE_OR_GENE_PRODUCT", 203, 211], ["IgGs", "PROTEIN", 12, 16], ["antibodies", "PROTEIN", 81, 91], ["Subconfluent HepG2 cells", "CELL_LINE", 130, 154], ["pCMV", "PROTEIN", 203, 207], ["NS3", "PROTEIN", 208, 211], ["Nonspecific IgGs", "PROBLEM", 0, 16], ["5% nonfat dried milk", "TREATMENT", 35, 55], ["antibodies", "TREATMENT", 81, 91], ["inIntracellular PGE2 measurements", "TEST", 97, 130], ["Subconfluent HepG2 cells", "TEST", 130, 154], ["pCMV", "TEST", 203, 207], ["NS3", "PROBLEM", 208, 211], ["IgGs", "OBSERVATION", 12, 16], ["HepG2 cells", "OBSERVATION", 143, 154]]], ["Forty-eight hours posttransfection, culture cells were washed thoroughly with cold phosphate-buffered saline, pH7.4, collected by centrifugation, and pellets were resuspended in PBS pH7.4 containing 0.01% Triton X-100, 0.01% EDTA, and 10% cocktail protease inhibitor (Roche).", [["cells", "ANATOMY", 44, 49], ["phosphate", "CHEMICAL", 83, 92], ["Triton X-100", "CHEMICAL", 205, 217], ["EDTA", "CHEMICAL", 225, 229], ["phosphate", "CHEMICAL", 83, 92], ["EDTA", "CHEMICAL", 225, 229], ["culture cells", "CELL", 36, 49], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 83, 108], ["Triton X-100", "SIMPLE_CHEMICAL", 205, 217], ["EDTA", "SIMPLE_CHEMICAL", 225, 229], ["culture cells", "CELL_LINE", 36, 49], ["culture cells", "TEST", 36, 49], ["cold phosphate", "TREATMENT", 78, 92], ["buffered saline", "TREATMENT", 93, 108], ["pellets", "TREATMENT", 150, 157], ["10% cocktail protease inhibitor", "TREATMENT", 235, 266]]], ["Cell membranes were broken to release intracellular PGE2.", [["Cell membranes", "ANATOMY", 0, 14], ["intracellular", "ANATOMY", 38, 51], ["PGE2", "CHEMICAL", 52, 56], ["PGE2", "CHEMICAL", 52, 56], ["Cell membranes", "CELLULAR_COMPONENT", 0, 14], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["PGE2", "SIMPLE_CHEMICAL", 52, 56], ["Cell membranes", "PROBLEM", 0, 14], ["intracellular PGE2", "TREATMENT", 38, 56]]], ["PGE2 levels were then assayed with the Biotrak Prostaglandin E2 Enzyme Immunoassay system (R&D Systems) according to the manufacturer's protocol.Statistical analysisAll experiments were reproducible and were carried out in duplicate or quadruplicate.", [["PGE2", "CHEMICAL", 0, 4], ["Prostaglandin E2", "CHEMICAL", 47, 63], ["PGE2", "CHEMICAL", 0, 4], ["Prostaglandin E2", "CHEMICAL", 47, 63], ["PGE2", "SIMPLE_CHEMICAL", 0, 4], ["PGE2 levels", "TEST", 0, 11], ["the Biotrak Prostaglandin", "TREATMENT", 35, 60], ["the manufacturer's protocol", "TREATMENT", 117, 144], ["Statistical analysis", "TEST", 145, 165]]], ["Student's t test for paired samples was used to determine statistical significance.", [["Student's t test", "TEST", 0, 16], ["paired samples", "TEST", 21, 35]]], ["In all cases where comparative data are presented, the autoradiographic images originated from the same exposure of the same gel: in some cases, for clarity of presentation, lanes containing samples not germane to this study were removed.", [["samples", "ANATOMY", 191, 198], ["comparative data", "TEST", 19, 35], ["the autoradiographic images", "TEST", 51, 78], ["this study", "TEST", 214, 224]]]], "d10bd161e943c8635e7f17c4cb1818f872796c4c": [["In that paper we related the computational power of fragments of programming languages to complexity classes defined by imposing time and space constraints on Turing machines.", [["Turing machines", "TREATMENT", 159, 174]]], ["E.g., FP is defined as the class of functions computable in polynomial time on a deterministic Turing machine.", [["a deterministic Turing machine", "TREATMENT", 79, 109]]], ["The definition puts constraints on the resources available to the Turing machines, but no constraints on the algorithms available to them.", [["the algorithms", "TEST", 105, 119]]], ["A Turing machine may compute a function in the class by any imaginable algorithm as long as it works in polynomial time.", [["Turing machine", "TREATMENT", 2, 16]]], ["A seminal example is Bellatoni and Cook's [2] characterization of FP.", [["FP", "PROBLEM", 66, 68], ["seminal", "ANATOMY", 2, 9]]], ["This language consists of a few initial functions and two definition schemes (safe composition and safe primitive recursion) which allow us to define new functions.", [["safe primitive recursion", "TREATMENT", 99, 123]]], ["It turns out that a function can be computed by a program written in Bellantoni & Cook's language if and only if it belongs to the complexity class FP.IntroductionThere is an obvious link between implicit computational complexity and reversible computing.", [["computational complexity", "OBSERVATION", 205, 229], ["reversible", "OBSERVATION_MODIFIER", 234, 244]]], ["A programming language based on natural reversible operations will impose restrictions on the way algorithms can be formulated, and thus, also restrictions on the computational resources needed to execute algorithms.", [["A programming language", "PROBLEM", 0, 22], ["natural reversible operations", "TREATMENT", 32, 61]]], ["Hence, the following question knocks at the door: Will it be possible find reversible programming languages that capture some of the standard complexity classes?", [["reversible programming languages", "PROBLEM", 75, 107]]], ["A few small modifications of this language yield a reversible language that captures the very well-known complexity class P.IntroductionOur languages are based on a couple of naturally reversible operations.", [["A few small modifications", "PROBLEM", 0, 25], ["a reversible language", "PROBLEM", 49, 70], ["naturally reversible operations", "TREATMENT", 175, 206], ["few", "OBSERVATION_MODIFIER", 2, 5], ["small", "OBSERVATION_MODIFIER", 6, 11], ["modifications", "OBSERVATION", 12, 25], ["reversible language", "OBSERVATION", 51, 70], ["reversible", "OBSERVATION_MODIFIER", 185, 195], ["operations", "OBSERVATION", 196, 206]]], ["To increase, or decrease, a natural number by 1 modulo a base b is such an operation: . . .", [["an operation", "TREATMENT", 72, 84], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["decrease", "OBSERVATION_MODIFIER", 16, 24]]], ["The successor of b \u2212 1 becomes 0, and then b \u2212 1 becomes the predecessor of 0.", [["b \u2212 1", "GENE_OR_GENE_PRODUCT", 17, 22]]], ["To move an element from the top of one stack to the top of another stack is another such operation as we can simply move the element back to the stack it came from.", [["another such operation", "TREATMENT", 76, 98]]], ["We will give priority to readability over technical accuracy, but still this is a fairly technical paper, and we will assume that the reader is faintly acquainted with Turing machines and basic complexity theory (standard textbooks are Arora and Barac [1] , Jones [7] and Sipser [16] ).IntroductionImplicit computational complexity theory is definitely a broader and richer research area than our short discussion above may indicate.", [["technical accuracy", "TEST", 42, 60], ["Turing machines", "TREATMENT", 168, 183]]], ["More on the subject can be found in Dal Lago [3] .Reversible Bottomless Stack (RBS) ProgramsAn infinite sequence of natural numbers s 1 , s 2 , s 3 , . . . is a bottomless stack if there exists k such that s i = 0 for all i > k.", [["Reversible Bottomless Stack (RBS)", "PROBLEM", 50, 83], ["natural numbers s", "TEST", 116, 133]]], ["We use x 1 , . . . , x n , 0 * ] to denote the bottomless stack s 1 , s 2 , s 3 , . . . where s i = x i when i \u2264 n, and s i = 0 when i > n.", [["stack s", "TEST", 58, 65]]], ["The syntax of the language RBS.", [["RBS", "DNA", 27, 30], ["language RBS", "OBSERVATION", 18, 30]]], ["The variable X in the loop command is not allowed to occur in the loop's body.Reversible Bottomless Stack (RBS) ProgramsThe syntax of the imperative programming language RBS is given in Fig. 1 .", [["body", "ANATOMY", 73, 77], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["variable X", "DNA", 4, 14], ["RBS", "DNA", 170, 173], ["variable", "OBSERVATION_MODIFIER", 4, 12]]], ["We will now explain the semantics of RBS.Reversible Bottomless Stack (RBS) ProgramsAn RBS program manipulates bottomless stacks, and each program variable holds such a stack.", [["RBS", "DNA", 37, 40], ["Reversible Bottomless Stack (RBS", "PROBLEM", 41, 73]]], ["When the execution of the program starts, the input m will be stored at the top of the stack hold by X 1 , that is, we have X 1 = m, 0 * ].", [["X 1", "PROTEIN", 101, 104]]], ["The execution base b is kept fixed during the entire execution.Reversible Bottomless Stack (RBS) ProgramsLet X and Y be program variables.", [["base", "OBSERVATION_MODIFIER", 14, 18]]], ["The command (X to Y) pops off the top element of the stack held by X and pushes it onto the stack held by Y, that isReversible Bottomless Stack (RBS) ProgramsThe command X + increases the the top element of the stack held by X by 1 (mod b), that isReversible Bottomless Stack (RBS) ProgramsThe command X \u2212 decreases the the top element of the stack held by X by 1 (mod b), that isReversible Bottomless Stack (RBS) ProgramsObserve that we have The semantics of the command C 1 ; C 2 is as expected.", [["C 2", "GENE_OR_GENE_PRODUCT", 478, 481], ["top element", "DNA", 34, 45], ["command X", "DNA", 162, 171], ["top element", "DNA", 192, 203], ["top element", "DNA", 324, 335]]], ["The command loop X { C } executes the command C repeatedly k times in a row where k is the top element of the stack held by X. Note that the variable X is not allowed to occur in C and, moreover, the command loop X { C } will not modify the stack held by X.Reversible Bottomless Stack (RBS) ProgramsLet C 2 be the program loop X 1 { X + 2 }; X + 2 ; (X 2 to X 1 ).", [["variable X", "PROTEIN", 141, 151], ["the stack", "TREATMENT", 237, 246]]], ["We haveReversible Bottomless Stack (RBS) Programssince the execution base is 18.", [["base", "ANATOMY_MODIFIER", 69, 73]]], ["All numbers stored on stacks during an execution will be strictly less than the execution base, and thus, less than or equal to max(m, 1) where m is the input.Reversible Bottomless Stack (RBS) ProgramsIntuitively, it should be clear that RBS programs are reversible in a very strong sense.", [["Reversible Bottomless Stack (RBS)", "PROBLEM", 159, 192]]], ["RBS is an inherently reversible programming language in the terminology of Matos [14] .", [["an inherently reversible programming language", "PROBLEM", 7, 52], ["inherently", "OBSERVATION_MODIFIER", 10, 20], ["reversible", "OBSERVATION_MODIFIER", 21, 31]]], ["The next definition and the following theorem will be a step in that direction.Definition 2.We define reverse command of C, written C R , inductively over the structure C:Definition 2.Theorem 3.", [["C R", "GENE_OR_GENE_PRODUCT", 132, 135]]], ["Let C be a program, and let X 1 , . . . , X n be the variables occurring in C. Furthermore, let m be any natural number.", [["Let C", "GENE_OR_GENE_PRODUCT", 0, 5], ["let X 1", "GENE_OR_GENE_PRODUCT", 24, 31], ["let m", "GENE_OR_GENE_PRODUCT", 92, 97]]], ["We will offer a proof in the next section.", [["the next section", "TREATMENT", 25, 41]]], ["1 An RBS program C decides the problem A if C accepts all m that belong to A and rejects all m that do not belong to A. Let S denote class of problems decidable by an RBS program.Program:Let A be the set of even numbers.", [["Let A", "GENE_OR_GENE_PRODUCT", 187, 192]]], ["We have not defined S by imposing resource bounds on Turing machines or any other machine models.", [["Turing machines", "TREATMENT", 53, 68]]], ["What can we say about the computational complexity of the problems we find in S?", [["the problems", "PROBLEM", 54, 66]]], ["First, we need some terminology and notation: We will say that a (bottomless) stack is a b-stack if every number stored on the stack is strictly smaller than b.", [["a b-stack", "TREATMENT", 87, 96]]], ["Furthermore, we will use V(C) to denote the set of program variables occurring in the command C, and for any positive integer m and any command C, we define the command C m by C 1 \u2261 C and C m+1 \u2261 C m ; C. Now, assume that C is an RBS command with V(C) \u2286 {X 1 , . . . , X n }.", [["C 1 \u2261 C", "CHEMICAL", 176, 183], ["C", "CHEMICAL", 188, 189], ["C 1 \u2261 C", "SIMPLE_CHEMICAL", 176, 183], ["C", "SIMPLE_CHEMICAL", 222, 223], ["any positive integer m", "PROBLEM", 105, 127]]], ["Furthermore, assume that C is executed in base b and that \u03b1 1 , . . . , \u03b1 n , \u03b2 1 , . . . , \u03b2 n are b-stacks.", [["\u03b1 1", "GENE_OR_GENE_PRODUCT", 58, 61], ["b-stacks", "OBSERVATION", 100, 108]]], ["We leave the details to the reader and proceed with the inductive cases.The Proof of Theorem 3Then there exist b-stacks \u03b3 1 , . . . , \u03b3 n such thatThe Proof of Theorem 3We apply our induction hypothesis both to C 1 and to C 2 and concludeThe Proof of Theorem 3It follows thatThe Proof of Theorem 3Finally, as Definition 2 states that (The Proof of Theorem 3This completes the proof of case (iv).The Proof of Theorem 3and let m be the top element of the stack \u03b1 i .The Proof of Theorem 3as the command C 0 will not be executed at all.", [["C 1", "GENE_OR_GENE_PRODUCT", 211, 214], ["C 2", "GENE_OR_GENE_PRODUCT", 222, 225], ["let m", "GENE_OR_GENE_PRODUCT", 421, 426], ["C 1", "PROTEIN", 211, 214], ["our induction hypothesis", "TREATMENT", 178, 202], ["case (iv)", "TREATMENT", 385, 394]]], ["Then we have C m 0 \u2261 C 0 , and an application of our main induction hypothesis to C 0 yields ( \u2020).", [["C 0", "CHEMICAL", 82, 85], ["C 0", "SIMPLE_CHEMICAL", 82, 85]]], ["Let m > 1.", [["Let m", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["The command X := k can then be simulated by the program (X to Z); X + ; X + ; . . .", [["X +", "SIMPLE_CHEMICAL", 72, 75]]], ["X + increase k times where Z is an auxiliary variable (Z works as a trash bin).", [["increase", "OBSERVATION_MODIFIER", 4, 12], ["k times", "OBSERVATION_MODIFIER", 13, 20]]], ["The command X := Y can be simulated by the programLOOP \u2212 Programswhere Z is an auxiliary variable (Z works as a trash bin).", [["command X", "DNA", 4, 13]]], ["Furthermore, the command pred(X) can be simulated by a program that uses auxiliary variables Y and Z (which represent natural numbers) and the simulations of the assignment statements given above:LOOP \u2212 ProgramsThis shows how RBS programs can simulate all the primitive LOOP \u2212 commands.", [["LOOP", "DNA", 270, 274]]], ["It is easy to see thatLOOP \u2212 ProgramsHence, any LOOP \u2212 program can be simulated by an RBS program given that the input is sufficiently large.", [["LOOP \u2212 ProgramsHence", "TREATMENT", 22, 42], ["any LOOP \u2212 program", "TREATMENT", 44, 62], ["an RBS program", "TREATMENT", 83, 97], ["large", "OBSERVATION_MODIFIER", 135, 140]]], ["On small inputs simulations might fail since the simulation of the assignment X := k only works if the execution base is strictly greater than k.LOOP \u2212 ProgramsThe LOOP \u2212 language turns out to be more expressive than one might expect at a first glance, and all sorts of conditional statements and if-then constructions are available in the language.", [["X", "DNA", 78, 79], ["LOOP", "DNA", 164, 168], ["small inputs simulations", "TREATMENT", 3, 27], ["small", "OBSERVATION_MODIFIER", 3, 8], ["LOOP", "OBSERVATION_MODIFIER", 164, 168]]], ["As an example, let us see how we can implement the construction if X = Y then C 1 else C 2 .LOOP \u2212 ProgramsWe will need some axillary variables X , Y , Z, U which do not occur in any of the commands C 1 and C 2 .", [["C 2", "GENE_OR_GENE_PRODUCT", 207, 210], ["some axillary variables", "PROBLEM", 120, 143], ["axillary", "ANATOMY", 125, 133]]], ["First we execute the programLOOP \u2212 ProgramsThis program sets both X and Y to 0 if X and Y hold the same number.", [["programLOOP", "DNA", 21, 32], ["X and Y to 0 if X and Y", "DNA", 66, 89]]], ["If X and Y hold different numbers, one of the two variables X , Y will be set to a number strictly greater than 0.", [["X and Y", "DNA", 3, 10]]], ["If X and Y hold different numbers, C 2 will be executed exactly once (and C 1 will not be executed at all).", [["X and Y", "DNA", 3, 10]]], ["The reader should note that this implementation of if-then-else construction does not contain any assignments of the form X := k where k > 1.LOOP \u2212 ProgramsIt is proved in Kristiansen [8] that LOOP \u2212 captures the complexity class LINSPACE, that is, the set of problems decidable in space O(n) on a deterministic Turing machine (n is the length of the input).", [["k", "TEST", 135, 136], ["LOOP \u2212 ProgramsIt", "TREATMENT", 141, 158], ["a deterministic Turing machine", "TREATMENT", 296, 326]]], ["The equality LINSPACE ? = ETIME is one of the many notorious open problems of complexity theory.", [["notorious", "OBSERVATION_MODIFIER", 51, 60]]], ["The general opinion is that the equality does not hold.RBS Programs that Simulates Time-Bounded Turing MachinesWe have seen that RBS programs (nearly) can simulate LOOP \u2212 programs.", [["LOOP \u2212 programs", "TREATMENT", 164, 179]]], ["Such a program may be of the form initiate the tape with the input m ; Y 1 := the input m ; Y 2 := the input m ; . . . ; Y k := the input m ;RBS Programs that Simulates Time-Bounded Turing MachinesWe represent the symbols in M 's alphabet a 1 , . . . a A by the numbers 1, . . . , A and M 's states q 1 , . . . q Q by the numbers 1, . . . , Q. We use two stacks to hold the content of the tape, and we use registers STATE and SCAN to hold respectively the current state and the scanned cell.", [["cell", "ANATOMY", 486, 490], ["cell", "CELL", 486, 490], ["SCAN", "PROTEIN", 426, 430], ["Y k", "TEST", 121, 124], ["the input m", "TEST", 128, 139], ["RBS Programs", "TEST", 141, 153], ["the tape", "TREATMENT", 385, 393], ["SCAN", "TEST", 426, 430]]], ["Each T s will take care of a transition a i , q k , a j , D, q and be of the form if SCAN = i and STATE = k then { SCAN := j; . . . push and pop . . . ; STATE := }.RBS Programs that Simulates Time-Bounded Turing MachinesWe are left with a minor problem: This will not work for small inputs.", [["SCAN", "TEST", 85, 89], ["SCAN", "TEST", 115, 119], ["left", "ANATOMY_MODIFIER", 227, 231]]], ["An RBS program will not be able to simulate (in any reasonable sense of the word) an arbitrary 2 k|m| time Turing machine M on small inputs, but still there will be an RBS program that decides the same problem as M .RBS Programs that Simulates Time-Bounded Turing MachinesWe have seen that it suffices to assign the constants 0 and 1 to variables in order to implement the if-then-else construction in LOOP \u2212 .", [["LOOP", "SIMPLE_CHEMICAL", 402, 406]]], ["This entails that the if-then-else construction will work on small inputs as the base of execution always will be strictly greater than 1.", [["small inputs", "TREATMENT", 61, 73]]], ["Hence, if the problem A is decided by a 2 k|m| time Turing machine M , there will also be an RBS program that decides A. This program will be of the formDefinition 5.Let |m| denote the number of digits required to write the natural number m in binary notation.", [["Let |m", "GENE_OR_GENE_PRODUCT", 166, 172]]], ["For any natural number k, let ETIME k be the class of problems decidable in time O(2 k|m| ) on a deterministic Turing machine.", [["a deterministic Turing machine", "TREATMENT", 95, 125]]], ["The proof of the inclusion S \u2286 ETIME should be straightforward to anyone experienced with Turing machines.", [["Turing machines", "TREATMENT", 90, 105]]], ["Thus, there exist constants k 0 , k 1 (not depending on m) such that k 0 (m+1) k1 bounds the number of primitive commands executed by C on input m.", [["constants k", "TEST", 18, 29], ["k", "TEST", 34, 35], ["k", "TEST", 69, 70]]], ["A Turing machine can simulate the execution of C on input m with polynomial overhead.", [["Turing machine", "TREATMENT", 2, 16]]], ["Thus there exist constants k 2 , k 3 such that k 2 (m+1) k3 bounds the number of steps a Turing machine needs to decide if m is in A. There exists k such that k 2 (m + 1) k3 < 2 k|m| .", [["k", "TEST", 27, 28], ["k", "TEST", 33, 34], ["k", "TEST", 47, 48], ["a Turing machine", "TREATMENT", 87, 103], ["k", "TEST", 147, 148], ["k", "TEST", 159, 160]]], ["Then there is a O(2 k|m| ) time Turing machine M that decides A. Now, M will run in time 2 k0|m| when k 0 is sufficiently large.", [["large", "OBSERVATION_MODIFIER", 122, 127]]], ["Hence, A \u2208 S. This proves the inclusion ETIME \u2286 S.A Characterization of PWould it not be nice if we could find a reversible language that captures a complexity class that is a bit more attractive than ETIME?", [["a reversible language", "PROBLEM", 111, 132]]], ["Now, P is for a number of reasons, which the reader might be aware of, one of most popular and important complexity classes.", [["P", "DNA", 5, 6]]], ["Luckily, it turns out that a few modifications of RBS yield a characterization of P.A Characterization of PFirst we modify the way RBS programs receive input.", [["RBS", "DNA", 50, 53]]], ["Any alphabet that contains at least two symbols will do and, for convenience, we will stick to the alphabet {a, b}.", [["{a", "GENE_OR_GENE_PRODUCT", 108, 110]]], ["The base of execution will at program start be set to the length of the input.", [["base", "OBSERVATION_MODIFIER", 4, 8]]], ["All commands available in the original version of RBS will be available in the new version.", [["RBS", "DNA", 50, 53]]], ["Moreover, all variables including X 1 , the variable that used to import the input, hold the zero stack when the execution of a program starts.A Characterization of P(* X3 is a pointer into the input X 1 holds the zero stack top element of X1 is 1 move pointer to the right end of loop ] and rejects by terminating with X1 = 1, 0 * ].A Characterization of PWe still have a reversible language.", [["X 1", "GENE_OR_GENE_PRODUCT", 34, 37], ["X 1", "DNA", 34, 37], ["P(* X3", "DNA", 165, 171], ["input X 1", "DNA", 194, 203], ["zero stack top element", "DNA", 214, 236], ["X1", "DNA", 240, 242], ["the zero stack", "TREATMENT", 89, 103], ["a reversible language", "PROBLEM", 371, 392], ["right", "ANATOMY_MODIFIER", 268, 273], ["reversible", "OBSERVATION_MODIFIER", 373, 383], ["language", "OBSERVATION", 384, 392]]], ["The two new commands are reversible.", [["two", "OBSERVATION_MODIFIER", 4, 7], ["new", "OBSERVATION_MODIFIER", 8, 11], ["reversible", "OBSERVATION_MODIFIER", 25, 35]]], ["The variable X j is not allowed to occur in C and will consequently not be modified by C. Thus, for x \u2208 {a, b}, we may extend Definition 2 byA Characterization of Pand Theorem 3 will still hold.A Characterization of PTo avoid confusion we will use RBS to denote our new version of RBS.", [["confusion", "DISEASE", 226, 235], ["X j", "DNA", 13, 16], ["RBS", "DNA", 248, 251], ["RBS", "DNA", 281, 284], ["confusion", "PROBLEM", 226, 235], ["RBS", "TREATMENT", 248, 251], ["variable X j", "OBSERVATION_MODIFIER", 4, 16]]], ["We require that the input to an RBS program is of length at least 2 (so we exclude the empty string and the one-symbol strings a and b).", [["RBS", "DNA", 32, 35]]], ["This is of course a bit artificial, but it seems to be the most convenient way to deal with a few annoying problems of technical nature.", [["a few annoying problems", "PROBLEM", 92, 115]]], ["Accordingly, we also require that every string in a language (see the definition below) is of length at least 2.Definition 7.A language L is a set of strings over the alphabet {a, b}, moreover, every string in L is of length at least 2.Definition 7.An RBS program C decides the language L if C accepts every string that belongs to L and rejects every string that does not belong to L. Let S be class of languages decidable by an RBS' program.Definition 7.Let |w| denote the length of the string w.", [["{a", "GENE_OR_GENE_PRODUCT", 176, 178], ["Let |w", "GENE_OR_GENE_PRODUCT", 455, 461]]], ["For any natural number k, let P k be the class of languages decidable in time O(|w| k ) on a deterministic Turing machine.", [["P k", "DNA", 30, 33], ["a deterministic Turing machine", "TREATMENT", 91, 121]]], ["Let P = i\u2208N P i .", [["N P i", "DNA", 10, 15]]], ["Just recall that the execution base of an RBS program is set to the length of the input.", [["RBS", "DNA", 42, 45]]], ["Hence, the number of primitive instructions executed by an RBS program will be bounded by |w| k where |w| is the length of the input w and k is a sufficiently large constant, and moreover, an RBS program of the formSome Final RemarksWe have argued that there is a link between implicit computational complexity theory and the theory of reversible computation, and we have showed that both ETIME and P can be captured by inherently reversible programming languages.", [["P", "DNA", 399, 400]]], ["Implicit characterizations by reversible formalisms might yield some new insights in this respect.", [["reversible formalisms", "PROBLEM", 30, 51], ["reversible formalisms", "OBSERVATION", 30, 51], ["some", "OBSERVATION_MODIFIER", 64, 68], ["new", "OBSERVATION_MODIFIER", 69, 72]]], ["It is beyond the scope of this paper to discuss or interpret the theorems proved above any further, but one might start to wonder how different aspects of reversibility relate to time complexity, space complexity and nondeterminism.Some Final RemarksThe author is not aware of any work in reversible computing that is closely related to the work presented above, but some work of Matos [14] is at least faintly related.", [["space complexity", "PROBLEM", 196, 212], ["space complexity", "OBSERVATION", 196, 212]]], ["Matos characterizes the primitive recursive functions by an inherently reversible loop-language.", [["primitive", "OBSERVATION_MODIFIER", 24, 33], ["recursive functions", "OBSERVATION", 34, 53], ["reversible loop", "OBSERVATION", 71, 86]]], ["2 Paolini et al. [15] do also characterize the primitive recursive functions by a reversible formalism.", [["a reversible formalism", "PROBLEM", 80, 102], ["reversible formalism", "OBSERVATION", 82, 102]]], ["Their work is of a recursiontheoretic nature and has a different flavor than ours, but it is possible that such studies might lead to interesting characterizations of complexity classes.Some Final RemarksWe finish off this paper by suggesting a small research project.", [["such studies", "TEST", 107, 119], ["small", "OBSERVATION_MODIFIER", 245, 250]]], ["It should be possible to extend RBS to an inherently reversible higher-order language.", [["RBS", "DNA", 32, 35], ["reversible", "OBSERVATION_MODIFIER", 53, 63], ["higher", "OBSERVATION", 64, 70]]], ["Second-order programs will manipulate stacks of stacks, third-order programs will manipulate stacks of stacks of stacks, and so on.", [["third-order programs", "TREATMENT", 56, 76]]], ["By the same token, RBS will induce a hierarchy: the class of languages decidable by a first-order RBS program, the class of languages decidable by a second-order RBS program, and so on.", [["RBS", "DNA", 19, 22]]]], "edd7390f2045b363c6bf868b3018c84ca2ee24b1": [["Training Versus ServiceThe novel coronavirus (SARS CoV-2) pandemic has introduced an unprecedented demand of health professionals across the nation.", [["coronavirus", "ORGANISM", 33, 44], ["SARS CoV-2", "ORGANISM", 46, 56], ["The novel coronavirus", "PROBLEM", 23, 44], ["pandemic", "PROBLEM", 58, 66], ["coronavirus", "OBSERVATION", 33, 44]]], ["To urgently meet patient care needs, some institutions have offered the option of early graduation to medical students as well as rapid credentialing of house staff into attending roles.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["Although education is often used to justify deployment of trainees to the frontlines, it is also important to consider risks of exposure to a contagion and the possibility of becoming vectors for the virus.", [["the virus", "PROBLEM", 196, 205]]], ["Other specialty organizations such as the American Heart Association (AHA) explicitly recommend adequately protecting trainees on the frontlines or not deploying them into these roles at all.", [["the frontlines", "TREATMENT", 130, 144]]], ["Likewise, as outlined by the AMA guiding principles, trainee vacations should be protected apart from COVID-19 related illness.", [["illness", "DISEASE", 119, 126], ["trainee vacations", "TREATMENT", 53, 70]]], ["It is important to approach these discussions empathically and acknowledge the personal, physical, and economic stresses that disproportionately affect trainees as a result of this pandemic, and to listen and act upon trainee concerns when possible.Training Versus ServiceThe AMA guiding principles for trainees can be found at this link:Training Versus Service\u2022 https://www.ama-assn.org/delivering-care/public-health/guiding-principlesprotect-resident-fellow-physicians-respondingDiminished volume of training procedures and ambulatory visitsBecause the volume of procedures and ambulatory visits have been markedly reduced for most trainees, many have expressed concerns over whether they will be viewed as \"ready\" to practice independently after completion of their fellowship.", [["trainees", "TREATMENT", 303, 311], ["training procedures", "TREATMENT", 502, 521]]], ["As noted in their shared document, \"Joint Principles: Physician Training during the COVID-19 Pandemic Statement\" 2 :Diminished volume of training procedures and ambulatory visits\"The ABMS and the ACGME endorse and rely upon the authority and judgement of clinical competency committees (CCCs) and training program directors (PDs) to determine readiness for unsupervised practice, and to inform specialty board decisions regarding eligibility for initial board certification.", [["training procedures", "TREATMENT", 137, 156], ["Joint", "ANATOMY", 36, 41]]], ["This authority and judgement are especially important during times of crises when traditional timeand volume-based educational standards may be challenged.", [["crises", "PROBLEM", 70, 76], ["traditional timeand volume", "TREATMENT", 82, 108]]], ["ABMS and ACGME understand and affirm that the judgment made by PDs and CCCs to assess trainees constitutes a vital responsibility that affects residents, fellows, and most importantly, the care of the public.\"Diminished volume of training procedures and ambulatory visitsSeparate from this joint statement, the ACGME has addressed the impact on clinical volume for trainees in their \"Response to the Coronavirus (COVID-19)\" 3 by stating the following:Diminished volume of training procedures and ambulatory visits\"The ACGME recognizes that institutions have reduced the volume of their elective visits and procedures and have redeployed residents to support the critical services of the hospital as a result of the COVID-19 pandemic.", [["training procedures", "TREATMENT", 230, 249], ["the Coronavirus", "TEST", 396, 411], ["training procedures", "TREATMENT", 472, 491], ["procedures", "TREATMENT", 606, 616], ["the COVID", "TEST", 711, 720], ["pandemic", "PROBLEM", 724, 732], ["joint", "ANATOMY", 290, 295]]], ["The program can delineate for the Review Committee how it was affected by the pandemic in the 'Major Changes and Other Updates section of the Annual Update.'\"Diminished volume of training procedures and ambulatory visitsWe believe this should provide fellows some degree of relief from the concern over meeting graduation requirements.", [["training procedures", "TREATMENT", 179, 198]]], ["Although various resources to accomplish this already exist (e.g., educational platforms of the various GI societies, such as the ASGE GI Leap online learning website, Gastrointestinal Endoscopy, and VideoGIE), additional training tools may need to be developed.Transitioning to virtual conferencesBecause clinical schedules have changed as a result of clinical reassignments or shelter-at-home risk reduction strategies, in-person conferences should continue in the form of virtual conferences.", [["Gastrointestinal Endoscopy", "TEST", 168, 194], ["additional training tools", "TREATMENT", 211, 236], ["risk reduction strategies", "TREATMENT", 395, 420], ["Gastrointestinal", "ANATOMY", 168, 184]]], ["Zoom has risen in popularity, increasing from 10 million to 200 million users in 3 months.", [["Zoom", "TREATMENT", 0, 4], ["risen", "OBSERVATION_MODIFIER", 9, 14], ["popularity", "OBSERVATION_MODIFIER", 18, 28], ["increasing", "OBSERVATION_MODIFIER", 30, 40]]], ["However, security concerns have been raised with the platform, which may be relevant if patient information is being discussed.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95]]], ["Breaches in software protections have led to unidentified individuals joining calls, the ability for webcams and microphones to be accessed, and concerns about data being sent to third parties.", [["microphones", "TREATMENT", 113, 124]]], ["Some of these platforms are free, whereas others require a monthly fee depending on the number of attendees who can be hosted on a call.", [["free", "OBSERVATION_MODIFIER", 28, 32]]], ["The decision to adopt a specific virtual platform may require further discussion and clearance by institutional legal counsel or similar administrative body.Decreased research opportunities, particularly for prospective clinical pursuitsThe COVID-19 pandemic has likely had a negative impact on fellows engaged in existing research projects.", [["body", "ANATOMY", 152, 156], ["body", "ORGANISM_SUBDIVISION", 152, 156], ["The COVID", "TEST", 237, 246]]], ["Scientific experiments in the lab may have been stopped and clinical studies may have been placed on hold due to a decline in patient visits or the inability to access records from offsite locations.", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133], ["clinical studies", "TEST", 60, 76], ["a decline", "PROBLEM", 113, 122]]], ["On the other hand, the pandemic has brought an explosion of opportunity for future and newly initiated research studies involving the digestive system, digestive health, and the practice of endoscopy, as well as opportunities to write manuscripts about completed research.", [["digestive system", "ANATOMY", 134, 150], ["digestive", "ANATOMY", 152, 161], ["digestive system", "MULTI-TISSUE_STRUCTURE", 134, 150], ["digestive", "ORGAN", 152, 161], ["research studies", "TEST", 103, 119], ["endoscopy", "TEST", 190, 199], ["digestive system", "ANATOMY", 134, 150]]], ["As a point of reference, Gastrointestinal Endoscopy (GIE) has experienced 122% increase in non-COVID related manuscript submissions in April 2020 and 155% increase in May 2020.", [["Gastrointestinal Endoscopy", "TEST", 25, 51], ["Gastrointestinal", "ANATOMY", 25, 41]]], ["In addition, Gastrointestinal Endoscopy and VideoGIE have implemented a temporary \"ultra-fast track\" option to move Covid-19-related articles through the peer review process more quickly.Inability to interview for jobs and training positionsThe current pandemic is changing many facets of the way we conduct our professional lives.", [["Gastrointestinal Endoscopy", "TEST", 13, 39], ["a temporary \"ultra-fast track\" option", "TREATMENT", 70, 107], ["Covid", "TEST", 116, 121], ["jobs and training positions", "TREATMENT", 214, 241], ["Gastrointestinal", "ANATOMY", 13, 29], ["pandemic", "OBSERVATION", 253, 261]]], ["However, there are positive aspects that come from virtual interviews.", [["positive", "OBSERVATION", 19, 27]]], ["For example, travel to in-person interviews can be expensive.", [["person", "SPECIES", 26, 32]]], ["5 Below are some tips for job candidates while using WBVC for an interview:Inability to interview for jobs and training positions\u2022 Treat the interview as if it were a regular face-to-face interview \u2022 Find a quiet, private, well-lit place that is free from distractions \u2022 Dress professionally \u2022 Have a pen and notepad accessible \u2022 Make sure your computer's audio and video capabilities are working well (ensure access to a strong wired or Wi-Fi signal or network connection, use a device with a high-resolution camera) \u2022 Close any unnecessary web browser tabs and applications \u2022 Use a clear and professional profile picture \u2022 When listening, nod and smile to show you are engaged \u2022 Use hand gestures when appropriate \u2022 Place nearby devices that you are not using in silent mode (e.g., your phone) For more tips on a successful video interview, visit the following links:Inability to interview for jobs and training positions\u2022 https://www.indeed.com/career-advice/interviewing/video-interview-guide.Inability to interview for jobs and training positions\u2022 https://www.themedicportal.com/blog/how-to-approach-a-skype-medicineinterview/ Below are suggestions for employers or program directors conducting interviews \u2022 Simulate an onsite experience as best as possible \u2022 Focus on the interviewee without other distractions \u2022 Anticipate technological issues \u2022 Consider providing a virtual tour of your facility \u2022 Take into account the need for breaks and the visual strain associated with video interviews \u2022 Consider a forum for multiple applicants (such as in advanced fellowship interviews) to communicate with one another \u2022 Anticipate an in-person visit once restrictions are lifted \u2022 Be transparent with changes in hiring practices or benefits that may occur as a result of COVID-19 \u2022 Communicate regularly with applicantsFewer educational activities sponsored by industryBecause fewer patients are being seen and reduced numbers of procedures are being performed as a result of the pandemic, our industry partners in gastroenterology may see reductions in revenue.", [["hand", "ANATOMY", 685, 689], ["COVID-19", "CHEMICAL", 1771, 1779], ["hand", "ORGANISM_SUBDIVISION", 685, 689], ["patients", "ORGANISM", 1883, 1891], ["patients", "SPECIES", 1883, 1891], ["a strong wired or Wi-Fi signal", "TREATMENT", 420, 450], ["a device", "TREATMENT", 478, 486], ["a high-resolution camera", "TREATMENT", 492, 516], ["hiring practices", "TREATMENT", 1712, 1728], ["COVID", "TEST", 1771, 1776], ["procedures", "TREATMENT", 1930, 1940], ["clear", "OBSERVATION", 584, 589], ["tips", "OBSERVATION_MODIFIER", 805, 809]]], ["This funding reduction will likely impact the development of locoregional courses and other educational events.", [["This funding reduction", "TREATMENT", 0, 22], ["locoregional courses", "TREATMENT", 61, 81], ["locoregional", "OBSERVATION", 61, 73]]], ["Since these courses often provide trainees with greater insight into a breadth of endoscopic procedures, it is hoped that industry may participate in the process of organizing novel educational resources such as video demonstrations that could be used in lieu of in-person training courses.", [["endoscopic procedures", "TREATMENT", 82, 103]]], ["Industry can potentially collaborate with societies in efforts like the newly announced ASGE Fellows Corner, InScope, weekly webinars and practice discussions and Endo Hangouts, where fellows can engage with experts in endoscopy in a virtual setting.", [["endoscopy", "TEST", 219, 228]]], ["Likewise, trainees are encouraged to supplement their education by utilizing social media platforms like Twitter to engage in regularly scheduled chats such as #MondayNightIBD () and #ScopingSundays ().Implications of COVID-19 for future national and regional conferencesDigestive Disease Week (DDW) 2020 and many other conferences had to be cancelled or postponed.", [["Digestive Disease", "DISEASE", 271, 288], ["Digestive", "ORGAN", 271, 280], ["COVID", "TEST", 218, 223]]], ["These meetings serve many functions for GI fellows: providing education in a variety of didactic formats (e.g., Hands-on courses, Meet-the-Professor luncheons, ASGE Learning Center, etc); opportunities to develop critical skills like public speaking and scientific presentation; the ability to showcase research efforts; career workshops and opportunities to network with colleagues and potential job prospects; and interactions with established and potential mentors in unique education-oriented venues.Implications of COVID-19 for future national and regional conferencesWith creative planning and enhancements in social media platforms (increased bandwidth to accommodate simultaneous large group participation, augmentation of audio and video functionality), many of these functions can be evolved into formats that can be delivered effectively via digital and virtual formats.", [["COVID", "TEST", 520, 525], ["creative planning", "TREATMENT", 578, 595], ["increased bandwidth", "PROBLEM", 640, 659], ["simultaneous large group participation", "TREATMENT", 675, 713], ["augmentation of audio", "TREATMENT", 715, 736], ["video functionality", "TEST", 741, 760]]], ["There are even potential advantages of the virtual format-it eliminates the need to rush back and forth between meeting rooms scattered across large convention centers and various hotels.", [["large", "OBSERVATION_MODIFIER", 143, 148]]], ["While nothing can quite reproduce the exhilaration and anxious anticipation associated with an in-person presentation at a scientific meeting, the experience of doing so virtually with hundreds of people watching represents a similar experience that requires the same degree of practice and preparation.Implications of COVID-19 for future national and regional conferencesPoster presentations can be converted from standard poster boards to digital format, and observers can peruse the digital posters silently on their own or choose to engage the presenter in a private virtual \"room\" to which the presenter is assigned.", [["people", "ORGANISM", 197, 203], ["people", "SPECIES", 197, 203], ["practice and preparation", "TREATMENT", 278, 302], ["COVID", "TEST", 319, 324]]], ["This format provides unique opportunities, such as durable written feedback for the presenter or scoring of posters by expert reviewers or by all meeting attendees to help guide selection of award recipients.", [["recipients", "ORGANISM", 197, 207]]], ["Many of the networking aspects of DDW and other meetings, such as job interviews and academic meetups, can also be accomplished virtually using a wide range of social media and digital meeting platforms.Making inpatient and outpatient services safer for house staffNo intervention, other than not working, can eliminate the risk of SARS-CoV-2 exposure to health care providers.", [["SARS", "DISEASE", 332, 336], ["social media", "TREATMENT", 160, 172], ["intervention", "TREATMENT", 268, 280], ["SARS", "PROBLEM", 332, 336]]], ["This is understandably a challenging and anxiety-provoking time for GI fellows, particularly those who are not involved in institutional conversations about planning and preparedness.", [["anxiety", "DISEASE", 41, 48], ["anxiety", "PROBLEM", 41, 48]]], ["Institutional leaders are working to ready their facilities and providers with guidance from regional and national organizations, such as the Centers for Disease Control (CDC), centered around key infection control principles:Making inpatient and outpatient services safer for house staff\u2022 Reinforcing relationships with key healthcare and public health partners, such as healthcare coalitions, state and national health entities, and infection control organizations. \u2022 Taking steps to protect their workforce by measures such as:Making inpatient and outpatient services safer for house staff\u2022 Screening of patients, visitors, and staff for symptoms of COVID-19 \u2022 Ensuring availability of and education about appropriate use of personal protective equipment (PPE) for various clinical scenarios, and strategizing with key personnel in the supply chain to avoid interruptions in provision of PPE and cleaning supplies (hand and surface disinfectants, soap, etc.) \u2022 Developing strict policies and procedures for isolation and quarantine after potential exposures \u2022 Providing robust educational materials about hand washing and other strategies to prevent transmission of infection \u2022 Separating patients with respiratory symptoms \u2022 Rescheduling elective, low-priority procedures and surgeries \u2022 Modifying workflows, processes, and making infrastructure adjustments to minimize face-to-face encounters at each possible point of contact while maintaining a satisfying patient experience \u2022 Limiting visits by people at higher risk of SARS-CoV-2 exposure (e.g., group residential settings, nursing home residents, etc.) \u2022 Providing easy access to SARS-CoV-2 testing and resources with up-todate information about the pandemic and any changes to institutional policies \u2022 Leveraging telehealth technologies for virtual inpatient and outpatient encounters and adapting coding and billing processes.Making inpatient and outpatient services safer for house staffMany of these steps are done \"behind the scenes\" and may not be readily apparent to house staff and trainees.", [["hand", "ANATOMY", 918, 922], ["surface", "ANATOMY", 927, 934], ["hand", "ANATOMY", 1108, 1112], ["respiratory", "ANATOMY", 1206, 1217], ["infection", "DISEASE", 197, 206], ["infection", "DISEASE", 435, 444], ["COVID", "DISEASE", 653, 658], ["infection", "DISEASE", 1169, 1178], ["respiratory symptoms", "DISEASE", 1206, 1226], ["SARS", "DISEASE", 1528, 1532], ["SARS", "DISEASE", 1640, 1644], ["patients", "ORGANISM", 607, 615], ["hand", "ORGANISM_SUBDIVISION", 918, 922], ["hand", "ORGANISM_SUBDIVISION", 1108, 1112], ["patients", "ORGANISM", 1192, 1200], ["patient", "ORGANISM", 1463, 1470], ["people", "ORGANISM", 1503, 1509], ["patients", "SPECIES", 607, 615], ["patients", "SPECIES", 1192, 1200], ["patient", "SPECIES", 1463, 1470], ["people", "SPECIES", 1503, 1509], ["Disease Control (CDC)", "PROBLEM", 154, 175], ["infection control organizations", "PROBLEM", 435, 466], ["symptoms", "PROBLEM", 641, 649], ["personal protective equipment", "TREATMENT", 728, 757], ["PPE", "TREATMENT", 891, 894], ["cleaning supplies", "TREATMENT", 899, 916], ["hand and surface disinfectants", "TREATMENT", 918, 948], ["procedures", "TREATMENT", 995, 1005], ["isolation", "TREATMENT", 1010, 1019], ["quarantine", "TREATMENT", 1024, 1034], ["robust educational materials", "TREATMENT", 1073, 1101], ["hand washing", "TREATMENT", 1108, 1120], ["other strategies", "TREATMENT", 1125, 1141], ["infection", "PROBLEM", 1169, 1178], ["respiratory symptoms", "PROBLEM", 1206, 1226], ["low-priority procedures", "TREATMENT", 1252, 1275], ["surgeries", "TREATMENT", 1280, 1289], ["SARS", "PROBLEM", 1528, 1532], ["infection", "OBSERVATION", 197, 206], ["infection", "OBSERVATION", 1169, 1178]]], ["GI fellows may be uniquely well suited for this evolution because they often have a high level of proficiency with digital platforms and the devices required to use them.", [["digital platforms", "TREATMENT", 115, 132], ["the devices", "TREATMENT", 137, 148]]], ["6 Examples include a lack of telemedicine experience, greater difficulty establishing rapport with patients, coordinating follow-up and subsequent patient care, and the need to learn new billing and coding requirements.ACGME and ABIM guidance related to the COVID-19 pandemicThere has been a significant amount of guidance from educational boards and licensing bodies during the COVID-19 pandemic.", [["patients", "ORGANISM", 99, 107], ["patient", "ORGANISM", 147, 154], ["patients", "SPECIES", 99, 107], ["patient", "SPECIES", 147, 154], ["the COVID", "TEST", 254, 263], ["the COVID", "TEST", 375, 384], ["pandemic", "PROBLEM", 388, 396], ["significant", "OBSERVATION_MODIFIER", 292, 303], ["amount", "OBSERVATION_MODIFIER", 304, 310]]], ["Trainees are encouraged to visit the ACGME website to view its responses to frequently asked questions surrounding training during COVID-19 (https://www.acgme.org/covid-19).", [["COVID", "TEST", 131, 136]]], ["Important questions addressed by the ACGME include:ACGME and ABIM guidance related to the COVID-19 pandemicSimilarly, the ABIM has attempted to address concerns expressed by trainees about board eligibility in the era of the pandemic.", [["the COVID", "TEST", 86, 95]]], ["In their statement, \"ABIM Board Eligibility and COVID-19,\" they issue reassurance for residents and fellows:ACGME and ABIM guidance related to the COVID-19 pandemic\"Specifically, ABIM does not anticipate interruptions of training related to COVID-19 adversely affecting Board Eligibility for the vast majority of otherwise competent residents and fellows.", [["COVID", "TEST", 241, 246]]], ["ABIM's recently clarified Leave of Absence and Vacation and Deficits in Required Training Time policies are in full effect and applicable to absences that might occur due to COVID-19.\"ACGME and ABIM guidance related to the COVID-19 pandemicFellows should visit the following site for the complete compendium of ABIM links to policies on Leave of Absence and Vacation, and Deficits in Required Training Time.ACGME and ABIM guidance related to the COVID-19 pandemic\u2022 http://view.mail.abim.org/?qs=9764094c8340e4b5ce42962ed5af570170bca85d9 1815bfbe3e5074eb81029401a994f96717fbb2e451893049561e56d52481644dc7 2ec73c681854acf85185c580a89572ca238f2ACGME and ABIM guidance related to the COVID-19 pandemicIn summary, the COVID-19 pandemic has dramatically altered the landscape of GI fellowship training.", [["Deficits", "PROBLEM", 60, 68], ["the COVID", "TEST", 442, 451], ["GI fellowship training", "TREATMENT", 773, 795]]], ["The myriad of challenges associated with the pandemic have spawned unique opportunities to expand the scope of the training landscape in terms of virtual conferences and telehealth.", [["myriad", "OBSERVATION_MODIFIER", 4, 10]]], ["We have also seen our professional societies augment their virtual educational platforms in order to meet this challenge.", [["this challenge", "TREATMENT", 106, 120]]], ["A major concern surrounds the hands-on aspect of endoscopic training, which still may be curtailed in many regions of the country and throughout the world.", [["endoscopic training", "TREATMENT", 49, 68], ["hands", "ANATOMY", 30, 35]]], ["The solution to this is complex and will evolve with the availability of point-of-service testing, personal protective equipment, and hopefully the eventual attainment of herd immunity.", [["herd", "ORGANISM_SUBDIVISION", 171, 175], ["The solution", "TREATMENT", 0, 12], ["personal protective equipment", "TREATMENT", 99, 128]]]], "88089e8bfd9f1cca17245de7b3b099cd3bdd088e": [["IntroductionHepatitis C virus (HCV) is the major causative agent of human chronic hepatitis and is closely associated with hepatocellular carcinoma [1] .", [["hepatocellular carcinoma", "ANATOMY", 123, 147], ["IntroductionHepatitis C", "DISEASE", 0, 23], ["chronic hepatitis", "DISEASE", 74, 91], ["hepatocellular carcinoma", "DISEASE", 123, 147], ["IntroductionHepatitis C virus", "ORGANISM", 0, 29], ["HCV", "ORGANISM", 31, 34], ["human", "ORGANISM", 68, 73], ["hepatocellular carcinoma", "CANCER", 123, 147], ["C virus", "SPECIES", 22, 29], ["human", "SPECIES", 68, 73], ["HCV", "SPECIES", 31, 34], ["human", "SPECIES", 68, 73], ["IntroductionHepatitis C virus (HCV)", "PROBLEM", 0, 35], ["human chronic hepatitis", "PROBLEM", 68, 91], ["hepatocellular carcinoma", "PROBLEM", 123, 147], ["virus", "OBSERVATION", 24, 29], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["hepatitis", "OBSERVATION", 82, 91], ["hepatocellular", "ANATOMY", 123, 137], ["carcinoma", "OBSERVATION", 138, 147]]], ["It is an enveloped virus and is classified as a separate genus in the family Flaviviridae [2] .", [["an enveloped virus", "PROBLEM", 6, 24], ["enveloped", "OBSERVATION_MODIFIER", 9, 18], ["virus", "OBSERVATION", 19, 24]]], ["The genome of HCV is a singlestranded, positive sense RNA of approximately 9.6 kb that encodes a polyprotein of approximately 3000 amino acid residues [3] [4] [5] .", [["amino acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 131, 141], ["HCV", "ORGANISM", 14, 17], ["amino acid", "AMINO_ACID", 131, 141], ["singlestranded, positive sense RNA", "RNA", 23, 57], ["HCV", "SPECIES", 14, 17], ["positive sense RNA", "PROBLEM", 39, 57], ["a polyprotein", "TEST", 95, 108], ["amino acid residues", "TEST", 131, 150], ["HCV", "OBSERVATION", 14, 17]]], ["The polyprotein precursor is processed cotranslationally and post-translationally by cellular ER peptidase and viral proteases to generate mature structural and nonstructural proteins [6] [7] [8] .", [["cellular", "ANATOMY", 85, 93], ["cellular", "CELL", 85, 93], ["ER peptidase", "GENE_OR_GENE_PRODUCT", 94, 106], ["cellular ER peptidase", "PROTEIN", 85, 106], ["viral proteases", "PROTEIN", 111, 126], ["mature structural and nonstructural proteins", "PROTEIN", 139, 183], ["The polyprotein precursor", "TREATMENT", 0, 25], ["viral proteases", "TEST", 111, 126], ["nonstructural proteins", "TEST", 161, 183]]], ["Cleavage at the junction of NS2-NS3 occurs autoproteolytically by the NS2-3 protease [9] , whereas cleavage of the downstream nonstructural proteins is performed by the viral NS3 serine protease [10] [11] [12] .IntroductionNonstructural protein 4A (NS4A) is a multifunctional protein with 54 amino acid residues.", [["amino acid", "CHEMICAL", 292, 302], ["serine", "CHEMICAL", 179, 185], ["amino acid", "CHEMICAL", 292, 302], ["NS2", "GENE_OR_GENE_PRODUCT", 28, 31], ["NS2-3", "GENE_OR_GENE_PRODUCT", 70, 75], ["Nonstructural protein 4A", "GENE_OR_GENE_PRODUCT", 223, 247], ["NS4A", "GENE_OR_GENE_PRODUCT", 249, 253], ["amino acid", "AMINO_ACID", 292, 302], ["NS2", "PROTEIN", 28, 31], ["NS3", "PROTEIN", 32, 35], ["NS2", "PROTEIN", 70, 73], ["downstream nonstructural proteins", "PROTEIN", 115, 148], ["viral NS3 serine protease", "PROTEIN", 169, 194], ["Nonstructural protein 4A", "PROTEIN", 223, 247], ["NS4A", "PROTEIN", 249, 253], ["multifunctional protein", "PROTEIN", 260, 283], ["Cleavage", "TREATMENT", 0, 8], ["NS3", "TREATMENT", 32, 35], ["the downstream nonstructural proteins", "PROBLEM", 111, 148], ["the viral NS3 serine protease", "TREATMENT", 165, 194], ["a multifunctional protein", "TREATMENT", 258, 283], ["amino acid residues", "TREATMENT", 292, 311]]], ["It acts as a cofactor of NS3 serine protease and plays an essential role in the NS4A-dependent cleavage at the NS3-NS4A and NS4B-NS5A junctions [13, 14] .", [["serine", "CHEMICAL", 29, 35], ["NS3 serine protease", "GENE_OR_GENE_PRODUCT", 25, 44], ["NS4A", "GENE_OR_GENE_PRODUCT", 80, 84], ["NS3 serine protease", "PROTEIN", 25, 44], ["NS4A", "PROTEIN", 80, 84], ["NS3", "PROTEIN", 111, 114], ["NS4A", "PROTEIN", 115, 119], ["NS4B", "PROTEIN", 124, 128], ["NS5A", "PROTEIN", 129, 133], ["NS3 serine protease", "TREATMENT", 25, 44], ["the NS4A", "TREATMENT", 76, 84], ["dependent cleavage", "PROBLEM", 85, 103], ["the NS3-NS4A", "TREATMENT", 107, 119], ["NS4B-NS5A junctions", "TREATMENT", 124, 143]]], ["Both NS4A and NS4B proteins were previously demonstrated to suppress translation in culture cells [15, 16] .", [["culture cells", "ANATOMY", 84, 97], ["NS4A", "GENE_OR_GENE_PRODUCT", 5, 9], ["NS4B", "GENE_OR_GENE_PRODUCT", 14, 18], ["culture cells", "CELL", 84, 97], ["NS4A", "PROTEIN", 5, 9], ["NS4B proteins", "PROTEIN", 14, 27], ["culture cells", "CELL_LINE", 84, 97], ["Both NS4A", "TREATMENT", 0, 9], ["NS4B proteins", "TREATMENT", 14, 27], ["culture cells", "TEST", 84, 97], ["NS4A", "OBSERVATION", 5, 9]]], ["However, neither NS4A nor NS4B affected the steady state level of canonical translational factors including eIF4G, eIF4E, PABP, and 4E-BP1 [16] .", [["NS4B", "GENE_OR_GENE_PRODUCT", 26, 30], ["eIF4G", "GENE_OR_GENE_PRODUCT", 108, 113], ["eIF4E", "GENE_OR_GENE_PRODUCT", 115, 120], ["PABP", "GENE_OR_GENE_PRODUCT", 122, 126], ["4E-BP1", "GENE_OR_GENE_PRODUCT", 132, 138], ["NS4A", "PROTEIN", 17, 21], ["NS4B", "PROTEIN", 26, 30], ["canonical translational factors", "PROTEIN", 66, 97], ["eIF4G", "PROTEIN", 108, 113], ["eIF4E", "PROTEIN", 115, 120], ["PABP", "PROTEIN", 122, 126], ["4E", "PROTEIN", 132, 134], ["BP1", "PROTEIN", 135, 138], ["NS4B", "PROBLEM", 26, 30], ["eIF4G", "TEST", 108, 113], ["eIF4E", "TEST", 115, 120], ["PABP", "TEST", 122, 126], ["NS4B", "OBSERVATION", 26, 30]]], ["The mechanisms by which the HCV NS4A and NS4B involved in the translational inhibition remained unclear.IntroductionIn this study, we have demonstrated that NS4A specifically interacted with eukaryotic elongation factor 1A (eEF1A) and inhibited both cap-and HCV IRES-dependent protein synthesis.", [["HCV NS4A", "ORGANISM", 28, 36], ["NS4B", "GENE_OR_GENE_PRODUCT", 41, 45], ["NS4A", "GENE_OR_GENE_PRODUCT", 157, 161], ["eukaryotic elongation factor 1A", "GENE_OR_GENE_PRODUCT", 191, 222], ["eEF1A", "GENE_OR_GENE_PRODUCT", 224, 229], ["cap", "GENE_OR_GENE_PRODUCT", 250, 253], ["HCV", "ORGANISM", 258, 261], ["HCV NS4A", "PROTEIN", 28, 36], ["NS4B", "PROTEIN", 41, 45], ["NS4A", "PROTEIN", 157, 161], ["eukaryotic elongation factor 1A", "PROTEIN", 191, 222], ["eEF1A", "PROTEIN", 224, 229], ["IRES", "DNA", 262, 266], ["HCV", "SPECIES", 28, 31], ["HCV", "SPECIES", 258, 261], ["the HCV NS4A", "TREATMENT", 24, 36], ["NS4B", "TREATMENT", 41, 45], ["this study", "TEST", 119, 129], ["NS4A", "PROBLEM", 157, 161], ["both cap", "TEST", 245, 253], ["HCV IRES", "PROBLEM", 258, 266], ["dependent protein synthesis", "PROBLEM", 267, 294], ["HCV IRES", "OBSERVATION", 258, 266], ["protein synthesis", "OBSERVATION", 277, 294]]], ["The inhibitory effect was mainly mediated by the central domain of NS4A and could be restored by the addition of recombinant eEF1A in an in vitro translation system.Plasmids(i) Plasmids pCRII-Topo-NS(3c-5An), pCRII-Topo-NS4B, and pcDNA-HCV-SG.", [["NS4A", "GENE_OR_GENE_PRODUCT", 67, 71], ["eEF1A", "GENE_OR_GENE_PRODUCT", 125, 130], ["pCRII", "GENE_OR_GENE_PRODUCT", 186, 191], ["Topo-NS(3c-5An", "GENE_OR_GENE_PRODUCT", 192, 206], ["pCRII-Topo", "GENE_OR_GENE_PRODUCT", 209, 219], ["central domain", "PROTEIN", 49, 63], ["NS4A", "PROTEIN", 67, 71], ["recombinant eEF1A", "PROTEIN", 113, 130], ["pCRII", "PROTEIN", 186, 191], ["Topo", "PROTEIN", 192, 196], ["5An", "PROTEIN", 203, 206], ["pCRII", "PROTEIN", 209, 214], ["Topo", "PROTEIN", 215, 219], ["NS4B", "PROTEIN", 220, 224], ["pcDNA-HCV", "PROTEIN", 230, 239], ["NS4A", "TREATMENT", 67, 71], ["recombinant eEF1A", "TREATMENT", 113, 130], ["Plasmids pCRII", "TREATMENT", 177, 191], ["NS", "TREATMENT", 197, 199], ["pCRII", "TREATMENT", 209, 214], ["Topo", "TREATMENT", 215, 219], ["NS4B", "TREATMENT", 220, 224], ["pcDNA-HCV", "TREATMENT", 230, 239], ["NS4A", "OBSERVATION", 67, 71], ["NS4B", "ANATOMY", 220, 224]]], ["Plasmid pCRII-Topo-NS(3c-5An) encompasses cDNA sequences of the HCV genome (genotype 1b) from nucleotides 4458-6381 inserted into pCR \u00d2 II-TOPO (Invitrogen).", [["nucleotides 4458-6381", "CHEMICAL", 94, 115], ["nucleotides", "CHEMICAL", 94, 105], ["Topo-NS(3c-5An", "GENE_OR_GENE_PRODUCT", 14, 28], ["HCV", "ORGANISM", 64, 67], ["II-TOPO", "GENE_OR_GENE_PRODUCT", 136, 143], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 145, 155], ["Plasmid pCRII-Topo-NS(3c-5An", "DNA", 0, 28], ["cDNA sequences", "DNA", 42, 56], ["HCV genome", "DNA", 64, 74], ["genotype 1b", "DNA", 76, 87], ["nucleotides 4458-6381", "DNA", 94, 115], ["pCR \u00d2 II", "DNA", 130, 138], ["TOPO", "DNA", 139, 143], ["Invitrogen", "DNA", 145, 155], ["HCV", "SPECIES", 64, 67], ["Plasmid pCRII", "TREATMENT", 0, 13], ["Topo-NS", "TREATMENT", 14, 21], ["cDNA sequences", "TEST", 42, 56], ["the HCV genome", "PROBLEM", 60, 74], ["nucleotides", "TEST", 94, 105], ["pCR", "TEST", 130, 133], ["TOPO (Invitrogen", "TREATMENT", 139, 155], ["HCV genome", "OBSERVATION", 64, 74]]], ["The cDNA fragment was generated from a serum sample of an HCV patient by reverse transcriptase-polymerase chain reaction (RT-PCR) with Advantage \u00d2 One-Step RT-PCR kit (BD Biosciences Clontech) and the primer sets 5\u00a2-CTCGCAG CGGGCAGGCAGGACTGG-3\u00a2 and 5\u00a2-CC CATCCACTTCCGTGAAGAA-3\u00a2 for the initial amplification and 5\u00a2-GCGGCGAG-GCGCGACTGGTAGG-3\u00a2 and 5\u00a2-CCCAT CCACTTCCGTGAAGAA-3\u00a2 for a further amplification.", [["serum sample", "ANATOMY", 39, 51], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["patient", "ORGANISM", 62, 69], ["cDNA fragment", "DNA", 4, 17], ["reverse transcriptase", "PROTEIN", 73, 94], ["BD Biosciences Clontech", "DNA", 168, 191], ["5\u00a2-GCGGCGAG-GCGCGACTGGTAGG-3\u00a2 and 5\u00a2-CCCAT CCACTTCCGTGAAGAA-3\u00a2", "DNA", 312, 374], ["patient", "SPECIES", 62, 69], ["HCV", "SPECIES", 58, 61], ["The cDNA fragment", "PROBLEM", 0, 17], ["a serum sample", "TEST", 37, 51], ["the primer sets", "TEST", 197, 212], ["CGGGCAGGCAGGACTGG", "TEST", 224, 241], ["CATCCACTTCCGTGAAGAA", "TEST", 255, 274], ["the initial amplification", "TEST", 282, 307], ["GCGGCGAG", "TEST", 315, 323], ["GCGCGACTGGTAGG", "TEST", 324, 338], ["a further amplification", "TREATMENT", 379, 402], ["cDNA fragment", "OBSERVATION", 4, 17], ["HCV", "OBSERVATION", 58, 61]]], ["An NS4B cDNA fragment was amplified from pCRII-Topo-NS(3c-5An) with primer set 5\u00a2-GGAATTCCATATGGCCTCA CACCTCCCTTACATCGAACAA-3\u00a2 and 5\u00a2-CGGGATCCTCTAGATCAGCATGGCGT GGAGCAGTCTTCATT-3\u00a2, and cloned into pCR \u00d2 II-TOPO to generate plasmid pCRII-Topo-NS4B.", [["pCR \u00d2 II-TOPO", "GENE_OR_GENE_PRODUCT", 197, 210], ["pCRII", "GENE_OR_GENE_PRODUCT", 231, 236], ["Topo", "GENE_OR_GENE_PRODUCT", 237, 241], ["NS4B cDNA fragment", "DNA", 3, 21], ["pCRII", "DNA", 41, 46], ["Topo-NS(3c-5An", "DNA", 47, 61], ["primer set 5", "DNA", 68, 80], ["pCR \u00d2 II", "DNA", 197, 205], ["TOPO", "DNA", 206, 210], ["pCRII", "DNA", 231, 236], ["Topo", "PROTEIN", 237, 241], ["NS4B", "PROTEIN", 242, 246], ["An NS4B cDNA fragment", "TREATMENT", 0, 21], ["pCRII", "TEST", 41, 46], ["NS", "TREATMENT", 52, 54], ["primer set", "TEST", 68, 78], ["CACCTCCCTTACATCGAACAA", "TEST", 102, 123], ["GGAGCAGTCTTCATT", "TEST", 161, 176], ["plasmid pCRII", "TREATMENT", 223, 236], ["NS4B", "PROBLEM", 242, 246], ["NS4B", "OBSERVATION", 3, 7], ["cDNA fragment", "OBSERVATION", 8, 21], ["NS4B", "ANATOMY", 242, 246]]], ["Plasmid pcDNA-HCV-SG represents a subgenomic replicon of HCV genomic type 1b and consists of the HCV-IRES, the neo gene, and the EMCV-IRES fused to the HCV sequences from NS3 to NS5B and the 3\u00a2 noncoding region.", [["Plasmid pcDNA-HCV-SG", "ORGANISM", 0, 20], ["HCV genomic type 1b", "ORGANISM", 57, 76], ["HCV", "ORGANISM", 97, 100], ["neo", "GENE_OR_GENE_PRODUCT", 111, 114], ["EMCV", "ORGANISM", 129, 133], ["HCV", "ORGANISM", 152, 155], ["NS3", "GENE_OR_GENE_PRODUCT", 171, 174], ["NS5B", "GENE_OR_GENE_PRODUCT", 178, 182], ["pcDNA-HCV", "DNA", 8, 17], ["SG", "DNA", 18, 20], ["HCV genomic type 1b", "DNA", 57, 76], ["HCV-IRES", "DNA", 97, 105], ["neo gene", "DNA", 111, 119], ["EMCV", "DNA", 129, 133], ["IRES", "DNA", 134, 138], ["HCV sequences", "DNA", 152, 165], ["NS3 to NS5B and the 3\u00a2 noncoding region", "DNA", 171, 210], ["HCV", "SPECIES", 57, 60], ["HCV", "SPECIES", 97, 100], ["EMCV", "SPECIES", 129, 133], ["HCV", "SPECIES", 152, 155], ["Plasmid pcDNA-HCV", "TREATMENT", 0, 17], ["HCV genomic type 1b", "PROBLEM", 57, 76], ["the HCV-IRES", "TREATMENT", 93, 105], ["the neo gene", "TREATMENT", 107, 119], ["the EMCV", "TREATMENT", 125, 133], ["the HCV sequences", "TEST", 148, 165], ["NS3", "TREATMENT", 171, 174], ["NS5B", "TREATMENT", 178, 182], ["SG", "ANATOMY", 18, 20], ["subgenomic replicon", "OBSERVATION", 34, 53], ["HCV genomic type 1b", "OBSERVATION", 57, 76], ["HCV", "OBSERVATION", 97, 100]]], ["These plasmids were used to generate expression plasmids of HCV NS3, NS4A and NS4B proteins.Plasmids(ii) Plasmids pCMV-Tag2C-NS4A and pGST-NS4A.", [["plasmids", "ANATOMY", 6, 14], ["HCV NS3", "ORGANISM", 60, 67], ["NS4A", "GENE_OR_GENE_PRODUCT", 69, 73], ["NS4B", "GENE_OR_GENE_PRODUCT", 78, 82], ["pCMV-Tag2C-NS4A", "GENE_OR_GENE_PRODUCT", 114, 129], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 134, 143], ["plasmids", "DNA", 6, 14], ["expression plasmids", "DNA", 37, 56], ["HCV NS3, NS4A and NS4B proteins", "PROTEIN", 60, 91], ["pCMV", "PROTEIN", 114, 118], ["Tag2C", "PROTEIN", 119, 124], ["NS4A", "PROTEIN", 125, 129], ["pGST", "PROTEIN", 134, 138], ["NS4A", "PROTEIN", 139, 143], ["HCV", "SPECIES", 60, 63], ["These plasmids", "TREATMENT", 0, 14], ["expression plasmids", "TREATMENT", 37, 56], ["HCV NS3", "TREATMENT", 60, 67], ["NS4A", "TREATMENT", 69, 73], ["NS4B proteins", "TREATMENT", 78, 91], ["Plasmids(ii", "TREATMENT", 92, 103], ["Plasmids pCMV", "TREATMENT", 105, 118], ["NS4A", "TREATMENT", 125, 129], ["pGST", "TREATMENT", 134, 138], ["NS4A", "TREATMENT", 139, 143]]], ["For generation of pCMV-Tag2C-NS4A, a full-length NS4A cDNA was amplified from pCRII-Topo-NS(3c-5An) with the primer set 5\u00a2-CGGGATCCATATG AGCACCTGGGTGCTTGTA-3\u00a2 and 5\u00a2-GGA ATTCAGCACTCCTCCATTTC-3\u00a2, the PCR fragment was digested with Bam-HI and EcoRI restriction endonucleases, and cloned into the BamHI-EcoRI site of pCMV-Tag2C (Stratagene).", [["pCMV", "GENE_OR_GENE_PRODUCT", 18, 22], ["Tag2C", "GENE_OR_GENE_PRODUCT", 23, 28], ["pCRII-Topo", "GENE_OR_GENE_PRODUCT", 78, 88], ["Bam-HI", "GENE_OR_GENE_PRODUCT", 230, 236], ["EcoRI", "GENE_OR_GENE_PRODUCT", 241, 246], ["BamHI", "GENE_OR_GENE_PRODUCT", 294, 299], ["EcoRI", "GENE_OR_GENE_PRODUCT", 300, 305], ["pCMV-Tag2C", "GENE_OR_GENE_PRODUCT", 314, 324], ["pCMV", "PROTEIN", 18, 22], ["Tag2C", "DNA", 23, 28], ["NS4A", "PROTEIN", 29, 33], ["full-length NS4A cDNA", "DNA", 37, 58], ["pCRII", "DNA", 78, 83], ["Topo-NS(3c-5An", "DNA", 84, 98], ["primer set 5\u00a2-CGGGATCCATATG AGCACCTGGGTGCTTGTA-3\u00a2 and 5\u00a2-GGA ATTCAGCACTCCTCCATTTC-3\u00a2", "DNA", 109, 193], ["PCR fragment", "DNA", 199, 211], ["Bam-HI and EcoRI restriction endonucleases", "DNA", 230, 272], ["BamHI-EcoRI site", "DNA", 294, 310], ["pCMV", "DNA", 314, 318], ["Tag2C", "DNA", 319, 324], ["Stratagene", "DNA", 326, 336], ["pCMV", "SPECIES", 18, 22], ["pCMV", "TEST", 18, 22], ["a full-length NS4A cDNA", "TREATMENT", 35, 58], ["pCRII", "TEST", 78, 83], ["NS", "TREATMENT", 89, 91], ["the primer set", "TREATMENT", 105, 119], ["AGCACCTGGGTGCTTGTA", "TEST", 137, 155], ["ATTCAGCACTCCTCCATTTC", "TEST", 170, 190], ["the PCR fragment", "PROBLEM", 195, 211], ["Bam-HI", "TREATMENT", 230, 236], ["EcoRI restriction endonucleases", "TREATMENT", 241, 272], ["Tag2C (Stratagene)", "TREATMENT", 319, 337]]], ["For generation of plasmid pGST-NS4A, plasmid pCMV-Tag2C-NS4A was digested with BamHI and treated with the Klenow fragment of DNA polymerase I prior to a further digestion with XhoI restriction endonuclease.", [["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 26, 35], ["pCMV-Tag2C-NS4A", "GENE_OR_GENE_PRODUCT", 45, 60], ["BamHI", "GENE_OR_GENE_PRODUCT", 79, 84], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["XhoI", "GENE_OR_GENE_PRODUCT", 176, 180], ["pGST", "DNA", 26, 30], ["NS4A", "PROTEIN", 31, 35], ["pCMV", "DNA", 45, 49], ["Tag2C", "DNA", 50, 55], ["NS4A", "PROTEIN", 56, 60], ["BamHI", "DNA", 79, 84], ["Klenow fragment", "DNA", 106, 121], ["DNA polymerase I", "PROTEIN", 125, 141], ["XhoI restriction endonuclease", "PROTEIN", 176, 205], ["plasmid pGST", "TREATMENT", 18, 30], ["NS4A", "TREATMENT", 31, 35], ["plasmid pCMV", "TREATMENT", 37, 49], ["NS4A", "TREATMENT", 56, 60], ["BamHI", "TREATMENT", 79, 84], ["the Klenow fragment of DNA polymerase", "TREATMENT", 102, 139], ["a further digestion", "TREATMENT", 151, 170], ["XhoI restriction endonuclease", "TREATMENT", 176, 205]]], ["The resulting fragment was inserted into the pGEX-6p-1 (GE Healthcare Bio-Sciences) from which the polylinker sequences between BamHI and XhoI had been deleted and the BamHI site blunted. (iii) Plasmids pcDNA-NS4A-V5HisTopo, pc DNA-NS3-V5HisTopo, and pcDNA-NS4B-V5HisTopo.", [["polylinker", "GENE_OR_GENE_PRODUCT", 99, 109], ["BamHI", "GENE_OR_GENE_PRODUCT", 128, 133], ["XhoI", "GENE_OR_GENE_PRODUCT", 138, 142], ["BamHI", "GENE_OR_GENE_PRODUCT", 168, 173], ["pcDNA", "GENE_OR_GENE_PRODUCT", 203, 208], ["pcDNA", "GENE_OR_GENE_PRODUCT", 251, 256], ["pGEX-6p-1", "DNA", 45, 54], ["polylinker sequences", "DNA", 99, 119], ["BamHI", "DNA", 128, 133], ["XhoI", "DNA", 138, 142], ["BamHI site", "DNA", 168, 178], ["pcDNA", "PROTEIN", 203, 208], ["NS4A", "PROTEIN", 209, 213], ["V5HisTopo", "PROTEIN", 214, 223], ["NS3", "PROTEIN", 232, 235], ["V5HisTopo", "PROTEIN", 236, 245], ["pcDNA", "PROTEIN", 251, 256], ["NS4B", "PROTEIN", 257, 261], ["V5HisTopo", "PROTEIN", 262, 271], ["The resulting fragment", "PROBLEM", 0, 22], ["the polylinker sequences", "TREATMENT", 95, 119], ["BamHI and XhoI", "TREATMENT", 128, 142], ["the BamHI site blunted", "PROBLEM", 164, 186], ["Plasmids pcDNA", "TEST", 194, 208], ["NS4A", "TEST", 209, 213], ["pc DNA", "TEST", 225, 231], ["NS3", "TREATMENT", 232, 235], ["V5HisTopo", "TREATMENT", 236, 245], ["pcDNA", "TREATMENT", 251, 256], ["NS4B", "TREATMENT", 257, 261], ["resulting", "OBSERVATION_MODIFIER", 4, 13], ["fragment", "OBSERVATION", 14, 22], ["blunted", "OBSERVATION_MODIFIER", 179, 186]]], ["For generation of plasmid pcDNA-NS4A-V5HisTopo, cDNA sequence of the full-length NS4A was amplified from pCMV- Tag2C-NS4A with the primer set 5\u00a2-CACCATGAGCACCTGGGTGCTTGTA3\u00a2 and 5\u00a2-GCACTCCTCCATTTCATC-3\u00a2, and cloned into pcDNA TM 3.1D/V5-His-TOPO \u00d2 (Invitrogen).", [["pcDNA-NS4A-V5HisTopo", "GENE_OR_GENE_PRODUCT", 26, 46], ["NS4A", "GENE_OR_GENE_PRODUCT", 81, 85], ["pCMV", "GENE_OR_GENE_PRODUCT", 105, 109], ["pcDNA", "ORGANISM", 219, 224], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 248, 258], ["NS4A", "PROTEIN", 32, 36], ["V5His", "PROTEIN", 37, 42], ["Topo", "PROTEIN", 42, 46], ["cDNA sequence", "DNA", 48, 61], ["NS4A", "PROTEIN", 81, 85], ["pCMV", "DNA", 105, 109], ["Tag2C", "DNA", 111, 116], ["NS4A", "PROTEIN", 117, 121], ["primer set 5\u00a2-CACCATGAGCACCTGGGTGCTTGTA3\u00a2 and 5\u00a2-GCACTCCTCCATTTCATC-3\u00a2", "DNA", 131, 201], ["pcDNA TM 3.1D/V5-His-TOPO \u00d2", "DNA", 219, 246], ["Invitrogen", "DNA", 248, 258], ["plasmid pcDNA", "TREATMENT", 18, 31], ["NS4A", "TREATMENT", 32, 36], ["the full-length NS4A", "TREATMENT", 65, 85], ["pCMV", "TEST", 105, 109], ["CACCATGAGCACCTGGGTGCTTGTA3", "TEST", 145, 171], ["GCACTCCTCCATTTCATC", "TEST", 180, 198], ["TM", "TEST", 225, 227], ["His-TOPO \u00d2 (Invitrogen)", "TREATMENT", 236, 259]]], ["For generation of pc DNA-NS3-V5HisTopo and pcDNA-NS4B-V5His-Topo, full length cDNA fragments of the HCV NS3 and NS4B were amplified from pcDNA-HCV-SG with the primer set 5\u00a2-CACCATGGCGCCCATCACTGCCTACG CTCAACAGA-3\u00a2 and 5\u00a2-CGTGAC-GACCTCCAGGTCAGCTGCCATGCAT GT-3\u00a2, and the primer set 5\u00a2-CAC CATGGCCTGACACCTCCCTTACATC GAACAA-3\u00a2 and 5\u00a2-GCATGGCGT GGAGCAGTCTTCATTA-3\u00a2, respectively, the resulting PCR fragments were cloned into pcDNA TM (vi) Plasmids pcDNA-eEF1A-V5HisTopo, pcD NA-eEF1A(1-240)-V5HisTopo, pcDNA-eEF1A(201-462)-V5HisTopo, and pcDNA-eEF1A-HisTopo.", [["DNA", "CELLULAR_COMPONENT", 21, 24], ["pcDNA", "GENE_OR_GENE_PRODUCT", 43, 48], ["V5His-Topo", "GENE_OR_GENE_PRODUCT", 54, 64], ["HCV NS3", "ORGANISM", 100, 107], ["NS4B", "GENE_OR_GENE_PRODUCT", 112, 116], ["pcDNA", "GENE_OR_GENE_PRODUCT", 419, 424], ["pcDNA-eEF1A", "GENE_OR_GENE_PRODUCT", 442, 453], ["pcD NA-eEF1A", "GENE_OR_GENE_PRODUCT", 465, 477], ["pcDNA-eEF1A(201-462)-V5HisTopo", "GENE_OR_GENE_PRODUCT", 496, 526], ["pcDNA-eEF1A-HisTopo", "GENE_OR_GENE_PRODUCT", 532, 551], ["pc DNA", "DNA", 18, 24], ["NS3", "PROTEIN", 25, 28], ["V5HisTopo", "DNA", 29, 38], ["pcDNA", "DNA", 43, 48], ["NS4B", "PROTEIN", 49, 53], ["V5His", "PROTEIN", 54, 59], ["Topo", "PROTEIN", 60, 64], ["cDNA fragments", "DNA", 78, 92], ["HCV NS3", "PROTEIN", 100, 107], ["NS4B", "PROTEIN", 112, 116], ["pcDNA-HCV", "DNA", 137, 146], ["primer set 5", "DNA", 159, 171], ["primer set 5", "DNA", 268, 280], ["PCR fragments", "DNA", 388, 401], ["pcDNA TM (vi) Plasmids pcDNA", "DNA", 419, 447], ["eEF1A", "PROTEIN", 448, 453], ["V5HisTopo", "PROTEIN", 454, 463], ["pcD", "PROTEIN", 465, 468], ["eEF1A", "PROTEIN", 472, 477], ["V5HisTopo", "DNA", 485, 494], ["pcDNA-eEF1A(201-462", "DNA", 496, 515], ["V5HisTopo", "DNA", 517, 526], ["pcDNA-eEF1A-HisTopo", "DNA", 532, 551], ["HCV", "SPECIES", 100, 103], ["pc DNA", "TEST", 18, 24], ["NS3", "TEST", 25, 28], ["V5HisTopo", "TEST", 29, 38], ["pcDNA", "TEST", 43, 48], ["NS4B", "TREATMENT", 49, 53], ["Topo", "TREATMENT", 60, 64], ["full length cDNA fragments", "TREATMENT", 66, 92], ["the HCV NS3", "TREATMENT", 96, 107], ["NS4B", "TREATMENT", 112, 116], ["CTCAACAGA", "TEST", 200, 209], ["CAC", "TEST", 282, 285], ["GAACAA", "TEST", 312, 318], ["GGAGCAGTCTTCATTA", "TEST", 339, 355], ["the resulting PCR fragments", "PROBLEM", 374, 401], ["Plasmids pcDNA", "TEST", 433, 447], ["eEF1A", "TEST", 448, 453], ["NA", "TEST", 469, 471], ["eEF1A", "TEST", 472, 477], ["pcDNA-eEF1A-HisTopo", "TREATMENT", 532, 551]]], ["For generation of plasmids pcDNA-eEF1A-V5HisTopo and its deletion mutants, RNA was isolated from Huh7 cells by a single step extraction method as described previously [17] .", [["plasmids", "ANATOMY", 18, 26], ["Huh7 cells", "ANATOMY", 97, 107], ["Topo", "CHEMICAL", 44, 48], ["pcDNA-eEF1A-V5His", "GENE_OR_GENE_PRODUCT", 27, 44], ["Topo", "GENE_OR_GENE_PRODUCT", 44, 48], ["Huh7 cells", "CELL", 97, 107], ["plasmids", "DNA", 18, 26], ["pcDNA-eEF1A", "DNA", 27, 38], ["V5His", "DNA", 39, 44], ["Topo", "PROTEIN", 44, 48], ["Huh7 cells", "CELL_LINE", 97, 107], ["plasmids pcDNA-eEF1A", "TREATMENT", 18, 38], ["Topo", "TREATMENT", 44, 48], ["its deletion mutants", "PROBLEM", 53, 73], ["Huh7 cells", "TREATMENT", 97, 107], ["a single step extraction method", "TREATMENT", 111, 142], ["Huh7 cells", "OBSERVATION", 97, 107]]], ["The RNA was used to perform RT-PCR with primers sets described below and the resulting cDNA fragments were cloned into pcDNA TM 3.1D/V5-His-TOPO \u00d2 .", [["pcDNA", "GENE_OR_GENE_PRODUCT", 119, 124], ["cDNA fragments", "DNA", 87, 101], ["pcDNA TM 3.1D/V5-His-TOPO \u00d2", "DNA", 119, 146], ["RT-PCR", "TEST", 28, 34], ["primers sets", "TEST", 40, 52], ["the resulting cDNA fragments", "PROBLEM", 73, 101], ["cDNA fragments", "OBSERVATION", 87, 101]]], ["The primer sets used in the amplification were EF-K (5\u00a2-CAC CATGGGAAAGGAAAAGA CTC-3\u00a2) and EF-R (5\u00a2-TTTAGCCTTCTGAGCTTTCT GG-3\u00a2) for generating pcDNA-eEF1A-V5HisTopo that represents V5His-tagged full length eEF1A, EF-K and EF-NR (5\u00a2-ACGAGTTGGTGGTAGGAT3\u00a2) for generating pcDNA-eEF1A(1-240)-V5HisTopo that represents V5His-tagged N-terminal eEF1A from amino acid residues 1-240, and EF-MK (5\u00a2-CACCATGCTGGAGCCAAG TGCTAA-3\u00a2) and EF-R for generating pcDNA-eEF1A(201-462)-V5HisTopo that represents V5His-tagged C-terminal eEF1A from amino acid residues 201-462.", [["amino acid", "CHEMICAL", 348, 358], ["amino acid residues 201-462", "CHEMICAL", 525, 552], ["amino acid", "CHEMICAL", 348, 358], ["C", "CHEMICAL", 503, 504], ["amino acid", "CHEMICAL", 525, 535], ["EF-R", "GENE_OR_GENE_PRODUCT", 90, 94], ["pcDNA-eEF1A-V5HisTopo", "GENE_OR_GENE_PRODUCT", 142, 163], ["V5His", "GENE_OR_GENE_PRODUCT", 180, 185], ["eEF1A", "GENE_OR_GENE_PRODUCT", 205, 210], ["EF-K", "GENE_OR_GENE_PRODUCT", 212, 216], ["EF-NR", "GENE_OR_GENE_PRODUCT", 221, 226], ["pcDNA", "GENE_OR_GENE_PRODUCT", 268, 273], ["Topo", "GENE_OR_GENE_PRODUCT", 292, 296], ["V5His", "GENE_OR_GENE_PRODUCT", 313, 318], ["amino acid", "AMINO_ACID", 348, 358], ["EF-R", "GENE_OR_GENE_PRODUCT", 423, 427], ["Topo", "GENE_OR_GENE_PRODUCT", 469, 473], ["V5His", "GENE_OR_GENE_PRODUCT", 490, 495], ["C-terminal eEF1A", "GENE_OR_GENE_PRODUCT", 503, 519], ["amino acid", "AMINO_ACID", 525, 535], ["residues 201-462", "AMINO_ACID", 536, 552], ["EF", "PROTEIN", 47, 49], ["EF-R", "DNA", 90, 94], ["pcDNA-eEF1A", "DNA", 142, 153], ["V5HisTopo", "DNA", 154, 163], ["V5His", "PROTEIN", 180, 185], ["eEF1A", "PROTEIN", 205, 210], ["EF", "PROTEIN", 212, 214], ["K", "PROTEIN", 215, 216], ["EF", "PROTEIN", 221, 223], ["NR", "DNA", 224, 226], ["5\u00a2-ACGAGTTGGTGGTAGGAT3\u00a2", "DNA", 228, 251], ["V5HisTopo", "DNA", 287, 296], ["V5His", "PROTEIN", 313, 318], ["N-terminal eEF1A", "PROTEIN", 326, 342], ["EF", "PROTEIN", 379, 381], ["\u00a2", "PROTEIN", 416, 417], ["EF", "PROTEIN", 423, 425], ["V5His", "PROTEIN", 464, 469], ["Topo", "PROTEIN", 469, 473], ["V5His", "PROTEIN", 490, 495], ["C-terminal eEF1A", "PROTEIN", 503, 519], ["the amplification", "TEST", 24, 41], ["EF", "TEST", 47, 49], ["K", "TEST", 50, 51], ["CAC", "TEST", 56, 59], ["CATGGGAAAGGAAAAGA", "TEST", 60, 77], ["CTC", "TEST", 78, 81], ["EF", "TEST", 90, 92], ["TTTAGCCTTCTGAGCTTTCT", "TEST", 99, 119], ["GG", "TEST", 120, 122], ["pcDNA-eEF1A", "TEST", 142, 153], ["V5His", "TEST", 180, 185], ["EF", "TEST", 212, 214], ["K", "TEST", 215, 216], ["EF", "TEST", 221, 223], ["NR", "TEST", 224, 226], ["V5His", "TEST", 313, 318], ["amino acid residues", "TEST", 348, 367], ["EF", "TEST", 379, 381], ["MK", "TEST", 382, 384], ["CACCATGCTGGAGCCAAG", "TEST", 389, 407], ["TGCTAA", "TEST", 408, 414], ["EF", "TEST", 423, 425], ["pcDNA-eEF1A(", "TEST", 443, 455], ["V5His", "TEST", 490, 495], ["amino acid residues", "TEST", 525, 544]]], ["For generation of plasmid pcDNA-eEF1A-HisTopo, the V5-epitope was removed from pcDNA-eEF1A-V5HisTopo following a digestion with XhoI and AgeI restriction endonucleases and the ends were blunted with the Klenow fragment of DNA polymerase I prior to self-ligation. (vii) Plasmids pGST-NS3, pGST-NS4B, and pGST-eEF1A.", [["pcDNA", "GENE_OR_GENE_PRODUCT", 26, 31], ["pcDNA-eEF1A-V5HisTopo", "GENE_OR_GENE_PRODUCT", 79, 100], ["XhoI", "GENE_OR_GENE_PRODUCT", 128, 132], ["AgeI restriction endonucleases", "GENE_OR_GENE_PRODUCT", 137, 167], ["DNA polymerase I", "GENE_OR_GENE_PRODUCT", 222, 238], ["pGST-NS3", "GENE_OR_GENE_PRODUCT", 278, 286], ["pGST-NS4B", "GENE_OR_GENE_PRODUCT", 288, 297], ["pGST-eEF1A", "GENE_OR_GENE_PRODUCT", 303, 313], ["-eEF1A", "PROTEIN", 31, 37], ["HisTopo", "PROTEIN", 38, 45], ["V5", "PROTEIN", 51, 53], ["pcDNA-eEF1A", "PROTEIN", 79, 90], ["V5HisTopo", "PROTEIN", 91, 100], ["XhoI and AgeI restriction endonucleases", "DNA", 128, 167], ["Klenow fragment", "DNA", 203, 218], ["DNA polymerase I", "PROTEIN", 222, 238], ["pGST", "PROTEIN", 278, 282], ["NS3", "PROTEIN", 283, 286], ["pGST", "PROTEIN", 288, 292], ["NS4B", "PROTEIN", 293, 297], ["pGST", "PROTEIN", 303, 307], ["eEF1A", "PROTEIN", 308, 313], ["a digestion", "TREATMENT", 111, 122], ["XhoI", "TREATMENT", 128, 132], ["AgeI restriction endonucleases", "TREATMENT", 137, 167], ["the Klenow fragment of DNA polymerase", "TREATMENT", 199, 236], ["self-ligation", "TREATMENT", 248, 261], ["Plasmids pGST", "TREATMENT", 269, 282], ["NS3", "TREATMENT", 283, 286], ["pGST", "TREATMENT", 288, 292], ["NS4B", "TREATMENT", 293, 297], ["pGST", "TREATMENT", 303, 307], ["ligation", "OBSERVATION", 253, 261]]], ["For construction of pGST-NS3, plasmid pcDNA-NS3-V5HisTopo was digested with NcoI and treated with the Klenow fragment of DNA polymerase I prior to a further digestion with XhoI restriction endonuclease.", [["pGST-NS3", "GENE_OR_GENE_PRODUCT", 20, 28], ["pcDNA-NS3-V5HisTopo", "GENE_OR_GENE_PRODUCT", 38, 57], ["NcoI", "GENE_OR_GENE_PRODUCT", 76, 80], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["XhoI", "GENE_OR_GENE_PRODUCT", 172, 176], ["pGST", "PROTEIN", 20, 24], ["NS3", "PROTEIN", 25, 28], ["NS3", "PROTEIN", 44, 47], ["V5HisTopo", "PROTEIN", 48, 57], ["NcoI", "DNA", 76, 80], ["Klenow fragment", "DNA", 102, 117], ["DNA polymerase I", "PROTEIN", 121, 137], ["XhoI restriction endonuclease", "PROTEIN", 172, 201], ["pGST", "TEST", 20, 24], ["NS3", "TREATMENT", 25, 28], ["plasmid pcDNA", "TREATMENT", 30, 43], ["NS3-V5HisTopo", "TREATMENT", 44, 57], ["NcoI", "TREATMENT", 76, 80], ["the Klenow fragment of DNA polymerase", "TREATMENT", 98, 135], ["a further digestion", "TREATMENT", 147, 166], ["XhoI restriction endonuclease", "TREATMENT", 172, 201]]], ["The resulting fragment was inserted into the pGEX-6p-1 from which the polylinker sequences between EcoRI and XhoI had been deleted and the EcoRI site blunted.", [["pGEX-6p-1", "GENE_OR_GENE_PRODUCT", 45, 54], ["polylinker", "GENE_OR_GENE_PRODUCT", 70, 80], ["EcoRI", "GENE_OR_GENE_PRODUCT", 99, 104], ["XhoI", "GENE_OR_GENE_PRODUCT", 109, 113], ["EcoRI", "GENE_OR_GENE_PRODUCT", 139, 144], ["pGEX-6p-1", "DNA", 45, 54], ["polylinker sequences", "DNA", 70, 90], ["EcoRI", "DNA", 99, 104], ["XhoI", "DNA", 109, 113], ["EcoRI site", "DNA", 139, 149], ["The resulting fragment", "PROBLEM", 0, 22], ["the polylinker sequences", "TEST", 66, 90], ["EcoRI and XhoI", "TREATMENT", 99, 113], ["the EcoRI site blunted", "PROBLEM", 135, 157], ["resulting", "OBSERVATION_MODIFIER", 4, 13], ["fragment", "OBSERVATION", 14, 22], ["blunted", "OBSERVATION_MODIFIER", 150, 157]]], ["A similar approach was taken to generate pGST-eEF1A from pcDNA-eEF1A-V5HisTopo.", [["pGST", "GENE_OR_GENE_PRODUCT", 41, 45], ["pcDNA-eEF1A-V5HisTopo", "GENE_OR_GENE_PRODUCT", 57, 78], ["pGST", "PROTEIN", 41, 45], ["-eEF1A", "PROTEIN", 45, 51], ["pcDNA-eEF1A", "PROTEIN", 57, 68], ["V5HisTopo", "PROTEIN", 69, 78]]], ["For generation of plasmid pGST-NS4B, pCRII-Topo-NS4B described earlier was digested with EcoRI restriction endonuclease and the resulting NS4B-containing fragment was inserted into the EcoRI site of pGEX-6p-1. (viii) Deletion mutants of the plasmid pGST-NS4A.", [["pGST-NS4B", "GENE_OR_GENE_PRODUCT", 26, 35], ["pCRII-Topo", "GENE_OR_GENE_PRODUCT", 37, 47], ["EcoRI", "GENE_OR_GENE_PRODUCT", 89, 94], ["EcoRI", "GENE_OR_GENE_PRODUCT", 185, 190], ["pGEX-6p-1", "GENE_OR_GENE_PRODUCT", 199, 208], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 249, 258], ["pGST", "DNA", 26, 30], ["NS4B", "PROTEIN", 31, 35], ["pCRII", "PROTEIN", 37, 42], ["Topo", "PROTEIN", 43, 47], ["NS4B", "PROTEIN", 48, 52], ["EcoRI restriction endonuclease", "DNA", 89, 119], ["NS4B-containing fragment", "DNA", 138, 162], ["EcoRI site", "DNA", 185, 195], ["pGEX-6p-1", "DNA", 199, 208], ["pGST", "PROTEIN", 249, 253], ["NS4A", "PROTEIN", 254, 258], ["plasmid pGST", "TREATMENT", 18, 30], ["NS4B", "TREATMENT", 31, 35], ["pCRII", "TEST", 37, 42], ["Topo", "TREATMENT", 43, 47], ["NS4B", "TREATMENT", 48, 52], ["EcoRI restriction endonuclease", "TREATMENT", 89, 119], ["the resulting NS4B-containing fragment", "TREATMENT", 124, 162], ["the plasmid pGST", "TREATMENT", 237, 253], ["NS4A", "PROBLEM", 254, 258], ["NS4B", "OBSERVATION", 138, 142], ["fragment", "OBSERVATION_MODIFIER", 154, 162]]], ["For construction of plasmids pGST-NS4A(1-34) and pGST-NS4A(21-54), cDNA fragments were obtained by PCR-amplification from pGST-NS4A with primer set 5 \u00a2 -CGGGATCCATATGAGCACCTGGGTGC TTGTA-3 \u00a2 and 5 \u00a2 -GGAATTCACTT CCCGGACAAGAT-3 \u00a2 and primer set 5 \u00a2 -GGAATTCCATATGGGCAGCGTGGTCA TTGT-3 and 5 \u00a2 -GGAATTCAGCACTCCTC CATTTC-3 \u00a2 , respectively, and the resultant fragments were digested with NdeI and EcoRI restriction endonucleases.", [["fragments", "ANATOMY", 354, 363], ["pGST-NS4A(1-34", "GENE_OR_GENE_PRODUCT", 29, 43], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 49, 58], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 122, 131], ["NdeI", "GENE_OR_GENE_PRODUCT", 383, 387], ["EcoRI", "GENE_OR_GENE_PRODUCT", 392, 397], ["plasmids", "DNA", 20, 28], ["pGST", "DNA", 29, 33], ["NS4A", "PROTEIN", 34, 38], ["pGST", "PROTEIN", 49, 53], ["NS4A", "PROTEIN", 54, 58], ["cDNA fragments", "DNA", 67, 81], ["pGST", "DNA", 122, 126], ["NS4A", "PROTEIN", 127, 131], ["primer set 5 \u00a2 -CGGGATCCATATGAGCACCTGGGTGC TTGTA-3 \u00a2 and 5 \u00a2 -GGAATTCACTT CCCGGACAAGAT-3", "DNA", 137, 225], ["primer set 5 \u00a2 -GGAATTCCATATGGGCAGCGTGGTCA TTGT-3", "DNA", 232, 281], ["5 \u00a2", "DNA", 286, 289], ["GGAATTCAGCACTCCTC CATTTC-3 \u00a2", "DNA", 291, 319], ["resultant fragments", "DNA", 344, 363], ["NdeI and EcoRI restriction endonucleases", "DNA", 383, 423], ["plasmids pGST", "TREATMENT", 20, 33], ["NS4A", "TREATMENT", 34, 38], ["pGST", "TEST", 49, 53], ["NS4A", "TREATMENT", 54, 58], ["cDNA fragments", "PROBLEM", 67, 81], ["PCR", "TEST", 99, 102], ["pGST", "TEST", 122, 126], ["primer set", "TEST", 137, 147], ["TTGTA", "TEST", 180, 185], ["CCCGGACAAGAT", "TEST", 211, 223], ["primer set", "TEST", 232, 242], ["TTGT", "TEST", 275, 279], ["GGAATTCAGCACTCCTC CATTTC", "TREATMENT", 291, 315], ["the resultant fragments", "PROBLEM", 340, 363], ["NdeI", "TREATMENT", 383, 387], ["EcoRI restriction endonucleases", "TREATMENT", 392, 423], ["resultant", "OBSERVATION_MODIFIER", 344, 353], ["fragments", "OBSERVATION", 354, 363]]], ["For construction of plasmids pGST-NS4A(1-20), pGST-NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , and pGST-NS4A(35-54), cDNA fragments with NdeI and EcoRI recognition sequences at the 5 \u00a2 and 3 \u00a2 ends, respectively, were generated by annealing the following synthetic oligonucleotide sets: 5 \u00a2 -TATGAGCACCTGGGTGCTTGTAGGCG GGGTCCTTGCAGCTCTGGCCGCATAC TG-3 \u00a2 and 5 \u00a2 -AATTCACGTTGTCAGG CAGTATGCGGCCAGAGCTGCAAGGAC CCCGCCTACAAGCACCCAGGTGCTCA-3 \u00a2 for pGST-NS4A(1-20), 5 \u00a2 -TATGGG CAGCGTGGTCATTGTGGGCAGGATC ATCTTGTCC GGGAAGTG-3 \u00a2 and 5 \u00a2 -AATTCACTTCCCGGACAAGATGATC CTGCCCACAATGACCACGCTGCCCA-3 \u00a2 for pGST-NS 4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , and 5 \u00a2 -TA TGCCGGCTGTCATTCCTGATAGGGA GGTTCTCTACCGGGAGTTCGATGAAA TGGAGGAGTGCTG -3 \u00a2 and 5 \u00a2 -AATTMC AGCACTCCTCCATTTCATCGAACTCC CGGTAGAGAACCTCCCTATCAGGAAT GACAGCCGGCA-3 \u00a2 for pGST-NS4A (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) .", [["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 29, 38], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 46, 55], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 132, 141], ["NdeI", "GENE_OR_GENE_PRODUCT", 170, 174], ["EcoRI", "GENE_OR_GENE_PRODUCT", 179, 184], ["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 474, 483], ["plasmids", "DNA", 20, 28], ["pGST", "DNA", 29, 33], ["NS4A", "PROTEIN", 34, 38], ["pGST", "PROTEIN", 132, 136], ["NS4A", "PROTEIN", 137, 141], ["cDNA fragments", "DNA", 150, 164], ["NdeI and EcoRI recognition sequences", "DNA", 170, 206], ["5 \u00a2 and 3 \u00a2 ends", "DNA", 214, 230], ["pGST", "PROTEIN", 474, 478], ["NS4A", "PROTEIN", 479, 483], ["plasmids pGST", "TREATMENT", 20, 33], ["pGST", "TEST", 132, 136], ["NS4A", "TEST", 137, 141], ["cDNA fragments", "TEST", 150, 164], ["NdeI", "TEST", 170, 174], ["EcoRI recognition sequences", "TEST", 179, 206], ["TG", "TEST", 379, 381], ["CCCGCCTACAAGCACCCAGGTGCTCA", "TEST", 439, 465], ["pGST", "TEST", 474, 478], ["NS4A", "TEST", 479, 483], ["GGGAAGTG", "TEST", 539, 547], ["CTGCCCACAATGACCACGCTGCCCA", "TEST", 587, 612], ["pGST", "TEST", 621, 625], ["TGGAGGAGTGCTG", "TEST", 769, 782], ["GACAGCCGGCA", "TEST", 858, 869], ["pGST", "TEST", 878, 882], ["NS4A", "TEST", 883, 887], ["NS4A", "ANATOMY", 34, 38], ["NS4A", "ANATOMY", 137, 141]]], ["These cDNA fragments were used to replace the cognate fragment of pGST-NS4A to generate the deletion mutants of GST-NS4A.Plasmids(ix) Plasmids pCMV-Luc and pJSS12.", [["pGST-NS4A", "GENE_OR_GENE_PRODUCT", 66, 75], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 112, 120], ["pCMV-Luc", "GENE_OR_GENE_PRODUCT", 143, 151], ["cDNA fragments", "DNA", 6, 20], ["pGST", "PROTEIN", 66, 70], ["NS4A", "PROTEIN", 71, 75], ["GST", "PROTEIN", 112, 115], ["NS4A", "PROTEIN", 116, 120], ["pCMV", "PROTEIN", 143, 147], ["Luc", "DNA", 148, 151], ["pJSS12", "DNA", 156, 162], ["These cDNA fragments", "PROBLEM", 0, 20], ["NS4A", "TREATMENT", 71, 75], ["NS4A", "PROBLEM", 116, 120], ["Plasmids(ix", "TREATMENT", 121, 132], ["Plasmids pCMV", "TREATMENT", 134, 147], ["pJSS12", "TREATMENT", 156, 162], ["cDNA fragments", "OBSERVATION", 6, 20]]], ["Plasmid pCMV-Luc represents a cap-dependent monocistronic reporter of firefly luciferase that is driven by the promoter of cytomegalovirus. pJSS12 represents a bicistronic luciferase reporter containing the structure components of CMV promoter-T7 promoter-Renilla luciferase-stem loop-IRES(HCV1-371)-Firefly luciferase-poly A. Transcription of the bicistronic reporter can be driven by the promoter of cytomegalovirus in culture cells or by the promoter of T7 RNA polymerase in vitro.", [["culture cells", "ANATOMY", 421, 434], ["pCMV-Luc", "GENE_OR_GENE_PRODUCT", 8, 16], ["luciferase", "GENE_OR_GENE_PRODUCT", 78, 88], ["cytomegalovirus", "ORGANISM", 123, 138], ["pJSS12", "GENE_OR_GENE_PRODUCT", 140, 146], ["luciferase", "GENE_OR_GENE_PRODUCT", 172, 182], ["CMV", "ORGANISM", 231, 234], ["luciferase", "GENE_OR_GENE_PRODUCT", 264, 274], ["luciferase-poly A.", "GENE_OR_GENE_PRODUCT", 308, 326], ["cytomegalovirus", "ORGANISM", 402, 417], ["culture cells", "CELL", 421, 434], ["T7", "GENE_OR_GENE_PRODUCT", 457, 459], ["pCMV", "DNA", 8, 12], ["Luc", "DNA", 13, 16], ["cap-dependent monocistronic reporter", "DNA", 30, 66], ["firefly luciferase", "DNA", 70, 88], ["pJSS12", "DNA", 140, 146], ["bicistronic luciferase reporter", "DNA", 160, 191], ["CMV promoter", "DNA", 231, 243], ["T7 promoter", "DNA", 244, 255], ["Renilla luciferase-stem loop-IRES(HCV1-371)-Firefly luciferase", "DNA", 256, 318], ["bicistronic reporter", "DNA", 348, 368], ["T7 RNA polymerase", "PROTEIN", 457, 474], ["Plasmid pCMV", "TREATMENT", 0, 12], ["a cap", "PROBLEM", 28, 33], ["firefly luciferase", "PROBLEM", 70, 88], ["cytomegalovirus", "PROBLEM", 123, 138], ["a bicistronic luciferase reporter", "TREATMENT", 158, 191], ["CMV promoter-T7 promoter", "TREATMENT", 231, 255], ["Renilla luciferase", "TEST", 256, 274], ["HCV1", "TEST", 290, 294], ["Firefly luciferase", "TREATMENT", 300, 318], ["the bicistronic reporter", "TREATMENT", 344, 368], ["cytomegalovirus in culture cells", "PROBLEM", 402, 434], ["cap", "OBSERVATION_MODIFIER", 30, 33], ["firefly luciferase", "OBSERVATION", 70, 88], ["cytomegalovirus", "OBSERVATION", 123, 138], ["bicistronic luciferase", "OBSERVATION", 160, 182], ["CMV promoter", "OBSERVATION", 231, 243], ["cytomegalovirus", "OBSERVATION", 402, 417], ["T7", "ANATOMY", 457, 459]]], ["Expression of the Renilla luciferase and firefly luciferase genes are directed by the cap-dependent and HCV-IRES-mediated mechanism, respectively.", [["Renilla", "GENE_OR_GENE_PRODUCT", 18, 25], ["luciferase", "GENE_OR_GENE_PRODUCT", 26, 36], ["firefly", "GENE_OR_GENE_PRODUCT", 41, 48], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["cap-", "GENE_OR_GENE_PRODUCT", 86, 90], ["Renilla luciferase and firefly luciferase genes", "DNA", 18, 65], ["IRES", "DNA", 108, 112], ["the Renilla luciferase", "TREATMENT", 14, 36], ["firefly luciferase genes", "TREATMENT", 41, 65], ["HCV-IRES", "TREATMENT", 104, 112], ["Renilla luciferase", "OBSERVATION", 18, 36]]], ["In addition, the stem loop structure is derived from the sequence 5\u00a2-GTACCCCGGTACGGCAGTG CCGTACGACGAATTCGTCGTACGGCA CTGCC GTACCGGGGTAC-3\u00a2 and was inserted into the bicistronic structure to prevent leaky scanning of ribosome.Expression and purification of GST fusion proteinsGST fusion plasmids were transformed into Escherichia coli BL21, or BL21(DE3) where indicated.", [["stem loop", "ANATOMY", 17, 26], ["ribosome", "ANATOMY", 215, 223], ["ribosome", "CELLULAR_COMPONENT", 215, 223], ["GST", "GENE_OR_GENE_PRODUCT", 255, 258], ["proteinsGST", "GENE_OR_GENE_PRODUCT", 266, 277], ["Escherichia coli", "ORGANISM", 316, 332], ["BL21", "ORGANISM", 333, 337], ["BL21", "GENE_OR_GENE_PRODUCT", 342, 346], ["DE3", "GENE_OR_GENE_PRODUCT", 347, 350], ["GST fusion proteinsGST fusion plasmids", "DNA", 255, 293], ["Escherichia coli BL21", "SPECIES", 316, 337], ["Escherichia coli BL21", "SPECIES", 316, 337], ["BL21", "SPECIES", 342, 346], ["DE3", "SPECIES", 347, 350], ["the stem loop structure", "PROBLEM", 13, 36], ["GTACCCCGGTACGGCAGTG CCGTACGACGAATTCGTCGTACGGCA CTGCC GTACCGGGGTAC", "TREATMENT", 69, 134], ["leaky scanning of ribosome", "PROBLEM", 197, 223], ["GST fusion proteinsGST fusion plasmids", "TREATMENT", 255, 293], ["Escherichia coli BL21", "TEST", 316, 337], ["stem loop", "OBSERVATION", 17, 26], ["bicistronic structure", "OBSERVATION", 164, 185], ["leaky scanning", "OBSERVATION", 197, 211], ["ribosome", "OBSERVATION_MODIFIER", 215, 223], ["Escherichia coli", "OBSERVATION", 316, 332]]], ["The bacterial cells were grown in LB or 2X YT medium containing 50 lg ampicillin/ml to a density of 0.6-0.8 at 600 nm.", [["cells", "ANATOMY", 14, 19], ["ampicillin", "CHEMICAL", 70, 80], ["ampicillin", "CHEMICAL", 70, 80], ["bacterial cells", "CELL", 4, 19], ["ampicillin", "SIMPLE_CHEMICAL", 70, 80], ["bacterial cells", "CELL_TYPE", 4, 19], ["The bacterial cells", "PROBLEM", 0, 19], ["lg ampicillin", "TREATMENT", 67, 80], ["a density", "TEST", 87, 96], ["bacterial cells", "OBSERVATION", 4, 19]]], ["Following an induction of the expression of GST fusion proteins with isopropyl-b-D-thiogalactopyranoside (IPTG), the bacterial cells were harvested and resuspended in lysis buffer consisting of 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1.5% N-laurylsarcosine, and 2% Triton X-100.", [["cells", "ANATOMY", 127, 132], ["isopropyl-b-D-thiogalactopyranoside", "CHEMICAL", 69, 104], ["IPTG", "CHEMICAL", 106, 110], ["Tris-HCl", "CHEMICAL", 200, 208], ["NaCl", "CHEMICAL", 225, 229], ["EDTA", "CHEMICAL", 236, 240], ["N-laurylsarcosine", "CHEMICAL", 247, 264], ["Triton X-100", "CHEMICAL", 273, 285], ["isopropyl-b-D-thiogalactopyranoside", "CHEMICAL", 69, 104], ["IPTG", "CHEMICAL", 106, 110], ["Tris", "CHEMICAL", 200, 204], ["HCl", "CHEMICAL", 205, 208], ["NaCl", "CHEMICAL", 225, 229], ["EDTA", "CHEMICAL", 236, 240], ["N-laurylsarcosine", "CHEMICAL", 247, 264], ["Triton X-100", "CHEMICAL", 273, 285], ["GST", "GENE_OR_GENE_PRODUCT", 44, 47], ["isopropyl-b-D-thiogalactopyranoside", "SIMPLE_CHEMICAL", 69, 104], ["IPTG", "SIMPLE_CHEMICAL", 106, 110], ["bacterial cells", "CELL", 117, 132], ["Tris-HCl", "SIMPLE_CHEMICAL", 200, 208], ["EDTA", "SIMPLE_CHEMICAL", 236, 240], ["N-laurylsarcosine", "SIMPLE_CHEMICAL", 247, 264], ["Triton X-100", "SIMPLE_CHEMICAL", 273, 285], ["GST fusion proteins", "PROTEIN", 44, 63], ["bacterial cells", "CELL_TYPE", 117, 132], ["GST fusion proteins", "TREATMENT", 44, 63], ["isopropyl", "TREATMENT", 69, 78], ["b-D-thiogalactopyranoside (IPTG", "TREATMENT", 79, 110], ["the bacterial cells", "PROBLEM", 113, 132], ["lysis buffer", "TREATMENT", 167, 179], ["pH", "TEST", 210, 212], ["NaCl", "TEST", 225, 229], ["EDTA", "TEST", 236, 240], ["laurylsarcosine", "TREATMENT", 249, 264], ["2% Triton", "TREATMENT", 270, 279], ["bacterial cells", "OBSERVATION", 117, 132]]], ["After two freeze-thaw cycles and sonication, cell lysates were separated into soluble and insoluble fractions.", [["cell lysates", "ANATOMY", 45, 57], ["cell lysates", "ORGANISM_SUBSTANCE", 45, 57], ["two freeze-thaw cycles", "TREATMENT", 6, 28], ["sonication", "TREATMENT", 33, 43], ["cell lysates", "TREATMENT", 45, 57], ["cell lysates", "OBSERVATION", 45, 57]]], ["For partial purification of GST fusion proteins, the soluble fractions were incubated with glutathione-Sepharose 4B beads (GE Healthcare Bio-Sciences) at 4\u00b0C for 2 h.", [["glutathione", "CHEMICAL", 91, 102], ["glutathione", "CHEMICAL", 91, 102], ["GST", "GENE_OR_GENE_PRODUCT", 28, 31], ["glutathione", "SIMPLE_CHEMICAL", 91, 102], ["GST fusion proteins", "PROTEIN", 28, 47], ["partial purification of GST fusion proteins", "TREATMENT", 4, 47], ["the soluble fractions", "TEST", 49, 70], ["glutathione-Sepharose 4B beads", "TREATMENT", 91, 121]]], ["Following a centrifugation in a microcentrifuge for 5 min, GST fusion proteins immobilized on the beads were spun-down and washed for five times with PBS.", [["beads", "ANATOMY", 98, 103], ["GST", "GENE_OR_GENE_PRODUCT", 59, 62], ["GST fusion proteins", "PROTEIN", 59, 78], ["a centrifugation in a microcentrifuge", "TREATMENT", 10, 47], ["GST fusion proteins", "TREATMENT", 59, 78], ["the beads", "TREATMENT", 94, 103], ["PBS", "TREATMENT", 150, 153]]], ["As a control, plasmid pGEX-6p-1 was transformed into the bacterial cells, and the expression and purification of GST protein were performed in parallel.", [["plasmid", "ANATOMY", 14, 21], ["cells", "ANATOMY", 67, 72], ["pGEX-6p-1", "CHEMICAL", 22, 31], ["pGEX-6p-1", "GENE_OR_GENE_PRODUCT", 22, 31], ["bacterial cells", "CELL", 57, 72], ["GST", "GENE_OR_GENE_PRODUCT", 113, 116], ["plasmid pGEX-6p-1", "DNA", 14, 31], ["bacterial cells", "CELL_TYPE", 57, 72], ["GST protein", "PROTEIN", 113, 124], ["plasmid pGEX", "TEST", 14, 26], ["the bacterial cells", "PROBLEM", 53, 72], ["purification of GST protein", "TEST", 97, 124], ["bacterial cells", "OBSERVATION", 57, 72]]], ["In the in vitro translation inhibition assay, GST fusion proteins of the HCV nonstructural proteins were recovered from the beads with 10 mM glutathione in 50 mM Tris-HCl (pH 8.0).", [["glutathione", "CHEMICAL", 141, 152], ["Tris-HCl", "CHEMICAL", 162, 170], ["glutathione", "CHEMICAL", 141, 152], ["Tris-HCl", "CHEMICAL", 162, 170], ["GST", "GENE_OR_GENE_PRODUCT", 46, 49], ["HCV", "ORGANISM", 73, 76], ["glutathione", "SIMPLE_CHEMICAL", 141, 152], ["Tris-HCl", "SIMPLE_CHEMICAL", 162, 170], ["GST fusion proteins", "PROTEIN", 46, 65], ["HCV nonstructural proteins", "PROTEIN", 73, 99], ["HCV", "SPECIES", 73, 76], ["assay", "TEST", 39, 44], ["GST fusion proteins", "TEST", 46, 65], ["the HCV nonstructural proteins", "PROBLEM", 69, 99], ["10 mM glutathione", "TREATMENT", 135, 152], ["pH", "TEST", 172, 174]]], ["In addition, eEF1A was recovered from beads-immobilized GST-eEF1A with PreScission TM Protease (GE Healthcare Bio-Sciences).Cell line and expression of recombinant proteins in culture cellsHuh7 cells (a human hepatoma cell line) were maintained at 37\u00b0C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum plus 100 units of penicillin, and 100 lg of streptomycin/ml.", [["Cell line", "ANATOMY", 124, 133], ["culture cellsHuh7 cells", "ANATOMY", 176, 199], ["hepatoma cell line", "ANATOMY", 209, 227], ["fetal calf serum", "ANATOMY", 320, 336], ["penicillin", "CHEMICAL", 355, 365], ["streptomycin", "CHEMICAL", 381, 393], ["penicillin", "CHEMICAL", 355, 365], ["streptomycin", "CHEMICAL", 381, 393], ["eEF1A", "GENE_OR_GENE_PRODUCT", 13, 18], ["GST-eEF1A", "GENE_OR_GENE_PRODUCT", 56, 65], ["Cell line", "CELL", 124, 133], ["culture cells", "CELL", 176, 189], ["Huh7 cells", "CELL", 189, 199], ["human", "ORGANISM", 203, 208], ["hepatoma cell line", "CELL", 209, 227], ["calf", "ORGANISM", 326, 330], ["serum", "ORGANISM_SUBSTANCE", 331, 336], ["penicillin", "SIMPLE_CHEMICAL", 355, 365], ["streptomycin", "SIMPLE_CHEMICAL", 381, 393], ["eEF1A", "PROTEIN", 13, 18], ["GST", "PROTEIN", 56, 59], ["eEF1A", "PROTEIN", 60, 65], ["recombinant proteins", "PROTEIN", 152, 172], ["culture cells", "CELL_LINE", 176, 189], ["Huh7 cells", "CELL_LINE", 189, 199], ["human hepatoma cell line", "CELL_LINE", 203, 227], ["human", "SPECIES", 203, 208], ["calf", "SPECIES", 326, 330], ["human", "SPECIES", 203, 208], ["PreScission TM Protease", "TREATMENT", 71, 94], ["Cell line", "TREATMENT", 124, 133], ["recombinant proteins", "PROBLEM", 152, 172], ["culture cells", "TEST", 176, 189], ["Huh7 cells", "PROBLEM", 189, 199], ["a human hepatoma cell line", "TREATMENT", 201, 227], ["10% fetal calf serum", "TREATMENT", 316, 336], ["penicillin", "TREATMENT", 355, 365], ["streptomycin", "TREATMENT", 381, 393], ["recombinant proteins", "OBSERVATION_MODIFIER", 152, 172], ["culture cells", "OBSERVATION", 176, 189], ["Huh7 cells", "OBSERVATION", 189, 199], ["hepatoma", "ANATOMY", 209, 217], ["cell line", "OBSERVATION", 218, 227], ["calf", "ANATOMY", 326, 330]]], ["Expression of recombinant proteins in Huh7 cells was preformed by DNA transfection with cationic liposomes (Invitrogen) or by infecting cells with recombinant vaccinia virus (vTF7-3) harboring T7 RNA polymerase gene followed by DNA transfection as described previously [18] .", [["Huh7 cells", "ANATOMY", 38, 48], ["cells", "ANATOMY", 136, 141], ["Huh7 cells", "CELL", 38, 48], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["cationic liposomes", "SIMPLE_CHEMICAL", 88, 106], ["Invitrogen", "SIMPLE_CHEMICAL", 108, 118], ["cells", "CELL", 136, 141], ["vaccinia virus", "ORGANISM", 159, 173], ["vTF7-3", "GENE_OR_GENE_PRODUCT", 175, 181], ["T7", "GENE_OR_GENE_PRODUCT", 193, 195], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["recombinant proteins", "PROTEIN", 14, 34], ["Huh7 cells", "CELL_LINE", 38, 48], ["T7 RNA polymerase gene", "DNA", 193, 215], ["vaccinia virus", "SPECIES", 159, 173], ["recombinant proteins in Huh7 cells", "PROBLEM", 14, 48], ["DNA transfection with cationic liposomes (Invitrogen)", "TREATMENT", 66, 119], ["infecting cells", "PROBLEM", 126, 141], ["recombinant vaccinia virus", "TREATMENT", 147, 173], ["vTF7", "TREATMENT", 175, 179], ["harboring T7 RNA polymerase gene", "TREATMENT", 183, 215], ["DNA transfection", "TREATMENT", 228, 244], ["Huh7 cells", "OBSERVATION", 38, 48], ["T7", "ANATOMY", 193, 195]]], ["Two days posttransfection, the transfected cells were harvested for further analysis.Cell line and expression of recombinant proteins in culture cellsPreparation of Huh7 cell lysates, in vitro translation products, and the NS4A(21-34) peptideCell line and expression of recombinant proteins in culture cellsTo perform GST pull-down assay, cell lysates were prepared from Huh7 cells grown to confluency with a lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% sodium deoxycholate, 1% NP-40, and 0.1% SDS.", [["cells", "ANATOMY", 43, 48], ["Cell line", "ANATOMY", 85, 94], ["culture cells", "ANATOMY", 137, 150], ["Huh7 cell lysates", "ANATOMY", 165, 182], ["culture cells", "ANATOMY", 294, 307], ["cell lysates", "ANATOMY", 339, 351], ["Huh7 cells", "ANATOMY", 371, 381], ["Tris-HCl", "CHEMICAL", 439, 447], ["NaCl", "CHEMICAL", 464, 468], ["sodium deoxycholate", "CHEMICAL", 473, 492], ["NP-40", "CHEMICAL", 497, 502], ["Tris", "CHEMICAL", 439, 443], ["HCl", "CHEMICAL", 444, 447], ["NaCl", "CHEMICAL", 464, 468], ["sodium deoxycholate", "CHEMICAL", 473, 492], ["cells", "CELL", 43, 48], ["Cell line", "CELL", 85, 94], ["culture cells", "CELL", 137, 150], ["Huh7 cell lysates", "CELL", 165, 182], ["culture cells", "CELL", 294, 307], ["GST", "GENE_OR_GENE_PRODUCT", 318, 321], ["cell lysates", "CELL", 339, 351], ["Huh7 cells", "CELL", 371, 381], ["Tris-HCl", "SIMPLE_CHEMICAL", 439, 447], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 473, 492], ["transfected cells", "CELL_LINE", 31, 48], ["recombinant proteins", "PROTEIN", 113, 133], ["culture cells", "CELL_LINE", 137, 150], ["NS4A", "PROTEIN", 223, 227], ["recombinant proteins", "PROTEIN", 270, 290], ["culture cells", "CELL_LINE", 294, 307], ["GST", "PROTEIN", 318, 321], ["Huh7 cells", "CELL_LINE", 371, 381], ["the transfected cells", "PROBLEM", 27, 48], ["further analysis", "TEST", 68, 84], ["Cell line", "TREATMENT", 85, 94], ["recombinant proteins", "PROBLEM", 113, 133], ["culture cells", "TEST", 137, 150], ["Huh7 cell lysates", "TREATMENT", 165, 182], ["vitro translation products", "TREATMENT", 187, 213], ["the NS4A", "TREATMENT", 219, 227], ["peptideCell line", "TREATMENT", 235, 251], ["recombinant proteins", "TREATMENT", 270, 290], ["culture cells", "TEST", 294, 307], ["GST pull", "TEST", 318, 326], ["cell lysates", "TREATMENT", 339, 351], ["Huh7 cells", "TREATMENT", 371, 381], ["a lysis buffer", "TREATMENT", 407, 421], ["pH", "TEST", 449, 451], ["NaCl", "TEST", 464, 468], ["1% sodium deoxycholate", "TREATMENT", 470, 492], ["NP", "TEST", 497, 499], ["transfected cells", "OBSERVATION", 31, 48], ["recombinant proteins", "OBSERVATION", 113, 133], ["culture cells", "OBSERVATION", 137, 150], ["Huh7 cell lysates", "OBSERVATION", 165, 182]]], ["In vitro translation was performed in the presence of [ 35 S]methionine (NEN) by the T N T \u00d2 Quick Coupled Transcription/Translation System (Promega).", [["[ 35 S]methionine", "CHEMICAL", 54, 71], ["[ 35 S]methionine", "CHEMICAL", 54, 71], ["NEN", "CHEMICAL", 73, 76], ["[ 35 S]methionine", "SIMPLE_CHEMICAL", 54, 71], ["NEN", "SIMPLE_CHEMICAL", 73, 76], ["methionine", "TREATMENT", 61, 71]]], ["In addition, the NS4A(21-34) peptide used in the in vitro translation inhibition assay was synthesized and purified through HPLC to > 85% purity.GST pull-down assayTo perform GST pull-down assay, GST fusion proteins immobilized on glutathione-Sepharose 4B beads were incubated independently with the Huh7 cell lysates or in vitro translation products at 4\u00b0C for 2 h.", [["Huh7 cell lysates", "ANATOMY", 300, 317], ["21-34) peptide", "CHEMICAL", 22, 36], ["glutathione", "CHEMICAL", 231, 242], ["glutathione", "CHEMICAL", 231, 242], ["GST", "GENE_OR_GENE_PRODUCT", 145, 148], ["GST", "GENE_OR_GENE_PRODUCT", 175, 178], ["GST", "GENE_OR_GENE_PRODUCT", 196, 199], ["glutathione", "SIMPLE_CHEMICAL", 231, 242], ["Huh7 cell lysates", "CELL", 300, 317], ["NS4A", "PROTEIN", 17, 21], ["GST", "PROTEIN", 145, 148], ["GST", "PROTEIN", 175, 178], ["GST fusion proteins", "PROTEIN", 196, 215], ["the NS4A", "TREATMENT", 13, 21], ["HPLC", "TEST", 124, 128], ["GST pull", "TEST", 145, 153], ["GST pull", "TEST", 175, 183], ["assay", "TEST", 189, 194], ["GST fusion proteins", "TREATMENT", 196, 215], ["glutathione-Sepharose 4B beads", "TREATMENT", 231, 261], ["the Huh7 cell lysates", "TREATMENT", 296, 317], ["vitro translation products", "TREATMENT", 324, 350]]], ["The protein-bound glutathione beads were then washed for five times with PBS and boiled for 5 min prior to SDS-PAGE.", [["glutathione", "CHEMICAL", 18, 29], ["glutathione", "CHEMICAL", 18, 29], ["glutathione", "SIMPLE_CHEMICAL", 18, 29], ["The protein-bound glutathione beads", "TREATMENT", 0, 35], ["PBS", "TREATMENT", 73, 76]]], ["Proteins that copurified with GST fusion proteins were visualized by Coomassie blue staining, silver staining, or autoradiography.", [["silver", "CHEMICAL", 94, 100], ["Coomassie blue", "CHEMICAL", 69, 83], ["silver", "CHEMICAL", 94, 100], ["GST", "GENE_OR_GENE_PRODUCT", 30, 33], ["Coomassie", "SIMPLE_CHEMICAL", 69, 78], ["silver", "SIMPLE_CHEMICAL", 94, 100], ["GST fusion proteins", "PROTEIN", 30, 49], ["GST fusion proteins", "PROBLEM", 30, 49], ["Coomassie blue staining", "TEST", 69, 92], ["silver staining", "TEST", 94, 109], ["autoradiography", "TEST", 114, 129]]], ["Identities of the copurified proteins were further examined by Western blot analysis.Coimmunoprecipitation and Western blot analysisTo perform coimmunoprecipitation experiments, transfected cells were washed twice with PBS and lysed in a RIPA buffer consisting of 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% sodium deoxycholate, 1% NP-40, 0.1% SDS, and Complete TM protease inhibitors (Roche).", [["cells", "ANATOMY", 190, 195], ["Tris-HCl", "CHEMICAL", 270, 278], ["NaCl", "CHEMICAL", 295, 299], ["sodium deoxycholate", "CHEMICAL", 304, 323], ["NP-40", "CHEMICAL", 328, 333], ["Tris", "CHEMICAL", 270, 274], ["HCl", "CHEMICAL", 275, 278], ["NaCl", "CHEMICAL", 295, 299], ["sodium deoxycholate", "CHEMICAL", 304, 323], ["cells", "CELL", 190, 195], ["Tris-HCl", "SIMPLE_CHEMICAL", 270, 278], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 304, 323], ["NP-40", "SIMPLE_CHEMICAL", 328, 333], ["copurified proteins", "PROTEIN", 18, 37], ["transfected cells", "CELL_LINE", 178, 195], ["the copurified proteins", "PROBLEM", 14, 37], ["blot analysis", "TEST", 71, 84], ["Coimmunoprecipitation", "TREATMENT", 85, 106], ["Western blot analysisTo", "TEST", 111, 134], ["coimmunoprecipitation experiments", "TREATMENT", 143, 176], ["transfected cells", "PROBLEM", 178, 195], ["PBS", "TREATMENT", 219, 222], ["a RIPA buffer", "TREATMENT", 236, 249], ["pH", "TEST", 280, 282], ["NaCl", "TEST", 295, 299], ["1% sodium deoxycholate", "TREATMENT", 301, 323], ["NP", "TEST", 328, 330], ["Complete TM protease inhibitors", "TREATMENT", 349, 380]]], ["Equivalent amounts of the cell lysates were incubated with specific antibodies for 16 h at 4\u00b0C and then with protein A Sepharose CL-4B (GE Healthcare Bio-Sciences) for additional 4 h.", [["cell lysates", "ANATOMY", 26, 38], ["cell lysates", "ORGANISM_SUBSTANCE", 26, 38], ["C", "SIMPLE_CHEMICAL", 93, 94], ["specific antibodies", "PROTEIN", 59, 78], ["the cell lysates", "TEST", 22, 38], ["specific antibodies", "TEST", 59, 78], ["protein", "TEST", 109, 116], ["A Sepharose CL", "TEST", 117, 131], ["amounts", "OBSERVATION_MODIFIER", 11, 18], ["cell lysates", "OBSERVATION", 26, 38]]], ["The immunoprecipitates were washed five times with RIPA buffer and resuspended in a lysis buffer consisting of 1.7 mM urea, 3.3% SDS, and 0.65 M b-mercaptoethanol.", [["immunoprecipitates", "ANATOMY", 4, 22], ["urea", "CHEMICAL", 118, 122], ["b-mercaptoethanol", "CHEMICAL", 145, 162], ["urea", "CHEMICAL", 118, 122], ["SDS", "CHEMICAL", 129, 132], ["b-mercaptoethanol", "CHEMICAL", 145, 162], ["urea", "SIMPLE_CHEMICAL", 118, 122], ["b-mercaptoethanol", "SIMPLE_CHEMICAL", 145, 162], ["The immunoprecipitates", "TREATMENT", 0, 22], ["RIPA buffer", "TREATMENT", 51, 62], ["a lysis buffer", "TREATMENT", 82, 96], ["1.7 mM urea", "TREATMENT", 111, 122], ["b-mercaptoethanol", "TREATMENT", 145, 162]]], ["The resultant supernatants were resolved on polyacrylamide gel and subjected to Western blot analysis.", [["supernatants", "ANATOMY", 14, 26], ["polyacrylamide", "CHEMICAL", 44, 58], ["The resultant supernatants", "PROBLEM", 0, 26], ["polyacrylamide gel", "TREATMENT", 44, 62], ["blot analysis", "TEST", 88, 101], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["supernatants", "OBSERVATION", 14, 26]]], ["Western blot analysis was performed as described previously [19] .", [["Western blot analysis", "TEST", 0, 21]]], ["The specific interactions between antigens and antibodies were detected by the enhanced chemiluminescence system (GE Healthcare Bio-Sciences).AntibodiesMouse monoclonal antibody against V5 epitope (GKPIPNPLLGLDST) was purchased from Invitrogen.", [["Mouse", "ORGANISM", 152, 157], ["monoclonal antibody against V5 epitope", "GENE_OR_GENE_PRODUCT", 158, 196], ["antigens", "PROTEIN", 34, 42], ["antibodies", "PROTEIN", 47, 57], ["Mouse monoclonal antibody", "PROTEIN", 152, 177], ["V5 epitope", "PROTEIN", 186, 196], ["GKPIPNPLLGLDST", "PROTEIN", 198, 212], ["Mouse", "SPECIES", 152, 157], ["Mouse", "SPECIES", 152, 157], ["Antibodies", "TEST", 142, 152], ["Mouse monoclonal antibody", "TEST", 152, 177], ["V5 epitope (GKPIPNPLLGLDST)", "TREATMENT", 186, 213]]], ["Rabbit polyclonal antibody against His-tag was purchased from Santa Cruz.", [["Rabbit", "ORGANISM", 0, 6], ["Rabbit polyclonal antibody", "PROTEIN", 0, 26], ["His-tag", "PROTEIN", 35, 42], ["Santa Cruz", "PROTEIN", 62, 72], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit polyclonal antibody", "TEST", 0, 26]]], ["Mouse monoclonal antibody against eEF1A was purchased from Upstate.", [["Mouse", "ORGANISM", 0, 5], ["eEF1A", "GENE_OR_GENE_PRODUCT", 34, 39], ["Upstate", "GENE_OR_GENE_PRODUCT", 59, 66], ["Mouse monoclonal antibody", "PROTEIN", 0, 25], ["eEF1A", "PROTEIN", 34, 39], ["Upstate", "PROTEIN", 59, 66], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse monoclonal antibody", "TEST", 0, 25]]], ["Goat polyclonal antibody against luciferase was purchased from Promega.RT-PCR of luciferase mRNAThe level of luciferase mRNA was examined by RT-PCR.", [["Goat", "GENE_OR_GENE_PRODUCT", 0, 4], ["luciferase", "GENE_OR_GENE_PRODUCT", 33, 43], ["luciferase mRNAThe", "GENE_OR_GENE_PRODUCT", 81, 99], ["luciferase", "GENE_OR_GENE_PRODUCT", 109, 119], ["Goat polyclonal antibody", "PROTEIN", 0, 24], ["luciferase", "PROTEIN", 33, 43], ["luciferase", "PROTEIN", 81, 91], ["luciferase mRNA", "RNA", 109, 124], ["Goat", "SPECIES", 0, 4], ["Goat", "SPECIES", 0, 4], ["Goat polyclonal antibody", "TEST", 0, 24], ["luciferase", "PROBLEM", 33, 43], ["RT-PCR of luciferase", "TEST", 71, 91], ["luciferase mRNA", "TEST", 109, 124], ["RT", "TEST", 141, 143], ["PCR", "TEST", 144, 147]]], ["In brief, total RNA was isolated from culture cells by using TRIzol \u00d2 reagent (Invitrogen).", [["culture cells", "ANATOMY", 38, 51], ["culture cells", "CELL", 38, 51], ["culture cells", "CELL_LINE", 38, 51], ["culture cells", "TEST", 38, 51], ["TRIzol \u00d2 reagent (Invitrogen", "TREATMENT", 61, 89]]], ["Reverse transcription was performed with the RNA template, AMV reverse transcriptase (Roche), and oligo-dT primer.", [["AMV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 59, 84], ["Roche", "GENE_OR_GENE_PRODUCT", 86, 91], ["RNA template", "DNA", 45, 57], ["AMV reverse transcriptase", "PROTEIN", 59, 84], ["Reverse transcription", "TREATMENT", 0, 21], ["the RNA template", "TREATMENT", 41, 57], ["AMV reverse transcriptase", "TREATMENT", 59, 84], ["oligo-dT primer", "TREATMENT", 98, 113]]], ["The products were subjected to polymerase chain reaction with the primer set 5\u00a2-CAGAGGACCTATGATTATGTC 3\u00a2 and 5\u00a2-CGGTACTTCGTCCACAAACACAA C-3\u00a2.", [["5\u00a2-CGGTACTTCGTCCACAAACACAA C-3\u00a2", "DNA", 109, 140], ["polymerase chain reaction", "PROBLEM", 31, 56], ["the primer set", "TEST", 62, 76], ["CAGAGGACCTATGATTATGTC", "TEST", 80, 101]]], ["In addition, primers 5\u00a2-GAAGGTGAAGG TCGGACTC-3\u00a2 and 5\u00a2-TTTAGCCTTCTGA GCTTTCTGG-3\u00a2 were used in parallel to analyze the level of GAPDH mRNA as an internal control.Translation inhibition assay in cell culture systemTo perform translation inhibition assay in culture cells, plasmids encoding V5-tagged HCV nonstructure proteins NS3, NS4A, NS4B, and NS4A mutants were independently cotransfected with the cap-dependent monocistronic luciferase reporter pCMV-Luc or the bicistronic luciferase reporter pJSS12 into Huh7 cells.", [["cell culture", "ANATOMY", 194, 206], ["culture cells", "ANATOMY", 256, 269], ["plasmids", "ANATOMY", 271, 279], ["Huh7 cells", "ANATOMY", 509, 519], ["GAPDH", "GENE_OR_GENE_PRODUCT", 128, 133], ["cell", "CELL", 194, 198], ["culture cells", "CELL", 256, 269], ["V5", "GENE_OR_GENE_PRODUCT", 289, 291], ["NS3", "GENE_OR_GENE_PRODUCT", 325, 328], ["NS4A", "GENE_OR_GENE_PRODUCT", 330, 334], ["NS4B", "GENE_OR_GENE_PRODUCT", 336, 340], ["luciferase", "GENE_OR_GENE_PRODUCT", 429, 439], ["pCMV-Luc", "GENE_OR_GENE_PRODUCT", 449, 457], ["luciferase reporter pJSS12", "GENE_OR_GENE_PRODUCT", 477, 503], ["Huh7 cells", "CELL", 509, 519], ["primers 5\u00a2-GAAGGTGAAGG TCGGACTC-3\u00a2 and 5\u00a2-TTTAGCCTTCTGA GCTTTCTGG-3\u00a2", "DNA", 13, 81], ["GAPDH mRNA", "RNA", 128, 138], ["culture cells", "CELL_LINE", 256, 269], ["V5", "PROTEIN", 289, 291], ["HCV nonstructure proteins", "PROTEIN", 299, 324], ["NS3", "PROTEIN", 325, 328], ["NS4A", "PROTEIN", 330, 334], ["NS4B", "PROTEIN", 336, 340], ["NS4A mutants", "PROTEIN", 346, 358], ["cap-dependent monocistronic luciferase reporter pCMV-Luc", "DNA", 401, 457], ["bicistronic luciferase reporter pJSS12", "DNA", 465, 503], ["Huh7 cells", "CELL_LINE", 509, 519], ["HCV", "SPECIES", 299, 302], ["primers", "TEST", 13, 20], ["GAAGGTGAAGG", "TEST", 24, 35], ["TCGGACTC", "TEST", 36, 44], ["TTTAGCCTTCTGA GCTTTCTGG", "TREATMENT", 55, 78], ["GAPDH mRNA", "TREATMENT", 128, 138], ["an internal control", "TREATMENT", 142, 161], ["Translation inhibition assay", "TEST", 162, 190], ["cell culture systemTo", "TEST", 194, 215], ["translation inhibition assay", "TEST", 224, 252], ["culture cells", "TEST", 256, 269], ["plasmids", "TEST", 271, 279], ["NS3", "TREATMENT", 325, 328], ["NS4A", "TREATMENT", 330, 334], ["NS4B", "TREATMENT", 336, 340], ["NS4A mutants", "TREATMENT", 346, 358], ["the cap", "TEST", 397, 404], ["GAPDH mRNA", "OBSERVATION", 128, 138], ["internal control", "OBSERVATION", 145, 161], ["Huh7 cells", "OBSERVATION", 509, 519]]], ["The cells were harvested 2 days posttransfection.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["harvested", "OBSERVATION", 15, 24]]], ["Luciferase activities were analyzed followed the procedures as described by the manufacturer (Promega) and measured with a luminometer (Orion II, Berthold).", [["the procedures", "TREATMENT", 45, 59], ["a luminometer (Orion II", "TREATMENT", 121, 144]]], ["In addition, the levels of luciferase protein and luciferase mRNA were examined by Western blot analysis and RT-PCR, respectively.Translation inhibition assay and restore experiment in in-vitro-translation systemIn-vitro-translation system was applied to study the inhibitory effects of NS4A on both cap-dependent and HCV IRES-mediated translation.", [["luciferase", "GENE_OR_GENE_PRODUCT", 27, 37], ["luciferase", "GENE_OR_GENE_PRODUCT", 50, 60], ["NS4A", "GENE_OR_GENE_PRODUCT", 287, 291], ["cap", "GENE_OR_GENE_PRODUCT", 300, 303], ["HCV", "ORGANISM", 318, 321], ["luciferase protein", "PROTEIN", 27, 45], ["luciferase mRNA", "RNA", 50, 65], ["NS4A", "PROTEIN", 287, 291], ["IRES", "DNA", 322, 326], ["HCV", "SPECIES", 318, 321], ["luciferase protein", "TEST", 27, 45], ["luciferase mRNA", "TEST", 50, 65], ["blot analysis", "TEST", 91, 104], ["RT-PCR", "TEST", 109, 115], ["Translation inhibition assay", "TEST", 130, 158], ["NS4A", "TREATMENT", 287, 291], ["HCV IRES", "TREATMENT", 318, 326]]], ["To perform cap-dependent in-vitro-translation inhibition assay, GST and GST-NS4A fusion proteins that were recovered from the Sepharose 4B beads as described earlier were preincubated with 5 ll of rabbit reticulocyte lysate (RRL, Promega) at 4\u00b0C for 1 h.", [["reticulocyte lysate", "ANATOMY", 204, 223], ["GST", "GENE_OR_GENE_PRODUCT", 64, 67], ["GST", "GENE_OR_GENE_PRODUCT", 72, 75], ["rabbit", "ORGANISM", 197, 203], ["reticulocyte lysate", "ORGANISM_SUBSTANCE", 204, 223], ["GST", "PROTEIN", 64, 67], ["GST", "PROTEIN", 72, 75], ["NS4A fusion proteins", "PROTEIN", 76, 96], ["rabbit", "SPECIES", 197, 203], ["rabbit", "SPECIES", 197, 203], ["cap", "TEST", 11, 14], ["translation inhibition assay", "TEST", 34, 62], ["GST", "TEST", 64, 67], ["GST", "TEST", 72, 75], ["NS4A fusion proteins", "TREATMENT", 76, 96], ["the Sepharose 4B beads", "TREATMENT", 122, 144], ["rabbit reticulocyte lysate", "TREATMENT", 197, 223], ["RRL, Promega)", "TREATMENT", 225, 238]]], ["Translation reaction was then carried out at 30\u00b0C for 90 min after addition of 250 ng of in vitro-transcribed monocistronic luciferase mRNA, amino acid mixtures, and RNase inhibitor, followed by luciferase activity assay.", [["amino acid", "CHEMICAL", 141, 151], ["amino acid", "CHEMICAL", 141, 151], ["luciferase", "GENE_OR_GENE_PRODUCT", 124, 134], ["amino acid", "AMINO_ACID", 141, 151], ["RNase", "GENE_OR_GENE_PRODUCT", 166, 171], ["luciferase", "GENE_OR_GENE_PRODUCT", 195, 205], ["monocistronic luciferase mRNA", "RNA", 110, 139], ["RNase", "PROTEIN", 166, 171], ["luciferase", "PROTEIN", 195, 205], ["Translation reaction", "PROBLEM", 0, 20], ["vitro-transcribed monocistronic luciferase mRNA", "TREATMENT", 92, 139], ["amino acid mixtures", "TREATMENT", 141, 160], ["RNase inhibitor", "TREATMENT", 166, 181], ["luciferase activity assay", "TEST", 195, 220]]], ["Alternatively, the translation reaction was performed in the presence of [ 35 S]methionine (NEN) and the inhibitory effects of NS4A on translation were analyzed by autoradiography following SDS-PAGE.", [["[ 35 S]methionine", "CHEMICAL", 73, 90], ["NEN", "CHEMICAL", 92, 95], ["[ 35 S]methionine", "CHEMICAL", 73, 90], ["NEN", "CHEMICAL", 92, 95], ["[ 35 S]methionine", "SIMPLE_CHEMICAL", 73, 90], ["NEN", "SIMPLE_CHEMICAL", 92, 95], ["NS4A", "GENE_OR_GENE_PRODUCT", 127, 131], ["NS4A", "PROTEIN", 127, 131], ["the translation reaction", "PROBLEM", 15, 39], ["methionine (NEN", "TREATMENT", 80, 95], ["NS4A on translation", "TREATMENT", 127, 146]]], ["On the other hand, in-vitro-translation inhibition assay was performed with synthetic NS4A(21-34) peptide and 500 ng of the bicistronic luciferase mRNA in-vitro-transcribed from plasmid pJSS12.", [["luciferase", "GENE_OR_GENE_PRODUCT", 136, 146], ["pJSS12", "GENE_OR_GENE_PRODUCT", 186, 192], ["NS4A", "PROTEIN", 86, 90], ["bicistronic luciferase mRNA", "RNA", 124, 151], ["plasmid pJSS12", "DNA", 178, 192], ["synthetic NS4A", "TREATMENT", 76, 90], ["the bicistronic luciferase mRNA", "TREATMENT", 120, 151], ["plasmid pJSS12", "TREATMENT", 178, 192]]], ["Luciferase activities of Renilla and firefly that represent the capdependent and HCV IRES-mediated translation, respectively, of the bicistronic reporter were analyzed using the Dual-Glo TM Luciferase Assay System (Promega).", [["Renilla", "GENE_OR_GENE_PRODUCT", 25, 32], ["firefly", "GENE_OR_GENE_PRODUCT", 37, 44], ["HCV", "ORGANISM", 81, 84], ["Renilla and firefly", "DNA", 25, 44], ["capdependent and HCV IRES", "DNA", 64, 89], ["bicistronic reporter", "DNA", 133, 153], ["HCV", "SPECIES", 81, 84], ["Luciferase activities of Renilla and firefly", "PROBLEM", 0, 44], ["the capdependent and HCV IRES", "TREATMENT", 60, 89], ["the Dual-Glo TM Luciferase", "TREATMENT", 174, 200]]], ["In addition, to examine the ability of eEF1A to restore the translation inhibition, eEF1A was released from GST-eEF1A by PreScission TM Protease, dialyzed to 50 mM Tris-HCl (pH 8.0), and incubated for 30 min with the reaction mixture of GST-NS4A protein and RRL in the cap-dependent in-vitro-translation inhibition assay.", [["Tris-HCl", "CHEMICAL", 164, 172], ["Tris-HCl", "CHEMICAL", 164, 172], ["eEF1A", "GENE_OR_GENE_PRODUCT", 39, 44], ["eEF1A", "GENE_OR_GENE_PRODUCT", 84, 89], ["GST-eEF1A", "GENE_OR_GENE_PRODUCT", 108, 117], ["PreScission TM Protease", "GENE_OR_GENE_PRODUCT", 121, 144], ["Tris-HCl", "SIMPLE_CHEMICAL", 164, 172], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 237, 245], ["eEF1A", "PROTEIN", 39, 44], ["eEF1A", "PROTEIN", 84, 89], ["GST", "PROTEIN", 108, 111], ["eEF1A", "PROTEIN", 112, 117], ["GST", "PROTEIN", 237, 240], ["NS4A protein", "PROTEIN", 241, 253], ["the translation inhibition", "TREATMENT", 56, 82], ["PreScission TM Protease", "TREATMENT", 121, 144], ["Tris", "TEST", 164, 168], ["pH", "TEST", 174, 176], ["the reaction", "TEST", 213, 225], ["GST", "TEST", 237, 240], ["NS4A protein", "TREATMENT", 241, 253]]], ["Luciferase activity was analyzed as described earlier.ResultsIdentification of cellular proteins specifically interact with the NS4A protein of HCV To learn the possible association of host factors with the HCV NS4A protein that may render NS4A pathogenic to the host, GST pull-down assay was performed to identify NS4A-interacting proteins.", [["cellular", "ANATOMY", 79, 87], ["Luciferase", "GENE_OR_GENE_PRODUCT", 0, 10], ["cellular", "CELL", 79, 87], ["HCV", "ORGANISM", 144, 147], ["HCV", "ORGANISM", 207, 210], ["GST", "GENE_OR_GENE_PRODUCT", 269, 272], ["cellular proteins", "PROTEIN", 79, 96], ["NS4A protein", "PROTEIN", 128, 140], ["host factors", "PROTEIN", 185, 197], ["HCV NS4A protein", "PROTEIN", 207, 223], ["NS4A", "PROTEIN", 240, 244], ["GST", "PROTEIN", 269, 272], ["NS4A", "PROTEIN", 315, 319], ["interacting proteins", "PROTEIN", 320, 340], ["HCV", "SPECIES", 144, 147], ["HCV", "SPECIES", 207, 210], ["cellular proteins", "PROBLEM", 79, 96], ["the NS4A protein", "TREATMENT", 124, 140], ["HCV", "PROBLEM", 144, 147], ["host factors", "PROBLEM", 185, 197], ["the HCV NS4A protein", "TREATMENT", 203, 223], ["GST pull", "TEST", 269, 277], ["NS4A", "PROBLEM", 315, 319]]], ["GST-NS4A protein was expressed in E. coli BL21 in the presence of IPTG (Figure 1a ).", [["IPTG", "CHEMICAL", 66, 70], ["IPTG", "CHEMICAL", 66, 70], ["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["E. coli", "ORGANISM", 34, 41], ["BL21", "ORGANISM", 42, 46], ["GST", "PROTEIN", 0, 3], ["NS4A protein", "PROTEIN", 4, 16], ["E. coli BL21", "SPECIES", 34, 46], ["E. coli", "SPECIES", 34, 41], ["NS4A protein", "TREATMENT", 4, 16], ["E. coli BL21", "PROBLEM", 34, 46], ["coli BL21", "OBSERVATION", 37, 46]]], ["Following purification with glutathione-Sepherose 4B beads, the GST-NS4A protein was subjected to GST pull-down assay with Huh7 cell extracts.", [["Huh7 cell extracts", "ANATOMY", 123, 141], ["glutathione", "CHEMICAL", 28, 39], ["glutathione", "CHEMICAL", 28, 39], ["glutathione", "SIMPLE_CHEMICAL", 28, 39], ["GST", "GENE_OR_GENE_PRODUCT", 64, 67], ["GST", "GENE_OR_GENE_PRODUCT", 98, 101], ["Huh7 cell", "CELL", 123, 132], ["extracts", "ORGANISM_SUBSTANCE", 133, 141], ["GST", "PROTEIN", 64, 67], ["NS4A protein", "PROTEIN", 68, 80], ["GST", "PROTEIN", 98, 101], ["glutathione", "TEST", 28, 39], ["Sepherose 4B beads", "TREATMENT", 40, 58], ["the GST", "TEST", 60, 67], ["NS4A protein", "TREATMENT", 68, 80], ["GST pull", "TEST", 98, 106], ["Huh7 cell extracts", "TREATMENT", 123, 141]]], ["Silver staining identified several proteins that specifically pulled down by the GST-NS4A protein (Figure 1b) .", [["Silver", "CHEMICAL", 0, 6], ["Silver", "CHEMICAL", 0, 6], ["GST", "GENE_OR_GENE_PRODUCT", 81, 84], ["GST", "PROTEIN", 81, 84], ["NS4A protein", "PROTEIN", 85, 97], ["Figure 1b", "PROTEIN", 99, 108], ["Silver staining", "PROBLEM", 0, 15], ["several proteins", "PROBLEM", 27, 43], ["the GST", "TEST", 77, 84], ["staining", "OBSERVATION", 7, 15], ["several", "OBSERVATION_MODIFIER", 27, 34], ["proteins", "OBSERVATION", 35, 43]]], ["The most abundant NS4A-interacting candidate protein was subjected to trypsin digestion and LC-MS/MS analysis.", [["trypsin", "GENE_OR_GENE_PRODUCT", 70, 77], ["NS4A", "PROTEIN", 18, 22], ["interacting candidate protein", "PROTEIN", 23, 52], ["trypsin", "PROTEIN", 70, 77], ["trypsin digestion", "PROBLEM", 70, 87], ["LC", "TEST", 92, 94], ["MS/MS analysis", "TEST", 95, 109], ["NS4A", "OBSERVATION", 18, 22]]], ["Thirty-four spectra that represent 19 independent tryptic fragments of 7-29 amino acid residues all identified the protein as human translation elongation factor 1 alpha-1 (eEF1A) (Figure 1c ).", [["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "AMINO_ACID", 76, 86], ["human translation elongation factor 1 alpha-1", "GENE_OR_GENE_PRODUCT", 126, 171], ["eEF1A", "GENE_OR_GENE_PRODUCT", 173, 178], ["Figure 1c", "GENE_OR_GENE_PRODUCT", 181, 190], ["human translation elongation factor 1 alpha-1", "PROTEIN", 126, 171], ["eEF1A", "PROTEIN", 173, 178], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["19 independent tryptic fragments", "PROBLEM", 35, 67], ["amino acid residues", "TREATMENT", 76, 95], ["the protein", "TEST", 111, 122], ["human translation elongation factor", "TEST", 126, 161], ["alpha", "TEST", 164, 169], ["19 independent", "OBSERVATION_MODIFIER", 35, 49], ["tryptic fragments", "OBSERVATION", 50, 67]]], ["Cellular factors that participate in protein synthesis are now well characterized.", [["Cellular factors", "PROTEIN", 0, 16], ["Cellular factors", "PROBLEM", 0, 16], ["protein synthesis", "PROBLEM", 37, 54], ["protein synthesis", "OBSERVATION", 37, 54]]], ["It is clear that eEF1A interacts with GTP and is responsible for binding aminoacyl-tRNA to the ribosome during polypeptide elongation [20] .HCV NS4A protein specifically interacts with eEF1A and inhibits both cap-dependent and HCV IRES-mediated protein synthesis in culture cellsPrevious studies have demonstrated that both NS4A and NS4B inhibit protein synthesis [15, 16] , but the molecular basis involved in the inhibition was not clear.", [["culture cells", "ANATOMY", 266, 279], ["GTP", "CHEMICAL", 38, 41], ["aminoacyl-tRNA", "CHEMICAL", 73, 87], ["GTP", "CHEMICAL", 38, 41], ["aminoacyl", "CHEMICAL", 73, 82], ["eEF1A", "GENE_OR_GENE_PRODUCT", 17, 22], ["GTP", "SIMPLE_CHEMICAL", 38, 41], ["ribosome", "CELLULAR_COMPONENT", 95, 103], ["eEF1A", "GENE_OR_GENE_PRODUCT", 185, 190], ["HCV", "ORGANISM", 227, 230], ["culture cells", "CELL", 266, 279], ["NS4A", "GENE_OR_GENE_PRODUCT", 324, 328], ["NS4B", "GENE_OR_GENE_PRODUCT", 333, 337], ["eEF1A", "PROTEIN", 17, 22], ["polypeptide elongation [20] .HCV NS4A protein", "PROTEIN", 111, 156], ["eEF1A", "PROTEIN", 185, 190], ["HCV IRES", "DNA", 227, 235], ["culture cells", "CELL_LINE", 266, 279], ["NS4A", "PROTEIN", 324, 328], ["NS4B", "PROTEIN", 333, 337], ["HCV", "SPECIES", 227, 230], ["GTP", "TREATMENT", 38, 41], ["binding aminoacyl", "TREATMENT", 65, 82], ["tRNA", "TREATMENT", 83, 87], ["polypeptide elongation", "PROBLEM", 111, 133], ["NS4A protein", "TREATMENT", 144, 156], ["HCV IRES", "PROBLEM", 227, 235], ["mediated protein synthesis", "TREATMENT", 236, 262], ["culture cells", "TEST", 266, 279], ["Previous studies", "TEST", 279, 295], ["both NS4A", "TREATMENT", 319, 328], ["NS4B inhibit protein synthesis", "TEST", 333, 363], ["clear", "OBSERVATION", 6, 11], ["clear", "OBSERVATION", 434, 439]]], ["By performing cotransfection experiments with an HCV NS3-, NS4A-, or NS4B-encoding plasmid and a cap-dependent monocistronic luciferase reporter into Huh7 cells, pecific inhibitory effects of NS4A and NS4B on the cap-dependent translation were detected in this study.", [["Huh7 cells", "ANATOMY", 150, 160], ["HCV NS3", "ORGANISM", 49, 56], ["NS4A", "GENE_OR_GENE_PRODUCT", 59, 63], ["luciferase", "GENE_OR_GENE_PRODUCT", 125, 135], ["Huh7 cells", "CELL", 150, 160], ["NS4A", "GENE_OR_GENE_PRODUCT", 192, 196], ["NS4B", "GENE_OR_GENE_PRODUCT", 201, 205], ["cap", "GENE_OR_GENE_PRODUCT", 213, 216], ["HCV NS3-, NS4A-, or NS4B-encoding plasmid", "DNA", 49, 90], ["cap-dependent monocistronic luciferase reporter", "DNA", 97, 144], ["Huh7 cells", "CELL_LINE", 150, 160], ["NS4A", "PROTEIN", 192, 196], ["NS4B", "PROTEIN", 201, 205], ["HCV", "SPECIES", 49, 52], ["an HCV NS3", "TREATMENT", 46, 56], ["NS4A", "TREATMENT", 59, 63], ["NS4B", "PROBLEM", 69, 73], ["encoding plasmid", "TREATMENT", 74, 90], ["a cap-dependent monocistronic luciferase", "TREATMENT", 95, 135], ["Huh7 cells", "TREATMENT", 150, 160], ["NS4A", "TREATMENT", 192, 196], ["NS4B", "TREATMENT", 201, 205], ["the cap-dependent translation", "TREATMENT", 209, 238], ["this study", "TEST", 256, 266], ["Huh7 cells", "OBSERVATION", 150, 160]]], ["The luciferase activity was significantly reduced when the reporter plasmid was coexpressed with NS4A or NS4B protein (Figure 2a ).", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["luciferase", "PROTEIN", 4, 14], ["reporter plasmid", "DNA", 59, 75], ["NS4A", "PROTEIN", 97, 101], ["NS4B protein", "PROTEIN", 105, 117], ["Figure 2a", "PROTEIN", 119, 128], ["the reporter plasmid", "TREATMENT", 55, 75], ["NS4A", "TREATMENT", 97, 101], ["NS4B protein", "TREATMENT", 105, 117], ["luciferase activity", "OBSERVATION", 4, 23]]], ["In addition, the effects correlated very well with the protein levels of luciferase (Figure 2b ), whereas the luciferase mRNA level was not affected by the HCV nonstructural proteins (Figure 2c ).", [["luciferase (Figure 2b", "GENE_OR_GENE_PRODUCT", 73, 94], ["luciferase", "GENE_OR_GENE_PRODUCT", 110, 120], ["luciferase", "PROTEIN", 73, 83], ["Figure 2b", "PROTEIN", 85, 94], ["luciferase mRNA", "RNA", 110, 125], ["HCV nonstructural proteins", "PROTEIN", 156, 182], ["Figure 2c", "PROTEIN", 184, 193], ["HCV", "SPECIES", 156, 159], ["the protein levels", "TEST", 51, 69], ["the luciferase mRNA level", "TEST", 106, 131], ["the HCV nonstructural proteins", "PROBLEM", 152, 182]]], ["Possible effects of the viral nonstructural proteins on HCV IRES-mediated translation were further examined by cotransfecting into Huh7 cells a bicistronic reporter that consists of the Renilla luciferase, the HCV IRES (genotype 1b), and the firefly luciferase genes.", [["Huh7 cells", "ANATOMY", 131, 141], ["HCV", "ORGANISM", 56, 59], ["Huh7 cells", "CELL", 131, 141], ["luciferase", "GENE_OR_GENE_PRODUCT", 194, 204], ["genotype 1b", "GENE_OR_GENE_PRODUCT", 220, 231], ["luciferase", "GENE_OR_GENE_PRODUCT", 250, 260], ["viral nonstructural proteins", "PROTEIN", 24, 52], ["HCV IRES", "DNA", 56, 64], ["Huh7 cells", "CELL_LINE", 131, 141], ["Renilla luciferase", "DNA", 186, 204], ["HCV IRES", "DNA", 210, 218], ["genotype 1b", "DNA", 220, 231], ["firefly luciferase genes", "DNA", 242, 266], ["HCV", "SPECIES", 56, 59], ["HCV", "SPECIES", 210, 213], ["the viral nonstructural proteins", "PROBLEM", 20, 52], ["HCV IRES", "TREATMENT", 56, 64], ["the Renilla luciferase", "TEST", 182, 204], ["the HCV IRES", "TEST", 206, 218], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["nonstructural proteins", "OBSERVATION", 30, 52], ["Renilla luciferase", "ANATOMY", 186, 204]]], ["Two days posttransfection, Dual-Glo TM luciferase assay (Promega) was performed.", [["luciferase", "PROTEIN", 39, 49], ["Dual-Glo TM luciferase assay", "TEST", 27, 55]]], ["Renilla luciferase activity represents the cap-dependent translation and firefly luciferase activity represents the HCV IRES-mediated translation.", [["Renilla", "GENE_OR_GENE_PRODUCT", 0, 7], ["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["cap", "GENE_OR_GENE_PRODUCT", 43, 46], ["luciferase", "GENE_OR_GENE_PRODUCT", 81, 91], ["HCV", "ORGANISM", 116, 119], ["luciferase", "PROTEIN", 8, 18], ["luciferase", "PROTEIN", 81, 91], ["HCV IRES", "DNA", 116, 124], ["HCV", "SPECIES", 116, 119], ["Renilla luciferase activity", "PROBLEM", 0, 27], ["the cap-dependent translation", "PROBLEM", 39, 68], ["firefly luciferase activity", "PROBLEM", 73, 100], ["the HCV IRES", "PROBLEM", 112, 124]]], ["The results demonstrated that both NS4A and NS4B inhibited HCV IRES-mediated translation to levels similar to those of the cap-dependent translation, whereas no effect was detected with the viral NS3 protein (Figure 2d ).", [["NS4A", "GENE_OR_GENE_PRODUCT", 35, 39], ["NS4B", "GENE_OR_GENE_PRODUCT", 44, 48], ["HCV", "ORGANISM", 59, 62], ["cap", "GENE_OR_GENE_PRODUCT", 123, 126], ["NS4A", "PROTEIN", 35, 39], ["NS4B", "PROTEIN", 44, 48], ["HCV IRES", "DNA", 59, 67], ["viral NS3 protein", "PROTEIN", 190, 207], ["Figure 2d", "PROTEIN", 209, 218], ["HCV", "SPECIES", 59, 62], ["both NS4A", "TREATMENT", 30, 39], ["NS4B", "TREATMENT", 44, 48], ["HCV IRES", "TREATMENT", 59, 67], ["the viral NS3 protein", "TEST", 186, 207], ["NS4A", "OBSERVATION", 35, 39]]], ["We proposed that through interacting with eEF1A, HCV NS4A protein may deplete or interfere eEF1A in forming functional complexes involved in both cap-dependent and IRES-mediated translation.", [["eEF1A", "GENE_OR_GENE_PRODUCT", 42, 47], ["HCV NS4A", "GENE_OR_GENE_PRODUCT", 49, 57], ["eEF1A", "GENE_OR_GENE_PRODUCT", 91, 96], ["cap", "GENE_OR_GENE_PRODUCT", 146, 149], ["eEF1A", "PROTEIN", 42, 47], ["HCV NS4A protein", "PROTEIN", 49, 65], ["eEF1A", "PROTEIN", 91, 96], ["IRES", "DNA", 164, 168], ["HCV", "SPECIES", 49, 52], ["HCV NS4A protein", "TREATMENT", 49, 65]]], ["To test this hypothesis, we first examined the specificity of the interaction between NS4A and eEF1A.", [["NS4A", "GENE_OR_GENE_PRODUCT", 86, 90], ["eEF1A", "GENE_OR_GENE_PRODUCT", 95, 100], ["NS4A", "PROTEIN", 86, 90], ["eEF1A", "PROTEIN", 95, 100], ["NS4A and eEF1A", "TREATMENT", 86, 100]]], ["GST fusion proteins of the viral NS3, NS4A, and NS4B were expressed in E. coli BL21(DE3) in the presence of IPTG, and immobilized on glutathione-Sepharose 4B beads (Figure 3a) .", [["IPTG", "CHEMICAL", 108, 112], ["glutathione", "CHEMICAL", 133, 144], ["IPTG", "CHEMICAL", 108, 112], ["glutathione", "CHEMICAL", 133, 144], ["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS3", "GENE_OR_GENE_PRODUCT", 33, 36], ["NS4A", "GENE_OR_GENE_PRODUCT", 38, 42], ["NS4B", "GENE_OR_GENE_PRODUCT", 48, 52], ["E. coli BL21", "ORGANISM", 71, 83], ["DE3", "CELL", 84, 87], ["IPTG", "SIMPLE_CHEMICAL", 108, 112], ["glutathione", "SIMPLE_CHEMICAL", 133, 144], ["GST fusion proteins", "PROTEIN", 0, 19], ["viral NS3", "PROTEIN", 27, 36], ["NS4A", "PROTEIN", 38, 42], ["NS4B", "PROTEIN", 48, 52], ["E. coli BL21", "SPECIES", 71, 83], ["E. coli BL21", "SPECIES", 71, 83], ["DE3", "SPECIES", 84, 87], ["GST fusion proteins", "TEST", 0, 19], ["the viral NS3", "TREATMENT", 23, 36], ["NS4A", "TREATMENT", 38, 42], ["NS4B", "PROBLEM", 48, 52], ["E. coli BL21", "PROBLEM", 71, 83], ["IPTG", "TREATMENT", 108, 112], ["glutathione", "TREATMENT", 133, 144], ["Sepharose 4B beads", "TREATMENT", 145, 163], ["viral NS3", "OBSERVATION", 27, 36], ["E. coli BL21", "OBSERVATION", 71, 83], ["IPTG", "OBSERVATION", 108, 112]]], ["GST pull-down assay was performed with Huh7 cell extracts followed by Western blot analysis with anti-eEF1A antibody.", [["Huh7 cell extracts", "ANATOMY", 39, 57], ["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["Huh7 cell", "CELL", 39, 48], ["extracts", "ORGANISM_SUBSTANCE", 49, 57], ["anti-eEF1A antibody", "GENE_OR_GENE_PRODUCT", 97, 116], ["GST", "PROTEIN", 0, 3], ["anti-eEF1A antibody", "PROTEIN", 97, 116], ["GST pull-down assay", "TEST", 0, 19], ["Huh7 cell extracts", "TREATMENT", 39, 57], ["Western blot analysis", "TEST", 70, 91], ["anti-eEF1A antibody", "TEST", 97, 116]]], ["The results demonstrated that NS4A but neither NS3 nor NS4B interacted with eEF1A in the GST pulldown system (Figure 3b) .", [["NS4A", "GENE_OR_GENE_PRODUCT", 30, 34], ["NS3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS4B", "GENE_OR_GENE_PRODUCT", 55, 59], ["eEF1A", "GENE_OR_GENE_PRODUCT", 76, 81], ["GST", "GENE_OR_GENE_PRODUCT", 89, 92], ["NS4A", "PROTEIN", 30, 34], ["NS3", "PROTEIN", 47, 50], ["NS4B", "PROTEIN", 55, 59], ["eEF1A", "PROTEIN", 76, 81], ["GST", "PROTEIN", 89, 92], ["NS4A", "TREATMENT", 30, 34], ["NS3", "PROBLEM", 47, 50], ["NS4B", "PROBLEM", 55, 59], ["NS4A", "OBSERVATION", 30, 34]]], ["To examine the interaction in culture cells, cotransfection experiments were performed in Huh7 cells with plasmids encoding V5-tagged NS4A (pcDNA-NS4A-V5) or NS4B (pcDNA-NS4B-V5) and a His-tagged eEF1A (pcDNA-eEF1A-HisTopo).", [["culture cells", "ANATOMY", 30, 43], ["Huh7 cells", "ANATOMY", 90, 100], ["plasmids", "ANATOMY", 106, 114], ["culture cells", "CELL", 30, 43], ["Huh7 cells", "CELL", 90, 100], ["V5", "GENE_OR_GENE_PRODUCT", 124, 126], ["pcDNA-NS4A-V5", "GENE_OR_GENE_PRODUCT", 140, 153], ["pcDNA-NS4B-V5", "GENE_OR_GENE_PRODUCT", 164, 177], ["eEF1A", "GENE_OR_GENE_PRODUCT", 196, 201], ["pcDNA-eEF1A-HisTopo", "GENE_OR_GENE_PRODUCT", 203, 222], ["culture cells", "CELL_LINE", 30, 43], ["Huh7 cells", "CELL_LINE", 90, 100], ["plasmids", "DNA", 106, 114], ["V5", "PROTEIN", 124, 126], ["NS4A", "PROTEIN", 134, 138], ["pcDNA", "PROTEIN", 140, 145], ["NS4A", "PROTEIN", 146, 150], ["V5", "PROTEIN", 151, 153], ["NS4B", "PROTEIN", 158, 162], ["pcDNA", "PROTEIN", 164, 169], ["NS4B", "PROTEIN", 170, 174], ["V5", "PROTEIN", 175, 177], ["His-tagged eEF1A", "PROTEIN", 185, 201], ["pcDNA", "PROTEIN", 203, 208], ["eEF1A", "PROTEIN", 209, 214], ["HisTopo", "PROTEIN", 215, 222], ["culture cells", "TEST", 30, 43], ["cotransfection experiments", "TEST", 45, 71], ["plasmids", "TREATMENT", 106, 114], ["NS4A", "TEST", 134, 138], ["pcDNA", "TEST", 140, 145], ["NS4A", "TEST", 146, 150], ["NS4B", "TEST", 158, 162], ["pcDNA", "TEST", 164, 169], ["NS4B", "TEST", 170, 174], ["a His-tagged eEF1A", "TEST", 183, 201], ["pcDNA", "TEST", 203, 208], ["HisTopo", "TREATMENT", 215, 222]]], ["Two days posttransfection, cell extracts were immunoprecipitated with anti-His antibody followed by Western blot analysis with anti-V5 antibody.", [["cell extracts", "ANATOMY", 27, 40], ["His", "CHEMICAL", 75, 78], ["cell extracts", "ORGANISM_SUBSTANCE", 27, 40], ["anti-V5", "GENE_OR_GENE_PRODUCT", 127, 134], ["anti-His antibody", "PROTEIN", 70, 87], ["anti-V5 antibody", "PROTEIN", 127, 143], ["cell extracts", "PROBLEM", 27, 40], ["His antibody", "TEST", 75, 87], ["blot analysis", "TEST", 108, 121], ["anti-V5 antibody", "TEST", 127, 143]]], ["As shown in Figure 3c , NS4A but not NS4B was coimmunoprecipitated with the eEF1A.", [["NS4A", "GENE_OR_GENE_PRODUCT", 24, 28], ["NS4B", "GENE_OR_GENE_PRODUCT", 37, 41], ["eEF1A", "GENE_OR_GENE_PRODUCT", 76, 81], ["NS4A", "PROTEIN", 24, 28], ["NS4B", "PROTEIN", 37, 41], ["eEF1A", "PROTEIN", 76, 81], ["NS4A", "TREATMENT", 24, 28], ["NS4B", "PROBLEM", 37, 41]]], ["These results indicate that, although both NS4A and NS4B are capable of inhibiting protein synthesis, binding to eEF1A is a unique characteristic of NS4A.", [["NS4A", "GENE_OR_GENE_PRODUCT", 43, 47], ["NS4B", "GENE_OR_GENE_PRODUCT", 52, 56], ["eEF1A", "GENE_OR_GENE_PRODUCT", 113, 118], ["NS4A", "GENE_OR_GENE_PRODUCT", 149, 153], ["NS4A", "PROTEIN", 43, 47], ["NS4B", "PROTEIN", 52, 56], ["eEF1A", "PROTEIN", 113, 118], ["NS4A", "PROTEIN", 149, 153], ["NS4B", "PROBLEM", 52, 56], ["inhibiting protein synthesis", "PROBLEM", 72, 100], ["NS4A", "PROBLEM", 149, 153], ["NS4A", "OBSERVATION", 43, 47], ["NS4A", "OBSERVATION", 149, 153]]], ["It is likely that NS4A and NS4B inhibit protein translation through different mechanisms.NS4A interacts with eEF1A through its N-terminal and central domainsTo identify the subdomains of NS4A responsible for interacting with eEF1A, deletion plasmids representing GST fusion proteins of various domains of the NS4A were generated and expressed in E. coli BL21.", [["plasmids", "ANATOMY", 241, 249], ["N", "CHEMICAL", 127, 128], ["NS4A", "GENE_OR_GENE_PRODUCT", 18, 22], ["NS4B", "GENE_OR_GENE_PRODUCT", 27, 31], ["NS4A", "GENE_OR_GENE_PRODUCT", 89, 93], ["eEF1A", "GENE_OR_GENE_PRODUCT", 109, 114], ["NS4A", "GENE_OR_GENE_PRODUCT", 187, 191], ["eEF1A", "GENE_OR_GENE_PRODUCT", 225, 230], ["GST", "GENE_OR_GENE_PRODUCT", 263, 266], ["NS4A", "GENE_OR_GENE_PRODUCT", 309, 313], ["E. coli BL21", "ORGANISM", 346, 358], ["NS4A", "PROTEIN", 18, 22], ["NS4B", "PROTEIN", 27, 31], ["NS4A", "PROTEIN", 89, 93], ["eEF1A", "PROTEIN", 109, 114], ["N-terminal and central domains", "PROTEIN", 127, 157], ["NS4A", "PROTEIN", 187, 191], ["eEF1A", "PROTEIN", 225, 230], ["deletion plasmids", "DNA", 232, 249], ["GST fusion proteins", "PROTEIN", 263, 282], ["NS4A", "PROTEIN", 309, 313], ["E. coli BL21", "SPECIES", 346, 358], ["E. coli BL21", "SPECIES", 346, 358], ["NS4A", "TREATMENT", 18, 22], ["NS4B inhibit protein translation", "TREATMENT", 27, 59], ["NS4A", "TREATMENT", 89, 93], ["NS4A", "TREATMENT", 187, 191], ["deletion plasmids", "TREATMENT", 232, 249], ["GST fusion proteins", "TREATMENT", 263, 282], ["the NS4A", "TREATMENT", 305, 313], ["E. coli BL21", "PROBLEM", 346, 358], ["likely", "UNCERTAINTY", 6, 12], ["NS4A", "OBSERVATION", 18, 22], ["central domains", "OBSERVATION", 142, 157], ["NS4A", "OBSERVATION", 187, 191], ["NS4A", "ANATOMY", 309, 313], ["E. coli BL21", "OBSERVATION", 346, 358]]], ["Following a partial purification, the GST-NS4A mutant proteins were subjected to GST pull-down assay with Huh7 cell extracts.", [["Huh7 cell extracts", "ANATOMY", 106, 124], ["GST", "GENE_OR_GENE_PRODUCT", 38, 41], ["GST", "GENE_OR_GENE_PRODUCT", 81, 84], ["Huh7 cell", "CELL", 106, 115], ["extracts", "ORGANISM_SUBSTANCE", 116, 124], ["GST", "PROTEIN", 38, 41], ["NS4A mutant proteins", "PROTEIN", 42, 62], ["GST", "PROTEIN", 81, 84], ["a partial purification", "TEST", 10, 32], ["the GST", "TEST", 34, 41], ["NS4A mutant proteins", "PROBLEM", 42, 62], ["GST pull", "TEST", 81, 89], ["Huh7 cell extracts", "TREATMENT", 106, 124], ["Huh7 cell", "OBSERVATION", 106, 115]]], ["As shown in Figure 4aNS4A interacts with the C terminus of eEF1AThe functional domain of eEF1A involved in the binding of NS4A was examined.", [["4aNS4A", "GENE_OR_GENE_PRODUCT", 19, 25], ["eEF1AThe", "GENE_OR_GENE_PRODUCT", 59, 67], ["eEF1A", "GENE_OR_GENE_PRODUCT", 89, 94], ["NS4A", "GENE_OR_GENE_PRODUCT", 122, 126], ["4aNS4A", "PROTEIN", 19, 25], ["C terminus", "PROTEIN", 45, 55], ["eEF1AThe functional domain", "PROTEIN", 59, 85], ["eEF1A", "PROTEIN", 89, 94], ["NS4A", "PROTEIN", 122, 126], ["the C terminus", "TREATMENT", 41, 55]]], ["Full-length eEF1A, its N terminus from amino acid residues 1-240 [eEF1A(1-240)], and the C terminus from amino acid residues 201-462 [eEF1A(201-462)] were synthesized in vitro by the T N T Quick Coupled Transcription/Translation system.", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 105, 115], ["N", "CHEMICAL", 23, 24], ["amino acid", "CHEMICAL", 39, 49], ["C", "CHEMICAL", 89, 90], ["amino acid", "CHEMICAL", 105, 115], ["eEF1A", "GENE_OR_GENE_PRODUCT", 12, 17], ["amino acid", "AMINO_ACID", 39, 49], ["amino acid", "AMINO_ACID", 105, 115], ["residues 201-462", "AMINO_ACID", 116, 132], ["eEF1A", "PROTEIN", 12, 17], ["N terminus", "PROTEIN", 23, 33], ["eEF1A", "PROTEIN", 66, 71], ["C terminus", "PROTEIN", 89, 99], ["eEF1A", "PROTEIN", 134, 139], ["amino acid residues", "TEST", 39, 58], ["eEF1A", "TEST", 66, 71], ["amino acid residues", "TEST", 105, 124], ["eEF1A", "TEST", 134, 139]]], ["The translation products were subjected to GST pull-down assay with partially purified GST and GST-NS4A fusion proteins.", [["GST", "GENE_OR_GENE_PRODUCT", 43, 46], ["GST", "GENE_OR_GENE_PRODUCT", 87, 90], ["GST", "GENE_OR_GENE_PRODUCT", 95, 98], ["translation products", "PROTEIN", 4, 24], ["GST", "PROTEIN", 43, 46], ["GST", "PROTEIN", 87, 90], ["GST", "PROTEIN", 95, 98], ["NS4A fusion proteins", "PROTEIN", 99, 119], ["The translation products", "TREATMENT", 0, 24], ["GST pull", "TEST", 43, 51], ["GST", "TEST", 95, 98], ["NS4A fusion proteins", "TREATMENT", 99, 119]]], ["As shown in Figure 4b , both the full-length eEF1A and the eEF1A(201-462) were pulled-down by the GST-NS4A fusion protein, but the eEF1A(1-240) could not.", [["eEF1A", "GENE_OR_GENE_PRODUCT", 45, 50], ["eEF1A", "GENE_OR_GENE_PRODUCT", 59, 64], ["GST", "GENE_OR_GENE_PRODUCT", 98, 101], ["eEF1A", "GENE_OR_GENE_PRODUCT", 131, 136], ["eEF1A", "PROTEIN", 45, 50], ["eEF1A", "PROTEIN", 59, 64], ["GST", "PROTEIN", 98, 101], ["NS4A fusion protein", "PROTEIN", 102, 121], ["eEF1A", "PROTEIN", 131, 136], ["the eEF1A", "TEST", 55, 64], ["the GST", "TEST", 94, 101], ["NS4A fusion protein", "TEST", 102, 121], ["the eEF1A", "TEST", 127, 136]]], ["These results indicate a specific interaction between NS4A and the C-terminal domain of eEF1A.The central domain of NS4A plays a critical role in the translation inhibitionIn Figure 4a , we have demonstrated that NS4A interacted with eEF1A through two independent domains within the N-terminal 34 amino acid residues.", [["amino acid", "CHEMICAL", 297, 307], ["C", "CHEMICAL", 67, 68], ["N", "CHEMICAL", 283, 284], ["amino acid", "CHEMICAL", 297, 307], ["NS4A", "GENE_OR_GENE_PRODUCT", 54, 58], ["eEF1A", "GENE_OR_GENE_PRODUCT", 88, 93], ["NS4A", "GENE_OR_GENE_PRODUCT", 116, 120], ["NS4A", "GENE_OR_GENE_PRODUCT", 213, 217], ["eEF1A", "GENE_OR_GENE_PRODUCT", 234, 239], ["amino acid", "AMINO_ACID", 297, 307], ["NS4A", "PROTEIN", 54, 58], ["C-terminal domain", "PROTEIN", 67, 84], ["eEF1A", "PROTEIN", 88, 93], ["NS4A", "PROTEIN", 116, 120], ["NS4A", "PROTEIN", 213, 217], ["eEF1A", "PROTEIN", 234, 239], ["N-terminal 34 amino acid residues", "PROTEIN", 283, 316], ["NS4A", "TREATMENT", 54, 58], ["the C-terminal domain of eEF1A", "TREATMENT", 63, 93], ["the N-terminal 34 amino acid residues", "TREATMENT", 279, 316], ["central", "ANATOMY_MODIFIER", 98, 105], ["NS4A", "OBSERVATION", 116, 120], ["acid residues", "OBSERVATION", 303, 316]]], ["To link the interaction between NS4A and eEF1A to the effect of NS4A on protein synthesis, translation inhibition assay was performed.", [["NS4A", "GENE_OR_GENE_PRODUCT", 32, 36], ["eEF1A", "GENE_OR_GENE_PRODUCT", 41, 46], ["NS4A", "GENE_OR_GENE_PRODUCT", 64, 68], ["NS4A", "PROTEIN", 32, 36], ["eEF1A", "PROTEIN", 41, 46], ["NS4A", "PROTEIN", 64, 68], ["NS4A", "TREATMENT", 32, 36], ["eEF1A", "TREATMENT", 41, 46], ["NS4A on protein synthesis", "TREATMENT", 64, 89], ["translation inhibition assay", "TEST", 91, 119]]], ["Huh7 cells were cotransfected with the monocistronic luciferase reporter and a plasmid representing NS4A(1-34) or NS4A (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) .", [["Huh7 cells", "ANATOMY", 0, 10], ["Huh7 cells", "CELL", 0, 10], ["luciferase", "GENE_OR_GENE_PRODUCT", 53, 63], ["Huh7 cells", "CELL_LINE", 0, 10], ["monocistronic luciferase reporter", "DNA", 39, 72], ["NS4A", "PROTEIN", 100, 104], ["Huh7 cells", "TREATMENT", 0, 10], ["NS4A", "TEST", 100, 104], ["NS4A", "TEST", 114, 118], ["NS4A", "OBSERVATION", 100, 104]]], ["Two days posttransfection, cells were harvested and analyzed for the luciferase activity and the levels of luciferase protein and mRNA.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["luciferase", "GENE_OR_GENE_PRODUCT", 69, 79], ["luciferase", "GENE_OR_GENE_PRODUCT", 107, 117], ["luciferase", "PROTEIN", 69, 79], ["luciferase protein", "PROTEIN", 107, 125], ["mRNA", "RNA", 130, 134], ["the luciferase activity", "TEST", 65, 88], ["luciferase protein", "TEST", 107, 125]]], ["As shown in Figure 5 , NS4A(1-34) inhibited both the luciferase activity and luciferase protein to levels compatible to the full-length NS4A protein did but had little effect on the level of luciferase mRNA.", [["luciferase", "GENE_OR_GENE_PRODUCT", 53, 63], ["luciferase", "GENE_OR_GENE_PRODUCT", 77, 87], ["luciferase", "GENE_OR_GENE_PRODUCT", 191, 201], ["NS4A", "PROTEIN", 23, 27], ["luciferase", "PROTEIN", 53, 63], ["luciferase protein", "PROTEIN", 77, 95], ["NS4A protein", "PROTEIN", 136, 148], ["luciferase mRNA", "RNA", 191, 206], ["NS4A", "TREATMENT", 23, 27], ["luciferase protein", "TEST", 77, 95], ["the full-length NS4A protein", "TREATMENT", 120, 148], ["luciferase mRNA", "PROBLEM", 191, 206]]], ["These results indicated that the N-terminal 34 amino acid residues are responsible for the inhibitory effect of NS4A on translation.", [["amino acid", "CHEMICAL", 47, 57], ["amino acid", "CHEMICAL", 47, 57], ["amino acid", "AMINO_ACID", 47, 57], ["NS4A", "GENE_OR_GENE_PRODUCT", 112, 116], ["N-terminal 34 amino acid residues", "PROTEIN", 33, 66], ["NS4A", "PROTEIN", 112, 116], ["the N-terminal 34 amino acid residues", "TREATMENT", 29, 66], ["NS4A on translation", "TREATMENT", 112, 131]]], ["To determine which of the The inhibitory effects of NS4A and NS4B proteins on cap-dependent translation.", [["NS4A", "GENE_OR_GENE_PRODUCT", 52, 56], ["NS4B", "GENE_OR_GENE_PRODUCT", 61, 65], ["cap", "GENE_OR_GENE_PRODUCT", 78, 81], ["NS4A", "PROTEIN", 52, 56], ["NS4B proteins", "PROTEIN", 61, 74], ["NS4A", "TREATMENT", 52, 56], ["NS4B proteins", "TREATMENT", 61, 74], ["cap-dependent translation", "TREATMENT", 78, 103]]], ["Plasmids pcDNA-NS3-V5, pcDNA-NS4A-V5, and pcDNA-NS4B-V5 encoding HCV NS3, NS4A, and NS4B, respectively, were independently cotransfected into Huh7 cells with the monocistronic luciferase reporter plasmid pCMV-Luc.", [["Huh7 cells", "ANATOMY", 142, 152], ["pcDNA", "GENE_OR_GENE_PRODUCT", 9, 14], ["V5", "GENE_OR_GENE_PRODUCT", 19, 21], ["pcDNA", "GENE_OR_GENE_PRODUCT", 23, 28], ["V5", "GENE_OR_GENE_PRODUCT", 34, 36], ["pcDNA-NS4B-V5", "GENE_OR_GENE_PRODUCT", 42, 55], ["HCV NS3", "ORGANISM", 65, 72], ["NS4A", "GENE_OR_GENE_PRODUCT", 74, 78], ["NS4B", "GENE_OR_GENE_PRODUCT", 84, 88], ["Huh7 cells", "CELL", 142, 152], ["luciferase", "GENE_OR_GENE_PRODUCT", 176, 186], ["Luc", "GENE_OR_GENE_PRODUCT", 209, 212], ["NS3", "PROTEIN", 15, 18], ["V5", "PROTEIN", 19, 21], ["pcDNA", "PROTEIN", 23, 28], ["NS4A", "PROTEIN", 29, 33], ["V5", "PROTEIN", 34, 36], ["pcDNA", "PROTEIN", 42, 47], ["NS4B", "PROTEIN", 48, 52], ["V5", "PROTEIN", 53, 55], ["HCV NS3", "PROTEIN", 65, 72], ["NS4A", "PROTEIN", 74, 78], ["NS4B", "PROTEIN", 84, 88], ["Huh7 cells", "CELL_LINE", 142, 152], ["monocistronic luciferase reporter plasmid", "DNA", 162, 203], ["pCMV", "DNA", 204, 208], ["Luc", "DNA", 209, 212], ["HCV", "SPECIES", 65, 68], ["Plasmids pcDNA", "TEST", 0, 14], ["NS3", "TEST", 15, 18], ["pcDNA", "TEST", 23, 28], ["NS4A", "TEST", 29, 33], ["pcDNA", "TEST", 42, 47], ["NS4B", "TREATMENT", 48, 52], ["HCV NS3", "TREATMENT", 65, 72], ["NS4A", "TREATMENT", 74, 78], ["NS4B", "TREATMENT", 84, 88], ["Huh7 cells", "TREATMENT", 142, 152], ["the monocistronic luciferase", "TREATMENT", 158, 186], ["NS4A", "ANATOMY", 29, 33], ["V5", "ANATOMY", 34, 36], ["NS4A", "ANATOMY", 74, 78]]], ["Two days posttransfection, cell lysates were harvested and equal amounts of the proteins were used to perform luciferase assay (panel a) and Western blot analysis (panel b).", [["cell lysates", "ANATOMY", 27, 39], ["cell lysates", "CELL", 27, 39], ["luciferase", "GENE_OR_GENE_PRODUCT", 110, 120], ["luciferase", "PROTEIN", 110, 120], ["cell lysates", "TEST", 27, 39], ["luciferase assay", "TEST", 110, 126], ["Western blot analysis", "TEST", 141, 162], ["cell lysates", "OBSERVATION", 27, 39]]], ["Meanwhile, total RNA was isolated to perform RT-PCR (panel c).", [["RT-PCR", "TEST", 45, 51]]], ["Luciferase activities derived from the transfected cells were normalized by the activity of the cells cotransfected with pCMV-Luc and pcDNA3.1(+) control vector.", [["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 96, 101], ["Luciferase", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 51, 56], ["cells", "CELL", 96, 101], ["pCMV-Luc", "GENE_OR_GENE_PRODUCT", 121, 129], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 134, 140], ["transfected cells", "CELL_LINE", 39, 56], ["pCMV", "PROTEIN", 121, 125], ["Luc", "DNA", 126, 129], ["pcDNA3", "DNA", 134, 140], ["1(+) control vector", "DNA", 141, 160], ["Luciferase activities", "TEST", 0, 21], ["pCMV", "TREATMENT", 121, 125], ["pcDNA3", "TREATMENT", 134, 140]]], ["Western blot analysis was performed with antibodies specific to luciferase and GAPDH as indicated.", [["luciferase", "GENE_OR_GENE_PRODUCT", 64, 74], ["GAPDH", "GENE_OR_GENE_PRODUCT", 79, 84], ["luciferase", "PROTEIN", 64, 74], ["GAPDH", "PROTEIN", 79, 84], ["Western blot analysis", "TEST", 0, 21], ["antibodies", "TREATMENT", 41, 51], ["GAPDH", "TEST", 79, 84]]], ["Intensities of the luciferase proteins were normalized in each set against the intensity of GAPDH and compared to the control.", [["luciferase", "GENE_OR_GENE_PRODUCT", 19, 29], ["GAPDH", "GENE_OR_GENE_PRODUCT", 92, 97], ["luciferase proteins", "PROTEIN", 19, 38], ["GAPDH", "PROTEIN", 92, 97], ["the luciferase proteins", "TEST", 15, 38], ["GAPDH", "PROBLEM", 92, 97]]], ["Relative intensities of the luciferase protein are shown.", [["luciferase", "GENE_OR_GENE_PRODUCT", 28, 38], ["luciferase protein", "PROTEIN", 28, 46], ["the luciferase protein", "TEST", 24, 46], ["intensities", "OBSERVATION_MODIFIER", 9, 20], ["luciferase protein", "OBSERVATION", 28, 46]]], ["RT-PCR of luciferase mRNA was performed with oligo-dT and primers as described in the materials and methods for 20 amplification cycles.", [["oligo-dT", "CHEMICAL", 45, 53], ["luciferase", "GENE_OR_GENE_PRODUCT", 10, 20], ["luciferase mRNA", "RNA", 10, 25], ["RT-PCR of luciferase mRNA", "TEST", 0, 25], ["oligo-dT and primers", "PROBLEM", 45, 65], ["20 amplification cycles", "TREATMENT", 112, 135], ["luciferase mRNA", "OBSERVATION", 10, 25]]], ["Intensities of the luciferase cDNA fragment were normalized in each set against the intensity of GAPDH and relative intensities as compared to the vector control are shown. (d) The inhibitory effects of NS4A and NS4B proteins on HCV IRES-mediated translation.", [["luciferase", "GENE_OR_GENE_PRODUCT", 19, 29], ["GAPDH", "GENE_OR_GENE_PRODUCT", 97, 102], ["NS4A", "GENE_OR_GENE_PRODUCT", 203, 207], ["NS4B", "GENE_OR_GENE_PRODUCT", 212, 216], ["HCV", "ORGANISM", 229, 232], ["luciferase cDNA fragment", "DNA", 19, 43], ["GAPDH", "PROTEIN", 97, 102], ["NS4A", "PROTEIN", 203, 207], ["NS4B proteins", "PROTEIN", 212, 225], ["HCV IRES", "DNA", 229, 237], ["HCV", "SPECIES", 229, 232], ["the luciferase cDNA fragment", "PROBLEM", 15, 43], ["GAPDH", "PROBLEM", 97, 102], ["NS4A", "TREATMENT", 203, 207], ["NS4B proteins", "TREATMENT", 212, 225], ["HCV IRES", "TREATMENT", 229, 237], ["luciferase", "OBSERVATION", 19, 29], ["cDNA fragment", "OBSERVATION", 30, 43], ["intensities", "OBSERVATION_MODIFIER", 116, 127]]], ["The bicistronic luciferase reporter plasmid pJSS12 was cotransfected independently with the HCV NS3-, NS4A-, and NS4B-encoding plasmid.", [["luciferase", "GENE_OR_GENE_PRODUCT", 16, 26], ["pJSS12", "GENE_OR_GENE_PRODUCT", 44, 50], ["HCV NS3", "ORGANISM", 92, 99], ["NS4A", "GENE_OR_GENE_PRODUCT", 102, 106], ["NS4B", "GENE_OR_GENE_PRODUCT", 113, 117], ["bicistronic luciferase reporter plasmid", "DNA", 4, 43], ["pJSS12", "DNA", 44, 50], ["HCV NS3-, NS4A-, and NS4B-encoding plasmid", "DNA", 92, 134], ["HCV", "SPECIES", 92, 95], ["The bicistronic luciferase reporter plasmid", "TREATMENT", 0, 43], ["the HCV NS3", "TREATMENT", 88, 99], ["NS4A", "TREATMENT", 102, 106], ["NS4B", "TREATMENT", 113, 117], ["encoding plasmid", "TREATMENT", 118, 134]]], ["The activities of Renilla luciferase and firefly luciferase that representing cap-dependent and HCV IRES-mediated translation, respectively, were analyzed 2 days posttransfection with Dual-Glo TM Luciferase Assay System as described in the Materials and methods.", [["Renilla", "GENE_OR_GENE_PRODUCT", 18, 25], ["luciferase", "GENE_OR_GENE_PRODUCT", 26, 36], ["firefly", "GENE_OR_GENE_PRODUCT", 41, 48], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["cap", "GENE_OR_GENE_PRODUCT", 78, 81], ["HCV", "ORGANISM", 96, 99], ["Renilla luciferase", "DNA", 18, 36], ["firefly luciferase", "DNA", 41, 59], ["HCV IRES", "DNA", 96, 104], ["HCV", "SPECIES", 96, 99], ["Renilla luciferase", "TEST", 18, 36], ["firefly luciferase", "TEST", 41, 59], ["cap-dependent", "PROBLEM", 78, 91], ["HCV IRES", "TREATMENT", 96, 104], ["Dual-Glo TM Luciferase Assay System", "TREATMENT", 184, 219], ["cap", "OBSERVATION_MODIFIER", 78, 81]]], ["Relative luciferase activities in the presence of the HCV nonstructural proteins were calculated by normalization of the activities in each set to that of the cells cotransfected with the reporter plasmid and pcDNA3.1(+) control vector. two eEF1A-interacting domains, NS4A(1-20) and NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , is essential for the translation inhibition, GST-NS4A and its deletion mutant proteins were purified (Figure 6a ) and used to perform a translation inhibition assay in a cell-free system.", [["cells", "ANATOMY", 159, 164], ["plasmid", "ANATOMY", 197, 204], ["cell", "ANATOMY", 530, 534], ["luciferase", "GENE_OR_GENE_PRODUCT", 9, 19], ["cells", "CELL", 159, 164], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 209, 215], ["eEF1A", "GENE_OR_GENE_PRODUCT", 241, 246], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 405, 413], ["cell", "CELL", 530, 534], ["luciferase", "PROTEIN", 9, 19], ["HCV nonstructural proteins", "PROTEIN", 54, 80], ["reporter plasmid", "DNA", 188, 204], ["pcDNA3", "DNA", 209, 215], ["1(+) control vector", "DNA", 216, 235], ["eEF1A", "PROTEIN", 241, 246], ["interacting domains", "PROTEIN", 247, 266], ["NS4A", "PROTEIN", 268, 272], ["GST", "PROTEIN", 405, 408], ["NS4A", "PROTEIN", 409, 413], ["deletion mutant proteins", "PROTEIN", 422, 446], ["HCV", "SPECIES", 54, 57], ["Relative luciferase activities", "PROBLEM", 0, 30], ["the HCV nonstructural proteins", "PROBLEM", 50, 80], ["the reporter plasmid", "TREATMENT", 184, 204], ["pcDNA3", "TREATMENT", 209, 215], ["NS4A", "TEST", 268, 272], ["NS4A", "TEST", 283, 287], ["the translation inhibition", "TEST", 377, 403], ["GST", "TEST", 405, 408], ["NS4A", "TREATMENT", 409, 413], ["its deletion mutant proteins", "PROBLEM", 418, 446], ["a translation inhibition assay", "TEST", 494, 524], ["luciferase activities", "OBSERVATION", 9, 30], ["NS4A", "ANATOMY", 268, 272]]], ["Increasing amounts of the purified GST fusion proteins were pre-incubated with RRL followed by in vitro translation reaction with the monocistronic luciferase mRNA as the reporter.", [["GST", "GENE_OR_GENE_PRODUCT", 35, 38], ["luciferase", "GENE_OR_GENE_PRODUCT", 148, 158], ["GST fusion proteins", "PROTEIN", 35, 54], ["monocistronic luciferase mRNA", "RNA", 134, 163], ["the purified GST fusion proteins", "TREATMENT", 22, 54], ["RRL", "TREATMENT", 79, 82], ["vitro translation reaction", "PROBLEM", 98, 124], ["amounts", "OBSERVATION_MODIFIER", 11, 18]]], ["The results demonstrated that both the GST-NS4A and GST-NS4A(21-34) significantly reduced the luciferase activity, whereas the effects of GST-NS4A(1-20) and GST-NS4A(35-54) proteins were negligible (Figure 6b ).", [["GST-NS4A", "GENE_OR_GENE_PRODUCT", 39, 47], ["GST", "GENE_OR_GENE_PRODUCT", 52, 55], ["luciferase", "GENE_OR_GENE_PRODUCT", 94, 104], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 138, 146], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 157, 165], ["GST", "PROTEIN", 39, 42], ["NS4A", "PROTEIN", 43, 47], ["GST", "PROTEIN", 52, 55], ["NS4A", "PROTEIN", 56, 60], ["luciferase", "PROTEIN", 94, 104], ["GST", "PROTEIN", 138, 141], ["NS4A", "PROTEIN", 142, 146], ["GST", "PROTEIN", 157, 160], ["NS4A(35-54) proteins", "PROTEIN", 161, 181], ["the GST", "TEST", 35, 42], ["NS4A", "TEST", 43, 47], ["GST", "TEST", 52, 55], ["NS4A", "TEST", 56, 60], ["the luciferase activity", "PROBLEM", 90, 113], ["GST", "TEST", 138, 141], ["NS4A", "TEST", 142, 146], ["GST", "TEST", 157, 160], ["NS4A", "TEST", 161, 165], ["proteins", "TEST", 173, 181], ["luciferase activity", "OBSERVATION", 94, 113]]], ["In addition, the GST-NS4A(21-34) protein had a stronger effect on the translation inhibition than that of the wild type.", [["GST", "GENE_OR_GENE_PRODUCT", 17, 20], ["GST", "PROTEIN", 17, 20], ["NS4A(21-34) protein", "PROTEIN", 21, 40], ["the GST", "TEST", 13, 20], ["NS4A", "TEST", 21, 25], ["stronger effect", "OBSERVATION_MODIFIER", 47, 62]]], ["It required less than half amount of GST-NS4A(21-34) protein to reach a 50%-inhibition when compared with the full-length NS4A protein (4.29 \u00c2 10 13 moles for full-length and 1.81 \u00c2 10 13 moles for the subdomain 21-34).", [["GST", "GENE_OR_GENE_PRODUCT", 37, 40], ["GST", "PROTEIN", 37, 40], ["NS4A(21-34) protein", "PROTEIN", 41, 60], ["NS4A protein", "PROTEIN", 122, 134], ["subdomain 21-34", "PROTEIN", 202, 217], ["GST-NS4A", "TREATMENT", 37, 45], ["NS4A protein", "TEST", 122, 134], ["length", "TEST", 164, 170], ["less", "OBSERVATION_MODIFIER", 12, 16]]], ["The effects of NS4A subdomains on the translation inhibition were also examined by analyzing the level of luciferase protein following an in-vitro-translation reaction in the presence of [ 35 S]methionine and 2 \u00c2 10 13 moles of the NS4A proteins.", [["[ 35 S]methionine", "CHEMICAL", 187, 204], ["[ 35 S]methionine", "CHEMICAL", 187, 204], ["luciferase", "GENE_OR_GENE_PRODUCT", 106, 116], ["[ 35 S]methionine", "SIMPLE_CHEMICAL", 187, 204], ["NS4A subdomains", "PROTEIN", 15, 30], ["luciferase protein", "PROTEIN", 106, 124], ["NS4A proteins", "PROTEIN", 232, 245], ["NS4A subdomains", "PROBLEM", 15, 30], ["luciferase protein", "TEST", 106, 124], ["methionine", "TREATMENT", 194, 204], ["the NS4A proteins", "TREATMENT", 228, 245]]], ["As shown in Figure 6c , GST-NS4A(21-34) had a greater effect than the GST-NS4A(1-20) whereas GST-NS4A(35-54) had no effect on the translation inhibition.", [["GST", "GENE_OR_GENE_PRODUCT", 24, 27], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 70, 78], ["GST", "GENE_OR_GENE_PRODUCT", 93, 96], ["GST", "PROTEIN", 24, 27], ["NS4A", "PROTEIN", 28, 32], ["GST", "PROTEIN", 70, 73], ["NS4A", "PROTEIN", 74, 78], ["GST", "PROTEIN", 93, 96], ["NS4A", "PROTEIN", 97, 101], ["GST", "TEST", 24, 27], ["NS4A", "TEST", 28, 32], ["the GST", "TEST", 66, 73], ["NS4A", "TEST", 74, 78], ["GST", "TEST", 93, 96], ["NS4A", "TEST", 97, 101]]], ["BL21(DE3) .", [["BL21", "GENE_OR_GENE_PRODUCT", 0, 4], ["DE3", "GENE_OR_GENE_PRODUCT", 5, 8], ["BL21", "PROTEIN", 0, 4], ["DE3", "PROTEIN", 5, 8], ["BL21", "SPECIES", 0, 4]]], ["Following a partial purification, the GST fusion proteins immobilized on the glutathione-Sepharose 4B beads were analyzed by SDS-PAGE.", [["glutathione", "CHEMICAL", 77, 88], ["glutathione", "CHEMICAL", 77, 88], ["GST", "GENE_OR_GENE_PRODUCT", 38, 41], ["glutathione", "SIMPLE_CHEMICAL", 77, 88], ["GST fusion proteins", "PROTEIN", 38, 57], ["a partial purification", "TREATMENT", 10, 32], ["the GST fusion proteins", "TREATMENT", 34, 57], ["the glutathione-Sepharose 4B beads", "TREATMENT", 73, 107]]], ["Coomassie blue staining is shown. (b) eEF1A specifically copurified with GST-NS4A.", [["Coomassie blue", "CHEMICAL", 0, 14], ["Coomassie", "SIMPLE_CHEMICAL", 0, 9], ["eEF1A", "GENE_OR_GENE_PRODUCT", 38, 43], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 73, 81], ["eEF1A", "PROTEIN", 38, 43], ["GST", "PROTEIN", 73, 76], ["NS4A", "PROTEIN", 77, 81], ["Coomassie blue staining", "TEST", 0, 23], ["NS4A", "TREATMENT", 77, 81]]], ["Huh7 cell extracts were incubated with partially purified GST-fusion proteins as indicated, followed by GST pull-down assay and Western blot analysis with antibody specific to eEF1A.", [["Huh7 cell extracts", "ANATOMY", 0, 18], ["Huh7 cell", "CELL", 0, 9], ["extracts", "ORGANISM_SUBSTANCE", 10, 18], ["GST", "GENE_OR_GENE_PRODUCT", 58, 61], ["GST", "GENE_OR_GENE_PRODUCT", 104, 107], ["eEF1A", "GENE_OR_GENE_PRODUCT", 176, 181], ["GST", "PROTEIN", 58, 61], ["fusion proteins", "PROTEIN", 62, 77], ["GST", "PROTEIN", 104, 107], ["eEF1A", "PROTEIN", 176, 181], ["Huh7 cell extracts", "TREATMENT", 0, 18], ["partially purified GST-fusion proteins", "TREATMENT", 39, 77], ["GST pull", "TEST", 104, 112], ["blot analysis", "TEST", 136, 149]]], ["Cell extract control represents Huh7 cell extract that was loaded directly onto the gel to serve as a control. (c) Interaction between NS4A and eEF1A in transfected culture cells.", [["Cell", "ANATOMY", 0, 4], ["Huh7 cell extract", "ANATOMY", 32, 49], ["culture cells", "ANATOMY", 165, 178], ["Cell", "CELL", 0, 4], ["Huh7 cell", "CELL", 32, 41], ["NS4A", "GENE_OR_GENE_PRODUCT", 135, 139], ["eEF1A", "GENE_OR_GENE_PRODUCT", 144, 149], ["culture cells", "CELL", 165, 178], ["NS4A", "PROTEIN", 135, 139], ["eEF1A", "PROTEIN", 144, 149], ["transfected culture cells", "CELL_LINE", 153, 178], ["Cell extract control", "TREATMENT", 0, 20], ["Huh7 cell extract", "TREATMENT", 32, 49], ["the gel", "TREATMENT", 80, 87], ["NS4A", "TREATMENT", 135, 139], ["eEF1A in transfected culture cells", "TREATMENT", 144, 178], ["Huh7 cell", "OBSERVATION", 32, 41]]], ["Plasmids pcDNA-NS4A-V5 and pcDNA-NS4B-V5 that encode V5 epitope-tagged NS4A and NS4B proteins, respectively, were independently cotransfected into Huh7 cells with plasmid pcDNA-eEF1A-HisTopo that encodes a His-tagged fusion protein of the fulllength eEF1A (eEF1A-His).", [["Huh7 cells", "ANATOMY", 147, 157], ["His", "CHEMICAL", 206, 209], ["pcDNA", "GENE_OR_GENE_PRODUCT", 9, 14], ["V5", "GENE_OR_GENE_PRODUCT", 20, 22], ["pcDNA-NS4B-V5", "GENE_OR_GENE_PRODUCT", 27, 40], ["V5", "GENE_OR_GENE_PRODUCT", 53, 55], ["NS4B", "GENE_OR_GENE_PRODUCT", 80, 84], ["Huh7 cells", "CELL", 147, 157], ["pcDNA-eEF1A-HisTopo", "GENE_OR_GENE_PRODUCT", 171, 190], ["eEF1A", "GENE_OR_GENE_PRODUCT", 250, 255], ["eEF1A-His", "GENE_OR_GENE_PRODUCT", 257, 266], ["pcDNA", "PROTEIN", 9, 14], ["NS4A", "PROTEIN", 15, 19], ["V5", "PROTEIN", 20, 22], ["pcDNA", "PROTEIN", 27, 32], ["NS4B", "PROTEIN", 33, 37], ["V5", "PROTEIN", 38, 40], ["V5 epitope", "PROTEIN", 53, 63], ["NS4A", "PROTEIN", 71, 75], ["NS4B proteins", "PROTEIN", 80, 93], ["Huh7 cells", "CELL_LINE", 147, 157], ["pcDNA-eEF1A", "PROTEIN", 171, 182], ["Topo", "PROTEIN", 186, 190], ["His-tagged fusion protein", "PROTEIN", 206, 231], ["fulllength eEF1A", "PROTEIN", 239, 255], ["eEF1A", "PROTEIN", 257, 262], ["His", "PROTEIN", 263, 266], ["Plasmids pcDNA", "TEST", 0, 14], ["NS4A", "TEST", 15, 19], ["pcDNA", "TEST", 27, 32], ["NS4B", "TREATMENT", 33, 37], ["V5 epitope", "TREATMENT", 53, 63], ["tagged NS4A", "TREATMENT", 64, 75], ["NS4B proteins", "TEST", 80, 93], ["Huh7 cells", "TEST", 147, 157], ["plasmid pcDNA-eEF1A", "TREATMENT", 163, 182], ["HisTopo", "PROBLEM", 183, 190]]], ["Cell lysates were prepared 2 days posttransfection to perform coimmunoprecipitation assay with antibodies against the His-tag of eEF1A-His protein and Western blot analysis with antibodies specific to the V5-epitope to detect V5-tagged NS4A and NS4B proteins.", [["Cell lysates", "ANATOMY", 0, 12], ["His", "CHEMICAL", 118, 121], ["Cell lysates", "CELL", 0, 12], ["eEF1A", "GENE_OR_GENE_PRODUCT", 129, 134], ["V5", "GENE_OR_GENE_PRODUCT", 226, 228], ["NS4B", "GENE_OR_GENE_PRODUCT", 245, 249], ["antibodies", "PROTEIN", 95, 105], ["eEF1A", "PROTEIN", 129, 134], ["His protein", "PROTEIN", 135, 146], ["antibodies", "PROTEIN", 178, 188], ["V5", "PROTEIN", 205, 207], ["V5", "PROTEIN", 226, 228], ["NS4A", "PROTEIN", 236, 240], ["NS4B proteins", "PROTEIN", 245, 258], ["Cell lysates", "PROBLEM", 0, 12], ["coimmunoprecipitation assay", "TEST", 62, 89], ["antibodies", "TEST", 95, 105], ["His protein", "TEST", 135, 146], ["Western blot analysis", "TEST", 151, 172], ["antibodies", "TEST", 178, 188], ["V5", "TEST", 226, 228], ["tagged NS4A", "TREATMENT", 229, 240], ["NS4B proteins", "TREATMENT", 245, 258], ["NS4B proteins", "OBSERVATION", 245, 258]]], ["Input lanes represent 5 % of the cell lysates used in the coimmunoprecipitation assay and were loaded directly onto the gel to serve as positive controls of Western blot analysis.", [["cell lysates", "ANATOMY", 33, 45], ["cell lysates", "ORGANISM_SUBSTANCE", 33, 45], ["the cell lysates", "TREATMENT", 29, 45], ["the coimmunoprecipitation assay", "TEST", 54, 85], ["the gel", "TREATMENT", 116, 123], ["Western blot analysis", "TEST", 157, 178]]], ["The effect of NS4A on the translation inhibition may be resulted from a competition between NS4A and translation factors that are involved in forming functional translation complexes with eEF1A.", [["NS4A", "GENE_OR_GENE_PRODUCT", 14, 18], ["NS4A", "GENE_OR_GENE_PRODUCT", 92, 96], ["eEF1A", "GENE_OR_GENE_PRODUCT", 188, 193], ["NS4A", "PROTEIN", 14, 18], ["NS4A", "PROTEIN", 92, 96], ["translation factors", "PROTEIN", 101, 120], ["translation complexes", "PROTEIN", 161, 182], ["eEF1A", "PROTEIN", 188, 193], ["NS4A", "TREATMENT", 14, 18], ["the translation inhibition", "TREATMENT", 22, 48], ["NS4A", "TREATMENT", 92, 96], ["translation factors", "TREATMENT", 101, 120]]], ["We therefore examined GST and GST fusion proteins of the wild-type NS4A and its deletion mutants were eluted out from the glutathione-Sepharose 4B beads. eEF1A was purified from bead-bound GST-eEF1A following a cleavage with PreScission TM Protease and dialyzed into 50 mM Tris-HCl (pH 8.0) as described in the Materials and methods.", [["glutathione", "CHEMICAL", 122, 133], ["Tris-HCl", "CHEMICAL", 273, 281], ["glutathione", "CHEMICAL", 122, 133], ["Tris-HCl", "CHEMICAL", 273, 281], ["GST", "GENE_OR_GENE_PRODUCT", 22, 25], ["GST", "GENE_OR_GENE_PRODUCT", 30, 33], ["wild-type NS4A", "ORGANISM", 57, 71], ["glutathione", "SIMPLE_CHEMICAL", 122, 133], ["eEF1A", "GENE_OR_GENE_PRODUCT", 154, 159], ["GST-eEF1A", "GENE_OR_GENE_PRODUCT", 189, 198], ["Tris-HCl", "SIMPLE_CHEMICAL", 273, 281], ["GST", "PROTEIN", 22, 25], ["GST fusion proteins", "PROTEIN", 30, 49], ["wild-type NS4A", "PROTEIN", 57, 71], ["eEF1A", "PROTEIN", 154, 159], ["GST", "PROTEIN", 189, 192], ["eEF1A", "PROTEIN", 193, 198], ["GST", "TEST", 22, 25], ["GST fusion proteins", "TREATMENT", 30, 49], ["type NS4A", "TREATMENT", 62, 71], ["its deletion mutants", "PROBLEM", 76, 96], ["the glutathione", "TEST", 118, 133], ["Sepharose 4B beads", "TREATMENT", 134, 152], ["a cleavage", "TREATMENT", 209, 219], ["PreScission TM Protease", "TREATMENT", 225, 248], ["pH", "TEST", 283, 285], ["Sepharose 4B beads", "OBSERVATION", 134, 152]]], ["The purified proteins were analyzed by SDS-PAGE.", [["The purified proteins", "TEST", 0, 21]]], ["Coomassie blue staining is shown. (b)-(c) Cap-dependent in-vitro-translation inhibition assay.", [["Coomassie blue", "CHEMICAL", 0, 14], ["Coomassie", "SIMPLE_CHEMICAL", 0, 9], ["Coomassie blue staining", "TEST", 0, 23], ["Cap-dependent in-vitro", "TREATMENT", 42, 64]]], ["Various amounts of the purified GST fusion proteins as indicated in panel b or 2 \u00c2 10 13 moles of the GST fusion proteins as indicated in panel c were pre-incubated with RRL for 1 h at 4\u00b0C. Translation reaction was then carried out at 30\u00b0C following addition of the monocistronic luciferase mRNA, amino acid mixtures, and RNase inhibitor in the absence (panel b) or presence (panel c) of [ 35 S]methionine.", [["amino acid", "CHEMICAL", 297, 307], ["[ 35 S]methionine", "CHEMICAL", 388, 405], ["amino acid", "CHEMICAL", 297, 307], ["[ 35 S]methionine", "CHEMICAL", 388, 405], ["GST", "GENE_OR_GENE_PRODUCT", 32, 35], ["GST", "GENE_OR_GENE_PRODUCT", 102, 105], ["C", "GENE_OR_GENE_PRODUCT", 238, 239], ["luciferase", "GENE_OR_GENE_PRODUCT", 280, 290], ["amino acid", "AMINO_ACID", 297, 307], ["RNase", "GENE_OR_GENE_PRODUCT", 322, 327], ["[ 35 S]methionine", "SIMPLE_CHEMICAL", 388, 405], ["purified GST fusion proteins", "PROTEIN", 23, 51], ["GST fusion proteins", "PROTEIN", 102, 121], ["monocistronic luciferase mRNA", "RNA", 266, 295], ["RNase", "PROTEIN", 322, 327], ["the purified GST fusion proteins", "TREATMENT", 19, 51], ["the GST fusion proteins", "TEST", 98, 121], ["Translation reaction", "PROBLEM", 190, 210], ["the monocistronic luciferase mRNA", "TREATMENT", 262, 295], ["amino acid mixtures", "TREATMENT", 297, 316], ["RNase inhibitor", "TREATMENT", 322, 337], ["methionine", "TREATMENT", 395, 405]]], ["The translation products were subjected to luciferase activity assay (panel b) or SDS-PAGE followed by autoradiography (panel c).", [["luciferase", "GENE_OR_GENE_PRODUCT", 43, 53], ["translation products", "PROTEIN", 4, 24], ["luciferase", "PROTEIN", 43, 53], ["luciferase activity assay", "TEST", 43, 68]]], ["Relative luciferase activities were calculated by normalization of the luciferase activities in the presence of the GST and GST-NS4A proteins to that without any GST proteins.", [["luciferase", "GENE_OR_GENE_PRODUCT", 9, 19], ["luciferase", "GENE_OR_GENE_PRODUCT", 71, 81], ["GST", "GENE_OR_GENE_PRODUCT", 116, 119], ["GST-NS4A", "GENE_OR_GENE_PRODUCT", 124, 132], ["GST", "GENE_OR_GENE_PRODUCT", 162, 165], ["luciferase", "PROTEIN", 9, 19], ["luciferase", "PROTEIN", 71, 81], ["GST", "PROTEIN", 116, 119], ["GST", "PROTEIN", 124, 127], ["NS4A proteins", "PROTEIN", 128, 141], ["GST proteins", "PROTEIN", 162, 174], ["Relative luciferase activities", "PROBLEM", 0, 30], ["the luciferase activities", "PROBLEM", 67, 92], ["the GST", "TEST", 112, 119], ["NS4A proteins", "TREATMENT", 128, 141], ["any GST proteins", "PROBLEM", 158, 174], ["luciferase activities", "OBSERVATION", 9, 30]]], ["Relative intensities of the luciferase protein were normalized against the intensity of luciferase protein in the presence of GST. (d) Translation restore experiments.", [["luciferase", "GENE_OR_GENE_PRODUCT", 28, 38], ["luciferase", "GENE_OR_GENE_PRODUCT", 88, 98], ["GST", "GENE_OR_GENE_PRODUCT", 126, 129], ["luciferase protein", "PROTEIN", 28, 46], ["luciferase protein", "PROTEIN", 88, 106], ["GST", "PROTEIN", 126, 129], ["the luciferase protein", "TEST", 24, 46], ["luciferase protein", "TEST", 88, 106], ["intensities", "OBSERVATION_MODIFIER", 9, 20]]], ["GST fusion proteins of 2 \u00c2 10 13 moles were preincubated with RRL for 1 h at 4\u00b0C followed by an additional incubation for 30 min in the presence of 0.5 lg purified recombinant eEF1A.", [["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["eEF1A", "GENE_OR_GENE_PRODUCT", 176, 181], ["GST fusion proteins", "PROTEIN", 0, 19], ["eEF1A", "PROTEIN", 176, 181], ["GST fusion proteins", "TEST", 0, 19], ["lg purified recombinant eEF1A", "TREATMENT", 152, 181]]], ["The ability of the purified eEF1A to restore the translation inhibition was analyzed by luciferase activity assay.", [["eEF1A", "GENE_OR_GENE_PRODUCT", 28, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 88, 98], ["eEF1A", "PROTEIN", 28, 33], ["luciferase", "PROTEIN", 88, 98], ["the purified eEF1A", "TREATMENT", 15, 33], ["the translation inhibition", "TREATMENT", 45, 71], ["luciferase activity assay", "TEST", 88, 113]]], ["Relative luciferase activities as compared to that of GST in the absence of exogenous eEF1A are shown.", [["luciferase", "GENE_OR_GENE_PRODUCT", 9, 19], ["GST", "GENE_OR_GENE_PRODUCT", 54, 57], ["eEF1A", "GENE_OR_GENE_PRODUCT", 86, 91], ["luciferase", "PROTEIN", 9, 19], ["GST", "PROTEIN", 54, 57], ["eEF1A", "PROTEIN", 86, 91], ["Relative luciferase activities", "PROBLEM", 0, 30], ["luciferase activities", "OBSERVATION", 9, 30], ["exogenous eEF1A", "OBSERVATION", 76, 91]]], ["The result represents the average of two independent experiments. (e) HCV IRES-mediated in-vitro-translation inhibition assay.", [["HCV", "ORGANISM", 70, 73], ["HCV IRES", "DNA", 70, 78], ["HCV", "SPECIES", 70, 73], ["HCV IRES", "TREATMENT", 70, 78]]], ["Various amounts of the NS4A(21-34) peptide as indicated were preincubated with RRL for 30 min at 4\u00b0C prior to the in-vitro-translation reaction.", [["NS4A", "PROTEIN", 23, 27], ["the NS4A", "TREATMENT", 19, 27], ["the in-vitro-translation reaction", "PROBLEM", 110, 143], ["amounts", "OBSERVATION_MODIFIER", 8, 15]]], ["In-vitro-translation reaction was performed as described in the legend to panel b except that the bicistronic luciferase reporter mRNA and NS4A(21-34) peptide were used.", [["luciferase", "GENE_OR_GENE_PRODUCT", 110, 120], ["bicistronic luciferase reporter mRNA", "RNA", 98, 134], ["NS4A", "PROTEIN", 139, 143], ["NS4A", "TEST", 139, 143]]], ["Luciferase activities of Renilla and firefly that represent cap-dependent and HCV IRES-mediated translation, respectively, were analyzed and normalized in each set against the luciferase activity of the reaction without addition of the NS4A(21-34) peptide.Dose-dependent inhibition of both cap-dependent and HCV IRES-mediated translation by the synthetic NS4A(21-34) peptideTo eliminate the possibility that the translation inhibition effect of GST-NS4A(21-34) is resulted from a trace contamination of inhibitors present in the protein preparation, a synthetic NS4A (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) peptide purified by HPLC to >85% purity was applied.", [["Renilla", "GENE_OR_GENE_PRODUCT", 25, 32], ["firefly", "GENE_OR_GENE_PRODUCT", 37, 44], ["cap", "GENE_OR_GENE_PRODUCT", 60, 63], ["HCV", "ORGANISM", 78, 81], ["luciferase", "GENE_OR_GENE_PRODUCT", 176, 186], ["HCV", "ORGANISM", 308, 311], ["GST", "GENE_OR_GENE_PRODUCT", 445, 448], ["24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) peptide", "SIMPLE_CHEMICAL", 583, 644], ["Renilla and firefly", "DNA", 25, 44], ["HCV IRES", "DNA", 78, 86], ["luciferase", "PROTEIN", 176, 186], ["NS4A", "PROTEIN", 236, 240], ["HCV IRES", "DNA", 308, 316], ["NS4A(21-34) peptideTo", "PROTEIN", 355, 376], ["GST", "PROTEIN", 445, 448], ["NS4A", "PROTEIN", 449, 453], ["HCV", "SPECIES", 78, 81], ["HCV", "SPECIES", 308, 311], ["Luciferase activities of Renilla", "PROBLEM", 0, 32], ["cap-dependent", "PROBLEM", 60, 73], ["HCV IRES", "TREATMENT", 78, 86], ["the reaction", "PROBLEM", 199, 211], ["the NS4A", "TREATMENT", 232, 240], ["HCV IRES", "TREATMENT", 308, 316], ["the synthetic NS4A", "TREATMENT", 341, 359], ["peptideTo", "TREATMENT", 367, 376], ["GST", "TEST", 445, 448], ["NS4A", "TEST", 449, 453], ["a trace contamination of inhibitors", "PROBLEM", 478, 513], ["a synthetic NS4A", "TEST", 550, 566], ["peptide", "TEST", 637, 644], ["HPLC", "TEST", 657, 661], ["Renilla", "ANATOMY", 25, 32], ["both cap", "OBSERVATION_MODIFIER", 285, 293], ["trace", "OBSERVATION_MODIFIER", 480, 485], ["contamination", "OBSERVATION", 486, 499]]], ["Meanwhile, the bicistronic luciferase reporter mRNA was used in the in vitro translation system to examine the inhibitory effect of the NS4A(21-34) peptide on both cap-and IRESdependent translation.", [["luciferase", "GENE_OR_GENE_PRODUCT", 27, 37], ["bicistronic luciferase reporter mRNA", "RNA", 15, 51], ["NS4A", "PROTEIN", 136, 140], ["the bicistronic luciferase reporter mRNA", "TREATMENT", 11, 51], ["the NS4A", "TREATMENT", 132, 140]]], ["The cap-dependent translation of Renilla luciferase and HCV IRES-mediated translation of firefly luciferase were analyzed by Dual-Glo TM luciferase assay.", [["Renilla", "GENE_OR_GENE_PRODUCT", 33, 40], ["luciferase", "GENE_OR_GENE_PRODUCT", 41, 51], ["HCV", "GENE_OR_GENE_PRODUCT", 56, 59], ["luciferase", "GENE_OR_GENE_PRODUCT", 97, 107], ["Renilla luciferase", "DNA", 33, 51], ["HCV IRES", "DNA", 56, 64], ["firefly luciferase", "PROTEIN", 89, 107], ["luciferase", "PROTEIN", 137, 147], ["HCV", "SPECIES", 56, 59], ["The cap", "TEST", 0, 7], ["Renilla luciferase", "TREATMENT", 33, 51], ["HCV IRES", "TREATMENT", 56, 64], ["firefly luciferase", "TREATMENT", 89, 107], ["Dual-Glo TM luciferase assay", "TEST", 125, 153], ["cap", "OBSERVATION_MODIFIER", 4, 7], ["dependent", "OBSERVATION_MODIFIER", 8, 17], ["Renilla luciferase", "OBSERVATION", 33, 51]]], ["The results clearly demonstrated a dose-dependent inhibitory effect of the NS4A(21-34) peptide on both cap-dependent and HCV IRES-mediated translation (Figure 6e ).DiscussionUpon virus infection, the translation machinery of host cells is known to be down-regulated.", [["cells", "ANATOMY", 230, 235], ["infection", "DISEASE", 185, 194], ["HCV", "ORGANISM", 121, 124], ["DiscussionUpon virus", "ORGANISM", 164, 184], ["host cells", "CELL", 225, 235], ["NS4A", "PROTEIN", 75, 79], ["HCV IRES", "DNA", 121, 129], ["host cells", "CELL_TYPE", 225, 235], ["HCV", "SPECIES", 121, 124], ["DiscussionUpon virus", "SPECIES", 164, 184], ["the NS4A", "TEST", 71, 79], ["HCV IRES", "TREATMENT", 121, 129], ["DiscussionUpon virus infection", "PROBLEM", 164, 194], ["host cells", "PROBLEM", 225, 235], ["HCV IRES", "OBSERVATION", 121, 129], ["infection", "OBSERVATION", 185, 194], ["host cells", "OBSERVATION", 225, 235]]], ["Viral proteins derive ability to modify or regulate the expression and function of translation factors that results in an inhibition of host protein synthesis [21] .", [["Viral proteins", "PROTEIN", 0, 14], ["translation factors", "PROTEIN", 83, 102], ["Viral proteins", "PROBLEM", 0, 14], ["translation factors", "PROBLEM", 83, 102], ["host protein synthesis", "TEST", 136, 158]]], ["Poliovirus-encoded proteases 2A and 3C cleave eIF4G (eIF4GI and eIF4GII) and PABP, respectively, of host cells [22, 23] .", [["cells", "ANATOMY", 105, 110], ["Poliovirus-encoded proteases 2A", "GENE_OR_GENE_PRODUCT", 0, 31], ["3C", "GENE_OR_GENE_PRODUCT", 36, 38], ["eIF4G", "GENE_OR_GENE_PRODUCT", 46, 51], ["eIF4GI", "GENE_OR_GENE_PRODUCT", 53, 59], ["eIF4GII", "GENE_OR_GENE_PRODUCT", 64, 71], ["PABP", "GENE_OR_GENE_PRODUCT", 77, 81], ["host cells", "CELL", 100, 110], ["Poliovirus-encoded proteases 2A and 3C", "PROTEIN", 0, 38], ["eIF4G", "PROTEIN", 46, 51], ["eIF4GI", "PROTEIN", 53, 59], ["eIF4GII", "PROTEIN", 64, 71], ["PABP", "PROTEIN", 77, 81], ["host cells", "CELL_TYPE", 100, 110], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus", "PROBLEM", 0, 10], ["encoded proteases 2A", "TREATMENT", 11, 31], ["3C cleave eIF4G (eIF4GI and eIF4GII)", "TREATMENT", 36, 72], ["PABP", "TREATMENT", 77, 81]]], ["The NSP3 of rotavirus substitutes the function of cellular PABP.", [["cellular", "ANATOMY", 50, 58], ["NSP3", "GENE_OR_GENE_PRODUCT", 4, 8], ["rotavirus", "ORGANISM", 12, 21], ["cellular", "CELL", 50, 58], ["PABP", "GENE_OR_GENE_PRODUCT", 59, 63], ["NSP3", "PROTEIN", 4, 8], ["cellular PABP", "PROTEIN", 50, 63], ["rotavirus", "SPECIES", 12, 21], ["rotavirus", "PROBLEM", 12, 21], ["cellular PABP", "TREATMENT", 50, 63], ["cellular PABP", "OBSERVATION", 50, 63]]], ["It binds to the 3\u00a2 end of the nonpolyadenylated viral mRNA and competes with PABP in binding to eIF4G [24] .", [["PABP", "GENE_OR_GENE_PRODUCT", 77, 81], ["eIF4G", "GENE_OR_GENE_PRODUCT", 96, 101], ["3\u00a2 end", "RNA", 16, 22], ["nonpolyadenylated viral mRNA", "RNA", 30, 58], ["PABP", "PROTEIN", 77, 81], ["eIF4G", "PROTEIN", 96, 101], ["the nonpolyadenylated viral mRNA", "TREATMENT", 26, 58], ["PABP in binding", "TREATMENT", 77, 92], ["viral mRNA", "OBSERVATION", 48, 58]]], ["In both cases, the viral proteins selectively inhibit translation of capped host mRNA but not the viral RNA.DiscussionHCV NS4A was previously demonstrated to inhibit protein synthesis through its N-terminal 40 amino acid residues [15] .", [["amino acid", "CHEMICAL", 210, 220], ["N", "CHEMICAL", 196, 197], ["amino acid", "CHEMICAL", 210, 220], ["amino acid", "AMINO_ACID", 210, 220], ["viral proteins", "PROTEIN", 19, 33], ["capped host mRNA", "RNA", 69, 85], ["viral RNA", "RNA", 98, 107], ["NS4A", "PROTEIN", 122, 126], ["N-terminal 40 amino acid residues", "PROTEIN", 196, 229], ["the viral proteins", "PROBLEM", 15, 33], ["capped host mRNA", "PROBLEM", 69, 85], ["the viral RNA", "PROBLEM", 94, 107], ["DiscussionHCV NS4A", "TREATMENT", 108, 126], ["protein synthesis", "TREATMENT", 166, 183], ["terminal 40 amino acid residues", "TREATMENT", 198, 229], ["capped host mRNA", "OBSERVATION", 69, 85], ["viral RNA", "OBSERVATION", 98, 107]]], ["But the steady state levels of eIF4G, eIF4E, PABP, and 4E-BP1 were not affected [16] .", [["eIF4G", "GENE_OR_GENE_PRODUCT", 31, 36], ["eIF4E", "GENE_OR_GENE_PRODUCT", 38, 43], ["PABP", "GENE_OR_GENE_PRODUCT", 45, 49], ["4E-BP1", "GENE_OR_GENE_PRODUCT", 55, 61], ["eIF4G", "PROTEIN", 31, 36], ["eIF4E", "PROTEIN", 38, 43], ["PABP", "PROTEIN", 45, 49], ["4E", "PROTEIN", 55, 57], ["BP1", "PROTEIN", 58, 61], ["eIF4G", "TEST", 31, 36], ["eIF4E", "TEST", 38, 43], ["PABP", "TEST", 45, 49]]], ["The molecular basis involved in the inhibitory effect of NS4A was not clear.", [["NS4A", "GENE_OR_GENE_PRODUCT", 57, 61], ["NS4A", "PROTEIN", 57, 61], ["NS4A", "PROBLEM", 57, 61], ["NS4A", "OBSERVATION", 57, 61], ["clear", "OBSERVATION", 70, 75]]], ["In this study, we found that HCV NS4A protein specifically interacted with the translation elongation factor, eEF1A (Figures 1 and 3) .", [["HCV", "ORGANISM", 29, 32], ["eEF1A", "GENE_OR_GENE_PRODUCT", 110, 115], ["Figures 1", "GENE_OR_GENE_PRODUCT", 117, 126], ["3", "GENE_OR_GENE_PRODUCT", 131, 132], ["HCV NS4A protein", "PROTEIN", 29, 45], ["translation elongation factor", "PROTEIN", 79, 108], ["eEF1A", "PROTEIN", 110, 115], ["Figures 1 and 3", "PROTEIN", 117, 132], ["HCV", "SPECIES", 29, 32], ["this study", "TEST", 3, 13], ["HCV NS4A protein", "PROBLEM", 29, 45], ["HCV", "OBSERVATION", 29, 32]]], ["The N-terminal and the central domains of the NS4A were involved independently in the interaction (Figure 4 ), but the central domain encompassing amino acid residues 21-34 played a major role in the inhibition of the cap-dependent and HCV IRES-mediated translation (Figures 6b, c, and e) .", [["amino acid residues 21-34", "CHEMICAL", 147, 172], ["amino acid", "CHEMICAL", 147, 157], ["NS4A", "GENE_OR_GENE_PRODUCT", 46, 50], ["amino acid", "AMINO_ACID", 147, 157], ["residues 21-34", "AMINO_ACID", 158, 172], ["c", "GENE_OR_GENE_PRODUCT", 279, 280], ["N-terminal and the central domains", "PROTEIN", 4, 38], ["NS4A", "PROTEIN", 46, 50], ["central domain", "PROTEIN", 119, 133], ["amino acid residues 21-34", "PROTEIN", 147, 172], ["HCV IRES", "DNA", 236, 244], ["HCV", "SPECIES", 236, 239], ["amino acid residues", "TEST", 147, 166], ["HCV IRES", "TREATMENT", 236, 244], ["N-terminal", "OBSERVATION_MODIFIER", 4, 14], ["central", "ANATOMY_MODIFIER", 23, 30], ["NS4A", "OBSERVATION", 46, 50], ["central", "ANATOMY_MODIFIER", 119, 126]]], ["The translation inhibitory effect caused by the NS4A(21-34) could be relieved by the addition of purified recombinant eEF1A into the translation system (Figure 6d) .", [["eEF1A", "GENE_OR_GENE_PRODUCT", 118, 123], ["NS4A", "PROTEIN", 48, 52], ["eEF1A", "PROTEIN", 118, 123], ["the NS4A", "TEST", 44, 52], ["purified recombinant eEF1A", "TREATMENT", 97, 123]]], ["Nevertheless, the translation inhibition was not fully restored, suggesting that binding of NS4A to the eEF1A may simultaneously deplete other translation factors that are associated with eEF1A.", [["NS4A", "GENE_OR_GENE_PRODUCT", 92, 96], ["eEF1A", "GENE_OR_GENE_PRODUCT", 104, 109], ["eEF1A", "GENE_OR_GENE_PRODUCT", 188, 193], ["NS4A", "PROTEIN", 92, 96], ["eEF1A", "PROTEIN", 104, 109], ["translation factors", "PROTEIN", 143, 162], ["eEF1A", "PROTEIN", 188, 193], ["the translation inhibition", "TEST", 14, 40], ["NS4A", "TREATMENT", 92, 96]]], ["Alternatively, other mechanisms may also involve in the inhibitory effect of NS4A.", [["NS4A", "GENE_OR_GENE_PRODUCT", 77, 81], ["NS4A", "PROTEIN", 77, 81], ["NS4A", "PROBLEM", 77, 81], ["NS4A", "OBSERVATION", 77, 81]]], ["In addition, although both HCV NS4A and NS4B proteins were shown to inhibit translation ( Figure 2 , and [15, 16] ), no interaction was detected between eEF1A and HCV NS4B protein ( Figure 3) .", [["HCV NS4A", "ORGANISM", 27, 35], ["NS4B", "GENE_OR_GENE_PRODUCT", 40, 44], ["eEF1A", "GENE_OR_GENE_PRODUCT", 153, 158], ["HCV NS4B", "GENE_OR_GENE_PRODUCT", 163, 171], ["HCV NS4A", "PROTEIN", 27, 35], ["NS4B proteins", "PROTEIN", 40, 53], ["eEF1A", "PROTEIN", 153, 158], ["HCV NS4B protein", "PROTEIN", 163, 179], ["HCV", "SPECIES", 27, 30], ["HCV", "SPECIES", 163, 166], ["both HCV NS4A", "TREATMENT", 22, 35], ["NS4B proteins", "TEST", 40, 53], ["Figure", "TEST", 90, 96], ["eEF1A", "TEST", 153, 158], ["HCV NS4B protein", "TEST", 163, 179], ["HCV NS4A", "OBSERVATION", 27, 35]]], ["These indicate that NS4B inhibits translation through a mechanism different from that of the NS4A protein.", [["NS4B", "GENE_OR_GENE_PRODUCT", 20, 24], ["NS4B", "PROTEIN", 20, 24], ["NS4A protein", "PROTEIN", 93, 105], ["NS4B", "PROBLEM", 20, 24], ["the NS4A protein", "TREATMENT", 89, 105], ["NS4B", "OBSERVATION", 20, 24]]], ["Recently, the interaction between eEF1A and HCV NS4A protein was also identified by yeasttwo hybrid screening [25] .DiscussionViral proteins including the NS5A protein of bovine viral diarrhea virus (BVDV) [26] , the RNAdependent RNA polymerase of vesicular stomatitis virus (VSV) [27] , and the Gag protein of human immunodeficiency virus (HIV) have been demonstrated to interact with eEF1A [28] .", [["bovine viral diarrhea", "DISEASE", 171, 192], ["vesicular stomatitis", "DISEASE", 248, 268], ["human immunodeficiency virus", "DISEASE", 311, 339], ["eEF1A", "GENE_OR_GENE_PRODUCT", 34, 39], ["HCV NS4A", "GENE_OR_GENE_PRODUCT", 44, 52], ["NS5A", "GENE_OR_GENE_PRODUCT", 155, 159], ["bovine viral diarrhea virus", "ORGANISM", 171, 198], ["BVDV", "ORGANISM", 200, 204], ["vesicular stomatitis virus", "ORGANISM", 248, 274], ["VSV", "ORGANISM", 276, 279], ["Gag", "GENE_OR_GENE_PRODUCT", 296, 299], ["human immunodeficiency virus", "ORGANISM", 311, 339], ["HIV", "ORGANISM", 341, 344], ["eEF1A", "GENE_OR_GENE_PRODUCT", 386, 391], ["eEF1A", "PROTEIN", 34, 39], ["HCV NS4A protein", "PROTEIN", 44, 60], ["DiscussionViral proteins", "PROTEIN", 116, 140], ["NS5A protein", "PROTEIN", 155, 167], ["RNAdependent RNA polymerase", "PROTEIN", 217, 244], ["Gag protein", "PROTEIN", 296, 307], ["eEF1A", "PROTEIN", 386, 391], ["bovine", "SPECIES", 171, 177], ["viral diarrhea virus", "SPECIES", 178, 198], ["vesicular stomatitis virus", "SPECIES", 248, 274], ["human immunodeficiency virus", "SPECIES", 311, 339], ["HIV", "SPECIES", 341, 344], ["HCV", "SPECIES", 44, 47], ["bovine viral diarrhea virus", "SPECIES", 171, 198], ["BVDV", "SPECIES", 200, 204], ["stomatitis virus", "SPECIES", 258, 274], ["VSV", "SPECIES", 276, 279], ["human immunodeficiency virus", "SPECIES", 311, 339], ["HIV", "SPECIES", 341, 344], ["HCV NS4A protein", "TREATMENT", 44, 60], ["yeasttwo hybrid screening", "TEST", 84, 109], ["DiscussionViral proteins", "TREATMENT", 116, 140], ["the NS5A protein", "TREATMENT", 151, 167], ["bovine viral diarrhea virus", "PROBLEM", 171, 198], ["the RNAdependent RNA polymerase", "TEST", 213, 244], ["vesicular stomatitis virus", "PROBLEM", 248, 274], ["the Gag protein", "TEST", 292, 307], ["human immunodeficiency virus", "PROBLEM", 311, 339], ["vesicular stomatitis virus", "OBSERVATION", 248, 274], ["immunodeficiency virus", "OBSERVATION", 317, 339]]], ["Functional roles of the interactions are not completely understood, but the interactions were proposed to be involved in the regulation of viral replication, translation, and assembly. eEF1A is a G protein that recruits aminoacyl-tRNA to the elongating ribosomes.", [["ribosomes", "ANATOMY", 253, 262], ["aminoacyl-tRNA", "CHEMICAL", 220, 234], ["aminoacyl", "CHEMICAL", 220, 229], ["eEF1A", "GENE_OR_GENE_PRODUCT", 185, 190], ["G protein", "GENE_OR_GENE_PRODUCT", 196, 205], ["ribosomes", "CELLULAR_COMPONENT", 253, 262], ["eEF1A", "PROTEIN", 185, 190], ["G protein", "PROTEIN", 196, 205], ["elongating ribosomes", "RNA", 242, 262], ["viral replication", "TREATMENT", 139, 156], ["a G protein", "TREATMENT", 194, 205], ["aminoacyl-tRNA", "TREATMENT", 220, 234], ["viral replication", "OBSERVATION", 139, 156]]], ["However, accumulated information leads us to believe that components of the translational apparatus also play important roles beyond protein synthesis. eEF1A couples the pathways of protein synthesis and degradation.", [["eEF1A", "GENE_OR_GENE_PRODUCT", 152, 157], ["eEF1A", "PROTEIN", 152, 157], ["protein synthesis", "PROBLEM", 182, 199]]], ["It interacts with ubiquitinated proteins and proteasome following ATP depletion and is involved in the proteasome-mediated cotranslational protein degradation [29] .", [["ATP", "CHEMICAL", 66, 69], ["ATP", "CHEMICAL", 66, 69], ["ATP", "SIMPLE_CHEMICAL", 66, 69], ["ubiquitinated proteins", "PROTEIN", 18, 40], ["proteasome", "PROTEIN", 45, 55], ["proteasome", "PROTEIN", 103, 113], ["cotranslational protein", "PROTEIN", 123, 146], ["ubiquitinated proteins", "TREATMENT", 18, 40], ["proteasome", "TREATMENT", 45, 55], ["ATP depletion", "TREATMENT", 66, 79], ["the proteasome-mediated cotranslational protein degradation", "TREATMENT", 99, 158], ["ubiquitinated proteins", "OBSERVATION", 18, 40], ["ATP depletion", "OBSERVATION", 66, 79]]], ["It was also demonstrated that eEF1A interacts with actin and is essential for the regulation of actin cytoskeleton and cell morphology [30] [31] [32] [33] .", [["cytoskeleton", "ANATOMY", 102, 114], ["cell", "ANATOMY", 119, 123], ["eEF1A", "GENE_OR_GENE_PRODUCT", 30, 35], ["actin", "GENE_OR_GENE_PRODUCT", 51, 56], ["actin", "GENE_OR_GENE_PRODUCT", 96, 101], ["cytoskeleton", "CELLULAR_COMPONENT", 102, 114], ["cell", "CELL", 119, 123], ["eEF1A", "PROTEIN", 30, 35], ["actin", "PROTEIN", 51, 56], ["actin", "PROTEIN", 96, 101], ["cell morphology", "TEST", 119, 134]]], ["In addition, overexpression of eEF1A is associated with oncogenic transformation and metastasis [34] [35] [36] .", [["eEF1A", "GENE_OR_GENE_PRODUCT", 31, 36], ["eEF1A", "PROTEIN", 31, 36], ["overexpression of eEF1A", "PROBLEM", 13, 36], ["oncogenic transformation", "PROBLEM", 56, 80], ["metastasis", "PROBLEM", 85, 95], ["associated with", "UNCERTAINTY", 40, 55], ["oncogenic transformation", "OBSERVATION", 56, 80], ["metastasis", "OBSERVATION", 85, 95]]], ["In this study, we found that HCV NS4A protein interacted with eEF1A and inhibited protein synthesis.", [["HCV", "ORGANISM", 29, 32], ["eEF1A", "GENE_OR_GENE_PRODUCT", 62, 67], ["HCV NS4A protein", "PROTEIN", 29, 45], ["eEF1A", "PROTEIN", 62, 67], ["HCV", "SPECIES", 29, 32], ["this study", "TEST", 3, 13], ["HCV NS4A protein", "PROBLEM", 29, 45], ["inhibited protein synthesis", "PROBLEM", 72, 99], ["HCV", "OBSERVATION", 29, 32]]], ["The interaction may result in a reduction of viral translation and replication leading to the escape of immune responses and establishment of chronic infection.", [["chronic infection", "DISEASE", 142, 159], ["viral translation", "TREATMENT", 45, 62], ["replication", "TREATMENT", 67, 78], ["immune responses", "PROBLEM", 104, 120], ["chronic infection", "PROBLEM", 142, 159], ["viral translation", "OBSERVATION", 45, 62], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["infection", "OBSERVATION", 150, 159]]], ["On the other hand, the interaction may also link the un-conventional roles of eEF1A to the pathogenesis of HCV NS4A protein.", [["eEF1A", "GENE_OR_GENE_PRODUCT", 78, 83], ["HCV", "ORGANISM", 107, 110], ["eEF1A", "PROTEIN", 78, 83], ["HCV NS4A protein", "PROTEIN", 107, 123], ["HCV", "SPECIES", 107, 110], ["HCV NS4A protein", "TREATMENT", 107, 123]]]], "PMC7336917": [["IntroductionThe Association of Program Directors in Surgery (APDS) was established in 1977 with a mission to further surgical education.1 Since that time, the vision of the organization has evolved but its purposes have remained the same.", [["further surgical education", "TREATMENT", 109, 135]]], ["A primary organizational meeting occurs each spring and a smaller secondary meeting occurs in the fall in conjunction with the American College of Surgeons (ACS) Clinical Congress.", [["ACS", "DISEASE", 157, 160]]], ["Final schedules were posted to www.apds.org and circulated in January 2020 (Table 1and Table 2), at which time registration was opened.IntroductionIn February 2020, it became clear to the APDS leadership that an in-person meeting in Seattle was threatened secondary to COVID-19.", [["COVID-19", "DNA", 269, 277], ["COVID", "TEST", 269, 274]]], ["Given the challenges of the current environment and its impact on surgical residency training and thus surgical residency leadership, the national meeting was a necessity to fulfill the mission of the APDS including supporting program directors and advancing the science of surgical education.IntroductionThe fast pace of COVID-19 in Seattle made the decision much easier.", [["APDS", "DISEASE", 201, 205], ["surgical residency training", "TREATMENT", 66, 93], ["surgical education", "TREATMENT", 274, 292], ["The fast pace of COVID", "TREATMENT", 305, 327]]], ["On February 29, the first known death from COVID-19 was reported in the state of Washington.", [["death", "DISEASE", 32, 37], ["COVID-19", "CHEMICAL", 43, 51], ["COVID", "TEST", 43, 48]]], ["On March 3, Seattle's mayor issued a civil emergency,2 and on March 6, the number of confirmed COVID-19 cases in Washington topped 100.3,4 On March 11, 2020, Washington's governor prohibited all gatherings over 250 in King, Snohomish, and Pierce counties, and this prohibition was expanded statewide on March 13.5", [["COVID", "DISEASE", 95, 100], ["COVID", "TEST", 95, 100]]]], "PMC7306746": []}